lamivudine has been researched along with HIV Coinfection in 2407 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 398 (16.54) | 18.2507 |
| 2000's | 1000 (41.55) | 29.6817 |
| 2010's | 711 (29.54) | 24.3611 |
| 2020's | 298 (12.38) | 2.80 |
| Authors | Studies |
|---|---|
| Grier, JP; Hernandez-Santiago, BI; Mathew, JS; Rapp, KL; Schinazi, RF | 1 |
| Benech, H; Da Silva, D; Durand-Gasselin, L; Grassi, J; Pruvost, A | 1 |
| Colonno, R; Dicker, I; Fan, L; Gali, V; Higley, H; Krystal, M; Lin, PF; Nowicka-Sans, B; Parkin, N; Tenney, D; Terry, B; Wang, C; Zhang, S | 1 |
| Bachmann, MH; Fessel, WJ; Kagan, RM; Mitsuya, Y; Shafer, RW; Shahriar, R; Varghese, V | 1 |
| Amblard, F; Bassit, L; Bondada, L; Coats, SJ; Detorio, M; Grier, J; Hernandez-Santiago, BI; Koontz, D; Mellors, JW; Rapp, KL; Schinazi, RF; Sluis-Cremer, N | 1 |
| Avila, C; Evans, TG; Karwowska, S; Lam, E; Limoli, K; Lin, K | 1 |
| Almond, MR; Buckheit, RW; Hartman, T; Keilholz, L; Lampert, BM; Lanier, ER; Mankowski, MK; Osterling, MC; Painter, GR; Ptak, RG | 1 |
| Bardin, C; Blanche, S; Bouazza, N; Diagbouga, S; Hien, H; Hirt, D; Msellati, P; Nacro, B; Ouiminga, A; Rouet, F; Tréluyer, JM; Urien, S; Van De Perre, P; Zoure, E | 1 |
| Agarwal, HK; Buckheit, KW; Buckheit, RW; Parang, K | 1 |
| Chen, W; De Clercq, E; Liu, X; Liu, Z; Pannecouque, C; Zhan, P | 1 |
| Agarwal, HK; Chhikara, BS; Doncel, GF; Parang, K | 1 |
| Chai, J; Chang, J; Chen, J; Han, Z; Hou, J; Huang, Z; Jin, X; Li, E; Liang, L; Peng, Y; Qiao, Y; Song, C; Sun, L; Wang, JH; Wang, Q; Wu, M; Yu, W; Zhang, B; Zhang, D; Zhang, Y; Zhao, Q | 1 |
| Amblard, F; Biteau, N; Coats, SJ; Ehteshami, M; Kasthuri, M; Michailidis, E; Patel, D; Schinazi, RF; Tber, Z | 1 |
| Alejos, B; Aranguren-Rivas, P; Arribas, JR; Bermejo-Plaza, L; Bisbal, O; Cadiñanos, J; Castro, JM; de Miguel, R; Delgado, R; Dominguez-Dominguez, L; Esteban-Cantos, A; García-Álvarez, M; Hernando, A; Martin-Carbonero, L; Mayoral, M; Montejano, R; Moreno, V; Pulido, F; Rial-Crestelo, D; Rodés, B; Rubio, R; Santacreu-Guerrero, M | 1 |
| Arancón Pardo, A; González Fernández, MÁ; González-García, J; Herrero Ambrosio, A; Jiménez-Nácher, I; Moreno Palomino, M; Moreno, F | 1 |
| Abdelzaher, AM; Elmaaty, AA; Hasan, MA; Serag, A; Tolba, EH | 1 |
| Battegay, M; Cueni, N; Dickenmann, M; Hollinger, A; Landmann, E; Leuppi-Taegtmeyer, A; Martinez, AE; Marzolini, C; Siegemund, M | 1 |
| Baxi, SM; Choden, T; Desai, M; Dorjee, K; Hubbard, AE; Reingold, AL | 1 |
| Aboud, M; Antinori, A; Arribas, JR; Brandon, DJ; Cahn, P; Clarke, AE; Curtis, L; Gartland, M; Girard, PM; Hung, CC; Man, CY; Ortiz, R; Pappa, KA; Rockstroh, JK; Sierra Madero, J; Sievers, J; Smith, KY; Underwood, M; Urbaityte, R; van Wyk, J; Wynne, B | 1 |
| Eggers, Y; Feldt, T; Fuchs, A; Häussinger, D; Heger, E; Hurissa, Z; Jarso, G; Jensen, BO; Kaiser, R; Knops, E; Lübke, N; Luedde, T; Orth, HM; Tufa, TB | 1 |
| Balboa-Barreiro, V; Castro-Iglesias, Á; Cid-Silva, P; Fernández-Oliveira, C; Giménez-Arufe, V; López-Calvo, S; Margusino-Framiñán, L; Martín-Herranz, I; Martínez-Pradeda, A; Mena-De-Cea, Á; Míguez-Rey, E; Rotea-Salvo, S; Vázquez-Rodríguez, P | 1 |
| Allavena, C; Bani-Sadr, F; Cabie, A; Cuzin, L; Deschanvres, C; Duvivier, C; Hocqueloux, L; Joly, V; Lamaury, I; Palich, R; Raffi, F; Rey, D; Reynes, J; Robineau, O | 1 |
| Adams, R; Buthelezi, S; Chetty, S; Chimukangara, B; Dawood, H; de Oliveira, T; Diallo, K; Dlamini, L; Duffus, WA; Giandhari, J; Grigalionyte, I; Hagen, MB; Lessells, RJ; Mogashoa, M; Moodley, P; Naidoo, K; Padayatchi, N; Singh, L; Yende-Zuma, N | 1 |
| Bartoloni, A; Borchi, B; Botta, A; Cavallo, A; Kiros, ST; Lagi, F; Meli, M; Pozzi, M; Sterrantino, G | 1 |
| Boyer, PL; Caplan, MR; Clark, P; Dewar, R; Ferris, AL; Hughes, SH; Johnson, A; Maldarelli, F; Mican, J; Rehm, CA; Sneller, MC | 1 |
| Ang, JH; Ang, LW; Hoo, GS; Law, HL; Lee, CC; Leo, YS; Lim, ZC; Ng, OT; Teng, CB; Wong, CS | 1 |
| Bon, I; Calza, L; Fulgaro, C; Lazzarotto, T; Legnani, G; Verucchi, G; Viale, P | 1 |
| Alkhatib, M; Borghetti, A; Borghi, V; Di Giambenedetto, S; Duca, L; Dusina, A; Zazzi, M | 1 |
| Andrieux-Meyer, I; Bekker, A; Capparelli, E; Cotton, MF; Cressey, R; Cressey, TR; du Toit, S; Groenewald, M; Kumar, M; Lallemant, M; Nielsen, J; Rabie, H; Salvadori, N; Than-In-At, K | 1 |
| Barbini, B; Campbell, L; Fox, J; Gilleece, Y; Ibrahim, F; Orkin, C; Post, FA; Samarawickrama, A; Tariq, S; Waters, L | 1 |
| Bon, I; Borderi, M; Calza, L; Colangeli, V; Lazzarotto, T; Miani, T; Nuti, B; Viale, P | 1 |
| Bowen, N; Inzaule, SC; Jordan, MR; Kiiru, JN; Kingwara, L; Momanyi, L; Ngugi, C; Nyanya, W; Oramisi, V | 1 |
| Musyoki, SK; Onyango, DM; Wandera, BO | 1 |
| Chen, P; Deng, L; Hong, Z; Li, C; Luo, X; Xia, J; Zheng, X; Zhou, L; Zhou, Y | 1 |
| Jamison, TF; Mear, SJ; Nguyen, LV; Rochford, AJ | 1 |
| Christensen, BL; Tan, DH | 1 |
| Aboud, M; Ait-Khaled, M; Ajana, F; Bisshop, F; De Wit, S; George, N; Leone, P; Osiyemi, O; Pappa, KA; Portilla, J; Routy, JP; Smith, KY; van Wyk, J; Wang, R; Wright, J; Wyen, C; Wynne, B | 1 |
| Alcaraz, A; Alejos, B; Alonso Socas, MDM; Belza, MJ; Espacio, R; Garaialde, A; García-Yubero, C; Gómez-Ayerbe, C; Gutiérrez Cuéllar, I; Hernández, J; Jarrín, I; Martínez Madrid, OJ; Muñoz Sánchez, J; Olalla, J; Pierola Ruiz de Galarreta, B; Ruiz-Algueró, M; Suárez-García, I | 1 |
| Baccini, M; Borghetti, A; Borghi, V; Callegaro, A; Dreassi, E; Gagliardini, R; Lodi, MA; Lombardi, F; Micheli, V; Modica, S; Montagnani, F; Pecorari, M; Rossetti, B; Zanelli, G; Zazzi, M | 1 |
| Bhatt, N; Couto, A; Cuco, RM; Degomme, O; Juga, A; Loquiha, O; Meggi, B; Osman, N; Sevene, E; Sidat, M; Temermam, M; Vubil, A | 1 |
| Anderson, M; Badal-Faesen, S; Bhattacharya, D; Chinula, L; Cloherty, G; Gaseitsiwe, S; Hawkins, C; Holzmayer, V; Kang, M; Kuhns, M; Lama, J; Matining, R; Mulinda, N; Murphy, R; Peters, M; Samaneka, W; Sugandhavesa, P; Thio, C | 1 |
| Egger, M; Goldstein, F; Hauser, A; Kouyos, RD; Reichmuth, ML; Riou, J; Wandeler, G | 1 |
| Fidler, S; Fox, J; Kulasegaram, R; Lee, MJ; Nori, A; Smith, C | 1 |
| Arnold, E; DeStefano, JJ; Dilmore, CR; Hoang, A; Ruiz, FX | 1 |
| Blair, E; Bontempo, G; Brites, C; Cheng, CY; Curtis, L; Degen, O; Galera, C; Hocqueloux, L; Llibre, JM; Maggiolo, F; Man, C; Osiyemi, O; Oyee, J; Taylor, S; Underwood, M; van Wyk, J; Wynne, B | 1 |
| de la Mora, L; García, F; Llibre, JM; Noguera-Julián, M; Paredes, R; Parera, M; Revollo, B; Viñuela, L | 1 |
| Awadu, JE; Coventry, A; Ezeamama, AE; Giordani, B; Sikorskii, A; Zalwango, S | 1 |
| Blanco, JR; de la Torre-Lima, J; Ferra, S; García-Vallecillos, C; Hidalgo-Tenorio, C; López-Lirola, A; López-Ruz, MÁ; Martínez, OJ; Montero, M; Omar, M; Palomares, J; Pasquau, J; Payeras, A; SanJoaquín, I; Terrón, A; Vinuesa, D | 1 |
| Arribas, JR; Bamford, A; Beguelin, C; Behrens, GMN; Boesecke, C; Cinque, P; Collins, S; Cotter, AG; De Miguel, R; Guaraldi, G; Kirk, O; Kowalska, JD; Mallon, PWG; Marzolini, C; Molina, JM; Podlekareva, D; Rauch, A; Ryom, L; Waalewijn, H; Welch, S; Winston, A | 1 |
| Avihingsanon, A; Azwa, I; Chaiwarith, R; Chan, YJ; Choi, JY; Ditangco, R; Do, CD; Gani, YM; Huy, BV; Jiamsakul, A; Khusuwan, S; Kiertiburanakul, S; Kim, JH; Kumarasamy, N; Lee, MP; Ly, PS; Merati, TP; Ng, OT; Pujari, S; Ross, J; Tanuma, J; Yunihastuti, E; Zhang, F | 1 |
| Alejos, B; Antonio Iribarren, J; Asensi, V; Galera, CE; García Yubero, C; Jarrín, I; Muñoz, A; Pascual-Carrasco, M; Pasquau, F; Riera Jaume, M; Ruiz-Algueró, M; Suárez-García, I | 1 |
| Bisbal, O; Busca, C; de Los Santos, I; Galera, C; Gutiérrez, F; Iribarren, JA; Jiménez, D; López-Huertas, MR; Martínez-Sanz, J; Moreno, E; Moreno, S; Muriel, A; Portilla, J; Serrano-Villar, S; Tejerina, F | 1 |
| Acosta, RK; Cihlar, T; D'Antoni, ML; Mulato, A; White, KL; Yant, SR | 1 |
| Ake, JA; Bahemana, E; Chang, D; Crowell, TA; Dear, NF; Esber, AL; Iroezindu, M; Kibuuka, H; Maswai, J; Owuoth, J; Polyak, CS; Singoei, V | 1 |
| Blanco, JR; Calzado Isbert, S; López Cortés, LF; Martínez-Sanz, J; Mena, Á; Moreno, E; Moreno, S; Muriel, A; Pineda, JA; Ron, R; Sánchez-Conde, M; Serrano-Villar, S | 1 |
| Casian, M; Chiriac, D; Grancea, C; Ianache, I; Oprea, C; Ruta, S; Sultana, C | 1 |
| Asienzo, J; Ategeka, G; Balyegisawa, A; Borok, M; Castelnuovo, B; Hoppe, A; Kaimal, A; Kambugu, A; Kiragga, A; Kityo, C; Lugemwa, A; Mirembe, G; Mugerwa, H; Musaazi, J; Odongpiny, ELA; Paton, NI; Siika, A; Walimbwa, S | 1 |
| Bouazza, N; Dahourou, DL; Dainguy, E; Desmonde, S; Eboua, F; Foissac, F; Hirt, D; Leroy, V; Malateste, K; Pressiat, C; Pruvost, A; Study Group, TMA; Tréluyer, JM; Urien, S; Yonaba, C | 1 |
| Carrozzo, G; Cattaneo, D; Gervasoni, C; Poloni, A; Riva, A | 1 |
| Blanco, JL; Callau, P; de la Mora, L; de Lazzari, E; Gonzalez-Cordón, A; Inciarte, A; Laguno, M; Mallolas, J; Martinez, E; Martinez-Rebollar, M; Rojas, J; Subirana, M; Torres, B | 1 |
| Gan, X; Hui, X; Li, Q; Sun, W | 1 |
| Ackley, C; Clarke, A; Fray, D; Garcia Rodriguez, D; Villa, G | 1 |
| Ahmed, FO; Aning, BD; Ansah, RO; Ayisi-Boateng, NK; Enimil, AK; Ojuang, DA; Okeke, CB; Opoku, S; Sakyi, SA; Sarfo, AD; Senu, E; Wekesa, DN | 1 |
| Bhattacharya, D; Butler, K; Chakhtoura, N; Currier, JS; Dula, D; Fowler, MG; George, K; Govender, V; Kiweewa, FM; Mohtashemi, N; Moodley, D; Musoke, P; Peters, MG; Ship, H; Tierney, C; Vhembo, T | 1 |
| Afonso Reis, E; Almeida-Brasil, CC; Ceccato, MDGB; de Oliveira Costa, J; Rodrigues, VA; Silveira, MR | 1 |
| Abongwa, LE; Bella, S; Charles, F; Domkam, I; Emmanuel, N; Eyongetah, M; Jude, B; Moungang, EC; Mua, FH; Ngum, V; Nyamache, AK; Okemo, P; Tamboh, TC; Torimiro, J | 1 |
| Aceiton, J; Bruguera, A; Casabona, J; Deig, E; Díaz, Y; Domingo, P; Imaz, A; Llibre, JM; Miro, JM; Moreno, S; Navarro, G; Navarro, J; Nomah, DK; Reyes-Urueña, J; Vivanco-Hidalgo, RM | 1 |
| Amstutz, A; Belus, JM; Brown, JA; Glass, TR; Klimkait, T; Labhardt, ND; Mokhele, K; Muhairwe, J; Nsakala, BL; Rakuoane, I; Tschumi, N | 1 |
| Aoun-Barakat, L; Cartwright, EJ; Casas, JP; Dickerman, BA; Hernán, MA; Justice, AC; Li, G; Lodi, S; Logan, RW; Park, LS; Rentsch, CT | 1 |
| Evans, D; Hans, L; Levin, L; Steegen, K; Technau, KG | 1 |
| Abdi, B; Bitilinyu-Bangoh, JE; Calvez, V; Descamps, D; Jahn, A; Kalua, T; Lê, MP; Marcelin, AG; Nicholas, S; Ousley, J; Peytavin, G; Schramm, B; Storto, A; Szumilin, E; Temfack, E | 1 |
| Alhassan, Y; Bokako, S; Burger, D; Byamugisha, J; Byrne, K; Chen, T; Chiong, J; Colbers, A; Hodel, EM; Hu, NC; Khoo, S; Kintu, K; Lamorde, M; Malaba, TR; Mrubata, M; Myer, L; Nakatudde, I; Orrell, C; Read, J; Read, L; Reynolds, H; Seden, K; Stemmet, LA; Taegtmeyer, M; Theunissen, H; Twimukye, A; Waitt, C; Wang, D | 1 |
| Figueredo, CC; Gomes, MP; Juneau, P; Kitamura, RSA; Kubis, GC; Navarro-Silva, MA; Nogueira, KDS; Vieira, F | 1 |
| Allard, SD; Ausselet, N; Darcis, G; De Scheerder, MA; De Wit, S; Delforge, M; Demeester, R; Florence, E; Henrard, S; Loeckx, M; Messiaen, P; Nasreddine, R; Yombi, JC | 1 |
| Jiao, Z; Liu, L; Liu, X; Lu, H; Meng, X; Sun, T; Wang, J; Wen, H; Xing, Y; Xu, F; Yin, L; Zhang, L; Zhang, M; Zhang, R | 1 |
| Antinori, A; Armenia, D; Calvez, V; Ceccherini-Silberstein, F; Charpentier, C; Descamps, D; Katlama, C; Lambert-Niclot, S; Marcelin, AG; Paredes, R; Perno, CF; Santoro, MM; Santos, JR; Teyssou, E | 1 |
| Katzenstein, D; Kouamou, V; Machekano, R; Manasa, J; Mapangisana, T; Maposhere, C; McCarty, K; Munyati, S; Mutsvangwa, J; Shamu, T | 1 |
| Bartolini, N; De Luca, A; Di Giambenedetto, S; Dragoni, F; Fabbiani, M; Giammarino, F; Lombardi, F; Moschese, D; Rossetti, B; Saladini, F; Spertilli Raffaelli, C; Vicenti, I; Zazzi, M | 1 |
| Afani Saud, A; Bettacchi, C; Chahin Anania, C; Correll, T; Eves, K; Grandhi, A; Hanna, GJ; Hepler, D; Hwang, C; Klopfer, SO; Molina, JM; Robertson, MN; Yazdanpanah, Y | 1 |
| Allahna, E; Christina S, P; Emmanuel, B; Hannah, K; John, O; Jonah, M; Joseph S, C; Julie A, A; Michael, I; Neha, S; Nicole, D; Trevor A, C; Valentine, S | 1 |
| Appolloni, L; Bon, I; Calza, L; Pensalfine, G; Viale, P; Vitale, S | 1 |
| Airewele, G; Bulsara, S; Despotovic, J; Elyanu, P; Grimes, A; Haq, H; Kekitiinwa, A; Kim, TO; Lubega, J; Lumumba, M; Matshaba, M; Musoke, P; Peckham-Gregory, E; Scheurer, M; Wanless, SR | 1 |
| Adebisi, SA; Adedeji, NO; Adedeji, TA; Ajeigbe, AK; Ajose, AO; Akande, AA; Fawale, MB; Jeje, OA; Okesina, BA; Smith, OS | 1 |
| Cai, K; Chen, W; He, Y; Liu, X; Rao, M; Sun, L; Wang, H; Xu, L; Zhang, L; Zhao, F | 1 |
| Cao, T; He, Y; Jia, X; Ju, B; Liu, J; Liu, X; Peng, Q; Rao, M; Song, Y; Sun, L; Wang, H; Wang, S; Xu, L; Zhang, H; Zhang, L; Zhang, Q; Zhao, F; Zhou, J; Zhou, Y | 1 |
| Cai, L; Guo, Z; He, S; Wang, Y; Wang, Z; Yan, D; Yang, X; Zheng, Y | 1 |
| Chen, C; Hu, Y; Huang, J; Lv, R; Ma, P; Pei, X; Qi, M; Su, Y; Wei, H; Yan, L; Ye, Z; Zhong, M; Zou, M | 1 |
| Abdusalaamu, K; Boulware, DR; Collins, L; Lukande, R; Meya, DB; Mishra, U; Namuju, OC; Nicol, MR; Pastick, KA; Wang, F | 1 |
| Hideta, K; Higasa, S; Hikasa, S; Kimura, T; Sawada, A; Shimabukuro, S; Tanaka, K; Tokugawa, T; Yanai, M | 1 |
| Airewele, G; Bulsara, S; Despotovic, J; Elyanu, P; Grimes, A; Haq, H; Kekitiinwa, A; Kim, TO; Lubega, J; Lumumba, M; Matshaba, M; Musoke, P; Peckham, E; Scheurer, M; Wanless, SR | 1 |
| Chen, T; Gui, F; Tan, J; Wei, G; Yang, J; Zhao, Y | 1 |
| Baxter, C; Beyer, A; Derkach, E; Lobodina, A; Pyadushkina, E; Rozenberg, V; Ugrekhelidze, D | 1 |
| Fu, Y; Gan, L; Li, J; Long, H; Song, C; Song, Y; Xie, X; Yang, X | 1 |
| Barrett, C; Joubert, G; Malherbe, J; Potgieter, S; Thibile, S | 1 |
| Aurpibul, L; Best, BM; Campbell, H; Cassim, H; Cooper, E; Flynn, P; Gray, KP; Krotje, C; McCarthy, K; McFarland, E; Melvin, AJ; Moye, J; Ounchanum, P; Rungmaitree, S; Scheckter, R; Teppler, H; Tobin, NH; Townley, E; Wan, H; Yedla, M; Yee, KL | 1 |
| Blackard, JT; Makatini, ZN; Mda, S; Miles, P; Towobola, OE | 1 |
| Callegaro, A; Cervo, A; Digaetano, M; Gulminetti, R; Maggiolo, F; Mussini, C; Pagnucco, L; Valenti, D | 1 |
| Gachohi, J; Karanja, S; Kombe, Y; Muhula, SO | 1 |
| Buzón, L; Dueñas, C; Pedrero-Tomé, R; Troya, J | 1 |
| Antinori, S; Baldin, G; Borghi, V; Capetti, A; Ciccullo, A; Cossu, MV; Di Giambenedetto, S; Farinacci, D; Giacomelli, A; Iannone, V; Lagi, F; Mussini, C; Passerotto, RA; Sterrantino, G | 1 |
| Chen, D; Du, Y; Huang, Z; Li, J; Wang, Y; Wen, Z; Yin, S; Zhong, H | 1 |
| Derkach, EV; Pyadushkina, EA | 1 |
| Aghokeng, A; Ateba Ndongo, F; Bilong, S; Djeuda, ABD; Eboumbou Moukoko, CE; Eyoum Bille, B; Fokam, J; Grace, N; Koki Ndombo, P; Moukoko Mbonjo, M; Ndjolo, A; Penda, CI | 1 |
| Ali, SM; Karoney, MJ; Kigen, G; Koech, MK | 1 |
| Achila, OO; Andegiorgish, AK; Ghebrat, HB; Ghebremeskel, GG; Ghebrenegus, AS; Leake, N; Mengistu, ST; Mesfin, AB; Wendmhuney, FG; Yeibyo, N; Yohannes, NA | 1 |
| Arribas, JR; Cabello, A; Curran, A; de la Cámara, SP; Del Amo, J; Díaz, A; Dueñas, C; Hernán, MA; Iribarren, JA; Jarrín, I; Macías, J; Mariño, AI; Martínez, E; Montero, M; Moreno, S; Polo, R | 1 |
| Andreoni, M; Barchi, V; De Simone, G; Iannazzo, R; Iannetta, M; Massa, B; Rindi, LV; Sarmati, L | 1 |
| Bendala-Estrada, AD; Bernardino, JI; Busca, C; Cadiñanos, J; Delgado-Hierro, A; Diaz-Almiron, M; Martin-Carbonero, L; Mican, R; Montejano, R; Montes, ML; Valencia, E | 1 |
| Antinori, A; Borghi, V; Castagna, A; Cozzi-Lepri, A; Gagliardini, R; Galli, L; Lorenzini, P; Maggiolo, F; Monforte, AD; Mussini, C; Tagliaferri, G; Tavelli, A | 1 |
| Cabello-Ubeda, A; de Quirós, JCLB; Górgolas, M; Gutiérrez, Á; Hernández Segurado, M; Martín Carbonero, L; Mena, Á; Palmier, E; Pinto, A; Pulido, F; Sanz, J; Tejerina, F; Torralba, M; Vázquez, P; Vergas, J | 1 |
| Ahn, JY; Choi, JY; Jeong, SJ; Kim, CH; Kim, J; Kim, JH; Ku, NS; Lee, JA; Lee, KH; Song, YG; Yeom, JS | 1 |
| Estripeaut, D; González-Alba, JM; Holguín, Á; Navarro, ML; Pinzón, R; Ventosa-Cubillo, J | 1 |
| Bhrusundi, M; Dravid, A; K R, R; Kulkarni, V; Madhukarrao, KM; Morkar, DN; Nageswaramma, S; Naik, KS; Pilawan, AS; Ramapuram, JT; S, A | 1 |
| Akpomiemie, G; Bosch, B; Chandiwana, N; Hill, A; McCann, K; Mirchandani, M; Qavi, A; Sokhela, S; Venter, WDF | 1 |
| Griesel, R; Hill, A; Keene, C; Maartens, G; Meintjes, G; Omar, Z; Simmons, B; van Zyl, G; Zhao, Y | 1 |
| Aristegui, I; Cahn, P; Cardozo, N; Cesar, C; Figueroa, MI; Fink, V; Frola, CE; Gun, A; Patterson, P; Radusky, PD; Sued, O; Zalazar, V | 1 |
| Abba, A; Beloumou, GA; Billong, SC; Bouba, NP; Ceccherini-Silberstein, F; Chenwi, CA; Colizzi, V; Dambaya, B; Djupsa Ndjeyep, SC; Eben-Moussi, E; Etame, NK; Fokam, J; Ka'e, AC; Kengni, AMN; Kouanfack, C; Meledie, AP; Molimbou, E; Mossiang, L; Ndjolo, A; Nka, AD; Perno, CF; Santoro, MM; Semengue, ENJ; Sosso, SM; Takou, D; Teto, G; Tommo Tchouaket, MC; Yagai, B; Zoung-Kanyi Bissek, AC | 1 |
| Andreoni, M; Basso, M; Battagin, G; Compagno, M; Ferrari, L; Iannetta, M; Malagnino, V; Mulas, T; Panese, S; Parisi, SG; Rossi, MC; Salpini, R; Sarmati, L; Scaggiante, R; Svicher, V; Teti, E; Zago, D; Zordan, M | 1 |
| Awadu, JE; Bovin, MJ; Ezeamama, AE; Giordani, B; Musoke, PM; Sikorskii, A; Zalwango, SK | 1 |
| Cassidy, T; Flowers, T; Goemaere, E; Griesel, R; Hill, A; Jackson, A; Keene, CM; Maartens, G; Meintjes, G; Ngwenya, O; Omar, Z; Sayed, K; Van Zyl, G; Zhao, Y | 1 |
| Chen, M; Huobu-Mo, M; Li, C; Li, J; Wu, M; Xiao, H; Zeng, L; Zhang, Y | 1 |
| Akodu, J; Ambrose, A; Barber, TJ; Bowman, C; Flores, K; Hart, J; Hunter, A; Kanitkar, T; Simoes, P | 1 |
| Ake, JA; Bahemana, E; Cavanaugh, JS; Crowell, TA; Dear, N; Esber, AL; Ganesan, K; Iroezindu, M; Kibuuka, H; Maswai, J; Mwesigwa, R; Owuoth, J; Parikh, AP; Polyak, CS; Reed, D; Shah, N; Singoei, V | 1 |
| Fan, X; Huang, H; Jiao, Y; Li, J; Wang, FS; Yu, XD; Zhang, D | 1 |
| Fukuda, A; Hongo, H; Kurosaki, E; Maeno, Y; Nagao, T; Sebata, A; Suzuki, M; Tofukuji, A; Watanabe, T | 1 |
| Nguyen, TK; Van Le, D | 1 |
| Buzón, L; de Los Santos, I; Díaz de Santiago, A; Dueñas, C; Egido, M; Ferreira, E; Gómez, J; Iglesias, A; Iribarren, JA; Martín, C; Morán, MÁ; Moreno, E; Pedrero, R; Pousada, G; Rodríguez, L; Sepulveda, MA; Troya, J | 1 |
| Aydın, Ö; Bektas, B; Cağ, Y; Ergen, P; Karadağ, FY; Keskin, H; Üçışık, AC | 1 |
| Evitt, LA; Grove, RA; Nanji, S; Okoli, C; Snedecor, SJ; van Wyk, J | 1 |
| Chen, H; Deng, Y; Gao, Y; Ge, X; Ge, Y; Lan, G; Li, B; Li, S; Liu, S; Luo, H; Luo, L; Meng, Q; Qin, G; Qin, H; Wang, Y; Wen, P; Wu, X; Yang, H; Zhu, J; Zhu, Q | 1 |
| Guan, W; Li, T; Li, Y; Lin, Q; Song, X; Xu, Y; Yu, W; Zhang, Y; Zhang, Z | 1 |
| Al-Harthi, L; Barbian, HJ; Gonzalez, H; Ho, S; Narasipura, SD; Olali, AZ; Olivares, LJ; Podany, AT; Ross, RD; Seaton, MS; Virdi, AK; Wallace, J; Winchester, LC | 1 |
| Albendín Iglesias, H; Alejos, B; Díaz, A; Hernando, V; Jarrín, I; Moreno, S; Peraire, J; Pérez Elías, MJ; Rial-Crestelo, D; Suárez-García, I; Tiraboschi, J; Vera García, M; Viñuela, L | 1 |
| Buzón, L; De la Fuente, S; De Los Santos, I; Dueñas-Gutiérrez, C; Ferreira, E; Gómez, J; Iribarren, JA; Moran, MA; Moreno, E; Pedrero-Tomé, R; Pousada, G; Troya, J | 1 |
| Hao, X; Li, B; Li, L; Ni, J; Tian, Z; Wu, L; Xiao, Y; Zhang, W; Zhao, D; Zhao, X | 1 |
| Ban, JK; Bunko, A; de Wet, JJ; Eberg, M; Ling, J; McKimm, M; Verdier, G | 1 |
| Cao, B; Ding, P; Huang, F; Huang, Y; Jiang, J; Jiang, T; Liu, M; Yu, Q; Yuan, T; Zhou, X | 1 |
| Arribas, JR; Bernardino, JI; Busca, C; Cadiñanos, J; De Miguel, R; González-García, J; Martín-Carbonero, L; Micán, R; Montejano, R; Montes, ML; Palmier, E; Pérez-Valero, I; Ramos, L; Serrano, L; Valencia, E | 1 |
| Caldeira, DB; Camargo, M; de Lima, IB; Dias, D; Diaz, RS; Galinskas, J; Hunter, JR; Nassar, I; Schechter, M; Sucupira, MC | 1 |
| Griesel, R; Hill, AM; Keene, CM; Maartens, G; Meintjes, G; Omar, Z; Simmons, B; Wiesner, L; Zhao, Y | 1 |
| Annicchiarico, G; Baglivi, A; Carini, E; Castagna, A; Della Torre, L; Galli, L; Gianotti, N; Lazzarin, A; Lolatto, R; Sampaolo, M | 1 |
| Ambe Chenwi, C; Angong Beloumou, G; Dambaya, B; Djupsa Ndjeyep, SC; Fokam, J; Ka'e, AC; Kouanfack, C; Mbopi Keou, FX; Mbouyap, PR; Mossiang, L; Ndjolo, A; Ngoufack Jagni Semengue, E; Nka, AD; Takou, D; Teto, G | 1 |
| Brenner, BG; Ibanescu, RI; Oliveira, M; Routy, JP; Thomas, R | 1 |
| Abdi, B; Arvieux, C; Duthe, JC; Hall, N; Katlama, C; Lamaury, I; Marcelin, AG; Menard, A; Palich, R; Perfezou, P; Seang, S | 1 |
| Eleje, GU; Ikechebelu, JI; Nwagha, UI; Okafor, HU; Ugwu, AO; Ugwu, EO; Umeh, UA | 1 |
| Fang, Z; Gang, X; Guoqiang, Z; Jing, C; Min, W; Ning, W; Wei, T; Xingzhi, W | 1 |
| Hachey, D; Shiluama, R; Singu, BS; van Woerden, I | 1 |
| Ambrosioni, J; Berrocal, L; Blanco, JL; Chivite, I; De La Mora, L; De Lazzari, E; Foncillas, A; González-Cordón, A; Inciarte, A; Laguno, M; Mallolas, J; Martínez, E; Martínez-Rebollar, M; Martínez-Serra, A; Torres, B | 1 |
| Ambe Chenwi, C; Billong, SC; Bouba, Y; Colizzi, V; Ebiama Lifanda, L; Efakika Gabisa, J; Fainguem, N; Flore Yimga, J; Fokam, J; Hadja, H; Halle, EG; Ka'e, AC; Kamgaing, N; Kembou, E; Kengni Ngueko, AM; Kesseng, D; Ketchaji, A; Mamgue Dzukam, FY; Moudourou, S; Nayang Mundo, RA; Ndiang Tetang, S; Ndjolo, A; Ndombo Koki, P; Ngoufack Jagni Semengue, E; Njom-Nlend, AE; Nka, AD; Nnomo Zam, MK; Pabo, W; Pamen, B; Perno, CF; Saounde Temgoua, E; Simo Kamgaing, R; Sosso, SM; Takou, D; Tangimpundu, C; Tommo Tchouaket, MC; Zoung-Kanyi Bissek, AC | 1 |
| Ait-Khaled, M; Górgolas Hernández-Mora, M; Kinder, C; Lutz, T; Moodley, R; Moore, R; Parry, CM; Podzamczer, D; Saggu, P; Underwood, M; van Wyk, J; Wang, R; Wright, J; Wynne, B | 1 |
| Avedissian, SN; Fletcher, CV; Mykris, TM; Podany, AT; Scarsi, KK; Weinhold, J; Winchester, LC | 1 |
| Amole, C; Jenkins, SY; Panos, Z; Resar, D; Ripin, D; Staple, A; Watkins, M | 1 |
| Abalat-Torrres, A; Arrieta-Aldea, I; Cañas-Ruano, E; Canepa, C; González-Mena, A; Guelar, A; Güerri-Fernández, R; Knobel, H; Knobel, P; Marcos, A; Villar-García, J | 1 |
| Curran, A; Diaz-Brito, V; Domingo, P; Garcia, B; Imaz, A; Morenilla, S; Niubó, J; Peñafiel, J; Podzamczer, D; Scévola, S; Soriano, I; Tiraboschi, J; Verdejo, G | 1 |
| Borghetti, A; Ciccullo, A; Di Giambenedetto, S; Fabbiani, M; Lombardi, F; Sanfilippo, A; Tamburrini, E | 1 |
| Burger, D; Chen, RQ; Colbers, A; Geerlings, S; Zino, L | 1 |
| Dominguez-Macias, M; Espinosa, N; Gutierrez-Valencia, A; Herrero, M; Lopez-Cortes, LE; Lopez-Cortes, LF; Lozano, C; Muñoz-Muela, E; Praena-Fernandez, JM; Roca-Oporto, C; Saborido-Alconchel, A; Serna-Gallego, A; Sotomayor, C; Trujillo-Rodriguez, M | 1 |
| Benfield, T; Gerstoft, J; Hove, JD; Knudsen, A; Møller, S; Pedersen, KBH; Siebner, HR | 1 |
| Agostini, E; Cattelan, A; Gardin, S; Leoni, D; Mazzitelli, M; Mengato, D; Putaggio, C; Sasset, L; Scaglione, V; Trunfio, M; Vania, E | 1 |
| Collier, AC; Delle Fratte, R; Eguchi, M; Ho, RJY; Melvin, AJ; Perazzolo, S; Stephen, ZR; Xu, X | 1 |
| Chunda-Liyoka, C; Kankasa, C; King, R; Matoka, B; Mennecier, A; Molès, JP; Mwiya, M; Nagot, N; Van de Perre, P; Wilfred-Tonga, MM | 1 |
| Chiarabini, T; Devred, I; Kayembe, K; Lacombe, K; Lambert-Niclot, S; Meyohas, MC; Rougier, H; Shinga, BW; Valin, N | 1 |
| Bansi-Matharu, L; Cambiano, V; Cowan, F; Ehrenkranz, P; Gilks, CF; Godfrey, C; Hargreaves, JR; Lundgren, JD; Phillips, AN; Revill, P; Rodger, A; Shahmanesh, M; Sibanda, E; Sikwese, K; Smith, J | 1 |
| Cui, H; Flexner, C; Monroe, MK; Sun, M; Wang, F; Wang, H | 1 |
| Buteaue, J; Dos Santos, G; Duval, N; Francois, K; Geffrard, H; Giron, A; Inzaule, SC; Jordan, MR; Journel, I; Pierre, E; Sued, O; Van Onacker, JD | 1 |
| Alemán Belando, S; Bravo Urbieta, J | 1 |
| Espinosa, A; Horta, AM; Lázaro, A; Mendoza, I; Sánchez, L; Torralba, M | 1 |
| Antinori, S; Borghi, V; Ciccullo, A; D'Ettorre, G; De Vito, A; Di Giambenedetto, S; Ducci, F; Giacomelli, A; Giacometti, A; Lagi, F; Madeddu, G; Mussini, C; Pincino, R; Sterrantino, G; Taramasso, L | 1 |
| Cossu, MV; Gervasoni, C; Giacomelli, A; Moschese, D | 1 |
| Bellecave, P; d'Arminio Monforte, A; Egger, M; Gill, MJ; Günthard, HF; Hossmann, S; Ingle, SM; Kouyos, RD; Kusejko, K; Lessells, R; Loosli, T; Maartens, G; Mouton, J; Okhai, H; Sabin, CA; Stecher, M; Sterne, JAC; van Sighem, A | 1 |
| Alagaratnam, J; Ambrosioni, J; Bamford, A; Boesecke, C; Calmy, A; Cinque, P; Guaraldi, G; Koval, A; Levi, L; Martínez, E; Marzolini, C; Mastrangelo, A; Mendao, L; Molina, JM; Oprea, C; Rockstroh, JK; Van Bremen, K; Waalewijn, H; Welch, S; Winston, A | 1 |
| Ait-Khaled, M; Espinosa, N; Fernvik, E; Grove, R; Gulminetti, R; Hagins, D; Man, C; Sierra Madero, J; Sievers, J; Tsai, HC; van Wyk, J; Wynne, B; Zolopa, A | 1 |
| Ambrosioni, J; Berrocal, L; Blanch, J; Blanco, JL; Borjabad, B; Chivite, I; De La Mora, L; De Lazzari, E; Foncillas, A; Gonzalez-Cordon, A; Inciarte, A; Laguno, M; Llobet, R; Mallolas, J; Martinez, E; Martinez-Rebollar, M; Miro, JM; Rocabert, A; Rodriguez, A; Sempere, A; Solbes, E; Torres, B | 1 |
| Chinula, L; Corbett, AH; Cottrell, ML; Gajer, P; Haddad, LB; Hurst, S; Kourtis, AP; Lantz, AM; Nelson, JAE; Nicol, MR; Ravel, J; Tang, JH; Tegha, G | 1 |
| Cai, W; Gu, F; Guo, P; He, Y; Hu, F; Lan, Y; Li, H; Li, L; Li, Y; Lin, W; Tang, X; Zhong, H | 1 |
| Chandiwana, P; Duri, K; Gumbo, FZ; Marere, T; Mataramvura, H; Mazengera, LR; Mazhandu, AJ; Munjoma, PT | 1 |
| Beghetto, B; Borella, R; Borghi, V; Cossarizza, A; Cozzi-Lepri, A; Cuomo, G; De Biasi, S; Digaetano, M; Fidanza, L; Gibellini, L; Guaraldi, G; Mattioli, M; Menozzi, M; Milic, J; Mussini, C; Nardini, G; Neroni, A; Orlando, G; Paolini, A; Roncaglia, E; Tartaro, DL | 1 |
| Deng, Y; He, L; Li, J; Wang, Y; Wei, Y; Wen, L; Xu, R; Zhong, H | 1 |
| Bertine, M; Cabié, A; Charpentier, C; Coppée, R; Descamps, D; Ghosn, J; Joly, V; Katlama, C; Landman, R; Mazouz, F; Peytavin, G; Raffi, F; Storto, A; Yazdanpanah, Y | 1 |
| Anuradha, S; Bhrusundi, M; Dravid, AN; Kulkarni, V; Madhukarrao, KM; Morkar, DN; Nageswaramma, S; Naik, KS; Pilawan, AS; Ramapuram, JT; Raveendra, KR | 1 |
| Chen, H; Chu, Y; Feng, W; Gershkovich, P; Ji, L; Marlow, M; Qin, C; Stocks, MJ; Wong, A | 1 |
| Cao, Y; Chu, M; Huang, H; Li, M; Qin, G; Zhuang, X; Zou, M | 1 |
| Cheng, J; He, S; He, Y; Liu, H; Lu, C; Yang, T; Yao, Y; Yin, K; Zhou, R | 1 |
| Genthe, B; Ndlela, L; Olatunji, OS; Omotola, EO | 1 |
| Cortés, LL; Fernández, E; Gálvez, C; García, C; Gutiérrez, A; Hidalgo-Tenorio, C; Jesús, SE; Omar, M; Pasquau, J; Santos, J; Sequera, S; Téllez, F | 1 |
| Chen, GJ; Chen, JH; Cheng, CY; Cheng, SH; Hung, CC; Hung, TC; Wei, JL | 1 |
| Badshah, C; DeJesus, E; Goldstein, D; Hanna, GJ; Hepler, D; Hwang, C; Johnson, M; Kumar, S; Mallolas, J; Molina, JM; Pozniak, A; Rodgers, A; Sklar, P; Teal, V; Teppler, H; Wong, A | 1 |
| Chen, IT; Chen, JK; Chen, YS; Lee, SS; Sy, CL; Tsai, HC; Tseng, YT; Weng, YW; Wu, KS | 1 |
| Cento, V; Perno, CF | 1 |
| Baldin, G; Borghetti, A; Capetti, A; Ciccullo, A; Cossu, MV; Di Giambenedetto, S; Passerini, M | 1 |
| Alves Saldanha, S; Battegay, M; Buclin, T; Cavassini, M; Courlet, P; Decosterd, LA; Guidi, M; Marzolini, C; Stader, F; Stoeckle, M | 1 |
| Aboud, M; Brown, D; de Ruiter, A; Demarest, J; Gatell, JM; Henegar, C; Quercia, R; Ragone, L; St Clair, M; Underwood, M; van Wyk, J; Vannappagari, V | 1 |
| Adkison, K; Boffito, M; Cahn, P; Demarest, J; Koteff, J; Paredes, R; Quercia, R; Van Wyk, J; Vincent, T; Waters, L | 1 |
| Alnouti, Y; Bade, AN; Dyavar Shetty, BL; Edagwa, B; Gautam, N; Gendelman, HE; Herskovitz, J; Ibrahim, IM; McMillan, J; Smith, N; Soni, D; Wojtkiewicz, MS | 1 |
| Badowski, ME; Brizzi, MB; Chiampas, TD; Michienzi, SM; Patel, MC; Young, JD | 1 |
| Antinori, A; Barchi, E; Bonfanti, P; Bonora, S; Borghi, V; Cattelan, AM; D'Ettorre, G; Degli Antoni, A; Di Biagio, A; Focà, E; Francisci, D; Limonta, S; Maggiolo, F; Mussini, C; Nozza, S; Roncaglia, E; Rusconi, S; Segala, D | 1 |
| Gao, S; Gui, X; Ke, H; Xiong, Y; Yang, R | 1 |
| Boricic, I; Dimitrijevic, B; Dragovic, G; Jevtovic, D; Nikolic, K; Salemovic, D; Tomanovic, N | 1 |
| Borghi, V; Di Giambenedetto, S; Francisci, D; Franzetti, M; Giacomelli, A; Lai, A; Lepore, L; Lombardi, F; Maggiolo, F; Magnani, G; Monno, L; Paolucci, S; Pecorari, M; Rusconi, S; Vicenti, I | 1 |
| Baijnath, S; Govender, T; Kruger, HG; Mdanda, S; Naicker, T; Ntshangase, S; Singh, SD | 1 |
| Saag, MS | 1 |
| Grobler, JA; Markowitz, M | 1 |
| Duarte, F; Soares, MA | 1 |
| Bela, B; Ibrahim, F; Kusumaningrum, A; Yunihastuti, E | 1 |
| Huang, YS; Hung, CC; Ko, WC; Lee, YC; Lee, YT; Li, CW; Lin, JJ; Lin, KY; Lin, SP; Liu, CE; Tang, HJ; Wang, NC; Yang, HJ | 1 |
| Adkison, K; Bakshi, K; Dumitrescu, TP; Fu, C; Joshi, S; Peddiraju, K; Spancake, C; Tenorio, AR; Wolstenholme, A; Yu, S; Zhang, Z | 1 |
| Cutrell, A; Double, J; Gibb, DM; Gilks, C; Grosskurth, H; Hakim, J; Kityo, CM; Lou, Y; McCoig, CC; Mugyenyi, PN; Munderi, P; Musoro, G; Perger, T; Ross, LL; Shaefer, MS; Tenorio, AR; Walker, AS | 1 |
| Chadwick, EG; Correia, KF; Crowell, CS; DiPerna, A; Hazra, R; Seage, GR; Smith, R; Van Dyke, RB; Williams, PL; Yildirim, C | 1 |
| Balakasi, K; Bardon, AR; Dovel, K; Fox, M; Haambokoma, M; Hoffman, RM; Hubbard, J; Kakwesa, G; Kalua, T; Moyo, C; Pisa, P; Rosen, S; Sanne, I; Siwale, Z; Xulu, T | 1 |
| Barreto, J; Borrego, P; Gomes, P; Gonçalves, F; Moranguinho, I; Rocha, J; Taveira, N | 1 |
| Chi, BH; Fairlie, L; Farhad, M; Fenton, T; Fowler, MG; Moodley, D; Naik, S; Nakabiito, C; Stringer, JSA; Venkatesh, KK | 1 |
| Agulló, V; Fernández-González, M; García, JA; García-Abellán, J; Gutiérrez, F; Masiá, M; Padilla, S | 1 |
| Datir, R; Derache, A; Gregson, J; Gupta, RK; Perno, CF; Pillay, D; Rhee, SY; Shafer, RS | 1 |
| Baldin, G; Borghetti, A; Borghi, V; Brescini, L; Capetti, A; Celani, L; Ciccullo, A; Colafigli, M; Cossu, MV; Di Giambenedetto, S; Dusina, A; Gennari, W; Giacomelli, A; Lagi, F; Latini, A; Madeddu, G; Mussini, C; Restelli, S; Rossetti, B; Rusconi, S; Sterrantino, G; Vignale, F | 1 |
| Diani, E; Gibellini, D; Lanzafame, M; Lattuada, E; Luise, D; Vecchi, M; Vincenzi, M | 1 |
| Aboud, M; Antinori, A; Arribas, JR; Brandon, DJ; Cahn, P; Clarke, AE; Gartland, M; Girard, PM; Hung, CC; Madero, JS; Man, CY; Ortiz, R; Pappa, KA; Rockstroh, JK; Sievers, J; Smith, KY; Tenorio, AR; Underwood, M; Urbaityte, R; van Wyk, J; Wynne, B | 1 |
| Baldin, G; Capetti, A; Celani, L; Ciccullo, A; Cossu, MV; Di Giambenedetto, S; Freedman, A; Giacomelli, A; Giacometti, A; Lagi, F; Latini, A; Madeddu, G; Rossetti, B; Rusconi, S; Sterrantino, G | 1 |
| Scott, LJ | 1 |
| Fischer, A; Gumede, SB; Lalla-Edward, ST; Venter, WDF | 1 |
| Aboud, M; Ait-Khaled, M; Ajana, F; Bisshop, F; De Wit, S; Gartland, MJ; Nascimento, MC; Osiyemi, O; Pappa, KA; Portilla Sogorb, J; Routy, JP; Smith, KY; Tenorio, AR; van Wyk, J; Wang, R; Wright, J; Wyen, C; Wynne, B | 1 |
| Godfrey, C; Gulick, R; Ha, B; Kumwenda, J; Nyaku, AN; Olefsky, M; Quiñones-Mateu, ME; Sax, PE; Smith, K; Taiwo, BO; Wallis, C; Zheng, L | 1 |
| Bossolasco, S; Castagna, A; Cinque, P; Dell'Acqua, R; Galizzi, N; Galli, L; Gianotti, N; Lazzarin, A; Maillard, M; Mastrangelo, A; Muccini, C; Poli, A | 1 |
| Ajibola, G; Batlang, O; Bennett, K; Capparelli, EV; Hughes, MD; Jean-Philippe, P; Kuritzkes, DR; Lichterfeld, M; Lockman, S; Makhema, J; Maswabi, K; Mohammed, T; Moyo, S; Sakoi, M; Shapiro, RL | 1 |
| Asboe, D; Dunn, DT; Gilson, R; Hill, T; Mackie, NE; Pozniak, A; Sabin, CA; Stirrup, OT; Tostevin, A | 1 |
| Baldin, G; Borghetti, A; Ciccullo, A; Di Giambenedetto, S; Lombardi, F | 1 |
| Li, A; Li, C; Li, H; Li, W; Li, X; Xia, W | 1 |
| Lodi, VJC; Monteiro, JCMS; Pires, CAA; Rego, RM | 1 |
| Aboud, M; Baril, JG; Bogner, J; Eron, J; Falcó, V; Gartland, M; Hung, CC; Koteff, J; Maggiolo, F; Man, CY; Mills, A; Pappa, KA; Sievers, J; Slim, J; Smith, KY; Tenorio, AR; Underwood, M; Urbaityte, R; Wynne, B | 1 |
| Teshale, AB; Tsegaye, AT; Wolde, HF | 1 |
| Azran, C; Dahan, A; Elazary, R; Elinav, H; Gibori, R; Horwitz, E; Israel, S; Porat, D | 1 |
| An, M; Ding, H; Han, X; Li, S; Ouyang, J; Wang, L; Zhang, M; Zhao, B | 1 |
| DiBenedetto, A; Fackler, P; Fan, L; Iwamoto, M; Khalilieh, S; Stoch, SA; Triantafyllou, I; Vallee, MH; Yee, KL | 1 |
| Davis, CC; Hassounah, S; Heredia, A; Kashanchi, F; Le, NM; Medina-Moreno, S; Mesplede, T; Oliveira, M; Zapata, JC | 1 |
| Calvez, V; Charpentier, C; Descamps, D; Jary, A; Lê, MP; Marcelin, AG; Peytavin, G; Wirden, M | 1 |
| Baldin, G; Borghetti, A; Ciccullo, A; Di Giambenedetto, S | 1 |
| Benalycherif, A; Burdet, C; Cabie, A; Charpentier, C; Collin, G; Descamps, D; Joly, V; Katlama, C; Landman, R; Lê, MP; Mentré, F; Peytavin, G; Raffi, F; Yazdanpanah, Y | 1 |
| Belmonti, S; Borghetti, A; Cauda, R; di Giambenedetto, S; Fabbiani, M; Lombardi, F; Marchetti, S; Tamburrini, E | 1 |
| Dollfus, C; Lemoine, A; Michot, J; Tounian, P; Viala, J | 1 |
| Anderson, J; Bagkeris, E; Boffito, M; Dickinson, L; Khoo, S; Mallon, P; McClure, M; Ndoutoumou, A; Post, FA; Sabin, C; Vera, J; Wang, X; Williams, I; Winston, A | 1 |
| Amzal, B; Cressey, TR; Jarupanich, T; Jourdain, G; Kanjanavikai, P; Klinbuayaem, V; Koetsawang, S; Lallemant, M; Le Coeur, S; Ngo-Giang-Huong, N; Rawangban, B; Sabsanong, P; Siriwachirachai, T; Sripan, P; Urien, S; Wanasiri, P | 1 |
| Baldin, G; Borghetti, A; Ciccullo, A; Di Giambenedetto, S; Dusina, A; Lassandro, AP | 1 |
| Azmi, M; Baber, ZU; Badlani, S; Dodani, SK; Nasim, A; Sheerani, M | 1 |
| Abrams, EJ; Bartilol, K; Batuka, J; Gitonga, M; Imbuki, E; Kimani, M; Lahuerta, M; Odhiambo, J; Odhiambo, S; Sugandhi, N; Syowai, M; Vakil, S; Wamicwe, J | 1 |
| Blackman, AL; Devanathan, AS; Heil, EL; Pandit, NS | 1 |
| He, J; Ma, R; Sun, S; Xu, B; Zhang, Q; Zhang, Y; Zhao, CS | 1 |
| Anthony, P; Best, BM; Cahn, P; Chakhtoura, N; Chokephaibulkit, K; Cressey, TR; de Lourdes B Teixeira, M; Essack, Z; Frenkel, LM; Fuller, TL; Gouvèa, MIS; Hennessy, R; João, EC; Laimon, L; Mathiba, R; Mirochnick, M; Mmbaga, BT; Moreira, LF; Morrison, RL; Ngocho, JS; Njau, BN; Pilotto, JHS; Prommas, S; Rolon, MJ; Shapiro, DE; Siberry, GK; Violari, A; Werarak, P | 1 |
| Alejos, B; Aranguren-Rivas, P; Arribas, JR; Bermejo-Plaza, L; Bisbal, O; Cadiñanos, J; Castro, JM; De Miguel, R; Delgado, R; Dominguez-Dominguez, L; Esteban-Cantos, A; Garcia-Alvarez, M; Hernando, A; Martin-Carbonero, L; Mayoral, M; Montejano, R; Moreno, V; Pulido, F; Rial-Crestelo, D; Rubio, R; Santacreu-Guerrero, M; Stella-Ascariz, N | 1 |
| Callebaut, C; Haubrich, R; Margot, N; McNicholl, I; Ram, R | 1 |
| Ho, S; Lee, CC; Leo, YS; Lye, DCB; Ng, OT; Wong, CS; Wong, JG | 1 |
| Li, X; Qiao, S; Shen, Z; Zhang, Q; Zhou, Y | 1 |
| Acosta, R; Arribas, JR; Brainard, DM; Brinson, C; Clarke, A; Collins, SE; DeJesus, E; Flamm, JA; Gupta, SK; Hagins, D; Huang, H; Maggiolo, F; Martin, H; Martorell, C; Orkin, C; Podzamczer, D; Sax, PE; Stellbrink, HJ; Stephens, JL; Thompson, MA; Wohl, D | 1 |
| Childs-Kean, LM; Miller, S; Santevecchi, BA | 1 |
| Fida, M; Mahmood, M; Temesgen, Z | 1 |
| Amponsah-Dacosta, E; Blackard, JT; Burnett, RJ; Gededzha, MP; Kyaw, T; Lukhwareni, A; Mphahlele, MJ; Selabe, SG | 1 |
| Chen, H; Hu, XL; Huang, XS; Luo, RH; Shen, XN; Tang, CR; Xiang, SY; Zhang, CT; Zheng, YT | 1 |
| Byakika-Kibwika, P; Kalyesubula, R; Nyende, L; Sekasanvu, E | 1 |
| Arribas, JR; Del Amo, J; Díaz, A; Hernán, MA; Jarrín, I; Martínez, E; Moreno, S; Polo, R | 1 |
| Adachi, E; Hoshina, T; Ikeuchi, K; Saito, M; Yotsuyanagi, H | 1 |
| Chang, SY; Chen, YT; Chen, YW; Huang, CK; Huang, SH; Huang, WC; Hung, CC; Lin, SW; Liu, WC; Ou, ST; Sun, HY | 1 |
| Eggers, C; Hoetelmans, R; Läer, S | 1 |
| Jianwei, L; Menghua, W; Qinwei, Y; Xin, Z; Yu, Z | 1 |
| Arrieta-Aldea, I; Brown, TT; Bujosa, D; Díez-Pérez, A; García-Giralt, N; González-Mena, A; Güerri-Fernández, R; Knobel, H; Lerma-Chippirraz, E; Pineda-Moncusi, M; Soldado-Folgado, J; Trenchs-Rodríguez, M; Villar-García, J | 1 |
| Bon, I; Borderi, M; Calza, L; Colangeli, V; Granozzi, B; Re, MC; Testi, D; Viale, P | 1 |
| Cai, WP; Deng, XZ; Hu, FY; Lan, Y; Li, F; Li, LH; Nie, Y | 1 |
| Alhassan, Y; Kambugu, A; Khoo, S; Lamorde, M; Malaba, T; Myer, L; Orrell, C; Reynolds, H; Taegtmeyer, M; Twimukye, A; Waitt, C | 1 |
| Adams-Huet, B; Bedimo, RJ; Maalouf, NM; Moore-Matthews, D; Nguyen, V; Poindexter, J | 1 |
| Boye, CS; Chemin, I; Cissé, AM; Cohen, D; Diop-Ndiaye, H; Dramé, A; Kébé-Fall, K; Laborde-Balen, G; Lô, G; Mboup, S; Ndiaye, AJS; Pujol, FH; Taverne, B; Touré-Kane, C; Toyé, RM | 1 |
| Axe, D; Ivos, M; Morris, JE | 1 |
| Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y | 1 |
| Kandala, B; Vaddady, P; Yee, KL | 1 |
| Arribas, JR; Battegay, M; Béguelin, C; Bhagani, S; Cinque, P; Collins, S; Cotter, A; De Miguel, R; Guaraldi, G; Kirk, O; Kowalska, JD; Mallon, P; Marzolini, C; Molina, JM; Podlekareva, D; Rauch, A; Ryom, L; Winston, A | 1 |
| Batra, H; Chawla, H; Das, BK; Hussain, AW; Kabra, SK; Katpara, S; Kumar, S; Lodha, R; Luthra, K; Singh, R; Singh, S | 1 |
| Belmonti, S; Borghetti, A; Ciccullo, A; Di Giambenedetto, S; Fabbiani, M; Lombardi, F | 1 |
| Cipriani, M; Kahlert, CR; Vernazza, P | 1 |
| Barbini, B; Campbell, L; Gilleece, Y; Hamzah, L; Ibrahim, F; Kegg, S; Post, FA; Samarawickrama, A; Vincent, R; Waters, L | 1 |
| Åstrøm, AN; Birungi, N; Engebretsen, IMS; Fadnes, LT; Tumwine, JK | 1 |
| Betha, TP; Dravid, A; Dravid, M; Gawali, R; Kore, S; Kulkarni, M; Mahajan, U; Rathod, N; Saraf, C; Sharma, AK | 1 |
| Baeten, JM; Haberer, JE; Hodges-Mameletzis, I; Mujugira, A | 1 |
| Blennow, K; Fuchs, D; Gisslén, M; Gostner, J; Martinez, E; Navarro-Alcaraz, A; Niubo, J; Piatti, C; Podzamczer, D; Rigo-Bonnin, R; Rojas, J; Tiraboschi, JM; Zetterberg, H | 1 |
| Bae, J; Cook, RL; Delcher, C; Francois, K; Joseph, N; Pessoa-Brandão, L; Puttkammer, N; Rich, SN; Robin, E; Yaghjyan, L | 1 |
| Booth, J; Chowdary, P; Khurram, MA; Mohamed, IH; Shetty, S; Yaqoob, M | 1 |
| Alejos, B; Aranguren-Rivas, P; Arribas, JR; Bermejo-Plaza, L; Bisbal, O; Cadiñanos, J; Castro, JM; de Miguel, R; Delgado, R; Dominguez-Dominguez, L; Esteban-Cantos, A; Garcia-Alvarez, M; Hernando, A; Martin-Carbonero, L; Mayoral, M; Montejano, R; Moreno, V; Pulido, F; Rial-Crestelo, D; Rubio, R; Santacreu-Guerrero, M | 1 |
| Arora, SK; Mehta, G; Sharma, A | 1 |
| Cao, TZ; He, Y; Liu, JY; Liu, XN; Rao, M; Song, Y; Sun, LQ; Tian, YM; Wang, H; Xu, LM; Zhang, LK; Zhao, F; Zhou, Y | 1 |
| Dunn, D; Gilks, C; Gilson, R; Hakim, J; Kaleebu, P; Kityo, C; Musoro, G; Pillay, D; Price, H; Vudriko, T | 1 |
| Baldin, G; Bellino, S; Belmonti, S; Borghetti, A; Ciccullo, A; Di Giambenedetto, S; Dusina, A; Emiliozzi, A; Lamonica, S; Lombardi, F; Moschese, D; Pezzotti, P; Tamburrini, E; Visconti, E; Whalen, M | 1 |
| Andrade Villanueva, J; Arribas, JR; Belaunzaran-Zamudio, PF; Cahn, P; Camiro-Zuñiga, A; Cecchini, DM; Crabtree-Ramírez, B; Figueroa, MI; Fink, VI; Gun, A; Lama, JR; Lopardo, G; Patterson, P; Sierra Madero, J; Sued, OG | 1 |
| Hanna, GJ; Hwang, C; Kumar, S; Lin, G; Martin, E; Molina, JM; Orkin, C; Sax, PE; Squires, KE; Sussmann, O; Teppler, H | 1 |
| Bossacoma Busquets, F; Fortuny, C; Noguera-Julián, A; Sánchez, E; Villaronga Flaqué, M | 1 |
| Hamzah, L; Post, FA | 1 |
| Aweeka, F; Bradford, S; Browning, R; Coletti, A; Costello, D; Graham, B; Hughes, E; Kamthunzi, P; Kawalazira, R; Mmbaga, BT; Moye, J; Musoke, P; Nathoo, K; Norman, J; Owor, M; Purdue, L; Reding, C; Tierney, C; Whalen, ME; Wiesner, L; Ziemba, L | 1 |
| Be, G; Cattaneo, P; Gottardo, R; Lanzafame, M; Lattuada, E; Luise, D; Piacentini, D; Razzaboni, E; Vento, S | 1 |
| Basu, A; Biswas, A; Das, BK; Nischal, N; Soneja, M; Sood, R; Wig, N | 1 |
| Bangirana, P; Batting, J; Cournil, A; Engebretsen, IMS; Kankasa, C; Meda, N; Molès, JP; Mwiya, M; Nagot, N; Nalugya, J; Ndeezi, G; Peries, M; Perre, PV; Quillet, C; Singata-Madliki, M; Tassembedo, S; Tonga, MW; Tumwine, J; Tylleskär, T | 1 |
| Baldin, G; Borghi, V; Ciccullo, A; Di Giambenedetto, S; Farinacci, D; Guaraldi, G; Lassandro, AP; Mussini, C | 1 |
| Bassa, A; Hill, A; Kumar, S; Mngqibisa, R; Nelson, M; Orkin, C; Rassool, M; Rodgers, A; Teal, V; Teppler, H; Winston, A | 1 |
| Ait-Khaled, M; Ajana, F; Jones, B; Nascimento, MC; Santos, J; Scholten, S; Smith, DE; Tenorio, AR; van Wyk, J; Wohlfeiler, M; Wright, J; Wynne, B | 1 |
| Amara, A; Armero, A; Chaix, ML; Ciaffi, L; Delaugerre, C; Eymard-Duvernay, S; Koulla-Shiro, S; Mpoudi Ngolle, M; Ndour, CT; Nere, ML; Ngom Gueye, NF; Reynes, J; Sawadogo, A | 1 |
| Bickel, M; Cahn, P; Greaves, W; Johnson, M; Kumar, P; Molina, JM; Morais, C; Rizzardini, G; Sklar, P; Wan, H; Xu, ZJ | 1 |
| Brunet, L; Fusco, GP; Fusco, JS; Hsu, RK; Mounzer, K; Ragone, L; Shaefer, MS; Tenorio, AR; Vannappagari, V; Wyatt, CM | 1 |
| Aguilera-Alonso, D; Beltrán-Pavez, C; Bernardino, JI; Díez, C; Guillen, S; Gutiérrez-López, M; Holguín, Á; Jiménez de Ory, S; Mellado, MJ; Navarro, M; Prieto, L; Ramos, JT; Sainz, T; Santos, MDM | 1 |
| Bhan, AK; Chung, RT; Ghany, MG; Hinerman, AS; Jain, MK; Khalili, M; King, WC; Kleiner, DE; Lisker-Melman, M; Sterling, RK; Sulkowski, M; Wahed, AS; Wong, DK | 1 |
| Boivin, MJ; Ezeamama, AE; Giordani, B; Musoke, PM; Sikorskii, A; Tuke, R; Zalwango, SK | 1 |
| Chunda-Liyoka, C; Eymard-Duvernay, S; Fao, P; Kania, D; Kankasa, C; Mennecier, A; Moles, JP; Mosqueira, B; Mwiya, M; Nagot, N; Rutagwera, D; Sakana, L; Tassembedo, S; Tylleskär, T; Van de Perre, P; Wilfred-Tonga, MM | 1 |
| Cassidy, T; Flowers, T; Gcwabe, Z; Goemaere, E; Goliath, R; Griesel, R; Hill, A; Jackson, A; Keene, CM; Maartens, G; Meintjes, G; Ngwenya, O; Sayed, K; Schutz, C; Simmons, B; van Zyl, G; Wiesner, L; Zhao, Y | 1 |
| Amara, A; Boffito, M; Challenger, E; Dickinson, L; Egan, D; Else, L; Fox, J; Herrera, C; Khoo, S; Lee, M; Lwanga, J; Mantori, S; Penchala, SD; Shattock, R | 1 |
| Afani Saud, A; Bettacchi, C; Chahin Anania, C; Correll, T; DeJesus, E; Eves, K; Grandhi, A; Hanna, GJ; Hwang, C; Molina, JM; Olsen Klopfer, S; Robertson, MN; Sklar, P; Yazdanpanah, Y | 1 |
| Chawana, TD; Ngara, B; Nhachi, CFB; Rusakaniko, S; Zvada, S | 1 |
| Pozniak, AL; Wood, BR | 1 |
| Angelis, K; Berhe, M; Dalessandro, M; Leone, PA; Matthews, JE; Merrill, D; Nguyen, C; Ortiz, R; Ramgopal, M; Rolle, CP; Singh, T; Underwood, MR; van Wyk, J; Wurapa, A; Wynne, BR; Zolopa, AR | 1 |
| Jones, S; Loh, C; Majumdar, A; Monaghan, M; Oware, A; Roderick, M; Urankar, K | 1 |
| Bonazzetti, C; Conti, F; Formenti, T; Galli, M; Giacomelli, A; Morena, V; Oreni, L; Pagani, G; Pezzati, L; Ridolfo, AL; Rusconi, S | 1 |
| Marukutira, T; Wood, BR | 1 |
| Alejos, B; Bernal, E; de Zárraga Fernández, MA; García Yubero, C; Jarrín, I; Moreno, C; Pérez-Is, L; Ruiz-Algueró, M; Samperiz Abad, G; Suárez-García, I; Zubero, Z | 1 |
| Lázaro, A; Mendoza, I; Torralba, M | 1 |
| Capetti, A; Celani, L; Ciccullo, A; Colafigli, M; D'Ettorre, G; De Vito, A; Di Giambenedetto, S; Durante, M; Dusina, A; Fabbiani, M; Lagi, F; Mazzitelli, M; Montagnani, F; Oreni, L; Rossetti, B; Rusconi, S; Sterrantino, G | 1 |
| Lu, H; Sun, J | 1 |
| Abdulghani, N; Blanco, JL; Clotet, B; de Lazzari, E; Domingo, P; Gatell, JM; Gutierrez, MM; Martínez, E; Mateo, MG; Negredo, E; Paredes, R; Podzamczer, D; Puig, J; Ribera, E; Rojas, J; Tiraboschi, J | 1 |
| Benamor Teixeira, ML; Chakhtoura, N; Coombs, RW; Frenkel, LM; Fuller, TL; Gouvêa, MI; Hennessey, R; João, EC; Mirochnick, M; Morrison, RL; Shapiro, DE; Whitson, K | 1 |
| Abdi, B; Calvez, V; Cuzin, L; Katlama, C; Marcelin, AG; Palich, R; Pourcher, V; Sayon, S; Schneider, L; Seang, S; Soulie, C; Teyssou, E; Tubiana, R; Valantin, MA; Wirden, M | 1 |
| Baldin, G; Borghi, V; Capetti, A; Ciccullo, A; Cossu, MV; d'Ettorre, G; De Vito, A; Di Giambenedetto, S; Gennari, W; Giacomelli, A; Giacometti, A; Latini, A; Madeddu, G; Mussini, C; Rusconi, S; Sterrantino, G | 1 |
| Khamadi, SA; Lihana, RW; Mabeya, SN; Ngugi, C; Nyamache, AK | 1 |
| Collier, AC; Daar, ES; Freedberg, KA; Losina, E; Parker, RA; Rabideau, DJ; Sax, PE; Tierney, C | 1 |
| Belmonti, S; Castagna, A; Cauda, R; D'Ettorre, G; De Luca, A; Di Giambenedetto, S; Fabbiani, M; Gagliardini, R; Latini, A; Lombardi, F; Quiros-Roldan, E | 1 |
| Ashworth, A; Barker, J; Davies, A; Feddy, L; Fedor, I; Ghazi Suliman, MA; Hayes, T; Kosmidis, C; Malagon, I; Ogungbenro, K; Stirling, S; Szabo-Barnes, A | 1 |
| Aboud, M; Brennan, C; Brinson, C; Granier, C; Hopking, J; Koteff, JA; Lake, JE; Logue, K; Santiago, L; Trottier, B; Wynne, B | 1 |
| Doherty, M; Ford, N; Gray, A; Vitoria, M | 1 |
| Callard, RE; Klein, NJ; Lewis, J; Majekodunmi, AO; Malyuta, R; Thorne, C; Volokha, A | 1 |
| Badal-Faesen, S; Brown, TT; Campbell, TB; Cardoso, SW; Erlandson, KM; Fiorillo, SP; Hakim, J; Kumarasamy, N; Kumwenda, J; Lalloo, U; Riviere, C; Sanchez, J | 1 |
| Díez-Pérez, A; González-Mena, A; Guelar, A; Güerri-Fernández, R; Herrera, S; Knobel, H; Molina-Morant, D; Trenchs-Rodríguez, M; Villar-García, J | 1 |
| Calza, L; Concia, E; Cucchetto, G; Lanzafame, M; Lattuada, E; Nicolè, S | 1 |
| Conrad, F; Govender, M; Maartens, G; Manning, K; Papavarnavas, NS | 1 |
| Amani-Bosse, C; Amorissani-Folquet, M; Avit, D; Blanche, S; Coulibaly, M; Dahourou, DL; Eboua, F; Kalmogho, A; Lepage, P; Leroy, V; Malateste, K; Meda, N; N'Gbeche, S; Ouédraogo, R; Ouédraogo, S; Salamon, R; Seguin-Devaux, C; Timité-Konan, M; Toni, T; Van de Perre, P; Yonaba, C | 1 |
| Kermode-Scott, B | 1 |
| Abram, ME; Callebaut, C; Kulkarni, R; Margot, NA; Miller, MD; Porter, D; White, K; Wong, P | 1 |
| Aarons, L; Borkird, T; Capparelli, EV; Cressey, TR; Jittayanun, K; Jourdain, G; Lallemant, M; Le Coeur, S; Luvira, A; Phanomcheong, S; Puangsombat, A; Punyawudho, B; Saenjum, C; Sukrakanchana, PO; Urien, S | 1 |
| Bagenda, L; Bertagnolio, S; Easterbrook, PJ; Hakim, J; Hoppe, A; Kambugu, A; Kiconco, M; Kityo, C; Mugyenyi, P; Nankya, I; Paton, NI; Thompson, J; van Oosterhout, JJ; Walker, AS | 1 |
| Chow, SC; Yuan, M; Zheng, J | 1 |
| Concia, E; Cucchetto, G; Lanzafame, M; Lattuada, E; Nicolè, S; Rigo, F; Vento, S | 1 |
| Kurmi, M; Singh, S | 1 |
| Maartens, G; Martinson, NA; Mochan, A; Muchichwa, P; Norman, J; Rakgokong, M; Sigauke, FR; Variava, E | 1 |
| Cahn, P; Figueroa, MI; Gun, A; Patterson, P; Rolón, MJ; Sued, O | 1 |
| Aghokeng, AF; Ayangma, L; Bado, G; Ciaffi, L; Delaporte, E; Diallo, M; Eymard-Duvernay, S; Girard, PM; Gueye, NFN; Izard, S; Kane, CT; Koulla-Shiro, S; Le Moing, V; Mbouyap, PR; Ndour, CT; Peeters, M; Reynes, J; Sawadogo, AB; Zoungrana, J | 1 |
| Incardona, F; Meini, G; Mloka, D; Mugusi, F; Mugusi, S; Neogi, U; Sönnerborg, A; Svärd, J; Zazzi, M | 1 |
| Gore, ML; Jatta, A; Lemoine, M; Ndow, G; Njie, R; Sabally, S; Sadiq, F; Shimakawa, Y; Sow, A; Suso, P; Tamba, S; Thursz, MR; Touré-Kane, C | 1 |
| Arendt, V; Gilson, G; Moutschen, M; Mukeba-Tshialala, D; Mutombo-Tshingwali, M; Nachega, JB | 1 |
| Avihingsanon, A; Burger, DM; Gatechompol, S; Maek-A-Nantawat, W; Ruxrungtham, K; Sapsirisavat, V; Sophonphan, J; Thammajaruk, N; Thiansanguankul, W; Ubolyam, S | 1 |
| Balboa-Barreiro, V; Castro-Iglesias, Á; Cid-Silva, P; Fernández-Bargiela, N; Llibre, JM; Margusino-Framiñán, L; Martín-Herranz, I; Pernas-Souto, B; Poveda, E | 1 |
| Awoke, T; Birlie, B; Braekers, R; Kasim, A; Shkedy, Z | 1 |
| Cassim, H; Gray, GE; Greeff, OBW; Lazarus, E; Liberty, A; Otwombe, K; Violari, A | 1 |
| Aboud, M; Aylott, A; Belonosova, E; Buchanan, AM; Falcó, V; Hagins, DP; Man, CY; Orrell, C; Porteiro, N; Smith, KY; Vavro, C; Walmsley, S; Wynne, B | 1 |
| Aubin, C; Cawston, H; Finkielsztejn, L; Guilmet, C; Laurisse, A; Marcelin, AG; Pialoux, G | 1 |
| de Boer, M; Hovens, J; Scheper, H; van Holten, N | 1 |
| Angel, JB; Clair, MS; Clotet, B; Crauwels, H; Dorey, D; Eron, JJ; Ford, SL; Gonzalez-Garcia, J; Griffith, SK; Gutierrez, F; Lutz, T; Margolis, DA; Mrus, J; Murray, M; Patel, P; Podzamczer, D; Richmond, GJ; Sloan, L; Smith, KY; Spreen, WR; Stellbrink, HJ; Sutton, KC; Williams, PE; Yazdanpanah, Y | 1 |
| Andolina, A; Carbone, A; Castagna, A; Franzin, M; Galizzi, N; Galli, L; Gianotti, N; Lazzarin, A; Merli, M; Muccini, C; Oltolini, C; Poli, A; Spagnuolo, V; Tadini, P | 1 |
| Brar, I; Cheng, A; Custodio, J; Daar, ES; Gallant, J; Girard, PM; Lazzarin, A; Martin, H; Mills, A; Orkin, C; Podzamczer, D; Quirk, E; Rockstroh, J; Tebas, P; Wei, X; White, K; Wohl, D | 1 |
| Brambilla, D; Ceffa, S; De Luca, A; Liotta, G; Luhanga, R; Magid, NA; Mancinelli, S; Marazzi, MC; Palombi, L; Sidumo, ZJ; Zanelli, G | 1 |
| Carini, E; Castagna, A; Danise, A; Galizzi, N; Galli, L; Gianotti, N; Lazzarin, A; Muccini, C; Poli, A; Spagnuolo, V | 1 |
| Agarwal, A; Alexander, PE; Chang, Y; Foroutan, F; Guyatt, GH; Hepworth, E; Lee, Y; Lesi, O; Mah Ming, J; Merglen, A; Mir, H; Mirza, R; Siemieniuk, RA; Zeraatkar, D; Zhang, Y | 1 |
| Baker, D; Bloch, M; Brown, D; Drummond, F; Ferrer, PE; Finlayson, R; Koh, K; Orth, D; Roth, N; Urbaityte, R | 1 |
| Cotarelo, M; Macías, J; Mancebo, M; Merchante, N; Merino, D; Montes-Ramírez, ML; Pérez-Pérez, M; Pineda, JA; Pulido, F; Raffo, M; Rivero-Juárez, A; Téllez, F | 1 |
| Brenner, BG; Ibanescu, RI; Mesplède, T; Oliveira, M; Wainberg, MA; Xu, H | 1 |
| Alejos, B; Arribas, JR; Barrufet, P; Cervero, M; Curran, A; Domingo, P; Iribarren, JA; Knobel, H; Lagarde, M; Palacios, R; Payeras, A; Pérez-Valero, I; Pulido, F; Ribera, E; Rivero, A; Rodríguez-Gómez, FJ; Ryan, P; Sanz, J; Téllez, MJ; Yllescas, M | 1 |
| Alzate Angel, JC; Duque Molina, MM; García García, HI | 1 |
| Janabi, M; Kabeho, A; Mayala, H; Nicholaus, P; Nkinda, A; Pallangyo, P | 1 |
| Charpentier, C; Meftah, N; Montes, B; Perrier, M; Reynes, J | 1 |
| Bossacoma Busquets, F; Fortuny, C; Noguera-Julian, A; Sanchez, E | 1 |
| Cottrell, ML; Kashuba, ADM; Prince, H; Schauer, AP; Sykes, C | 1 |
| Akunuri, S; Kallampallil, J; Leong, S; Maweni, R | 1 |
| Aroke, D; Bechem, NN; Dimala, CA; Kadia, BM | 1 |
| Acosta, E; Bezins, B; Godfrey, C; Gulick, RM; Haas, D; Nyaku, A; Sax, PE; Sha, B; Smith, KY; Stefanescu, A; Taiwo, BO; Van Dam, C; Wallis, CL; Zheng, L | 1 |
| Bernheimer, J; Fairlie, L; Fick, C; Kuhn, L; Sipambo, N | 1 |
| Acosta, EP; Benson, CA; Berzins, B; Colasanti, J; Fichtenbaum, CJ; Koletar, SL; Li, JZ; Marconi, VC; Moser, CB; Nyaku, AN; Sax, PE; Taiwo, BO; Wilkin, T | 1 |
| Ahmadi, NE; Ahsani-Nasab, S; Bayanolhagh, S; Esmaeilzadeh, A; Lolaie, M; Moallemi, S; Mohraz, M; Narouei, A; Sadeghi, L; SeyedAlinaghi, S; Tabatabai, RA | 1 |
| Domínguez-Castro, M; Figueroa-Damián, R; Flores-García, Z; Hernández-Pineda, J; Loaiza-Flores, G; López-Martínez, M; Plazola-Camacho, N; Ramírez-Ramírez, A; Rodríguez-Delgado, RG; Sánchez-Serrano, E | 1 |
| Campbell, S; Gill, MJ; Gill, VC; Krentz, HB | 1 |
| Dalzero, S; Degli Antoni, A; Floridia, M; Guaraldi, G; Liuzzi, G; Masuelli, G; Personeni, C; Pinnetti, C; Ravizza, M; Sansone, M; Spinillo, A; Tamburrini, E; Tassis, B | 1 |
| Boswell, R; Foisy, MM; Hughes, CA | 1 |
| Bigoloni, A; Carini, E; Castagna, A; Galizzi, N; Galli, L; Gianotti, N; Lazzarin, A; Mancusi, D; Nozza, S; Poli, A; Tambussi, G; Termini, R | 1 |
| Awodele, O; Oshikoya, KA; Popoola, TD | 1 |
| Castelnuovo, B; Gonza, P; Kambugu, A; Kiragga, AN; Mbabazi, O; Mubiru, F; Musomba, R; Ratanshi, RP | 1 |
| Chetty, T; Coutsoudis, A; Thorne, C | 1 |
| Koteff, J; Kuritzkes, D; McCoig, C; Moore, K; Perno, CF; Quercia, R; St Clair, M | 1 |
| Castelli, F; Cheng, A; Cox, S; Crofoot, G; Das, M; DeJesus, E; Di Perri, G; Estrada, V; Mallon, PWG; Peyrani, P; Podzamczer, D; Post, FA; Raffi, F; Rhee, MS; Ruane, P; Winston, A; Yan, M | 1 |
| Bourrel, R; Lapeyre-Mestre, M; Montastruc, JL; Rwagitinywa, J; Sommet, A | 1 |
| Havenith, TR; Posthouwer, D; van Dam, PM; van Geffen, MW | 1 |
| Collier, AC; Ho, RJY; Kinman, LM; Koehn, J; Kraft, JC; Lane, S; Lee, W; McConnachie, LA | 1 |
| Blanco, JL; Casadella, M; Clotet, B; de Lazzari, E; Gatell, JM; Mallolas, J; Martinez, E; Negredo, E; Paredes, R; Rojas, J | 1 |
| Antinori, A; Castagna, A; Cauda, R; Chinello, P; Ciccarelli, N; Colafigli, M; D'Avino, A; d'Ettorre, G; De Luca, A; Del Pin, B; Di Giambenedetto, S; Fabbiani, M; Focà, E; Francisci, D; Gagliardini, R; Grima, P; Latini, A; Lombardi, F; Madeddu, G; Orofino, G; Quiros Roldan, E; Rusconi, S | 1 |
| Barr, E; Chadwick, EG; Currier, JS; Hernandez-Diaz, S; Hoffman, RM; Huo, Y; Patel, K; Rough, K; Seage, GR; Shapiro, DE; Williams, PL | 1 |
| Amiel, C; Chaix, ML; Charpentier, C; Delaugerre, C; Descamps, D; Dufayard, J; Flandre, P; Grude, M; Guinard, J; Lambert-Niclot, S; Le Guillou-Guillemette, H; Maillard, A; Marcelin, AG; Mirand, A; Montes, B; Morand-Joubert, L; Mourez, T; Reigadas, S; Rodallec, A; Vallet, S | 1 |
| Bonolo, PF; Ceccato, MDGB; Costa, JO; Dos Santos, H; Mendes, JC; Reis, AMM; Silveira, MR | 1 |
| Baldin, G; Belmonti, S; Borghetti, A; Castagna, A; Cauda, R; Ciccullo, A; De Luca, A; Di Giambenedetto, S; Latini, A; Lombardi, F; Quiros-Roldan, E | 1 |
| Garner, O; Iardino, A; Lorusso, G; Lotta, F | 1 |
| Bayisa, G; Bokore, A; Korme, B | 1 |
| Crespo, M; Esteban, H; Gutiérrez, F; Hernández-Quero, J; Iribarren, JA; Mariño, A; Pasquau, J; Pérez-Molina, JA; Pérez-Valero, I; Rivero, A; Rubio, R; Santos, J; Sanz, J; Terrón, A | 1 |
| Bachiller, P; Barrufet, P; Boix, V; Cabello, A; Cervero, M; Gómez, C; Matarranz, M; Montejano, R; Ryan, P; Samperiz, G; Santos, I; Sanz, J; Sepúlveda, MA; Solís, J; Troya, J; Valencia, E; Vera, F; Yllescas, M | 1 |
| Antony, J; Ashoor, HM; Blondal, E; Finkelstein, Y; Ghassemi, M; Gough, K; Hemmelgarn, BR; Hutton, B; Ivory, JD; Khan, PA; Lillie, E; Straus, SE; Tricco, AC; Vafaei, A; Veroniki, AA | 1 |
| Andreatta, K; Brar, I; Brinson, C; Cheng, A; Custodio, J; Liu, H; López-Cortés, L; Martin, H; Mills, A; Molina, JM; Podzamczer, D; Quirk, E; Ruane, P; Stellbrink, HJ; Ward, D | 1 |
| Dubrocq, G; Rakhmanina, N | 1 |
| Iavarone, M; Maggioni, M; Merli, M; Orcese, C; Puoti, M; Rossotti, R | 1 |
| Appiah, LT; Beloukas, A; Chadwick, D; Geretti, AM; Phillips, RO; Ruggiero, A; Sarfo, FS; Smith, C; Stockdale, AJ; Villa, G | 1 |
| Cochrane, S; Daniel, J; Forsyth, S; Smit, E | 1 |
| Alejos, B; Arribas, JR; Coscia, C; De Luca, A; Di Giambenedetto, S; Gatell, JM; Moreno, S; Perez-Molina, JA; Pitch, J; Pulido, F; Ribera, E; Zamora, J | 1 |
| Abrams, EJ; Arpadi, S; Mogashoa, M; Mutiti, A; Nxele, M; Pepeta, L; Rivadeneira, ED; Sogaula, N; Teasdale, CA; Wang, C; Yuengling, KA | 1 |
| Desai, M; Dinh, C; Gonzalez, R; Haaland, RE; Heneine, W; Katana, A; Martin, A; Menendez, C; Otieno, K; Slutsker, L; Williamson, J | 1 |
| Baillargeon, G; Diaz, M; Harzke, AJ; Koranek, A; Sandmann, R; Tong, E; Zepeda, S | 1 |
| Jiang, X; Luo, A; Ren, H | 1 |
| Chmelík, V; Chrdle, A; Jerhotová, Z; Linka, M; Vacík, M | 1 |
| Espinosa, N; Fernandez-Magdaleno, T; García, C; Gutierrez-Valencia, A; López-Cortés, LF; Milanés-Guisado, Y; Pasquau, J; Viciana, P | 1 |
| Baldin, G; Capetti, A; Ciccullo, A; Colafigli, M; Cossu, MV; d'Ettorre, G; De Luca, A; Di Giambenedetto, S; Giacomelli, A; Lagi, F; Modica, S; Restelli, S; Rusconi, S; Sterrantino, G | 1 |
| Bukin, EK; Chounta, V; Garib, SA; Holbrook, T; Piercy, J; Punekar, YS; Tremblay, G | 1 |
| Edelstein, H; Maruff, P; Robertson, K; Ross, LL; Shaefer, MS; Small, CB; Wohl, D | 1 |
| Akakpo, AS; Bassowa, A; Dapam, AN; Kombaté, K; Laouali, AY; Mahamadou, G; Mensah, E; Mouhari-Toure, A; Pitché, P; Saka, B; Teclessou, JN | 1 |
| De la Torre, J; Del Arco, A; García de Lomas, JM; García-Alegría, J; Márquez, E; Nieto, M; Olalla, J; Pérez-Stachowski, J; Prada, JL; Tortajada, B | 2 |
| Bernheimer, J; Davies, MA; Eley, B; Fairlie, L; Patten, G; Rabie, H; Sawry, S; Technau, K | 1 |
| Carelli, M; Chiesi, S; Diani, E; Gibellini, D; Lanzafame, M; Lattuada, E; Nicole, S; Piacentini, D; Rizzardo, S; Vento, S | 1 |
| Adeyeye, CM; Ali, I; Aliu, R; Awodele, O; Oni, Y | 1 |
| Deeks, ED | 1 |
| Mugusi, S; Ngaimisi, E; Sasi, P; Sungi, SS; Ulenga, N | 1 |
| Alfredo, C; Auld, A; Bhatt, N; Bila, D; Buck, WC; Cossa, L; DeVos, J; Houston, J; Jani, I; Jobarteh, K; Macassa, E; Sabatier, J; Sousa, A; Vaz, P; Yang, C | 1 |
| Chen, QY; Fang, ZL; Harrison, TJ; Hu, LP; Jia, HH; Li, KW; Liang, SJ; Ren, CC; Wang, C; Wang, XY; Yang, QL | 1 |
| Badowski, ME; Michienzi, SM; Schriever, CA | 1 |
| Benson, CA; Berzins, B; Deng, Q; Fichtenbaum, CJ; Gianella, S; Marconi, VC; Moser, C; Oliveira, MF; Sax, P; Taiwo, BO; Vargas, M; Wilkin, T | 1 |
| Eberle, J; Kroidl, A | 1 |
| Aboud, M; Antinori, A; Arribas, JR; Cahn, P; Clarke, AE; Currie, A; Fettiplace, A; Gartland, M; Girard, PM; Hung, CC; Madero, JS; Man, C; Ortiz, R; Pappa, K; Rockstroh, JK; Sievers, J; Smith, K; Tenorio, AR; Underwood, M; Wynne, B | 1 |
| Naing, C; Poovorawan, Y; Tong, KS | 1 |
| Cabello, A; Cañamares, I; Cuevas, G; Matarranz, M; Montejano, R; Ryan, P; Solís, J; Troya, J; Walther, LÁ | 1 |
| Baptiste, SL; Etya'ale, HM; Taro, TB | 1 |
| Amri, I; Argoud, AL; Benalycherif, A; Burdet, C; Cabié, A; Charpentier, C; Descamps, D; Joly, V; Katlama, C; Landman, R; Mentre, F; Peytavin, G; Vigan, M; Yazdanpanah, Y; Yeni, P | 1 |
| Bell, TG; Kramvis, A; Singh, L; Yousif, M | 1 |
| Bärnighausen, TW; Geldsetzer, P; Gómez-Olivé, FX; Harling, G; Kahn, K; Manne-Goehler, J; Montana, L; Rohr, J; Siedner, M; Tollman, S; Wagner, R; Wiesner, L | 1 |
| de Oliveira, MA; Franco, JB; Martins E Martins, F; Maureira Pena, LJ; Ortega, KL | 1 |
| Baldin, G; Belmonti, S; Borghetti, A; Ciccullo, A; D'Avino, A; Di Giambenedetto, S; Dusina, A; Emiliozzi, A; Gagliardini, R; Lassandro, AP; Lombardi, F; Moschese, D | 1 |
| Kan, W; Leng, X; Liao, L; Liu, P; Ruan, Y; Shao, Y; Wang, J; Xing, H; Xu, W; Yan, J; You, Y; Zuo, Z | 1 |
| Chasela, CS; Corbett, A; Davis, NL; Hudgens, MG; Jamieson, DJ; Kaullen, J; Kourtis, AP; Miller, WC; Nelson, JAE; Sichali, D | 1 |
| Allavena, C; André-Garnier, E; Billaud, E; Grégoire, M; Guimard, T; Hall, N; Jovelin, T; Khatchatourian, L; Le Guen, L; Morrier, M; Perré, P; Raffi, F; Reliquet, V; Rodallec, A; Volteau, C | 1 |
| Rijnders, BJA; Rokx, C | 1 |
| Allavena, C; André, M; Avettand-Fènoël, V; Bernard, L; Billaud, E; Esnault, JL; Hocqueloux, L; Le Moal, G; Parienti, JJ; Prazuck, T; Raffi, F; Rey, D; Roncato-Saberan, M; Sunder, S; Valéry, A | 1 |
| Fujiwara, T; Kawauchi-Miki, S; Miki, S; Seki, T; Yoshinaga, T | 1 |
| Dong, X; Li, J; Liu, J; Xu, Y; Yang, B; Yang, C; Zhang, M | 1 |
| Arendt, G; Orhan, E; Schlonies, S; Stüve, O | 1 |
| Heldwein, S; Jaeger, H; Noe, S; Page, M; Wolf, E | 1 |
| Baldin, G; Belmonti, S; Borghetti, A; Ciccullo, A; De Luca, A; Di Giambenedetto, S; Emiliozzi, A; Gagliardini, R; Lamonica, S; Lombardi, F; Montagnani, F; Moschese, D; Visconti, E | 1 |
| Bai, F; Battisti, A; Bavaro, DF; Bezenchek, A; De Luca, A; Di Carlo, D; Di Giambenedetto, S; Gagliardini, R; Giachè, S; Incardona, F; Lo Caputo, S; Pecorari, M; Salomoni, E; Zazzi, M; Zuccalà, P | 1 |
| Acosta, EP; Berzins, B; Godfrey, C; Gulick, RM; Haas, DW; Nyaku, AN; Olefsky, M; Sax, PE; Sha, BE; Smith, KY; Taiwo, BO; Van Dam, CN; Wallis, CL; Zheng, L | 1 |
| Capetti, A; Cattaneo, D; Rizzardini, G | 1 |
| Casado, JL; Fontecha, M; Monsalvo, M; Moreno, A; Rodriguez-Sagrado, MA; Vivancos, MJ | 1 |
| Cha, A; Fischetti, B; Shah, K; Taft, DR | 1 |
| Acosta, RK; Chang, S; Garner, W; Lutz, J; Majeed, S; Martin, H; Martin, R; Quirk, E; SenGupta, D; Wei, X; White, KL; Willkom, M | 1 |
| Chendi, BH; Eyoh, A; Ikomey, GM; Jacobs, GB; Lyonga, E; Mesembe, M; Okomo Assoumou, MC; Yekwa, EL | 1 |
| Powis, KM; Siberry, GK | 1 |
| Blanche, S; Engebretsen, I; Kankasa, C; Meda, N; Mwiya, M; Nagot, N; Peries, M; Singata-Madliki, M; Tumwine, JK; Tylleskär, T; Van de Perre, P | 1 |
| Huang, JP; Huang, WH; Luo, SD; Luo, XL; Mo, LD; Ni, ZY; Su, GS; Su, HZ; Wu, JY | 1 |
| Avihingsanon, A; Boettiger, D; Chaiwarith, R; Kantipong, P; Kiertiburanakul, S; Pongpech, N; Ross, J | 1 |
| Abraham, OC; Barnabas, R; Chacko, G; Kannangai, R; Karthik, R; Manesh, A; Mani, S; Varghese, GM | 1 |
| Bragantini, D; Calza, L; Lanzafame, M; Lattuada, E; Nicolè, S; Rizzardo, S; Tacconelli, E | 1 |
| Casado-Castillo, F; Kelly, P; Saad, M | 1 |
| Aboud, M; Bedimo, R; Berzins, B; Gillman, J; Gulick, R; Janulis, P; Smith, K; Taiwo, B; Wallis, CL | 1 |
| Alves Saldanha, S; Brown, JA; Calmy, A; Cavassini, M; Courlet, P; Csajka, C; Decosterd, LA; Labhardt, ND; Marzolini, C; Stoeckle, M | 1 |
| Acosta, R; Antinori, A; Baumgarten, A; Brainard, D; Brinson, C; Clarke, A; Collins, SE; Hagins, D; Martin, H; Ramgopal, MN; Thompson, MA; Wei, X; Wohl, DA; Yazdanpanah, Y | 1 |
| Barber, TJ | 1 |
| Halquist, MS; Hauser, KF; Jones, AM; Kashuba, ADM; Kim, WK; Knapp, PE; Leibrand, CR; Masuda, QN; McRae, M; Paris, JJ | 1 |
| DeJesus, E; Hanna, G; Hwang, C; Kumar, S; Lombaard, J; Martin, E; Molina, JM; Orkin, C; Rodgers, A | 1 |
| Aizire, J; Boivin, MJ; Familiar-Lopez, I; Fowler, MG; Kawalazira, R; Kuteesa, A; Maliwichi-Senganimalunje, L; Mallewa, M; Mutebe, A; Namukooli, JL; Nyakato, M; Ogwang, LW; Ruiseñor-Escudero, H; Sikorskii, A; Taha, TE | 1 |
| Fida, M; Rizza, SA; Temesgen, Z | 1 |
| Beksinska, M; Brown, TT; Eneh, P; Fowler, MG; Isingel, E; Kabwigu, S; Kaiser, T; Kiweewa Matovu, F; Nakalega, R; Nicol, MR; Staley, C; Sykes, C | 1 |
| Archary, M; Bobat, R; Hennig, S; LaRussa, P; Mcllleron, H; Sibaya, T; Wiesner, L | 1 |
| Chang, SY; Chen, GJ; Cheng, A; Chuang, YC; Huang, SH; Huang, YC; Huang, YS; Hung, CC; Lin, KY; Liu, WC; Su, YC; Sun, HY | 1 |
| Ferrante, S; Parks, DC; Punekar, Y; Radford, M | 1 |
| Antinori, A; Baldin, G; Belmonti, S; Borghetti, A; Cauda, R; Ciccullo, A; Cingolani, A; Di Giambenedetto, S; Emiliozzi, A; Lombardi, F; Moschese, D; Speziale, D | 1 |
| Blanch, J; Blanco, JL; de Lazzari, E; Gonzalez-Cordon, A; Inciarte, A; Laguno, M; Lonca, M; Mallolas, J; Martinez, E; Martinez-Rebollar, M; Plana, M; Rodriguez, A; Rojas, J; Sanchez-Palomino, S; Tricas, A | 1 |
| Gompels, M; Johnston, S; Nicholls, J; Tan, M | 1 |
| Boyer, S; Calmy, A; Delaporte, E; Eymard-Duvernay, S; Kouanfack, C; Leroy, S; Mpoudi-Etame, M; Omgba Bassega, P; Peeters, M | 1 |
| Avettand-Fènoël, V; De Dieuleveult, B; Gardiennet, E; Gubavu, C; Guinard, J; Hocqueloux, L; Lefeuvre, S; Lopez, P; Mille, C; Prazuck, T; Rouzioux, C; Sève, A | 1 |
| Katzenstein, D; Kouamou, V; Makadzange, AT; Manasa, J; McGregor, AM; Ndhlovu, CE | 1 |
| Anugulruengkitt, S; Chokephaibulkit, K; Cressey, TR; Jantarabenjakul, W; Ounchanum, P; Pancharoen, C; Punnahitanon, S; Puthanakit, T; Sophonphan, J; Srirompotong, U; Suntarattiwong, P | 1 |
| Chagomerana, MB; DiPrete, BL; Harrington, BJ; Hosseinipour, MC; Jumbe, AN; Limarzi, L; Ngongondo, M; Wallie, SD | 1 |
| Adebisi, SA; Adedeji, NO; Adedeji, TA | 1 |
| Bayonne Kombo, ES; Gathse, A | 1 |
| Agarwal, K; Bruce, M; Byrne, R; Carey, I; Childs, K; Joshi, D; Taylor, C | 1 |
| Lungu, M; Mathews, T; Tapsfield, J; van Oosterhout, JJ | 1 |
| Gupta, S; Healy, SA; Melvin, AJ | 1 |
| Gatanaga, H; Hayashida, T; Oka, S; Tanuma, J | 1 |
| de la Torre, J; del Arco, A; Olalla, J; Pombo, M; Prada, JL; Urdiales, D | 1 |
| Anderson, PL; Erlandson, KM; Schoen, JC | 1 |
| Cook, L; Day, SL; Graham, SM; Jerome, KR; Kim, HN; Mandaliya, KN; Masese, LN; McClelland, RS; Odem-Davis, K; Scott, J | 1 |
| Alobwede, SM; Kongnyuy, EJ; Shey, MS; Wiysonge, CS | 1 |
| Endo, T; Fujii, T; Gatanaga, H; Higasa, S; Horiba, M; Ishisaka, M; Kaneda, S; Kikuchi, Y; Koibuchi, T; Komatsu, H; Matsushita, S; Mitsuya, H; Naito, T; Nishijima, T; Oka, S; Tachikawa, N; Takada, K; Takano, M; Tanabe, Y; Tateyama, M; Uchiumi, H; Ueda, M; Yamamoto, M; Yokomaku, Y; Yoshida, M | 1 |
| Aboím, L; Borges, A; Castelo-Branco, C; Guerreiro, C; Mendes, N | 1 |
| Choo, HW; Davis, J; Fang, J; Hansson, AG; Langdon, G; Layton, G; Tawadrous, M; Vourvahis, M | 1 |
| Arnett, DK; Bagchi, S; Chi, BH; Heimburger, DC; Kabagambe, EK; Kiage, JN; Koethe, JR; Nyirenda, CK; Wellons, MF | 1 |
| Angeletti, C; Antonucci, G; Armignacco, O; Cassola, G; De Stefano, G; Girardi, E; Grossi, P; Mazzotta, F; Orani, A; Pagano, G; Petrosillo, N; Puoti, M; Sagnelli, C; Sagnelli, E | 1 |
| Bedogni, G; Cococcioni, L; Fabiano, V; Giacomet, V; Mora, S; Stucchi, S; Viganò, A; Zuccotti, GV | 1 |
| Holmes, D | 1 |
| Perelson, AS; Zhang, J | 1 |
| Aguilar, A; De La Torre, J; Del Arco, A; García-Alegría, J; Olalla, J; Pombo, M; Prada, JL; Ruiz-Mateas, F; Urdiales, D | 1 |
| Delaporte, E; Desclaux, A; Koita Fall, MB; Ndoye, I; Taverne, B | 1 |
| Antinori, A; Bansi, L; Boumis, E; Callegaro, A; Ceccherini-Silberstein, F; Dunn, D; Fearnhill, E; Forbici, F; Francisci, D; Maggiolo, F; Mussini, C; Nicastri, E; Palamara, G; Perno, CF; Sabin, C; Santoro, MM; Zazzi, M; Zoncada, A | 1 |
| Chamnanchanunt, S; Chierakul, W; Desakorn, V; Kiertiburanakul, S; Kyaw, NL; Manosuthi, W; Pitisuttithum, P; Sungkanuparph, S; Thanachartwet, V | 1 |
| Blanche, S; Bouazza, N; Diagbouga, S; Hien, H; Hirt, D; Msellati, P; Nacro, B; Ouiminga, A; Rouet, F; Tréluyer, JM; Urien, S; Van de Perre, P; Zoure, E | 1 |
| Abgrall, S; Antinori, A; Cavassini, M; Costagliola, D; Crane, HM; Gill, MJ; Gomez Sirvent, JL; Guest, JL; Ingle, SM; Manzardo, C; May, MT; Mercie, P; Mugavero, MJ; Phillips, A; Reekie, J; Reiss, P; Saag, MS; Samji, H; Stephan, C; Sterling, TR; Sterne, JA; Tate, J; Wasmuth, JC | 1 |
| Gatanaga, H; Kikuchi, Y; Komatsu, H; Nishijima, T; Oka, S; Tanuma, J; Teruya, K; Tsukada, K | 1 |
| Boonsuk, S; Butchon, R; Chokephaibulkit, K; Kullert, N; Kulpeng, W; Phanuphak, N; Pilasant, S; Tantivess, S; Teerawattananon, Y; Tosanguan, K; Voramongkol, N; Werayingyong, P | 1 |
| Bosco, O; Cruciani, M; Malena, M; Mengoli, C; Parisi, SG; Serpelloni, G | 1 |
| DeJesus, E; Edelstein, H; Felizarta, F; Ha, B; Hao, R; Huhn, G; Kumar, P; Pappa, K; Ross, L; Sloan, L; Small, CB; Stancil, B | 1 |
| Blanche, S; Chaix, ML; Frange, P | 2 |
| Massawe, A; Mghamba, FW; Minzi, OM; Sasi, P | 1 |
| de Pineda, AT; Escobar, G; Holguín, Á; Martín, L; Nieto, AI; Quezada, AY; Ruiz, LE; Yebra, G | 1 |
| Bekker, LG; Gupta-Wright, A; Lawn, SD; Wood, R | 1 |
| An, JH; Jang, HC; Jang, MO; Jung, SI; Kang, SJ; Kim, J; Kim, SE; Park, KH | 1 |
| Cauda, R; Digiambenedetto, S; Fabbiani, M; Fortuna, S; Lisi, L; Navarra, P; Ragazzoni, E | 1 |
| Botes, ME; Hamers, RL; Hoepelman, AI; Ive, P; Rinke de Wit, TF; Sigaloff, KC; Siwale, M; Stevens, WS; Wallis, CL; Zaaijer, HL | 1 |
| Arribas, JR; Compston, J; Domingo, P; Gartland, M; Granier, C; Moyle, GJ; Orkin, C; Pearce, H; Sedani, S; Stellbrink, HJ | 1 |
| Barreiro, P; Poveda, E; Soriano, V; Vispo, E | 1 |
| Chang, SC; Chang, SY; Chuang, YC; Hung, CC; Sheng, WH; Sun, HY; Tsai, MS | 1 |
| Berhanu, R; Fox, MP; Long, L; Maskew, M; Sanne, I; Shearer, K | 1 |
| Ahmed-Jushuf, I; Arumainayagam, J; Carlin, EM; Chandramani, S; Das, S; Ghanem, M; Kumari, B; Pammi, M; Riddell, L | 1 |
| Ampofo, WK; Barnor, JS; Brandful, JA; Ibe, S; Ishikawa, K; Nii-Trebi, NI; Ofori, SB; Sugiura, W; Yamaoka, S | 1 |
| Gedefaw, L; Sahlemariam, Z; Yemane, T; Yilma, D | 1 |
| Crowther, NJ; Dickens, C; Dix-Peek, T; Duarte, R; Evans, D; Menezes, CN; Prinsloo, A; Raal, F; Rassool, M; Sanne, I; Van Amsterdam, D | 1 |
| Bertrand, J; Blanc, FX; Borand, L; Chea, P; Chou, M; Mentré, F; Nay, KH; Taburet, AM; Verstuyft, C | 1 |
| de Oliveira, T; Lessells, RJ; Manasa, J; McGrath, N; Naidu, KK; Newell, ML; Skingsley, A | 1 |
| Blanco, J | 1 |
| Bansi-Matharu, L; Bibby, D; Bulteel, N; Churchill, D; Dunn, D; Hill, T; Nelson, M; Sabin, C | 1 |
| Albrecht, H; Almond, S; Baril, JG; Belonosova, E; Brennan, C; Domingo, P; Gatell, JM; Jaeger, H; Min, S; Quiros-Roldan, E; Raffi, F | 1 |
| Adkison, K; Burger, D; Danhof, M; Della Pasqua, O; Jacqz-Aigrain, E; Piana, C; Zhao, W | 2 |
| Alix, AF; Caby, F; Calin, R; Clavel, CO; Dommergues, M; Dommergues, MA; Gliga, SS; Katlama, C; Marcelin, AG; Quetin, F; Schneider, L; Stitou, H; Tubiana, R; Valantin, MA | 1 |
| Llibre, JM; Ramiro, MA | 1 |
| Bentaleb, H; Cisse, VM; Dia Badiane, NM; Dieng, AB; Diop, BM; Diop, SA; Diouf, A; Fortes Déguénonvo, L; Ka, D; Lakhe, NA; Leye, MM; Manga, MN; Ndour, CT; Seydi, M; Soumaré, M; Sow, PS | 1 |
| Aoki, M; Desai, DV; Kodama, EN; Maeda, K; Mitsuya, H; Nakata, H | 1 |
| Antela, A; Clumeck, N; Duiculescu, D; Eberhard, A; Granier, C; Gutiérrez, F; Hocqueloux, L; Maggiolo, F; Min, S; Nichols, G; Pappa, K; Sandkovsky, U; Walmsley, SL; Wynne, B | 1 |
| Gisolf, EH; Langebeek, N; Legrand, J; Nieuwkerk, PT; Reiss, P; Richter, C; Sprangers, MA; Sprenger, HG | 1 |
| Chappuy, H; Diagbouga, S; Drabo, A; Hien, A; Hien, H; Meda, N; Msellati, P; Nacro, B; Nicolas, J; Ouiminga, A; Rouet, F; Somé, J; Tamboura, H; Van de Perre, P; Yaméogo, S; Zoure, E | 1 |
| Doherty, M; Ford, N; Gray, A; Hill, A; Mills, EJ; Shubber, Z; Vitoria, M | 1 |
| Lu, H; Qi, T; Shen, Y; Wang, J; Wang, Z | 1 |
| Doumbo, OK; Guirou, EA; Hendrix, CW; Kayentao, K; Nyunt, MM; Parsons, TL; Plowe, CV; Venkatesan, M | 1 |
| Adedeji, WA; Adewole, IF; Akinola, IT; Akinyinka, OO; Aweeka, FT; Darin, KM; Fehintola, FA; Lindegardh, N; Ma, Q; Morse, GD; Murphy, RL; Ojengbede, O; Parikh, S; Scarsi, KK; Taiwo, B; Tarning, J | 1 |
| Anino, E; Choge, JK; Khayeka-Wandabwa, C; Kweka, EJ; Ngemu, EK; Oyoo-Okoth, E | 1 |
| Ananworanich, J; Bowonwattanuwong, C; Bunupuradah, T; Hirschel, B; Jirajariyavej, S; Klinbuayaem, V; Mahanontharit, A; Munsakul, W; Ruxrungtham, K; Sophonphan, J | 1 |
| Chamnanphon, M; Jantararoungtong, T; Koomdee, N; Manosuthi, W; Prommas, S; Puangpetch, A; Santon, S; Sukasem, C | 1 |
| Bharti, A; Chakravarty, J; Goel, R; Meena, LP; Rai, M; Sundar, S; Tiwary, NK | 1 |
| Aklillu, E; Gustafsson, LL; Kuteesa, RB; Mukonzo, JK; Nanzigu, S; Ogwal-Okeng, J; Owen, JS; Ross, C; Sewankambo, N; Thabane, L | 1 |
| Ding, P; He, C; He, J; Hsi, JH; Liao, L; Ling, H; Liu, Y; Ruan, Y; Shao, Y; Tong, Y; Wang, J; Wang, X; Xing, H; Xu, X; Zhou, Q; Zou, X | 1 |
| Choun, K; De Weggheleire, A; Lynen, L; Phirum, L; Thai, S; van Griensven, J | 1 |
| Kitaichi, T; Kitazono, Y; Kurita, T; Miura, T; Nagao, T | 1 |
| Amorosa, VK; Chang, KM; De La Torre, P; Frank, I; Gross, R; Hafkin, JS; Kostman, JR; Lo Re, V; Localio, AR; Mounzer, K; Osborn, MK; Stern, JJ | 1 |
| Doran, C; Ngo, AD; Shakeshaft, A; Tran, DA; Wilson, DP; Zhang, L | 1 |
| Dunn, DT; Gibb, DM; Gilks, CF; Goodall, RL; Kaleebu, P; Kasirye, R; Kityo, C; Mambule, I; Mugyenyi, P; Pillay, D; Walker, AS | 1 |
| Amin, J; Cooper, DA; Cordery, DV; Emery, S; Haskelberg, H; Kelleher, AD | 1 |
| Abraham, T; Saad, N; Wu, G | 1 |
| Aberg, JA; Hollabaugh, K; Kang, M; Koletar, SL; Pham, V; Smurzynski, M; Wu, K | 1 |
| Adams, EJ; Ahmed, I; Carlin, E; Sadique, Z; Taylor, R | 1 |
| Chimbwandira, FM; Chirwa, Z; Crampin, AC; Dasgupta, AN; Glynn, JR; Jahn, A; Katundu, C; Kayange, M; Koole, O; Price, AJ; Saul, JL; Zaba, B | 1 |
| Abongomera, G; Arach, B; Asiimwe, AR; Cook, A; Gibb, DM; Kabamba, D; Kayiwa, J; Kekitiinwa, A; Kenny, J; Kityo, C; Klein, N; Komunyena, J; Mirembe, G; Mulenga, V; Musiime, V; Nansubuga, C; Walker, SA; Wavamunno, P; Zangata, D | 1 |
| Allworth, A; Amin, J; Carr, A; Ebeling, PR; Emery, S; Haskelberg, H; Pocock, N | 1 |
| Crowe, SM; David, M; Gare, J; Hearps, AC; Imara, U; Kaima, P; Kelly-Hanku, A; Kombati, Z; Ryan, CE; Siba, PM; Timbi, D | 1 |
| Arnold, V; Barcellos, NT; Brites, C; Chêne, G; De Castro, N; Delaugerre, C; Fagard, C; Grinsztejn, B; Madruga, JV; Molina, JM; Morgado, M; Patey, O; Pilotto, JH; Santini-Oliveira, M; Santos, BR; Veloso, VG; Vorsatz, C | 1 |
| Abbas, SQ; Abro, AG; Baig-Ansari, N; Kazi, MA; Mir, F; Qamar, FN; Rizvi, A; Zaidi, AK | 1 |
| Arribas, J; Deckx, H; Duiculescu, D; Florence, E; Hung, CC; Sension, M; Stevens, M; Tebas, P; Vanveggel, S; Wilkin, T | 1 |
| Kabra, SK; Lodha, R; Mukherjee, A; Singh, R; Singla, M; Sirohiwal, A; Vajpayee, M; Velpandian, T | 1 |
| Barreiro, P; De Mendoza, C; Fernandez-Montero, JV; Labarga, P; Soriano, V | 1 |
| Barchiesi, F; Cirioni, O; Fragola, V; Gabrielli, E; Giacometti, A; Marchionni, E; Massella, M; Weimer, LE | 1 |
| Brown, LA; Ferrell, D; Giunta, B; Jin, J; Obregon, D; Sadic, E; Smith, AJ; Tan, J | 1 |
| Sax, PE | 2 |
| Andrade-Villanueva, J; Arribas, JR; Cahn, P; Figueroa, MI; Gatell, JM; Lama, JR; Norton, M; Patterson, P; Rolon, MJ; Sierra Madero, J; Sued, O | 1 |
| Manosuthi, W; Nilkamhang, S; Sukasem, C; Sungkanuparph, S; Thongyen, S | 1 |
| Lee, D; Nguyen, NH; Yee, BE | 1 |
| Bhatti, L; DeJesus, E; Edelstein, H; Margolis, DA; Ross, LL; Shaefer, MS; Small, CB; Weinberg, WG; Wohl, DA; Zhao, HH | 2 |
| Asensi, V; Bachiller, P; Blanco, JR; Camacho, A; Castaño, M; Clotet, B; Curto, J; Espinosa, N; Flores, J; Force, L; Gomez-Sirvent, JL; Imaz, A; Iribarren, JA; Knobel, H; López Bernaldo De Quirós, JC; Martín, T; Moreno, V; Ocampo, A; Perez, I; Podzamczer, D; Rojas, J; Rozas, N; Valencia, E; Vergas, J; Viciana, P | 1 |
| Coffin, CS; Gill, MJ; Michalak, TI; Mulrooney-Cousins, PM; Nishikawa, S; Osiowy, C; van der Meer, F; van Marle, G | 1 |
| Barthe, Y; Bouix, C; Cacoub, P; Carrat, F; Lascoux-Combe, C; Lebossé, F; Maynard-Muet, M; Miailhes, P; Piroth, L; Pol, S; Rey, D; Sogni, P; Zoulim, F | 1 |
| Antonopoulou, S; Chini, M; Demopoulos, CA; Fragopoulou, E; Gargalianos, P; Lazanas, MC; Mangafas, N; Papakonstantinou, VD; Psarra, K; Stamatakis, GM; Tsogas, N; Tsoupras, AB | 1 |
| Gui, T; Guo, W; Jia, L; Jiao, L; Li, H; Li, J; Li, L; Liu, S; Liu, Y; Zhuang, D | 1 |
| Chen, S; Letendre, SL; Mills, AM; Min, SS; Piscitelli, SC; Song, IH; Tashima, KT; Thomas, DA | 1 |
| Ananworanich, J; Bunupuradah, T; Keadpudsa, S; Prasitsuebsai, W; Puthanakit, T; Sahakijpicharn, T; Srimuan, A; Techasaensiri, C; Thammajaruk, N | 1 |
| Barreto-de-Souza, V; Frolova, S; Karpenko, I; Khandazhinskaya, A; Kochetkov, S; Margolis, L; Vanpouille, C; Zicari, S | 1 |
| McCarthy, M | 1 |
| Clumeck, N; Delforge, M; Ilunga, J; Kabeya, K; Kadiebwe, D; Kapend, L; Kasamba, E; Matanda, S; Milolo, C; Mwamba, C; Necsoi, C; Vaira, D | 1 |
| Cai, J; Xiao, J; Zhang, Q | 1 |
| Bosco, O; Cruciani, M; Malena, M; Mengoli, C; Moyle, G; Parisi, SG; Serpelloni, G | 1 |
| Fujita, J; Haranaga, S; Higa, F; Nakamura, K; Tamayose, M; Tasato, D; Tateyama, M; Yara, S | 1 |
| Aoudjane, S; Beloukas, A; Chaponda, M; Geretti, AM; González Del Castillo, AA; Hopkins, M; Khoo, S; Noguera, M; O'Connor, J; van Oosterhout, JJ | 1 |
| Daar, ES; Gupta, SK; Ha, B; Kitch, D; McComsey, GA; Melbourne, K; Sax, PE; Tierney, C; Wyatt, CM | 1 |
| Amici, R; Andreotti, M; Buonomo, E; Ceffa, S; Giuliano, M; Jere, H; Leone, P; Mancinelli, S; Mancini, MG; Marazzi, MC; Palombi, L; Pirillo, MF; Sagno, JB; Scarcella, P; Vella, S | 1 |
| Antinori, A; Bonora, S; Castagna, A; d'Arminio Monforte, A; De Luca, A; Maserati, R; Perno, CF | 1 |
| Camejo, RR; Cuffe, R; Gilchrist, KA; Lim, JW; Nichols, G; Patel, DA; Pulgar, S; Snedecor, SJ; Stephens, J; Sudharshan, L; Tang, WY | 1 |
| Bartlett, JA; Crump, JA; Grossmann, H; Masenga, EJ; Mavura, DR; Minja, E | 1 |
| Dugas, TR; Glover, M; Hebert, VY; Nichols, K; Thibeaux, TM; Xue, SY; Zavecz, JA | 1 |
| Bouazza, N; Burger, D; Capparelli, EV; Fauchet, F; Foissac, F; Kiechel, JR; Lallemant, M; Treluyer, JM; Urien, S | 1 |
| Dziuban, EJ; Koumans, EH; Raizes, E | 1 |
| Che, J; Chen, X; Cheng, Y; Dong, T; Meng, Q; Qian, X; Tong, B | 1 |
| Bañón, S; Casado, JL; Moreno, A; Moreno, S; Perez-Elías, MJ; Rodriguez, MA; Santiuste, C | 1 |
| André, P; Cotte, L; Monneret, G; Ramière, C; Ronfort, C; Saison, J; Tardy, JC; Trabaud, MA; Venet, F | 1 |
| Blanche, S; Flynn, P; Giaquinto, C; Kakuda, TN; Komar, S; Lathouwers, E; Noguera-Julian, A; Opsomer, M; Van de Casteele, T; Welch, S | 1 |
| Ariyoshi, K; Auwanit, W; Pathipvanich, P; Rojanawiwat, A; Sawanpanyalert, P; Tsuchiya, N; Wichukchinda, N | 1 |
| Almond, S; Arasteh, K; Brennan, C; Brinson, C; Cuffe, RL; Eron, J; Górgolas, M; Granier, C; Nichols, WG; Pappa, K; Rachlis, A; Raffi, F; Walmsley, S | 1 |
| Mistry, N; Oakeshott, P; Sereboe, L | 1 |
| Berendes, S; Campbell, TB; Cardoso, SW; Christian, P; Gupta, A; Gupte, N; Kanyama, C; Lama, JR; Mwelase, N; Pillay, S; Riviere, C; Samaneka, W; Semba, RD; Shivakoti, R; Sugandhavesa, P; Tang, AM; Yang, WT | 1 |
| Connolly, C; Harries, A; Kellerman, T; Lienhardt, C; McIlleron, H; Naiker, S; Pym, A; Reddy, T; Wiesner, L | 1 |
| Commenges, D; Prague, M; Thiébaut, R | 1 |
| Moreira, J | 1 |
| Fukutake, K; Goseki, Y; Hara, S; Kobayashi, M; Kuriiwa, F; Mizukami, H; Takata, Y; Yoshida, K | 1 |
| Albano, J; Gee, C; Koram, N; Tilson, H; Vannappagari, V | 1 |
| Bierman, W; Bravenboer, B; Gisolf, E; Groeneveld, P; Hoepelman, AI; Koopmans, PP; Langebeek, N; Legrand, JC; Mulder, PG; Richter, C; Sprenger, HG; Ten Kate, RW; Ten Napel, CH; van der Werf, Ts; Vriesendorp, R | 1 |
| Alves, M; Guidet, B; Janneau-Magrino, L; Legendre, N; Pateron, D; Yordanov, Y | 1 |
| Álvarez, ML; Arterburn, S; Berenguer, J; Clotet, B; Curran, A; Estrada, V; Ferrer, P; Larrousse, M; Martínez, E; Negredo, E; Pulido, F; Ribera, E; Rubio, R; Sanz, J | 1 |
| Barreiro, P; de Mendoza, C; Peña, JM; Soriano, V | 1 |
| Borsa-Lebas, F; Cacoub, P; Carrat, F; Fillion, A; Lacombe, K; Lopes, A; Loustaud-Ratti, V; Miailhes, P; Piroth, L; Pol, S; Rosenthal, E; Salmon, D | 1 |
| Back, DJ; Burger, D; Lamorde, M; Schapiro, JM | 1 |
| Chakrabarti, S; Chakravarty, R; Guha, SK; Pal, A; Saha, B; Saha, D; Sarkar, N | 1 |
| Anderson, J; Dhar, J; Ebrahimi, R; Ewan, J; Fisher, M; Moyle, GJ; Orkin, C; Wang, H; Wilkins, E | 1 |
| A Rostad, C; Anderson, EJ; Camacho-Gonzalez, AF; Chakraborty, R; O Akerele, D; Spearman, P; Thompson, AB; Wynn, BA | 1 |
| Deeks, ED; Greig, SL | 1 |
| Deulina, MO; Ivanova, ES; Kanestri, VG; Kravchenko, AV; Pokrovsky, VV; Popova, AA; Yakovlev, AA; Zimina, VN | 1 |
| Alonso-Villaverde, C; Ferrer, E; Martinez-Picado, J; Maso, M; Muñoz-Moreno, JA; Ouchi, D; Podzamczer, D; Prats, A; Puertas, MC; Rozas, N; Tiraboschi, JM | 1 |
| Aurpibul, L; Chokephaibulkit, K; Cressey, TR; Phongsamart, W; Sirisanthana, V; Sricharoenchai, S; Sudjaritruk, T; Wittawatmongkol, O | 1 |
| Bader, J; Glass, TR; Klimkait, T; Labhardt, ND; Lejone, TI; Puga, D; Ringera, I | 1 |
| Goto, H; Hayashi, K; Hirooka, Y; Honda, T; Ishigami, M; Ishikawa, T; Ishizu, Y; Itoh, A; Katano, Y; Kuzuya, T; Luo, F; Nakano, I | 1 |
| Han, Y; Li, T; Li, Y; Qiu, Z; Song, X; Xie, J; Zhu, T | 1 |
| Blanche, S; Bonnet, D; Delmas, S; Dollfus, C; Faye, A; Khoshnood, B; Le Chenadec, J; Lelong, N; Mandelbrot, L; Sibiude, J; Tubiana, R; Warszawski, J | 1 |
| Anglaret, X; Boyd, A; Danel, C; Delaugerre, C; Eholié, SP; Gabillard, D; Girard, PM; Lacombe, K; le Carrou, J; Maylin, S; Moh, R; Zoulim, F | 1 |
| He, C; Hsi, JH; Kan, W; Leng, X; Liao, L; Ruan, Y; Shao, Y; Wang, J; Xing, H | 1 |
| Domingo, P; Rivero, A | 1 |
| Fan, P; Li, J; Li, N; Liang, Y; Ma, Y; Sun, D; Wang, Z; Yang, W; Zhu, Q | 1 |
| Aris, E; Baernighausen, T; Chalamilla, G; Fawzi, W; Hertzmark, E; Jackson, E; Machumi, L; Muya, A; Mwanyika-Sando, M; Sando, D; Spiegelman, D | 1 |
| Borghetti, A; Cauda, R; Ciccarelli, N; Colafigli, M; D'Avino, A; De Luca, A; Di Giambenedetto, S; Fabbiani, M; Gagliardini, R; Mondi, A | 1 |
| Clark, KF; Finocchario-Kessler, S; Gautney, BJ; Goggin, K; Khamadi, S; Okoth, V | 1 |
| Dorman, E; Peng, S; Rosenblatt, L; Sorensen, S; Tafazzoli, A; Villasis-Keever, A | 1 |
| Priya, MR; Rajendran, NN | 1 |
| Inui, A; Isonuma, H; Naito, T; Saita, M; Suzuki, A; Uehara, Y | 1 |
| Barlow-Mosha, L; Cotton, M; Dominguez, K; Ford, N; Penazzato, M | 1 |
| Donnen, P; Koy, T; Malandala, GL; Mukumbi, H; Wilmet-Dramaix, M | 1 |
| Appiah, LT; Beloukas, A; Bhagani, S; Bonnett, L; Chadwick, D; Dusheiko, G; Geretti, AM; Phillips, RO; Sarfo, FS; Stockdale, AJ | 1 |
| Bazile, J; Beste, JA; Chingoli, F; Crocker, JT; Elmore, SN; Gopal, S; Herce, ME; Kalanga, N; Keck, JW; Mailosi, B; Phiri, A; Rigodon, J; Tengatenga, L; Wroe, EB | 1 |
| Arribas, JR; Cabié, A; Crespo, M; Domingo, P; Dronda, F; Estrada, V; Gatell, JM; Girard, PM; Iribarren, JA; Knobel, H; Landman, R; Mallolas, J; Martínez-Rebollar, M; Montero, M; Pich, J; Podzamczer, D; Portilla, J; Pulido, F; Weiss, L; Zamora, FX | 1 |
| Antela, A; Esteban, H; Estébanez, M; Mariño, A; Moreno, S; Navarro, J; Pasquau, J; Perez-Molina, JA; Riera, M; Rivero, A; Rubio, R; Santos, J; Sanz-Moreno, J; Suárez-Lozano, I; Troya, J | 1 |
| Dodoo, AN; Lartey, M; Leufkens, HG; Mantel-Teeuwisse, AK; Nartey, ET; Nortey, PA; Tetteh, RA | 1 |
| Assuied, A; De Castro, N; Fagard, C; Grinsztejn, B; Grondin, C; Molina, JM; Pilotto, JH; Sauvageon, H; Taburet, AM; Veloso, V | 1 |
| Apica, B; Ocama, P; Opio, K; Seremba, E | 1 |
| Henry, K; LaMarca, A; Ross, LL; Schneider, S; Shaefer, MS; Squires, KE; Tashima, K; Young, B; Zhao, HH | 1 |
| Bollen, P; Burger, D; Reiss, P; Schapiro, J | 1 |
| Battegay, M; Bernasconi, E; Bihl, F; Calmy, A; Caminada, AP; Cavassini, M; Ledergeber, B; Martinetti, G; Rickenbach, M; Vernazza, P; Wandeler, G; Weber, R | 1 |
| Bridges, AS; Cohen, MS; Dumond, JB; Fiscus, SA; Forrest, A; Kashuba, AD; Kendrick, R; Reddy, YS; Troiani, L; Yang, KH | 1 |
| Baumgarten, A; Berenguer, J; Felizarta, F; Florence, E; Granier, C; Khuong-Josses, MA; Kilby, JM; Lutz, T; Pappa, K; Podzamczer, D; Portilla, J; Roth, N; Walmsley, S; Wong, D; Wynne, B | 1 |
| Gao, GF; Gohda, J; Gu, L; Guan, S; Han, Y; Hosoya, N; Huang, Y; Ishida, T; Iwamoto, A; Kawana-Tachikawa, A; Li, T; Li, Y; Liu, W; Song, X; Xie, J; Yang, F; Zhu, T | 1 |
| Avi, R; Huik, K; Jõgeda, EL; Kallas, E; Karki, T; Lutsar, I; Margus, T; Pauskar, M | 1 |
| Antony, J; Arumugam, K; D'Souza, G; De Costa, A; Kumar, DS; Kumarasamy, N; Poongulali, S; Rewari, BB; Shastri, S; Shet, A | 1 |
| Anglaret, X; Boyd, A; Danel, C; Delaugerre, C; Eholié, SP; Gabillard, D; Girard, PM; Lacombefor, K; Mahjoub, N; Maylin, S; Moh, R; Zoulim, F | 1 |
| Bonnet, F; Calmy, A; Ciaffi, L; Delhumeau, C; Fampou, JC; Hill, A; Menga, G; Nchotu Ngang, P; Rougemont, M; Stoll, B | 1 |
| Bhagani, S; Boum, Y; Calisti, G; Foster, GM; Geretti, AM; Muhindo, R; Wilson, LA | 1 |
| Amin, J; Boyd, MA; Cooper, DA; Emery, S; Kelleher, AD; Losso, M; Madero, JS; Molina, JM; Moore, CL; Renjifo, B; Ruxrungtham, K; Teppler, H; Wolff, M; Wood, R | 1 |
| Chim, B; Choun, K; Lorent, N; Lynen, L; Thai, S; van Griensven, J | 1 |
| He, C; Huang, H; Liao, L; Liu, J; Ruan, Y; Shao, Y; Wang, J; Wang, Z; Xing, H; Yang, S; Yue, Y | 1 |
| Abongomera, G; Asiimwe, A; Burger, D; Chabala, C; Chintu, C; Cook, AD; Gibb, DM; Kekitiinwa, A; Kenny, J; Kityo, C; Klein, N; McIlleron, H; Mirembe, G; Mulenga, V; Musiime, V; Owen-Powell, E; Thomason, MJ; Walker, AS | 1 |
| Falasca, F; Fantauzzi, A; Floridia, M; Mezzaroma, I; Spanedda, P; Turriziani, O; Vullo, V | 1 |
| Ayudhaya, OP; Bouazza, N; Cressey, TR; Foissac, F; Ingsrisawang, L; Jittayanun, K; Jourdain, G; Jungpipun, J; Lallemant, M; Le Coeur, S; Ngo-Giang-Huong, N; Puangsombat, A; Sripan, P; Srirompotong, U; Traisathit, P; Tréluyer, JM; Urien, S | 1 |
| Beach, MC; Callon, W; Cohn, J; Korthuis, PT; Moore, RD; Saha, S; Wilson, IB | 1 |
| Manosuthi, S; Manosuthi, W; Nilkamhang, S; Sungkanuparph, S; Thongyen, S | 1 |
| Bañón, S; Casado, JL | 1 |
| Bailly, F; Cotelle, P | 1 |
| Bon, I; Borderi, M; Calza, L; Colangeli, V; Conti, M; Danese, I; Magistrelli, E; Mancini, R; Motta, R; Re, MC; Viale, P | 1 |
| Arends, J; Chene, G; Cosin, J; Dabis, F; Daikos, G; de Wit, S; Mallolas, J; Montforte, Ad; Mussini, C; Peters, L; Raben, D; Rockstroh, J; Smit, C; Zangerle, R; Zinkernagel, A | 1 |
| Boissonnault, M; Charest, L; Galanakis, C; Huchet, E; Longpré, D; Machouf, N; Murphy, D; Thomas, R; Trottier, B; Vézina, S | 1 |
| Gorantla, S; Lu, Y; Makarov, E; Senanayake, TH; Vinogradov, SV; Warren, G | 1 |
| Agarwal, AK; Chakravarty, J; Chaturbhuj, DN; Chourasia, A; Kurle, S; Mishra, RN; Paranjape, RS; Rai, M; Singh, PN; Sundar, S; Tripathy, SP | 1 |
| Cai, W; Caughey, B; Chung, C; Dai, Z; Hu, F; Lan, Y; Li, L; Tang, X; Zhang, K | 1 |
| Blanche, S; Engebretsen, IMS; Hofmeyr, GJ; Jackson, D; Kankasa, C; Kwagala, M; Lombard, C; Maréchal, V; Meda, N; Mwiya, M; Nagot, N; Ndeezi, G; Neboua, D; Neveu, D; Rekacewicz, C; Rutagwera, D; Singata, M; Siuluta, C; Some, E; Sommerfelt, H; Sunday, A; Traore, H; Tumwine, JK; Tylleskär, T; Vallo, R; Van de Perre, P | 1 |
| Freedberg, KA; Girouard, MP; Gulick, RM; Paltiel, AD; Parker, RA; Sax, PE; Taiwo, B; Walensky, RP; Weinstein, MC | 1 |
| Anderson, PH; Ebeling, PR; Emery, S; Fairley, CK; Kimlin, MG; Klassen, KM | 1 |
| Andreotti, M; Floridia, M; Galluzzo, CM; Giuliano, M; Jere, H; Liotta, G; Luhanga, R; Mancinelli, S; Marazzi, MC; Marchei, E; Mwenda, R; Palombi, L; Pichini, S; Pirillo, MF; Sagno, JB; Vella, S | 1 |
| Arastéh, K; Bergmann, F; Chaves, RL; Cooper, DA; Cordery, DV; Neto, JL; Robinson, P; Ruxrungtham, K; Scherer, J; Zajdenverg, R | 1 |
| Balogun, K; Banko, N; Loutfy, M; MacGillivray, J; Mohammadi, H; Murphy, KE; Papp, E; Serghides, L; Shah, R; Silverman, M; Walmsley, SL; Yudin, MH | 1 |
| Du, S; Guo, F; Han, Y; Li, T; Li, Y; Lv, W; Qiu, Z; Song, X; Thio, CL; Wang, H; Wang, N; Xie, J; Zhu, T | 1 |
| Archampong, TN; Boamah, I; Flanigan, T; Gillani, FS; Kenu, E; Kwara, A; Lartey, M; Obo-Akwa, A; Sagoe, KW; Yang, H | 1 |
| Gosnell, BI; John, MA; Manzini, TC; Moosa, MS; Ramdial, P | 1 |
| Duwal, S; von Kleist, M | 1 |
| Likanonsakul, S; Nakayama, EE; Nitiyanontakij, R; Prasithsirikul, W; Sangsajja, C; Shioda, T; Suntisuklappon, B | 1 |
| Cai, WP; He, HL; Huang, SB; Ling, XM; Liu, YF; Wang, H; Wang, M; Wang, XC; Wei, FL; Wu, H; Wu, YS; Wu, ZY; Yang, L; Zhang, FJ; Zhang, WW | 1 |
| Gras, L; Rijnders, B; Rokx, C; van de Vijver, D; Verbon, A | 1 |
| Chang, SC; Chang, SY; Hung, CC; Kuo, CH; Lin, SW; Liu, WC; Su, YC; Sun, HY; Tang, SY; Tsai, MS; Wu, BR | 1 |
| Maharaj, N; Moodley, D; Moodley, T; Sartorius, B; Sebitloane, M | 1 |
| González-Domenech, CM; Hernández-Quero, J; Martínez, MA; Mayorga, ML; Olalla, J; Omar, M; Palacios, R; Pérez-Camacho, I; Pérez-Hernández, IA; Romero, A; Romero, JM; Santos, J | 1 |
| Cárden-Santana, MA; Carrillo-Díaz, T; Castillo-Sainz, R; Suárez-Lorenzo, I | 1 |
| Aboud, S; Bosch, R; Duggan, C; Fawzi, WW; Kisenge, R; Kupka, R; Liu, E; Manji, KP | 1 |
| Adler, H; Boon, G; Carty, C; Goldswain, C; Harper, K; Jackson, V; Lambert, JS; Linder, V | 1 |
| Aklillu, E; Bisaso, RK; Gustafsson, LL; Mukonzo, JK; Ogwal-Okeng, J; Owen, JS | 1 |
| Cook, A; Gibb, DM; Kasirye, P; Mhute, T; Mugarura, L; Munjoma, M; Musiime, V; Nahirya-Ntege, P; Naidoo-James, B; Nankya, I; Ndashimye, E; Snowden, W; Spyer, MJ; Thomason, MJ; Thoofer, NK; Walker, AS | 1 |
| Amici, R; Andreotti, M; Galluzzo, CM; Giuliano, M; Jere, H; Liotta, G; Mancinelli, S; Marazzi, MC; Palombi, L; Pirillo, MF; Sagno, JB; Scarcella, P; Vella, S | 1 |
| Bolduc, P; Cheeseman, SH; Colgate, E; Roder, N | 1 |
| Allavena, C; Bani-Sadr, F; Cabié, A; Cheret, A; Chirouze, C; Cotte, L; Cuzin, L; Flandre, P; Katlama, C; Pugliese, P; Rey, D | 1 |
| Hsi, J; Liao, L; Liu, J; Pan, X; Ruan, Y; Shao, Y; Su, B; Wang, Z; Wu, J; Xing, H; Yan, J; Zhang, J | 1 |
| Cheng, X; Fraenkel, L; Han, Y; Hsieh, E; Insogna, KL; Li, T; Xia, W; Yin, MT; Zhu, T | 1 |
| Crespo, M; Curran, A; Domingo, P; Gatell, J; Mallolas, J; Martinez-Rebollar, M; Mateo, GM; Navarro, J; Podzamczer, D; Ribera, E; Saumoy, M | 1 |
| Baldin, G; Borghetti, A; Cauda, R; Ciccarelli, N; Ciccullo, A; D'Avino, A; De Luca, A; Di Giambenedetto, S; Fabbiani, M; Fanti, I; Gagliardini, R; Lamonica, S; Mondi, A; Trecarichi, E | 1 |
| Archampong, TN; Blackard, JT; Boyce, CL; Kenu, E; Kwara, A; Lartey, M; Obo-Akwa, A; Sagoe, KW | 1 |
| Battegay, M; Bernasconi, E; Braun, DL; Darling, K; Günthard, HF; Hirzel, C; Hoffmann, M; Kouyos, RD; Kovari, H; Marzel, A; Rougemont, M; Scherrer, AU; Shilaih, M | 1 |
| Behrens, G; Borg, P; Bouee, S; M Llibre, J; Moyle, G; Piontkowsky, D; Raffi, F; Reilly, G; Rogatto, F | 1 |
| Barnett, BS; Chaweza, T; Hosseinipour, MC; Ngambi, W; Phiri, S; Tweya, H | 1 |
| Andany, N; Gold, WL | 1 |
| Amaral, E; Bahamondes, L; Bahamondes, MV; Brito, MB; Duarte, G; Ferriani, RA; Prandini, TR; Quintana, SM; Ragazini, CS; Vieira, CS | 1 |
| Amponsah-Dacosta, E; Blackard, JT; Gededzha, MP; Lukhwareni, A; Mphahlele, MJ; Rakgole, JN; Selabe, SG | 1 |
| Carbone, A; Castagna, A; Galli, L; Gianotti, N; Lazzarin, A; Merli, M; Nozza, S; Poli, A; Ripa, M; Salpietro, S | 1 |
| Belyhun, Y; Liebert, UG; Maier, M | 1 |
| Ananworanich, J; Chokephaibulkit, K; Do, VC; Kerr, SJ; Kosalaraksa, P; Kurniati, N; Nguyen, LV; Prasitsuebsai, W; Singtoroj, T; Sohn, AH; Sudjaritruk, T; Teeraananchai, S; Truong, KH | 1 |
| Azu, OO; Jegede, AI; Naidu, EC; Offor, U; Onanuga, IO | 1 |
| Cao, C; Chen, H; Chen, R; Huang, J; Jiang, J; Li, J; Liang, B; Liang, H; Pan, P; Su, Q; Ye, L; Zhao, F; Zhuang, D | 1 |
| Cun, LQ; Duan, S; He, N; Li, PY; Shi, Y; Xu, YW; Yang, WQ; Yao, ST; Yao, Y; Yin, CY; Zhai, ZJ; Zhang, YD | 1 |
| Achhra, AC; Amin, J; Boyd, MA; Mwasakifwa, G | 1 |
| Amici, R; Andreotti, M; Buonomo, E; Floridia, M; Galluzzo, CM; Giuliano, M; Jere, H; Liotta, G; Mancinelli, S; Marazzi, MC; Palombi, L; Sagno, JB; Scarcella, P; Vella, S | 1 |
| Belmonti, S; Borghetti, A; Cauda, R; De Luca, A; Di Giambenedetto, S; Fabbiani, M; Lombardi, F | 1 |
| Khatri, A; Menon, R; Podsadecki, T; Trinh, R; Zhao, W | 1 |
| Ammassari, A; Antinori, A; Bellagamba, R; Borghi, V; Colafigli, M; D'Ettorre, G; Di Giambenedetto, S; Fabbiani, M; Giannetti, A; Latini, A; Loiacono, L; Lorenzini, P; Sterrantino, G; Zaccarelli, M | 1 |
| Emerson, CR; Todd, S | 1 |
| Acerete, L; Curto, J; Ferrer, E; Imaz, A; Kashuba, AD; Martinez-Picado, J; Niubó, J; Ouchi, D; Podzamczer, D; Rozas, N; Sykes, C; Vila, A | 1 |
| Carpio, F; DeJesus, E; Fusco, G; Fusco, J; Henegar, C; Hsu, R; Lackey, P; Mills, A; Pierone, G; Wohlfeiler, M | 1 |
| Comi, L; Maggiolo, F | 1 |
| Chen, H; Guo, W; Huang, J; Jiang, J; Liang, B; Liang, H; Liao, Y; Su, J; Xu, X; Ye, L; Zang, N | 1 |
| Dahlby, JS; Guillemi, SA; Harris, M; Hogg, RS; Hull, MW; Lima, VD; Ling, SH; Montaner, JS; Werb, R; Yip, B; Zhang, W | 1 |
| Bani-Sadr, F; Cabie, A; Cotte, L; de Boissieu, P; Delobel, P; Dramé, M; Garraffo, R; Huleux, T; Poizot-Martin, I; Raffi, F; Rey, D | 1 |
| García-Arieta, A; Gordon, J; Gwaza, L; Leufkens, H; Potthast, H; Stahl, M; Welink, J | 1 |
| Ascione, T; Boccia, G; Carleo, MA; De Caro, F; Pagliano, P; Tortora, F | 1 |
| Amariles, P; Galindo, J; Galindo-Orrego, X; González-Avendaño, S; Hincapié, JA; Mueses-Marín, HF | 1 |
| Barrufet, P; Berenguer, J; Boix, V; Carrero, A; Castaño, M; Esteban, H; Galindo, MJ; González-García, J; Hontañón, V; Imaz, A; Knobel, H; Moreno, S; Podzamczer, D; Raffo, M; Ribera, E; Ryan, P; Solís, J; Suárez-Lozano, I; Terrón, JA; Troya, J; Yllescas, M | 1 |
| Evans, CD; Flynn, DM; Fong, PS; Korthuis, PT | 1 |
| Bernardino, JI; Martín-Carbonero, L; Montejano, R; Montes, ML; Moreno, V; Valencia, ME | 1 |
| Abach, J; Abongomera, G; Chabala, C; Colebunders, R; Cook, A; Gibb, DM; Kekitiinwa, A; Kityo, C; Lamorde, M; Mulenga, V; Musiime, V; Thomason, M; Walker, AS | 1 |
| Alioni, S; Izudi, J; Kerukadho, E; Ndungutse, D | 1 |
| Bienczak, A; Bouazza, N; Burger, D; Capparelli, EV; Cressey, TR; Denti, P; Foissac, F; Lallemant, M; McIlleron, H; Penazzato, M; Treluyer, JM; Urien, S | 1 |
| Albert, J; Blaxhult, A; Carlander, C; Eriksen, J; Flamholc, L; Gisslén, M; Josephson, F; Karlström, O; Navér, L; Sönnerborg, A; Svedhem, V; Yilmaz, A | 1 |
| Brophy, JC; Chan, AK; Hawkes, MT; Mateyu, G; Mwinjiwa, E; Sodhi, SK | 1 |
| Amin, J; Azwa, I; Belloso, WH; Boyd, MA; Chetchotisakd, P; Cooper, DA; Emery, S; Hoy, J; Kumarasamy, N; Lombaard, J; Mallon, PW; Mohapi, L; Molina, JM; Moore, CL; Phanuphak, P; Wood, R | 1 |
| Makvandi, M | 1 |
| Asari, V; Baxter, C; Garrett, N; Grobler, A; Karim, QA; Karim, SSA; Majola, N; Naicker, N; Naidoo, A; Werner, L | 1 |
| Bhattarai, S; Fallon, JP; Galang, H; Habeeb, R; Johnson, TM; Shukla, PP; Sison, R; Slim, J | 1 |
| Blanche, S; Blume, J; Bouazza, N; Foissac, F; Harper, K; Hirt, D; Illamola, SM; Kankasa, C; Meda, N; Nagot, N; Singata-Madliki, M; Tréluyer, JM; Tumwine, JK; Tylleskär, T; Van de Perre, P | 1 |
| Akkina, R; Akkina, SR; Habu, Y; Hu, S; Kumar, DM; Neff, CP; Seki, T | 1 |
| Clumeck, N; de Oliveira, T; Gregson, J; Gupta, RK; Hamers, RL; Hoffmann, CJ; Hunt, G; Kaleebu, P; Kanki, P; Kantor, R; Kerschberger, B; Lockman, S; Marconi, VC; Ndembi, N; Pillay, D; Raizes, E; Shafer, RW; van Vuuren, C; Yang, C | 1 |
| Kondapi, AK; Kumar, P; Lakshmi, YS | 1 |
| Barlow-Mosha, L; Borkowsky, W; Chen, J; Chi, BH; Deygoo, N; Duffy, PE; Gabriel, EE; Hobbs, CV; Ilmet, T; Jean Philippe, P; Kamthunzi, P; Kirmse, B; Li, Y; Mofenson, L; Musoke, P; Neal, J; Palumbo, P; Parikh, S; Petzold, E; Prescott, W; Tauzie, J; Tegha, G | 1 |
| Alteri, C; Bernardi, S; Bertoli, A; Liuzzi, G; Manno, EC; Palma, P; Perno, CF; Rossi, P; Tchidjou, HK; Zangari, P | 1 |
| Harrison, M; Matjila, M; Riemer, L; Tooke, L | 1 |
| An, PN; Chuc, NT; Cuong, DD; Diwan, V; El-Khatib, Z; Larsson, M; Le, NK; Marrone, G; Santacatterina, M; Sönnerborg, A; Thorson, A; Van Tam, V | 1 |
| Bonjoch, A; Clotet, B; Domingo, P; Echeverría, P; Estany, C; Estrada, V; Gutiérrez, MD; Mateo, GM; Negredo, E; Ornelas, A; Puig, J; Toro, J | 1 |
| Aurpibul, L; Bunupuradah, T; Hansudewechakul, R; Kanjanavanit, S; Kosalaraksa, P; Lumbiganon, P; Puthanakit, T; Taeprasert, P | 1 |
| Cattaneo, D; Clementi, E; Cozzi, V; Galli, M; Gervasoni, C; Meraviglia, P; Minisci, D; Riva, A | 1 |
| Chang, SC; Chang, SY; Chuang, YC; Huang, YS; Hung, CC; Lee, KY; Liu, WC; Sheng, WH; Su, YC; Sun, HY | 1 |
| Bastiaans, DET; Burger, DM; Jacqz-Aigrain, E; Janssen, EJH; Knibbe, CAJ; Lyall, H; Välitalo, PAJ; van Rossum, AMC | 1 |
| Curto, J; Domingo, P; Gatell, JM; Mallolas, J; Ordoñez-Llanos, J; Podzamczer, D; Ribera, E; Saumoy, M; Tiraboschi, JM | 1 |
| Antinori, A; Borghetti, A; Castagna, A; Cauda, R; Chinello, P; Ciccarelli, N; Colafigli, M; D'Ettorre, G; De Luca, A; Di Giambenedetto, S; Di Pietro, M; Fabbiani, M; Focà, E; Francisci, D; Grima, P; Latini, A; Madeddu, G; Mondi, A; Orofino, G; Quiros Roldan, E; Rusconi, S | 1 |
| Ahmad, S; Brima, N; Chaponda, M; Davies, C; Hay, P; Johnson, M; Kingston, M; Lewis, JM; Marshall, N; Mulka, L; Muqbill, G; Nelson, M; Shaw, J; Smith, C; Tomkins, A; Torkington, A; Waters, L; Williams, D | 1 |
| Naidoo, P; Soorju, V | 1 |
| Dunn, DT; Gilks, C; Goodall, RL; Gupta, RK; Kaleebu, P; Kityo, C; Mugarura, L; Munderi, P; Nkurunziza, P; Pattery, T; Pillay, D | 1 |
| Rawizza, H | 1 |
| Bessong, PO; Gachara, G; Kimbi, HK; Lum, E; Magoro, T; Mavhandu, L; Ndip, RN | 1 |
| Coovadia, H; Coutsoudis, A; Kankasa, C; Meda, N; Nagot, N; Tumwine, JK; Tylleskär, T; Van de Perre, P | 1 |
| Casari, S; Castelli, F; Festa, E; Izzo, I; Lanza, P; Odolini, S; Vavassori, A; Zaltron, S | 1 |
| Benatti, S; Callegaro, A; Digaetano, M; Gulminetti, R; Maggiolo, F; Mussini, C; Pagnucco, L; Ripamonti, D; Valenti, D | 1 |
| Bhagani, S; Chaloner, C; Johnson, MA; Lampe, FC; Lodwick, RK; Phillips, AN; Sabin, CA; Smith, CJ; Tyrer, M; Youle, M | 1 |
| Basseila, GB; Bokilo, AD; Dokekias, AE; Galiba, FO; Malanda, F; Nsitou, MB; Ntsimba, P | 1 |
| Calabresi, A; Carosi, G; Cologni, G; Costarelli, S; Lapadula, G; Puoti, M; Quiros-Roldan, E; Tirelli, V; Torti, C; Zaltron, S | 1 |
| Camacho, RJ; Clotet, B; Cozzi-Lepri, A; Deforche, K; Kjaer, J; Lundgren, JD; Moreau, Y; Phillips, A; Theys, K; Van Laethem, K; Vandamme, AM | 1 |
| Azwa, A; Harania, RS; Nelson, M; Sokwala, A; Stebbing, J | 1 |
| Bläckberg, J; Duberg, AS; Fischler, B; Friman, S; Karlström, O; Lindh, M; Norkrans, G; Reichard, O; Sangfeldt, P; Söderström, A; Sönnerborg, A; Uhnoo, I; Weiland, O; Wejstål, R; Wiström, J | 1 |
| Rong-Rong, Y; Shi-Cheng, G; Xi-En, G; Yong-Xi, Z | 1 |
| Balakrishnan, P; Kumarasamy, N; Murugavel, KG; Priya, B; Saghayam, S; Shankar, EM; Solomon, S; Sundaram, M; Venkatesh, KK | 1 |
| Breidinger, SA; Chen, J; Friedman, EJ; Gottesdiener, KM; Iwamoto, M; Kost, JT; Lasseter, KC; Stek, JE; Stone, JA; Teppler, H; Wagner, JA; Wenning, LA | 1 |
| Grobusch, MP; John, MA; Menezes, CN; Rhemtula, YA | 1 |
| Gazzard, BG; Jackson, A; Maitland, D; Mandalia, S; Moyle, GJ; Osorio, J | 1 |
| Braude, J; Galambos, MR; Joelson, D; Johnson, M; Rubin, RA; Saifee, S; Sellers, M; Shrestha, R | 1 |
| Back, D; Boffito, M; Byakika-Kibwika, P; D'Avolio, A; Di Perri, G; Kalemeera, F; Khoo, S; Lamorde, M; Mauro, S; Mayanja-Kizza, H; Merry, C; Ryan, M | 1 |
| Klinbuayaem, V; Leechanachai, P; Leenasirimakul, P; Phusua, A; Pornprasert, S; Saetung, R; Sanguansermsri, T; Sukunthamala, K; Thunjai, B | 1 |
| Apisarnthanarak, A; Kitkungvan, D; Laowansiri, P; Mundy, LM | 1 |
| Kisic, M; Martínez, MA; Martinez-Picado, J; Mendieta, J; Menéndez-Arias, L; Parera, M; Puertas, MC | 1 |
| Cortes, C; Domingo, P; Ferrer, E; Gatell, JM; Gutierrez, M; Leon, A; Niubo, J; Pedrol, E; Podzamczer, D; Puig, T; Sanchez, P; Veloso, S | 1 |
| Boue, F; Cohen-Codar, I; Delfraissy, JF; Dellamonica, P; Flandre, P; Marcellin, F; Norton, M; Raffi, F; Spire, B; Van Philippe, N | 1 |
| Cotter, BR; Currier, JS; Dubé, MP; Fichtenbaum, CJ; Gerschenson, M; Komarow, L; Mitchell, CK; Murphy, RL; Parker, RA; Squires, K; Stein, JH; Torriani, FJ | 1 |
| Amin, J; Avihingsanon, A; Bowden, S; Cooper, DA; Dore, GJ; Lewin, SR; Locarnini, S; Marks, P; Matthews, GV; Petcharapirat, P; Rerknimitr, R; Ruxrungtham, K; Sasadeusz, J | 1 |
| Brandão-Mello, CE; Brett-Smith, H; Cassetti, I; Gazzard, B; Hall, A; Huang, AK; Mendes-Corrêa, MC; Pessôa, MG; Phiri, P; Soriano, V | 1 |
| Abrams, EJ; Becquet, R; Blanche, S; Coffie, PA; Dabis, F; Ekouevi, DK; Horo, A; Leroy, V; Thiebaut, R; Tonwe-Gold, B | 1 |
| Ajayi, SO; Akingbola, TS; Brown, BJ; Oladokun, R; Omigbodun, OO; Osinusi, K | 1 |
| Bánhegyi, D; Bannister, WP; Chiesi, A; Friis-Møller, N; Gargalianos, P; Kirk, O; Lundgren, JD; Mocroft, A; van Lunzen, J; Viard, JP | 1 |
| Hsu, R; Lanier, ER; Oie, KL; Pappa, KA; Ross, LL; Rouse, EG | 1 |
| Morrow, JS; Redfield, RR | 1 |
| Angels Ribas, M; Asensi, V; Berenguer, J; Domingo, P; Gimeno, JL; González, J; Miralles, P; Pedrol, E; Pérez-Molina, JA; Ribera, E; Santamaría, JM; Santos, J; Terrón, JA | 1 |
| Angel, JB; Fätkenheuer, G; Greaves, W; Hoffmann, C; Horst, H; Landovitz, RJ; Long, J; Opravil, M | 1 |
| Berrisford, AE; Boulle, AM; Jaspan, HB | 1 |
| Aste, N; Atzori, L; Ferreli, C; Pau, M; Pilloni, L; Pinna, AL | 1 |
| Chung, MH; John-Stewart, GC; Kiarie, JN; Kinuthia, J; Lehman, DA; Njiri, F; Overbaugh, J; Richardson, BA | 1 |
| del Arco, A; Gálvez, MC; Gutiérrez-Ravé, V; Hidalgo, C; Lozano, F; Muñoz, L; Palacios, R; Ríos, MJ; Rivero, A; Santos, J | 1 |
| Likanonsakul, S; Manosuthi, W; Prasithisirikul, W; Sungkanuparph, S; Tantanathip, P | 1 |
| Barreiro, P; Collado, A; de Los Santos Gil, I; González-Serrano, M; Hernández-Burruezo, JJ; López-Cortés, LF; López-Ruz, MA; Macías, J; Martín-Rico, P; Merino, D; Mira, JA; Muñoz, L; Pineda, JA; Ríos-Villegas, MJ; Rivero, A; Soriano, V; Torres-Tortosa, M; Tural, C; Viciana, P | 1 |
| Bhattacharya, D; Donovan, RM; Imperial, JC; Israelski, D; Katzenstein, D; Keeffe, EB; Wong, A | 1 |
| Cohen, MS | 1 |
| Burty, C; Christian, B; Ghomari, K; May, T; Pavel, S; Pouaha, J; Rabaud, C; Vermersch, A; Yazdanpanah, Y | 1 |
| Cosin, J; Crespo, M; Domingo, P; Galindo, MJ; García-Alcalde, ML; Garrido, M; Geijo, P; López-Aldeguer, J; Lozano, F; Muñoz, A; Pedrol, E; Ribera, E; Roca, B; Sánchez, T; Suárez-Lozano, I; Teira, R; Terrón, A; Vergara, A; Viciana, P; Vidal, F; Viladés, C | 1 |
| Boutté, P; Monpoux, F; Pitelet, G; Richelme, C | 1 |
| Deeks, SG; Hoh, R; Kuritzkes, DR; Marconi, VC; Martin, JN; Paredes, R; Parkin, NT; Petropoulos, CJ; Sagar, M | 1 |
| Babiker, AG; Cotton, MF; Gibb, DM; Jean-Philippe, P; Madhi, SA; McIntyre, JA; Steyn, J; Violari, A | 1 |
| Fais, VC; Gonçales Junior, FL; Gonçales, NS; Jardim, RN; Pereira, JS | 1 |
| Carter, MM; Cook, DL; Copeland, WC; Cordova, EM; McCash, CL; Ming, J; Pons, RM; Seilkop, SK; Torres, SM; Walker, DM; Walker, VE | 1 |
| Bergroth, T; Ekici, H; Freedman, A; Gisslén, M; Goh, LE; Johnson, MA; Lampe, F; Loes, SK; Sönnerborg, A | 1 |
| Gerondelis, P; Irlbeck, DM; Lanier, E; Parkin, N; Ross, LL; Rouse, E; St Clair, MH; Trinh, L; Underwood, MR | 1 |
| Allavena, C; Calvez, V; Chavanet, P; Diemer, M; Duong, M; Hoen, B; Hoizey, G; Lang, JM; May, T; Meyer, P; Peytavin, G; Rey, D; Schmit, JL; Schmitt, MP; Spire, B | 1 |
| Calza, L; Manfredi, R | 2 |
| Bernassola, M; Cappiello, G; Ceccherini-Silberstein, F; De Sanctis, GM; Gori, C; Gubertini, G; Longo, R; Micheli, V; Niero, F; Perno, CF; Salpini, R; Spanò, A; Svicher, V; Trignetti, M; Visca, M | 1 |
| Benhamou, Y; Dominguez, S; Duvivier, C; Ingiliz, P; Katlama, C; Poynard, T; Thibault, V; Valantin, MA | 1 |
| Amrine-Madsen, H; Demarest, JF; Irlbeck, DM; Kitrinos, KM | 1 |
| Burgisser, P; Cavassini, M; Giulieri, SG; Günthard, HF; Knoepfel, SA; Metzner, KJ; Rauch, P; Yerly, S | 1 |
| Bangsberg, DR; Byakika-Tusiime, J; Chinn, LW; Kroetz, DL; Obua, C; Oyugi, JH | 1 |
| Amini-Bavil-Olyaee, S; Lutz, T; Sheldon, J; Tacke, F; Trautwein, C | 1 |
| Calleja, JL; Peñas, B | 2 |
| Barreiro, P; García-Samaniego, J; Martín-Carbonero, L | 1 |
| Capparelli, E; Fowler, MG; Holland, D; Masaba, R; Mirochnick, M; Odhiambo, P; Thigpen, MC; Thomas, T; Weidle, PJ; Zeh, C | 1 |
| Avihingsanon, A; Bowden, S; Dore, GJ; Lewin, SR; Locarnini, SA; Marks, P; Matthews, G; Perelson, AS; Ribeiro, RM; Ruxrungtham, K | 1 |
| George, C; Jayakumar, B; Lal, L; Yesoda, A | 1 |
| Parienti, JJ | 2 |
| Aurpibul, L; Puthanakit, T; Sirisanthana, T; Sirisanthana, V | 1 |
| Chen, XJ; Yu, K; Zhou, F | 1 |
| Arrifin, N; Audsley, J; Ayres, A; Bartholomeusz, A; Crowe, SM; Lewin, SR; Locarnini, SA; Mijch, A; Sasadeusz, J; Yuen, LK | 1 |
| Kombat, K; Mouhari-Touré, A; Pitche, P; Saka, B; Tchangaï-Walla, K | 1 |
| Bergroth, T; Ekici, H; Gisslén, M; Hagberg, L; Sönnerborg, A | 1 |
| Alvarez-Uria, G; Ratcliffe, L; Vilar, J | 1 |
| Hicks, CB | 1 |
| Casoli, V; Délia, G; Martin, D; Rousvoal, A | 1 |
| Jongwutiwes, U; Malathum, K; Sungkanuparph, S | 1 |
| Baxter, L; Bryant, J; Hird, S | 1 |
| Allavena, C; Cahn, P; Clotet, B; Côté, H; Harris, M; Montaner, J; Negredo, E; Ochoa, C; Raffi, F; Singer, J; Thorne, A; Zala, C | 1 |
| Moreno, V; Valencia, ME | 2 |
| Albrecht, H | 2 |
| Ayen, R; Clotet, B; Grassi, J; Levi, M; Negredo, E; Pruvost, A; Puig, J; Théodoro, F | 1 |
| Gills Ray, VL; Lee, H; Silkiss, RZ | 1 |
| Afonso, AO; Cunha, SM; Lemey, P; Machado, ES; Nissley, DV; Oliveira, RH; Soares, MA | 1 |
| Bernstein, BM; Campo, RE; Chiu, YL; Cotte, L; Da Silva, BA; Gathe, JC; Gazzard, B; Hicks, CB; King, MS; Klein, CE | 1 |
| Ahmed, A; Babrzadeh, F; Egholm, M; Gharizadeh, B; Hanczaruk, B; Holmes, SP; Liu, T; Margeridon-Thermet, S; Shafer, RW; Shahriar, R; Shulman, NS; Simen, BB; Wang, C | 1 |
| Mathew, M; McComsey, G; McGrath, D; Rightmire, A; Wirtz, V; Yang, R | 1 |
| Garcia, MV; Moutschen, M; Mukeba-Tshialala, D; Vaira, D | 1 |
| DeJesus, E; Hicks, CB; Lancaster, CT; Liao, Q; Pakes, GE; Pappa, KA; Ross, LL; Sension, MG; Sloan, LM; Wohl, DA | 1 |
| Belsey, E; Berzins, B; Chen, D; Choi, J; da Silva, B; Gerschenson, M; Kim, C; Libutti, DE; McComsey, GA; Murphy, RL; Shore, J; Taiwo, B; Weinstein, J | 1 |
| Ariyoshi, K; Auwanit, W; Matsubayashi, T; Matsuyama, A; Mukoyama, Y; Pathipvanich, P; Rojanawiwat, A; Saeng-aroon, S; Sawanpanyalert, P; Tsuchiya, N; Yasuda, T | 1 |
| Barr, EA; Davies, JK; Forster-Harwood, J; Kinzie, K; Levin, MJ; McFarland, EJ; Pappas, J; Paul, SM; Salbenblatt, CR; Soda, E; Vazquez, A; Weinberg, A | 1 |
| Adlington, R; Richens, J; Shahmanesh, M | 1 |
| Phulsunder, A; Shanbag, P; Zaki, SA | 1 |
| Finkielsztejn, L; Firtion, G; Jullien, V; Krivine, A; Launay, O; Pannier, E; Rozenberg, F | 1 |
| Arnaiz, JA; Arranz, JA; Arribas, JR; Barragán, P; Barrufet, P; Blanco, JL; Casas, E; Clotet, B; Cosín, J; Cruceta, A; Curran, A; Dalmau, D; Ferrer, E; Gatell, JM; González, A; Gutiérrez, F; Knobel, H; Llibre, JM; Loncá, M; Mallolas, J; Martínez, E; Miró, JM; Pich, J; Podzamczer, D; Ribera, E; Roca, V; Sanz, J; Segura, F | 1 |
| Cabié, A; Chêne, G; Girard, PM; Katlama, C; Mercié, P; Michelet, C; Monchecourt, F; Morand-Joubert, L; Pétour, P; Trylesinski, A; Verdon, R | 1 |
| Black, V; Guidozzi, F | 1 |
| Alabi, A; Corrah, T; Cotten, M; Jallow, S; Janssens, W; Jaye, A; McConkey, SJ; Peterson, K; Rowland-Jones, S; Sarge-Njie, R; Vanham, G; Whittle, H | 1 |
| Brinkman, K; Danner, SA; Geerlings, SE; Hassink, EA; Lips, P; Reiss, P; Ristola, M; Sutinen, J; van Agtmael, MA; van Vonderen, MG | 1 |
| Borroto-Esoda, K; Harris, J; Lansdon, EB; Miller, MD; O'Neal, W; Svarovskaia, ES; Wakeford, C; Waters, JM; White, KL | 1 |
| Dewar, R; Dybul, M; Kityo, C; Mbamanya, F; Mugyenyi, P; Quinn, TC; Reynolds, SJ; Ssali, F | 1 |
| Dauer, B; Gute, P; Khaykin, P; Klauke, S; Staszewski, S; Stephan, C; Stuermer, M | 1 |
| Irunde, H; Minzi, OM; Moshiro, C | 1 |
| Chaix, ML; Cohen-Codar, I; Delaugerre, C; Delfraissy, JF; Dellamonica, P; Flandre, P; Ghosn, J; Jaeger, H; Norton, M; Raffi, F; Rouzioux, C; Shürmann, D; Taburet, AM; Van, PN | 1 |
| Antonucci, G; Capobianchi, MR; Iacomi, F; Mariano, A; Piselli, P; Puro, V; Solmone, M; Vairo, F; Vincenti, D | 1 |
| Brinkman, K; Danner, SA; Geerlings, SE; Hassink, EA; Milinkovic, A; Reiss, P; Ristola, M; van Agtmael, MA; van Eeden, A; van Vonderen, MG | 1 |
| Bernstein, BM; Brown, TT; da Silva, BA; King, MS; McComsey, GA; Qaqish, RB | 1 |
| Flor-Parra, F; López-Cortés, LF; Mata, RC; Pérez-Romero, P; Viciana, P | 1 |
| Arasteh, K; Ebrahimi, R; Fenske, S; Freiwald, M; Gallo, L; Kuhlmann, B; Mertenskoetter, T; Ranneberg, R; Weitner, L | 1 |
| Bellos, N; Fine, D; Kumar, PN; Lackey, P; Patel, P; Shaefer, MS; Sloan, L; Smith, KY; Sutherland-Phillips, DH; Vavro, C; Wannamaker, P; Yau, L | 1 |
| Ebrahimi, R; Ewan, J; Fisher, M; Kingston, M; Liu, H; Moyle, GJ; Orkin, C; Reilly, G; Shahmanesh, M; Wilkins, E | 1 |
| Cohen, C; Dejesus, E; Elion, R; Gathe, JC; Ha, B; Hsu, RK; Lanier, R; Paulsen, D; Redfield, RR; Ross, L; Yau, L | 1 |
| Arribas López, JR | 1 |
| Christie, CD; Evans-Gilbert, T; Moore, J; Palmer, P; Pierre, RB; Rodriguez, B; Steel-Duncan, J; White, YR | 1 |
| Bowden, S; Dore, GJ; Goodman, Z; Lewin, SR; Locarnini, S; Marks, P; Matthews, GV; Philp, FH; Sasadeusz, J; Seaberg, E; Tang, Y; Thio, CL | 1 |
| Kongnyuy, EJ; Shang, J; Shey, M; Wiysonge, CS | 1 |
| Andreotti, M; Antonelli, G; Ceccarelli, G; d'Ettorre, G; Massetti, P; Mastroianni, CM; Rizza, C; Turriziani, O; Vella, S; Vullo, V | 1 |
| Boamah, I; Court, MH; Kashuba, AD; Kenu, E; Kwara, A; Lartey, M; Oliver-Commey, J; Rezk, NL | 1 |
| Hanekom, WA; Maartens, G; Meintjes, G; Rangaka, MX; Seldon, R; Wilkinson, KA; Wilkinson, RJ | 1 |
| Tedaldi, EM; van den Berg-Wolf, M | 1 |
| Cheng, AK; Enejosa, J; Margot, NA; McColl, DJ; Miller, MD | 1 |
| Chaix, ML; Cohen-Codar, I; Delfraissy, JF; Dellamonica, P; Flandre, P; Ghosn, J; Girard, PM; Ngovan, P; Norton, M; Raffi, F | 1 |
| Ananworanich, J; Boonrak, P; Bunupuradah, T; Burger, D; Gorowara, M; Jupimai, T; Pancharoen, C; Phasomsap, C; Puthanakit, T; Ruxrungtham, K; van der Lugt, J | 1 |
| Bonkoungou, V; Carosi, G; Carvalho, AC; Dembele, M; Kouanda, S; Matteelli, A; Monno, L; Regazzi, M; Saleri, N; Sanou, MJ; Simporé, J; Villani, P | 1 |
| Barreiro, P; Fernández, JV; Labarga, P; Medrano, J; Soriano, V; Tuma, P; Vispo, E | 1 |
| Beltrame, A; Bozzano, F; Cenderello, G; Costa, P; De Maria, A; Di Biagio, A; Fenoglio, D; Ferrea, G; Pagano, G | 1 |
| Bickel, M; Bodtländer, A; Gute, P; Klauke, S; Knecht, GK; Kurowski, M; Lutz, T; Stephan, C; von Hentig, N | 1 |
| Bisseye, C; Buelli, F; Castelli, F; Gnoula, C; Ilboudo, D; Karou, D; Nikiema, JB; Odolini, S; Ouermi, D; Pietra, V; Pignatelli, S; Sagna, T; Sanou, DS; Sia, DJ; Simpore, J | 1 |
| Hill, A; Sawyer, W | 1 |
| Back, D; Else, L; Fraser, W; Khoo, S; Molyneux, E; Moons, P; Poerksen, G; Pollock, L; Walker, S | 1 |
| Birbeck, GL | 1 |
| Hogan, BK; Lewis, JS; Nierenberg, NE; Patterson, TF; Thompson, GR | 1 |
| Boccafoglio, F; Concia, E; Gottardi, M; Lanzafame, M; Lattuada, E; Soldani, F | 1 |
| Battegay, M; Bernasconi, E; Fux, CA; Klimkait, T; Louvel, S; Opravil, M; Speck, R; Vogel, M; Weber, R; Wolf, E | 1 |
| Albrecht, H; Jorgensen, P; Marcus, U; Schürmann, D; Suttorp, N | 1 |
| Amin, J; Baker, D; Bloch, M; Carr, A; Cooper, DA; Emery, S; Martin, A | 2 |
| Reiss, P | 1 |
| Eklund, M; Gray, GE; Hall, DB; Hopley, M; Martinson, NA; Mayers, D; McIntyre, JA; Moodley, D; Robinson, P | 1 |
| John-Stewart, GC; Lehman, DA; Overbaugh, J | 1 |
| Karunaianantham, R; Narayanan, PR; Rajesh, L; Swaminathan, S | 1 |
| Evans, J; Jarrin, I; Lafuente-Lafuente, C; Mazeron, MC; Parrinello, M; Schnepf, N; Sellier, P; Simoneau, G | 1 |
| Ackermans, MT; Blümer, RM; Danner, SA; Hassink, EA; Reiss, P; Sauerwein, HP; Serlie, MJ; Sutinen, J; van Agtmael, MA; van Vonderen, MG; Yki-Jarvinen, H | 1 |
| Cheng, I; Kuritzkes, DR; Paredes, R; Tuomala, RE | 2 |
| Kurtyka, D; Somboonwit, C; Velez, AP | 1 |
| Louie, M; Marfatia, S; Mear, I; Meunier, J; Regnault, A; Viala-Danten, M | 1 |
| Aldrovandi, GM; Chu, C; Foca, M; Ha, BF; Li, D; McIntosh, K; Meyer, WA; Moye, J; Rich, KC; Shearer, WT; Thompson, B; Walter, J | 1 |
| Burke, A; Dunn, DT; Gibb, DM; Gilks, CF; Goodall, RL; Kaleebu, P; Katundu, P; Kityo, C; Lyagoba, F; McCormick, A; Munderi, P; Ndembi, N; Pillay, D; Robertson, V; Walker, AS; Yirrell, DL | 1 |
| Amuron, B; Birungi, J; Bunnell, R; Coutinho, A; Foster, S; Grosskurth, H; Jaffar, S; Kyomuhangi, R; Levin, J; Mermin, J; Nabiryo, C; Namara, G; Ndembi, N; Opio, A; Tappero, JW | 1 |
| Bravo, I; Carosi, G; Clotet, B; del Arco, A; Echeverría, P; Gálvez, J; Gómez, JL; López, JC; López-Blazquez, R; Mariño, A; Moreno, A; Negredo, E; Ocampo, A; Pedrol, E; Pérez-Alvarez, N; Portilla, J; Prieto, A; Rubio, R; Viladés, C | 1 |
| Anitha, S; Hemanth Kumar, AK; Kumaraswami, V; Narendran, G; Padmapriyadarsini, C; Rajasekaran, S; Ramachandran, G; Subramanyam, S; Swaminathan, S | 1 |
| Belem, AM; Bisseye, C; Gnoula, C; Ilboudo, D; Kabre, GB; Karou, DS; Nikiema, JB; Onadja, SM; Ouermi, D; Pietra, V; Pignatelli, S; Sanou, DS; Simpore, J | 1 |
| Collier, AC; Daar, ES; Farajallah, A; Fischl, MA; Geiseler, PJ; Godfrey, C; Ha, B; Jahed, NC; Johnson, VA; Katzenstein, D; Koletar, SL; Mollan, K; Myers, L; Peeples, L; Rooney, JF; Sax, PE; Tierney, C; Woodward, WC | 1 |
| Asahchop, EL; Brenner, BG; Moisi, D; Ntemgwa, M; Toni, TA; Wainberg, MA | 1 |
| Barros, C; Botecchia, M; de Mendoza, C; Del Romero, J; Madejon, A; Rodriguez, C; Soriano, V; Treviño, A; Tuma, P | 1 |
| Bartlett, JA; Crump, JA; Kiwera, RA; Moon, AM; Ole-Nguyaine, S; Ramadhani, HO; Shao, HJ; Shao, JF; Thielman, NM; Uiso, LO; Woods, CW | 1 |
| Kumar, PN; Patel, P | 1 |
| Abaine, D; Aber, M; Ahimbisibwe, F; Akao, J; Akuma, S; Amuron, B; Amurwon, J; Angweng, E; Anywar, W; Atwiine, D; Atwiine, S; Awio, P; Babiker, A; Babiker, AG; Bafana, T; Bagaya, L; Bahendeka, S; Bakeinyaga, GT; Barungi, G; Bassett, M; Bohannon, J; Boocock, K; Borok, M; Bray, D; Breckenridge, A; Bulaya-Tembo, R; Buluma, E; Burke, A; Burke, C; Byakwaga, H; Byamukama, A; Byaruhanga, R; Chakonza, L; Chidziva, E; Chigwedere, E; Chimanzi, J; Chimbetete, C; Chirairo, H; Chirara, M; Chirema, O; Chitsungo, S; Chivhunga, T; Coutinho, A; Darbyshire, JH; Drasiku, A; Dunn, D; Enzama, R; Etukoit, B; Fadhiru, K; Ferrier, A; Florence, A; Foster, S; Gazzard, B; Generous, L; Gibb, DM; Gilks, C; Gilks, CF; Goodall, R; Grosskurth, H; Grundy, C; Haguma, W; Hakim, J; Hill, C; Hughes, P; Jamu, A; Jangano, M; Jones, S; Kabanda, J; Kabuye, G; Kagina, G; Kajungu, D; Kaleebu, P; Kambungu, A; Kankunda, R; Karungi, J; Kasirye, R; Katabira, E; Katabira, H; Katundu, P; Khauka, P; Kigozi, J; Kikaire, B; Kityo, C; Komugyena, J; Kulume, R; Kusiima, A; Kyomugisha, H; Labeja, O; Lara, AM; Latif, A; Levin, J; Lubwama, E; Lutwama, F; Lyagoba, F; Machingura, I; Machingura, J; Makota, S; Mambule, I; Mapinge, F; Mapuchere, C; Massa, R; Matenga, J; Matongo, M; Maweni, C; Mawora, A; McCormick, A; McLaren, A; Mdege, N; Moyo, K; Muchabaiwa, L; Mudzingwa, S; Mufuka-Kapuya, C; Muganzi, A; Mugisha, A; Mugurungi, O; Mugyenyi, P; Muhweezi, D; Muhwezi, A; Mukiibi, S; Mukose, A; Mulindwa, G; Mulindwa, M; Munderi, P; Murungi, S; Musana, H; Musoro, G; Mutowo, J; Mutsai, S; Muvirimi, C; Muyingo, S; Muzambi, M; Mwebesa, D; Mwesigwa, P; Nabankema, E; Nabongo, P; Naidoo, B; Nairuba, R; Nakahima, W; Nakazibwe, M; Nakiyingi, J; Nalumenya, R; Namale, L; Namara, W; Namata, I; Namazzi, A; Namuli, T; Namyalo, M; Nanfuka, A; Nanfuka, R; Nassuna, G; Ndembi, N; Newland, C; Ngorima, N; Nimwesiga, E; Nsibambi, D; Nyachwo, L; Nyiraguhirwa, D; Ochai, R; Ojiambo, H; Ojiambo, W; Oketta, F; Omony, W; Otim, T; Oyugi, J; Palfreeman, A; Pascoe, M; Pearce, G; Peto, L; Peto, T; Phiri, M; Pillay, D; Pozniak, A; Puddephatt, C; Rahim, S; Rauchenberger, M; Reid, A; Robertson, V; Ronald, A; Rooney, J; Ruberantwari, A; Rutikarayo, N; Sabiiti, J; Sadik, F; Sematala, F; Serwadda, D; Sheehan, S; Simango, M; Smith, M; Snowden, W; Spencer-Drake, C; Spyer, M; Ssali, F; Steens, JM; Svovanapasis, P; Takubwa, J; Taylor, K; Taziwa, F; Tinago, G; Todd, J; Tugume, S; Tukamushaba, J; Tumukunde, D; Tumusiime, C; Twijukye, C; Vere, L; Waita, R; Wakholi, BN; Walker, AS; Walusimbi, J; Wangati, K; Wanyama, J; Wapakhabulo, AC; Warambwa, C; Warara, R; Wavamunno, P; Weller, I; Whitworth, J; Wilkes, H; Winogron, D; Yirrell, D; Zalwango, A; Zalwango, E; Zawedde, C; Zengeza, E | 1 |
| Cohen, C; DeJesus, E; Elion, R; Gerondelis, P; Ha, B; Horton, J; Lanier, ER; Ross, LL; Rouse, E | 1 |
| Barragán, P; Casamitjana, R; Deulofeu, R; Gatell, JM; Gutiérrez, F; Larrousse, M; Loncá, M; Mallolas, J; Martínez, E; Pérez, I; Pich, J; Podzamczer, D | 1 |
| Mauss, S | 1 |
| Gervain, J; Horváth, G; Hunyady, B; Makara, M; Pár, A; Szalay, F; Telegdy, L; Tornai, I | 1 |
| Boothby, M; Gathercole, LL; McGee, KC; McTernan, PG; Nightingale, P; Shahmanesh, M; Shojaee-Moradie, F; Tomlinson, JW; Umpleby, AM | 1 |
| Agosti, MR; Ayala, SG; Barboni, G; García, MK; Quarleri, J; Salomón, H; Vignoles, M | 1 |
| Battegay, M; Bernasconi, E; Cavassini, M; Elzi, L; Furrer, H; Hirschel, B; Ledergerber, B; Marzolini, C; Vernazza, P; Weber, R | 1 |
| Cooper, V; Fisher, M; Gellaitry, G; Horne, R; Lange, AC; Vrijens, B; White, D | 1 |
| Bruzzone, B; Colao, G; De Silvestri, A; Di Biagio, A; Di Pietro, M; Maserati, R; Re, MC; Tinelli, C; Uglietti, A; Zazzi, M | 1 |
| Babiker, AG; Darbyshire, JH; Gibb, DM; Gilks, CF; Grosskurth, H; Kityo, C; Mugyenyi, P; Munderi, P; Reid, A; Ssali, F; Walker, AS | 1 |
| Clumeck, N; Coakley, E; Cooper, DA; Dejesus, E; Goodrich, J; Hackman, F; Heera, J; Horban, A; Ive, P; Mayer, H; Mingrone, H; Mohapi, L; Reeves, JD; Reyes-Teran, G; Saag, M; Sullivan, J; Tawadrous, M; Ting, N; Van Der Ryst, E; Walmsley, S; Westby, M | 1 |
| Airoldi, M; Cossarizza, A; De Biasi, S; Gibellini, L; Maggiolo, F; Mussini, C; Nasi, M; Pinti, M; Ravasio, V; Roat, E; Suter, F | 1 |
| Corbett, AH; Hosseinipour, MC; Kanyama, C; Kashuba, AD; Kazembe, P; Mkupani, P; Mwansambo, C; Nyirenda, J; Rezk, NL; Sichali, D; Tien, H; Weigel, R | 1 |
| Böni, J; Bürgisser, P; Demeter, LM; Ehteshami, M; Götte, M; Günthard, HF; Klimkait, T; Ledergerber, B; Nijhuis, M; Schuurman, R; Symons, J; von Wyl, V; Yerly, S | 1 |
| Achenbach, CJ; Murphy, RL; Scarsi, KK | 1 |
| Campo, RE; Cohen, C; Grimm, K; Maa, J; Seekins, D; Shangguan, T | 1 |
| Landman, GW; Soonawala, D | 1 |
| Deshpande, A; Fleury, HJ; Jeannot, AC; Pinson, P; Schrive, MH; Wittkop, L | 1 |
| Berg, CL; Coffin, CS; Curry, MP; Dove, LM; Nissen, NN; Ragni, M; Regenstein, FG; Roland, ME; Sherman, KE; Stock, PG; Terrault, NA | 1 |
| Kiertiburanakul, S; Manosuthi, W; Sungkanuparph, S; Wongprasit, P | 1 |
| Ariyoshi, K; Auwanit, W; Ayuthaya, PI; Kannagi, M; Pathipvanich, P; Rojanawiwat, A; Saeng-aroon, S; Sawanpanyalert, P; Sugiura, W; Tsuchiya, N | 1 |
| Burger, D; Chintu, C; Ewings, F; Gibb, DM; Kabamba, D; Kankasa, C; L'homme, R; Mulenga, V; Thomason, M; Walker, AS | 1 |
| Camacho, RJ; Deforche, K; Libin, P; Theys, K; Van Laethem, K; Vandamme, AM | 1 |
| Butini, L; Cirioni, O; Costantini, A; Giacometti, A; Montroni, M; Scalise, G | 1 |
| Branco, T; Cavassini, M; Domingo, P; Fisher, M; Givens, N; Khuong-Josses, MA; Lim, ML; Moyle, GJ; Norden, AG; Pearce, HC; Podzamczer, D; Post, FA; Rieger, A; Stellbrink, HJ; Vavro, C | 1 |
| Capparelli, E; Chokephaibulkit, K; Chotpitayasunondh, T; Cressey, TR; Eksaengsri, A; Hongsiriwan, S; McIntosh, K; Muresan, P; Plipat, N; Prasitsuebsai, W; Sirisanthana, V; Smith, ME; Toye, M; Vanprapar, N; Yogev, R | 1 |
| Ajuna, P; Bagenda, D; Barlow-Mosha, L; Church, JD; Eshleman, SH; Mubiru, M; Musoke, P; Towler, WI | 1 |
| Benalycherif, A; Bennai, Y; Diallo, MB; Fall, MB; Girard, PM; Gueye, NF; Kane, CT; Landman, R; Mboup, S; Ndiaye, B; Peytavin, G; Sow, PS | 1 |
| Kumwenda, JJ; Manary, M; Moore, E; Ndekha, M; van Oosterhout, JJ; Zijlstra, EE | 1 |
| Bichet, JC; Delfraissy, JF; Ghosn, J; Sahali, S | 1 |
| Chirara, M; Gilks, CF; Goodall, RL; Joyce, A; Katundu, P; McCormick, AL; Ndembi, N; Pillay, D; Walker, S; Yirrell, D | 1 |
| Chintu, C; Ferrier, A; Ford, D; Gibb, DM; Grant, PR; Gupta, RK; Kabamba, D; Kalumbi, M; Mulenga, V; Pillay, D; Walker, AS | 1 |
| Bravenboer, B; Gisolf, EH; Groeneveld, PH; Hoepelman, AI; Koopmans, PP; Langebeek, N; Legrand, JC; Mulder, PG; Richter, C; Sprenger, HG; Ten Kate, RW; Ten Napel, CH; van der Werf, TS; Van Kasteren, ME; Vriesendorp, R | 1 |
| Burger, D; Chesshyre, E; Khoo, S; Molyneux, E; Moons, P; Poerksen, G; Pollock, L | 1 |
| Barnas, D; Bazmi, H; Bixby, C; Jemsek, J; Koontz, D; Mellors, JW | 1 |
| Di Bisceglie, AM; Firnhaber, C; Maskew, M; McNamara, L; Reyneke, A; Schulze, D | 1 |
| Apisarnthanarak, A; Mundy, LM | 1 |
| Ahmed, YI; Chasela, CS; Chigwenembe, M; Ellington, SR; Fiscus, SA; Hoffman, IF; Hosseinipour, MC; Hudgens, MG; Jamieson, DJ; Kacheche, Z; Kamwendo, DD; Kayira, D; Kazembe, P; Knight, RJ; Kourtis, AP; Martinson, F; Mofolo, IA; Sichali, DS; Soko, A; Tegha, G; van der Horst, CM; Wiener, JB | 1 |
| Chang, LW; Harris, J; Humphreys, EH | 1 |
| Harwell, J; Hutton, E; Luzuriaga, K; Meng, CY; Pean, P; Pugatch, D; Somasundaran, M; Sophan, S; Trzmielina, S | 1 |
| Akhavan-Mogaddam, J; Emadi, SE; Emadi, SN; Moshkforoush, A; Sobhani, B; Yousefi, M | 1 |
| Bellos, N; Dejesus, E; Murphy, D; Patel, LG; Ross, LL; Shaefer, MS; Squires, KE; Wannamaker, PG; Young, B; Zhao, HH | 1 |
| Brinkman, K; Claessen, FA; Mulder, JW; Prins, JM; Regez, RM; Sonder, GJ; van den Hoek, A; Veenstra, J | 1 |
| Gianini, RJ; Gomes-Gouvêa, MS; Leite, OM; Locarnini, S; Martins, LG; Mendes-Correa, MC; Pinho, JR; Santana, RA; Silva, MH; Sitnik, R; Uip, DE; Yuen, L | 1 |
| Banda, HN; Chasela, C; Eron, JJ; Farr, SL; Fiscus, SA; Jamieson, DJ; Johnson, JA; Kashuba, AD; Kourtis, AP; Lipscomb, J; Matiki, C; Mpaso, M; Nelson, JA; Ng'ombe, TJ; Tegha, GL; van der Horst, C; Wiener, J | 1 |
| Abrams, EJ; Amani-Bosse, C; Chaix, ML; Coffie, PA; Dabis, F; Ekouevi, DK; Leroy, V; Tonwe-Gold, B | 1 |
| Buck, WC; Kabue, MM; Kazembe, PN; Kline, MW | 1 |
| Daddacha, W; Kim, B; Van Cor-Hosmer, SK | 1 |
| Feng, Y; Huang, J; Huang, Y; Liao, L; Liu, S; Ma, L; Qu, S; Shao, Y; Sun, J; Xing, H; Yu, X; Yuan, L | 1 |
| Gerstoft, J; Hansen, AB; Nielsen, H; Obel, N; Pedersen, C | 1 |
| Binka, M; Boukobza, S; Calvez, V; Fourati, S; Katlama, C; Malet, I; Marcelin, AG; Sayon, S; Simon, A; Simon, V; Wirden, M | 1 |
| Alcaro, S; Alteri, C; Antinori, A; Artese, A; Balzarini, J; Ceccherini-Silberstein, F; Costa, G; Forbici, F; Narciso, P; Perno, CF; Santoro, MM; Schols, D; Svicher, V; Tommasi, C; Van Laethem, K; Zaccarelli, M | 1 |
| Abrams, EJ; Coovadia, A; Hu, CC; Hunt, G; Kuhn, L; Martens, L; Meyers, T; Morris, L; Sherman, G; Stehlau, R; Tsai, WY | 1 |
| Arribas, JR; Compston, J; Gerstoft, J; Hughes, S; Lambert, J; Lazzarin, A; Leather, D; Orkin, C; Pearce, H; Rizzardini, G; Sprenger, HG; Stellbrink, HJ; Sture, G; Van Wijngaerden, E; Zucchi, P | 1 |
| Aba, YT; Aoussi, EF; Bissagnene, E; Eholié, SP; Ehui, E; Kadio, A; Kakou, AR; Kassi, A; Ondounda, M; Ouattara, I; Tanon, A | 1 |
| Allegri, R; Amadasi, S; Carosi, G; Cristini, G; Gatti, F; Izzo, I; Mendeni, M; Motta, D; Paraninfo, G; Quiros-Roldan, E; Torti, C | 1 |
| Castelnuovo, B; Kamya, MR; Kiragga, A; Manabe, Y | 1 |
| Burger, D; Chijoka, C; Chintu, C; Cook, A; Ferrier, A; Gibb, DM; Kabamba, D; Kalengo, C; Kankasa, C; Kityo, C; Mulenga, V; Thomason, M; Walker, AS | 1 |
| Bachani, D; Chan, PL; Deshpande, A; Rajasekaran, S; Rewari, BB; Srikantiah, P | 1 |
| Bouzas, MB; Cassino, L; Giuliano, SF; Laufer, N; Quarleri, J | 1 |
| Gitau, R; Graham, SM; Jalalian-Lechak, Z; Jaoko, W; Kiarie, JN; Mandaliya, K; Masese, L; McClelland, RS; Ndinya-Achola, J; Overbaugh, J; Peshu, N; Richardson, BA | 1 |
| Rutherford, GW; Siegfried, N; Spaulding, A | 1 |
| Gomes-Gouvêa, MS; Guastini, Cde F; Lemos, MF; Mendes-Correa, MC; Oba, IT; Pinho, JR; Silva, AC; Spina, AM | 1 |
| Asensi, V; Miró, JM; Rodríguez-Guardado, A; Tuset, M | 1 |
| Anglaret, X; Attia, A; Chenal, H; Danel, C; Eholié, S; Gabillard, D; Messou, E; N'Dri-Yoman, T; Polneau, S; Seyler, C; Toni, T; Wakasugi, N | 1 |
| Amin, J; Cooper, DA; Cordery, DV; Hesse, K | 1 |
| Biwolé-Sida, M; Bork, K; Coudray, M; Cournil, A; Delaporte, E; Essomba, CN; Kouanfack, C; Laurent, C; Tonfack, CA | 1 |
| Delaporte, E; Diouf, A; Etard, JF; Girard, PM; Landman, R; Laurent, C; Molinari, N; Ndoye, I; Ngom Guèye, NF; Sow, PS; Tchatchueng Mbougua, JB | 1 |
| Benhamou, Y; Pais, R | 1 |
| Nwankwo, N; Seker, H | 1 |
| Adkison, K; Bakeera-Kitaka, S; Burger, D; Gibb, DM; Kekitiinwa, A; Kendall, L; Mugyenyi, P; Musiime, V; Musoke, P; Odongo, F; Snowden, WB; Thomason, M; Walker, AS | 1 |
| Back, DJ; Boffito, M; Jackson, AG; Mandalia, S; Moyle, GJ; Randell, PA; Taylor, J; Tjia, JF | 1 |
| Castagna, A; Cossarini, F; Galli, L; Gianotti, N; Spagnuolo, V | 1 |
| Crane, HM; Feldman, BJ; Grunfeld, C; Kitahata, MM; Lederman, MM; Moore, R; Mugavero, MJ; Rodriguez, B; Saag, MS; Van Rompaey, S; Willig, JH | 1 |
| Borroto-Esoda, K; Goodman, DD; Margot, NA; McColl, DJ; Miller, MD; Svarovskaia, ES; Zhong, L; Zhou, Y | 1 |
| Boué, F; Briot, K; Cohen-Codar, I; Delfraissy, JF; Flandre, P; Knysz, B; Kolta, S; Morlat, P; Norton, M; Pintado, C; Rode, R; Roux, C; Valantin, MA; Van, PN | 1 |
| Mallet, V; Pol, S; Vallet-Pichard, A | 1 |
| Alvarez, SM; de Jesús Asencio Montiel, I; Flores, RA; Martínez, JG; Mata Marín, JA | 1 |
| Arcilla, MS; Back, NK; Frissen, JP; Hamers, RL; Wensing, AM | 1 |
| Bracciale, L; Cauda, R; D'Avino, A; De Luca, A; Di Giambenedetto, S; Doino, M; Fabbiani, M; Marzocchetti, A; Navarra, P | 1 |
| Baldelli, F; Floridia, M; Francisci, D; Martinelli, L; Masini, G; Weimer, LE; Zazzi, M | 1 |
| Chimsuntorn, S; Lueangniyomkul, A; Mankatitham, W; Manosuthi, W; Nilkamhang, S; Sungkanuparph, S; Suntisuklappon, B; Tantanathip, P; Thongyen, S | 1 |
| Ekwunife, OI; Iwuamadi, UI; Udeogaranya, OP; Ukwe, CV | 1 |
| Avettand-fenoel, V; Blanche, S; Briand, N; Chaix, ML; Frange, P; Mahlaoui, N; Moshous, D; Rouzioux, C; Veber, F | 1 |
| Gold, WL; Koblic, PM; la Porte, CJ; Lee, TC | 1 |
| Badiane, CI; Batista, G; Bazolo, N; Guèye, NF; Manga, NM; Poda, A; Sané, O; Sow, PS | 1 |
| Honda, M; Ishisaka, M; Ishizuka, N; Kimura, S; Oka, S | 1 |
| Cooper, V; Ewan, J; Fisher, M; Horne, R; Liu, HC; Moyle, GJ; Reilly, G | 1 |
| Chan, DJ; Jeganathan, S; Maruszak, H; Smith, DE | 1 |
| Blevins, M; Burlison, JR; Ciampa, PJ; Moon, TD; Rothman, RL; Sidat, M; Vermund, SH | 1 |
| Chen, XY; Gui, X; Yang, RR; Zhu, Y | 1 |
| Blanche, S; Bouazza, N; Frange, P; Hirt, D; Rey, E; Tréluyer, JM; Urien, S | 1 |
| Anh, DT; Bang, ND; Chau, NV; Chau, TT; Chinh, NT; de Jong, M; Dong, DT; Dung, NH; Dung, NT; Farrar, JJ; Hai, NN; Hien, NQ; Hien, TT; Lan, NN; Lan, NT; Mai, NT; Mai, PP; Minh, NH; Phu, NH; Quy, HT; Simmons, CP; Thai, PV; Thoa, NT; Tien, NA; Török, ME; Wolbers, M; Yen, NT | 1 |
| Daar, ES; Ha, B; Jahed, NC; Kitch, D; McComsey, GA; Melbourne, K; Myers, L; Sax, PE; Tebas, P; Tierney, C | 1 |
| Bryson, Y; Camarca, M; Mirochnick, M; Mofenson, L; Moye, J; Nielsen-Saines, K; Pilotto, JH; Pinto, J; Rossi, S; Veloso, VG; Watts, DH | 1 |
| Aghasadeghi, MR; Ardestani, MS; Bahramali, G; Davar Siadat, S; Delbaz, SA; Farahani, A; Memarnejadian, A; Mohraz, M; Mostafavi, E; Sadat, SM; Saraji, AA; Vahabpour, R | 1 |
| Arendt, V; Gras, A; Henry, AP; Karasi, JC; Karasi-Omes, C; Sauvageot, N; Schmit, JC; Schneider, S; Seguin-Devaux, C; Ternes, AM | 1 |
| Barragán, P; Bonet, R; Curran, A; Gatell, JM; Knobel, H; Loncá, M; Martínez, E; Negredo, E; Ordoñez-Llanos, J; Podzamczer, D; Ribera, E; Saumoy, M | 1 |
| Gonzalez-García, J; Labarga, P; Pineda, JA; Poveda, E; Rodriguez, C; Santos, J; Sobrino, P; Soriano, V; Tuma, P; Tural, C; Vidal, F | 1 |
| Dlamini, J; Hadigan, C; Khabo, P; Kowo, H; Ledwaba, L; Maja, P; Mokhathi, T; Mokwena, N; Orsega, S; Proschan, M; Tsoku, M | 1 |
| Chan, K; Cooper, C; Hogg, RS; Klein, MB; Loutfy, MR; Machouf, N; Montaner, JS; Raboud, J; Rourke, SB; Tan, DH; Tsoukas, C; Walmsley, S | 1 |
| Deng, L; Gao, S; Gui, X; Liang, K; Rong, Y; Xiong, Y; Yan, Y; Yang, R; Zhang, Y | 1 |
| Brocklehurst, P; Siegfried, N; Sint, TT; van der Merwe, L | 1 |
| Azzoni, L; Firnhaber, C; Foulkes, AS; Fox, L; Glencross, DK; Gross, R; Hunt, G; Montaner, LJ; Morris, L; Sanne, I; Schulze, D; Stevens, W; Van Amsterdam, D; Yin, X | 1 |
| Atun, R; Ben-Smith, A; Chimbwandira, F; Chirwa, Z; Gilks, CF; Harries, AD; Jahn, A; Lynen, L; Makombe, SD; Meguid, T; Midiani, D; Mnthambala, A; Schouten, EJ; Shawa, M; Van Damme, W; van Oosterhout, JJ; Zachariah, R; Zolfo, M | 1 |
| Bacheler, L; Dunn, DT; Gilks, C; Goodall, RL; Kaleebu, P; Kityo, C; Munderi, P; Pillay, D; Ranopa, M; Van Houtte, M | 1 |
| Rizzardini, G; Zucchi, P | 1 |
| Chantarangsu, S; Chantratita, W; Charoenyingwattana, A; Kamatani, N; Kiertiburanakul, S; Kubo, M; Mahasirimongkol, S; Manosuthi, W; Mushiroda, T; Nakamura, Y; Sungkanuparph, S; Sura, T; Takahashi, A; Tantisiriwat, W | 1 |
| Ammassari, A; Castagna, A; Delaugerre, C; Ghosn, J; Medrano, J; Molina, JM; Pavie, J; Porcher, R; Rusconi, S; Torti, C; Valin, N | 1 |
| Boom, WH; Charlebois, E; Havlir, DV; Lin, R; Mayanja-Kizza, H; Mugerwa, RD; Mugyenyi, P; Mupere, E; Nanteza, MW; Srikantiah, P; Whalen, CC | 1 |
| Hu, Z; Kuritzkes, DR | 1 |
| Barro, M; Diagbouga, S; Diasso, Y; Drabo, A; Foulongne, V; François, R; Hien, A; Hien, H; Michel, S; Msellati, P; Nacro, B; Ouiminga, A; Some, J; Tamboura, H; Van De Perre, P; Yaméogo, S; Zouré, E | 1 |
| Amole, CD; Brisebois, C; Brown Ripin, DH; Essajee, S; Koehler, E; Levin, AD; Moore, MC; Sickler, JJ; Singh, IR | 1 |
| Dou, Z; Durako, S; Jiao, JH; Ma, Y; Xu, J; Yu, L; Zhang, F; Zhao, Y | 1 |
| Calis, JC; de Wit, TF; Geelen, SP; Sigaloff, KC; van Vugt, M | 1 |
| Cent, A; Chung, MH; Cook, L; Jerome, KR; John-Stewart, G; Kim, HN; Lule, G; Morrow, RA; Richardson, B; Scott, J; Tapia, K | 1 |
| Bruzzone, B; Caligiuri, P; Di Biagio, A; Icardi, G; Rosso, R; Taramasso, L; Viscoli, C | 1 |
| Hull, MW; Montaner, JS | 1 |
| Budhathoki, C; Collier, AC; Daar, ES; Farajallah, A; Feinberg, J; Fischl, MA; Godfrey, C; Ha, B; Jahed, NC; Katzenstein, D; Mollan, K; Murphy, RL; Myers, L; Rooney, JF; Sax, PE; Tashima, K; Tierney, C; Woodward, WC | 1 |
| Balungi, J; Burger, DM; Bwakura-Dangarembizi, M; Ferrier, A; Fillekes, Q; Gibb, DM; Keishanyu, R; Kendall, L; Lutakome, J; Natukunda, E; Walker, AS | 1 |
| Razonable, RR | 1 |
| González-Duarte, A; Pinales, R; Ramirez, C; Sierra-Madero, J | 1 |
| Frederiksen, CA; Langdahl, BL; Laursen, AL; Melchjorsen, J; Nielsen, US; Rasmussen, TA; Tolstrup, M; Østergaard, L | 1 |
| Cabello Úbeda, A; Górgolas, M; Sanz Moreno, J; Williams, F | 1 |
| Alvarez, Y; Hioe, CE; Nàdas, A; Tuen, M | 1 |
| Anwikar, SR; Bandekar, MS; Kshirsagar, NA; Pazare, AP; Smrati, B; Tatke, PA | 1 |
| Gibb, DM; Gilks, CF; Grosskurth, H; Hakim, J; Kityo, C; Mambule, I; Munderi, P; Reid, A; Ssali, F; Stöhr, W; Walker, AS | 1 |
| Ananworanich, J; Bhakeecheep, S; Bowonwattanuwong, C; Bunupuradah, T; Chetchotisakd, P; Hirschel, B; Jirajariyavej, S; Kantipong, P; Klinbuayaem, V; Munsakul, W; Petoumenos, K; Prasithsirikul, W; Ruxrungtham, K; Sirivichayakul, S; Sungkanuparph, S | 1 |
| Bagnarelli, P; Biagioni, G; Butini, L; Costantini, A; Ferreri, ML; Manzin, A; Marinelli, K; Monachetti, A; Montroni, M | 1 |
| Branger, M; Collin, G; Fraqueiro, G; Gervais, A; Hamet, G; Lada, O; Marcellin, P; Martinot-Peignoux, M; Matheron, S; Moucari, R; Peytavin, G; Roquebert, B | 1 |
| Benaboud, S; Blanche, S; Bouazza, N; Chappuy, H; Firtion, G; Hirt, D; Launay, O; Pannier, E; Rey, E; Tréluyer, JM; Urien, S | 1 |
| Angarano, G; Bellacosa, C; Graziano, G; Maggi, P; Montinaro, V; Pietanza, S; Strippoli, GF; Volpe, A | 1 |
| Henderson, DK | 1 |
| Back, DJ; Else, LJ; Khoo, SH; Taylor, S | 1 |
| Aurpibul, L; Capparelli, E; Chokephaibulkit, K; Cressey, TR; Eksaengsri, A; Hongsiriwon, S; Kabat, B; Limwongse, C; McIntosh, K; Muresan, P; Ngampiyaskul, C; Sirisanthana, V; Smith, ME; Toye, M; Wittawatmongkol, O; Yogev, R | 1 |
| Chang, SC; Chang, SY; Chen, MY; Chen, PJ; Hsieh, SM; Hung, CC; Kao, JH; Liu, CJ; Sheng, WH | 1 |
| Agut, H; Caumes, E; Challine, D; Deback, C; Lascaux, AS; Lévy, Y; Melica, G | 1 |
| Capparelli, EV; Chokephaibulkit, K; Cressey, TR; McKinney, R; Mirochnick, M; Nikanjam, M; Tremoulet, AH | 1 |
| Adkison, KK; Bakeera-Kitaka, S; Burger, DM; Gibb, DM; Kasirye, P; Kekitiinwa, A; Kendall, L; Mhute, T; Nahirya-Ntege, P; Snowden, W; Ssenyonga, M; Tumusiime, C; Walker, AS | 1 |
| Beck-Sagué, CM; Fernandez, AD; Leonardo-Guerrero, J; Nicholas, SW; Roman-Pouriet, J; Schmidt, NC | 1 |
| Aboulker, JP; Bocquentin, M; Charreau, I; Izopet, J; Marchou, B; Molina, JM; Taburet, AM; Tangre, P; Trancart, S | 1 |
| Gatanaga, H; Kikuchi, Y; Nishijima, T; Oka, S; Teruya, K; Tsukada, K | 1 |
| Borderi, M; Calza, L; Colangeli, V; Grossi, G; Manfredi, R; Motta, R; Salvadori, C; Trapani, F; Viale, P | 1 |
| Branger, M; Collin, G; Fraqueiro, G; Gervais, A; Lada, O; Leclerc, L; Marcellin, P; Martinot-Peignoux, M; Matheron, S; Moucari, R; Peytavin, G; Roquebert, B | 1 |
| Berrino, L; Scaglione, F | 1 |
| Chang, HM; Chen, YS; Lee, SS; Tsai, HC; Wann, SR | 1 |
| Aghokeng, AF; Bourgeois, A; Delaporte, E; Ducos, J; Kenfack, A; Kouanfack, C; Laurent, C; Mondain, AM; Mpoudi-Ngolé, E | 1 |
| Boltz, VF; Chow, JY; Coffin, JM; Gray, GE; Hall, DB; Hopley, MJ; Maldarelli, F; Martinson, NA; Mayers, D; McIntyre, JA; Mellors, JW; Palmer, S; Robinson, P | 1 |
| Conradie, F; Fox, M; Ive, P; McIntyre, J; Orrell, C; Papathanasopolous, MA; Sanne, I; Stevens, W; Wallis, CL; Wood, R; Zeinecker, J | 1 |
| Arnaiz, JA; Clotet, B; Cruceta, A; Dalmau, D; Diaz-Brito, V; Domingo, P; García, F; Gatell, JM; Knobel, H; León, A; Peraire, J | 1 |
| Bessong, PO; Masebe, TM; Meyer, D; Ndip, RN; Nwobegahay, J | 1 |
| Desakorn, V; Dhitavat, J; Karmacharya, BM; Kyaw, NL; Maek-a-nantawat, W; Pitisuttithum, P; Sahassananda, D; Tansuphaswadikul, S; Thanachartwet, V | 1 |
| Balzarini, J; Derudas, M; Grivel, JC; Introini, A; Lisco, A; Margolis, L; McGuigan, C; Merbah, M; Munawwar, A; Schinazi, RF; Vanpouille, C | 1 |
| Amoroso, A; Edozien, A; Etienne-Mesubi, M; Hossain, MB; Obiefune, M; Ojoo, S; Redfield, RR; Sheneberger, R; Stafford, K | 1 |
| Kanki, PJ; Shafer, RW; Tang, MW | 1 |
| Anastos, K; Burger, H; Foley, B; Hamy, F; Kemal, KS; Klimkait, T; Mayers, D; Minin, VN; Petrovic, K; Ramirez, CM; Suchard, MA; Weiser, B | 1 |
| Agu, KA; Akpoigbe, KJ; Badru, T; Chabikuli, O; Eluwa, GI; Hamelmann, C | 1 |
| Aubron-Olivier, C; Calvez, V; Charpentier, C; Descamps, D; Katlama, C; Landman, R; Marcelin, AG; Simon, A; Valantin, MA; Wirden, M; Yeni, P | 1 |
| Barragan, P; Crespo, M; Curran, A; Falco, V; Gatell, JM; Imaz, A; Lonca, M; Martinez, E; Martinez, M; Podzamczer, D; Ribera, E; Vidal-Sicart, S | 1 |
| Dugange, F; Harms, G; Hauser, A; Kuecherer, C; Kunz, A; Lau, I; Mbezi, P; Sewangi, J; Theuring, S; Ziske, J | 1 |
| Anderson, PL; Bushman, LR; Gardner, EM; Klein, B; Lichtenstein, K; Mawhinney, S; Meditz, A; Predhomme, J; Rower, JE; Zheng, JH | 1 |
| Luaengniyomkul, A; Mankhatitham, W; Manosuthi, W | 1 |
| Brinkman, K; Furrer, H; Fux, CA; Garcia, EF; Hoek, FJ; Krediet, RT; Reiss, P; van Straalen, JP; Vrouenraets, SM; Wit, FW | 1 |
| Domingo, P; Gutierrez, Mdel M; Mateo, MG; Vidal, F | 1 |
| Ascenzi, P; Ivanovic, J; Montesano, C; Narciso, P; Notari, S; Pucillo, LP; Sergi, M | 1 |
| Birn, H; Erlandsen, EJ; Jensen, D; Langdahl, BL; Laursen, AL; Nielsen, US; Rasmussen, TA; Tolstrup, M; Østergaard, L | 1 |
| Alavian, SM; Jazayeri, SM | 1 |
| Naggie, S; Sulkowski, MS | 1 |
| Adair, LS; Chasela, CS; Ellington, SR; Fiscus, SA; Hoffman, I; Hosseinipour, MC; Hudgens, MG; Jamieson, DJ; Kacheche, Z; Kamwendo, DD; Kayira, D; King, CC; Knight, RJ; Kourtis, AP; Martinson, F; Mofolo, IA; Sichali, DS; Soko, A; Tegha, G; van der Horst, C; Wiener, JB | 1 |
| Burger, DM; Chintu, C; Cook, A; Gibb, DM; McIlleron, H; Merry, C; Mulenga, V; Oudijk, JM; Walker, AS | 1 |
| Han, Y; Li, T; Li, Y; Wang, H; Zhang, C; Zhang, X; Zhu, T | 1 |
| Chidziva, E; Gibb, DM; Gilks, CF; Grosskurth, H; Hakim, J; Kizito, H; Kyomugisha, H; Munderi, P; Musoke, P; Nalumenya, R; Nathoo, K; Russell, EC; Spyer, M; Tumukunde, D; Walker, AS; Zalwango, E | 1 |
| Goliath, R; Meintjes, G; Seldon, R; Wilkinson, KA; Wilkinson, RJ | 1 |
| Shah, I | 1 |
| Abrams, EJ; Barlow-Mosha, L; Bobat, R; Chi, BH; Cotton, MF; Eshleman, SH; Hughes, MD; Jean-Philippe, P; Kamthunzi, P; Khadse, S; Lindsey, JC; Millar, L; Mofenson, LM; Moultrie, H; Mujuru, HA; Palumbo, P; Petzold, E; Purdue, L; Schimana, W; Violari, A | 1 |
| Bastos, FI; Bethel, J; Bryson, YJ; Camarca, M; Ceriotto, M; Dickover, R; Fonseca, R; Gray, G; Grinsztejn, B; Joao, EC; Kreitchmann, R; Machado, D; Mirochnick, M; Mofenson, LM; Moreira, RI; Morgado, MG; Moye, J; Mussi-Pinhata, MM; Nielsen-Saines, K; Pilotto, JH; Pinto, J; Santos, B; Siberry, G; Theron, G; Veloso, VG; Watts, DH; Xu, J | 1 |
| Amin, J; Carr, A; Ebeling, PR; Emery, S; Haskelberg, H; Hoy, JF | 1 |
| Denti, P; Karlsson, MO; McIlleron, H; Ren, Y; Smith, P; van der Walt, JS; Zhang, C | 1 |
| Cohen, M; Cole, S; Dou, Z; Eron, J; Liu, Z; Ma, Y; Napravnik, S; Wohl, D; Zhang, F; Zhang, Y; Zhao, D; Zhu, H | 1 |
| Aguilar, C; Brown, RS; Buti, M; Fagan, EA; Leu, CS; Pereira, MR; Tilson, HH; Verna, EC | 1 |
| Jaye, A; Oko, F; Okomo, U; Peterson, I; Peterson, K; Togun, T; Townend, J | 1 |
| Chianura, L; Errante, I; Moioli, MC; Orcese, C; Orso, M; Puoti, M; Rossotti, R; Schiantarelli, C; Schlacht, I; Travi, G; Vigo, B; Villa, MR; Volonterio, A | 1 |
| Bruzzone, B; Caligiuri, P; Di Biagio, A; Giacobbe, DR; Mikulska, M; Taramasso, L; Viscoli, C | 1 |
| Gibbs, C; Guyer, B; Haddad, M; McColl, DJ; Miller, MD; Su, C | 1 |
| Akinkuotu, A; Chasela, C; Hosseinipour, MC; Jamieson, DJ; Johnson, DC; King, CC; Kourtis, AP; Maliwichi, M; Moses, A; Mwafongo, A; van der Horst, C | 1 |
| Buranabanjasatean, S; Buranawanitchakorn, Y; Gaudy-Graffin, C; Goudeau, A; Halue, G; Jourdain, G; Khamduang, W; Kunkongkapan, S; Lallemant, M; Luekamlung, N; Moreau, A; Ngo-Giang-Huong, N; Sirirungsi, W | 1 |
| Ankcorn, M; Appiah, L; Chadwick, D; Foster, G; Geretti, AM; Phillips, R; Sarfo, S; Schwab, U; Stanley, A | 1 |
| Fätkenheuer, G; Hartmann, P; Jung, N; Lehmann, C; Rubbert, A; Schömig, E; Taubert, D | 1 |
| Auerbach, B; Castelnuovo, B; Hermans, S; Kuznik, A; Lamorde, M; Manabe, YC; Semeere, A; Sempa, J; Ssennono, M; Ssewankambo, F | 1 |
| Abel, F; Behrens, G; Domingo, P; Maserati, R; Pearce, G; Rieger, A; Wang, H | 1 |
| Amici, R; Andreotti, M; Ceffa, S; Erba, F; Galluzzo, C; Giuliano, M; Jere, H; Liotta, G; Luhanga, R; Mancinelli, S; Marazzi, MC; Maulidi, M; Palombi, L; Pirillo, M; Sagno, JB; Vella, S | 1 |
| Alvarez, A; Calatayud, S; De Pablo, C; Esplugues, JV; Martí-Cabrera, M; Orden, S | 1 |
| Bonovas, S; Hatzakis, A; Nikolopoulos, G; Tsiodras, S | 1 |
| Ananworanich, J; Bhakeecheep, S; Bowonwattanuwong, C; Bunupuradah, T; Chetchotisakd, P; Hirschel, B; Jirajariyavej, S; Klinbuayaem, V; Mahanontharit, A; Munsakul, W; Prasithsirikul, W; Ruxrungtham, K; Sophonphan, J; Valcour, V | 1 |
| Bocchiola, B; Cahua, T; Castagna, A; Danise, A; Galli, L; Gianotti, N; Lazzarin, A; Maillard, M; Panzini, P; Pazzi, A; Salpietro, S; Zandonà, D | 1 |
| Halpern, J; Merigan, TC; Olshen, RA; Rath, BA | 1 |
| Amin, J; Cooper, DA; Cordery, DV; Emery, S; Kelleher, AD; Martin, A | 1 |
| Margolis, DA; Pakes, GE; Ross, LL; Santiago, L; Shaefer, MS; Sloan, LM; Squires, KE; Wine, BC; Young, B; Zhao, HH | 1 |
| Hofmeyr, J; Kankasa, C; Karamagi, C; Meda, N; Nagot, N; Neveu, D; Nikodem, C; Sommerfelt, H; Tumwine, JK; Tylleskär, T; Van de Perre, P | 1 |
| Grabmeier-Pfistershammer, K; Kosi, L; Payer, BA; Peck-Radosavljevic, M; Reiberger, T; Rieger, A; Strassl, R | 1 |
| Cohen, MS; Dumond, JB; Forrest, A; Garonzik, SM; Kashuba, AD; Kendrick, RN; Nicol, MR; Patterson, KB | 1 |
| Ananworanich, J; Bhakeecheep, S; Bowonwatanuwong, C; Bunupuradah, T; Chetchotisakd, P; Hirschel, B; Jirajariyavej, S; Kantipong, P; Kerr, SJ; Klinbuayaem, V; Munsakul, W; Prasithsirikul, W; Ruxrungtham, K; Sophonphan, J; Sungkanuparph, S | 1 |
| Caroleo, B; De Sarro, G; Di Mizio, G; Gallelli, L; Palleria, C; Staltari, O | 1 |
| Brumme, CJ; Chapman, D; Dong, W; Harrigan, PR; Heera, J; James, I; Lewis, M; McGovern, RA; Mo, T; Portsmouth, S; Thielen, A; Valdez, H; Woods, CK; Zhong, X | 1 |
| Bajunirwe, F; Kiwanuka, J; Nyesigire Ruhinda, E | 1 |
| Andriamanantena, D; Ficko, C; Flateau, C; Rapp, C; Reggad, A | 1 |
| Casado, JL; de la Calle, C; del Palacio, M; Moreno, A; Moreno, S; Perez-Elías, MJ | 1 |
| Chersich, M; Fairlie, L; Kuhn, L; Meyers, T; Moultrie, H; Palmer, M | 1 |
| Capparelli, E; Essex, M; Leidner, J; Lockman, S; Makhema, J; Moffat, C; Moss, M; Moyo, S; Ogwu, A; Rossi, S; Shapiro, RL | 1 |
| Agbaji, O; Ekong, E; Graham, C; Hawkins, C; Idoko, J; Kanki, P; Meloni, S; Muazu, M; Murphy, R; Nimzing, L; Sankalé, JL; Thio, CL | 1 |
| Collier, AC; Daar, ES; Fichtenbaum, CJ; Fink, H; Gerschenson, M; Kosmiski, L; Libutti, DE; McComsey, GA; O'Riordan, M; Santana, JL; Sax, PE | 1 |
| Abrams, EJ; Arpadi, S; Coovadia, A; Kuhn, L; Martens, L; Patel, F; Shiau, S; Strehlau, R | 2 |
| Ananworanich, J; Chomchey, N; Gerschenson, M; Hongchookiat, P; Jadwattanakul, T; Kerr, SJ; Kim, JH; Mathajittiphun, P; Phanuphak, N; Phanuphak, P; Pinyakorn, S; Praihirunyakit, P; Rungrojrat, P; Shikuma, C; Teeratakulpisarn, N; Valcour, V | 1 |
| Banerjee, A; Biswas, A; Chakrabarti, S; Chakravarty, R; Datta, S; Guha, SK; Pal, A; Panigrahi, R; Saha, B; Sarkar, N | 1 |
| Basse, CD; Dia, NM; Dieng, AB; Diop, BM; Diop, SA; Fortes-Déguénonvo, L; Manga, NM; Ndaw, G; Ndour, CT; Seydi, M; Soumaré, M; Sow, PS | 1 |
| Lueangniyomkul, A; Mankatitham, W; Manosuthi, S; Manosuthi, W; Nilkamhang, S; Sukasem, C; Sungkanuparph, S; Thongyen, S | 1 |
| Boonchawalit, S; Harada, S; Matsushita, S; Yamaguchi, A; Yoshimura, K; Yusa, K | 1 |
| Armishaw, J; Cameron, PU; Chuah, J; Cooper, DA; Crowe, SM; Fairley, C; Gouillou, M; Hearps, A; Koelsch, KK; Leeansyah, E; Lewin, SR; Liu, JP; Pierce, AB; Smit, de V; Solomon, A; Spelman, T; Tennakoon, S; Velayudham, P | 1 |
| Adams, O; Bolten, M; Borkhardt, A; Laws, HJ; Neubert, J; Niehues, T; Pfeffer, M; Reuter, S; Stannigel, H | 1 |
| Benson, P; Bredeek, UF; Brinson, C; Campo, R; Dau, L; DeJesus, E; Flaherty, J; Fralich, T; Guyer, B; Henry, K; Khanlou, H; Logue, K; Piontkowsky, D; Wang, H; White, K | 1 |
| Cauda, R; Ciccarelli, N; Cingolani, A; Colafigli, M; D'Avino, A; De Luca, A; Di Giambenedetto, S; Fabbiani, M; Farina, S; Mondi, A; Murri, R; Navarra, P; Sidella, L; Tamburrini, E | 1 |
| Bagenda, DS; Barlow-Mosha, LN; Butler, LM; Fowler, MG; Mubiru, MC; Mudiope, PK; Musoke, PM | 1 |
| Arribas, JR; Arrizabalaga, J; Bernardino, JI; Domingo, P; Martinez, E; Muñoz, J; Ocampo, A; Portilla, J; Pulido, F; Torres, R | 1 |
| Bohjanen, PR; Hicks, CB; Johnson, MD; Miller, CR; Petros, WP; Szczech, LA; Wray, DW | 1 |
| Antinori, A; Bedini, A; Bertoli, A; Borghi, V; Bugarini, R; Cossarizza, A; D'Arrigo, R; Esposito, R; Mongiardo, N; Mussini, C; Perno, CF | 1 |
| Acosta, EP; Eron, JJ; Fiscus, SA; Gerber, JG; Gulick, RM; Murphy, RL; Pereira, AS; Smeaton, LM; Snyder, S; Tidwell, RR | 1 |
| Chantawuttinan, T; Dabtham, K; Hawkins, D; Hill, AM; Kanshana, S; Moyle, GJ; Sirichthaporn, P; Somburanasin, P; Supajatura, V; Vithayasai, V; Wattanatchariya, N | 1 |
| Beijnen, JH; de Koning, LA; Heymans, HS; Hoetelmans, RM; Lange, JM; Scherpbier, HJ; van Heeswijk, RP | 1 |
| Aukrust, P; Frøland, SS; Kvale, D; Mellbye, OJ; Müller, F; Nordøy, I; Tjønnfjord, GE | 1 |
| Piliero, PJ; Sax, PE | 1 |
| Calvo, J; González-Macías, J; Hernández, JL; Ramos, C; Saiz, N; Salesa, R; Yánez, L | 1 |
| Sterling, TR | 1 |
| Brunet, C; Costello, RT; Dignat-George, F; Gastaut, JA; Olive, D; Sampol, J | 1 |
| Corral, A; de Mendoza, C; Gallego, O; Rodés, B; Soriano, V | 1 |
| Cooley, TP; Modest, GA; Zacks, JF | 1 |
| Brun-Vézinet, F; Delagnes, M; Descamps, D; Flandre, P; Meiffredy, V; Peytavin, G; Raffi, F; Saidi, Y | 1 |
| Aranda, M; Badía, X; Barrufet, P; Cahn, P; Casado, A; Casiró, A; Consiglio, E; Estela, J; Ferrer, E; Gatell, JM; González, A; Llibre, JM; Lozano, L; Luna, E; Lupo, S; Maños, M; Martínez-Lacasa, J; Miró, JM; Ocaña, I; Pedrol, E; Perez, JL; Perez, P; Podzamczer, D | 1 |
| Aldamiz-Etxebarría, M; Andonegui Navarro, J | 1 |
| Dusak, BA; Goodwin, SD; Kuritzkes, DR; Rooney, JF; Skowron, G; Squires, KE; Stevens, M; Thompson, MA; Tolson, JM; Yuen, GJ | 1 |
| Likanonsakul, S; Moolasart, P | 1 |
| Prescott, LM | 2 |
| Hurwitz, SJ; Schinazi, RF | 1 |
| Livrozet, JM; Miossec, P; Touraine, JL; Wegrzyn, J | 1 |
| Aboulker, JP; Certain, A; Flandre, P; Gérard, L; Guiramand-Hugon, S; Jacomet, C; Joly, V; Launay, O; Lévy, C; Morand-Joubert, L; Peytavin, G; Rivet, S; Yéni, P | 1 |
| Bon, I; Borderi, M; Furlini, G; Gibellini, D; La Placa, M; Monari, P; Re, MC; Schiavone, P; Vitone, F | 1 |
| Bates, M; Chappey, C; Hellmann, NS; Maroldo, L; Parkin, N; Petropoulos, CJ | 1 |
| Chemlal, K; de Truchis, P; Devidas, A; Force, G; Mamet, JP; Mechali, D; Praindhui, D; Pulik, M; Rouveix, E; Welker, Y | 1 |
| Anderson, ML; Kawanishi, H; Shah, N; Vasseur, BG | 1 |
| Dieterich, DT | 1 |
| Alcoba-Leza, M; Carro-Fernández, JA; Cuevas-González, MJ; Martín-Sánchez, V; Mostaza-Fernández, JL; Ortega-Valín, L; Ortiz de Urbina-González, JJ; Pérez-Simón, Mdel R; Rodríguez-María, M | 1 |
| Duan, C; Kuritzkes, DR; Lu, J; MaWhinney, S; Shugarts, D; Stoeckli, TC; Uy, J | 1 |
| Fernando, SL; Keogh, GL; Quin, J; Steele, RH; Stojkova, V | 1 |
| Chaisilwattana, P; Chalermchockcharoenkit, A; Chearskul, S; Chokephaibulkit, K; Opartkiattikul, N; Sirimai, K; Sutthent, R; Vanprapar, N | 1 |
| Díaz, B; González-Lahoz, J; Núñez, M; Pérez-Olmeda, M; Ríos, P; Soriano, V | 1 |
| Aberg, JA; Crippin, J; Kessels, L; Lisker-Melman, M; Powderly, WG; Ristig, MB; Tebas, P | 1 |
| Liu, X; Schinazi, RF | 1 |
| Almond, LM; Back, DJ; De Vries, C; Gould, J; Hoggard, PG; Kewn, S; Khoo, SH; Lou, Y; Maherbe, A; Sales, SD; Wood, R | 1 |
| Aboulker, JP; Flandre, P; Harel, M; Joly, V; Leturque, N; Meiffredy, V; Yeni, P | 1 |
| Aboulker, JP; Brun-Vézinet, F; Descamps, D; Flandre, P; Harel, M; Izopet, J; Joly, V; Lastère, S; Meiffrédy, V; Peytavin, G; Tamalet, C; Yéni, P; Zeng, AF | 1 |
| Brun-Vézinet, F; Calvez, V; Cécile, A; Collin, G; Costagliola, D; Damond, F; Delaugerre, C; Descamps, D; Katlama, C; Marcelin, AG; Matheron, S; Simon, A; Valantin, MA; Yvon, A | 1 |
| Atwine, D; Kebba, A; Kityo, C; Mwebaze, R; Nakityo, R; Peter, M | 1 |
| Benhamou, Y; Thibault, V; Tubiana, R | 1 |
| Khanna, N | 1 |
| Aggarwal, V; Hakim, A; Pai-Dhungat, JV; Parikh, F; Satija, P; Sharma, B | 1 |
| Arnaud, A; Mauboussin, JM; Peyrière, H; Rouanet, I; Vincent, D | 1 |
| Diaz, RS; Filho, AC; Medeiros, R | 1 |
| Christiansen, FT; Den Boer, M; Hammond, E; Mallal, S; Martin, AM; Martinez, OP; Moore, H; Nolan, D; Pace, C; Taylor, L | 1 |
| Boshoff, L; Coovadia, H; Gigliotti, M; Gray, G; Hall, D; Hofmyer, J; McIntyre, J; Moodley, D; Moodley, J; Nikodem, C; Robinson, P; Sullivan, JL | 1 |
| Arnedo, M; Barberá, MJ; Ferrer, E; Fumero, E; Gatell, JM; Gudiol, F; McKenna, P; Pérez, JL; Podzamczer, D; Pumarola, T; Rinehart, A | 1 |
| Veres, N | 1 |
| Brun, S; Di Mascio, M; Ho, DD; Hogan, C; Hurley, A; Louie, M; Markowitz, M; Perelson, AS; Rooney, J; Ruiz, N; Simon, V; Sun, E | 1 |
| Carr, A; Cooper, DA; Cunningham, PH; Duncombe, C; Grey, PA; Hecht, FM; Kahn, JO; Kaufmann, GR; Petersen, A; Quan, DC; Smith, DE; Zaunders, JJ | 1 |
| Antunes, F; Bánhegyi, D; Clotet, B; Clumeck, N; Gatell, J; Gonzalez-Lahoz, J; Gulick, R; Horban, A; Johnson, VA; Katlama, C; Lange, JM; Montaner, J; Moroni, M; Murphy, RL; Pavia, AT; Reiss, P; Schmidt, RE; Sommadossi, JP; Squires, K; Staszewski, S; van der Valk, M; van Eeden, A; van Leeuwen, R; van Leth, F; van Weert, L | 1 |
| D'Aquila, RT; Flynn, T; Giguel, F; Hicks, JL; Hirsch, MS; Johnston, M; Rosenberg, ES; Sax, PE; Sutton, L; Tremblay, CL; Walker, BD | 1 |
| Beauvais, L; Clumeck, N; Fenske, S; Gazzard, B; Katlama, C; Lafeuillade, A; Lazzarin, A; Mallolas, J; Mamet, JP | 1 |
| Antinori, A; Bellocchi, MC; Bertoli, A; Cingolani, A; D'Arrigo, R; De Longis, P; De Luca, A; Di Giambenedetto, S; Forbici, F; Girardi, E; Gori, C; Liuzzi, G; Noto, P; Perno, CF; Tozzi, V; Trotta, MP; Zaccarelli, M | 1 |
| James, JS | 7 |
| Arici, C; Callegaro, A; Goglio, A; Gregis, G; Maggiolo, F; Quinzan, G; Ripamonti, D; Suter, F; Tebaldi, A | 1 |
| Aquilina, C; Boué, F; Brun-Vezinet, F; Descamps, D; Goetschel, A; Lafeuillade, A; Livrozet, JM; Mamet, JP; Matheron, S; Thiaux, C; Troisvallets, D | 1 |
| Ibbotson, T; Perry, CM | 1 |
| Brault, C; Chennebault, JM; Loison, J; Payan, C; Peigne, M | 1 |
| Chakraborty, R; Cross, A; D'Agostino, A; Musoke, R; Palakudy, T | 1 |
| Herrmann, SE; James, IR; John, M; Mallal, SA; McKinnon, EJ; Moore, CB; Nolan, DA; White, AJ | 1 |
| Singh, G | 1 |
| Bailey, VL; Bowles, FB; Finn, TS; Haas, DW; Harris, VL; Johnson, B; Nicotera, J; Raffanti, S; Saah, AJ; Schranz, J; Stone, J | 1 |
| Amici, R; Galluzzo, CM; Germinario, E; Giuliano, M; Kituuka, P; Magoni, M; Mmirro, F; Okong, P; Palmisano, L; Vella, S | 1 |
| Boucher, CA; Haverkamp, M; Hoepelman, AI; Smit, M; Weersink, A | 1 |
| Bachiller Luque, P; de Luis Román, DA; Eiros Bouza, JM; Ortega Lafont, M; Ortiz de Lejarazu, R | 1 |
| Ayres, A; Bartholomeusz, A; Cooley, L; Crowe, S; Lewin, S; Locarnini, S; Mijch, A; Sasadeusz, J | 1 |
| Korman, TM; Tapley, N; Woolley, I | 1 |
| Brook, MG; Dale, AW; Jones, K; Miller, RF | 1 |
| Bazin, GR; Braga, RC; Calvet, GA; Cruz, ML; d'Ippolito, MM; João, EC; Matos, HJ; Menezes, JA; Salgado, LT; Silva, SS | 1 |
| Antoun, Z; Demonty, N; Gazzard, B; Gordon, D; Katlama, C; Mallolas, J; Moroni, M; Schürmann, D | 1 |
| Das, P | 1 |
| Albrecht, MA; Bosch, RJ; Katzenstein, DA; Winters, MA | 1 |
| Albert, J; Blaxhult, A; Brandin, E; Broström, C; Gisslen, M; Gyllensten, K; Hagberg, L; Lindborg, L; Tuvesson, B | 1 |
| Bruun, JN | 1 |
| Chuenyam, T; Cooper, D; Emery, S; Lange, J; Phanuphak, P; Ruxrungtham, K; Sirivichayakul, S; Techasathit, W; Ubolyam, S; Ungsedhapand, C | 1 |
| Cohen, J | 3 |
| Anderson, PL; Fletcher, CV; Kakuda, TN; Kawle, S | 1 |
| Chen, J; DiNubile, MJ; Fischl, MA; Harvey, CM; Hirsch, MS; Hirschel, B; Leavitt, RY; McMahon, D; Squires, K; Staszewski, S; Steigbigel, RT | 1 |
| Brown, LS; Crawford, KH; Farthing, CF; Goodwin, SD; Racine, J; Rawlings, MK; Scott, RC; Shaefer, MS; Thompson, MA; Tolson, JM; Williams, VC | 1 |
| Macher, A; Paul, SM; Thomas, D | 1 |
| Chodakewitz, JA; Eron, JJ; Gonzalez, C; Gulick, RM; Havlir, D; Isaacs, R; McMahon, D; Meibohm, A; Mellors, JW; Mosley, A; Richman, DD; Robertson, M | 1 |
| Crippin, J; Drechsler, H; Lisker-Melman, M; Ristig, M; Tebas, P | 1 |
| Barber, RE; Lonergan, JT; Mathews, WC | 1 |
| Bonard, D; Dabis, F; Ekouévi, DK; Huet, C; Minga, A; Rouet, F; Rouzioux, C; Salamon, R; Toni, TA | 1 |
| Benson, C; Bosch, RJ; Connick, E; Haas, DW; Kessler, H; Kim, RB; Kuritzkes, D; Landay, A; Lederman, MM; Li, H; Wilkinson, GR; Wu, H | 1 |
| Bellos, NC; Burnside, AE; Farthing, CE; Fischl, MA; Kauf, TL; Shaefer, MS; Thompson, MA; Wannamaker, PG; Williams, VC | 1 |
| Barry, DW; Harris, J; Hulett, L; Mommeja-Marin, H; Moxham, C; Quinn, JB; Rousseau, FS; Sanne, I; Wakeford, C; Wang, LH | 1 |
| Fagard, C; Günthard, HF; Hirschel, B; Perrin, L; Yerly, S | 1 |
| Chang, AL; Chang, SC; Chen, DS; Chen, MY; Chen, PJ; Fang, CT; Hung, CC | 1 |
| Moyle, GJ | 2 |
| Abreu, T; Andrade, M; Barbosa, R; Bondarovsky, M; Costa, TP; Halpern, M; Lambert, JS; Machado, ES; Nogueira, SA; Perez, M | 1 |
| Becker, MI; D'Aquila, RT; De Gruttola, V; Delapenha, R; Dubé, MP; Fischl, MA; Gedeon, L; Hirsch, MS; Merigan, TC; Murphy, RL; Pettinelli, C; Pollard, RB; Robbins, GK; Shafer, RW; Smeaton, LM; Snyder, SW; van der Horst, C; Vella, S | 1 |
| D'Aquila, RT; De Gruttola, V; Gripshover, BM; Haubrich, R; Hirsch, MS; Johnson, VA; Kaul, P; Martinez, AI; McCarty, SD; Merigan, TC; Morse, GD; Nokta, MA; Robbins, GK; Shafer, RW; Smeaton, LM; Snyder, SW; Swingle, M; Vella, S | 1 |
| Feinberg, J | 4 |
| Becker, S; Feinberg, J | 1 |
| Brinkman, K; Frissen, PH; Hoogewerf, M; Regez, RM; Schouten, WE; Weigel, HM | 1 |
| Cahn, P; Giordano, M; Kelleher, T; Murphy, RL; Percival, L; Phanuphak, P; Sanne, I | 1 |
| Danner, SA; Gruzdev, B; Jurriaans, S; Lange, JM; Peeters, M; Prins, JM; Rakhmanova, A; Sankatsing, SU; van't Klooster, G; Weverling, GJ | 1 |
| Camino, N; Núñez, M; Puoti, M; Soriano, V | 1 |
| Arasteh, K; Eron, J; Millard, J; Naderer, OJ; Pollard, RB; Raffi, F; Stellbrink, HJ; Teofilo, E; Wire, MB; Wood, R; Yeo, J | 1 |
| Gallant, JE | 3 |
| Erbelding, EJ | 1 |
| Lai, CL; Poynard, T; Ratziu, V; Yuen, MF | 1 |
| Bauer, E; Bernstein, B; Brun, S; Cernohous, P; Gu, K; Hsu, A; Kempf, DJ; King, MS; Moseley, J; Sun, E | 1 |
| Boghossian, J; Gray, GE; Millard, JM; Nadler, JP; Quinones, AR; Rodriguez-French, A; Sepulveda, GE; Wannamaker, PG | 1 |
| Antinori, A; Bellagamba, R; Bellocchi, MC; Bonfigli, S; Boumis, E; D'Arrigo, R; De Longis, P; Forbici, F; Gori, C; Liuzzi, G; Narciso, P; Perno, CF; Soldani, F; Tozzi, V; Trotta, MP; Zaccarelli, M | 1 |
| Gazzard, BG; Gotch, F; Hand, J; Imami, N; Nelson, M; Pires, A; Portsmouth, S; Stebbing, J | 1 |
| Bagnis, CI; Beaufils, H; Benhamou, Y; Brosgart, C; Deray, G; Hannon, H; Izzedine, H; Poynard, T; Sullivan, M | 1 |
| Jackson, B; Mmiro, F | 1 |
| Hernández-Quero, J; Martínez-Ramírez, M; Muñoz-Medina, L; Parra-Ruiz, J; Serrano-Falcón, C | 1 |
| Conway, B | 1 |
| Agher, R; Ait-Mohand, H; Bricaire, F; Calvez, V; Costagliola, D; Duvivier, C; Ghosn, J; Katlama, C; Marcelin, AG; Myrto, A; Peytavin, G; Schneider, L | 1 |
| Angel, JB; Badley, AD; Cooper, CL; Hawley, N; Lum, JJ; Mbisa, G; Parato, K; Phenix, B | 1 |
| Boyle, BA | 2 |
| Pendergrass, S; Qazi, S; Uckun, FM; Venkatachalam, TK | 1 |
| Antoniou, T; Arbess, G; Gough, K; Yoong, D | 1 |
| Benhamou, Y | 1 |
| Bini, T; Bongiovanni, M; Chiesa, E; Monforte, Ad | 1 |
| do Lago, RF; Harrison, LH; Mendelsohn, AB; Moreira, RI; Moulton, LH; Schechter, M | 1 |
| Akinsete, O; Brundage, R; Henry, K; Shet, A; Weller, D | 1 |
| Cardellach, F; Casademont, J; García-Viejo, MA; Gatell, JM; López, S; Martínez, E; Milinkovic, A; Miró, O; Nunes, V; Pedrol, E; Rodríguez-Santiago, B; Soler, A | 1 |
| Chantratita, W; Panburana, P; Phuapradit, W; Sirinavin, S; Vibhagool, A | 1 |
| Thio, CL | 1 |
| Ala, A; Dieterich, DT | 1 |
| Benson, C; Brun, SC; Eron, JJ; Gulick, RM; Hicks, C; Kessler, HA; King, KR; King, MS; Murphy, RL; White, AC | 1 |
| Abrams, EJ; Adams, ME; Divi, RL; Nagashima, K; Nesel, CJ; O'Neill, JP; Poirier, MC; Seilkop, SK; Wade, NA; Walker, VE | 1 |
| Barrett, H; Bassett, RL; Hazelwood, JD; Johnson, VA; Kuritzkes, DR; Rhodes, RA; Young, RK | 1 |
| Fletcher, CV; McIntosh, K; Nachman, SA; Pelton, S; Stanley, K; Wiznia, A; Yogev, R | 1 |
| Fleck, F | 1 |
| Maggiolo, F; Ripamonti, D; Suter, F | 1 |
| Acosta, EP; Gulick, RM; Klingman, KL; Kuritzkes, DR; Lustgarten, S; Maher, WE; Meyer, WA; Murphy, RL; Pilcher, CD; Reichman, RC; Ribaudo, HJ; Schackman, BR; Shikuma, CM; Snyder, S; Squires, KE; Witt, MD | 1 |
| McComsey, GA; Piliero, PJ | 1 |
| Elefsiniotis, IS; Mpotsi, C; Pantazis, KD; Paparizos, V | 1 |
| Baseler, M; Beck, I; Coffin, J; Daucher, M; Davey, RT; Dewar, R; Dybul, M; Ehler, L; Fauci, AS; Frenkel, L; Hallahan, CW; Maldarelli, F; Metcalf, JA; Nies-Kraske, E; Palmer, S; Piscitelli, SC; Powers, A; Rock Kress, DM; Weigand, A | 1 |
| Cahn, P; Giordano, M; Kelleher, T; Mancini, M; Murphy, R; Pantaleo, G; Phanuphak, P; Pokrovskiy, V; Rozenbaum, W; Sension, M; Wood, R | 1 |
| Cardiello, P; Cooper, DA; Emery, S; Juengprasert, N; Kroon, ED; Lange, JM; Phanuphak, P; Ratanasuwan, W; Ruxrungtham, K; Siangphoe, U; Srasuebkul, P; Tongtalung, M; Ubolyam, S; Ungsedhapand, C | 1 |
| Fisher, M | 1 |
| Beliaeva, VV; Bogoslovskaia, EV; Kravchenko, AV; Miroshnichenko, AV; Serebrovskaia, LV; Sitdykova, IuR | 1 |
| Belfiori, B; Civljak, R; Deparis, P; Francisci, D; Ghinelli, F; Ippolito, G; Modestino, R; Puro, V; Roda, R; Sighinolfi, L | 1 |
| Drake, A; Mijch, A; Sasadeusz, J | 1 |
| Bernstein, BM; Brun, SC; Cernohous, P; Feinberg, J; King, MS; Montaner, JS; Sanne, I; Sherer, R; Sun, E; Walmsley, SL | 1 |
| Cassol, S; El-Sadr, W; Friedland, G; Jack, C; Karim, QA; Karim, SA; Lalloo, U | 1 |
| Berger, A; Brodt, HR; Lennemann, TS; Lutz, T; Mösch, M; Staszewski, S; Stephan, C; Stürmer, M | 1 |
| Delfraissy, JF; Gatell, JM; Giordano, M; Jemsek, J; Lazzarin, A; Pokrovskiy, V; Powderly, WG; Rivero, A; Rozenbaum, W; Schrader, S; Sension, M; Squires, K; Thiry, A; Vibhagool, A | 1 |
| Cheng, AK; Coakley, DF; DeJesus, E; Gallant, JE; Lu, B; Miller, MD; Pozniak, AL; Staszewski, S; Suleiman, JM; Toole, JJ | 1 |
| Murphy, MJ; Wilcox, RD | 1 |
| Benhamou, Y; Cahour, A; Katlama, C; Lada, O; Poynard, T; Thibault, V | 1 |
| Cahn, P; Carosi, G; Jordan, JC; Montroni, M; Pearce, G; Pharo, CE; Schechter, M; Smaill, F; Soto-Ramirez, L; Thomas, NE; Vibhagool, A | 1 |
| Cahn, P; Carosi, G; Jordan, JC; Pharo, CE; Schechter, M; Smaill, F; Soto-Ramirez, L; Steel, HM; Thomas, NE; Vibhagool, A | 1 |
| Cao, Y; McCoig, CC; Ramilo, O; Saavedra-Lozano, J; Vitetta, ES | 1 |
| De Luca, A; Di Giambenedetto, S | 1 |
| Castillo, SA; DeJesus, E; Farthing, CF; Gough, K; Grinsztejn, B; Madison, SJ; McCarty, D; Schrader, SR; Sension, MG; Shortino, DD; Thomas, DA | 1 |
| Carides, GW; Cook, JR; Coplan, PM; DiNubile, MJ; Hammer, SM; Heyse, JF; Meibohm, AR; Nguyen, BY; Wu, AW | 1 |
| Badsi, E; Bendenoun, M; Bergmann, JF; Caulin, C; Cazals-Hatem, D; Cervoni, J; Clevenbergh, P; Diemer, M; Evans, J; Mazeron, MC; Sellier, P; Vincent, V | 1 |
| Rosa, U; Sepkowitz, D; Smith, PR; Tripuraneni, NS; Weedon, J | 1 |
| Maida, I; Nuñez, M; Soriano, V | 1 |
| Benhamou, Y; Bonyhay, L | 1 |
| Bernard, E; Del Giudice, P; Dellamonica, P; Marq, L; Perrin, C; Vandenbos, F | 1 |
| Arabe, J; Gomes, SA; Santos, EA; Sucupira, MV | 1 |
| Sterling, RK; Sulkowski, MS | 1 |
| Demeter, LM; Erice, A; Eshleman, SH; Fischl, MA; Hammer, SM; Hellmann, NS; Ribaudo, HJ | 1 |
| Abduch, R; Duarte, G; El Beitune, P; Figueiró-Filho, EA; Marcolin, AC; Quintana, SM | 1 |
| Bonny, T; Brand, JD; Brothers, CH; Buendia, CB; Castillo, SA; DeJesus, E; Gerstoft, J; Hernandez, J; Herrera, G; Lanier, ER; Scott, TR; Teofilo, E | 1 |
| Bani-Sadr, F; Molina, JM; Palmer, P; Scieux, C | 1 |
| Hadziyannis, SJ; Papatheodoridis, GV | 1 |
| Zhou, YH; Zhuang, H | 1 |
| Anekthananon, T; Ratanasuwan, W; Sonjai, A; Suwanagool, S; Techasathit, W | 1 |
| Hirschel, B | 1 |
| Ambu, S; Ancarani, F; Bonasso, M; Bruno, R; Cozzi-Lepri, A; d'Arminio Monforte, A; Ferraro, T; Puoti, M; Santantonio, T; Toti, M; Tundo, P | 1 |
| Ait-Khaled, M; Gibb, D; Givens, N; Griffin, P; Irlbeck, D; Lanier, ER; St Clair, M; Stone, C; Tisdale, M; Underwood, M; Walker, S | 1 |
| Bassetti, D; Bassetti, M; Briozzo, A; Cruciani, M; Di Biagio, A; Ferrazin, A; Gatti, G; Rosso, R | 1 |
| Burchett, SK; Ciupak, G; Delke, I; Frenkel, L; Hitti, J; Huang, S; Mathias, A; Mofenson, L; Rathore, M; Samelson, R; Shapiro, DE; Smith, ME; Unadkat, JD; Wade, NA; Watts, DH; Yasin, S | 1 |
| Berg, T; Bergk, A; Mauss, S; Reinke, P; Schürmann, D; van Bömmel, F; Wiedenmann, B; Wünsche, T | 1 |
| Bartlett, JA; Bellos, NC; Eron, JJ; Johnson, J; Johnson, VA; Keller, A; Kuritzkes, DR; Santana, JL; St Clair, MH | 1 |
| Benson, CA; Haas, DW; Lamarca, A; McDonald, CK; Mondou, E; Quinn, JB; Rousseau, F; Rublein, J; Steinhart, CR; van der Horst, C | 1 |
| Däumer, M; Kaiser, R; Matz, B; Rockstroh, JK; Schewe, CK; Schildgen, O; Vogel, M; Weitner, L | 1 |
| Baumann, D; Bernasconi, E; Blasko, M; Calmy, A; Chave, JP; Furrer, H; Ledergerber, B; Opravil, M; Perrin, L; Vernazza, P | 1 |
| Boucher, CA; Haverkamp, MH; Hoepelman, IM; Smit, MC; Weersink, AJ | 1 |
| Desai, A; Narang, VS; Purandare, S | 1 |
| Bower, M; Fisher, M; Gazzard, B; Johnson, M; Jones, R; Mandalia, S; Moyle, G; Nelson, M; Orkin, C; Stebbing, J | 1 |
| Byrne, CM; Coughlan, S; Hall, WW; Hopkins, SM; Lyons, FE; Mulcahy, FM | 1 |
| Berger, F; Gatell, J; Hoffmann, C; Holm, S; Kuhlmann, B; Martínez, E; Mauss, S; Milinkovic, A; Schmutz, G | 1 |
| Dando, TM; Scott, LJ | 1 |
| Figueroa, L; Figueroa-Damián, R; Poblano, A; Schnaas, L | 1 |
| Butala, N; Daver, NG; Joshi, SR; Kelkar, D; Patwardhan, MR | 1 |
| Brenner, BG; Petrella, M; Routy, JP; Turner, D; Wainberg, MA | 1 |
| Ibarra Barrueta, O; Iglesias Lambarri, A; Illaro Uranga, A; Lertxundi Etxebarría, U; Martínez Bengoechea, MJ; Santos Ibáñez, A | 1 |
| Béguinot, I; Burty, C; Christian, B; Grandidier, M; Jeanmaire, H; May, T; Penalba, C; Rabaud, C | 1 |
| Aarnoutse, RE; Burger, DM; Verweij-van Wissen, CP | 1 |
| Bartsch, G; El-Sadr, WM; Gibert, C; Grunfeld, C; Kotler, D; Peng, G; Raghavan, S; Shlay, JC; Visnegarwala, F; Wang, J | 1 |
| Christie, CD; Evans-Gilbert, T; Pierre, R; Rodriquez, B; Steel-Duncan, JC | 1 |
| Benhamou, Y; Bonacini, M; Brook, G; Cargnel, A; Puoti, M; Rockstroh, J; Soriano, V; Thio, C | 1 |
| Becquet, R; Bequet, L; Dabis, F; Dequae-Merchadou, L; Ekouevi, DK; Fassinou, P; Horo, A; Leroy, V; Rouet, F; Rouzioux, C; Sakarovitch, C; Viho, I; Welffens-Ekra, C | 1 |
| Coupal, L; Gilmore, N; Grover, SA; Mukherjee, J | 1 |
| Chaix, ML; Delaugerre, C; Peytavin, G; Roudiere, L; Rouzioux, C; Viard, JP | 1 |
| Aboulker, JP; Gérard, L; Guiramand-Hugon, S; Launay, O; Marcellin, F; Morand-Joubert, L; Yeni, P | 1 |
| Badaro, R; de Wet, J; Hall, DB; Huisamen, CB; Lange, JM; Montaner, JS; van Leth, F; Vandercam, B; Wit, FW | 1 |
| Havlir, DV; Ignacio, CC; Koelsch, KK; Lu, B; Margot, N; Miller, MD; Strain, MC; Wong, JK | 1 |
| Beijnen, JH; Huitema, AD; Kappelhoff, BS; Lange, J; MacGregor, TR; van Leth, F | 1 |
| Cahn, P; Castillo, SA; Craig, C; DeJesus, E; Gordon, DN; Moyle, GJ; Scott, TR; Zhao, H | 1 |
| Bedoni, AJ; Figueiredo, RM; Garcia, MT; Moretti, ML; Papaiordanou, PM; Resende, MR | 1 |
| Dourakis, SP; Elefsiniotis, IS; Katsambas, N; Mpotsi, C; Pantazis, KD; Paparizos, V | 1 |
| Farthing, C; Guyer, B; Khanlou, H; Yeh, V | 1 |
| Balakrishnan, P; Carpenter, CC; Cecelia, A; Flanigan, TP; Kumarasamy, N; Mayer, KH; Solomon, S; Vallabhaneni, S | 1 |
| Cuadrado, JM; Jover, F; Martínez-Baltanás, A; Roig, P | 1 |
| Bodasing, N; Burger, DM; Cleary, PR; de Baar, MP; Kumwenda, JJ; Mallewa, J; Nyirenda, C; Schuurman, R; van Oosterhout, JJ; Zijlstra, EE | 1 |
| Bergshoeff, A; Burger, D; Farrelly, L; Flynn, J; Gibb, D; Khoo, S; Le Prevost, M; Lyall, H; Novelli, V; Verweij, C; Walker, S | 1 |
| Boyd, M; Bunyaprawit, P; Burger, D; Chuenyam, T; Cooper, D; Horsakulchai, M; Lange, J; Mahanontharit, A; Mootsikapun, P; Phanuphak, P; Ruxrungtham, K; Sangkote, J; Ubolyam, S | 1 |
| Andrieux-Meyer, I; Bourgeois, A; Calmy, A; Ciaffi, L; Delaporte, E; Lactuock, B; Laurent, C; Liégeois, F; Mougnutou, R; Mpoudi-Ngolé, E; Nkoué, N; Zekeng, L | 1 |
| D'Agostino, C; d'Ettorre, G; Lichtner, M; Massetti, AP; Mastroianni, CM; Vullo, V | 1 |
| Gazzard, BG; McCormick, K; Moyle, GJ; Osorio, J; Portsmouth, SD | 1 |
| Amin, J; Carr, A; Cooper, DA; McAllister, J; Winston, A | 1 |
| Andreoli, A; Bandelier, C; Bianchi-Demicheli, F; Damsa, C; Lazignac, C; Maris, S; Vidailhet, P | 1 |
| Cohn, SE; Mrus, JM; Tsevat, J; Williams, PL; Wu, AW | 1 |
| Bergroth, T; Sönnerborg, A; Yun, Z | 1 |
| Eto, K; Kamihira, A; Kimura, T; Matsushita, S; Mitsuya, H; Oka, S; Shirasaka, T; Takano, M; Yoshimura, K | 1 |
| Bowonwatanuwong, C; Desakorn, V; Krudsood, S; Pitisuttithum, P; Tin, EE; Wilairatana, P | 1 |
| Beijnen, JH; Huitema, AD; Kappelhoff, BS; Mairuhu, AT; Schellens, JH | 1 |
| Chan, KC; Lee, SS; Wong, KH | 1 |
| Cunha, RV; Dal Fabbro, MM; Freitas, GM; Lindenberg, Ade S; Nogueira, SA; Paniago, AM | 1 |
| Abduch, R; Duarte, G; El Beitune, P; Figueiró-Filho, EA; Machado, AA; Quintana, SM | 1 |
| Davis, EA; DeJesus, E; Hill-Zabala, C; Lang, J; Lanier, ER; Liao, Q; Markowitz, M; Shaefer, M | 1 |
| Bonjoch, A; Clotet, B; De la Torre, J; Galvez, J; Martínez, E; Miralles, C; Miranda, J; Muñoz-Moreno, JA; Paredes, R; Prieto, A; Videla, S; Vilades, C | 1 |
| Bushman, L; Campbell, TB; Fletcher, CV; Johnson, SC; Kuritzkes, DR; Lanier, ER; Merigan, TC; Shulman, NS; Young, RK; Zolopa, AR | 1 |
| Chaisilwattana, P; Chokephaibulkit, K; Phongsamart, W; Sutthent, R; Vanprapar, N | 1 |
| Bellido, D; Casado, JL; Chamorro, AJ; Moreno, S | 1 |
| Angel-Moreno-Maroto, A; Hernández-Cabrera, M; Pérez-Arellano, JL; Suárez-Castellano, L | 1 |
| Clark, N; Guyer, B; Hawkins, T; Kearney, BP; St Claire, RL; Veikley, W | 1 |
| Brun-Vézinet, F; Collin, G; Delaunay, C; Descamps, D; Flandre, P; Landman, R; Miller, M; Peytavin, G; Trylesinski, A | 1 |
| Chêuc, G; Cotte, L; Debord, T; Decazes, JM; Ferchal, F; Journot, V; Madelaine, I; Molina, JM; Pellegrin, I; Rancinan, C; Sombardier, MN | 1 |
| Murphy, RL | 1 |
| Baird, I; Cohen, C; Elion, R; Green, L; Green, S; Schrader, S; Ward, D | 1 |
| Amel, EB; Amel, LO; Amine, SM; Asma, J; Fethi, T; Mohamed, C; Mounira, G; Taoufik, BC | 1 |
| Shiber, JR | 1 |
| Barroso, PF; Boechat, LJ; Melo, MF; Schechter, M; Vettore, MV | 1 |
| Arendt, V; Fundira, L; Lemmer, P; Omes, C; Schneider, S; Schuman, M; Tayari, JC; Wennig, R | 1 |
| Young, SM | 1 |
| Capparelli, E; Connor, JD; Essex, M; Holland, DT; Lockman, S; Mirochnick, M; Peter, T; Shapiro, RL; Stevens, L; Thior, I; Wester, C | 1 |
| Guan, R | 1 |
| Adedoyin, JA; Adewole, TA; Araoyinbo, ID; Audu, RA; Eisen, G; Idigbe, EO; Kanki, P; Musa, AZ; Odunukwe, NN; Onwujekwe, DI; Onyewuche, JI; Salu, OB | 1 |
| Colonno, R; Discotto, L; Friborg, J; Weinheimer, S; Yang, H | 1 |
| Capparelli, E; Chokephaibulkit, K; Cressey, TR; Frederix, K; Kolladarungkri, T; Phongsamart, W; Plipat, N; Vanprapar, N | 1 |
| Abrams, EJ; Borkowsky, W; Britto, P; Chadwick, EG; Flynn, PM; Hughes, M; Luzuriaga, K; Palumbo, P; Powell, C; Rodman, JH; Yogev, R | 1 |
| Blanco, JL; Crespo, M; Deig, E; Falcó, V; González, A; Miró, JM; Ocaña, I; Pahissa, A; Pedrol, E; Ribera, E; Rodríguez-Pardo, D; Rubio, M; Soler, A | 1 |
| Alston-Smith, BL; Dubé, MP; Kitch, DW; Mulligan, K; Parker, RA | 1 |
| Chernicoff, H; Gilmore, A; Jordan, J; Legorreta, A; Rosenzweig, JC; Yu, A | 1 |
| Ariën, KK; Arts, EJ; Colebunders, RL; Gali, Y; Troyer, RM; Vanham, G | 1 |
| Back, D; Borucki, MJ; Dieterich, D; Gries, JM; Hoggard, PG; Lissen, E; Rodriguez-Torres, M; Soriano, V; Sulkowski, M; Torriani, FJ; Wang, K | 1 |
| Alhassoon, OM; Brown, GG; Ellis, RJ; Gonzalez, R; Grant, I; Letendre, S; McCutchan, JA; Patterson, TL; Schweinsburg, BC; Taylor, MJ; Videen, JS | 1 |
| Bunn, JE; Kilonzo, SN; Klufio, A; Kuria, E; Mbugua, C; Speight, CG; Taegtmeyer, M | 1 |
| Biberfeld, G; Coovadia, H; Cortina-Borja, M; Dabis, F; Goudsmit, J; Gray, G; Grulich, A; Haverkamp, G; Kilewo, Ch; Kituuka, P; Lange, JM; Leroy, V; Massawe, A; McIntyre, J; Ndugwa, Ch; Newell, ML; Okong, P; Saba, J; Sakarovitch, C; von Briesen, H; Weverling, GJ | 1 |
| Azuaje, C; Domingo, P; Falco, V; Gatell, JM; Lopez, RM; Lopez-Colomes, JL; Mallolas, J; Ocaña, I; Pahissa, A; Pou, L; Ribera, E; Sambea, MA; Sánchez, P; Soriano, A | 1 |
| Clark, PL; Hinthorn, D; Myers, SA; Torrente, S | 1 |
| Kuritzkes, DR | 1 |
| Berger, DS; Gallant, JE; Johnson, J; Liao, Q; Lim, ML; Rodriguez, AE; Ross, L; Shaefer, MS; Weinberg, WG; Young, B | 1 |
| Billaud, E; Bugnon, F; Cua, E; Cuzin, L; Dellamonica, P; Delpierre, C; Massip, P; Pugliese, P; Raffi, F | 1 |
| Dejesus, E; Florance, A; Herrera, G; Hill-Zabala, C; Shaefer, M; Sosa, N; Vavro, C; Watson, M | 1 |
| Black, FT; Jørgensen, LB; Kjems, J; Mohey, R; Møller, BK; Obel, N | 1 |
| Allers, K; Huelsmann, PM; John, MJ; Metzner, KJ; Rauch, P | 1 |
| Bester, R; Cotton, MF; de Waal, N; Rabie, H | 1 |
| Anderson, AM; Bartlett, JA | 1 |
| Domingo, JC; Domingo, P; Matias-Guiu, X; Richart, C; Sambeat, MA; Sirvent, JJ; Torres, F; Veloso, S; Vendrell, J; Vidal, F | 1 |
| Gochicoa Rangel, LG; Miranda Novales, MG; Palacios Saucedo, G; Solórzano Santos, F; Vázquez Rosales, G | 1 |
| Girault, V | 1 |
| Hill-Zabala, C; Irlbeck, D; Jefferson, T; Rodriguez, A; Shaefer, M; Sloan, L; Watson, M; Yau, L | 1 |
| Galeano, V; Galli, A; Gutiérrez, S; Lioni, M; Maturo, M; Quian, J; Serra, M; Visconti, A | 1 |
| Baker, A; Crawford, W; Jassen, A; Jooste, JP; Van Zyl, AJ | 1 |
| Arora, SK; Sachdeva, N; Sehgal, S | 1 |
| Kessler, HA | 1 |
| Chiu, SS; Jones, BM; Lau, YL; Lim, WW; Wong, WH | 1 |
| Beld, MG; Lange, JM; Pogány, K; Prins, JM; Wit, FW; Zaaijer, HL | 1 |
| Balfour, HH; Brundage, RC; Cavert, W; Fox, K; Henry, K; Kurpad, AV; Raj, TD; Ravindran, GD; Vezina, HE; Weller, D | 1 |
| Bellón, JM; Berenguer, J; Camba, M; Flores, J; Gatell, JM; Hernández-Quero, J; Knobel, H; Miguélez, M; Pérez-Elías, MJ; Podzamczer, D; Resino, S; Rivas-González, P; Sala, M; Santos, I; Soriano, V | 1 |
| Black, FT; Jørgensen, LB; Kjems, J; Mohey, R; Møller, BK; Obel, N; Tolstrup, M | 1 |
| de Man, RA; de Vries-Sluijs, TE; Hansen, BE; Osterhaus, AD; van der Eijk, AA; van der Ende, ME | 1 |
| Averitt, D; Kumar, PN; Pakes, GE; Pappa, KA; Rodriguez-French, A; Shaefer, MS; Tashima, KT; Thompson, MA; Wannamaker, PG; Williams, VC | 1 |
| Arribas, JR; Campo, RE; Cheng, AK; Chuck, S; DeJesus, E; Enejosa, J; Gallant, JE; Gazzard, B; Lu, B; McColl, D; Pozniak, AL; Toole, JJ | 1 |
| Bequet, L; Chaix, ML; Dabis, F; Ekouevi, DK; Leroy, V; Menan, H; Peytavin, G; Rouet, F; Rouzioux, C; Tonwe-Gold, B; Toure, H; Viho, I | 1 |
| Anunnatsiri, S; Boonyaprawit, P; Chetchotisakd, P; Mootsikapun, P | 1 |
| Bernard, M; Bouhour, D; Boulliat, J; Fleury, J; Laurent-Coriat, C; Tilikete, C; Vighetto, A | 1 |
| Black, FT; Katzenstein, TL; Kjems, J; Mohey, R; Obel, N | 1 |
| Bekker, V; Jurriaans, S; Kuijpers, TW; Lange, JM; Scherpbier, HJ; van Leth, F | 1 |
| Benhamou, Y; Fleury, H; Katlama, C; Le Teuff, G; Pellegrin, I; Piketty, C; Rozenbaum, W; Trimoulet, P; Trylesinski, A; Urbinelli, R | 1 |
| Bienstock, RJ; Copeland, WC; Haase, CP; Hosseini, SH; Kohler, JJ; Lewis, W; Ludaway, T; McNaught, J; Russ, R; Santoianni, R; Stuart, T | 1 |
| Bonjoch, A; Bravo, I; Clotet, B; Heilek-Sneider, GM; Martinez-Picado, J; Moltó, J; Negredo, E; Ruiz, L; Valle, M | 1 |
| Fisher, M; Gazzard, B; Higgs, C; Johnson, M; Mandalia, S; Moyle, G; Nelson, M; Teague, A | 1 |
| Barberá Farré, JR; Beato Pérez, JL; Cuadra García-Tenorio, F; Geijo Martínez, MP; Maciá Martínez, MA; Marcos Sánchez, F; Martínez Alfaro, E; Moreno Mendaña, JM; Rodríguez Zapata, M; Sanz Moreno, J; Sanz Sanz, J; Solera Santos, J | 1 |
| Beijnen, JH; Boron-Kaczmarska, A; Hall, DB; Huitema, AD; Johnson, D; Kappelhoff, BS; Lange, JM; Leith, J; Leth, FV; Livrozet, JM; Losso, MH; Saag, MS; Wit, FW | 1 |
| Boeri, E; Carini, E; Castagna, A; Cernuschi, M; Clementi, M; Danise, A; Galli, A; Galli, L; Gianotti, N; Hasson, H; Lazzarin, A; Menzo, S | 1 |
| Ayres, A; Bartholomeusz, A; Cooper, DA; Dore, GJ; Lewin, S; Locarnini, S; Matthews, GV; Sasaduesz, J; Seaberg, E; Thio, CL | 1 |
| Balestre, E; Boucher, S; Capdepont, S; Dabis, F; Dupon, M; Fleury, H; Masquelier, B; Thiébaut, R | 1 |
| Koh, MT | 1 |
| de Baar, MP; de Ronde, A; Ruiter, JP; Tebas, P; Timmermans, EC; Wanders, RJ | 1 |
| Godon-Hardy, S; Kossorotoff, M; Mas, JL; Mateus, C; Serre, I; Touzé, E; Zuber, M | 1 |
| Mahomed, FA; Rutherford, GW; Siegfried, NL; Van Deventer, PJ | 1 |
| Boyd, MA; Burger, DM; Cooper, DA; Duncombe, CJ; Hassink, EA; Khongphattanayothin, M; Lange, J; Phanuphak, P; Reiss, P; Ruxrungtham, K; Srasuebkul, P; Stek, M; Ubolyam, S | 1 |
| Clumeck, N; Craig, C; Domingo, P; Fu, K; Gordon, D; Lamarca, A; Plettenberg, A; Scott, T; Watson, M; Zhao, H | 1 |
| Bower, M; Gazzard, B; Nelson, M; Pollock, K; Stebbing, J | 1 |
| Antunes, F; Chiesi, A; Goebel, FD; Katlama, C; Knysz, B; Ledergerber, B; Lundgren, JD; Mocroft, A; Phillips, AN; Reiss, P | 1 |
| Calmy, A; Ferradini, L; Ford, N; Pinoges, L; Szumilin, E; Zachariah, R | 1 |
| Carr, A | 1 |
| Burger, DM; Clapson, M; Farrelly, L; Flynn, J; Gibb, DM; Green, H; Head, S; LePrevost, M; Lyall, H; Novelli, V; Walker, AS | 1 |
| Hammerstrom, TS; Laessig, KA; Lewis, LL | 1 |
| Arora, SK; Datta, U; Sachdeva, N; Sehgal, S; Sud, A | 1 |
| Amici, R; Bassani, L; Dehò, L; Galluzzo, CM; Germinario, EA; Giuliano, M; Mmiro, F; Okong, P; Vella, S; Vyankandondera, J | 1 |
| Amiel, C; Guessant, S; Kara, A; Lebrette, MG; Marechal, Eda S; Pialoux, G; Quercia, R; Renaud, S; Schneider, V; Thevenet, S | 1 |
| Jenny-Avital, ER | 1 |
| Alabi, A; Aveika, A; Corrah, T; Jallow, S; Janssens, W; Kaye, S; McConkey, SJ; Rowland-Jones, S; Sabally, S; Sarge-Njie, R; Vanham, G; Whittle, H | 1 |
| Anderson, PL; Aquilante, CL; Fletcher, CV; Lamba, J; Schuetz, E | 1 |
| Brown, J; Heffernan-Vacca, S; Millery, M; Neu, N; Stimell, M | 1 |
| Essex, M; Gaseitsiwe, S; Gilbert, PB; Heymann, SJ; Lagakos, S; Lockman, S; Makhema, J; Ndung'u, T; Novitsky, V; Shapiro, RL; Smeaton, LM; Stevens, L; Thior, I; Wester, C | 1 |
| Burger, D; de Groot, R; van der Lee, M; Verweel, G | 1 |
| Bowornkitikajorn, P; Chearskul, S; Chokephaibulkit, K; Chotpitayasunondh, T; Phongsamart, W; Samkoset, R; Sutthent, R; Tarunothai, U; Vanprapar, N | 1 |
| Piacenti, FJ | 1 |
| D'Argenio, DZ; Flynn, PM; Robbins, BL; Rodman, JH; Wilcox, CK; Zhou, Z | 1 |
| Dabis, F; Nightingale, S | 1 |
| DeJesus, E; Eron, J; Estrada, V; Gathe, J; Katlama, C; Lackey, P; Patel, L; Shaefer, M; Staszewski, S; Sutherland-Phillips, D; Vavro, C; Wannamaker, P; Yau, L; Yeni, P; Yeo, J; Young, B | 1 |
| Fätkenheuer, G; Lehmann, C; Wyen, C | 1 |
| Hall, DB; Lange, JM; Reiss, P; van Leth, F | 1 |
| Olatunji, PO; Olawumi, HO | 1 |
| Acosta, EP; Bastow, B; Carlson, M; Gulick, RM; Klingman, KL; Koletar, SL; Kuritzkes, DR; Lalama, C; Meyer, WA; Murphy, RL; Pilcher, CD; Reichman, RC; Ribaudo, HJ; Schackman, BR; Schouten, J; Shikuma, CM; Squires, KE | 1 |
| Cheng, A; Lu, B; Margot, NA; Miller, MD | 1 |
| Chan-Tack, KM; Edozien, A | 1 |
| Benhammou, V; Blanche, S; Rustin, P; Tardieu, M; Warszawski, J | 1 |
| Grant, RM; Levy, V | 1 |
| Brothers, CH; Castillo, SA; Hernandez, JE | 1 |
| Arici, C; Castagna, A; Cozzi-Lepri, A; Dabis, F; De Luca, A; Garrido, M; Gervais, A; Gill, J; Ledergerber, B; Lundgren, JD; Milazzo, L; Moller, NF; Monforte, Ad; Mussini, C; Ourishi, N; Paraninfo, G; Puoti, M; Raffi, F; Rickenbach, M; Rockstroh, J; Suarez-Lozano, I; Winnock, M | 1 |
| Bartlett, JA; Griffith, S; Herrera, G; Irlbeck, D; Johnson, J; Liao, Q; Rodriguez, A; Shaefer, MS; Sosa, N | 1 |
| Farthing, C; Khanlou, H | 1 |
| Berg, T; Berger, F; Bruno, R; Carlebach, A; Hoffmann, C; Jaeger, H; Lutz, T; Mauss, S; Nelson, M; Rockstroh, J; Schmutz, G; Schürmann, D; Schwarze-Zander, C; Sheldon, J; Soriano, V; Stoehr, A; von Boemmel, F; Wolf, E | 1 |
| Barreiro, P; Camino, N; Díaz-Pollán, B; González-Lahoz, J; Martín-Carbonero, L; Núñez, M; Ramos, B; Soriano, V | 1 |
| Friedland, G; Jack, C; Khoo, S; Lalloo, U | 1 |
| Bernard-Henry, C; Cheneau, C; de Mautort, E; Hess, G; Krebs, M; Lang, JM; Partisani, M; Priester, M; Rey, D | 1 |
| Arribas, JR; Campo, RE; Chen, SS; Cheng, AK; DeJesus, E; Enejosa, J; Gallant, JE; Gazzard, B; McColl, D; Pozniak, AL; Toole, JJ | 1 |
| d'Ettorre, G; Mastroianni, CM; Vullo, V | 1 |
| Burger, DM; Dijkema, T; Gibb, DM; L'homme, RF; van der Ven, AJ; Warris, A | 1 |
| Averbuch, D; Einhorn, M; Engelhard, D; Gottesman, G; Gradstein, S; Grisaru-Soen, G; Grossman, Z; Kedem, E; Lanier, ER; Ofir, M; Schapiro, JM | 1 |
| Arabe, J; Gomes, SA; Mello, FC; Niel, C; Rolla, VC; Santos, EA; Sucupira, MV | 1 |
| Berg, T; Kuecherer, C; Neifer, S; Poggensee, G; Schlote, F; Somogyi, S | 1 |
| Boucher, CA; Derdelinckx, I; Halima, Y; Hill, A; Lange, JM; Wainberg, MA | 1 |
| Desakorn, V; Dhitavat, J; Getahun, A; Pitisuttithum, P; Tansuphasawadikul, S | 1 |
| Alonso, C; Aranda, M; Barrufet, P; Berenguer, J; Crespo, M; del Río, L; Delegido, A; Ferrer, E; Fisac, C; Gatell, JM; Lérida, A; Llibre, JM; Lonca, M; Martínez-Lacasa, J; Merino, E; Niubo, J; Pedreira, JD; Podzamczer, D; Pulido, F; Ribas, MA; Ribera, E; Rubio, R; Sanchez, P; Sanz, J; Veloso, S | 1 |
| Han, N; Lan, MD; Liu, ZY; Lu, LH; Wei, HS; Yao, J; Zhang, FJ; Zhao, HX | 1 |
| Sims, KA; Woodland, AM | 1 |
| Andreotti, M; Ceffa, S; Cusato, M; Germano, P; Giuliano, M; Guidotti, G; Liotta, G; Loureiro, S; Mancini, MG; Marazzi, MC; Palombi, L; Pirillo, MF; Regazzi, M; Vella, S; Villani, P | 1 |
| Corbett, AH; Hosseinipour, MC; Kanyama, C; Kashuba, AD; Mshali, I; Phakati, S; Rezk, NL; van der Horst, C | 1 |
| Moyle, G; Waters, L | 1 |
| De Rossi, A; Giaquinto, C; Rampon, O | 1 |
| Cecelia, AJ; Kumarasamy, N; Mayer, K; Saghayam, S; Solomon, S; Wanke, C | 1 |
| Aguilar, I; Hidalgo, A; Palacios, R; Santos, J | 1 |
| Hester, J; Jain, MK; Lee, WM; Parekh, NK | 1 |
| Neal, EF; Poston, PA; Robbins, BL; Rodman, JH; Slaughter, C | 1 |
| Fleckman, P; Williams, LH | 1 |
| Chantratita, W; Chumpathat, N; Kiertiburanakul, S; Manosuthi, W; Piyavong, B; Sungkanuparph, S | 1 |
| Allers, K; Fischer, M; Günthard, HF; Knoepfel, SA; Metzner, KJ; Opravil, M; Rauch, P; Walter, H | 1 |
| Barreiro, P; García-Samaniego, J; Labarga, P; Martín-Carbonero, L; Núñez, M; Ramos, B; Rios, P; Romero, M; Sheldon, J; Soriano, V | 1 |
| Becquet, R; Bedikou, G; Bequet, L; Dabis, F; Ekouevi, DK; Fassinou, P; Leroy, V; Sakarovitch, C; Timite-Konan, M; Viho, I | 1 |
| Angelousi, AG; Charatsis, GG; Falagas, ME; Lampropoulos, KM; Panos, GZ | 1 |
| Bastow, B; Glesby, MJ; Gulick, RM; Kuritzkes, DR; Meyer, WA; Ribaudo, HJ; Shikuma, CM; Tashima, KT; Webb, N; Yang, Y | 1 |
| Amellal, B; Calvez, V; Castro, ND; Chêne, G; Cotte, L; Gourlain, K; Journot, V; Molina, JM; Palmer, P; Pédrono, G; Rancinan, C | 1 |
| Galli, M; Gervasoni, C; Grinelli, E; Ortu, M; Rusconi, S; Vigano, O | 1 |
| Samuels, DC | 1 |
| Bickel, M; Buehler, A; Harmjanz, A; Lorenz, MW; Ruhkamp, D; Sitzer, M; Staszewski, S; Steinmetz, H; Stephan, C; von Kegler, S | 1 |
| Albrecht, M; Benson, C; da Silva, BA; Eron, J; Glesby, M; Gulick, R; Hanna, GJ; Hicks, C; Kessler, H; King, MS; Landay, A; McMillan, FI; Murphy, R; Thompson, M; White, AC; Wolfe, P | 1 |
| Asiimwe, F; Behumbiize, P; Brooks, JT; Forna, F; Liechty, CA; Mermin, J; Solberg, P; Tong, T; Weidle, PJ; Were, W | 1 |
| Certain, A; Clavel, F; Costagliola, D; Dalban, C; Descamps, D; Duval, X; Launay, O; Mouajjah, S; Peytavin, G; Ralaimazava, P; Verdon, R | 1 |
| Bezerra, EM; Caetano, EW; Cavada, BS; Flores, MZ; Freire, VN; Lemos, V; Pereira, BG; Pinheiro, MV; Righi, A; Vianna-Soares, CD | 1 |
| Attar, N; Comanor, L; Elkin, C; Jain, MK; Keiser, P; Kipnis, P; Lee, WM; Leung, K; Ocampo, A; White, C | 1 |
| Arranz, JA; Asensi, V; del Arco, A; Estrada, V; Galindo, MJ; Lozano, F; Morales, D; Muñoz, A; Palacios, R; Rivero, A; Santos, J | 1 |
| Chen, YM; Chuah, J; Cooper, DA; Ditangco, R; Frost, KR; Kamarulzaman, A; Kumarasamy, N; Law, MG; Lee, CK; Li, PC; Merati, TP; Paton, NI; Phanuphak, P; Pujari, S; Vibhagool, A; Zhang, F; Zhou, J | 1 |
| Bekker, V; Jurriaans, S; Kuijpers, TW; Lange, JM; Pajkrt, D; Scherpbier, HJ | 1 |
| Keiser, P; Nassar, N | 2 |
| Ait-Khaled, M; Brun-Vézinet, F; Collin, G; Craig, C; Damond, F; Delarue, S; Descamps, D | 1 |
| Bruun, JN; Clumeck, N; Dellamonica, P; Dragsted, UB; Fox, Z; Gerstoft, J; Hill, A; Katlama, C; Kjaer, J; Lundgren, JD; Mathiesen, L; Phillips, AN; Youle, M | 1 |
| Boucher, S; Fleury, H; Lavignolle-Aurillac, V; Masquelier, B; Neau, D; Ragnaud, JM; Recordon-Pinson, P; Schrive, MH | 1 |
| Al-Sharqui, A; Manavi, K; McDonald, A | 1 |
| Ejele, OA; Erhabor, O; Nwauche, CA | 1 |
| Chow, DC; Khawcharoenporn, T; Shikuma, CM; Williams, AE | 1 |
| Cimerman, S; Diaz, RS; Lewi, DS; Sucupira, MC | 1 |
| Bergshoeff, AS; Burger, DM; de Groot, R; Gibb, DM; Green, H; Hartwig, NG; La Porte, CJ; Lyall, H; Rakhmanina, N; Soldin, S; Verweel, G; Verwey-Van Wissen, CP | 1 |
| Jaruratanasirikul, S; Mahatthanatrakul, W; Ridtitid, W; Sriwiriyajan, S | 1 |
| Becker, S; Bernstein, B; Calhoun, D; Cameron, DW; da Silva, B; Foit, C; Hanna, GJ; King, MS; Klein, C; Tokimoto, D | 1 |
| Gulick, RM; Klingman, KL; Koletar, SL; Kuritzkes, DR; Meyer, WA; Reichman, R; Ribaudo, HJ; Riddler, SA; Santana, J; Shikuma, C; Squires, KE | 1 |
| Bendenoun, M; Mazeron, MC; Sanson-le Pors, MJ; Schnepf, N; Sellier, P; Zini, JM | 1 |
| De Munter, P; Schrooten, Y; Van Laethem, K; Van Ranst, M; Van Wijngaerden, E; Vandamme, AM; Verbesselt, R | 1 |
| Khongnorasat, S; Kiertiburanakul, S; Rattanasiri, S; Sungkanuparph, S | 1 |
| Chaovavanich, A; Kiertiburanakul, S; Manosuthi, W; Sungkanuparph, S | 1 |
| Ananworanich, J; Chetchotisakd, P; Gayet-Ageron, A; Hirschel, B; Jupimai, T; Le Braz, M; Prasithsirikul, W; Rooney, JF; Ruxrungtham, K; Ubolyam, S | 1 |
| Niamba, P; Taïeb, A; Traoré, A | 1 |
| Brun, SC; Coffin, JM; Davey, RT; Dewar, R; Hanna, GJ; Kempf, DJ; King, MS; Kovacs, JA; Liu, S; Maldarelli, F; Mellors, JW; Metcalf, JA; Mican, J; Palmer, S; Polis, MA; Rehm, C; Rock-Kress, D; Wiegand, A | 1 |
| Allers, K; Harrer, T; Metzner, KJ; Rauch, P | 1 |
| Gibb, DM; Grosskurth, H; Khoo, S; Kikaire, B; Mugyenyi, P; Munderi, P; Namale, L; Reid, A; Ssali, F; Walker, AS | 1 |
| Dore, GJ; Matthews, GV | 1 |
| Kumar, AK; Kumar, P; Kumaraswami, V; Ramachandran, G; Swaminathan, S | 1 |
| Kagan, RM; Lee, TS; Lewinski, MA; Lloyd, RM; Potts, SJ; Ross, L | 1 |
| Vogenthaler, NS | 1 |
| Abzug, MJ; Brady, M; Brogly, SB; Crain, MJ; Hughes, MD; Jean-Philippe, P; Mofenson, LM; Oleske, J; Seage, GR; Van Dyke, R; Ylitalo, N | 1 |
| Butler, K; Candeias, F; Castelli-Gattinara, G; Compagnucci, A; de Rossi, A; Della Negra, M; Feiterna-Sperling, C; Giaquinto, C; Gibb, DM; Green, H; Harper, L; Levy, J; Pillay, D; Saidi, Y; Walker, AS; Wintergerst, U | 1 |
| Anastos, K; Cohen, M; Cole, S; Hessol, NA; Justman, J; Kaplan, RC; Lu, D; Shi, Q; Tien, PC; Vigen, C; Young, M | 1 |
| Ket-Aim, S; Poolsup, N; Suksomboon, N | 1 |
| Gripshover, B; Gupta, S; Hammond, SP; Hatano, H; Hu, Z; Kalayjian, RC; Kuritzkes, DR; Smith, D; Whitcomb, J; Wild, M | 1 |
| Abernethy, J; Bell, F; Burger, DM; Chileshe, R; Chintu, C; Ellis, JC; Ewings, FM; Gibb, DM; L'homme, RF; Molyneux, E; Mulenga, V; van Oosterhout, JJ; Walker, AS | 1 |
| Bernasconi, E; Bersinger, NA; Cavassini, M; Elzi, L; Furrer, H; Fux, CA; Hirschel, B; Mueller, B; Mueller, NJ; Schmid, P; Wunder, DM | 1 |
| Dauer, B; Doerr, HW; Haberl, A; Hanke, N; Knecht, G; Locher, L; Moesch, M; Mueller, A; Staszewski, S; Stürmer, M | 1 |
| Bouzas, MB; Cahn, P; Carrillo, MG; Giuliano, SF; Laufer, N; Moretti, F; Pérez, H; Quarleri, J; Salomon, H | 1 |
| Antenozzi, S; Hulse, S; Luque, A; Shahzad, U; Smith, B; Tanzman, E; Wang, D | 1 |
| Bettendorf, D; Bosch, RJ; Eron, JJ; Fiscus, S; Frank, I; Petch, L | 1 |
| Daga, SR; Natu, SA | 1 |
| Kastelein, JJ; Lange, JM; Mmiro, F; Okong, P; Pakker, N; Reiss, P; Sankatsing, RR; Stroes, ES; Vyankandondera, J; Wit, FW | 1 |
| Bertelsen, L; Jakobsen, MR; Laursen, A; Mohey, R; Obel, N; Ostergaard, L; Tolstrup, M | 1 |
| Calvez, V; Chaix, ML; Delaugerre, C; Girard, PM; Katlama, C; Marcelin, AG; Morand-Joubert, L; Soulié, C | 1 |
| Dubé, MP; Grinspoon, SK; Mulligan, K; Parker, RA; Robbins, GK; Roubenoff, R; Tebas, P | 1 |
| Brumme, CJ; Harrigan, PR; Hogg, RS; Montaner, JS; Tam, LW; Yip, B | 1 |
| Bhat, S; Brennan, TP; Chong, CR; Hale, B; Hegarty, R; Jilek, BL; Liu, JO; McMahon, MA; Shen, L; Siliciano, RF; Thio, CL; Wind-Rotolo, M; Xing, S; Zhou, Y | 1 |
| Mellors, JW; Parikh, UM; Sluis-Cremer, N; Zelina, S | 1 |
| Celesia, BM; Massimino, SD; Mavilla, S; Mughini, MT; Nunnari, G; Onorante, A; Russo, R | 1 |
| Dubé, MP; Grinspoon, SK; Komarow, L; Mulligan, K; Parker, RA; Robbins, GK; Roubenoff, R; Tebas, P | 1 |
| Garcia-Gasco, P; Sheldon, J; Soriano, V | 1 |
| Clavel, F; Dam, E; Gerstoft, J; Joergensen, LB; Laursen, AL; Mathiesen, S; Roge, B | 1 |
| Cascone, A; Colella, G; Di Martino, F; Filippini, A; Filippini, P; Lanza, A; Martini, S; Masiello, A; Pisapia, R | 1 |
| Liu, J; Wu, S; Yan, Y; Yue, J | 1 |
| Castelnuovo, B; Kambugu, A; Mugasha, EB; Ocama, P; Songa, PM | 1 |
| Campbell, O; de Morais, EN; Duarte, G; El-Beitune, P; Mauad-Filho, F; Quintana, SM; Rodrigues, LC; Spara-Gadelha, P | 1 |
| Amorim, AP; Campos, CP; Custódio, FL; Ferrão, SB; Fonseca, BA; Gaspar, GG; Golin, NA; Marangoni, AT; Melo, Ld; Morejón, KM; Ponzi, CC; Santana, RC; Vanni, T | 1 |
| Abad, J; Amorós-Quiles, I; Belda, A; Borrás-Blasco, J; Casterá, E; Rosique-Robles, D | 1 |
| Abdel-Megeed, MF; Kashuba, AD; Rezk, NL | 1 |
| Beadsworth, M; Burger, DM; Kumwenda, JJ; Longwe, T; Mateyu, G; van Oosterhout, JJ; Zijlstra, EE | 1 |
| Cohen, DE; Golub, SA; Mayer, KH; Rosenthal, L | 1 |
| Daniels, E; Gaglio, PJ; Sterling, R; Tedaldi, E | 1 |
| Chevallier, M; Chevallier, P; Lebouché, B; Miailhes, P; Pradat, P; Trabaud, MA; Trepo, C; Zoulim, F | 1 |
| Tillmann, HL | 1 |
| Pensi, T | 1 |
| Campbell, O; Duarte, G; El Beitune, P; Quintana, SM; Rodrigues, LC | 1 |
| Ayres, A; Bartholomeusz, A; Colledge, D; Dore, GJ; Lewin, SR; Littlejohn, M; Locarnini, SA; Matthews, GV; Revill, PA; Sasaduesz, J; Thio, CL; Yuen, L | 1 |
| Giry, C; Hebert, JC; Lartigau-Roussin, C; Malvy, D; Pettinelli, ME; Receveur, MC | 1 |
| Bakeera-Kitaka, S; Castelnuovo, B; Colebunders, R; Gasasira, AF; Kambugu, A; Kamya, MR; Katabira, E; Kekitiinwa, A; Mayanja-Kizza, H; Mwebaze-Songa, P; Quinn, TC; Ronald, A; Schaefer, P; Semitala, F; Spacek, LA; Thomas, DL | 1 |
| Diquet, B; Goujard, C; Legrand, M; Mentré, F; Panhard, X; Taburet, AM | 1 |
| Ayliffe, U; Dervisevic, S; Garcia-Diaz, A; Geretti, AM; Gilson, R; Johnson, M; Nebbia, G; Smith, C; Tedder, R | 1 |
| Ansari, AW; Heiken, H; Schmidt, RE | 1 |
| Doerr, HW; Staszewski, S; Stürmer, M | 1 |
| Corona, G; Innocenti, F; Sandron, S; Sartor, I; Tirelli, U; Toffoli, G; Vaccher, E | 1 |
| Abrams, EJ; Amani-Bosse, C; Becquet, R; Coffie, PA; Dabis, F; Ekouevi, DK; El-Sadr, WM; Leroy, V; Rouet, F; Tonwe-Gold, B; Toure, S; Viho, I | 1 |
| Bridges, AS; Cohen, MS; Corbett, AH; Dumond, JB; Jung, BH; Kashuba, AD; Patterson, KB; Rezk, NL; Stewart, PW; Yeh, RF | 1 |
| Boom, WH; Charlebois, ED; Havlir, DV; Kayanja, HK; Lin, R; Mayanja-Kizza, H; Mugerwa, RD; Srikantiah, P; Walusimbi, MN; Whalen, CC | 1 |
| Crumpacker, CS; Gilde, LR; Gotuzzo, E; Isaacs, RD; Kovacs, C; Markowitz, M; Mendo, F; Miller, MD; Morales-Ramirez, JO; Nguyen, BY; Prada, G; Ratanasuwan, W; Teppler, H; Wan, H; Wenning, LA | 1 |
| Dratwa, M; Guillaume, MP; Mesquita, M | 1 |
| Gulick, RM; Kuritzkes, DR; Ribaudo, HJ | 1 |
| Adile, SL; Chandrakar, AK; Garg, ML; Pandey, N; Patel, S | 1 |
| Dzombo, D; Essajee, S; Jelagat, J; Mandaliya, K; Mwalimu, M; Shikely, K; Song, R | 1 |
| Burnett, RJ; Leeuw, YG; Lukhwareni, A; Mphahlele, MJ; Selabe, SG; Song, E | 1 |
| Acosta, EP; Bryson, Y; Capparelli, EV; Holland, D; Luzuriaga, K; Mirochnick, M; Patel, P; Tremoulet, AH; Wara, D; Zorrilla, C | 1 |
| Barrufet, P; Crespo, M; Ferrer, E; Gatell, JM; Llibre, JM; Niubo, J; Podzamczer, D; Sanchez, P; Sanz, J; Veloso, S | 1 |
| Acosta, EP; Bassett, R; Eron, JJ; Fischl, MA; Johnson, VA; Kuritzkes, DR; Long, MC; Moore, JD; Sommadossi, JP | 1 |
| Altinbaş, A; Büyükaşik, Y; Ozkaya, G; Unal, S | 1 |
| Agrofoglio, L; Bénech, H; Negredo, E; Pruvost, A; Théodoro, F | 1 |
| Bergroth, T; Lidman, K; Sönnerborg, A; Svedhem, V | 1 |
| Chantratitra, W; Kiertiburanakul, S; Manosuthi, W; Sungkanuparph, S | 1 |
| Ananworanich, J; Bunupuradah, T; Leng, LK; Pancharoen, C; Sosothikul, D; Thisyakorn, U; Trinavarat, P | 1 |
| Asensi, V; Barreiro, P; de Mendoza, C; Estrada, V; González-Lahoz, J; Jiménez-Nacher, I; Palacios, R; Rivas, P; Rodríguez-Novoa, S; Sánchez-Conde, M; Santos, J; Sanz, J; Sola, J; Soriano, V | 1 |
| Dimarco, M; Dodard, C; Guilbaud, R; Marier, JF; Monif, T; Morelli, G; Singla, AK; Thudi, NR; Tippabhotla, SK | 1 |
| Kanouse, DE; Landovitz, RJ; Moe, A; Reback, C; Rotheram-Fuller, E; Shoptaw, S; Wang, J | 1 |
| David, N; Hammond, J; Krantz, E; Malan, DR; McGrath, D; Wirtz, V | 1 |
| Arribas, JR; Campo, RE; Chen, SS; Cheng, AK; Dejesus, E; Enejosa, J; Gallant, JE; Gazzard, B; Holmes, CB; McColl, D; Pozniak, AL; Toole, JJ | 1 |
| Chersich, MF; Urban, MF | 1 |
| Easley, KA; Lennox, JL; Lu, C; Ofotokun, I; Smithson, SE | 1 |
| Colson, P; Henry, M; Solas, C; Tamalet, C; Tomei, C; Villacian, J | 1 |
| Chayama, K; Takahashi, S | 1 |
| Harada, S; Kaku, M; Koike, K; Mizokami, M; Oka, S | 1 |
| Bansal, A; Mahajan, VK; Sarin, S; Sharma, NL; Sud, N | 1 |
| Battegay, M; Bernasconi, E; Bucher, HC; Cavassini, M; Furrer, H; Günthard, H; Hirschel, B; Opravil, M; Vernazza, P; von Wyl, V; Wolbers, M; Yerly, S | 1 |
| Balkan, S; Delfraissy, JF; Fernandez, M; Ferradini, L; Laureillard, D; Ly, N; Ngeth, C; Pinoges, L; Prak, N; Puertas, G; Quillet, C; Rouzioux, C; Taburet, AM | 1 |
| Chen, J; Cooper, DA; Emery, S; Hazuda, DJ; Kelleher, AD; Law, M; Murray, JM; Nguyen, BY; Teppler, H | 1 |
| Ba, M; Calvez, V; Carcelain, G; Dakouo, ML; Derache, A; Doumbia, A; Haidara, I; Jarrousse, B; Katlama, C; Maïga, A; Marcelin, AG; Peytavin, G | 1 |
| Chaisson, RE; Charalambous, S; Churchyard, GJ; Fielding, KL; Grant, AD; Hoffmann, CJ; Innes, C; Sulkowski, MS; Thio, CL | 1 |
| Díaz-Curiel, M; Fernández-Guerrero, ML; García-Delgado, R; Górgolas, M; Goyenechea, A; Rivas, P | 1 |
| Ackermans, M; Blümer, RM; Danner, SA; Hassink, E; Reiss, P; Sauerwein, HP; Sutinen, J; van Agtmael, MA; van Vonderen, MG; Yki-Jarvinen, H | 1 |
| Boeri, E; Castagna, A; Clementi, M; Danise, A; Galli, L; Gianotti, N; Lazzarin, A; Menzo, S; Tiberi, S | 1 |
| Ariyoshi, K; Auwanit, W; Kannagi, M; Matsuda, M; Pathipvanich, P; Rojanawiwat, A; Saeng-Aroon, S; Sawanpanyalert, P; Sugiura, W; Taguchi, M; Yoshida, LM | 1 |
| Aguiar, RA; Aleixo, A; Cleto, S; Kakehasi, FM; Lin, E; Melo, VH; Pinto, JA; Tupinambás, U | 1 |
| Anaky, MF; Blanche, S; Chaix, ML; Fassinou, P; Inwoley, A; Kpozehouen, A; Msellati, P; Rouet, F; Rouzioux, C | 1 |
| Colebunders, R; Kigonya, C; Lutwama, F | 1 |
| Bill, R; Cohen, D; Fisher, A; Grasso, C; Mayer, KH; Mimiaga, MJ; Van Derwarker, R | 1 |
| Guillemi, S; Gutiérrez, S; Harrigan, PR; Jahnke, N; Montaner, JS; Montessori, V | 1 |
| Asenjo, MA; Barrufet, P; Domingo, P; Gatell, JM; Gutiérrez, F; Knobel, H; Mallolas, J; Pedrol, E; Peñaranda, M; Peraire, J; Pich, J; Vidal, F | 1 |
| Chauvin, JP; Cohen-Codar, I; Delaugerre, C; Delfraissy, JF; Flandre, P; Ghosn, J; Girard, PM; Horban, A; Norton, M; Rouzioux, C; Taburet, AM; Van, PN | 1 |
| Dunn, D; Mihailidis, C; Pillay, D; Pozniak, A | 1 |
| Abrams, EJ; Becquet, R; Chaix, ML; Clarisse, AB; Coffie, PA; Dabis, F; Ekouevi, DK; Leroy, V; N'dri-Yoman, T; Rouzioux, C; Tonwe-Gold, B; Viho, I | 1 |
| Bambara, RA; Chugh, P; Jamburuthugoda, VK; Kim, B; Operario, DJ; Purohit, V; Santos-Velazquez, JM; Skasko, M; Szymanski, EA; Wedekind, JE | 1 |
| Andreoni, M; Antinori, A; Castagna, A; Ceccherini-Silberstein, F; De Luca, A; Gianotti, N; Lorenzini, P; Maggiolo, F; Mussini, C; Nasto, P; Perno, CF; Torti, C; Trotta, MP | 1 |
| Aurpibul, L; Lee, B; Mangklabruks, A; Puthanakit, T; Sirisanthana, T; Sirisanthana, V | 1 |
| de la Torres, J; Gálvez, MC; López, M; López-Cortés, LF; Lozano, F; Palacios, R; Ríos, MJ; Rivero, A; Santos, J | 1 |
| Becquet, R; Dabis, F; Dequae-Merchadou, L; Ekouevi, DK; Horo, A; Leroy, V; Rouet, F; Rouzioux, C; Sakarovitch, C; Timité-Konan, M; Tonwe-Gold, B; Viho, I | 1 |
| Carosi, G; Ceresoli, F; Cologni, G; Cossarizza, A; Costarelli, S; Gargiulo, F; Lapadula, G; Magoni, M; Manca, N; Nasi, M; Nichelatti, M; Pinti, M; Quiros-Roldan, ME; Torti, C | 1 |
| Balu, RB; Brachman, PS; Cohen, CJ; Harley, WB; Kubota, M; Lim, ML; Schneider, S; Shaefer, MS; Sutherland-Phillips, DH; Williams, VC | 1 |
| Chantratita, W; Kiertiburanakul, S; Manosuthi, W; Pairoj, W; Saekang, N; Sungkanuparph, S | 1 |
| Burger, DM; Chintu, C; Ewings, FM; Gibb, DM; Kabamba, D; Kankasa, C; L'homme, RF; Mulenga, V; Thomason, MJ; Walker, AS | 1 |
| Asif, G; Hurwitz, SJ; Schinazi, RF | 1 |
| Bourgeois, A; Calmy, A; Ciaffi, L; Delaporte, E; Kouanfack, C; Koulla-Shiro, S; Laurent, C; Mougnutou, R; Mpoudi-Ngolé, E; Nkoué, N | 1 |
| Abel, S; Muirhead, GJ; Ridgway, CE; Russell, D; Whitlock, LA | 1 |
| Ananworanich, J; Côté, HC; Hill, A; Hirschel, B; Jupimai, T; Kerr, SJ; Laopraynak, N; Nuesch, R; Ruxrungtham, K; Saenawat, S | 1 |
| Herrera, L; Moreno, S; Sánchez-de la Rosa, R | 1 |
| Bresson, JL; Chaix, ML; Cohen-Codar, I; Delfraissy, JF; Galimand, J; Ghosn, J; Girard, PM; Peytavin, G; Raffi, F; Rouzioux, C | 1 |
| Biberfeld, G; Karlsson, K; Kilewo, C; Lyamuya, E; Massawe, A; Mhalu, F; Swai, A | 1 |
| Bateman, C | 1 |
| Traynor, K | 1 |
| Antoniou, T; Balla, S; Du Mont, J; Husson, H; Loutfy, MR; Macdonald, S; Myhr, T; Rachlis, A | 1 |
| Cahn, P; Coll, P; Gómez, A; Laufer, N; Lottner, J; Pérez, H; Rolón, M; Salomón, H; Vignoles, M | 1 |
| Bénech, H; Dehée, A; Dollfus, C; Durand-Gasselin, L; Garbarg-Chenon, A; Grassi, J; Leverger, G; Pruvost, A; Tabone, MD; Vaudre, G | 1 |
| Anglaret, X; Dabis, F; Dakoury-Dogbo, N; Diakite, N; Duvignac, J; Grundmann, C; Karcher, S; Kouadio, B; Marlink, R; Seyler, C; Toure, S; Traore, M | 1 |
| Lankoandé, D; Millogo, A; Sawadogo, AB; Yaméogo, AA; Yaméogo, I | 1 |
| Aweeka, F; Jayewardene, AL; Lebrecht, D; Venhoff, AC; Venhoff, N; Walker, UA | 1 |
| Audsley, J; Baden, R; Caro, J; Hunter, H; Lewin, SR; Matthews, G; McMahon, MA; Mijch, A; Olender, SA; Sasadeusz, J; Siliciano, RF; Thio, CL | 1 |
| Bonjoch, A; Clotet, B; Domingo, P; Galindo, MJ; Iribarren, J; Llibre, JM; Martinez-Picado, J; Negredo, E; Pérez-Alvarez, N; Schapiro, J | 1 |
| Faetkenheuer, G; Hartmann, P; Jung, N; Knispel, M; Lehmann, C; Rubbert, A; Stellbrink, HJ; Taubert, D; van Lunzen, J | 1 |
| Gibert, CL; Grunfeld, C; Peng, G; Sharma, S; Shlay, JC | 1 |
| Bonny, T; Clumeck, N; Currier, J; Kleim, JP; Lazzarin, A; McCarty, D; Millard, J; Slims, J; Sloan, L; Steel, H | 1 |
| Nelson, H | 1 |
| Benoit, SL; Eron, JJ; Fallon, MA; Jemsek, J; Kuritzkes, DR; MacArthur, RD; Quinn, JB; Rubin, M; Santana, J | 1 |
| Merigan, TC | 1 |
| Christopherson, C; Collis, P; Danner, SA; de Jong, D; Loveday, C; Mulder, J; Nijhuis, M; Schipper, P; Schuurman, R; van Leeuwen, R | 1 |
| Harrigan, PR; Kemp, SD; Larder, BA | 1 |
| Gunnarsson, G; Hammer, SM | 1 |
| Boucher, CA; Hill, A; Ingrand, D; Katlama, C; Kitchen, V; McBride, M; McDade, H; Tubiana, R; van Leeuwen, R; Weber, J | 1 |
| Cooley, TP; Hirst, HM; Montaner, JS; Pluda, JM; Quinn, JB; Reinhalter, NE; Ruedy, J; Shay, LE; Vicary, CA; Warthan, SN | 1 |
| Benhamou, Y; Dohin, E; Gentilini, M; Huraux, JM; Katlama, C; Lunel-Fabiani, F; Opolon, P; Poynard, T | 1 |
| Dudley, MN | 1 |
| Morris, DM; Selinger, K | 1 |
| Dionne, G; Gao, Q; Gu, Z; Hiscott, J; Wainberg, MA | 1 |
| Costigliola, P; Degrassi, A; Facchini, A; Lisignoli, G; Monaco, MC; Ricchi, E; Toneguzzi, S | 1 |
| Barbosa, P; Buchbinder, S; Feinberg, M; Harrer, E; Harrer, T; Johnson, RP; Walker, BD | 1 |
| Hui, F; Kavlick, MF; Kojima, E; Mitsuya, H; Pluda, JM; Shirasaka, T; Yarchoan, R | 1 |
| Staszewski, S | 2 |
| Boucher, CA; Cammack, N; Hill, A; Ingrand, D; Loveday, C; Robert, C; Weber, J | 1 |
| Boehme, R; Bonhoeffer, S; Hill, AM; McDade, H; Nowak, MA; Thomas, HC | 1 |
| Borkow, G; Castriota, G; Drosopoulos, WC; Gu, Z; Hsu, M; Islam, S; Manne, J; Parniak, M; Prasad, VR; Salomon, H; Song, Q; Wainberg, MA | 1 |
| Balis, F; Brouwers, P; Church, J; Farley, M; Goldsmith, J; Keller, A; Lewis, LL; Mueller, B; Pizzo, PA; Rubin, M; Shearer, GM; Sloas, M; Venzon, D; Wheeler, S; Wood, L; Yuen, G | 1 |
| Danner, SA; Dellarnonica, P; Harrigan, PR; Hill, AM; Johnson, MA; Loveday, C; McDade, H; Picazo, JJ; Skinhøj, P; Staszewski, S; Verity, L | 1 |
| Clumeck, N; Hill, AM; Ingrand, D; Johnson, M; Katlama, C; Loveday, C; Mallolas, J; McDade, H; Pearce, G; Staszewski, S | 1 |
| Bartlett, JA; Benoit, SL; Ehmann, WC; Fallon, MA; Johnson, VA; Quinn, JB; Rubin, M; Self, PL; Sepulveda, GE; Tsoukas, C | 1 |
| Rowe, PM | 1 |
| Costes, O; Lafeuillade, A; Poggi, C; Profizi, N; Tamalet, C | 1 |
| Andries, K; De Brabander, M; De Crée, J; De Raeymaeker, M; Miller, V; Moeremans, M; Pearce, G; Peeters, M; Rehmet, S; Stark, T; Staszewski, S; Stoffels, P; Van den Broeck, R; Verbiest, W | 1 |
| Gerberding, JL | 1 |
| Costes, O; Djediouane, A; Lafeuillade, A; Poggi, C; Profizi, N; Tamalet, C | 1 |
| Lane, HC; Masur, H; Spooner, KM | 1 |
| Coen, DM | 1 |
| Bartlett, JA; Eron, JJ; Hill, AM; Johnson, J; Phillips, AN; Price, S; Rubin, M; Self, P | 1 |
| Bakhtiari, M; Benoit, SL; Eron, JJ; Fallon, MA; Griffin, A; Kuritzkes, DR; Poticha, D; Quinn, JB; Rubin, M; Shugarts, DL | 1 |
| Slavkin, HC | 1 |
| Pierce, PF; Schnittman, SM | 1 |
| Havlir, DV; Katlama, C | 1 |
| Faulds, D; Lea, AP | 1 |
| Balzarini, J; De ClercQ, E; Karlsson, A; Kleim, JP; Pelemans, H | 2 |
| Schattner, A | 1 |
| Mörike, EM | 1 |
| Carr, A; Cooper, DA; Emery, S; Kelleher, A; Law, M | 1 |
| Balagué, M; Cabrera, C; Clotet, B; De Clercq, E; Martínez-Picado, J; Puig, T; Romeu, J; Ruiz, L; Schmit, JC; Segura, A; Sirera, G; Tural, C; Vandamme, AM | 1 |
| Preston, BD | 1 |
| Berkhout, B; Boucher, C; Keulen, W; Nijhuis, M; Schuurman, R | 1 |
| Patrick, DM | 1 |
| Bartlett, J; Eron, J; Gilbert, C; Hill, AM; Johnson, J; Johnson, VA; Keller, A; Kuritzkes, DR; Phillips, AN | 1 |
| Lafeuillade, A; Pellegrino, P; Poggi, C; Profizi, N; Sayada, C | 1 |
| Back, D; Barry, M; Gibbons, S; Merry, C; Mulcahy, F | 1 |
| Borkow, G; Gu, Z; Hsu, M; Parniak, MA; Wainberg, MA | 1 |
| Eron, JJ | 1 |
| Stephenson, J | 1 |
| Belohradsky, BH; Eberle, J; Gürtler, L; Notheis, G; Sölder, B; Wintergerst, U | 1 |
| Aguirrebengoa, K; Mallolas, J; Torres Tortosa, M; Uriz, J | 1 |
| Bonhoeffer, S; Coffin, JM; Nowak, MA | 1 |
| Back, NK; Berkhout, B; Boucher, CA; Keulen, W; van Wijk, A | 1 |
| Bartlett, J; Eron, JJ; Hill, AM; Johnson, J; Katlama, C; McDade, H; Sawyer, W; Staszewski, S | 1 |
| Faulds, D; Perry, CM | 1 |
| Hirschel, B; Rutschmann, O | 1 |
| Boulton, A | 1 |
| Heins, JR | 1 |
| Costes, O; Lafeuillade, A; Poggi, C; Profizi, N; Tamalet, C; Tourres, C | 1 |
| Cavert, W; Danner, SA; Gebhard, K; Goudsmit, J; Haase, AT; Henry, K; McDade, H; Mills, R; Notermans, DW; Schuwirth, CM; Staskus, K; Wietgrefe, SW; Zhang, ZQ; Zupancic, M | 1 |
| Cao, Y; Essunger, P; Ho, DD; Hurley, A; Markowitz, M; Perelson, AS; Saksela, K; Vesanen, M | 1 |
| Craig, C; Moyle, G | 1 |
| Costello, CE; Nelson, MR; Walsh, JC | 1 |
| Heylen, R; Miller, R | 1 |
| Ohta, Y; Shinkai, I | 1 |
| Fantini, J; Lafeuillade, A; Poggi, C; Tamalet, C; Yahi, N | 1 |
| Mueller, BU | 1 |
| Wainberg, MA | 1 |
| Ahle, D; Bushnell, S; Chang, C; Collins, ML; Detmer, J; Fine, E; Ho, DD; Horn, T; Irvine, B; Kolberg, J; Shen, LP; Tyner, D; Urdea, MS; Zayati, C | 1 |
| Böhler, T; Debatin, KM; Geiss, M; Haas, J; Herr, I | 1 |
| Boucher, CA; Danner, S; de Groot, T; de Jong, D; Keulen, W; Lange, J; Nijhuis, M; Schuurman, R; van Leeuwen, R | 1 |
| Collins, DO; Sakamoto, A | 1 |
| Castilla, J; Gómez-Cano, M; González-Lahoz, J; Laguna, F; Soriano, V | 1 |
| Chenoweth, CE; Gobetti, JP | 1 |
| Balfour, HH; Chodakewitz, JA; Currier, JS; Demeter, LM; Deyton, LR; Eron, JJ; Feinberg, JE; Fischl, MA; Grimes, JM; Hammer, SM; Hughes, MD; Squires, KE | 1 |
| Chodakewitz, JA; Emini, EA; Eron, JJ; Gonzalez, C; Gulick, RM; Havlir, D; Jonas, L; McMahon, D; Meibohm, A; Mellors, JW; Richman, DD; Valentine, FT | 1 |
| Lafeuillade, A; Poggi, C; Profizi, N; Tamalet, C | 1 |
| Escribano Hernández, A | 1 |
| Ahmed, A; Cohn, G; Ehrenpreis, ED; Lissoos, TW; Schiano, TD; Siano, C; Zaitman, D | 1 |
| Feingold, A; Meislich, D; Rudy, B; Rutstein, RM; Word, B | 1 |
| Emini, E; Günthard, HF; Haase, AT; Havlir, DV; Ignacio, CC; Kwok, S; Richman, DD; Wong, JK; Zhang, ZQ | 1 |
| Conway, B; Fransen, S; Montaner, JS; O'Shaughnessy, MV; Raboud, J; Rae, S; Rouleau, D; Shillington, A; Zala, C | 1 |
| Günthard, HF; Havlir, DV; Hezareh, M; Ignacio, CC; Richman, DD; Spina, CA; Wong, JK | 1 |
| Crespo, J; Pons-Romero, F | 1 |
| Casas, E; Gómez-Cano, M; González-Lahoz, J; Soriano, V; Valencia, E; Villalba, N | 1 |
| Hauri, D; John, H; Müller, NJ; Opravil, M | 1 |
| Gisslén, M; Hagberg, L; Norkrans, G; Svennerholm, B | 1 |
| Alaeus, A; Albert, J; Cox, S; Palmer, S | 1 |
| Gerstoft, J | 1 |
| Goldstein, H; Katopodis, NF; Kim, A; Kollmann, TR; Pettoello-Mantovani, M; Raker, C; Wiltshire, H; Yurasov, S | 1 |
| Edelstein, RE; Frenkel, LM; Manns-Arcuino, LA; Nickerson, DA; Tobe, VO | 1 |
| Cavert, W; Danner, SA; de Jong, JJ; de Wolf, F; Foudraine, NA; Goodwin, C; Goudsmit, J; Jurriaans, S; Kauffmann, RH; Leonard, JM; McDade, H; Meenhorst, PL; Notermans, DW; Schuwirth, CM | 1 |
| Chapanduka, ZC; Matchaba, PT | 1 |
| Barton, S; Blaxhult, A; Clotet, B; Goebel, FD; Hirschel, B; Katlama, C; Lundgren, JD; Pedersen, C; Phillips, AN; Vella, S | 1 |
| Guatelli, JC; Günthard, HF; Havlir, DV; Ignacio, CC; Richman, DD; Riggs, NL; Wong, JK | 1 |
| Conway, B; Hogg, RS; Montaner, JS; O'Shaughnessy, MV; Rhone, SA; Schechter, MT; Sherlock, C; Yip, B | 1 |
| Hester, EK; Peacock, JE | 1 |
| DeMasi, R; Hill, AM; Montaner, JS | 1 |
| Adams, O; Horneff, G; Wahn, V | 1 |
| Gray, CM; Merigan, TC; Schapiro, JM; Winters, MA | 1 |
| Bai, J; Daar, ES; Giorgi, JV; Hausner, MA; Majchrowicz, M; Tamaddon, M | 1 |
| Burt, MS; Mills, RJ; Scott-Lennox, JA | 1 |
| Conway, B; Durakovic, C; Fransen, S; Harris, M; Montaner, JS; Raboud, J; Rae, S; Shillington, A | 1 |
| Bloor, S; de Béthune, MP; Harrigan, PR; Hertogs, K; Kemp, SD; Larder, BA; Miller, V; Pauwels, R; Phillips, A; Rottmann, C; Staszewski, S | 1 |
| Stevens, TP; Watson, WJ; Weinberg, GA | 1 |
| Bloor, S; de Béthune, MP; Gröschel, B; Harrigan, PR; Hertogs, K; Kemp, SD; Larder, BA; Miller, V; Pauwels, R; Staszewski, S; Stürmer, M | 1 |
| Aboulker, JP; Batisse, D; Belec, L; Castiel, P; Gilquin, J; Gonzalez-Canali, G; Jayle, D; Karmochkine, M; Kazatchkine, MD; Piketty, C; Si Mohamed, A; Weiss, L | 1 |
| Batisse, D; Belec, L; Karmochkine, M; Kazatchkine, MD; Piketty, C; Si Mohamed, A | 1 |
| Kahn, JG; Marseille, E; Saba, J | 1 |
| Angius, AG; Carminati, G; Cusini, M; Tarantini, G; Zerboni, R | 1 |
| Balis, FM; Brouwers, P; Deutsch, PJ; Jarosinski, PF; Ju, W; Mistry, G; Mueller, BU; Nelson, RP; Pizzo, PA; Sei, S; Sleasman, J; Smith, S; Steinberg, SM; Winchell, G; Wood, LV; Zeichner, S; Zwerski, S | 1 |
| Dalod, M; Deschemin, JC; Dumon, B; Gomard, E; Harzic, M; Hoen, B; Levy, JP; Pellegrin, I; Sereni, D; Venet, A | 1 |
| Chiozzi, MH; Connick, E; Fox, L; Kessler, H; Kotzin, BL; Kuritzkes, DR; Landay, A; Lederman, MM; Leonard, JM; Martinez, A; Roe, JD; Rousseau, F; Spritzler, J; St Clair, M; Wade, M | 1 |
| Belohradsky, BH; Eberle, J; Gürtler, L; Hoffmann, F; Notheis, G; Petropoulou, T; Sölder, B; Wintergerst, U | 1 |
| Jürgens, H; Pollmann, H; Richter, H | 1 |
| Chodakewitz, JA; Condra, JH; Emini, EA; Eron, JJ; Gonzalez, C; Gulick, RM; Havlir, D; Holder, D; Isaacs, R; Jonas, L; McMahon, D; Meibohm, A; Mellors, JW; Richman, DD; Schleif, WA | 1 |
| Clotet, B; Gómez-Cano, M; Leal, M; Pérez-Olmeda, M; Pineda, JA; Puig, T; Rubio, A; Ruiz, L; Soriano, V; Xaus, N; Zamora, L | 1 |
| Frothingham, R | 1 |
| Berrey, MM; Chun, TW; Corey, L; Engel, D; Fauci, AS; Shea, T | 1 |
| Boucher, CA; de Groot, T; Nijhuis, M; Ran, LJ; Schuitemaker, H; Schuurman, R; Tijnagel, JM; van 't Wout, AB; van Leeuwen, R | 1 |
| Boeri, E; Carrera, P; Gianotti, N; Lazzarin, A; Tambussi, G | 1 |
| Saint-Marc, T; Touraine, JL | 1 |
| Clotet, B; De Clercq, E; Desmyter, J; Puig, T; Rossau, R; Ruiz, L; Schmit, JC; Stuyver, L; Van Laethem, K; Vandamme, AM; Vanderlinden, I | 1 |
| Danner, SA; de Wolf, F; Goudsmit, J; Hoetelmans, RM; Jurriaans, S; Lange, JM; Lukashov, VV; Notermans, DW; Prins, JM; Roos, M; Schuitemaker, H; Weverling, GJ | 1 |
| Bellman, PC | 1 |
| Carpenter, WM; Cuny, E | 1 |
| Kibayashi, K; NG'walali, PM; Tsunenari, S | 1 |
| Danner, SA; de Wolf, F; Goudsmit, J; Mittler, J; Notermans, DW; Perelson, AS | 1 |
| de Jong, JJ; de Wolf, F; Foudraine, NA; Jan Weverling, G; Jurriaans, S; Keet, IP; Lange, JM; Maas, J; Roos, MT; van Benthem, BH; Vandermeulen, K | 1 |
| Bogner, JR; Goebel, F; Jung, C | 1 |
| Bachmeyer, C; Blum, L | 1 |
| Tashima, KT | 1 |
| Beijnen, JH; Hoetelmans, RM; Mennhorst, PL; Mulder, JW; Profijt, M | 1 |
| Britsch, P; Dettling, M; Müller-Oerlinghausen, B | 1 |
| Akeb, F; Fridland, A; Grassi, J; Guedj, R; Lancaster, D; Pinkerton, FH; Robbins, BL; Tran, TT | 1 |
| Beveridge, A; Carr, A; Cooper, DA; Cunningham, P; Duncombe, C; French, M; Kaufmann, GR; Sayer, D | 1 |
| Heald, AE; Pieper, CF; Schiffman, SS | 1 |
| Angel, JB; Cameron, DW; Garber, GE; Hawley-Foss, N; Houston, S; Kravcik, S; Sutherland, D; Victor, G | 1 |
| Saag, MS; Schooley, RT | 1 |
| Coovadia, H; Goodwin, C; Harrigan, PR; Johnson, MA; Moodley, D; Moodley, J; Moore, KH; Pillay, K; Plumb, R; Saba, J; Stone, C; van Leeuwen, R | 1 |
| Brouwers, P; Johnson, GM; Keller, A; McKinney, RE; McNamara, J; Mitchell, WG; Mofenson, L; O'Donnell, KJ; Spector, SA; Stanley, K; Wara, DW; Wiznia, A; Yogev, R; Yong, FH | 1 |
| Lindbloom, EJ; Stevermer, JJ | 1 |
| Bassett, RL; Boone, G; Collier, AC; Havlir, DV; Hirsch, MS; Holohan, MK; Ioannidis, JP; Leavitt, R; Marschner, IC; Richman, DD; Tebas, P | 1 |
| Aboulker, JP; Brun-Vezinet, F; Delfraissy, JF; Dellamonica, P; Flandre, P; Gastaut, JA; Meiffrédy, V; Pialoux, G; Raffi, F; Yeni, P | 1 |
| Li, YF; Solas, C; Sommadossi, JP; Xie, MY; Zhou, XJ | 1 |
| Conly, J; Fletcher, D; Keystone, D; Salit, I; Tseng, A; Walmsley, S | 1 |
| Aquilina, C; Roueire, A; Viraben, R | 1 |
| Bréchot, C; Carnot, F; Landau, A; Pialoux, G; Pol, S; Zylberberg, H | 1 |
| Battegay, M; Bisset, LR; Cone, RW; Grob, PJ; Huber, W; Opravil, M; Vernazza, PL; Weber, R | 1 |
| Bonnez, W; Evans, TG; Fitzgerald, T; Gibbons, DC; Reichman, RC; Soucier, HR | 1 |
| Balis, FM; Church, JA; Farley, M; Goldsmith, JC; Keller, A; Lewis, LL; Mueller, BU; Pizzo, PA; Rubin, M; Venzon, DJ; Yuen, GJ | 1 |
| Anton, KE; Cherrington, JM; Lamy, PD; Miller, MD; Mulato, AS | 1 |
| Gitterman, SR; Pratt, RD; Struble, KA | 1 |
| Izopet, J; Marchou, B; Massip, P; Pasquier, C; Puel, J; Salama, G; Sandres, K | 1 |
| Clerici, M; Ferrante, P; Rusconi, S; Saresella, M; Viganó, A | 1 |
| Brew, BJ; Markus, R | 1 |
| Beckmann, A; Berger, A; Borchard, C; Dötterer, H; Eppner, MT; Esser, S; Exner, V; Fiedler, M; Goos, M; Hengge, UR; Müller, K; Wiehler, H | 1 |
| Clark, NM; Dieng Sarr, A; Kanki, PJ; Kazanjian, P; Markovitz, DM; Sankalé, JL; Winfield, R | 1 |
| Béguinot, I; Dehlinger, V; Etienne, JC; Jaussaud, R; Léone, J; Pennaforte, JL; Rouger, C; Strady, C | 1 |
| Baron, F; Daniel, C; Moutschen, M | 1 |
| Dickinson, BP; Flanigan, T; Mega, A; Mileno, MD; Mylonakis, E; Rich, JD; Schiffman, FJ | 1 |
| Braner, HJ; Funk, M; Groeschel, B; Kornhuber, B; Kreuz, W; Linde, R | 1 |
| Axelrod, J; DiVito, MM; Ernest, JM; Hitti, J; Livingston, E; Money, DM; Robbins, D; Silverman, NS; Watts, DH | 1 |
| Bruisten, SM; de Wolf, F; Frissen, PH; Jurriaans, S; Lange, JM; Mulder, JW; Reijers, MH; Schuitemaker, H; ten Kate, RW; van Leeuwen, R; Weigel, HM; Weverling, GJ; Wit, FW | 1 |
| Borleffs, JC; Boucher, CA; Cohen Stuart, JW; Hamman, D; Miedema, F; Roos, M | 1 |
| Caliendo, AM; Currier, JS; D'Aquila, RT; DeGruttola, V; Eron, JJ; Frank, I; Gerber, JG; Gulick, RM; Kuritzkes, DR; Murphy, RL; Smeaton, L; Sommadossi, JP; Tung, R | 1 |
| Phillips, L | 1 |
| Chancellor, JV; Hill, AM; Sabin, CA; Simpson, KN; Youle, M | 1 |
| Kempel, A; Lacey, L; Mauskopf, J; Simpson, K | 1 |
| Spenatto, N; Viraben, R | 1 |
| Lawrence, J; Merigan, TC; Schapiro, JM; Winters, MA | 1 |
| Delfraissy, JF; Goujard, C; Guillet, JG; Lantz, O; Lefebvre, P; Martinon, F; Michelet, C; Peguillet, I; Taoufik, Y | 1 |
| Ammälä, P; Ristola, M; Salo, E; Suni, J | 1 |
| Brunet, C; Chambost, H; Giraud, P; Michel, G; Perrimond, H; Tamalet, C; Thuret, I | 1 |
| Justesen, US; Mygind, LH; Pedersen, C; Pedersen, SS | 1 |
| Hosaka, H; Kubo, S; Nagai, K; Nakamura, N; Nonaka, H; Shinohara, M | 1 |
| Coll, M; Montull, S; Pardo, MJ; Pedrol, E | 1 |
| Chodakewitz, J; Cook, J; Coplan, P; Dasbach, E; Markson, L; Meibohm, A; Mellors, J; Nguyen, BY; Yin, D | 1 |
| Bubl, R; Di Gallo, A; Engelcke, G; Rinaldi, D; Rohrer, T; Rudin, C | 1 |
| de Wolf, F; Foudraine, NA; Hoetelmans, RM; Keet, IP; Lange, JM; Maas, JJ; Portegies, P; van Benthem, BH | 1 |
| Bricaire, F | 1 |
| de Man, RA; Niesters, HG; Schalm, SW; Wolters, LM | 1 |
| Bettoli, V; D'Antuono, A; Marzaduri, S; Piraccini, BM; Tosti, A | 1 |
| Borleffs, JC; Boucher, CA; Bravenboer, B; Burger, DM; Cohen Stuart, JW; Hamann, D; Hoetelmans, RM; Juttmann, JR; Koopmans, PP; Kroon, FP; Meenhorst, PL; Richter, C; Schuurman, R; Sprenger, HG | 1 |
| Cassano, P; Clumeck, N; De Wit, S; Gerard, M; Hermans, P; Kabeya, K; O'Doherty, E | 1 |
| Asensi, V; Carton, JA; Maradona, JA; Martínez, A; Rodríguez, M | 1 |
| Chittick, GE; McDowell, JA; Wang, LH | 1 |
| Carr, A; Cooper, DA; Cunningham, PH; Grey, P; Jaramillo, AB; Kaufmann, GR; Kelleher, AD; Smith, D; Vizzard, J; Wright, R; Zaunders, JJ | 1 |
| Chêne, G; Cotte, L; Debord, T; Decazes, JM; Ferchal, F; Journot, V; Madelaine, I; Molina, JM; Pellegrin, I; Rancinan, C; Sombardier, MN | 1 |
| Fine, N; Hurwitz, JJ; Rachlis, AR | 1 |
| Agut, H; Autran, B; Calvez, V; Katlama, C; Li, TS; Neumann, AU; Robert, C; Tubiana, R | 1 |
| Bassett, R; Bell, D; Eron, JJ; Fife, K; Fischl, MA; Johnson, VA; Kuritzkes, DR; Maenza, J; Marschner, I; Murphy, RL; Pettinelli, C; Rosandich, ME; Sommadossi, JP; Wood, K | 1 |
| Goulder, PJ; Jones, NG; Kalams, SA; Ogg, GS; Shea, AK; Trocha, AK; Walker, BD | 1 |
| Connick, E; Fox, L; Kessler, H; Kuritzkes, DR; Landay, A; Lederman, MM; Patki, AH; Purvis, SF; Spritzler, J; St Clair, M; Valdez, H | 1 |
| Gómez-Cano, M; Holguín, A; Soriano, V; Villalba, N | 1 |
| Chien, JW; Lederman, MM; McClernon, D; McComsey, G; St Clair, M; Valdez, H | 1 |
| Hogg, RS; Jahnke, N; Montaner, JS; O'Shaughnessy, M; Yip, B | 1 |
| Atkins, M; Barrett, C; Cooper, DA; Dore, GJ; Goh, LE; Thakrar, B | 1 |
| Hirsch, M; Hirschel, B; Lange, J; Leavitt, R; Meibohm, A; Mellors, J; Rawlins, S; Scerpella, E; Squires, K; Staszewski, S; Steigbigel, R | 1 |
| Ahmad, M; Brennan, JM; Caliendo, AM; Fiske, WD; Flanigan, TP; Gormley, JM; Tashima, KT | 1 |
| Adams, O; Braunstein, S; Horneff, G; Niehues, T; Wahn, V | 1 |
| Cane, PA; Mutimer, D; Pillay, D | 1 |
| Cruceta, A; Gallart, T; García, F; Gatell, JM; Miró, JM; O'Brien, WA; Pantaleo, G; Plana, M; Pumarola, T; Vidal, C | 1 |
| Belohradsky, BH; Grubert, TA; Lutz-Friedrich, R; Rolinski, B; Wintergerst, U | 1 |
| Agut, H; Benhamou, Y; Bochet, M; Bricaire, F; Katlama, C; Opolon, P; Poynard, T; Seguret, C; Thibault, V | 1 |
| Bessesen, M; Condreay, L; Ives, D; Lawrence, S; Sherman, KE | 1 |
| Battegay, M; Cone, RW; Hirschel, B; Ledergerber, B; Opravil, M; Vernazza, P; Zinkernagel, C | 1 |
| Beauvais, L; Bicart-See, A; Bourezane, Y; Dubeaux, B; Dumon, B; Fleury, H; Harzic, M; Hoen, B; Lascoux, C; Raffi, F; Ragnaud, JM; Séréni, D; Venet, A | 1 |
| Boyle, B; Corral, LG; Elbeik, T; Haslett, PA; Kaplan, G; Klausner, JD; Kunachiwa, W; Makonkawkeyoon, S; Maneekarn, N; Metatratip, P; Moreira, A; Shen, Z; Vongchan, P | 1 |
| Bloch, M; Carr, A; Cunningham, P; Smith, D; Vasak, E | 1 |
| Ait-Khaled, M; Braganza, R; Clarke, JR; Lyall, H; McClure, MO; Mirza, A; Parker, D; Stainsby, C; Taylor, GP; Weber, JN; Wright, A | 1 |
| Aleman, S; Loré, K; Sönnerborg, A; Visco-Comandini, U | 1 |
| Barret, B; Blanche, S; Ciraru-Vigneron, N; Delfraissy, JF; Desguerre, I; Firtion, G; Lacroix, C; Mandelbrot, L; Mayaux, MJ; Rötig, A; Rouzioux, C; Rustin, P; Slama, A; Tardieu, M | 1 |
| Carlo, DJ; Kaplan, MH; Marecki, M; Moss, RB; Patterson, BK; Pawha, S | 1 |
| Ahrens, P; Funk, MB; Hoffmann, F; Kornhuber, B; Kreuz, W; Linde, R; Notheis, G; Schuster, T; Wintergerst, U | 1 |
| Kan, VL; Nylen, ES | 1 |
| Deray, G; Diquet, B; Izzedine, H; Jouan, M; Launay-Vacher, V; Theou, N | 1 |
| Gill, MJ; Johns, DG | 1 |
| Adorni, F; Citterio, P; d'Arminio-Monforte, A; Galazzi, M; Galli, M; Gianotto, M; Grassini, A; Kurtagic, S; La Seta-Catamancio, S; Milazzo, L; Moroni, M; Rusconi, S; Testa, L | 1 |
| Benhamou, Y; Bochet, M; Bricaire, F; Caumes, E; Di Martino, V; Katlama, C; Opolon, P; Poynard, T; Thibault, V | 1 |
| Gill, MJ; Lacey, L | 1 |
| Lacey, L; Lindrooth, R; Mauskopf, J; Pham, S; Saag, M; Sawyer, W | 1 |
| Behrens, M; Lacey, L; Schrappe, M; Staszewski, S; Trueman, P; Youle, M | 1 |
| Gill, MJ; Hopkinson, PK; Lacey, L; Leblanc, F; Montaner, J | 1 |
| Chatterton, ML; Scott, J; Scott-Lennox, J; Wu, AW | 1 |
| di Gennaro, G; Donada, C; Donadon, V; Nasti, G; Tirelli, U | 1 |
| Cohen, MS; Dunn, JA; Eron, JJ; Fiscus, SA; Hall, JE; Kashuba, AD; Pereira, AS; Tidwell, RR; Troiani, L | 1 |
| Back, D; Barrett, JE; Barry, MG; Churchus, R; Kapoor, A; Lloyd, J; Moore, KH; Pakes, GE; Shaw, S | 1 |
| Albrecht, D; Lorenzen, T; Plettenberg, A; Stoehr, A; Weitzel, T | 1 |
| Black, FT; Blaxhult, A; Gerstoft, J; Jensen-Fangel, S; Kirk, O; Larsen, L; Lundgren, JD; Obel, N; Pedersen, C | 1 |
| Fowler, VG; Hicks, CB; Kirkland, KB | 1 |
| Bartlett, JA; Eron, JJ; Hussey, EK; Moore, KH; Pakes, GE; Yuen, GJ | 1 |
| Wood, LV | 1 |
| Bricalli, D; Clerici, M; Dally, L; Pirillo, M; Principi, N; Sala, N; Saresella, M; Trabattoni, D; Vella, S; Viganò, A | 1 |
| Kikuchi, Y; Oka, S; Tachikawa, N; Yasuoka, A; Yoshizawa, S | 1 |
| Temesgen, Z; Wright, AJ | 1 |
| Arlotto, C; Bernard, A; Bernard-Pomier, G; Breittmayer, JP; Dellamonica, P; Pradier, C; Pugliese, P; Roger, PM | 1 |
| Asjö, B; Dyrhol-Riise, AM; Olofsson, J; Voltersvik, P | 1 |
| Arrizabalaga, J; Clotet, BG; Cruceta, A; Dalmau, D; Gallart, T; García, F; Gatell, JM; Gomez-Sirvent, JL; Grau, I; Knobel, H; Miró, JM; O'Brien, WA; Podzamczer, D; Pumarola, T; Romeu, J; Sambeat, MA | 1 |
| Antunes, F; Brown, DJ; Clumeck, N; Fetter, A; Haubrich, R; Kahl, L; Lang, W; Pagano, G; Richman, D; Schooley, R; Sereni, D; Stein, A; Thompson, M; van der Ende, ME | 1 |
| Homeff, G; Niehues, T; Schmidt, B; Wahn, V; Walter, H | 1 |
| Feingold, KR; Grunfeld, C; Khovidhunkit, W; Memon, RA; Mulligan, K; Pang, M; Schambelan, M; Shigenaga, JK | 1 |
| Farina, D; Johnson, P; Labriola, DF; Manion, DJ; Morales-Ramirez, J; Rachlis, A; Ruiz, NM; Skiest, D; Stanford, J; Staszewski, S; Stryker, R; Tashima, KT | 1 |
| Flepp, M; Jost, J; Ledergerber, B; Opravil, M; Paris, D; Ruef, C; Weber, R; Zimmerli, S | 1 |
| Connick, E; Kessler, H; Kuritzkes, D; Landay, AL; Lederman, MM; Olinger, G; Spear, GT; Spritzler, J; St Clair, M; Sullivan, BL; Wu, H | 1 |
| Borleffs, JC; Boucher, CA; de Boer, RJ; Hamann, D; Hazenberg, MD; Miedema, F; Otto, SA; Stuart, JW | 1 |
| Ap, S; Berrey, MM; Brown, DJ; Corey, L; Huang, Y; Malhotra, U; Markee, J; McElrath, MJ; Musey, L; Schacker, T | 1 |
| Connick, E; Francis, I; Gross, B; Kessler, HA; Kuritzkes, D; Landay, A; Lederman, MM; McCune, JM; Smith, KY; Spritzler, J; Valdez, H | 1 |
| Chiozzi, MH; Connick, E; D'Arc Roe, J; Fox, L; Kessler, H; Kotzin, BL; Kuritzkes, DR; Landay, A; Lederman, MM; Leonard, JM; Martinez, A; Rousseau, F; Sevin, AD; Spritzler, J; St Clair, M | 1 |
| Arnedo, A; Gómez, CJ; Roca, B | 3 |
| Arts, EJ; García Lerma, JG; Heneine, W; Mas, A; Quiñones-Mateu, ME; Soriano, V | 1 |
| Katlama, C | 1 |
| De Cabooter, N; Plum, J; Van Der Gucht, B; Verhofstede, C; Wanzeele, FV | 1 |
| Claudel, P; Muller, P; Strobel, M | 1 |
| Aboulker, JP; Bazin, B; Brun-Vézinet, F; Calvez, V; Collin, G; Delaugerre, C; Descamps, D; Flandre, P; Meiffredy, V; Peytavin, G; Pialoux, G; Raffi, F; Robert-Delmas, S | 1 |
| Collier, AC; Havlir, DV; Hellmann, NS; Hirsch, MS; Petropoulos, CJ; Richman, DD; Sommadossi, JP; Tebas, P; Whitcomb, JM | 1 |
| Henry, K; Staudinger, R | 1 |
| Enting, RH; Foudraine, NA; Jurriaans, S; Lange, JM; Portegies, P; van der Poll, T; Weverling, GJ | 1 |
| Borkowsky, W; Fiscus, S; Jimenez, E; Lee, S; McIntosh, K; Mofenson, L; Nachman, SA; Pelton, S; Pitt, J; Rathore, M; Smith, ME; Stanley, K; Wells, B; Wiznia, A; Yogev, R | 1 |
| Lucchesi, C; Simini, B | 1 |
| Bakhtiari, M; Connick, E; Kessler, H; Kuritzkes, DR; Landay, A; Lederman, MM; Sevin, A; Spritzler, J; St Clair, M; Wu, H; Young, B | 1 |
| Copeland, KF; Fransen, S; Rosenthal, KL; Smaill, F; Smieja, M | 1 |
| Alexander, CS; Harrigan, PR; Mo, T; Montaner, JS; Raboud, JM; Rae, S; Rouleau, D; Zala, C | 1 |
| De Mautort, E; Fritsch, S; Kempf-Durepaire, G; Krantz, V; Lang, JM; Nicolle, M; Partisani, M; Rey, D; Schmitt, C; Stoll-Keller, F | 1 |
| Alcorn, T; Bloor, S; De Vroey, V; Dehertogh, P; Hertogs, K; Larder, BA; Miller, V; Stürmer, M; van Cauwenberge, A; van Den Eynde, C; van Houtte, M; Wegner, S | 1 |
| Bassetti, D; Bassetti, M; Gatti, G; Principi, N; Sala, N; Vella, S; Vigano', A | 1 |
| Bare, C; Bedard, J; Bogan, MR; Buckheit, RW; Gobbi, A; Linquist-Stepps, VD; McCune, JM; Moreno, ME; Rando, RF; Stoddart, CA | 1 |
| Gazzard, BG; Moyle, GJ | 3 |
| Gartland, M; Gatell, J; Lange, J | 1 |
| Gil Aguado, A; González Lahoz, J; Lavilla Uriol, P; Valencia Ortega, ME | 1 |
| Campi, G; Casorati, G; Corey, L; Demarest, JF; Kaufmann, D; Lazzarin, A; Lenge, C; Pantaleo, G; Rizzardi, GP; Soudeyns, H; Tambussi, G | 1 |
| Murray, JD; Nelson, PW; Perelson, AS | 1 |
| Anderson, J; El-Gadi, S; Forster, G; Murphy, M; Parkin, JM; Pinching, AJ | 1 |
| Bassetti, S; Bisset, LR; Cone, RW; Fischer, M; Huber, W; Knuchel, MC; Lorenzi, P; Lüthy, R; Opravil, M; Ott, P; Roos, M; Vernazza, PL; Weber, R | 1 |
| Bakhtiari, M; Eron, JJ; Gingeras, TR; Johnson, J; Kennedy, M; Kuritzkes, DR; Poticha, D; Rubin, M; Shugarts, D | 1 |
| Ait-Khaled, M; Cutrell, A; Griffin, P; Harrigan, R; Katlama, C; Mesogiti, D; Miller, V; Pearce, G; Staszewski, S; Stone, C; Tisdale, M | 1 |
| Asjö, B; Dyrhol-Riise, AM; Olofsson, J; Røsok, BI; Voltersvik, P | 1 |
| Bernasconi, E; Carota, A; Magenta, L; Moccetti, T; Piffaretti, JC | 1 |
| Andreotti, M; Bricalli, D; Clerici, M; Dally, LG; Di Fabio, S; Ferrante, P; Pirillo, M; Principi, N; Saresella, M; Vanzulli, A; Vella, S; Vigano, A | 1 |
| Beguinot, I; Bernard, P; Derancourt, C; Drobacheff, C; Verraes, S | 1 |
| Clumeck, N | 1 |
| Carlebach, A; Gute, P; Haberl, A; Miller, V; Nisius, G; Staszewski, S | 1 |
| Anderson, RD | 1 |
| Bart, PA; Chapuis, A; De Boer, RJ; Fox, CH; Halkic, N; Hoover, S; Lange, JM; Lazzarin, A; Miller, V; Notermans, DW; Pantaleo, G; Perrin, L; Rizzardi, GP; Staszewski, S; Tambussi, G | 1 |
| Arion, D; Götte, M; Parniak, MA; Wainberg, MA | 1 |
| Aoki, M; Genka, I; Kikuchi, Y; Oka, S; Tachikawa, N; Teruya, K; Yamaguchi, M; Yamamoto, Y; Yasuoka, A; Yasuoka, C | 1 |
| Aizawa, S; Aoki, M; Ida, S; Kikuchi, Y; Oka, S; Sakai-Hachiya, A; Tachikawa, N; Yasuoka, A | 1 |
| Borowski, L; Day, RB; Fan, Z; Hildebrand, WH; Hoji, A; Huang, XL; Kalinyak, C; Margolick, JB; McMahon, DK; Mellors, JW; Riddler, SA; Rinaldo, CR | 1 |
| Diaz, C; Febo, I; Font, E; Garcia, R; Rodriguez Orengo, JF; Rodriguez, JL; Rosario, O; Santana, J | 1 |
| Butler, KM; Clarke, SM; Condon, S; Healy, CM; Mulcahy, F | 1 |
| Babiker, A; de Rossi, A; Gibb, DM; Grosch-Woerner, I; Klein, N; Newberry, A | 1 |
| Clotet, B; De Clercq, E; Desmyter, J; Evans, C; Hermans, P; Muyldermans, G; Ruiz, L; Schmit, JC; Schneider, F; Simons, P; Stuyver, L; Van Laethem, K; Van Vaerenbergh, K; Van Wanzeele, F; Van Wijngaerden, E; Vandamme, AM; Verhofstede, C | 1 |
| Bizzoni, L; Cassone, A; Girmenia, C; Martino, P; Mazzucconi, MG | 1 |
| Currier, JS; D'Aquila, RT; Eron, JJ; Fiscus, SA; Gulick, RM; Lennox, JL; Murphy, RL; Rogers, MD; Smeaton, LM; Tung, R | 1 |
| Casado, JL; Moreno, S | 1 |
| Bäuerle, M; Goldwich, A; Graedner, I; Harrer, E; Harrer, T; Kalden, JR; Schmitt, M | 1 |
| Becker, S; Eron, JJ; Fisher, RL; Ruane, PJ; Sawyer, GA; Shaefer, MS; Tolson, JM; Yetzer, ES | 1 |
| Tovo, PA | 1 |
| Allende, MC; Belloso, WH; Benetucci, JA; Cahn, PE; Davey, RT; Emery, S; Lane, HC; Lasala, MC; Law, MG; Lopardo, G; Losso, MH; Nelson, E; Salomon, H; Saracco, M | 1 |
| Conway, B; Fransen, S; Mayers, DL; Montaner, JS; Montessori, V; O'Shaughnessy, MV; Rouleau, D; Shillington, A; Weislow, O | 1 |
| Agnoli, M; Al-Harthi, L; Landay, A; Pottage, J; Siegel, J; Spritzler, J | 1 |
| Danner, SA; Gisolf, EH; Hoetelmans, RW; van Heeswijk, RP | 1 |
| Carrington, M; Havlir, DV; Ioannidis, JP; McDermott, DH; Murphy, PM; O'Brien, TR; Richman, DD | 1 |
| Beylot, J; Dabis, F; Dequae-Merchadou, L; Marimoutou, C; Mercié, P; Morlat, P; Neau, D; Pellegrin, I | 1 |
| Burger, DM; de Graeff-Meeder, ER; De Groot, R; Geelen, SP; Hartwig, NG; Hop, WC; Niesters, HG; Osterhaus, AD; Scherpbier, HJ; Slieker, WA; Suur, MH; van Rossum, AM; Veerman, AJ; Weemaes, CM | 1 |
| Antinori, S; Clerici, M; Galli, M; Gervasoni, C; Pizzuto, M; Ridolfo, AL; Santambrogio, S; Trabattoni, D | 1 |
| Boschini, A; Calista, D | 1 |
| Bordes, I; Cotte, L; Detmer, J; Kolberg, J; Leriche-Guerin, K; Regis, C; Ritter, J; Trabaud, MA; Trépo, C | 1 |
| Boucher, CA; Brown, AJ; Frost, SD; Nijhuis, M; Schuurman, R | 1 |
| Bray, D; Clerici, M; Colombo, F; Dix, LP; Fusi, ML; Milazzo, F; Piconi, S; Rizzardini, G; Trabattoni, D | 1 |
| Aladdin, H; Dickmeiss, E; Gerstoft, J; Hede, A; Jørgensen, LB; Katzenstein, TL; Nielsen, C; Nielsen, H | 1 |
| Chodakewitz, JA; Condra, JH; Emini, EA; Eron, JJ; Gonzalez, C; Gulick, RM; Havlir, D; Isaacs, R; Jonas, L; McMahon, D; Meibohm, A; Mellors, JW; Richman, DD; Valentine, FT | 1 |
| Deres, K; Rübsamen-Waigmann, H | 1 |
| Cohen, MS; Dunn, JA; Eron, JJ; Hall, JE; Kenney, KB; Pereira, AS; Tidwell, RR | 1 |
| Atkins, M; Cane, PA; Cooper, D; Pillay, D; Ratcliffe, D | 1 |
| Carr, A; Chuah, J; Cooper, DA; Emery, S; French, M; Hoy, J; Hudson, J; Law, M; Sayer, D | 1 |
| Bergmann, F; Carls, H; Fätkenheuer, G; Fenske, S; Knechten, H; Nadler, M; Oette, M; Rieke, A; Rockstroh, JK; Thiesen, A; Wiesel, W | 1 |
| Chieco-Bianchi, L; De Rossi, A; Del Mistro, A; Giaquinto, C; Zamarchi, R | 1 |
| Alkhuja, S; Johri, S; Siviglia, G; Soni, A | 1 |
| Baumann, P; Decosterd, LA; Eap, CB; Marzolini, C; Telenti, A; Troillet, N | 1 |
| Mandelbrot, L | 1 |
| Bavoux, F; Blanche, S; Loubeyre-Unique, C | 1 |
| Atkinson, B; Isaacson, J; Knowles, M; Mazabel, E; Patick, AK | 1 |
| Fukutake, K; Ito, A; Kawata, K; Kuwabara, R; Tatsunami, S; Yamada, K | 1 |
| James, IR; John, M; Mallal, SA; McKinnon, EJ; Moore, CB | 1 |
| Goldfarb-Rumyantzev, AS; Gumpeni, R; Jeyakumar, A; Rubin, D | 1 |
| Ahmed, PS; Bedard, J; Bowlin, TL; Chambers, P; Clarke, J; Kelly, LA; Rando, RF; Taylor, DL; Tyms, AS; Wood, LJ | 1 |
| Bryson, YJ; Deville, J; Equils, O; Garratty, E; Krogstad, P; Nielsen, K; Plaeger, S; Sim, MS; Tapia, M; Wei, LS | 1 |
| Binley, JM; Clas, B; Hurley, A; Ketas, T; Little, S; Markowitz, M; Moore, JP; Richman, D; Schiller, D; Trkola, A | 1 |
| Berrey, MM; Burckhardt, B; Clumeck, N; Cooper, DA; Corey, L; Lazzarin, A; Markowitz, M; Mehrotra, D; Perrin, L; Robertson, M; Smith, D; Weber, R | 1 |
| Babiker, AG; Clarke, JR; Hooker, MH; Kaye, S; Tedder, R; Weber, JN | 1 |
| Dworkin, MS; Wan, PC | 1 |
| Degen, O; Stellbrink, HJ; van Lunzen, J | 1 |
| Bucy, RP; Gnann, JW; Goepfert, PA; Kilby, JM; Miller, AP; Saag, MS; Sillers, M | 1 |
| Collier, AC; Havlir, DV; Hirsch, MS; Ioannidis, JP; Richman, DD; Tebas, P | 1 |
| Clark, R; Cohen, C; Cooley, T; Grosso, R; Gulick, R; Marlowe, SI; Mauney, J; Mulanovich, V; Santana, J; Schoellkopf, N; Squires, KE; Stevens, M; Tebas, P; Uffelman, K; Wright, D; Yangco, B | 1 |
| Bellos, N; Eron, JJ; Esinhart, J; Grosso, R; Jemsek, J; Murphy, RL; Parenti, DM; Peterson, D; Pottage, J; Rashbaum, BC; Schoellkopf, N; Sepulveda, G; Stevens, M; Swindells, S | 1 |
| Belohradsky, BH; Rolinski, B; Stojanov, S; Wintergerst, U | 1 |
| Justesen, US; Pedersen, C | 1 |
| Kennedy, I; Williams, S | 1 |
| Arathoon, E; Benetucci, L; Cahn, P; Chodakewitz, J; Chung, MO; Collier, AC; Currier, J; de Jesus Pedro, R; Gallant, JE; Haas, DW; Harvey, C; Lewi, DS; Mehrotra, D; Nguyen, BY; Noriega, LM; Paar, D; Ramirez-Ronda, CH; Thompson, MA; Uip, DE; Uribe, P; White, AC | 1 |
| Drake, SM; Hoetelmans, RM; Pillay, D; Taylor, S; van Heeswijk, RP; White, DJ; Workman, J | 1 |
| Bamberger, JD; Hirozawa, A; Katz, MH; Kimmerling, R; Myles, JE | 1 |
| Albrecht, MA; Balfour, HH; Hammer, SM; Hughes, MD; Katzenstein, DA; Liou, SH; Murphy, R; Para, MF; Valdez, H | 1 |
| Chiodo, F; Fiacchi, P; Manfredi, R; Riolo, U | 1 |
| Dubois, F; Dutronc, H; Fleury, HJ; Neau, D; Ragnaud, JM; Robert, D; Schvoerer, E | 1 |
| Ippolito, G; Puro, V | 1 |
| García, H; Rodriguez, JF; Rodriguez, JL; Rosario, O; Santana, J | 1 |
| Clough, LA; Donlon, R; Fiscus, S; Fletcher, CV; Haas, DW; Harris, VL; Johnson, BW; Kates, RE; Larder, B; Lloyd, RM; McKinsey, J; Nicotera, J; Raffanti, S; Schmidt, D; Shoup, RE; Spearman, P; Wilkinson, GR | 1 |
| Barlow, GD; France, AJ | 1 |
| Anderson, PL; Brundage, RC; Bushman, LR; Fletcher, CV; Kakuda, TN; Kawle, SP; Remmel, RP; Weller, D | 1 |
| Pozo, F; Rivero, A; Serrano, R; Tenorio, A; Torre-Cisneros, J; Vidal, E | 1 |
| Boers, PH; Gruters, RA; Guillon, C; Ly, TD; Osterhaus, AD; Schutten, M; van der Ende, ME | 1 |
| Alonso, MM; Arrizabalaga, J; Clotet, B; Cruceta, A; Dalmau, D; Ferrer, E; Frances, A; Gallart, T; García, F; Gatell, JM; Gomez-Sirvent, JL; Knobel, H; Miró, JM; O'Brien, WA; Pumarola, T; Romeu, J; Ruiz, I; Segura, F; Vidal, F | 1 |
| Briones, C; Corral, A; Gallego, O; Soriano, V | 1 |
| Cushing, H; Khouri, S | 1 |
| Bonfanti, P; Carradori, S; Faggion, I; Gabbuti, A; Iemoli, E; Landonio, S; Niero, F; Pusterla, L; Quirino, T; Ricci, E | 1 |
| Brothers, CH; Feinberg, J; Fischl, M; Goodgame, JC; Hardy, WD; Jablonowski, H; Morrow, P; Nacci, P; Pedneault, L; Pottage, JC; Stein, A; Vafidis, I; Yeo, J | 1 |
| La Seta Catamancio, S; Parker, D; Rusconi, S; Sheridan, F | 1 |
| Giménez-Doménech, R; Kindelán, JM; Madueño, J; Vidal-Verdú, E | 1 |
| Blaxhult, A; Rajs, J; Sundelin, B | 1 |
| Gallart, T; Garcia, F; Gatell, JM; Maleno, MJ; Miró, JM; Plana, M; Tortajada, C | 1 |
| Allen, DY; Carlan, S; Cu-Uvin, S; Dobles, AR; Garb, J; Harwell, JI; Jones, TB; Morris, AB; Vajaranant, M; Zorrilla, C | 1 |
| Fiore, TC; Tashima, KT | 1 |
| Arnaiz, JA; Blanco, JL; Carné, X; Codina, C; Cruceta, A; García-Viejo, MA; Gatell, JM; Giner, V; Mallolas, J; Martínez, E; Pumarola, T; Sarasa, M; Soriano, A; Soy, D; Tuset, M | 1 |
| Darque, A; Moore, JD; Sommadossi, JP; Valette, G; Zhou, XJ | 1 |
| Ceballos-Garcia, L; Ceballos-Salobreña, A; Gaitán-Cepeda, LA; Lezama-Del Valle, D | 1 |
| Carter, LM; Ellis, BA; Peters, BS; Wolstencroft, RA | 1 |
| Parkin, N; Resch, W; Stuelke, EL; Swanstrom, R; Watkins, T | 1 |
| Acosta, EP; Anderson, PL; Brundage, RC; Fletcher, CV; Henry, K; Kakuda, TN; Page, LM; Rhame, FS; Schacker, TW | 1 |
| Deray, G; Izzedine, H; Launay-Vacher, V | 1 |
| Butera, ST; Heneine, W; Pau, CP; Roberts, BD; Weinstock, H | 1 |
| Busch, M; Hecht, FM; Kahn, J; Levy, JA; Martinez-Marino, B; Ong, JC; Stranford, SA | 1 |
| Fernandez, AD; McNeeley, DF | 1 |
| Acosta, EP; Collier, AC; Havlir, DV; Hirsch, M; Richman, DD; Sommadossi, JP; Tebas, P; Zhou, XJ | 1 |
| Barreiro, P; Gonzalez-Lahoz, J; Soriano, V | 1 |
| Brown, T; Feingold, AR; Meislich, D; Rudy, BJ; Rutstein, RM | 1 |
| Bellman, PC; Fisher, RL; Henry, K; Liao, Q; Norris, D; Ross, LL; Shaefer, MS; Wallace, RJ | 1 |
| Dworkin, MS; Wan, PT | 1 |
| Albrecht, M; Balfour, H; Hammer, S; Hughes, MD; Katzenstein, DA; Liou, SH; Murphy, R; Para, M | 1 |
| Bamberger, JD; Chambers, D; Chesney, M; Coates, TJ; Franses, K; Kahn, JO; Katz, MH; Martin, JN; Roland, ME | 1 |
| Collier, AC; Hirsch, MS; Hoering, A; Kuroda, MJ; Letvin, NL; Lifton, MA; Markee, J; McElrath, MJ; Sabath, DE; Schmitz, JE; Seth, A; Sevin, A | 1 |
| Carr, A; Cooper, DA; Cunningham, PH; Goh, LE; Grey, P; Kaufmann, GR; Smith, D; Suzuki, K; Zaunders, JJ | 1 |
| Acosta, E; Currier, JS; D'Aquila, RT; Eron, JJ; Gerber, JG; Gulick, RM; Kuritzkes, DR; Murphy, RL; Smeaton, LM; Snyder, S; Sommadossi, JP; Tung, R | 1 |
| Bottasso, OA; Giovannoni, AG; Luraghi, MR; Montero, A; Sen, L | 1 |
| Abbate, I; Antonelli, G; Capobianchi, MR; D'Offizi, G; Dianzani, F; Galati, V; Pandolfi, F; Pierdominici, M; Turriziani, O | 1 |
| Hoetelmans, RM; Jurriaans, S; Lange, JM; Mulder, JW; Reijers, MH; Richter, C; Roos, MT; Schuitemaker, H; Sprenger, H; Ten Kate, RW; Ter Hofstede, HJ; Weigel, HM; Weverling, GJ; Wit, FW | 1 |
| Baudouin, SV; Morris, AA; Snow, MH | 1 |
| Benson, C; Bertz, R; Brun, S; Eron, JJ; Gulick, R; Hammer, S; Hicks, C; Hsu, A; Japour, A; Kessler, HA; King, M; Murphy, RL; Sun, E; Thompson, M; White, AC | 1 |
| Thompson, CA | 1 |
| Autran, B; Carcelain, G; Damond, F; Dehée, A; Delphin, N; Girard, PM; Jacomet, C; Mariot, P; Nicolas, JC; Rozenbaum, W; Saimot, AG; Schneider, V | 1 |
| Citterio, P; De Pasquale, MP; Galli, M; Kurtagic, S; La Seta Catamancio, S; Rusconi, S | 1 |
| Achilli, G; Bruno, R; Debiaggi, M; Filice, G; Patruno, SF; Pistorio, A; Romero, E; Sacchi, P; Zara, F | 1 |
| Brotas, V; Cooper, D; Cutrell, A; Gathe, J; Hammer, SM; Hetherington, S; Hicks, C; Isaacs, R; Johnson, M; Keiser, P; Montaner, J; Raffi, F; Spreen, W; Staszewski, S; Steel, H; Thorborn, D; Tortell, S | 1 |
| Jankelevich, S; Mackall, CL; Mueller, BU; Nelson, RP; Nguyen, BY; Pizzo, PA; Serchuck, L; Sleasman, JW; Smith, S; Steinberg, SM; Wood, LV; Yarchoan, R; Zeichner, SL; Zwerski, S | 1 |
| Arendt, G; Hefter, H; Theisen, A; von Giesen, HJ | 1 |
| Briones, C; del Romero, J; Hertogs, K; Pérez-Olmeda, M; Rodríguez, C; Soriano, V | 1 |
| Bani-Sadr, F; Gassin, M; Hoff, J; Raffi, F | 1 |
| Arazo, P; Manero, FJ; Sesma, J | 1 |
| Loveday, C | 1 |
| Anderson, RM; Cane, PA; Ferguson, NM; Pillay, D; Taylor, S | 1 |
| Fournier, S; Maillard, A; Molina, JM | 1 |
| Agarwal, S; Sarin, SK | 1 |
| Brown, AJ; Emini, E; Eron, J; Fiscus, S; Frost, SD; Gamagami, R; Gulick, R; Günthard, HF; Haase, A; Havlir, DV; Ignacio, CC; Isaacs, R; Jonas, L; Meibohm, A; Mellors, J; Richman, DD; Schleif, W; Valentine, F; Wong, JK; Zhang, ZQ | 1 |
| Clerici, M; Gray, G; Kuhn, L; Meddows-Taylor, S; Shearer, GM; Tiemessen, C; Trabattoni, D | 1 |
| Bastian, H; Batallan, A; Benifla, JL; Faucher, P; Madelenat, P; Matheron, S; Morau, G | 1 |
| Ambinder, R; Flexner, C; Grochow, L; Hamzeh, F; Harrington, W; Herndier, B; Kaplan, L; Lee, J; Levine, A; Ratner, L; Redden, D; Scadden, D; Straus, D; Tan, B; Tang, S | 1 |
| Achilli, G; Bruno, R; De Santolo, A; Debiaggi, M; Filice, G; Maserati, R; Pistorio, A; Romero, E; Sacchi, P; Spinillo, A; Zara, F | 1 |
| Crémieux, AC; Demarles, D; Gillotin, C; Katlama, C; Raffi, F; Yuen, GJ | 1 |
| Barret, B; Bénifla, JL; Berrebi, A; Blanche, S; Bongain, A; Burgard, M; Chaix, ML; Ciraru-Vigneron, N; Crenn-Hébert, C; Delfraissy, JF; Lachassine, E; Landreau-Mascaro, A; Mandelbrot, L; Mayaux, MJ; Rekacewicz, C; Rouzioux, C | 1 |
| Shaffer, N | 1 |
| Farthing, C; Graham, E; Pilson, RS; Sension, MG; Shaffer, AG; Siemon-Hryczyk, P | 1 |
| Balzarini, J; De Clercq, E; Desmyter, J; Esnouf, R; Kleim, JP; Pannecouque, C; Schmit, JC; Van Laethem, K; Van Remoortel, B; Vandamme, AM; Witvrouw, M | 1 |
| Caldwell, P; Furlan, S; Ho, D; Hurley, A; Johnson, J; Kost, RG; Markowitz, M; Smiley, L; Talal, A; Vesanen, M; Zhang, L | 1 |
| Beguinot, I; Bevilacqua, S; Canton, P; Dorvaux, V; May, T; Rabaud, C; Schuhmacher, H | 1 |
| Ahrlund-Richter, L; Britton, S; Larsson, S; Maijgren-Steffensson, C; Sönnerborg, A; Vahlne, A | 1 |
| Cammack, N; Church, J; Goldsmith, J; Gu, Z; Keller, A; Lewis, L; Pizzo, P; Salomon, H; Spira, B; Wainberg, MA; Wheeler, S | 1 |
| Altisent, C; Bravo, R; García-Samaniego, J; Gómez-Cano, M; González-Lahoz, J; Ruiz, I; Soriano, V | 1 |
| Boucher, CA; Danner, SA; Lange, JM; Nijhuis, M; Reiss, P; Schuurman, R; van Leeuwen, R | 1 |
| Kessler, HA; Nerad, JL | 1 |
| Mascolini, M | 3 |
| Gilden, D | 3 |
| Cheng, B | 1 |
| Poscher, M | 1 |
| Conant, M | 1 |
| Rubin, M | 1 |
| Japour, AJ | 1 |
| Levin, J | 1 |
| Baker, R | 3 |
| Chang, HE | 1 |
| Boucher, CA | 1 |
| Smart, T | 2 |
| Torres, G | 2 |
| Cooper, EC | 1 |
| Falkenberg, J; Gilden, D; Torres, G | 1 |
| Randall, P | 1 |
| Doepel, L; Folkers, G | 1 |
| Coppedge, B | 1 |
| Woodward, J | 1 |
| Cadman, JA | 1 |
| Baker, R; Bowers, M | 2 |
| Bowersox, J | 1 |
| Miller, G | 1 |
| Cadman, J | 1 |
| Friedland, GH; Gulick, RM | 1 |
| Hanna, L | 2 |
| Highleyman, L | 1 |
| Gomez, E | 1 |
| Matthews, GV; Nelson, MR | 1 |
| Farrell, P; Lindgren, P; Shalit, P | 1 |
| Cunningham, S; Eshleman, SH; Jackson, JB; Johnson, G; Krogstad, P; Lee, S; Nachman, S; Palumbo, P; Wang, YG; Wantman, M; Wei, LJ; Wiznia, A | 1 |
| Asjö, B; Berg, OG; Dyrhol-Riise, AM; Kleivbo, S; Olofsson, J; Voltersvik, P | 1 |
| Gellett, LR; Haddon, L; Maskell, GF | 1 |
| Burlina, A; D'Elia, R; De Romeo, A; De Rossi, A; Giacomet, V; Giaquinto, C; Rampon, O; Ruga, E; Sturkenboom, M | 1 |
| Funk, MB; Klingebiel, T; Kreuz, W; Linde, R; Notheis, G; Schuster, T; Wintergerst, U | 1 |
| Buranapraditkun, S; Cooper, DA; Kroon, ED; Kunanusont, C; Lange, JM; Pakker, N; Phanuphak, P; Ruxrungtham, K; Sonjai, A; Suwanagool, S; Tiengrim, S; Ubolyam, S; Ungsedhapand, C; Yimsuan, N | 1 |
| Danner, SA; de Boer, RJ; Goudsmit, J; Huismans, R; Jebbink, MF; Lukashov, VV | 1 |
| Corzo, JE; Gómez-Mateos , J; Lozano, F; Ramayo, E | 1 |
| Bassett, R; Collier, AC; Condra, J; Gilbert, P; Günthard, HF; Havlir, DV; Hirsch, MS; Ignacio, C; Levitan, D; Richman, DD; Tebas, P; Wong, JK | 1 |
| Johnson, MA; Moodley, D; Moodley, J; Moore, KH; Mudd, PN; Naidoo, K; Pakes, GE; Pillay, K | 1 |
| Holodniy, M; Mole, L; Schmidgall, D | 1 |
| Battegay, M; Bisset, LR; Cone, RW; Dubs, RW; Fischer, M; Grob, PJ; Opravil, M; Vernazza, PL; Weber, R | 1 |
| Kuchimanchi, U; Rooney, G | 1 |
| García-Lerma, JG; Heneine, W; Nidtha, S | 1 |
| Bakker, M; Cremers, J; Danner, SA; de Jong, JJ; de Ronde, A; Goudsmit, J; Hellings, JA; Nijholt, L; Notermans, DW; Roos, MT | 1 |
| Allan, DA; Behrman, AJ | 1 |
| Gartland, M | 1 |
| Bentata, M; David, F; Delfraissy, JF; Katlama, C; Lanier, ER; Mamet, JP; Massip, P; Rozenbaum, W; Trepo, C; Vavro, C; Zucman, D | 1 |
| Adams, EM; Bennett, K; Collier, AC; Gilbert, PB; Goodwin, D; Havlir, DV; Hirsch, MS; Holohan, MK; Richman, DD; Schnittman, S; Tebas, P; Wheat, LJ | 1 |
| Angelini, E; Chêne, G; Clavel, F; Ferchal, F; Maillard, A; Molina, JM; Picard, V; Race, E | 1 |
| Aaron, L; Carnot, F; Pialoux, G | 1 |
| Bartlett, JG; del Rio, C | 1 |
| Benhamou, Y; Bochet, M; Brosgart, C; Calvez, V; Fievet, MH; Fry, J; Gibbs, CS; Katlama, C; Namini, H; Poynard, T; Thibault, V; Vig, P | 1 |
| MacGowan, DJ; Scelsa, SN; Waldron, M | 1 |
| Boucher, CA; Cohen Stuart, JW; de Jong, D; Kaye, S; Kovacs, C; Righart, M; Schuurman, R; Visser, CJ; Wensing, AM | 1 |
| Chadapaud, S; Chouraqui, M; Delbeke, E; Hittinger, G; Lafeuillade, A; Poggi, C | 1 |
| Chadapaud, S; Halfon, P; Hittinger, G; Khiri, H; Lafeuillade, A; Poggi, C | 1 |
| Chung, RT; Kim, AY; Polsky, B | 1 |
| Anderson, R; Chapman, SK; Clendeninn, N; Conant, M; Myers, R; Saag, MS; Sension, M; Tebas, P | 1 |
| Alba, L; Antinori, A; Grisetti, S; Liuzzi, G; Sette, P; Zaccarelli, M | 1 |
| Bruno, R; Ciappina, V; Filice, G; Montagna, M; Panebianco, R; Regazzi, MB; Sacchi, P; Villani, P | 1 |
| Bruno, R; Filice, G; Malfitano, A; Sacchi, P | 1 |
| Duan, C; Kuritzkes, DR; McHenry, CS; Petropoulos, CJ; Poticha, D; Stoeckli, TC; Whitcomb, JM | 1 |
| Cane, P; Gazzard, B; Matthews, GV; Nelson, M; Pillay, D; Ratcliffe, D | 1 |
| Akanmu, AS; Akinsete, I; Davies, AO; Eshofonie, AO; Okany, CC | 1 |
| Bosch, RJ; Coombs, RW; Demeter, LM; Fischl, MA; Fiscus, SA; Grimes, JM; Hammer, SM; Hughes, MD; Jackson, JB; Spector, SA; Squires, KE | 1 |
| Carlebach, A; Gute, P; Haberl, A; Miller, V; Rottmann, C; Staszewski, S | 1 |
| Bickel, M; Jacobi, V; Rickerts, V; Staszewski, S; Tews, J | 1 |
| Agut, H; Aubron-Olivier, C; Katlama, C; Thibault, V | 1 |
| Lamson, MJ; Leitz, G; MacGregor, TR; Sabo, JP; Yong, CL | 1 |
| Abbadessa, V; Andreoni, M; D'Ettorre, G; Dalle, NE; Gallo, I; Mancino, G; Narciso, P; Nicastri, E; Parisi, SG; Sarmati, L; Traina, C; Vullo, V | 1 |
| Back, DJ; Hoggard, PG; Jones, K; Kewn, S; Khoo, SH; Maher, B; Sales, SD | 1 |
| Belson, M; Chun, TW; Connors, M; Davey, RT; Dybul, M; Fauci, AS; Hallahan, CW; Herpin, B; Hidalgo, B; Justement, JS; Metcalf, JA; Migueles, SA; Perry, C | 1 |
| L'Héritier, A; Lang, JM; Rey, D | 1 |
| Aubron-Olivier, C; Benhamou, Y; Bernard, B; Di Martino, V; Poynard, T; Thabut, D; Thibault, V | 1 |
| Fischl, MA; Gao, H; Gensler, T; Graham, NM; Hernandez, JE; Hessenthaler, SM; Kirkland, LR; McClernon, DR; Paar, D; Pittman, G; Rosenzweig, JR; Tashima, KT | 1 |
| Henry, K; Jenny-Avital, E | 1 |
| Altisent, C; Briones, C; Domingo, E; Mas, A; Pérez-Olmeda, M; Soriano, V | 1 |
| Ayres, A; Bonacini, M; Gibbs, C; Kurz, A; Locarnini, S | 1 |
| Appay, V; Furtado, M; Hansasuta, P; Havlir, DV; McMichael, AJ; Richman, DD; Rowland-Jones, SL; Schrier, RD; Spina, CA; Sutton, J; Wolinsky, SM; Wong, JK | 1 |
| Fundarò, C; Genovese, O; Rendeli, C; Salvaggio, E; Tamburrini, E | 1 |
| Anyiwo, CE; Ifeanyichukwu, M | 1 |
| Barceló, M; Domingo, P | 1 |
| Delaporte, E; Malonga-Mouellet, G; Mansaray, H; Mavoungou, R; Mistoul, I; Peeters, M; Vergne, L | 1 |
| de Oliveira Pinto, LM; Gougeon, ML; Lecoeur, H; Ledru, E; Patey, O; Rapp, C | 1 |
| Jaccard, R; Jenni, R; Opravil, M; Speich, R | 1 |
| Bettendorf, D; Bucy, RP; Chan, E; Evans, T; Gonzalez, CJ; Landay, AL; Phair, JP; Schmitz, JL; Schnizlein-Bick, CT; Spritzler, J; Squires, KE | 1 |
| McLean, K; Winston, A | 1 |
| Kikuchi, Y; Oka, S; Yazaki, H | 1 |
| Anderson, PL; Brundage, RC; Fletcher, CV; Gross, CR; Henry, K; Kakuda, TN; Schacker, TW | 1 |
| Aboulker, JP; Brun Vezinet, F; Calvez, V; Descamps, D; Flandre, P; Harel, M; Hazebrouck, S; Meiffredy, V; Peytavin, G; Pialoux, G; Raffi, F | 1 |
| Andersson, J; Cooper, D; Goh, LE; Hoen, B; Janossy, G; Kinloch, S; Lampe, F; Perrin, L; Tilling, R; Tsoukas, C; Zaunders, J | 1 |
| Maggiolo, F; Maserati, R; Migliorino, M; Pan, A; Provettoni, G; Rizzi, L; Rizzi, M; Suter, F | 1 |
| Aguayo, R; Dieudonne, A; Jackson, JB; Johnson, G; Khoury, M; Krogstad, P; Lee, S; McNamara, J; Mendez, H; Moye, J; Nachman, S; Stanley, K; Wiznia, A | 1 |
| Burger, DM; de Groot, R; Geelen, SP; Hartwig, NG; Hop, WC; Osterhaus, AD; Scherpbier, HJ; Schutten, M; van Lochem, EG; van Rossum, AM; Weemaes, CM; Wolfs, TF | 1 |
| Antiochos, BB; Fernandez, JJ; Olivero, OA; Poirier, MC; St Claire, ME; Wagner, JL | 1 |
| Cai, W; Cao, Y; Ding, Y; Gao, M; Li, L; Mei, S; Zhang, F | 1 |
| Beardsell, A; Braitstein, P; Chan, K; Hogg, RS; McLeod, A; Montaner, JS; O'Shaughnessy, MV | 2 |
| Stekelenburg, J | 1 |
| Bacheler, L; Bazmi, H; Diamond, S; Erickson-Viitanen, S; Gallagher, K; Garber, S; Geleziunas, R; Hammond, J; Klabe, R; Liotta, DC; Manion, DJ; Mellors, J; Otto, MJ; Pierce, M; Rayner, M; Schinazi, RF; Stuyver, L; Trainor, G; Wu, JT; Zhang, H | 1 |
| Benhamou, Y; Bochet, MV; Bombled, T; Calvez, V; Delaugerre, C; Katlama, C; Marcelin, AG; Peytavin, G; Thibault, V | 1 |
| de Wolf, F; Jurriaans, S; Lange, JM; Prins, JM; van Praag, RM; Wit, FW | 1 |
| Chaix, ML; Delfraissy, JF; Deveau, C; Dubeaux, B; Garrigue, I; Goujard, C; Harzic, M; Hoen, B; Meyer, L; Ngo, N; Pellegrin, I; Rouzioux, C; Sereni, D | 1 |
| Kroll, H; Ndagijimana, JM; Niehues, T | 1 |
| Cooper, DA; Dore, GJ | 1 |
| Fukuda, Y; Hayashi, K; Nakano, I; Takamatsu, J; Toyoda, H | 1 |
| Schechter, M | 1 |
| Perrin, L | 1 |
| Klinowska-Skupniewska, J; Prandota-Schoepp, A | 1 |
| Ray, SC; Sulkowski, MS; Thomas, DL | 1 |
| Hasegawa, H; Hattori, T; Ishikawa, M; Kaku, M; Kikuchi, M; Ohno, I; Okada, S | 1 |
| Aboulker, JP; Brun-Vezinet, F; Certain, A; Descamps, D; Flandre, P; Gastaut, JA; Goujard, C; Joly, V; Meiffredy, V; Remy, G; Ruffault, A; Yeni, P | 1 |
| Post, JJ | 1 |
| Bartlett, JA; Bucy, RP; Fiscus, SA; Gryszowska, V; Miralles, GD; Ottinger, J; Pruitt, SK; Sevin, AD; Silberman, M | 1 |
| Beltrami, EM; Cardo, DM; de la Torre, N; Luo, CC | 1 |
| Brůcková, M; Linka, M; Reinis, M; Stanková, M; Vandasová, J | 1 |
| Castell Salvá, R; Tomás Salvá, M | 1 |
| Arribas, J; Beall, G; Bernstein, B; Brun, S; Japour, A; Johnson, D; Johnson, M; King, M; Lalonde, R; Ruane, P; Sun, E; Walmsley, S | 1 |
| Di Perri, G; Maiello, A; Quario, M; Racca, D; Sinicco, A; Zeme, DA | 1 |
| Jurriaans, S; Lange, JM; Weel, J; Weverling, GJ; Wit, FW | 1 |
| Zoulim, F | 1 |
| Danner, SA; Donn, KH; Hall, ST; Harker, AJ; Hussey, EK; Jonker, P; Lange, JM; van Leeuwen, R | 1 |
170 review(s) available for lamivudine and HIV Coinfection
| Article | Year |
|---|---|
HIV nucleoside reverse transcriptase inhibitors.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; Humans; Nucleosides; Reverse Transcriptase Inhibitors | 2022 |
Lactic acidosis and hyperlactatemia associated with lamivudine accumulation and sepsis in a kidney transplant recipient-a case report and review of the literature.
Topics: Acidosis, Lactic; Aged; Anti-HIV Agents; HIV Infections; Humans; Hyperlactatemia; Kidney Transplantation; Lamivudine; Male; Sepsis | 2021 |
Hepatitis B virus genetic multiplicity and the associated HBV lamivudine resistance mutations in HBV/HIV co-infection in Western Kenya: A review article.
Topics: Anti-Retroviral Agents; Coinfection; Drug Resistance, Viral; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Kenya; Lamivudine; Mutation | 2022 |
An up-to-date evaluation of dolutegravir/abacavir/lamivudine for the treatment of HIV.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Piperazines; Pyridones | 2022 |
Acquired HIV drug resistance mutations on first-line antiretroviral therapy in Southern Africa: Systematic review and Bayesian evidence synthesis.
Topics: Adult; Anti-Retroviral Agents; Bayes Theorem; Drug Resistance, Viral; Emtricitabine; HIV Infections; HIV-1; Humans; Lamivudine; Mutation; Tenofovir; Viral Load; Zidovudine | 2022 |
Structural basis of HIV inhibition by L-nucleosides: Opportunities for drug development and repurposing.
Topics: Antiviral Agents; Drug Repositioning; Hepatitis B virus; HIV Infections; Humans; Lamivudine | 2022 |
Factors associated with viral suppression and rebound among adult HIV patients on treatment: a retrospective study in Ghana.
Topics: Adult; Anti-HIV Agents; Ghana; HIV Infections; Humans; Lamivudine; Nevirapine; Retrospective Studies; Viral Load; Zidovudine | 2022 |
An indirect comparison of 144-week efficacy, safety, and tolerability of dolutegravir plus lamivudine and second-generation integrase inhibitor-based, 3-drug, single-tablet regimens in therapy-naive people with HIV-1.
Topics: Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV Seropositivity; HIV-1; Humans; Lamivudine; RNA; Tablets | 2023 |
Antivirals for prevention of hepatitis B virus mother-to-child transmission in human immunodeficiency virus positive pregnant women co-infected with hepatitis B virus.
Topics: Antiviral Agents; Coinfection; DNA, Viral; Emtricitabine; Female; Hepatitis B e Antigens; Hepatitis B virus; HIV; HIV Infections; HIV Seropositivity; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Pregnancy; Pregnant Women; Ritonavir; Tenofovir; Zidovudine | 2023 |
Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-naïve, virologically-suppressed patients: Latest evidence from the literature on their efficacy and safety.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Drug Therapy, Combination; Equivalence Trials as Topic; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Reverse Transcriptase Inhibitors; Rilpivirine; Sustained Virologic Response | 2020 |
Prevalence of pretreatment and acquired HIV-1 mutations associated with resistance to lamivudine or rilpivirine: a systematic review.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Genome, Viral; Global Health; HIV Infections; HIV-1; Humans; Lamivudine; Mutation; Prevalence; Rilpivirine; Treatment Outcome | 2019 |
Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection.
Topics: Anti-Retroviral Agents; Clinical Trials as Topic; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Mutation; Oxazines; Piperazines; Pyridones; RNA, Viral; Treatment Failure | 2020 |
Dolutegravir/lamivudine (Dovato)--a two-drug complete regimen for HIV-1 infection.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Drug Combinations; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones | 2019 |
Islatravir for the treatment and prevention of infection with the human immunodeficiency virus type 1.
Topics: Animals; Anti-HIV Agents; Deoxyadenosines; Drug Combinations; Drug Evaluation, Preclinical; HIV Infections; HIV-1; Humans; Lamivudine; Macaca mulatta; Pre-Exposure Prophylaxis; Pyridones; Reverse Transcriptase Inhibitors; Simian Acquired Immunodeficiency Syndrome; Simian Immunodeficiency Virus; Triazoles; Viral Load | 2020 |
Human Immunodeficiency Virus-1 Viral Load Is Elevated in Individuals With Reverse-Transcriptase Mutation M184V/I During Virological Failure of First-Line Antiretroviral Therapy and Is Associated With Compensatory Mutation L74I.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure; Viral Load | 2020 |
Dolutegravir/Lamivudine Single-Tablet Regimen: A Review in HIV-1 Infection.
Topics: Adolescent; Adult; Anti-HIV Agents; Child; Drug Combinations; Drug Resistance, Viral; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Tablets | 2020 |
Dolutegravir plus lamivudine for the treatment of HIV-1 infection.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones | 2020 |
Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection.
Topics: Adult; Anti-HIV Agents; Clinical Trials as Topic; Drug Administration Schedule; Drug Combinations; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Oxazines; Piperazines; Pyridones; Tablets; Treatment Outcome | 2020 |
Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; Acyclic Monoterpenes; Adenine Nucleotides; Adhesins, Escherichia coli; Adipocytes; Adipocytes, Brown; Adipogenesis; Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adsorption; Adult; Aeromonas hydrophila; Africa; Aged; Aged, 80 and over; Agrobacterium tumefaciens; Air; Air Pollutants; Air Pollution; Air Pollution, Indoor; Algorithms; Alkaloids; Alkynes; Allosteric Regulation; Amines; Amino Acid Sequence; Amino Acids; Amino Acids, Branched-Chain; Aminoisobutyric Acids; Aminopyridines; Amyotrophic Lateral Sclerosis; Anaerobic Threshold; Angiography; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animal Distribution; Animal Feed; Animal Nutritional Physiological Phenomena; Animals; Ankle Joint; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Inflammatory Agents; Antibodies, Bacterial; Antifungal Agents; Antimalarials; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Antiretroviral Therapy, Highly Active; Antiviral Agents; Aotidae; Apelin; Apoptosis; Arabidopsis Proteins; Argentina; Arginine; Artemisinins; Arthritis, Experimental; Arthritis, Rheumatoid; Arthroscopy; Aspergillus; Aspergillus niger; Asteraceae; Asthma; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Auditory Cortex; Autoantibodies; Autophagy; Bacteria; Bacterial Infections; Bacterial Proteins; Bacterial Typing Techniques; Base Composition; Base Sequence; Basketball; Beclin-1; Benzhydryl Compounds; Benzimidazoles; Benzo(a)pyrene; Benzofurans; Benzoxazines; Bereavement; beta Catenin; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Betacoronavirus; Betaine; Binding Sites; Biofilms; Biological Assay; Biological Availability; Biological Evolution; Biomarkers; Biomechanical Phenomena; Biopolymers; Biopsy; Bismuth; Blood Glucose; Blood Platelets; Blood Pressure; Body Composition; Body Weight; Bone Marrow; Bone Marrow Cells; Bone Regeneration; Boron; Botrytis; Brain Ischemia; Brain Neoplasms; Brain-Derived Neurotrophic Factor; Brazil; Breast Neoplasms; Breath Tests; Bronchoalveolar Lavage Fluid; Burkholderia; C-Reactive Protein; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Calcification, Physiologic; Calcium; Calcium Signaling; Calorimetry, Differential Scanning; Cameroon; Camptothecin; Candida; Candida albicans; Capillaries; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Carbohydrate Conformation; Carbon; Carbon Dioxide; Carbon Isotopes; Carcinoma, Ovarian Epithelial; Cardiac Output; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Cardiovascular Diseases; Caregivers; Carps; Case-Control Studies; Catalase; Catalysis; Cats; CD4 Lymphocyte Count; Cell Culture Techniques; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Cellulose; Centrosome; Ceratopogonidae; Chickens; Child; China; Cholera Toxin; Choline; Cholinesterases; Chromatography, High Pressure Liquid; Chromatography, Liquid; Chromatography, Micellar Electrokinetic Capillary; Chromatography, Reverse-Phase; Chronic Disease; Cinnamates; Cities; Citrates; Climate Change; Clinical Trials, Phase III as Topic; Coal; Coal Mining; Cohort Studies; Coinfection; Colchicine; Colony Count, Microbial; Colorectal Neoplasms; Coloring Agents; Common Cold; Complement Factor H; Computational Biology; Computer Simulation; Continuous Positive Airway Pressure; Contrast Media; Coordination Complexes; Coronary Artery Bypass; Coronavirus 3C Proteases; Coronavirus Infections; Coronavirus Protease Inhibitors; Corynebacterium glutamicum; Cosmetics; COVID-19; Creatinine; Cross-Sectional Studies; Crotonates; Crystallography, X-Ray; Cues; Culicidae; Culture Media; Curcuma; Cyclopentanes; Cyclopropanes; Cymbopogon; Cystine; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Cytokines; Databases, Genetic; Death; Dendritic Cells; Density Functional Theory; Depsides; Diabetes Mellitus, Type 2; Diamond; Diarylheptanoids; Dibenzofurans; Dibenzofurans, Polychlorinated; Diclofenac; Diet; Dietary Carbohydrates; Dietary Supplements; Diffusion Magnetic Resonance Imaging; Dioxins; Diphenylamine; Disease Outbreaks; Disease Susceptibility; Disulfides; Dithiothreitol; Dizocilpine Maleate; DNA Methylation; DNA-Binding Proteins; DNA, Bacterial; Dogs; Dose-Response Relationship, Drug; Double-Blind Method; Doublecortin Protein; Drosophila melanogaster; Droughts; Drug Carriers; Drug Combinations; Drug Delivery Systems; Drug Liberation; Drug Resistance; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Dust; Dynactin Complex; Dysferlin; Echo-Planar Imaging; Echocardiography; Edaravone; Egypt; Elasticity; Electrodes; Electrolytes; Emodin; Emtricitabine; Endometriosis; Endothelium, Vascular; Endotoxins; Energy Metabolism; Energy Transfer; Enterobacteriaceae; Enterococcus faecalis; Enterotoxigenic Escherichia coli; Environmental Monitoring; Enzyme Inhibitors; Epidemiologic Factors; Epigenesis, Genetic; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Vaccines; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Esterases; Esterification; Ethanol; Ethiopia; Ethnicity; Eucalyptus; Evidence-Based Practice; Exercise; Exercise Tolerance; Extracorporeal Membrane Oxygenation; Family; Fatty Acids; Feedback; Female; Ferric Compounds; Fibrin Fibrinogen Degradation Products; Filtration; Fish Diseases; Flavonoids; Flavonols; Fluorodeoxyglucose F18; Follow-Up Studies; Food Microbiology; Food Preservation; Forests; Fossils; Free Radical Scavengers; Freund's Adjuvant; Fruit; Fungi; Gallium; Gender Identity; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Genes, Bacterial; Genes, Plant; Genetic Predisposition to Disease; Genitalia; Genotype; Glomerulonephritis, IGA; Glottis; Glucocorticoids; Glucose; Glucuronides; Glutathione Transferase; Glycogen Synthase Kinase 3 beta; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Grassland; Guinea Pigs; Half-Life; Head Kidney; Heart Atria; Heart Rate; Heart Septum; HEK293 Cells; Hematopoietic Stem Cells; Hemodynamics; Hep G2 Cells; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hepatocytes; Hesperidin; High-Frequency Ventilation; High-Temperature Requirement A Serine Peptidase 1; Hippocampus; Hirudins; History, 20th Century; History, 21st Century; HIV Infections; Homeostasis; Hominidae; Housing, Animal; Humans; Hydrocarbons, Brominated; Hydrogen Bonding; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydroxybutyrates; Hydroxyl Radical; Hypertension; Hypothyroidism; Image Interpretation, Computer-Assisted; Immunoconjugates; Immunogenic Cell Death; Indoles; Infant, Newborn; Infant, Premature; Infarction, Middle Cerebral Artery; Inflammation; Inflammation Mediators; Infrared Rays; Inhibitory Concentration 50; Injections, Intravenous; Interferon-gamma; Interleukin-23; Interleukin-4; Interleukin-6; Intermediate Filaments; Intermittent Claudication; Intestine, Small; Iridoid Glucosides; Iridoids; Iron; Isomerism; Isotope Labeling; Isoxazoles; Itraconazole; Kelch-Like ECH-Associated Protein 1; Ketoprofen; Kidney Failure, Chronic; Kinetics; Klebsiella pneumoniae; Lactams, Macrocyclic; Lactobacillus; Lactulose; Lakes; Lamivudine; Laparoscopy; Laparotomy; Laryngoscopy; Leucine; Limit of Detection; Linear Models; Lipid A; Lipopolysaccharides; Listeria monocytogenes; Liver; Liver Cirrhosis; Logistic Models; Longitudinal Studies; Losartan; Low Back Pain; Lung; Lupinus; Lupus Erythematosus, Systemic; Machine Learning; Macular Degeneration; Madin Darby Canine Kidney Cells; Magnetic Phenomena; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Magnetics; Malaria, Falciparum; Male; Mannans; MAP Kinase Signaling System; Mass Spectrometry; Melatonin; Membrane Glycoproteins; Membrane Proteins; Meniscectomy; Menisci, Tibial; Mephenytoin; Mesenchymal Stem Cells; Metal Nanoparticles; Metal-Organic Frameworks; Methionine; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Mice, Obese; Mice, Transgenic; Microbial Sensitivity Tests; Microcirculation; MicroRNAs; Microscopy, Video; Microtubules; Microvascular Density; Microwaves; Middle Aged; Minimally Invasive Surgical Procedures; Models, Animal; Models, Biological; Models, Molecular; Models, Theoretical; Molecular Docking Simulation; Molecular Structure; Molecular Weight; Morus; Mouth Floor; Multicenter Studies as Topic; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Muscle, Skeletal; Myocardial Ischemia; Myocardium; NAD; NADP; Nanocomposites; Nanoparticles; Naphthols; Nasal Lavage Fluid; Nasal Mucosa; Neisseria meningitidis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms, Experimental; Neural Stem Cells; Neuroblastoma; Neurofilament Proteins; Neurogenesis; Neurons; New York; NF-E2-Related Factor 2; NF-kappa B; Nicotine; Nitriles; Nitrogen; Nitrogen Fixation; North America; Observer Variation; Occupational Exposure; Ochrobactrum; Oils, Volatile; Olea; Oligosaccharides; Omeprazole; Open Field Test; Optimism; Oregon; Oryzias; Osmolar Concentration; Osteoarthritis; Osteoblasts; Osteogenesis; Ovarian Neoplasms; Ovariectomy; Oxadiazoles; Oxidation-Reduction; Oxidative Stress; Oxygen; Ozone; p38 Mitogen-Activated Protein Kinases; Pakistan; Pandemics; Particle Size; Particulate Matter; Patient-Centered Care; Pelargonium; Peptides; Perception; Peripheral Arterial Disease; Peroxides; Pets; Pharmaceutical Preparations; Pharmacogenetics; Phenobarbital; Phenols; Phenotype; Phosphates; Phosphatidylethanolamines; Phosphines; Phospholipids; Phosphorus; Phosphorylation; Photoacoustic Techniques; Photochemotherapy; Photosensitizing Agents; Phylogeny; Phytoestrogens; Pilot Projects; Plant Components, Aerial; Plant Extracts; Plant Immunity; Plant Leaves; Plant Oils; Plants, Medicinal; Plasmodium berghei; Plasmodium falciparum; Platelet Activation; Platelet Function Tests; Pneumonia, Viral; Poaceae; Pogostemon; Poloxamer; Poly I; Poly(ADP-ribose) Polymerase Inhibitors; Polychlorinated Biphenyls; Polychlorinated Dibenzodioxins; Polycyclic Compounds; Polyethylene Glycols; Polylysine; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Population Dynamics; Portasystemic Shunt, Transjugular Intrahepatic; Positron Emission Tomography Computed Tomography; Postoperative Complications; Postprandial Period; Potassium Cyanide; Predictive Value of Tests; Prefrontal Cortex; Pregnancy; Prepulse Inhibition; Prevalence; Procalcitonin; Prodrugs; Prognosis; Progression-Free Survival; Proline; Proof of Concept Study; Prospective Studies; Protein Binding; Protein Conformation; Protein Domains; Protein Folding; Protein Multimerization; Protein Sorting Signals; Protein Structure, Secondary; Proton Pump Inhibitors; Protozoan Proteins; Psychometrics; Pulse Wave Analysis; Pyridines; Pyrrolidines; Quality of Life; Quantum Dots; Quinoxalines; Quorum Sensing; Radiopharmaceuticals; Rain; Random Allocation; Randomized Controlled Trials as Topic; Rats; Rats, Sprague-Dawley; Rats, Wistar; RAW 264.7 Cells; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Receptor, PAR-1; Receptors, CXCR4; Receptors, Estrogen; Receptors, Glucocorticoid; Receptors, Interleukin-1; Receptors, Interleukin-17; Receptors, Notch; Recombinant Fusion Proteins; Recombinant Proteins; Reducing Agents; Reflex, Startle; Regional Blood Flow; Regression Analysis; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Tract Diseases; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Risk Assessment; Risk Factors; Rituximab; RNA, Messenger; RNA, Ribosomal, 16S; ROC Curve; Rosmarinic Acid; Running; Ruthenium; Rutin; Sarcolemma; Sarcoma; Sarcopenia; Sarcoplasmic Reticulum; SARS-CoV-2; Scavenger Receptors, Class A; Schools; Seasons; Seeds; Sequence Analysis, DNA; Severity of Illness Index; Sex Factors; Shock, Cardiogenic; Short Chain Dehydrogenase-Reductases; Signal Transduction; Silver; Singlet Oxygen; Sinusitis; Skin; Skin Absorption; Small Molecule Libraries; Smoke; Socioeconomic Factors; Soil; Soil Microbiology; Solid Phase Extraction; Solubility; Solvents; Spain; Spectrometry, Mass, Electrospray Ionization; Spectroscopy, Fourier Transform Infrared; Speech; Speech Perception; Spindle Poles; Spleen; Sporothrix; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Stomach Neoplasms; Stress, Physiological; Stroke Volume; Structure-Activity Relationship; Substrate Specificity; Sulfonamides; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Rate; T-Lymphocytes, Cytotoxic; Tandem Mass Spectrometry; Temperature; Tenofovir; Terpenes; Tetracycline; Tetrapleura; Textiles; Thermodynamics; Thiobarbituric Acid Reactive Substances; Thrombin; Thyroid Hormones; Thyroid Neoplasms; Tibial Meniscus Injuries; Time Factors; Tissue Distribution; Titanium; Toluidines; Tomography, X-Ray Computed; Tooth; Tramadol; Transcription Factor AP-1; Transcription, Genetic; Transfection; Transgender Persons; Translations; Treatment Outcome; Triglycerides; Ubiquinone; Ubiquitin-Specific Proteases; United Kingdom; United States; Up-Regulation; Vascular Stiffness; Veins; Ventricular Remodeling; Viral Load; Virulence Factors; Virus Replication; Vitis; Voice; Voice Quality; Wastewater; Water; Water Pollutants, Chemical; Water-Electrolyte Balance; Weather; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Young Adult; Zoogloea | 2022 |
Lamivudine/Tenofovir Disoproxil Fumarate is an Appropriate PrEP Regimen.
Topics: Administration, Oral; Anti-HIV Agents; HIV Infections; Homosexuality; Humans; Lamivudine; Pre-Exposure Prophylaxis; Tenofovir | 2020 |
Experience of SARS-CoV-2 infection in two kidney transplant recipients living with HIV-1 infection.
Topics: Adult; Anti-Bacterial Agents; Anti-HIV Agents; Atovaquone; CD4 Lymphocyte Count; CD4-CD8 Ratio; COVID-19; Dideoxynucleosides; Female; Glucocorticoids; Graft Rejection; HIV Infections; HIV-1; Humans; Immunocompromised Host; Immunosuppressive Agents; Kidney Transplantation; Lamivudine; Male; Middle Aged; Mycophenolic Acid; Pneumonia, Pneumocystis; Prednisolone; Raltegravir Potassium; RNA, Viral; SARS-CoV-2; Tacrolimus; Trimethoprim, Sulfamethoxazole Drug Combination | 2021 |
Inflammatory Myositis Secondary to Anti-Retroviral Therapy in a Child; Case Report and Review of the Literature.
Topics: Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Child, Preschool; Female; HIV Infections; Humans; Lamivudine; Myositis; Raltegravir Potassium; Viral Load | 2021 |
Candidates for inclusion in a universal antiretroviral regimen: are lamivudine and emtricitabine interchangeable?
Topics: Anti-HIV Agents; Deoxycytidine; Emtricitabine; HIV Infections; HIV-1; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Treatment Outcome | 2017 |
Antiretroviral therapy for pregnant women living with HIV or hepatitis B: a systematic review and meta-analysis.
Topics: Adult; Anti-Retroviral Agents; Drug Combinations; Emtricitabine; Female; Hepatitis B; HIV Infections; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Ritonavir; Tenofovir; Young Adult; Zidovudine | 2017 |
Zidovudine/Lamivudine vs. Abacavir/Lamivudine vs. Tenofovir/Emtricitabine in fixed-dose combinations as initial treatment for HIV patients: a systematic review and network meta-analysis.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; Humans; Lamivudine; Network Meta-Analysis; Randomized Controlled Trials as Topic; Treatment Outcome; Zidovudine | 2017 |
Dolutegravir Dual Therapy as Maintenance Treatment in HIV-Infected Patients: A Review.
Topics: Anti-HIV Agents; Darunavir; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Observational Studies as Topic; Oxazines; Piperazines; Pyridones; Randomized Controlled Trials as Topic; Rilpivirine | 2018 |
Twenty-Five Years of Lamivudine: Current and Future Use for the Treatment of HIV-1 Infection.
Topics: Anti-HIV Agents; Drug Development; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Reverse Transcriptase Inhibitors | 2018 |
Comparative safety and effectiveness of perinatal antiretroviral therapies for HIV-infected women and their children: Systematic review and network meta-analysis including different study designs.
Topics: Abnormalities, Drug-Induced; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Congenital Abnormalities; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant; Infant, Low Birth Weight; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Network Meta-Analysis; Nevirapine; Perinatal Care; Pregnancy; Pregnancy Complications, Infectious; Stavudine; Stillbirth; Zidovudine | 2018 |
The pharmacokinetics, pharmacodynamics, and clinical role of fixed dose combination of tenofovir disoproxil fumarate, lamivudine and reduced dose efavirenz (TLE-400) in treating HIV-1 infection.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dose-Response Relationship, Drug; Drug Combinations; HIV Infections; HIV-1; Humans; Lamivudine; Tenofovir | 2018 |
Individual patient data meta-analysis of randomized controlled trials of dual therapy with a boosted PI plus lamivudine for maintenance of virological suppression: GeSIDA study 9717.
Topics: Data Interpretation, Statistical; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Randomized Controlled Trials as Topic; Ritonavir; Viral Load | 2018 |
Lamivudine plus tenofovir combination therapy versus lamivudine monotherapy for HBV/HIV coinfection: a meta-analysis.
Topics: Alanine Transaminase; Antiviral Agents; Coinfection; Drug Therapy, Combination; Hepatitis B; Hepatitis B e Antigens; HIV Infections; Humans; Lamivudine; RNA, Viral; Tenofovir; Treatment Outcome | 2018 |
Doravirine: First Global Approval.
Topics: Anti-HIV Agents; Drug Approval; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Pyridones; Reverse Transcriptase Inhibitors; Tablets; Tenofovir; Triazoles | 2018 |
Comparative effectiveness of anti-viral drugs with dual activity for treating hepatitis B and HIV co-infected patients: a network meta-analysis.
Topics: Adenine; Adult; Aged; Antiviral Agents; Coinfection; Emtricitabine; Female; Hepatitis B; Hepatitis B virus; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Network Meta-Analysis; Organophosphonates; Tenofovir; Treatment Outcome; Young Adult | 2018 |
Alternative switching strategies based on regimens with a low genetic barrier: do clinicians have a choice nowadays?
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Combinations; Drug Resistance, Viral; Drug Substitution; HIV Infections; HIV-1; Humans; Lamivudine; Raltegravir Potassium; Rilpivirine; Treatment Outcome; Viral Load | 2019 |
Community and activists demand for tenofovir/emtricitabine or lamivudine/dolutegravir and routine viral load testing.
Topics: Anti-HIV Agents; Drug Monitoring; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Residence Characteristics; Tenofovir; Viral Load | 2019 |
Regression of human immunodeficiency virus-associated oral Kaposi sarcoma with combined antiretroviral therapy: A case report and literature review.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Combinations; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Mouth Neoplasms; Ritonavir; Sarcoma, Kaposi; Zidovudine | 2019 |
Drug-drug interactions of a two-drug regimen of dolutegravir and lamivudine for HIV treatment.
Topics: Anti-HIV Agents; Drug Interactions; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Piperazines; Pyridones | 2019 |
Dolutegravir plus lamivudine dual therapy - a new option for initial antiretroviral therapy.
Topics: Anti-HIV Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Equivalence Trials as Topic; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones | 2019 |
Comparative efficacy and safety and dolutegravir and lamivudine in treatment naive HIV patients.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Randomized Controlled Trials as Topic; RNA, Viral; Viral Load | 2019 |
Genital Human Immunodeficiency Virus-1 RNA and DNA Shedding in Virologically Suppressed Individuals Switching From Triple- to Dual- or Monotherapy: Pooled Results From 2 Randomized, Controlled Trials.
Topics: Anti-HIV Agents; DNA; Emtricitabine; Female; Genitalia; HIV Infections; HIV-1; Humans; Lamivudine; Male; Randomized Controlled Trials as Topic; RNA; Viral Load | 2020 |
HIV/HBV coinfection in children and antiviral therapy.
Topics: Adolescent; Adult; Antiviral Agents; Child; Child, Preschool; Coinfection; Female; Hepatitis B; HIV Infections; Humans; Lamivudine; Male; Young Adult | 2013 |
Clinical pharmacokinetics of antiretroviral drugs in older persons.
Topics: Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; Dose-Response Relationship, Drug; Drug Interactions; Guidelines as Topic; HIV Infections; HIV Protease Inhibitors; Humans; Kidney; Lamivudine; Liver; Lopinavir; Middle Aged; Oligopeptides; Pyridines; Young Adult | 2013 |
Co-formulated abacavir-lamivudine-zidovudine for initial treatment of HIV infection and AIDS.
Topics: Acquired Immunodeficiency Syndrome; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Combinations; HIV Infections; Humans; Lamivudine; Nelfinavir; Oligopeptides; Pyridines; Randomized Controlled Trials as Topic; Zidovudine | 2013 |
Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Drug Substitution; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lipids; Maintenance Chemotherapy; Middle Aged; Nevirapine; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Treatment Failure; Viral Load; Young Adult; Zidovudine | 2013 |
Hepatitis B in HIV-infected patients.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Coinfection; Drug Resistance, Viral; Hepatitis B Vaccines; Hepatitis B, Chronic; Hepatitis D; HIV Infections; Humans; Lamivudine; Organophosphonates; Tenofovir | 2013 |
Comparative efficacy of Lamivudine and emtricitabine: a systematic review and meta-analysis of randomized trials.
Topics: Adult; Anti-HIV Agents; Databases, Bibliographic; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Therapeutic Equivalency; Treatment Outcome; Viral Load | 2013 |
Dolutegravir for the treatment of adult patients with HIV-1 infection.
Topics: Adult; Clinical Trials as Topic; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Drug Interactions; Drug Resistance, Viral; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Pyrrolidinones; Quinolones; Raltegravir Potassium | 2014 |
Dolutegravir, abacavir and lamivudine as HIV therapy.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Dideoxynucleosides; Drug Resistance, Viral; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones | 2014 |
Virological efficacy of abacavir: systematic review and meta-analysis.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Emtricitabine; HIV Infections; Humans; Lamivudine; Organophosphonates; Randomized Controlled Trials as Topic; Tenofovir; Treatment Outcome | 2014 |
48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Lipids; Lopinavir; Nitriles; Organophosphonates; Oxazines; Piperazines; Pyridones; Pyrimidines; Pyrrolidinones; Raltegravir Potassium; Randomized Controlled Trials as Topic; Rilpivirine; Ritonavir; Tenofovir; Time Factors; Treatment Outcome; Viral Load | 2014 |
Advances in treating drug-resistant hepatitis B virus in HIV-infected patients.
Topics: Antiviral Agents; Coinfection; Drug Resistance, Viral; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine | 2015 |
Triumeq--a 3-drug combination for HIV.
Topics: Animals; Anti-HIV Agents; Clinical Trials as Topic; Dideoxynucleosides; Drug Combinations; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones | 2015 |
Antiretroviral drugs for prevention of mother-to-child transmission: pharmacologic considerations for a public health approach.
Topics: Adenine; Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Child; Cyclopropanes; Drug Resistance, Viral; Drug Therapy; HIV; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Organophosphonates; Public Health; Tenofovir | 2014 |
Abacavir/dolutegravir/lamivudine single-tablet regimen: a review of its use in HIV-1 infection.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Drug Resistance, Viral; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Medication Adherence; Mutation; Oxazines; Piperazines; Practice Guidelines as Topic; Pyridones; Reverse Transcriptase Inhibitors; Tablets | 2015 |
[Safety profile of dolutegravir].
Topics: Bone Remodeling; Clinical Trials as Topic; Creatinine; Dideoxynucleosides; Drug Combinations; Drug Hypersensitivity; Drug Therapy, Combination; Gastrointestinal Diseases; Headache; Hepatitis, Viral, Human; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Immune Reconstitution Inflammatory Syndrome; Kidney Tubules; Lamivudine; Lipid Metabolism; Mood Disorders; Organic Cation Transport Proteins; Organic Cation Transporter 2; Oxazines; Piperazines; Pyridones; Respiration Disorders; Sleep Initiation and Maintenance Disorders | 2015 |
Choice of antiretroviral drugs for postexposure prophylaxis for children: a systematic review.
Topics: Anti-HIV Agents; Child; Child, Preschool; Cohort Studies; Dideoxynucleosides; Drug Combinations; Female; HIV Infections; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Nevirapine; Post-Exposure Prophylaxis; Pregnancy; Prospective Studies; Randomized Controlled Trials as Topic; Ritonavir; Zidovudine | 2015 |
Clinical pharmacokinetics and pharmacodynamics of dolutegravir used as a single tablet regimen for the treatment of HIV-1 infection.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Administration Schedule; Drug Interactions; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; RNA, Viral; Tablets | 2015 |
Dutrebis (lamivudine and raltegravir) for use in combination with other antiretroviral products for the treatment of HIV-1 infection.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biological Availability; Drug Combinations; HIV Infections; HIV-1; Humans; Lamivudine; Raltegravir Potassium; Tablets | 2015 |
The preclinical discovery and development of dolutegravir for the treatment of HIV.
Topics: Animals; Dideoxynucleosides; Drug Combinations; Drug Design; Drug Evaluation, Preclinical; Drug Resistance, Viral; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Oxazines; Piperazines; Pyridones | 2015 |
Care of Patients With HIV Infection: Antiretroviral Drug Regimens.
Topics: Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Emtricitabine; HIV Fusion Inhibitors; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Tenofovir | 2016 |
Efficacy and safety of contemporary dual-drug antiretroviral regimens as first-line treatment or as a simplification strategy: a systematic review and meta-analysis.
Topics: Anti-HIV Agents; Cyclohexanes; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Male; Maraviroc; Middle Aged; Odds Ratio; Reverse Transcriptase Inhibitors; Risk; Triazoles; Viral Load | 2016 |
Abacavir + dolutegravir + lamivudine for the treatment of HIV.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Tablets | 2016 |
Dolutegravir(DTG, S/GSK1349572) combined with other ARTs is superior to RAL- or EFV-based regimens for treatment of HIV-1 infection: a meta-analysis of randomized controlled trials.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Raltegravir Potassium; Randomized Controlled Trials as Topic; Tenofovir; Treatment Outcome | 2016 |
Update on occult hepatitis B virus infection.
Topics: Antiviral Agents; Coinfection; DNA, Viral; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; HIV Infections; Humans; Interferons; Lamivudine; Liver Cirrhosis; Liver Transplantation; Mutation; Occupational Exposure; Prevalence; Renal Dialysis; RNA Splicing; Viral Load | 2016 |
Treatment of chronic hepatitis B infection: an update of Swedish recommendations.
Topics: Adenine; Antiviral Agents; Carcinoma, Hepatocellular; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B, Chronic; HIV Infections; Humans; Immunocompromised Host; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Transplantation; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Sweden; Tenofovir | 2008 |
[Entecavir].
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Clinical Trials as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Liver Cirrhosis; Liver Transplantation; Multicenter Studies as Topic; Organophosphonates; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load; Virus Replication | 2008 |
[Hepatitis B in patients with HIV infection].
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Comorbidity; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B; Hepatitis B Vaccines; Hepatitis B virus; HIV; HIV Infections; Humans; Interferon-alpha; Lamivudine; Nucleosides; Organophosphonates; Practice Guidelines as Topic; Pyrimidinones; Reverse Transcriptase Inhibitors; Telbivudine; Tenofovir; Thymidine; Virus Replication | 2008 |
[Adipose tissue hypertrophy after Lipostructure in HIV patient with antiretroviral treatment. Case report and literature review].
Topics: Adipose Tissue; Adult; Anti-Retroviral Agents; Drug Combinations; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Hypertrophy; Lamivudine; Male; Postoperative Complications; Zidovudine | 2009 |
Non-occupational postexposure prophylaxis for HIV: a systematic review.
Topics: Anti-HIV Agents; Cost-Benefit Analysis; Databases, Bibliographic; Drug Combinations; Drug Therapy, Combination; HIV Infections; HIV Seropositivity; Humans; Lamivudine; Lopinavir; Premedication; Pyrimidinones; Ritonavir; Substance Abuse, Intravenous; Time Factors; Treatment Outcome; Unsafe Sex; Zidovudine | 2009 |
[A fixed dose anti-HIV combination for the poor? Triomune].
Topics: Africa; Anti-HIV Agents; Developing Countries; Drug Administration Schedule; Drug Combinations; HIV Infections; Humans; Lamivudine; Nevirapine; Stavudine | 2009 |
[The "induction-maintenance" strategy].
Topics: Adipose Tissue; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Lopinavir; Pyrimidinones; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Outcome; Viral Load; Virus Replication; Zidovudine | 2008 |
A combination drug of abacavir-lamivudine-zidovudine (Trizivir) for treating HIV infection and AIDS.
Topics: Acquired Immunodeficiency Syndrome; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Drug Combinations; HIV Infections; Humans; Lamivudine; Nelfinavir; Oligopeptides; Pyridines; Randomized Controlled Trials as Topic; Zidovudine | 2009 |
Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
Topics: Adenine; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Intention to Treat Analysis; Lamivudine; Male; Organophosphonates; Randomized Controlled Trials as Topic; Regression Analysis; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load | 2009 |
Abacavir and lamivudine combination.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Dideoxynucleosides; Drug Combinations; Drug Monitoring; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors | 2009 |
Lamivudine for the treatment of HIV.
Topics: Animals; Anti-HIV Agents; Clinical Trials as Topic; Drug Utilization; HIV Infections; HIV-1; Humans; Lamivudine; Legislation, Drug; Reverse Transcriptase Inhibitors | 2010 |
Therapy of chronic hepatitis B: new goals and new treatments.
Topics: Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Gene Products, pol; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Interferons; Lamivudine; Virus Replication | 2009 |
Abacavir/lamivudine fixed-dose combination antiretroviral therapy for the treatment of HIV.
Topics: Anti-HIV Agents; Area Under Curve; Clinical Trials as Topic; Dideoxynucleosides; Drug Combinations; Drug Interactions; Half-Life; HIV Infections; Humans; Lamivudine; Metabolic Clearance Rate; Myocardial Infarction | 2010 |
HIV-HBV coinfection among South African patients receiving antiretroviral therapy.
Topics: Anti-HIV Agents; Drug Therapy, Combination; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Prevalence; Reverse Transcriptase Inhibitors; South Africa | 2010 |
Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy.
Topics: Adolescent; Adult; Anti-HIV Agents; Deoxycytidine; Developing Countries; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Treatment Failure | 2010 |
Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Lamivudine; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Zidovudine | 2010 |
The impact of human immunodeficiency virus on viral hepatitis.
Topics: Adenine; Antiviral Agents; Deoxycytidine; Disease Progression; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B; Hepatitis C; Hepatitis Viruses; HIV Infections; Humans; Interferon-alpha; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Telbivudine; Tenofovir; Thymidine | 2011 |
Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Zidovudine | 2011 |
Abacavir and lamivudine for the treatment of human immunodeficiency virus.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Clinical Trials, Phase III as Topic; Dideoxynucleosides; HIV; HIV Infections; Humans; Lamivudine; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors | 2011 |
HIV-1-resistance-associated mutations after failure of first-line antiretroviral treatment among children in resource-poor regions: a systematic review.
Topics: Adolescent; Africa; Alkynes; Anti-HIV Agents; Asia; Benzoxazines; Child; Child, Preschool; Cross-Sectional Studies; Cyclopropanes; Developing Countries; Drug Resistance, Viral; Female; Health Resources; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Latin America; Lopinavir; Male; Mutation; Nevirapine; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Treatment Failure; Viral Load; Zidovudine | 2011 |
Antiviral drugs for viruses other than human immunodeficiency virus.
Topics: Acyclovir; Adenine; Amantadine; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Foscarnet; Ganciclovir; Guanine; Hepatitis; Hepatitis B, Chronic; Hepatitis C; Herpesviridae Infections; HIV Infections; Humans; Influenza, Human; Interferons; Lamivudine; Nucleosides; Oligopeptides; Organophosphonates; Oseltamivir; Proline; Protease Inhibitors; Pyrimidinones; Ribavirin; Telbivudine; Thymidine; Valacyclovir; Valganciclovir; Valine; Virus Replication; Zanamivir | 2011 |
Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid).
Topics: Adenine; Adult; Amniotic Fluid; Anti-HIV Agents; Cyclohexanes; Enfuvirtide; Female; Fetal Blood; Fetus; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Maraviroc; Nevirapine; Organophosphonates; Peptide Fragments; Placenta; Pregnancy; Pregnancy Complications, Infectious; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Tenofovir; Triazoles; Viral Load; Zidovudine | 2011 |
Noncirrhotic portal hypertension associated with didanosine: a case report and literature review.
Topics: Aged, 80 and over; Antiretroviral Therapy, Highly Active; Ascites; Chemical and Drug Induced Liver Injury; Didanosine; Fatal Outcome; HIV Infections; HIV-1; Humans; Hypertension, Portal; Lamivudine; Male; Nevirapine; Portal Vein; Thrombosis; Tomography, X-Ray Computed | 2012 |
A review of the virological efficacy of the 4 World Health Organization-recommended tenofovir-containing regimens for initial HIV therapy.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Lamivudine; Nevirapine; Organophosphonates; Tenofovir; Treatment Failure; Viral Load; World Health Organization | 2012 |
Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Coinfection; Deoxycytidine; Dideoxynucleosides; Disease Progression; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Emtricitabine; Hepatitis C, Chronic; HIV Infections; Homosexuality, Male; Humans; Interferon-alpha; Lamivudine; Liver Cirrhosis; Liver Diseases; Male; Oligopeptides; Organophosphonates; Polyethylene Glycols; Proline; Pyrrolidinones; Raltegravir Potassium; Recombinant Proteins; Ribavirin; Serine Proteinase Inhibitors; Substance Abuse, Intravenous; Tenofovir; Treatment Outcome | 2012 |
Antiretrovirals for HIV Exposure Prophylaxis.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Emtricitabine; HIV; HIV Infections; Humans; Lamivudine; Occupational Exposure; Organophosphonates; Stavudine; Tenofovir; Zidovudine | 2012 |
Hepatitis B virus resistance to lamivudine and its clinical implications.
Topics: Antiviral Agents; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine | 2002 |
Lamivudine/zidovudine/abacavir: triple combination tablet.
Topics: Administration, Oral; Anti-HIV Agents; Biological Availability; Dideoxynucleosides; Drug Combinations; Drug Resistance, Viral; HIV Infections; Humans; Lamivudine; Randomized Controlled Trials as Topic; Treatment Outcome; Zidovudine | 2003 |
Contraindicated antiretroviral drug combinations.
Topics: Anti-Retroviral Agents; Contraindications; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Saquinavir; Stavudine; Zalcitabine | 2003 |
Abacavir plus lamivudine: a thymidine analogue-sparing NRTI backbone.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; HIV Infections; Humans; Lamivudine; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors | 2003 |
Viral hepatitis B.
Topics: Adenine; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Genotype; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Interferon-alpha; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Viral Load | 2003 |
The continuing evolution of HIV therapy.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Carbamates; CD4 Lymphocyte Count; Cyclopropanes; Delayed-Action Preparations; Deoxycytidine; Didanosine; Dideoxynucleosides; Drug Monitoring; Emtricitabine; Furans; HIV Infections; Humans; Lamivudine; Nevirapine; Oligopeptides; Organophosphates; Organophosphonates; Organophosphorus Compounds; Oxazines; Pyridines; Randomized Controlled Trials as Topic; Stavudine; Sulfonamides; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2003 |
Management of chronic hepatitis B in the HIV-infected patient.
Topics: Adenine; Algorithms; Antiviral Agents; Clinical Trials as Topic; Decision Trees; Drug Therapy, Combination; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2004 |
Editorial comment: HIV and HBV coinfection--a coming-of-age in treatment strategies.
Topics: Adenine; Antiviral Agents; Comorbidity; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Guanine; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2004 |
Nucleoside combinations for antiretroviral therapy: efficacy of stavudine in combination with either didanosine or lamivudine.
Topics: Adult; Aged; Anti-HIV Agents; Didanosine; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Randomized Controlled Trials as Topic; Stavudine; Viral Load | 1998 |
Prognostic factors in lactic acidosis syndrome caused by nucleoside reverse transcriptase inhibitors: report of eight cases and review of the literature.
Topics: Acidosis, Lactic; Adult; Didanosine; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; New York; Reverse Transcriptase Inhibitors; Stavudine; Syndrome; Zidovudine | 2004 |
Treatment of hepatitis B virus infection in patients coinfected with HIV.
Topics: Adenine; Antiviral Agents; Hepatitis B, Chronic; HIV Infections; Humans; Interferon-alpha; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2004 |
Hepatitis C virus in the setting of HIV or hepatitis B virus coinfection.
Topics: Adenine; Antiviral Agents; Comorbidity; Hepacivirus; Hepatitis B virus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Organophosphonates; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Proteins; Ribavirin; Risk Factors | 2004 |
Antiretroviral therapy during pregnancy and early neonatal life: consequences for HIV-exposed, uninfected children.
Topics: Anti-HIV Agents; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Prenatal Exposure Delayed Effects; Zidovudine | 2004 |
Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection.
Topics: Adenine; Antiviral Agents; Clinical Trials as Topic; Drug Approval; Drug Resistance, Viral; Hepatitis B e Antigens; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Organophosphonates | 2004 |
Abacavir plus lamivudine: a review of their combined use in the management of HIV infection.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine | 2005 |
Rationale for maintenance of the M184v resistance mutation in human immunodeficiency virus type 1 reverse transcriptase in treatment experienced patients.
Topics: Amino Acid Substitution; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Virus Replication | 2004 |
The impact of abacavir on lipids and lipodystrophy.
Topics: Acquired Immunodeficiency Syndrome; Cross-Sectional Studies; Dideoxynucleosides; Dose-Response Relationship, Drug; Drug Administration Schedule; Evidence-Based Medicine; Female; HIV Infections; Humans; Hyperlipidemias; Incidence; Lamivudine; Lipodystrophy; Male; Randomized Controlled Trials as Topic; Risk Assessment | 2005 |
Care of patients with chronic hepatitis B and HIV co-infection: recommendations from an HIV-HBV International Panel.
Topics: Adenine; Antiviral Agents; Comorbidity; Deoxycytidine; Disease Progression; Drug Monitoring; Emtricitabine; Hepatitis B, Chronic; HIV Infections; Humans; Interferon-alpha; Lamivudine; Organophosphonates; Tenofovir | 2005 |
Treatment of chronic hepatitis B in HIV co-infected patients.
Topics: Antiretroviral Therapy, Highly Active; Comorbidity; Disease Progression; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Recurrence; Reverse Transcriptase Inhibitors; Risk Factors | 2005 |
Piloting post-exposure prophylaxis in Kenya raises specific concerns for the management of childhood rape.
Topics: Adolescent; Adult; Anti-HIV Agents; Body Weight; Child; Child Abuse, Sexual; Child, Preschool; Feasibility Studies; Female; HIV Infections; Humans; Infant; Kenya; Lamivudine; Male; Pilot Projects; Practice Guidelines as Topic; Rape; Risk Factors; Rural Health; Sexually Transmitted Diseases; Zidovudine | 2006 |
Is there a difference in the efficacy of peripartum antiretroviral regimens in reducing mother-to-child transmission of HIV in Africa?
Topics: Adult; Anti-HIV Agents; Breast Feeding; Drug Combinations; Female; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Male; Perinatal Care; Randomized Controlled Trials as Topic; Regression Analysis; Risk Factors; Treatment Outcome; Zidovudine | 2005 |
Fixed dose combination abacavir/lamivudine in the treatment of HIV-1 infection.
Topics: Animals; Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; HIV Infections; HIV-1; Humans; Lamivudine | 2005 |
[The treatment of HIV infection].
Topics: Adenine; Anti-Retroviral Agents; Carbamates; Chemical and Drug Induced Liver Injury; Clinical Trials as Topic; Drug Therapy, Combination; Furans; HIV Infections; Humans; Lamivudine; Nevirapine; Organophosphates; Organophosphonates; Risk Factors; Sulfonamides; Tenofovir; Zidovudine | 2005 |
Triple-nucleoside analog antiretroviral therapy: is there still a role in clinical practice? A review.
Topics: Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Dideoxynucleosides; Drug Combinations; HIV Infections; Humans; Lamivudine; Practice Guidelines as Topic; Practice Patterns, Physicians'; Prognosis; Treatment Outcome; Zidovudine | 2005 |
Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Nevirapine; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Stavudine | 2006 |
An update and review of antiretroviral therapy.
Topics: Adenine; Animals; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Carbamates; Clinical Trials as Topic; Deoxycytidine; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Drugs, Investigational; Emtricitabine; Enfuvirtide; Furans; HIV Envelope Protein gp41; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Oligopeptides; Organophosphates; Organophosphonates; Patient Compliance; Peptide Fragments; Pyridines; Pyrones; Reverse Transcriptase Inhibitors; Sulfonamides; Tenofovir | 2006 |
Evidence behind the WHO guidelines: hospital care for children: what antiretroviral agents and regimens are effective in the prevention of mother-to-child transmission of HIV?
Topics: Anti-HIV Agents; Breast Feeding; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Nevirapine; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors; World Health Organization; Zidovudine | 2006 |
Antiretroviral therapy for hepatitis B virus-HIV-coinfected patients: promises and pitfalls.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Antiviral Agents; Deoxycytidine; Drug Combinations; Emtricitabine; Guanine; Hepatitis B; Hepatitis B virus; HIV Infections; HIV-1; Humans; Lamivudine; Organophosphonates; Preventive Medicine; Tenofovir | 2006 |
Evolving simplified treatment strategies for HIV infection: the role of a single-class quadruple-nucleoside/nucleotide regimen of trizivir and tenofovir.
Topics: Adenine; Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; HIV Infections; HIV-1; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Zidovudine | 2006 |
Criteria for drugs used in pre-exposure prophylaxis trials against HIV infection.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Clinical Trials as Topic; Cost-Benefit Analysis; Drug Combinations; HIV Infections; Humans; Lamivudine; Research Design | 2006 |
Entecavir: a new nucleoside analog for the treatment of chronic hepatitis B infection.
Topics: Animals; Antiviral Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Guanine; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine | 2006 |
Abacavir/lamividune combination in the treatment of HIV-1 infection: a review.
Topics: Dideoxynucleosides; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine | 2006 |
Antiretroviral therapy for prevention of mother-to-child HIV transmission : focus on single-dose nevirapine.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Nevirapine; Pregnancy | 2006 |
Didanosine, lamivudine-emtricitabine and efavirenz as initial therapy in naive patients.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Deoxycytidine; Didanosine; Drug Resistance, Viral; Emtricitabine; HIV; HIV Infections; Humans; Lamivudine; Oxazines; Quality of Life; Reverse Transcriptase Inhibitors | 2006 |
Computational models of antiviral toxicity.
Topics: Anti-HIV Agents; Computer Simulation; Drug-Related Side Effects and Adverse Reactions; HIV Infections; Humans; Lamivudine; Molecular Structure; Stavudine; Zidovudine | 2007 |
Abacavir sulfate/lamivudine/zidovudine fixed combination in the treatment of HIV infection.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Dideoxynucleosides; Dose-Response Relationship, Drug; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Treatment Outcome; Zidovudine | 2007 |
Systematic review of the efficacy of antiretroviral therapies for reducing the risk of mother-to-child transmission of HIV infection.
Topics: Anti-HIV Agents; Antimetabolites; Antiretroviral Therapy, Highly Active; Child; Female; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Nevirapine; Pregnancy; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Risk Factors; Treatment Outcome; Zidovudine | 2007 |
[Entecavir: a new hope for the treatment of chronic hepatitis B].
Topics: Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; DNA, Viral; Double-Blind Method; Drug Resistance, Viral; Guanine; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Liver Cirrhosis; Liver Transplantation; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Recurrence; Treatment Outcome; Viremia | 2007 |
Treatment of chronic hepatitis B in HIV-infected patients in 2007.
Topics: Adenine; Antiviral Agents; Guanine; Hepatitis B, Chronic; HIV Infections; Humans; Interferon-alpha; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Telbivudine; Tenofovir; Thymidine | 2007 |
Quadruple nucleoside therapy with zidovudine, lamivudine, abacavir and tenofovir in the treatment of HIV.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Resistance, Multiple, Viral; HIV Infections; HIV-1; Humans; Lamivudine; Mutation; Organophosphonates; Practice Guidelines as Topic; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure; Treatment Outcome; Viral Load; Zidovudine | 2007 |
[Attention-getting sexually transmitted diseases: Hepatitis B].
Topics: Adenine; Adenosine; Antiviral Agents; Comorbidity; Drug Therapy, Combination; Genotype; Guanine; Guanosine; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Sexually Transmitted Diseases, Viral | 2007 |
An approach to antiretroviral treatment of HIV disease. Nucleoside monotherapy.
Topics: Antiviral Agents; Didanosine; HIV Infections; HIV-1; Humans; Lamivudine; Nucleosides; Stavudine; Zalcitabine; Zidovudine | 1995 |
Clinical pharmacokinetics of nucleoside antiretroviral agents.
Topics: Animals; Didanosine; Dideoxynucleosides; HIV Infections; Humans; Lamivudine; Stavudine; Zalcitabine; Zidovudine | 1995 |
Prophylaxis for occupational exposure to HIV.
Topics: Antiviral Agents; Health Personnel; HIV Infections; Humans; Lamivudine; Occupational Exposure; Protease Inhibitors; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1996 |
Guide to major clinical trials of antiretroviral therapy administered to patients infected with human immunodeficiency virus.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Meta-Analysis as Topic; Reverse Transcriptase Inhibitors; Stavudine; Zalcitabine; Zidovudine | 1996 |
Wheel keeps turning for antiviral combination chemotherapy.
Topics: Antiviral Agents; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; Lamivudine; Virus Diseases; Zidovudine | 1996 |
Newer nucleosides: lamivudine and stavudine.
Topics: Anti-HIV Agents; HIV Infections; Humans; Lamivudine; Nucleosides; Stavudine | 1996 |
Ritonavir.
Topics: Administration, Oral; Anti-HIV Agents; Biological Availability; CD4-Positive T-Lymphocytes; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Drug Tolerance; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Leukocyte Count; Randomized Controlled Trials as Topic; Ritonavir; RNA, Messenger; Zalcitabine; Zidovudine | 1996 |
[Nucleoside analogs inhibiting reverse transcriptase: use in adult patient with HIV infection].
Topics: Adult; Anti-HIV Agents; Clinical Trials as Topic; Didanosine; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Stavudine; Zalcitabine; Zidovudine | 1996 |
Reductions in HIV-1 disease progression for zidovudine/lamivudine relative to control treatments: a meta-analysis of controlled trials.
Topics: Adolescent; Adult; Anti-HIV Agents; Centers for Disease Control and Prevention, U.S.; Disease Progression; Double-Blind Method; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; United States; Zidovudine | 1997 |
Lamivudine. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in the management of HIV infection.
Topics: Adult; Anti-HIV Agents; Clinical Trials as Topic; HIV Infections; Humans; Lamivudine | 1997 |
Antiretroviral therapy: a guide to the most important trials.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Indinavir; Lamivudine; Nevirapine; Pyridines; Ritonavir; Saquinavir; Stavudine; Viral Load; Zalcitabine; Zidovudine | 1997 |
The development of resistance of HIV-1 to zalcitabine.
Topics: Amino Acids; Anti-HIV Agents; Didanosine; Drug Resistance, Microbial; Genetic Variation; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Models, Molecular; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Zalcitabine | 1997 |
Adverse effects and drug interactions of medications commonly used in the treatment of adult HIV positive patients: Part 2.
Topics: Adolescent; Adult; Anti-HIV Agents; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Indinavir; Lamivudine; Ritonavir; Saquinavir | 1997 |
Antiviral chemotherapy.
Topics: Adult; Antiviral Agents; Child; HIV Infections; Humans; Indinavir; Lamivudine; Nevirapine; Protease Inhibitors; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Stavudine | 1997 |
Platelet dysfunction as the cause of spontaneous bleeding in two haemophilic patients taking HIV protease inhibitors.
Topics: Adolescent; Adult; Anti-HIV Agents; Hemophilia A; Hemorrhage; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Reverse Transcriptase Inhibitors; Zidovudine | 1998 |
[Antiretroviral treatment in human immunodeficiency virus infection].
Topics: Antiviral Agents; Didanosine; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Ritonavir; Saquinavir; Stavudine; Treatment Outcome; Viral Load; Zalcitabine; Zidovudine | 1997 |
Antiretroviral chemotherapy.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Oxazines; Ritonavir; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 1998 |
Toxicity of antiretroviral agents.
Topics: Anti-HIV Agents; Didanosine; Health Personnel; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Occupational Exposure; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 1997 |
Combined treatment with zidovudine, lamivudine, nelfinavir and ganciclovir in an infant with human immunodeficiency virus type 1 infection and cytomegalovirus encephalitis: case report and review of the literature.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiviral Agents; Cytomegalovirus Infections; Diseases in Twins; Drug Therapy, Combination; Encephalitis, Viral; Female; Ganciclovir; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Infant, Premature; Infant, Premature, Diseases; Lamivudine; Nelfinavir; Zidovudine | 1999 |
Antiretrovirals.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Cyclopropanes; Delavirdine; Didanosine; Dideoxynucleosides; Female; Furans; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Oxazines; Pregnancy; Pregnancy Complications, Infectious; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Stavudine; Sulfonamides; Zalcitabine; Zidovudine | 1999 |
Review of NNRTIs: 'today and tomorrow'.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Oxazines; Reverse Transcriptase Inhibitors; Zidovudine | 1999 |
Coming therapies: abacavir.
Topics: Anti-HIV Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Zidovudine | 1999 |
Finding a role for zalcitabine in the HAART era.
Topics: Anti-HIV Agents; Drug Resistance; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Saquinavir; Zalcitabine; Zidovudine | 1998 |
[Early treatment of sexual exposure to human immunodeficiency virus].
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Nelfinavir; Probability; Risk Factors; Sexual Behavior; Sexual Partners; Time Factors; Zidovudine | 2000 |
Stavudine plus a non-thymidine nucleoside reverse transcriptase inhibitor as a backbone for highly active antiretroviral therapy.
Topics: Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Retroviridae; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 1998 |
Intracellular studies of the nucleoside reverse transcriptase inhibitor active metabolites: a review.
Topics: Adult; Aged; Anti-HIV Agents; Antimetabolites; Cells, Cultured; Child; Chromatography, High Pressure Liquid; Clinical Trials as Topic; Female; HIV Infections; Humans; Lamivudine; Leukocytes, Mononuclear; Male; Middle Aged; Phosphates; Phosphorylation; Polyphosphates; Radioimmunoassay; Reverse Transcriptase Inhibitors; Time Factors; Zidovudine | 2000 |
Development of resistance and perspectives for future therapies against hepatitis B infections: lessons to be learned from HIV.
Topics: Drug Resistance, Microbial; Drug Therapy, Combination; Hepatitis B; HIV Infections; Humans; Lamivudine; Microbial Sensitivity Tests; Prognosis; Reverse Transcriptase Inhibitors; Treatment Outcome | 1999 |
Recurrence of the acute HIV syndrome after interruption of antiretroviral therapy in a patient with chronic HIV infection: A case report.
Topics: Acute Disease; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Chronic Disease; Disease Progression; Drug Therapy, Combination; Fever; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Male; Recurrence; Reverse Transcriptase Inhibitors; RNA, Viral; Syndrome; Viral Load; Zidovudine | 2000 |
Occupational exposure to HIV and post-exposure prophylaxis in healthcare workers.
Topics: Anti-HIV Agents; Health Personnel; HIV Infections; HIV Seropositivity; Humans; Indinavir; Infectious Disease Transmission, Patient-to-Professional; Lamivudine; Occupational Exposure; Reverse Transcriptase Inhibitors; United Kingdom; Zidovudine | 2000 |
Management of the infant born to a mother infected with human immunodeficiency virus type 1 (HIV-1): current concepts.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Administration Schedule; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Nevirapine; Pregnancy; Zidovudine | 2000 |
International perspectives on antiretroviral resistance. Nucleoside reverse transcriptase inhibitor resistance.
Topics: Dideoxynucleosides; Disease Progression; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; Genotype; HIV Infections; HIV Protease; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Reverse Transcriptase Inhibitors; Zidovudine | 2001 |
Management protocols for hepatitis B.
Topics: Antiviral Agents; Clinical Protocols; Drug Therapy, Combination; Hepatitis B, Chronic; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Lamivudine; Reverse Transcriptase Inhibitors | 2001 |
The management of chronic hepatitis B infection.
Topics: Antiviral Agents; DNA, Viral; Hepatitis B Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Interferon-alpha; Lamivudine; Reverse Transcriptase Inhibitors; Sexually Transmitted Diseases, Viral; Treatment Outcome | 2001 |
Anti-retroviral treatment in Nigeria: a review.
Topics: Anti-HIV Agents; Clinical Trials as Topic; HIV Infections; Humans; Lamivudine; Nigeria; Zidovudine | 2000 |
The impact of HIV therapy on co-infection with hepatitis B and hepatitis C viruses.
Topics: Antiretroviral Therapy, Highly Active; Drug Therapy, Combination; Hepatitis B; Hepatitis C; HIV Infections; Humans; Lamivudine; Liver; Ribavirin; Viremia | 2001 |
[Impact of HIV on HCV, GBV-C/HGV, and HBV infection].
Topics: Anti-HIV Agents; Antibiosis; Antiretroviral Therapy, Highly Active; Drug Therapy, Combination; Flaviviridae Infections; GB virus C; Hemophilia A; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatitis, Viral, Human; HIV Infections; HIV-1; Humans; Interferons; Lamivudine; Liver Neoplasms; Liver Transplantation; Prognosis; Ribavirin | 2002 |
HIV vaccine evaluation center in Rio de Janeiro, Brazil.
Topics: Adolescent; Adult; AIDS Vaccines; Anti-HIV Agents; Behavior Therapy; Bisexuality; Brazil; Clinical Trials, Phase II as Topic; Disease Transmission, Infectious; Enzyme-Linked Immunosorbent Assay; Follow-Up Studies; HIV Antibodies; HIV Envelope Protein gp120; HIV Infections; HIV Seropositivity; Homosexuality; Humans; Incidence; Lamivudine; Male; Middle Aged; Safety; Sensitivity and Specificity; Zidovudine | 2002 |
Trizivir.
Topics: Antiretroviral Therapy, Highly Active; Biological Availability; Clinical Trials as Topic; Dideoxynucleosides; Drug Combinations; Drug Evaluation; HIV Infections; HIV-1; Humans; Intestinal Absorption; Lamivudine; Zidovudine | 2002 |
A preliminary benefit-risk assessment of lamivudine for the treatment of chronic hepatitis B virus infection.
Topics: Antiviral Agents; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Liver Transplantation; Pregnancy; Risk Assessment | 2002 |
675 trial(s) available for lamivudine and HIV Coinfection
| Article | Year |
|---|---|
Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children?
Topics: Adolescent; Africa, Western; Alkynes; Anti-HIV Agents; Area Under Curve; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Reverse Transcriptase Inhibitors; Treatment Outcome | 2010 |
Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infection.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Treatment Outcome | 2022 |
Pharmacokinetics and Safety of the Abacavir/Lamivudine/Lopinavir/Ritonavir Fixed-Dose Granule Formulation (4-in-1) in Neonates: PETITE Study.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Infant, Newborn; Lamivudine; Lopinavir; Ritonavir | 2022 |
Bone mineral density, kidney function and participant-reported outcome measures in women who switch from tenofovir disoproxil emtricitabine and a nonnucleoside reverse transcriptase inhibitor to abacavir, lamivudine and dolutegravir.
Topics: Adult; Anti-HIV Agents; Bone Density; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Kidney; Lamivudine; Middle Aged; Oxazines; Patient Reported Outcome Measures; Piperazines; Pyridones; Reverse Transcriptase Inhibitors; Tenofovir | 2022 |
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 F
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Lipids; Oxazines; Piperazines; Pyridones; RNA; Tenofovir | 2022 |
Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, N
Topics: Adult; Anti-HIV Agents; Biomarkers; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; RNA, Viral | 2023 |
DOLAVI Real-Life Study of Dolutegravir Plus Lamivudine in Naive HIV-1 Patients (48 Weeks).
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Seropositivity; HIV-1; Homosexuality, Male; Humans; Lamivudine; Male; Oxazines; Piperazines; Pyridones; Sexual and Gender Minorities; Viral Load | 2022 |
Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non
Topics: Anti-HIV Agents; Darunavir; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Prospective Studies; Pyridones; Ritonavir; RNA; Tenofovir; Viral Load; Zidovudine | 2022 |
Qualitative study exploring the experiences and perceptions of dolutegravir/lamivudine dual antiretroviral therapy (the PEDAL study) in people living with HIV: protocol.
Topics: Anti-HIV Agents; Drug Combinations; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Quality of Life | 2022 |
Brief Report: Impact of Antiretroviral Regimen on Pregnancy and Infant Outcomes in Women With HIV/ HBV Coinfection.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Coinfection; Emtricitabine; Female; Hepatitis B e Antigens; HIV Infections; Humans; Infant, Newborn; Lamivudine; Pregnancy; Pregnancy Outcome; Tenofovir; Zidovudine | 2022 |
72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Emtricitabine; Female; Follow-Up Studies; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Male; Oxazines; Piperazines; Postpartum Period; Pregnancy; Pyridones; Tenofovir; Viral Load | 2022 |
Tenofovir, Lamivudine, and Dolutegravir Among Rural Adolescents in Zimbabwe: A Cautionary Tale.
Topics: Adolescent; Adult; Anti-HIV Agents; Child; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Oxazines; Protease Inhibitors; Tenofovir; Viral Load; Young Adult; Zimbabwe | 2022 |
Brief Report: Efficacy and Safety of Oral Islatravir Once Daily in Combination With Doravirine Through 96 Weeks for Treatment-Naive Adults With HIV-1 Infection Receiving Initial Treatment With Islatravir, Doravirine, and Lamivudine.
Topics: Adult; Anti-HIV Agents; Deoxyadenosines; Drug Combinations; HIV Infections; HIV-1; Humans; Lamivudine; Pyridones; Reverse Transcriptase Inhibitors; RNA; Tenofovir; Triazoles | 2022 |
Six-Months Retention on Treatment and Attrition Risk Factors among People Living with HIV in Kibera Informal Settlement, Nairobi, Kenya.
Topics: Anti-HIV Agents; HIV Infections; Humans; Kenya; Lamivudine; Risk Factors | 2022 |
Efficacy and safety of 400 mg efavirenz versus standard 600 mg dose when taken with tenofovir and lamivudine combination in Indian adult patients with HIV-1 infection: An open-label, interventional, randomized, non-inferiority trial.
Topics: Adult; HIV Infections; HIV-1; Humans; India; Lamivudine; Tenofovir | 2022 |
Weight and Metabolic Changes After Switching From Tenofovir Alafenamide/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC + DTG, and TDF/FTC/Efavirenz to TDF/Lamivudine/DTG.
Topics: Adenine; Anti-HIV Agents; Benzoxazines; Emtricitabine; HIV Infections; Humans; Lamivudine; Tenofovir | 2023 |
Initial Supplementary Dose of Dolutegravir in Second-Line Antiretroviral Therapy: A Noncomparative, Double-Blind, Randomized Placebo-Controlled Trial.
Topics: Adult; Anti-Retroviral Agents; Benzoxazines; Emtricitabine; HIV Infections; Humans; Lamivudine; RNA; Tenofovir | 2023 |
Retention among transgender women treated with dolutegravir associated with tenofovir/lamivudine or emtricitabine in Argentina: TransViiV study.
Topics: Adult; Anti-Retroviral Agents; Argentina; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Prospective Studies; Pyridones; Tenofovir; Transgender Persons | 2023 |
Dolutegravir Plus 3TC in Virologically Suppressed PLWHIV: Immunological Outcomes in a Multicenter Retrospective Cohort in Spain during the COVID-19 Pandemic.
Topics: COVID-19; HIV Infections; Humans; Lamivudine; Pandemics; Retrospective Studies; Spain | 2023 |
No Meaningful Drug-Drug Interactions Are Associated with the Coadministration of ACC007, Lamivudine, and Tenofovir Disoproxil Fumarate.
Topics: Anti-HIV Agents; Cohort Studies; Drug Interactions; HIV Infections; Humans; Lamivudine; Tenofovir | 2023 |
Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial.
Topics: Adult; Anti-Retroviral Agents; Antitubercular Agents; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Infant; Isoniazid; Lamivudine; Rifampin; RNA; South Africa; Tenofovir; Tuberculosis; Viral Load | 2023 |
Decay of HIV RNA in Seminal Plasma and Rectal Fluid in Treatment-Naive Adults Starting Antiretroviral Therapy With Dolutegravir Plus Lamivudine or Bictegravir/Emtricitabine/Tenofovir Alafenamide.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Pyridones; RNA, Viral; Semen | 2023 |
Decay kinetics of HIV-1-RNA in seminal plasma with dolutegravir/lamivudine versus dolutegravir plus emtricitabine/tenofovir alafenamide in treatment-naive people living with HIV.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Kinetics; Lamivudine; Male; Oxazines; Pyridones; RNA, Viral; Semen | 2023 |
Changes in weight, body composition and metabolic parameters after switch to dolutegravir/lamivudine compared with continued treatment with dolutegravir/abacavir/lamivudine for virologically suppressed HIV infection (The AVERTAS trial): a randomised, open
Topics: Body Composition; Body Weight; Cardiovascular Diseases; Denmark; HIV Infections; Humans; Lamivudine; Quality of Life | 2023 |
Facilitators and barriers to infant post-natal HIV prophylaxis, a qualitative sub-study of the PROMISE-EPI trial in Lusaka, Zambia.
Topics: Female; Focus Groups; HIV Infections; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Post-Exposure Prophylaxis; Qualitative Research; Zambia | 2023 |
Evaluating immunological and inflammatory changes of treatment-experienced people living with HIV switching from first-line triple cART regimens to DTG/3TC
Topics: CD4-CD8 Ratio; HIV Infections; Humans; Interleukin-6; Lamivudine; Tenofovir | 2023 |
Safety of low dose efavirenz regimen in Indian adults with HIV-1 infection: Insights from a phase 4 interventional randomised trial.
Topics: Adult; Anti-HIV Agents; Benzoxazines; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Tenofovir; Treatment Outcome; Viral Load | 2023 |
Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations.
Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation; Pyridones; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Triazoles | 2019 |
A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naïve patients with CD4<200 cells/uL (the PRADAR study).
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Darunavir; Delayed Diagnosis; Dideoxynucleosides; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Raltegravir Potassium; Ritonavir | 2019 |
Bioequivalence and Food Effect Assessment of 2 Fixed-Dose Combination Formulations of Dolutegravir and Lamivudine.
Topics: Administration, Oral; Adult; Area Under Curve; Body Mass Index; Drug Therapy, Combination; Fasting; Female; Food; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Reverse Transcriptase Inhibitors; Safety; Therapeutic Equivalency | 2020 |
Association between HIV antiretroviral therapy and preterm birth based on antenatal ultrasound gestational age determination: a comparative analysis.
Topics: Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; Gestational Age; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Logistic Models; Lopinavir; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Premature Birth; Risk; Ritonavir; Tenofovir; Ultrasonography, Prenatal; Young Adult; Zidovudine | 2019 |
Durable Efficacy of Dolutegravir Plus Lamivudine in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: 96-Week Results From the GEMINI-1 and GEMINI-2 Randomized Clinical Trials.
Topics: Adolescent; Adult; Anti-HIV Agents; Double-Blind Method; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; RNA, Viral; Young Adult | 2020 |
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phas
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Pharmaceutical Preparations; Piperazines; Pyridones; Tenofovir; Treatment Outcome; Viral Load | 2020 |
Brief Report: Virologic Response by Baseline Viral Load With Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Analysis.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Tenofovir; Viral Load; Young Adult | 2020 |
Comparative Bioavailability of Oral Granule Formulations of the HIV Antiretroviral Drugs Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Biological Availability; Cross-Over Studies; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Pyridones; Reverse Transcriptase Inhibitors; Tablets; Tenofovir; Triazoles; Young Adult | 2020 |
Pharmacovirological analyses of blood and male genital compartment in patients receiving dolutegravir + lamivudine dual therapy as a switch strategy (ANRS 167 LAMIDOL trial).
Topics: Anti-HIV Agents; Chromatography, Liquid; Genitalia, Male; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Leukocytes, Mononuclear; Male; Oxazines; Piperazines; Pyridones; Tandem Mass Spectrometry; Viral Load | 2020 |
Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV Integrase Inhibitors; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Outcome Assessment, Health Care; Pregnancy; Pregnancy Complications, Infectious; Raltegravir Potassium; Viral Load; Young Adult; Zidovudine | 2020 |
Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO).
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; High-Throughput Nucleotide Sequencing; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation; Oxazines; Pilot Projects; Piperazines; Pyridones; RNA, Viral; Viral Load | 2020 |
Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir-containing regimens for initial treatment of HIV-1 infection: week 144 results from two randomised, double-blind, multicentre, phase 3, non-inferiority trials
Topics: Adenine; Adult; Aged; Alanine; Dideoxynucleosides; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; RNA, Viral; Tenofovir; Treatment Outcome; Young Adult | 2020 |
Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; Acyclic Monoterpenes; Adenine Nucleotides; Adhesins, Escherichia coli; Adipocytes; Adipocytes, Brown; Adipogenesis; Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adsorption; Adult; Aeromonas hydrophila; Africa; Aged; Aged, 80 and over; Agrobacterium tumefaciens; Air; Air Pollutants; Air Pollution; Air Pollution, Indoor; Algorithms; Alkaloids; Alkynes; Allosteric Regulation; Amines; Amino Acid Sequence; Amino Acids; Amino Acids, Branched-Chain; Aminoisobutyric Acids; Aminopyridines; Amyotrophic Lateral Sclerosis; Anaerobic Threshold; Angiography; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animal Distribution; Animal Feed; Animal Nutritional Physiological Phenomena; Animals; Ankle Joint; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Inflammatory Agents; Antibodies, Bacterial; Antifungal Agents; Antimalarials; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Antiretroviral Therapy, Highly Active; Antiviral Agents; Aotidae; Apelin; Apoptosis; Arabidopsis Proteins; Argentina; Arginine; Artemisinins; Arthritis, Experimental; Arthritis, Rheumatoid; Arthroscopy; Aspergillus; Aspergillus niger; Asteraceae; Asthma; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Auditory Cortex; Autoantibodies; Autophagy; Bacteria; Bacterial Infections; Bacterial Proteins; Bacterial Typing Techniques; Base Composition; Base Sequence; Basketball; Beclin-1; Benzhydryl Compounds; Benzimidazoles; Benzo(a)pyrene; Benzofurans; Benzoxazines; Bereavement; beta Catenin; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Betacoronavirus; Betaine; Binding Sites; Biofilms; Biological Assay; Biological Availability; Biological Evolution; Biomarkers; Biomechanical Phenomena; Biopolymers; Biopsy; Bismuth; Blood Glucose; Blood Platelets; Blood Pressure; Body Composition; Body Weight; Bone Marrow; Bone Marrow Cells; Bone Regeneration; Boron; Botrytis; Brain Ischemia; Brain Neoplasms; Brain-Derived Neurotrophic Factor; Brazil; Breast Neoplasms; Breath Tests; Bronchoalveolar Lavage Fluid; Burkholderia; C-Reactive Protein; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Calcification, Physiologic; Calcium; Calcium Signaling; Calorimetry, Differential Scanning; Cameroon; Camptothecin; Candida; Candida albicans; Capillaries; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Carbohydrate Conformation; Carbon; Carbon Dioxide; Carbon Isotopes; Carcinoma, Ovarian Epithelial; Cardiac Output; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Cardiovascular Diseases; Caregivers; Carps; Case-Control Studies; Catalase; Catalysis; Cats; CD4 Lymphocyte Count; Cell Culture Techniques; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Cellulose; Centrosome; Ceratopogonidae; Chickens; Child; China; Cholera Toxin; Choline; Cholinesterases; Chromatography, High Pressure Liquid; Chromatography, Liquid; Chromatography, Micellar Electrokinetic Capillary; Chromatography, Reverse-Phase; Chronic Disease; Cinnamates; Cities; Citrates; Climate Change; Clinical Trials, Phase III as Topic; Coal; Coal Mining; Cohort Studies; Coinfection; Colchicine; Colony Count, Microbial; Colorectal Neoplasms; Coloring Agents; Common Cold; Complement Factor H; Computational Biology; Computer Simulation; Continuous Positive Airway Pressure; Contrast Media; Coordination Complexes; Coronary Artery Bypass; Coronavirus 3C Proteases; Coronavirus Infections; Coronavirus Protease Inhibitors; Corynebacterium glutamicum; Cosmetics; COVID-19; Creatinine; Cross-Sectional Studies; Crotonates; Crystallography, X-Ray; Cues; Culicidae; Culture Media; Curcuma; Cyclopentanes; Cyclopropanes; Cymbopogon; Cystine; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Cytokines; Databases, Genetic; Death; Dendritic Cells; Density Functional Theory; Depsides; Diabetes Mellitus, Type 2; Diamond; Diarylheptanoids; Dibenzofurans; Dibenzofurans, Polychlorinated; Diclofenac; Diet; Dietary Carbohydrates; Dietary Supplements; Diffusion Magnetic Resonance Imaging; Dioxins; Diphenylamine; Disease Outbreaks; Disease Susceptibility; Disulfides; Dithiothreitol; Dizocilpine Maleate; DNA Methylation; DNA-Binding Proteins; DNA, Bacterial; Dogs; Dose-Response Relationship, Drug; Double-Blind Method; Doublecortin Protein; Drosophila melanogaster; Droughts; Drug Carriers; Drug Combinations; Drug Delivery Systems; Drug Liberation; Drug Resistance; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Dust; Dynactin Complex; Dysferlin; Echo-Planar Imaging; Echocardiography; Edaravone; Egypt; Elasticity; Electrodes; Electrolytes; Emodin; Emtricitabine; Endometriosis; Endothelium, Vascular; Endotoxins; Energy Metabolism; Energy Transfer; Enterobacteriaceae; Enterococcus faecalis; Enterotoxigenic Escherichia coli; Environmental Monitoring; Enzyme Inhibitors; Epidemiologic Factors; Epigenesis, Genetic; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Vaccines; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Esterases; Esterification; Ethanol; Ethiopia; Ethnicity; Eucalyptus; Evidence-Based Practice; Exercise; Exercise Tolerance; Extracorporeal Membrane Oxygenation; Family; Fatty Acids; Feedback; Female; Ferric Compounds; Fibrin Fibrinogen Degradation Products; Filtration; Fish Diseases; Flavonoids; Flavonols; Fluorodeoxyglucose F18; Follow-Up Studies; Food Microbiology; Food Preservation; Forests; Fossils; Free Radical Scavengers; Freund's Adjuvant; Fruit; Fungi; Gallium; Gender Identity; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Genes, Bacterial; Genes, Plant; Genetic Predisposition to Disease; Genitalia; Genotype; Glomerulonephritis, IGA; Glottis; Glucocorticoids; Glucose; Glucuronides; Glutathione Transferase; Glycogen Synthase Kinase 3 beta; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Grassland; Guinea Pigs; Half-Life; Head Kidney; Heart Atria; Heart Rate; Heart Septum; HEK293 Cells; Hematopoietic Stem Cells; Hemodynamics; Hep G2 Cells; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hepatocytes; Hesperidin; High-Frequency Ventilation; High-Temperature Requirement A Serine Peptidase 1; Hippocampus; Hirudins; History, 20th Century; History, 21st Century; HIV Infections; Homeostasis; Hominidae; Housing, Animal; Humans; Hydrocarbons, Brominated; Hydrogen Bonding; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydroxybutyrates; Hydroxyl Radical; Hypertension; Hypothyroidism; Image Interpretation, Computer-Assisted; Immunoconjugates; Immunogenic Cell Death; Indoles; Infant, Newborn; Infant, Premature; Infarction, Middle Cerebral Artery; Inflammation; Inflammation Mediators; Infrared Rays; Inhibitory Concentration 50; Injections, Intravenous; Interferon-gamma; Interleukin-23; Interleukin-4; Interleukin-6; Intermediate Filaments; Intermittent Claudication; Intestine, Small; Iridoid Glucosides; Iridoids; Iron; Isomerism; Isotope Labeling; Isoxazoles; Itraconazole; Kelch-Like ECH-Associated Protein 1; Ketoprofen; Kidney Failure, Chronic; Kinetics; Klebsiella pneumoniae; Lactams, Macrocyclic; Lactobacillus; Lactulose; Lakes; Lamivudine; Laparoscopy; Laparotomy; Laryngoscopy; Leucine; Limit of Detection; Linear Models; Lipid A; Lipopolysaccharides; Listeria monocytogenes; Liver; Liver Cirrhosis; Logistic Models; Longitudinal Studies; Losartan; Low Back Pain; Lung; Lupinus; Lupus Erythematosus, Systemic; Machine Learning; Macular Degeneration; Madin Darby Canine Kidney Cells; Magnetic Phenomena; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Magnetics; Malaria, Falciparum; Male; Mannans; MAP Kinase Signaling System; Mass Spectrometry; Melatonin; Membrane Glycoproteins; Membrane Proteins; Meniscectomy; Menisci, Tibial; Mephenytoin; Mesenchymal Stem Cells; Metal Nanoparticles; Metal-Organic Frameworks; Methionine; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Mice, Obese; Mice, Transgenic; Microbial Sensitivity Tests; Microcirculation; MicroRNAs; Microscopy, Video; Microtubules; Microvascular Density; Microwaves; Middle Aged; Minimally Invasive Surgical Procedures; Models, Animal; Models, Biological; Models, Molecular; Models, Theoretical; Molecular Docking Simulation; Molecular Structure; Molecular Weight; Morus; Mouth Floor; Multicenter Studies as Topic; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Muscle, Skeletal; Myocardial Ischemia; Myocardium; NAD; NADP; Nanocomposites; Nanoparticles; Naphthols; Nasal Lavage Fluid; Nasal Mucosa; Neisseria meningitidis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms, Experimental; Neural Stem Cells; Neuroblastoma; Neurofilament Proteins; Neurogenesis; Neurons; New York; NF-E2-Related Factor 2; NF-kappa B; Nicotine; Nitriles; Nitrogen; Nitrogen Fixation; North America; Observer Variation; Occupational Exposure; Ochrobactrum; Oils, Volatile; Olea; Oligosaccharides; Omeprazole; Open Field Test; Optimism; Oregon; Oryzias; Osmolar Concentration; Osteoarthritis; Osteoblasts; Osteogenesis; Ovarian Neoplasms; Ovariectomy; Oxadiazoles; Oxidation-Reduction; Oxidative Stress; Oxygen; Ozone; p38 Mitogen-Activated Protein Kinases; Pakistan; Pandemics; Particle Size; Particulate Matter; Patient-Centered Care; Pelargonium; Peptides; Perception; Peripheral Arterial Disease; Peroxides; Pets; Pharmaceutical Preparations; Pharmacogenetics; Phenobarbital; Phenols; Phenotype; Phosphates; Phosphatidylethanolamines; Phosphines; Phospholipids; Phosphorus; Phosphorylation; Photoacoustic Techniques; Photochemotherapy; Photosensitizing Agents; Phylogeny; Phytoestrogens; Pilot Projects; Plant Components, Aerial; Plant Extracts; Plant Immunity; Plant Leaves; Plant Oils; Plants, Medicinal; Plasmodium berghei; Plasmodium falciparum; Platelet Activation; Platelet Function Tests; Pneumonia, Viral; Poaceae; Pogostemon; Poloxamer; Poly I; Poly(ADP-ribose) Polymerase Inhibitors; Polychlorinated Biphenyls; Polychlorinated Dibenzodioxins; Polycyclic Compounds; Polyethylene Glycols; Polylysine; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Population Dynamics; Portasystemic Shunt, Transjugular Intrahepatic; Positron Emission Tomography Computed Tomography; Postoperative Complications; Postprandial Period; Potassium Cyanide; Predictive Value of Tests; Prefrontal Cortex; Pregnancy; Prepulse Inhibition; Prevalence; Procalcitonin; Prodrugs; Prognosis; Progression-Free Survival; Proline; Proof of Concept Study; Prospective Studies; Protein Binding; Protein Conformation; Protein Domains; Protein Folding; Protein Multimerization; Protein Sorting Signals; Protein Structure, Secondary; Proton Pump Inhibitors; Protozoan Proteins; Psychometrics; Pulse Wave Analysis; Pyridines; Pyrrolidines; Quality of Life; Quantum Dots; Quinoxalines; Quorum Sensing; Radiopharmaceuticals; Rain; Random Allocation; Randomized Controlled Trials as Topic; Rats; Rats, Sprague-Dawley; Rats, Wistar; RAW 264.7 Cells; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Receptor, PAR-1; Receptors, CXCR4; Receptors, Estrogen; Receptors, Glucocorticoid; Receptors, Interleukin-1; Receptors, Interleukin-17; Receptors, Notch; Recombinant Fusion Proteins; Recombinant Proteins; Reducing Agents; Reflex, Startle; Regional Blood Flow; Regression Analysis; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Tract Diseases; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Risk Assessment; Risk Factors; Rituximab; RNA, Messenger; RNA, Ribosomal, 16S; ROC Curve; Rosmarinic Acid; Running; Ruthenium; Rutin; Sarcolemma; Sarcoma; Sarcopenia; Sarcoplasmic Reticulum; SARS-CoV-2; Scavenger Receptors, Class A; Schools; Seasons; Seeds; Sequence Analysis, DNA; Severity of Illness Index; Sex Factors; Shock, Cardiogenic; Short Chain Dehydrogenase-Reductases; Signal Transduction; Silver; Singlet Oxygen; Sinusitis; Skin; Skin Absorption; Small Molecule Libraries; Smoke; Socioeconomic Factors; Soil; Soil Microbiology; Solid Phase Extraction; Solubility; Solvents; Spain; Spectrometry, Mass, Electrospray Ionization; Spectroscopy, Fourier Transform Infrared; Speech; Speech Perception; Spindle Poles; Spleen; Sporothrix; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Stomach Neoplasms; Stress, Physiological; Stroke Volume; Structure-Activity Relationship; Substrate Specificity; Sulfonamides; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Rate; T-Lymphocytes, Cytotoxic; Tandem Mass Spectrometry; Temperature; Tenofovir; Terpenes; Tetracycline; Tetrapleura; Textiles; Thermodynamics; Thiobarbituric Acid Reactive Substances; Thrombin; Thyroid Hormones; Thyroid Neoplasms; Tibial Meniscus Injuries; Time Factors; Tissue Distribution; Titanium; Toluidines; Tomography, X-Ray Computed; Tooth; Tramadol; Transcription Factor AP-1; Transcription, Genetic; Transfection; Transgender Persons; Translations; Treatment Outcome; Triglycerides; Ubiquinone; Ubiquitin-Specific Proteases; United Kingdom; United States; Up-Regulation; Vascular Stiffness; Veins; Ventricular Remodeling; Viral Load; Virulence Factors; Virus Replication; Vitis; Voice; Voice Quality; Wastewater; Water; Water Pollutants, Chemical; Water-Electrolyte Balance; Weather; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Young Adult; Zoogloea | 2022 |
Bone mineral density, kidney function, weight gain and insulin resistance in women who switch from TDF/FTC/NNRTI to ABC/3TC/DTG.
Topics: Adult; Anti-HIV Agents; Bone Density; Dideoxynucleosides; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Insulin Resistance; Kidney; Lamivudine; Middle Aged; Oxazines; Piperazines; Pyridones; Tenofovir; Weight Gain | 2021 |
Antiretroviral treatment and its impact on oral health outcomes in 5 to 7 year old Ugandan children: A 6 year follow-up visit from the ANRS 12174 randomized trial.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Case-Control Studies; Child; Child, Preschool; Dental Caries; Drug Therapy, Combination; Female; Gingivitis; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Male; Oral Health; Outcome Assessment, Health Care; Prevalence; Quality of Life; Ritonavir; Tooth Eruption; Uganda | 2020 |
Long-term efficacy of dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: Week 96 results of ART-PRO pilot study.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Pilot Projects; Piperazines; Pyridones; Retrospective Studies; Viral Load | 2021 |
New Insights on Long-Term Hepatitis B Virus Responses in HIV-Hepatitis B virus Co-infected Patients: Implications for Antiretroviral Management in Hepatitis B virus-Endemic Settings.
Topics: Adult; Alanine Transaminase; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Cohort Studies; Coinfection; DNA, Viral; Drug Resistance, Viral; Emtricitabine; Female; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Retrospective Studies; Uganda; Zimbabwe | 2021 |
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Emtricitabine; Fumarates; HIV Infections; HIV-1; Humans; Lamivudine; Pyridones; Tenofovir; Treatment Outcome; Triazoles | 2021 |
Pharmacokinetics and Safety of Zidovudine, Lamivudine, and Lopinavir/Ritonavir in HIV-infected Children With Severe Acute Malnutrition in Sub-Saharan Africa: IMPAACT Protocol P1092.
Topics: Africa South of the Sahara; Anti-HIV Agents; Area Under Curve; Child, Preschool; Chromatography, Liquid; Cohort Studies; Drug Combinations; Drug Elimination Routes; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; Humans; Infant; Lamivudine; Lopinavir; Male; Patient Safety; Ritonavir; Severe Acute Malnutrition; Tandem Mass Spectrometry; Zidovudine | 2021 |
Growth, clinical and neurodevelopmental outcomes at school age are similar for children who received 1-year lamivudine or lopinavir/ritonavir HIV prophylaxis in early life.
Topics: Anti-HIV Agents; Burkina Faso; Chemoprevention; Child; Child Development; Child, Preschool; Female; Follow-Up Studies; HIV Infections; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Male; Neuropsychological Tests; Ritonavir; South Africa; Surveys and Questionnaires; Uganda; Zambia | 2021 |
Efficacy, safety and central nervous system effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudine.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Central Nervous System; Cyclopropanes; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Pyridones; Tenofovir; Treatment Outcome; Triazoles | 2021 |
Brief Report: Improvement in Metabolic Health Parameters at Week 48 After Switching From a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen to the 2-Drug Regimen of Dolutegravir/Lamivudine: The TANGO Study.
Topics: Adult; Alanine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Blood Glucose; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Insulin Resistance; Lamivudine; Lipids; Metabolic Syndrome; Oxazines; Piperazines; Pyridones; Tenofovir; Viral Load; Weight Gain | 2021 |
Brief Report: Switching to DOR/3TC/TDF Maintains HIV-1 Virologic Suppression Through Week 144 in the DRIVE-SHIFT Trial.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Pyridones; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Triazoles; Weight Gain; Weight Loss | 2021 |
Design and challenges of a large HIV prevention clinical study on mother-to-child transmission: ANRS 12397 PROMISE-EPI study in Zambia and Burkina Faso.
Topics: Adolescent; Adult; Anti-HIV Agents; Breast Feeding; Burkina Faso; COVID-19; Cross-Sectional Studies; Female; HIV Infections; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Pandemics; Pre-Exposure Prophylaxis; Research Design; SARS-CoV-2; Viral Load; Young Adult; Zambia | 2021 |
Pharmacokinetic/pharmacodynamic investigation of raltegravir with or without lamivudine in the context of HIV-1 pre-exposure prophylaxis (PrEP).
Topics: Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Pre-Exposure Prophylaxis; Raltegravir Potassium | 2021 |
Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase 2b, randomised, double-blind, dose-ranging trial.
Topics: Adult; Anti-HIV Agents; Deoxyadenosines; Drug Dosage Calculations; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Pyridones; Triazoles; Young Adult | 2021 |
Pharmacokinetic-pharmacodynamic modelling of atazanavir in hair among adolescents on antiretroviral treatment in Zimbabwe.
Topics: Adolescent; Anti-Retroviral Agents; Atazanavir Sulfate; Caregivers; Female; Hair; HIV Infections; Humans; Lamivudine; Male; Medication Adherence; Models, Biological; Overweight; Ritonavir; Tenofovir; Thinness; Viral Load; Zimbabwe | 2021 |
Dolutegravir/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV.
Topics: Adult; Anti-HIV Agents; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Oxazines; Piperazines; Pyridones | 2021 |
Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial.
Topics: Adult; Anti-HIV Agents; Cholesterol, HDL; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones | 2021 |
Brief Report: Vaginal Viral Shedding With Undetectable Plasma HIV Viral Load in Pregnant Women Receiving 2 Different Antiretroviral Regimens: A Randomized Clinical Trial.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Pregnancy; Pregnancy Complications, Infectious; Pregnant Women; Raltegravir Potassium; Vigna; Viral Load; Virus Shedding; Zidovudine | 2021 |
Impact of Medication Adherence on Virologic Failure in A5202: A Randomized, Partially Blinded, Phase 3B Study.
Topics: Adult; Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Medication Adherence; RNA, Viral; Self Report; Tenofovir; Treatment Failure; Viral Load | 2017 |
Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; DNA, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Viral Load | 2017 |
Dolutegravir/abacavir/lamivudine versus current ART in virally suppressed patients (STRIIVING): a 48-week, randomized, non-inferiority, open-label, Phase IIIb study.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Canada; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Substitution; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; RNA, Viral; Treatment Outcome; United States; Viral Load | 2017 |
Insulin-Like Growth Factor Is Associated with Changes in Body Composition with Antiretroviral Therapy Initiation.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Body Composition; Cyclopropanes; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Insulin-Like Growth Factor I; Lamivudine; Male; Prospective Studies; Tenofovir; Zidovudine | 2017 |
Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Burkina Faso; Child, Preschool; Cote d'Ivoire; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Female; Genotype; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Lamivudine; Lopinavir; Male; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Outcome; Viral Load | 2017 |
Assessment of Nevirapine Prophylactic and Therapeutic Dosing Regimens for Neonates.
Topics: Anti-HIV Agents; Breast Feeding; Chemoprevention; Clinical Protocols; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Male; Nevirapine; Practice Guidelines as Topic; Pregnancy; Pregnancy Complications, Infectious; Thailand; World Health Organization; Zidovudine | 2017 |
Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial.
Topics: Adolescent; Adult; Africa South of the Sahara; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Public Health; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Outcome; Viral Load; Young Adult | 2017 |
Dolutegravir-lamivudine as initial therapy in HIV-1 infected, ARV-naive patients, 48-week results of the PADDLE (Pilot Antiretroviral Design with Dolutegravir LamivudinE) study.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Oxazines; Pilot Projects; Piperazines; Pyridones; Viral Load | 2017 |
Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-la
Topics: Adult; Africa South of the Sahara; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cameroon; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Senegal; Viral Load | 2017 |
Efficacy and safety of a once-daily single-tablet regimen of tenofovir, lamivudine, and efavirenz assessed at 144 weeks among antiretroviral-naïve and experienced HIV-1-infected Thai adults.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Prospective Studies; Tablets; Tenofovir; Thailand | 2017 |
Fixed-dose combination dolutegravir, abacavir, and lamivudine versus ritonavir-boosted atazanavir plus tenofovir disoproxil fumarate and emtricitabine in previously untreated women with HIV-1 infection (ARIA): week 48 results from a randomised, open-label
Topics: Adult; Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Middle Aged; Oxazines; Piperazines; Pyridones; Tenofovir; Treatment Outcome | 2017 |
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.
Topics: Adult; Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Female; Global Health; HIV Infections; HIV-1; Humans; Injections, Intramuscular; Lamivudine; Male; Pyridones; Reverse Transcriptase Inhibitors; Rilpivirine; Viral Load | 2017 |
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Topics: Adenine; Adult; Alanine; Amides; Anti-Retroviral Agents; Dideoxynucleosides; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Internationality; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Prognosis; Pyridones; Risk Assessment; Survival Rate; Tenofovir; Treatment Outcome; Young Adult | 2017 |
Changes in Liver Steatosis After Switching From Efavirenz to Raltegravir Among Human Immunodeficiency Virus-Infected Patients With Nonalcoholic Fatty Liver Disease.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Body Mass Index; Body Weight; Cyclopropanes; Dideoxynucleosides; Drug Substitution; Drug Therapy, Combination; Elasticity Imaging Techniques; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Raltegravir Potassium; Tenofovir; Triglycerides; Waist-Hip Ratio | 2017 |
Dual Therapy With Darunavir and Ritonavir Plus Lamivudine vs Triple Therapy With Darunavir and Ritonavir Plus Tenofovir Disoproxil Fumarate and Emtricitabine or Abacavir and Lamivudine for Maintenance of Human Immunodeficiency Virus Type 1 Viral Suppressi
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Darunavir; Dideoxynucleosides; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Medication Therapy Management; Middle Aged; Ritonavir; RNA, Viral; Tenofovir; Viral Load | 2017 |
Dolutegravir Plus Lamivudine Maintains Human Immunodeficiency Virus-1 Suppression Through Week 48 in a Pilot Randomized Trial.
Topics: Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Pilot Projects; Piperazines; Pyridones | 2018 |
Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial.
Topics: Adenine; Adult; Aged; Anti-Retroviral Agents; Dideoxynucleosides; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2018 |
Dolutegravir-based maintenance monotherapy versus dual therapy with lamivudine: a planned 24 week analysis of the DOLAM randomized clinical trial.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV Seropositivity; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation; Oxazines; Piperazines; Pyridones; RNA, Viral; Viral Load | 2018 |
Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Ritonavir; RNA, Viral; Treatment Failure; Treatment Outcome; Viral Load | 2018 |
Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Biomarkers; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Inflammation; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Viral Load | 2018 |
Neurocognitive safety after 96 weeks on dual therapy with atazanavir/ritonavir plus lamivudine: results of the neurocognitive substudy of the SALT randomized clinical trial.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Female; HIV Infections; Humans; Lamivudine; Longitudinal Studies; Male; Middle Aged; Neurocognitive Disorders; Ritonavir | 2018 |
Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phas
Topics: Adult; Aged; Amides; Anti-HIV Agents; Dideoxynucleosides; Double-Blind Method; Drug Substitution; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Sustained Virologic Response; Tenofovir; Viral Load; Young Adult | 2018 |
No difference in effectiveness of treatment simplification to boosted or unboosted atazanavir plus lamivudine in virologically suppressed in HIV-1-infected patients.
Topics: Adult; Atazanavir Sulfate; Disease-Free Survival; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation; RNA, Viral; Survival Rate | 2018 |
Similar neurocognitive outcomes after 48 weeks in HIV-1-infected participants randomized to continue tenofovir/emtricitabine + atazanavir/ritonavir or simplify to abacavir/lamivudine + atazanavir.
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cognition; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Interleukin-6; Lamivudine; Male; Memory, Short-Term; Middle Aged; Neuropsychological Tests; Prospective Studies; Ritonavir; Tenofovir | 2019 |
Immunovirological outcome and HIV-1 DNA decay in a small cohort of HIV-1-infected patients deintensificated from Abacavir/Lamivudine/Dolutegravir to Lamivudine plus Dolutegravir.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; Dideoxynucleosides; DNA, Viral; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Viral Load; Young Adult | 2018 |
Variability of efavirenz plasma concentrations among pediatric HIV patients treated with efavirenz based combination antiretroviral therapy in Dar es Salaam, Tanzania.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Biological Variation, Population; Child; Child, Preschool; Cyclopropanes; Drug Monitoring; Female; HIV Infections; Humans; Lamivudine; Male; Tanzania; Zidovudine | 2018 |
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferior
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Double-Blind Method; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; RNA, Viral; Tenofovir; Viral Load | 2019 |
Dolutegravir and lamivudine maintenance therapy in HIV-1 virologically suppressed patients: results of the ANRS 167 trial (LAMIDOL).
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Monitoring; Drug Resistance, Neoplasm; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Treatment Outcome; Viral Load; Young Adult | 2019 |
Dolutegravir Monotherapy Versus Dolutegravir/Abacavir/Lamivudine for Virologically Suppressed People Living With Chronic Human Immunodeficiency Virus Infection: The Randomized Noninferiority MONotherapy of TiviCAY Trial.
Topics: Adult; Anti-HIV Agents; Confidence Intervals; Dideoxynucleosides; Drug Resistance, Viral; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Mutation; Oxazines; Piperazines; Pyridones | 2019 |
Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500 000 copies/mL: week 48 outcomes from ACTG 5353.
Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Male; Mutation; Oxazines; Pilot Projects; Piperazines; Pyridones; RNA, Viral; Treatment Failure; Viral Load; Young Adult | 2019 |
Growth in HIV-1-exposed but uninfected infants treated with lopinavir-ritonavir versus lamivudine: a secondary analysis of the ANRS 12174 trial.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Ritonavir; Treatment Outcome; Viral Load; Young Adult | 2019 |
Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lamivudine; Male; Oxazines; Piperazines; Pyridones; Tenofovir; Treatment Outcome; Viral Load | 2019 |
Once-daily Doravirine in Human Immunodeficiency Virus Type 1-Infected, Antiretroviral-naive Adults: An Integrated Efficacy Analysis.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Emtricitabine; HIV Infections; HIV-1; Humans; Lamivudine; Pyridones; Treatment Outcome; Triazoles | 2020 |
Population pharmacokinetics of abacavir and lamivudine in severely malnourished human immunodeficiency virus-infected children in relation to treatment outcomes.
Topics: Anti-HIV Agents; Biological Availability; Body Weight; Child; Child Nutrition Disorders; Child, Preschool; Dideoxynucleosides; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Dosage Calculations; Female; Follow-Up Studies; HIV; HIV Infections; Humans; Infant; Lamivudine; Male; Models, Biological; Nutritional Support; Severity of Illness Index; South Africa; Time Factors; Time-to-Treatment; Treatment Outcome; Viral Load | 2019 |
A 24-week pilot study of dual maintenance therapy with raltegravir and lamivudine.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; Humans; Lamivudine; Maintenance Chemotherapy; Male; Middle Aged; Pilot Projects; Raltegravir Potassium; Treatment Outcome; Young Adult | 2019 |
Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1.
Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Male; Obesity; Oxazines; Piperazines; Pregnancy; Pyridones; RNA, Viral; Tenofovir; Viral Load; Weight Gain | 2019 |
Prevalence, clinical and virologic outcomes of hepatitis B virus co-infection in HIV-1 positive Kenyan women on antiretroviral therapy.
Topics: Adult; Alanine Transaminase; Anti-Retroviral Agents; CD4-Positive T-Lymphocytes; Cohort Studies; Coinfection; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B; HIV Infections; HIV-1; Humans; Kaplan-Meier Estimate; Kenya; Lamivudine; Logistic Models; Prevalence; Proportional Hazards Models; Prospective Studies; Sex Workers; Treatment Outcome | 2013 |
Abacavir/lamivudine versus tenofovir/emtricitabine with atazanavir/ritonavir for treatment-naive Japanese patients with HIV-1 infection: a randomized multicenter trial.
Topics: Adenine; Adult; Anti-HIV Agents; Antiviral Agents; Asian People; Atazanavir Sulfate; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Oligopeptides; Organophosphonates; Pilot Projects; Pyridines; Ritonavir; Tenofovir; Treatment Outcome | 2013 |
Pharmacokinetic interactions between lersivirine and zidovudine, tenofovir disoproxil fumarate/emtricitabine and abacavir/lamivudine.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug Interactions; Emtricitabine; Female; Healthy Volunteers; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Nitriles; Organophosphonates; Pyrazoles; Tenofovir; Young Adult; Zidovudine | 2013 |
Long-term body composition and metabolic changes in HIV-infected children switched from stavudine to tenofovir and from protease inhibitors to efavirenz.
Topics: Absorptiometry, Photon; Adenine; Adolescent; Alkynes; Anti-Retroviral Agents; Benzoxazines; Blood Glucose; Body Composition; Child; Child, Preschool; Cohort Studies; Cyclopropanes; Female; HIV Infections; Humans; Lamivudine; Linear Models; Lipids; Longitudinal Studies; Male; Organophosphonates; Stavudine; Tenofovir | 2013 |
A novel pharmacokinetic approach to predict virologic failure in HIV-1-infected paediatric patients.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Area Under Curve; Benzoxazines; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Child; Child, Preschool; Cyclopropanes; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Models, Theoretical; Predictive Value of Tests; Treatment Failure; Viral Load | 2013 |
Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Biomarkers; C-Reactive Protein; Carbamates; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Female; Fibrin Fibrinogen Degradation Products; Fibrinogen; Furans; HIV Infections; Humans; Interleukin-6; Lamivudine; Male; Middle Aged; Organophosphates; Plasminogen; Prospective Studies; Ritonavir; Sulfonamides; Vascular Cell Adhesion Molecule-1; Young Adult | 2013 |
Variability of raltegravir plasma levels in the clinical setting.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; HIV Infections; Humans; Lamivudine; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Tenofovir | 2013 |
96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Bone and Bones; Bone Density; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Kidney; Lamivudine; Male; Organophosphonates; Tenofovir; Time Factors; Treatment Outcome | 2013 |
A randomized clinical trial comparing metabolic parameters after 48 weeks of standard- and low-dose stavudine therapy and tenofovir disoproxil fumarate therapy in HIV-infected South African patients.
Topics: Adenine; Adult; Alkynes; Analysis of Variance; Anthropometry; Anti-HIV Agents; Benzoxazines; Biomarkers; Body Composition; Cyclopropanes; DNA, Mitochondrial; Dose-Response Relationship, Drug; Drug Substitution; Female; Glucose; HIV Infections; Humans; Inflammation; Lamivudine; Lipid Metabolism; Male; Middle Aged; Phosphorous Acids; South Africa; Stavudine | 2014 |
Dependence of efavirenz- and rifampicin-isoniazid-based antituberculosis treatment drug-drug interaction on CYP2B6 and NAT2 genetic polymorphisms: ANRS 12154 study in Cambodia.
Topics: Alkynes; Anti-HIV Agents; Antitubercular Agents; Aryl Hydrocarbon Hydroxylases; Arylamine N-Acetyltransferase; Benzoxazines; Cambodia; Chromatography, Liquid; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Interactions; HIV Infections; Humans; Isoniazid; Lamivudine; Plasma; Polymorphism, Single Nucleotide; Rifampin; Spectrophotometry, Ultraviolet; Stavudine; Tuberculosis | 2014 |
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Dideoxynucleosides; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Kaplan-Meier Estimate; Lamivudine; Male; Organophosphonates; Oxazines; Piperazines; Pyridones; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Tenofovir | 2013 |
Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
Topics: Adult; Aged; Aged, 80 and over; Anti-Retroviral Agents; Dideoxynucleosides; Double-Blind Method; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; RNA, Viral; Young Adult | 2013 |
A simplified combination antiretroviral therapy regimen enhances adherence, treatment satisfaction and quality of life: results of a randomized clinical trial.
Topics: Adult; Antiretroviral Therapy, Highly Active; Belgium; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Medication Adherence; Middle Aged; Netherlands; Odds Ratio; Patient Satisfaction; Quality of Life; Ritonavir; Zidovudine | 2014 |
24-Month adherence, tolerance and efficacy of once-a-day antiretroviral therapy with didanosine, lamivudine, and efavirenz in African HIV-1 infected children: ANRS 12103/12167.
Topics: Adolescent; Africa; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Preschool; Confidence Intervals; Cyclopropanes; Didanosine; Female; HIV Infections; Humans; Lamivudine; Male; Medication Adherence; RNA, Viral; Surveys and Questionnaires; Viral Load | 2013 |
Effectiveness of option B highly active antiretroviral therapy (HAART) prevention of mother-to-child transmission (PMTCT) in pregnant HIV women.
Topics: Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Counseling; Drug Administration Schedule; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Infusions, Intravenous; Kenya; Lamivudine; Medication Adherence; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; Socioeconomic Factors; Viral Load; Viremia; Young Adult; Zidovudine | 2014 |
HIV-1 genital shedding in HIV-infected patients randomized to second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; Follow-Up Studies; Genitalia; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Organophosphonates; Risk Factors; Ritonavir; Tenofovir; Time Factors; Treatment Outcome; Viral Load; Virus Shedding | 2014 |
High level of viral suppression and low switch rate to second-line antiretroviral therapy among HIV-infected adult patients followed over five years: retrospective analysis of the DART trial.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cross-Sectional Studies; Dideoxynucleosides; Drug Combinations; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Probability; Retrospective Studies; RNA, Viral; Tenofovir; Uganda; Viral Load; Zidovudine | 2014 |
HLA alleles association with changes in bone mineral density in HIV-1-infected adults changing treatment to tenofovir-emtricitabine or abacavir-lamivudine.
Topics: Adenine; Adult; Alleles; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Density; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; HLA-DQ Antigens; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir | 2014 |
Anthropometric measurements and lipid profiles to detect early lipodystrophy in antiretroviral therapy experienced HIV-infected children in the CHAPAS-3 trial.
Topics: Anthropometry; Anti-HIV Agents; Child; Child, Preschool; Cross-Sectional Studies; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lipid Metabolism; Lipodystrophy; Lipoproteins, HDL; Lipoproteins, LDL; Male; Nevirapine; Stavudine; Triglycerides; Viral Load; Zidovudine | 2014 |
Hip structural parameters over 96 weeks in HIV-infected adults switching treatment to tenofovir-emtricitabine or abacavir-lamivudine.
Topics: Adenine; Anti-HIV Agents; Bone Density; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug Substitution; Emtricitabine; Female; Hip Joint; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Radiography; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2014 |
Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial.
Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Brazil; Coinfection; Cyclopropanes; Drug Therapy, Combination; Female; France; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Tenofovir; Treatment Outcome; Tuberculosis; Viral Load | 2014 |
Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials.
Topics: Absorptiometry, Photon; Adolescent; Adult; Aged; Aged, 80 and over; Alkynes; Anti-HIV Agents; Benzoxazines; Body Fat Distribution; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Rilpivirine; Tenofovir; Young Adult; Zidovudine | 2014 |
Dual therapy with lopinavir and ritonavir plus lamivudine versus triple therapy with lopinavir and ritonavir plus two nucleoside reverse transcriptase inhibitors in antiretroviral-therapy-naive adults with HIV-1 infection: 48 week results of the randomise
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; Young Adult | 2014 |
Simplification to abacavir/lamivudine + atazanavir maintains viral suppression and improves bone and renal biomarkers in ASSURE, a randomized, open label, non-inferiority trial.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Biomarkers; Dideoxynucleosides; Drug Combinations; Female; HIV Infections; Humans; Lamivudine; Lipids; Male; Middle Aged; Oligopeptides; Pyridines; Treatment Outcome; Viral Load; Young Adult | 2014 |
Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Coinfection; Deoxycytidine; Drug Carriers; Emtricitabine; Female; Hepatitis B e Antigens; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Interferon-alpha; Lamivudine; Male; Middle Aged; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Tenofovir; Treatment Outcome; Viral Load | 2014 |
ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects.
Topics: Adult; Anti-HIV Agents; Cerebrospinal Fluid; Dideoxynucleosides; Drug Combinations; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Plasma; Pyridones; RNA, Viral; Treatment Outcome; Viral Load | 2014 |
First-line antiretroviral therapy with nevirapine versus lopinavir-ritonavir based regimens in a resource-limited setting.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2014 |
Changes in proteinuria and albuminuria with initiation of antiretroviral therapy: data from a randomized trial comparing tenofovir disoproxil fumarate/emtricitabine versus abacavir/lamivudine.
Topics: Adenine; Adult; Albuminuria; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Linear Models; Male; Organophosphonates; Proteinuria; Tenofovir | 2014 |
Pharmacokinetics of sifuvirtide in treatment-naive and treatment-experienced HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Didanosine; Double-Blind Method; Drug Combinations; Enfuvirtide; Female; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Peptide Fragments; Peptides; Ritonavir | 2014 |
Efficacy and safety of darunavir/ritonavir at 48 weeks in treatment-naïve, HIV-1-infected adolescents: results from a phase 2 open-label trial (DIONE).
Topics: Adolescent; Anemia; CD4 Lymphocyte Count; Darunavir; Dideoxynucleosides; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Medication Adherence; Nausea; Neutropenia; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Time Factors; Viral Load; Vomiting; Zidovudine | 2014 |
Pre-antiretroviral therapy serum selenium concentrations predict WHO stages 3, 4 or death but not virologic failure post-antiretroviral therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Body Mass Index; C-Reactive Protein; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Didanosine; Disease Progression; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Logistic Models; Male; Multivariate Analysis; Oligopeptides; Prospective Studies; Pyridines; Risk Factors; Selenium; World Health Organization; Zidovudine | 2014 |
Randomized pharmacokinetic evaluation of different rifabutin doses in African HIV- infected tuberculosis patients on lopinavir/ritonavir-based antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Antibiotics, Antitubercular; Black People; Coinfection; Cross-Over Studies; Drug Therapy, Combination; Female; HIV Infections; Humans; Isoniazid; Lamivudine; Lopinavir; Male; Neutropenia; Rifabutin; South Africa; Stavudine; Tuberculosis; Uveitis | 2014 |
A randomized controlled trial of single-class maintenance therapy with abacavir/lamivudine/zidovudine after standard triple antiretroviral induction therapy: final 96-week results from the FREE study.
Topics: Adult; Aged; Anti-HIV Agents; Belgium; CD4 Lymphocyte Count; Clinical Protocols; Dideoxynucleosides; Disease Progression; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lipids; Male; Middle Aged; Netherlands; Prospective Studies; RNA, Viral; Treatment Outcome; Viral Load; Zidovudine | 2015 |
Switching from zidovudine/lamivudine to tenofovir/emtricitabine improves fat distribution as measured by fat mass ratio.
Topics: Absorptiometry, Photon; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Fat Distribution; Drug Combinations; Drug Substitution; Emtricitabine; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Regression Analysis; Tenofovir; Zidovudine | 2015 |
A randomized comparative trial of continued abacavir/lamivudine plus efavirenz or replacement with efavirenz/emtricitabine/tenofovir DF in hypercholesterolemic HIV-1 infected individuals.
Topics: Adult; Alkynes; Benzoxazines; Cholesterol; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Hypercholesterolemia; Lamivudine; Male; Middle Aged; Tenofovir | 2015 |
Week 120 efficacy of tenofovir, lamivudine and lopinavir/r-based second-line antiretroviral therapy in treatment-experienced HIV patients.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; China; Cohort Studies; Drug Resistance, Viral; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Ritonavir; Tenofovir | 2015 |
In utero exposure to zidovudine and heart anomalies in the ANRS French perinatal cohort and the nested PRIMEVA randomized trial.
Topics: Adult; Anti-HIV Agents; Drug Combinations; Echocardiography; Female; Follow-Up Studies; France; Heart Defects, Congenital; Heart Septal Defects, Ventricular; HIV Infections; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Male; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimester, First; Sex Factors; Uterus; Young Adult; Zidovudine | 2015 |
Low risk of lamivudine-resistant HBV and hepatic flares in treated HIV-HBV-coinfected patients from Côte d'Ivoire.
Topics: Adult; Alanine Transaminase; Antiretroviral Therapy, Highly Active; Antiviral Agents; Aspartate Aminotransferases; Coinfection; Cote d'Ivoire; DNA, Viral; Drug Resistance, Viral; Emtricitabine; Female; Genotype; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; HIV-2; Humans; Lamivudine; Male; Prospective Studies; Tenofovir; Viral Load | 2015 |
Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a random
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Intention to Treat Analysis; Lamivudine; Lopinavir; Maintenance Chemotherapy; Male; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Viral Load | 2015 |
Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Drug Substitution; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Viral Load; Zidovudine | 2015 |
Pharmacokinetics of Raltegravir in HIV-Infected Patients on Rifampicin-Based Antitubercular Therapy.
Topics: Adult; Anti-HIV Agents; Antibiotics, Antitubercular; Coinfection; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Raltegravir Potassium; Rifampin; Tenofovir; Tuberculosis | 2015 |
The ASSURE study: HIV-1 suppression is maintained with bone and renal biomarker improvement 48 weeks after ritonavir discontinuation and randomized switch to abacavir/lamivudine + atazanavir.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Biomarkers; Bone Density; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Combinations; Drug Substitution; Female; HIV Infections; Humans; Kidney; Lamivudine; Lipids; Male; Middle Aged; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load | 2016 |
Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial.
Topics: Anti-HIV Agents; Dideoxynucleosides; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones | 2015 |
Emergence of Lamivudine-Resistant HBV during Antiretroviral Therapy Including Lamivudine for Patients Coinfected with HIV and HBV in China.
Topics: Adolescent; Adult; Anti-Retroviral Agents; China; Coinfection; Drug Resistance, Viral; Female; Hepatitis B; Hepatitis B virus; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Virus Replication; Young Adult | 2015 |
Safety of zidovudine dose reduction in treatment-naïve HIV infected patients. A randomized controlled study (MiniZID).
Topics: Adult; Anemia; Anti-HIV Agents; Cameroon; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Nevirapine; Prospective Studies; Treatment Outcome; Zidovudine | 2016 |
Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.
Topics: Adult; Anti-HIV Agents; Dideoxynucleosides; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Medication Adherence; Middle Aged; Ritonavir; South Australia; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2015 |
Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children (CHAPAS-3): an open-label, parallel-group, randomised controlled trial.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant; Lamivudine; Male; Nevirapine; Stavudine; Tablets; Uganda; Zambia; Zidovudine | 2016 |
Contribution of different antiretroviral regimens containing zidovudine, lamivudine and ritonavir-boosted lopinavir on HIV viral load reduction during pregnancy.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Pregnancy; Pregnancy Complications, Infectious; Ritonavir; Thailand; Viral Load; Zidovudine | 2016 |
Extended pre-exposure prophylaxis with lopinavir-ritonavir versus lamivudine to prevent HIV-1 transmission through breastfeeding up to 50 weeks in infants in Africa (ANRS 12174): a randomised controlled trial.
Topics: Africa South of the Sahara; Anti-HIV Agents; Breast Feeding; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Pre-Exposure Prophylaxis; Ritonavir | 2016 |
Associations between vitamin D metabolites, antiretroviral therapy and bone mineral density in people with HIV.
Topics: Adult; Anti-HIV Agents; Body Mass Index; Bone Density; Calcitriol; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Hip Joint; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Osteoporosis; Prospective Studies; Tenofovir; Vitamin D | 2016 |
Tipranavir/Ritonavir (500/200 mg and 500/100 mg) Was Virologically Non-Inferior to Lopinavir/Ritonavir (400/100 mg) at Week 48 in Treatment-Naïve HIV-1-Infected Patients: A Randomized, Multinational, Multicenter Trial.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Disease Progression; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Gastrointestinal Diseases; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Proportional Hazards Models; Pyridines; Pyrones; Ritonavir; Sulfonamides; Tenofovir; Young Adult | 2016 |
Proportion and factors associated with Hepatitis B viremia in antiretroviral treatment naïve and experienced HIV co-infected Ghanaian patients.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiviral Agents; Coinfection; Cross-Sectional Studies; Female; Ghana; Hepatitis B; Hepatitis B virus; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Tenofovir; Viral Load; Viremia; Young Adult | 2016 |
Exclusive Breast-feeding Protects against Mother-to-Child Transmission of HIV-1 through 12 Months of Age in Tanzania.
Topics: Adult; Anti-HIV Agents; Breast Feeding; Double-Blind Method; Female; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Male; Milk, Human; Mothers; Pregnancy; Pregnancy Complications, Infectious; Tanzania | 2016 |
Once vs twice-daily abacavir and lamivudine in African children.
Topics: Adolescent; Africa; Anti-HIV Agents; Child; Child, Preschool; Dideoxynucleosides; Drug Resistance, Viral; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; Humans; Immune Reconstitution; Infant; Lamivudine; Male; Medication Adherence; Sustained Virologic Response; Treatment Outcome | 2016 |
Longitudinal increase in vitamin D binding protein levels after initiation of tenofovir/lamivudine/efavirenz among individuals with HIV.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Bone Resorption; Cyclopropanes; Female; HIV Infections; Humans; Lamivudine; Longitudinal Studies; Male; Middle Aged; Plasma; Tenofovir; Vitamin D-Binding Protein; Young Adult | 2016 |
Improvement of BMD after Switching from Lopinavir/R Plus Two Nucleos(T)ide Reverse Transcriptase Inhibitors to Lopinavir/R Plus Lamivudine: OLE-LIP Substudy.
Topics: Adult; Antiretroviral Therapy, Highly Active; Bone Density; Bone Diseases; CD4 Lymphocyte Count; Drug Substitution; Female; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Reverse Transcriptase Inhibitors; Risk Factors; Viral Load | 2016 |
An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy.
Topics: Adult; Algorithms; Anti-HIV Agents; Cobicistat; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Oxazines; Patient Safety; Piperazines; Pyridones; Quinolones; Risk; Tenofovir | 2016 |
Bleeding patterns of HIV-infected women using an etonogestrel-releasing contraceptive implant and efavirenz-based or lopinavir/ritonavir-based antiretroviral therapy.
Topics: Adolescent; Adult; Alkynes; Amenorrhea; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Desogestrel; Drug Combinations; Drug Implants; Drug Interactions; Female; HIV Infections; Humans; Lamivudine; Lopinavir; Metrorrhagia; Prospective Studies; Ritonavir; Young Adult; Zidovudine | 2016 |
Drug-Drug Interaction between the Direct-Acting Antiviral Regimen of Ombitasvir-Paritaprevir-Ritonavir plus Dasabuvir and the HIV Antiretroviral Agent Dolutegravir or Abacavir plus Lamivudine.
Topics: 2-Naphthylamine; Adult; Anilides; Anti-HIV Agents; Anti-Retroviral Agents; Carbamates; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Drug Interactions; Female; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lactams, Macrocyclic; Lamivudine; Macrocyclic Compounds; Male; Middle Aged; Oxazines; Piperazines; Proline; Pyridones; Ritonavir; Sulfonamides; Uracil; Valine | 2016 |
Effectiveness and safety of generic version of abacavir/lamivudine and efavirenz in treatment naïve HIV-infected patients: a nonrandomized, open-label, phase IV study in Cali-Colombia, 2011-2012.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cardiovascular Diseases; Colombia; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Drugs, Generic; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Treatment Outcome; Viral Load | 2016 |
Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-lin
Topics: Absorptiometry, Photon; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Composition; CD4 Lymphocyte Count; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; International Cooperation; Lamivudine; Lopinavir; Male; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Viral Load | 2017 |
Efficacy and safety of tenofovir-containing antiretroviral therapy in women who acquired HIV while enrolled in tenofovir gel prophylaxis trials.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Emtricitabine; Female; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Patient Safety; Pregnancy; Primary Prevention; RNA, Viral; South Africa; Tenofovir; Treatment Outcome; Vaginal Creams, Foams, and Jellies; Viral Load; Zidovudine | 2017 |
Clinical experience with dolutegravir/abacavir/lamivudine in HIV-HCV co-infected patients treated with a sofosbuvir-based regimen-safety and efficacy.
Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Coinfection; Dideoxynucleosides; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Sofosbuvir; Treatment Outcome; Viral Load | 2016 |
Malaria in HIV-Infected Children Receiving HIV Protease-Inhibitor- Compared with Non-Nucleoside Reverse Transcriptase Inhibitor-Based Antiretroviral Therapy, IMPAACT P1068s, Substudy to P1060.
Topics: Antimalarials; CD4 Lymphocyte Count; Child; Child, Preschool; Coinfection; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant; Lamivudine; Lopinavir; Malaria, Falciparum; Malawi; Male; Nevirapine; Plasmodium falciparum; Reverse Transcriptase Inhibitors; Ritonavir; Viral Load; Zidovudine | 2016 |
Impact of peer support on virologic failure in HIV-infected patients on antiretroviral therapy - a cluster randomized controlled trial in Vietnam.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cluster Analysis; Counseling; Female; HIV Infections; Humans; Lamivudine; Male; Nevirapine; Peer Group; Social Support; Stavudine; Treatment Outcome; Vietnam; Viral Load | 2016 |
Switching from a ritonavir-boosted PI to dolutegravir as an alternative strategy in virologically suppressed HIV-infected individuals.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Density; Dideoxynucleosides; Drug Combinations; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lipids; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Ritonavir; Viral Load | 2017 |
Dose evaluation of lamivudine in human immunodeficiency virus-infected children aged 5 months to 18 years based on a population pharmacokinetic analysis.
Topics: Adolescent; Anti-HIV Agents; Area Under Curve; Biological Availability; Body Weight; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; HIV Infections; Humans; Infant; Lamivudine; Male; Models, Statistical; Population | 2017 |
Atherogenic properties of LDL particles after switching from Truvada or Kivexa plus lopinavir/r to lamivudine plus lopinavir/r: OLE-MET substudy.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biomarkers; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Combinations; Drug Substitution; Female; HIV Infections; Humans; Lamivudine; Lipid Metabolism; Lipids; Lipoproteins, LDL; Lopinavir; Male; Viral Load | 2017 |
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M).
Topics: Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Coinfection; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Ritonavir; RNA, Viral; Viral Load; Young Adult | 2017 |
Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients.
Topics: CD4 Lymphocyte Count; Comorbidity; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Prospective Studies; Pyridones; RNA, Viral; Treatment Outcome; Viral Load | 2017 |
Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; DNA Mutational Analysis; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Tenofovir; Time Factors; Treatment Outcome; Virus Replication | 2008 |
Changes in antioxidant profile among HIV-infected individuals on generic highly active antiretroviral therapy in southern India.
Topics: Adult; Albumins; Alkynes; Anti-HIV Agents; Antioxidants; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Therapy, Combination; Drugs, Generic; Female; Glutathione Peroxidase; Glutathione Reductase; HIV Infections; Humans; India; Lamivudine; Male; Oxidative Stress; Reverse Transcriptase Inhibitors; Stavudine; Uric Acid; Young Adult; Zidovudine | 2008 |
Lack of a significant drug interaction between raltegravir and tenofovir.
Topics: Adenine; Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2008 |
Switching from twice-daily abacavir and lamivudine to the once-daily fixed-dose combination tablet of abacavir and lamivudine improves patient adherence and satisfaction with therapy.
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Chi-Square Distribution; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Patient Compliance; Patient Satisfaction; Reverse Transcriptase Inhibitors; Statistics, Nonparametric; Viral Load | 2008 |
Steady-state pharmacokinetic comparison of generic and branded formulations of stavudine, lamivudine and nevirapine in HIV-infected Ugandan adults.
Topics: Adult; Anti-HIV Agents; Chromatography, High Pressure Liquid; Drugs, Generic; Female; HIV Infections; Humans; Lamivudine; Male; Nevirapine; Plasma; Spectrophotometry, Ultraviolet; Stavudine; Surveys and Questionnaires; Uganda | 2008 |
Zidovudine/lamivudine/abacavir plus tenofovir in HIV-infected naive patients: a 96-week prospective one-arm pilot study.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Endpoint Determination; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Pilot Projects; Prospective Studies; Spain; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2008 |
Effect of lopinavir/ritonavir monotherapy on quality of life and self-reported symptoms among antiretroviral-naive patients: results of the MONARK trial.
Topics: Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Pyrimidinones; Quality of Life; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Outcome; Viral Load; Zidovudine | 2008 |
Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Brachial Artery; CD4 Lymphocyte Count; Cyclopropanes; Endothelium, Vascular; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Organophosphonates; Prospective Studies; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Tenofovir; Time Factors; Zidovudine | 2008 |
A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; DNA, Viral; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Prospective Studies; Tenofovir; Thailand; Treatment Outcome; Zidovudine | 2008 |
Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Guanine; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Lamivudine; Linear Models; Male; Middle Aged; Single-Blind Method; Virus Replication | 2008 |
Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Prospective Studies; RNA, Viral; Severity of Illness Index; Treatment Outcome; Viral Load; Zidovudine | 2008 |
Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclopropanes; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Piperazines; Pyrimidines; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Viral Load; Zidovudine | 2008 |
Highly active antiretroviral therapy versus zidovudine/nevirapine effects on early breast milk HIV type-1 Rna: a phase II randomized clinical trial.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; HIV Seropositivity; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Milk, Human; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; RNA, Viral; Treatment Outcome; Zidovudine | 2008 |
Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone.
Topics: Adenine; Adult; Anti-HIV Agents; Blood; Cohort Studies; Deoxycytidine; Dideoxynucleosides; Emtricitabine; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Middle Aged; Multivariate Analysis; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Tenofovir; Treatment Outcome; Viral Load | 2008 |
Effectiveness and safety of didanosine, lamivudine and efavirenz versus zidovudine, lamivudine and efavirenz for the initial treatment of HIV-infected patients from the Spanish VACH cohort.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cohort Studies; Cyclopropanes; Didanosine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Prospective Studies; Spain; Treatment Outcome | 2009 |
Early antiretroviral therapy and mortality among HIV-infected infants.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Disease Progression; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Male; Pyrimidinones; Ritonavir; Treatment Failure; Zidovudine | 2008 |
High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.
Topics: Adenine; Adult; Amino Acid Substitution; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation, Missense; Nevirapine; Organophosphonates; Tenofovir; Treatment Outcome; Viral Load; Viral Proteins | 2009 |
[Two novel fixed formulations of nucleoside analogues (tenofovir-emtricitabine, and abacavir-lamivudine). Prospective, open study on clinical practice and therapeutic perspectives, in patients naïve and in subjects pre-treated with antiretrovirals].
Topics: Adenine; Adult; Antiviral Agents; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Prospective Studies; Reverse Transcriptase Inhibitors; Tenofovir | 2008 |
Efficacy and safety of adefovir dipivoxil plus pegylated interferon-alpha2a for the treatment of lamivudine-resistant hepatitis B virus infection in HIV-infected patients.
Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Reverse Transcriptase Inhibitors; Treatment Outcome | 2008 |
Virologic failure in first-line human immunodeficiency virus therapy with a CCR5 entry inhibitor, aplaviroc, plus a fixed-dose combination of lamivudine-zidovudine: nucleoside reverse transcriptase inhibitor resistance regardless of envelope tropism.
Topics: Anti-HIV Agents; Benzoates; Diketopiperazines; Drug Combinations; Drug Resistance, Viral; env Gene Products, Human Immunodeficiency Virus; HIV Infections; HIV-1; Humans; Lamivudine; Phylogeny; Piperazines; Receptors, CCR5; Reverse Transcriptase Inhibitors; Spiro Compounds; Treatment Failure; Tropism; Zidovudine | 2009 |
Steady state bioequivalence of generic and innovator formulations of stavudine, lamivudine, and nevirapine in HIV-infected Ugandan adults.
Topics: Adult; Anti-HIV Agents; Cross-Over Studies; Drugs, Generic; Drugs, Investigational; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Patient Compliance; Stavudine; Therapeutic Equivalency; Uganda | 2008 |
Viral dynamics of hepatitis B virus DNA in human immunodeficiency virus-1-hepatitis B virus coinfected individuals: similar effectiveness of lamivudine, tenofovir, or combination therapy.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biopsy; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B; Hepatitis B virus; HIV Infections; HIV-1; Humans; Immunosuppression Therapy; Lamivudine; Liver; Male; Middle Aged; Models, Biological; Organophosphonates; Prospective Studies; Tenofovir; Viral Load; Young Adult | 2009 |
Efficacy of non-nucleoside reverse transcriptase inhibitor-based highly active antiretroviral therapy in Thai HIV-infected children aged two years or less.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant; Lamivudine; Male; Nevirapine; Reverse Transcriptase Inhibitors; Stavudine; Thailand; Treatment Outcome | 2009 |
A randomized, open-label study of a nucleoside analogue reverse transcriptase inhibitor-sparing regimen in antiretroviral-naive HIV-infected patients.
Topics: Adult; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Male; Nevirapine; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Viral Load; Zidovudine | 2009 |
Abacavir/3TC vs. tenofovir/FTC: interim results from ACTG 5202.
Topics: Adenine; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2008 |
Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir.
Topics: Adenine; Adult; Anti-HIV Agents; Area Under Curve; Cross-Sectional Studies; Dideoxynucleosides; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Longitudinal Studies; Lopinavir; Male; Middle Aged; Organophosphonates; Pilot Projects; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome | 2009 |
Predictors of loss of virologic response in subjects who simplified to lopinavir/ritonavir monotherapy from lopinavir/ritonavir plus zidovudine/lamivudine.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Medication Adherence; Plasma; Pyrimidinones; Ritonavir; Time Factors; Treatment Outcome; Viral Load; Zidovudine | 2009 |
Changes in body composition with ritonavir-boosted and unboosted atazanavir treatment in combination with Lamivudine and Stavudine: a 96-week randomized, controlled study.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Body Composition; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Oligopeptides; Pyridines; Ritonavir; Stavudine | 2009 |
Comparison of once-daily fosamprenavir boosted with either 100 or 200 mg of ritonavir, in combination with abacavir/lamivudine: 96-week results from COL100758.
Topics: Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Resistance, Viral; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphates; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Treatment Outcome; Viral Load; Young Adult | 2009 |
A simplification trial switching from nucleoside reverse transcriptase inhibitors to once-daily fixed-dose abacavir/lamivudine or tenofovir/emtricitabine in HIV-1-infected patients with virological suppression.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Spain; Tenofovir; Treatment Failure; Treatment Outcome | 2009 |
A randomized trial of two-drug versus three-drug tenofovir-containing maintenance regimens in virologically controlled HIV-1 patients.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; France; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir; Treatment Outcome; Viral Load | 2009 |
First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Density; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Nevirapine; Osteoporosis; Pyrimidinones; Ritonavir; Young Adult; Zidovudine | 2009 |
Protease inhibitor resistance analysis in the MONARK trial comparing first-line lopinavir-ritonavir monotherapy to lopinavir-ritonavir plus zidovudine and lamivudine triple therapy.
Topics: Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Pyrimidinones; Ritonavir; Treatment Outcome; Zidovudine | 2009 |
Zidovudine/lamivudine for HIV-1 infection contributes to limb fat loss.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Biomarkers; Body Composition; Glucose; HIV Infections; HIV-1; Humans; Lamivudine; Lipids; Lipodystrophy; Lopinavir; Male; Middle Aged; Pyrimidinones; Zidovudine | 2009 |
Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen.
Topics: Absorptiometry, Photon; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Bone Density; Cyclopropanes; Female; HIV Infections; Humans; Inflammation Mediators; Lamivudine; Lopinavir; Male; Middle Aged; Osteoporosis; Prospective Studies; Pyrimidinones; Receptors, Tumor Necrosis Factor, Type I; Receptors, Tumor Necrosis Factor, Type II; Risk Factors; Ritonavir; Zidovudine | 2009 |
Switch from a ZDV/3TC-based regimen to a completely once daily (QD) regimen of emtricitabine/tenofovir DF fixed dose combination plus a third QD agent (SONETT).
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Drug Administration Schedule; Drug Combinations; Emtricitabine; Female; Hemoglobins; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Prospective Studies; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load; Young Adult; Zidovudine | 2009 |
Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cardiovascular Diseases; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Double-Blind Method; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Organophosphonates; Pyrimidinones; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome | 2009 |
A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals.
Topics: Adenine; Adipose Tissue; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Emtricitabine; Extremities; Female; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Lipids; Male; Middle Aged; Organophosphonates; Tenofovir; Young Adult; Zidovudine | 2009 |
Modulation of K65R selection by zidovudine inclusion: analysis of HIV resistance selection in subjects with virologic failure receiving once-daily abacavir/lamivudine/zidovudine and tenofovir DF (study COL40263).
Topics: Adenine; Adult; Amino Acid Substitution; Anti-HIV Agents; Dideoxynucleosides; Drug Administration Schedule; Drug Resistance, Multiple, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Pilot Projects; RNA, Viral; Tenofovir; Treatment Failure; Zidovudine | 2009 |
Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cross-Sectional Studies; DNA, Viral; Female; Genotype; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Mutation; Viral Load | 2009 |
Interindividual variability in pharmacokinetics of generic nucleoside reverse transcriptase inhibitors in TB/HIV-coinfected Ghanaian patients: UGT2B7*1c is associated with faster zidovudine clearance and glucuronidation.
Topics: Adult; AIDS-Related Opportunistic Infections; Drug Combinations; Drug Therapy, Combination; Drugs, Generic; Female; Ghana; Glucuronides; Glucuronosyltransferase; Half-Life; HIV Infections; Humans; Lamivudine; Liver; Male; Middle Aged; Polymorphism, Genetic; Reverse Transcriptase Inhibitors; Stavudine; Tuberculosis; Zidovudine | 2009 |
Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naïve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934.
Topics: Adenine; Alkynes; Amino Acid Substitution; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Genome, Viral; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Mutation, Missense; Organophosphonates; Tenofovir; Treatment Failure; Zidovudine | 2009 |
Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial.
Topics: Antiretroviral Therapy, Highly Active; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Intention to Treat Analysis; Lamivudine; Lopinavir; Male; Medication Adherence; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Treatment Outcome; Zidovudine | 2010 |
96-Week MERIT ES analysis shows efficacy of Celsentri=Selzentry.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CCR5 Receptor Antagonists; CD4 Lymphocyte Count; Cyclohexanes; Cyclopropanes; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Lamivudine; Maraviroc; Reverse Transcriptase Inhibitors; Time Factors; Treatment Outcome; Triazoles; Zidovudine | 2009 |
Raltegravir as effective as efavirenz in 144-week data.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Double-Blind Method; Drug Therapy, Combination; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; Reverse Transcriptase Inhibitors; Tenofovir; Time Factors; Treatment Outcome | 2009 |
Pharmacokinetics and 48 week efficacy of low-dose lopinavir/ritonavir in HIV-infected children.
Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Child; Child, Preschool; Female; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Plasma; Pyrimidinones; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load; Zidovudine | 2009 |
[Efficacy and safety of TAM-sparing antiretroviral regimens in naïve HIV-positive patients].
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Hyperinsulinism; Hyperlipidemias; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Prospective Studies; Tenofovir; Thymidine; Treatment Outcome; Young Adult | 2009 |
Simplification of antiretroviral therapy with tenofovir-emtricitabine or abacavir-Lamivudine: a randomized, 96-week trial.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; Female; HIV Infections; HLA-B Antigens; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir; Treatment Outcome; Viral Load | 2009 |
Efficacy of short-course AZT plus 3TC to reduce nevirapine resistance in the prevention of mother-to-child HIV transmission: a randomized clinical trial.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Mutation; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; Treatment Outcome; Viral Load; Zidovudine | 2009 |
Antiretroviral drug-resistant mutations at baseline and at time of failure of antiretroviral therapy in HIV type 1-coinfected TB patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Didanosine; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; India; Lamivudine; Male; Mutation; Nevirapine; Reverse Transcriptase Inhibitors; Treatment Failure; Tuberculosis | 2009 |
Insulin sensitivity in multiple pathways is differently affected during zidovudine/lamivudine-containing compared with NRTI-sparing combination antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Blood Glucose; Body Composition; Drug Therapy, Combination; HIV Infections; Humans; Insulin Resistance; Intra-Abdominal Fat; Lamivudine; Lipids; Lipolysis; Liver; Male; Middle Aged; Zidovudine | 2010 |
Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus Nevirapine and zidovudine-lamivudine plus Abacavir.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; Humans; Kaplan-Meier Estimate; Lamivudine; Male; Mutation; Nevirapine; RNA, Viral; Uganda; Viral Load; Zidovudine | 2010 |
Rates of virological failure in patients treated in a home-based versus a facility-based HIV-care model in Jinja, southeast Uganda: a cluster-randomised equivalence trial.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Community Health Services; Female; HIV; HIV Infections; Home Care Services; Humans; Lamivudine; Male; Nevirapine; Organophosphonates; Stavudine; Tenofovir; Uganda; Zidovudine | 2009 |
Similar antiviral efficacy and tolerability between efavirenz and lopinavir/ritonavir, administered with abacavir/lamivudine (Kivexa), in antiretroviral-naïve patients: a 48-week, multicentre, randomized study (Lake Study).
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Drug Hypersensitivity; Female; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Pyrimidinones; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load; Withholding Treatment | 2010 |
Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.
Topics: Adenine; Adolescent; Adult; Analysis of Variance; Anti-HIV Agents; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Double-Blind Method; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Female; Fractures, Bone; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; RNA, Viral; Tenofovir; Therapeutic Equivalency; Time Factors; Treatment Failure; Viral Load; Young Adult | 2009 |
Early versus delayed fixed dose combination abacavir/lamivudine/zidovudine in patients with HIV and tuberculosis in Tanzania.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Immune Reconstitution Inflammatory Syndrome; Lamivudine; Male; Pilot Projects; Tanzania; Tuberculosis; Viral Load; Zidovudine | 2009 |
Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial.
Topics: Adenine; Adolescent; Adult; Africa; Aged; Anemia; Anti-Retroviral Agents; CD4 Lymphocyte Count; Creatinine; Dideoxynucleosides; Disease Progression; Drug Monitoring; Female; Glomerular Filtration Rate; Hemoglobins; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Male; Middle Aged; Neutropenia; Neutrophils; Nevirapine; Organophosphonates; RNA, Viral; Tenofovir; Urea; Viral Load; Zidovudine | 2010 |
Abacavir-based therapy does not affect biological mechanisms associated with cardiovascular dysfunction.
Topics: Adenine; Adult; Anti-HIV Agents; Biomarkers; Cardiovascular Diseases; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lipids; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load | 2010 |
Adipocyte differentiation, mitochondrial gene expression and fat distribution: differences between zidovudine and tenofovir after 6 months.
Topics: Adenine; Adipocytes; Adipose Tissue; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cell Differentiation; Cyclopropanes; Drug Therapy, Combination; Fatty Acids; Female; Gene Expression; Genes, Mitochondrial; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Male; Mitochondria; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Up-Regulation; Zidovudine | 2009 |
The impact of once-nightly versus twice-daily dosing and baseline beliefs about HAART on adherence to efavirenz-based HAART over 48 weeks: the NOCTE study.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Culture; Cyclopropanes; Didanosine; Drug Combinations; Female; HIV Infections; Humans; Lamivudine; Male; Medication Adherence; Middle Aged; Surveys and Questionnaires; Zidovudine | 2010 |
Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts.
Topics: Adult; Body Weight; CD4 Lymphocyte Count; Dideoxynucleosides; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Medication Adherence; Middle Aged; Nevirapine; Recurrence; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Uganda; Viral Load; Zidovudine | 2010 |
Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Anti-Retroviral Agents; Antiviral Agents; Benzoxazines; CCR5 Receptor Antagonists; Cyclohexanes; Cyclopropanes; Double-Blind Method; Drug Combinations; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Maraviroc; Middle Aged; Receptors, CCR5; Treatment Outcome; Triazoles; Viral Load; Viral Tropism; Young Adult; Zidovudine | 2010 |
Mitochondrial changes during D-drug-containing once-daily therapy in HIV-positive treatment-naive patients.
Topics: Adenine; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cross-Sectional Studies; Cyclopropanes; Didanosine; Dideoxynucleosides; DNA, Mitochondrial; Drug Administration Schedule; Female; HIV; HIV Infections; Humans; Lamivudine; Male; Mitochondria; Organophosphonates; Reverse Transcriptase Inhibitors; RNA; RNA, Mitochondrial; Tenofovir | 2010 |
Pharmacokinetics of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian children.
Topics: Adolescent; Anti-HIV Agents; Body Weight; Child; Child, Preschool; Cross-Over Studies; Dosage Forms; Drug Administration Schedule; Drugs, Generic; Female; HIV; HIV Infections; Humans; Infant; Lamivudine; Malawi; Male; Nevirapine; Prospective Studies; Stavudine | 2010 |
Switch from protease inhibitor- to efavirenz-based antiretroviral therapy improves quality of life, treatment satisfaction and adherence with low rates of virological failure in virologically suppressed patients.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Patient Compliance; Patient Satisfaction; Quality of Life; Reverse Transcriptase Inhibitors; Treatment Outcome; United States; Viral Load | 2010 |
Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study.
Topics: Adenine; Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; beta 2-Microglobulin; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Kidney; Lamivudine; Male; Middle Aged; Organophosphonates; Retinol-Binding Proteins; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2010 |
A chewable pediatric fixed-dose combination tablet of stavudine, lamivudine, and nevirapine: pharmacokinetics and safety compared with the individual liquid formulations in human immunodeficiency virus-infected children in Thailand.
Topics: Administration, Oral; Anti-HIV Agents; Child; Child, Preschool; Cross-Over Studies; Female; HIV Infections; Humans; Infant; Lamivudine; Male; Nevirapine; Plasma; Stavudine; Tablets; Thailand | 2010 |
Analysis of drug resistance in children receiving antiretroviral therapy for treatment of HIV-1 infection in Uganda.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child, Preschool; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Molecular Sequence Data; Nevirapine; Prospective Studies; Reverse Transcriptase Inhibitors; Sequence Analysis, DNA; Stavudine; Treatment Outcome; Uganda | 2010 |
Efficacy and safety of unboosted atazanavir in combination with lamivudine and didanosine in naive HIV type 1 patients in Senegal.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oligopeptides; Pilot Projects; Pyridines; Reverse Transcriptase Inhibitors; RNA, Viral; Senegal; Treatment Outcome | 2010 |
Lack of minority K65R-resistant viral populations detected after repeated treatment interruptions of tenofovir/zidovudine and lamivudine in a resource-limited setting.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Combinations; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Lamivudine; Mutation; Viral Load; Zidovudine | 2010 |
Abacavir/lamivudine/zidovudine maintenance after standard induction in antiretroviral therapy-naïve patients: FREE randomized trial interim results.
Topics: Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Viral Load; Young Adult; Zidovudine | 2010 |
Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-<36 months.
Topics: Anti-HIV Agents; Child, Preschool; Dideoxynucleosides; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Infant; Lamivudine; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome | 2010 |
Maternal or infant antiretroviral drugs to reduce HIV-1 transmission.
Topics: Adult; Anti-Retroviral Agents; Breast Feeding; CD4 Lymphocyte Count; Drug Hypersensitivity; Drug Therapy, Combination; Female; HIV Infections; HIV Seronegativity; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Kaplan-Meier Estimate; Lamivudine; Male; Neutropenia; Nevirapine; Pregnancy; Risk Factors; Stevens-Johnson Syndrome; Young Adult; Zidovudine | 2010 |
Similar efficacy and tolerability of atazanavir compared with atazanavir/ritonavir, each with abacavir/lamivudine after initial suppression with abacavir/lamivudine plus ritonavir-boosted atazanavir in HIV-infected patients.
Topics: Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir; Treatment Outcome; Viral Load; Young Adult | 2010 |
Bone mineral density changes in protease inhibitor-sparing vs. nucleoside reverse transcriptase inhibitor-sparing highly active antiretroviral therapy: data from a randomized trial.
Topics: Absorptiometry, Photon; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Bone Density; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Pyrimidinones; Ritonavir; Zidovudine | 2011 |
Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial.
Topics: Anti-HIV Agents; Child, Preschool; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Male; Maternal Exposure; Nevirapine; Protease Inhibitors; Pyrimidinones; RNA, Viral; Stavudine; Treatment Outcome; Viremia | 2010 |
Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study.
Topics: Absorptiometry, Photon; Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Bone and Bones; Bone Density; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Europe; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir; Young Adult | 2010 |
Safety and effectiveness of antiretroviral drugs during pregnancy, delivery and breastfeeding for prevention of mother-to-child transmission of HIV-1: the Kesho Bora Multicentre Collaborative Study rationale, design, and implementation challenges.
Topics: Africa, Eastern; Africa, Southern; Africa, Western; Anti-Retroviral Agents; Breast Feeding; Child, Preschool; Clinical Protocols; Cohort Studies; Delivery, Obstetric; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Mothers; Nevirapine; Pregnancy; Pyrimidinones; Research Design; Ritonavir; Zidovudine | 2011 |
Strategies for nevirapine initiation in HIV-infected children taking pediatric fixed-dose combination "baby pills" in Zambia: a randomized controlled trial.
Topics: Alanine Transaminase; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; Child; Exanthema; HIV Infections; Humans; Lamivudine; Nevirapine; Stavudine; Zambia | 2010 |
Long-term effectiveness and safety of didanosine combined with lamivudine and efavirenz or nevirapine in antiretroviral-naive patients: a 9-year cohort study in Senegal.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Treatment Outcome; Viral Load; Zidovudine | 2011 |
Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and abacavir in HIV type-1-infected Ugandan children in the ARROW Trial.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Child; Child, Preschool; Confidence Intervals; Cross-Over Studies; Cyclopropanes; Dideoxynucleosides; Drug Administration Schedule; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Uganda | 2010 |
Effect of boosted fosamprenavir or lopinavir-based combinations on whole-body insulin sensitivity and lipids in treatment-naive HIV-type-1-positive men.
Topics: Adenine; Adipose Tissue; Adult; Anti-HIV Agents; Blood Glucose; Carbamates; Confidence Intervals; Drug Administration Schedule; Drug Combinations; Dyslipidemias; Furans; HIV Infections; HIV-1; Humans; Insulin; Insulin Resistance; Lamivudine; Lipids; Lopinavir; Male; Organophosphates; Organophosphonates; Pyrimidinones; Ritonavir; Sulfonamides; Tenofovir | 2010 |
Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy.
Topics: Adenine; Adult; Alkynes; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Organophosphonates; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Tenofovir; Treatment Failure; Viral Load | 2011 |
Fat tissue distribution changes in HIV-infected patients treated with lopinavir/ritonavir. Results of the MONARK trial.
Topics: Absorptiometry, Photon; Adult; Anti-HIV Agents; Body Fat Distribution; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Pyrimidinones; Ritonavir; Zidovudine | 2011 |
Tenofovir discontinuation could predispose to urolithiasis in atazanavir-treated patients.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Male; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Urolithiasis | 2011 |
Metabolic benefits of switching to tenofovir/lamivudine after long-term use of stavudine/lamivudine in NNRTI-based antiretroviral regimens: a prospective study.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Female; HIV Infections; Humans; Lamivudine; Lipid Metabolism; Male; Middle Aged; Organophosphonates; Prospective Studies; Stavudine; Tenofovir; Treatment Outcome | 2011 |
Open-label randomized multicenter selection study of once daily antiretroviral treatment regimen comparing ritonavir-boosted atazanavir to efavirenz with fixed-dose abacavir and lamivudine.
Topics: Acquired Immunodeficiency Syndrome; Adult; Alanine Transaminase; Alkynes; Anti-Retroviral Agents; Atazanavir Sulfate; Benzoxazines; Bilirubin; Cholesterol; Cyclopropanes; Dideoxynucleosides; Dose-Response Relationship, Drug; Drug Therapy, Combination; Follow-Up Studies; HIV Infections; Humans; Japan; Lamivudine; Oligopeptides; Pyridines; Ritonavir; Treatment Outcome | 2011 |
Beliefs about antiretroviral therapy, treatment adherence and quality of life in a 48-week randomised study of continuation of zidovudine/lamivudine or switch to tenofovir DF/emtricitabine, each with efavirenz.
Topics: Adenine; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Combinations; Drug Substitution; Drug Therapy, Combination; Emtricitabine; Female; Health Knowledge, Attitudes, Practice; HIV Infections; HIV-1; Humans; Lamivudine; Male; Medication Adherence; Middle Aged; Organophosphonates; Quality of Life; Tenofovir; Treatment Outcome; Young Adult; Zidovudine | 2011 |
Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)--associated tuberculous meningitis.
Topics: Adult; Alkynes; Anti-HIV Agents; Anti-Inflammatory Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; Benzoxazines; Cyclopropanes; Dexamethasone; Double-Blind Method; Female; HIV Infections; Humans; Lamivudine; Male; Placebos; Time Factors; Treatment Outcome; Trimethoprim, Sulfamethoxazole Drug Combination; Tuberculosis, Meningeal; Zidovudine | 2011 |
Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG
Topics: Absorptiometry, Photon; Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Bone Density; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; Fractures, Bone; HIV Infections; Humans; Intention to Treat Analysis; Lamivudine; Male; Middle Aged; Oligopeptides; Organophosphonates; Osteoporosis; Pyridines; Risk Factors; Ritonavir; Tenofovir; Viral Load | 2011 |
Low-density lipoprotein size and lipoprotein-associated phospholipase A2 in HIV-infected patients switching to abacavir or tenofovir.
Topics: Adenine; Adult; Anti-HIV Agents; Cardiovascular Diseases; Cholesterol, LDL; Clinical Protocols; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lipoproteins; Lipoproteins, LDL; Male; Middle Aged; Organophosphonates; Phospholipases A2; Reverse Transcriptase Inhibitors; Tenofovir | 2011 |
Lactic acidosis and symptomatic hyperlactataemia in a randomized trial of first-line therapy in HIV-infected adults in South Africa.
Topics: Acidosis, Lactic; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; Humans; Incidence; Lactates; Lamivudine; Male; Reverse Transcriptase Inhibitors; South Africa; Stavudine; Treatment Outcome | 2011 |
Randomized trial of time-limited interruptions of protease inhibitor-based antiretroviral therapy (ART) vs. continuous therapy for HIV-1 infection.
Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; HIV Infections; Lamivudine; Lopinavir; Protease Inhibitors; Ritonavir; Stavudine; Zidovudine | 2011 |
Residual activity of two HIV antiretroviral regimens prescribed without virological monitoring.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Lamivudine; Nevirapine; RNA, Viral; Viral Load; Zidovudine | 2011 |
A randomized trial of punctuated antiretroviral therapy in Ugandan HIV-seropositive adults with pulmonary tuberculosis and CD4⁺ T-cell counts of ≥ 350 cells/μL.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antitubercular Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Dideoxynucleosides; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Survival Analysis; Treatment Outcome; Tuberculosis, Pulmonary; Uganda; Young Adult; Zidovudine | 2011 |
Short-term virological efficacy, immune reconstitution, tolerance, and adherence of once-daily dosing of didanosine, lamivudine, and efavirenz in HIV-1-infected African children: ANRS 12103 Burkiname.
Topics: Alkynes; Benzoxazines; CD4 Lymphocyte Count; Child; Cyclopropanes; Didanosine; Female; HIV Infections; Humans; Lamivudine; Male; Patient Compliance; Reverse Transcriptase Inhibitors; Viral Load | 2011 |
HBV lamivudine resistance among hepatitis B and HIV coinfected patients starting lamivudine, stavudine and nevirapine in Kenya.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; HIV Infections; Humans; Kenya; Lamivudine; Male; Nevirapine; Stavudine; Treatment Outcome; Viral Load | 2011 |
Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Double-Blind Method; Emtricitabine; Female; HIV; HIV Infections; Humans; Kaplan-Meier Estimate; Lamivudine; Male; Middle Aged; Organophosphonates; RNA, Viral; Tenofovir; Viral Load | 2011 |
Pediatric underdosing of efavirenz: a pharmacokinetic study in Uganda.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Female; HIV Infections; Humans; Lamivudine; Male; Uganda | 2011 |
Evaluation of cardiovascular biomarkers in HIV-infected patients switching to abacavir or tenofovir based therapy.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biomarkers; Cardiovascular Diseases; Deoxycytidine; Dideoxynucleosides; E-Selectin; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Plasma; Tenofovir; Vascular Cell Adhesion Molecule-1 | 2011 |
Glomerular dysfunction and associated risk factors over 4-5 years following antiretroviral therapy initiation in Africa.
Topics: Adenine; Adult; Africa; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Creatinine; Dideoxynucleosides; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney Diseases; Kidney Glomerulus; Lamivudine; Male; Nevirapine; Organophosphonates; Risk Factors; Tenofovir; Time Factors; Zidovudine | 2011 |
Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; Rilpivirine; RNA, Viral; Stavudine | 2011 |
Predictors of limb fat gain in HIV positive patients following a change to tenofovir-emtricitabine or abacavir-lamivudine.
Topics: Adenine; Adipose Tissue; Adult; Biomarkers; Body Fat Distribution; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Extremities; HIV Infections; Humans; Lamivudine; Middle Aged; Organophosphonates; Predictive Value of Tests; Tenofovir | 2011 |
Pharmacokinetics and safety of a new paediatric fixed-dose combination of zidovudine/lamivudine/nevirapine in HIV-infected children.
Topics: Anti-HIV Agents; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Biological Availability; Body Weight; Child; Child, Preschool; Cytochrome P-450 CYP2B6; Drug Administration Schedule; Drug Combinations; Drug Dosage Calculations; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; HIV; HIV Infections; Humans; Infant; Lamivudine; Male; Nevirapine; Oxidoreductases, N-Demethylating; Reverse Transcriptase Inhibitors; Tablets; Zidovudine | 2011 |
Developmental pharmacokinetic changes of Lamivudine in infants and children.
Topics: Adolescent; Age Factors; Aging; Anti-HIV Agents; Area Under Curve; Child; Child, Preschool; Creatinine; HIV Infections; Humans; Infant; Infant, Newborn; Lamivudine; Models, Biological; Reverse Transcriptase Inhibitors | 2012 |
Presence of lamivudine or emtricitabine is associated with reduced emergence of nonnucleoside reverse transcriptase inhibitor mutations in an efavirenz-based intermittent antiretroviral treatment regimen.
Topics: Adult; Alkynes; Amino Acid Substitution; Anti-HIV Agents; Benzoxazines; Chromatography, High Pressure Liquid; Cyclopropanes; Deoxycytidine; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Half-Life; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Mutation; Reverse Transcriptase Inhibitors; Viral Load | 2012 |
Short-course Combivir after single-dose nevirapine reduces but does not eliminate the emergence of nevirapine resistance in women.
Topics: Anti-HIV Agents; Drug Combinations; Drug Resistance, Viral; Female; Genotype; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; RNA, Viral; Viral Load; Zidovudine | 2012 |
Post-exposure prophylaxis for HIV infection: a clinical trial comparing lopinavir/ritonavir versus atazanavir each with zidovudine/lamivudine.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Oligopeptides; Post-Exposure Prophylaxis; Pyridines; Ritonavir; Zidovudine | 2012 |
Treatment outcomes of recommended first-line antiretroviral regimens in resource-limited clinics.
Topics: Adenine; Adult; Age Factors; Anti-HIV Agents; CD4 Lymphocyte Count; Cross-Sectional Studies; Deoxycytidine; Developing Countries; Drug Costs; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Organophosphonates; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2012 |
Changes in body composition and mitochondrial DNA in HIV-1-infected patients switching to fixed-dose abacavir/lamivudine or tenofovir/emtricitabine: a substudy of the BICOMBO trial.
Topics: Adenine; Adult; Anti-HIV Agents; Body Composition; Bone Density; Deoxycytidine; Dideoxynucleosides; DNA, Mitochondrial; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir | 2012 |
Lipid profile changes in Thai HIV and tuberculosis co-infected patients receiving non-nucleoside reverse transcriptase inhibitors-based antiretroviral therapy.
Topics: Adolescent; Adult; Alkynes; Benzoxazines; Cholesterol, HDL; Coinfection; Cyclopropanes; Female; HIV Infections; Humans; Lamivudine; Lipids; Male; Middle Aged; Nevirapine; Prospective Studies; Reverse Transcriptase Inhibitors; Stavudine; Thailand; Triglycerides; Tuberculosis; Young Adult | 2012 |
A comparison of measured and estimated glomerular filtration rate in successfully treated HIV-patients with preserved renal function.
Topics: Adenine; Adult; Anti-HIV Agents; Body Mass Index; Deoxycytidine; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; Humans; Lamivudine; Linear Models; Male; Middle Aged; Netherlands; Organophosphonates; Pilot Projects; Research Design; Statistics, Nonparametric; Tenofovir; Treatment Outcome; Zidovudine | 2012 |
Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial.
Topics: Adenine; Adult; Alkaline Phosphatase; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biomarkers; Bone and Bones; Bone Density; Creatinine; Cystatin C; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Kidney; Kidney Function Tests; Lamivudine; Male; Middle Aged; Organophosphonates; Osteocalcin; Tenofovir; Time Factors; Treatment Outcome | 2012 |
Maternal and infant antiretroviral regimens to prevent postnatal HIV-1 transmission: 48-week follow-up of the BAN randomised controlled trial.
Topics: Adult; Anti-Retroviral Agents; Breast Feeding; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Nevirapine; Pregnancy; Young Adult; Zidovudine | 2012 |
Pharmacokinetics of nevirapine in HIV-infected children under 3 years on rifampicin-based antituberculosis treatment.
Topics: Anti-HIV Agents; Antibiotics, Antitubercular; Case-Control Studies; Child, Preschool; Coinfection; Female; HIV Infections; Humans; Infant; Lamivudine; Male; Nevirapine; Rifampin; Stavudine; Treatment Outcome; Tuberculosis; Zambia | 2012 |
Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial.
Topics: Abortion, Spontaneous; Adenine; Adult; Anti-HIV Agents; Body Height; Body Weight; Breast Feeding; Burns; Cause of Death; Child, Preschool; Congenital Abnormalities; Drug Combinations; Female; Follow-Up Studies; Fractures, Bone; Growth; HIV Infections; HIV Seropositivity; Humans; Infant; Infant Mortality; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Male; Measles; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Prevalence; Respiratory Tract Infections; Tenofovir; Uganda; Zidovudine; Zimbabwe | 2012 |
Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children.
Topics: Anti-Retroviral Agents; CD4 Lymphocyte Count; Child, Preschool; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant; Kaplan-Meier Estimate; Lamivudine; Lopinavir; Male; Nevirapine; Ritonavir; RNA, Viral; Zidovudine | 2012 |
Three postpartum antiretroviral regimens to prevent intrapartum HIV infection.
Topics: Anti-Retroviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant Formula; Infant, Newborn; Infectious Disease Transmission, Vertical; Kaplan-Meier Estimate; Lamivudine; Male; Nelfinavir; Nevirapine; Postpartum Period; Pregnancy; Pregnancy Complications, Infectious; Zidovudine | 2012 |
Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine.
Topics: Absorptiometry, Photon; Adenine; Adult; Bone Density; Bone Remodeling; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2012 |
Treatment outcomes among HIV-1 and HIV-2 infected children initiating antiretroviral therapy in a concentrated low prevalence setting in West Africa.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Child, Preschool; Cohort Studies; Cyclopropanes; Drug Combinations; Female; Follow-Up Studies; Gambia; HIV Infections; HIV-1; HIV-2; Humans; Infant; Kaplan-Meier Estimate; Lamivudine; Lopinavir; Male; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Outcome; Viral Load; Zidovudine | 2012 |
Tenofovir use and renal insufficiency among pregnant and general adult population of HIV-infected, ART-naïve individuals in Lilongwe, Malawi.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Body Mass Index; CD4 Lymphocyte Count; Creatinine; Cyclopropanes; Drug Combinations; Female; HIV Infections; Humans; Lamivudine; Malawi; Male; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Renal Insufficiency; Tenofovir | 2012 |
Switching to tenofovir/emtricitabine from abacavir/lamivudine in HIV-infected adults with raised cholesterol: effect on lipid profiles.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cholesterol; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug Substitution; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; HIV; HIV Infections; Humans; Lamivudine; Lipids; Lopinavir; Male; Medication Adherence; Middle Aged; Organophosphorus Compounds; Ritonavir; Treatment Outcome | 2012 |
Neurocognitive impairment in patients randomized to second-line lopinavir/ritonavir-based antiretroviral therapy vs. lopinavir/ritonavir monotherapy.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Cognition Disorders; Depression; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Viral Load | 2012 |
Inflammatory biomarker changes and their correlation with Framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/lamivudine/atazanavir with or without ritonavir in ARIES.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; Biomarkers; C-Reactive Protein; Coronary Disease; Dideoxynucleosides; Drug Combinations; Female; HIV Infections; Humans; Inflammation; Interleukin-6; Lamivudine; Lipids; Longitudinal Studies; Male; Middle Aged; Oligopeptides; Pyridines; Risk Assessment; Ritonavir; Treatment Outcome; Young Adult | 2013 |
Lopinavir/Ritonavir versus Lamivudine peri-exposure prophylaxis to prevent HIV-1 transmission by breastfeeding: the PROMISE-PEP trial Protocol ANRS 12174.
Topics: Africa; Anti-HIV Agents; Breast Feeding; Chemoprevention; Female; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Male; Pregnancy; Ritonavir; Treatment Outcome | 2012 |
Pharmacokinetic modelling of efavirenz, atazanavir, lamivudine and tenofovir in the female genital tract of HIV-infected pre-menopausal women.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Female; Genitalia, Female; HIV Infections; Humans; Lamivudine; Models, Biological; Oligopeptides; Organophosphonates; Premenopause; Pyridines; Reverse Transcriptase Inhibitors; Tenofovir | 2012 |
A randomized comparison of second-line lopinavir/ritonavir monotherapy versus tenofovir/lamivudine/lopinavir/ritonavir in patients failing NNRTI regimens: the HIV STAR study.
Topics: Adenine; Adult; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Male; Organophosphonates; Ritonavir; Tenofovir | 2012 |
Population-based sequencing of the V3-loop can predict the virological response to maraviroc in treatment-naive patients of the MERIT trial.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Cyclohexanes; Drug Combinations; Drug Therapy, Combination; Female; Genotype; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Lamivudine; Male; Maraviroc; Middle Aged; Polymerase Chain Reaction; Retrospective Studies; Sequence Analysis, DNA; Triazoles; Viral Load; Viral Tropism; Young Adult; Zidovudine | 2012 |
Anaemia in HIV-infected children: severity, types and effect on response to HAART.
Topics: Adolescent; Anemia; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; Cross-Sectional Studies; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Infant; Lamivudine; Logistic Models; Male; Nevirapine; Prevalence; Prospective Studies; Severity of Illness Index; Treatment Outcome; Uganda; Zidovudine | 2012 |
Therapeutic levels of lopinavir in late pregnancy and abacavir passage into breast milk in the Mma Bana Study, Botswana.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Botswana; Breast Feeding; Dideoxynucleosides; Female; HIV Infections; HIV-1; Humans; Infant; Lactation; Lamivudine; Lopinavir; Middle Aged; Milk, Human; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; Viral Load; Zidovudine | 2013 |
Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202.
Topics: Adenine; Adipose Tissue; Adult; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; DNA, Mitochondrial; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Male; Mitochondria; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Treatment Outcome | 2013 |
Metabolic abnormalities and body composition of HIV-infected children on Lopinavir or Nevirapine-based antiretroviral therapy.
Topics: Anti-HIV Agents; Body Composition; Child; Child, Preschool; Cross-Sectional Studies; Drug Therapy, Combination; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Infant; Insulin Resistance; Lamivudine; Lipids; Lopinavir; Male; Nevirapine; Ritonavir; South Africa; Stavudine | 2013 |
A 72-week randomized study of the safety and efficacy of a stavudine to zidovudine switch at 24 weeks compared to zidovudine or tenofovir disoproxil fumarate when given with lamivudine and nevirapine.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Diet; Drug Administration Schedule; Drug Substitution; Female; Glomerular Filtration Rate; Hemoglobins; HIV Infections; Humans; Lamivudine; Male; Nevirapine; Organophosphonates; Peripheral Nervous System Diseases; Stavudine; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2012 |
SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen.
Topics: Adenine; Adult; Aged; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Biomarkers; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Kaplan-Meier Estimate; Lamivudine; Male; Middle Aged; Organophosphonates; Prospective Studies; Protease Inhibitors; Proteinuria; Risk; Tenofovir | 2013 |
Switching to lopinavir/ritonavir with or without abacavir/lamivudine in lipoatrophic patients treated with zidovudine/abacavir/lamivudine.
Topics: Absorptiometry, Photon; Adipose Tissue; Adult; Antiretroviral Therapy, Highly Active; Atrophy; Body Composition; Chemistry, Pharmaceutical; Dideoxynucleosides; Female; HIV Infections; HIV Protease Inhibitors; Humans; Intention to Treat Analysis; Lamivudine; Lipids; Lipodystrophy; Lopinavir; Male; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Failure | 2013 |
Steady-state pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with end-stage renal disease receiving chronic dialysis.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Female; Half-Life; HIV Infections; Humans; Kidney Failure, Chronic; Lamivudine; Male; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Prospective Studies; Renal Dialysis; Reverse Transcriptase Inhibitors | 2002 |
Kinetics of CD4 cells after discontinuation of antiretroviral therapy in patients with virological failure and a CD4 cell count greater than 500 cells/microl.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Female; Genotype; HIV; HIV Infections; Humans; Lamivudine; Male; Mutation; RNA, Viral; Time Factors; Viral Load | 2002 |
Anti-HIV agents. Indinavir--3 years and still going strong.
Topics: Adipose Tissue; Adult; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Male; Viral Load; Zidovudine | 2000 |
The pharmacokinetics of amprenavir, zidovudine, and lamivudine in the genital tracts of men infected with human immunodeficiency virus type 1 (AIDS clinical trials group study 850).
Topics: Adult; Anti-HIV Agents; Carbamates; Drug Therapy, Combination; Furans; Genitalia, Male; HIV Infections; HIV-1; Humans; Lamivudine; Male; RNA, Viral; Semen; Statistics, Nonparametric; Sulfonamides; Zidovudine | 2002 |
Safety and efficacy of saquinavir soft-gelatin capsules + zidovudine + optional lamivudine in pregnancy and prevention of vertical HIV transmission.
Topics: Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Pregnancy; Pregnancy Complications, Infectious; Safety; Saquinavir; Thailand; United Kingdom; Viremia; Zidovudine | 2002 |
The pharmacokinetics of nelfinavir in HIV-1-infected children.
Topics: Administration, Oral; Anti-HIV Agents; Area Under Curve; Child; Child, Preschool; Chromatography, High Pressure Liquid; Cross-Over Studies; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Nelfinavir; Powders; Stavudine; Tablets | 2002 |
Adherence to antiretroviral therapy and outcomes in HIV-infected patients enrolled in an induction/maintenance randomized trial.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Male; Patient Compliance; RNA, Viral; Treatment Outcome; Zidovudine | 2002 |
A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study).
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Argentina; Cohort Studies; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Nevirapine; Reverse Transcriptase Inhibitors; RNA, Viral; Spain; Treatment Outcome; Zidovudine | 2002 |
Once-daily quadruple-drug therapy with adefovir dipivoxil, Lamivudine, Didanosine, and efavirenz in treatment-naive human immunodeficiency virus type 1-infected patients.
Topics: Adenine; Adult; Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Kidney Diseases; Lamivudine; Male; Organophosphonates; Oxazines; Pulse Therapy, Drug; Reverse Transcriptase Inhibitors; RNA, Viral; Time Factors; Treatment Outcome | 2002 |
The efficacy of combined zidovudine and lamivudine compared with that of combined zidovudine, lamivudine and nelfinavir in asymptomatic and early symptomatic HIV-infected children.
Topics: CD4 Lymphocyte Count; Child, Preschool; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Nelfinavir; Reverse Transcriptase Inhibitors; Thailand; Treatment Outcome; Viral Load; Zidovudine | 2002 |
Nevirapine or lamivudine plus stavudine and indinavir: examples of 2-class versus 3-class regimens for the treatment of human immunodeficiency virus type 1.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; Humans; Indinavir; Lamivudine; Male; Nevirapine; Outcome Assessment, Health Care; Stavudine | 2002 |
Efficacy and safety of a quadruple combination Combivir + abacavir + efavirenz regimen in antiretroviral treatment-naive HIV-1-infected adults: La Francilienne.
Topics: Administration, Oral; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; France; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Pilot Projects; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Viral Load; Zidovudine | 2002 |
Short-course therapy with zidovudine plus lamivudine for prevention of mother-to-child transmission of human immunodeficiency virus type 1 in Thailand.
Topics: Adolescent; Adult; Anti-HIV Agents; Drug Administration Schedule; Female; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Prospective Studies; Thailand; Zidovudine | 2002 |
Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Follow-Up Studies; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir; Virus Replication | 2002 |
Tenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failed.
Topics: Adenine; Adult; Alanine Transaminase; Antiviral Agents; Cohort Studies; Drug Therapy, Combination; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; HIV Infections; Humans; Interferon-alpha; Lamivudine; Liver Cirrhosis; Middle Aged; Organophosphonates; Organophosphorus Compounds; Pilot Projects; Tenofovir; Time Factors; Viral Load | 2002 |
Time-dependent changes in HIV nucleoside analogue phosphorylation and the effect of hydroxyurea.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Interactions; Drug Resistance, Viral; Female; HIV Infections; Humans; Hydroxyurea; Lamivudine; Leukocytes, Mononuclear; Male; Middle Aged; Nevirapine; Nucleosides; Phosphorylation; Reverse Transcriptase Inhibitors; Zidovudine | 2002 |
Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Constitution; Body Mass Index; Female; Follow-Up Studies; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Indinavir; Lamivudine; Male; Middle Aged; Risk Factors; Stavudine; Zidovudine | 2002 |
Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine or stavudine, each in combination with lamivudine and indinavir.
Topics: Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Male; Mutation; Patient Compliance; RNA, Viral; Stavudine; Viral Load; Zidovudine | 2002 |
Accumulation of mitochondrial DNA mutations in human immunodeficiency virus-infected patients treated with nucleoside-analogue reverse-transcriptase inhibitors.
Topics: Base Sequence; DNA Mutational Analysis; DNA Polymerase gamma; DNA Primers; DNA-Directed DNA Polymerase; DNA, Mitochondrial; DNA, Ribosomal; HIV Infections; Humans; Lamivudine; Molecular Sequence Data; Mutagenesis; Nucleic Acid Synthesis Inhibitors; Polymorphism, Single-Stranded Conformational; Reverse Transcriptase Inhibitors; RNA, Ribosomal; Stavudine; Time Factors | 2003 |
A multicenter randomized controlled trial of nevirapine versus a combination of zidovudine and lamivudine to reduce intrapartum and early postpartum mother-to-child transmission of human immunodeficiency virus type 1.
Topics: Adult; Anti-HIV Agents; Delivery, Obstetric; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Labor, Obstetric; Lamivudine; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors; Treatment Outcome; Zidovudine | 2003 |
Genotype and phenotype at baseline and at failure in human immunodeficiency virus-infected antiretroviral-naive patients in a randomized trial comparing zidovudine and lamivudine plus nelfinavir or nevirapine.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Argentina; Cohort Studies; Drug Therapy, Combination; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Middle Aged; Mutation; Nelfinavir; Nevirapine; Phenotype; Reverse Transcriptase Inhibitors; Spain; Treatment Failure; Zidovudine | 2003 |
Determining the relative efficacy of highly active antiretroviral therapy.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Organophosphonates; Organophosphorus Compounds; Oxazines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome | 2003 |
Greater reversal of CD4+ cell abnormalities and viral load reduction after initiation of antiretroviral therapy with zidovudine, lamivudine, and nelfinavir before complete HIV type 1 seroconversion.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Male; Nelfinavir; Prospective Studies; RNA, Viral; Viral Load; Zidovudine | 2003 |
A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients.
Topics: Adolescent; Adult; Aged; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Lipids; Male; Middle Aged; Nevirapine; Treatment Outcome | 2003 |
TRIZAL study: switching from successful HAART to Trizivir (abacavir-lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence results.
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Antiviral Agents; Chi-Square Distribution; Cholesterol; Dideoxynucleosides; Drug Combinations; Drug Hypersensitivity; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Protease Inhibitors; RNA, Viral; Statistics, Nonparametric; Triglycerides; Viral Load; Zidovudine | 2003 |
Salvage therapy with abacavir in HIV-1-infected patients with previously documented M184V mutation: a possibility of NRTI recycling.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Mutation; Pilot Projects; Reverse Transcriptase Inhibitors; RNA, Viral; Salvage Therapy; Viral Load | 2003 |
Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Reverse Transcriptase Inhibitors; RNA, Viral; Time Factors; Treatment Outcome; Zidovudine | 2003 |
Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients.
Topics: Adult; Body Composition; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Male; Middle Aged; Stavudine; Zidovudine | 2003 |
Effects of ritonavir on indinavir pharmacokinetics in cerebrospinal fluid and plasma.
Topics: Adult; Anti-HIV Agents; Blood-Brain Barrier; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Immunoglobulin G; Indinavir; Lamivudine; Male; Middle Aged; Ritonavir; Stavudine | 2003 |
Comparison of metabolic abnormalities 48 weeks after switching from highly active antiretroviral therapy containing a non-nucleoside reverse transcriptase inhibitor to Trizivir versus continued highly active antiretroviral therapy.
Topics: Antiretroviral Therapy, Highly Active; Cholesterol; Dideoxynucleosides; Drug Combinations; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Zidovudine | 2003 |
Feeding risk cut for HIV-infected women.
Topics: Anti-HIV Agents; Breast Feeding; Didanosine; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; Risk Factors; Rwanda; Uganda; Zidovudine | 2003 |
Clinical impact of the M184V mutation on switching to didanosine or maintaining lamivudine treatment in nucleoside reverse-transcriptase inhibitor-experienced patients.
Topics: Anti-HIV Agents; Didanosine; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Proportional Hazards Models; Reverse Transcriptase Inhibitors; RNA, Viral; Viral Load | 2003 |
Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors.
Topics: Anti-HIV Agents; Didanosine; Drug Resistance, Multiple; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 2003 |
Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Chromatography, High Pressure Liquid; Cytidine Triphosphate; Dideoxynucleotides; Female; Half-Life; HIV Infections; Humans; Immunoassay; Lamivudine; Male; Prospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Severity of Illness Index; Sex Factors; Zidovudine | 2003 |
Long-term efficacy, safety, and tolerability of indinavir-based therapy in protease inhibitor-naive adults with advanced HIV infection.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Diarrhea; Double-Blind Method; Drug Therapy, Combination; Fatigue; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Male; Middle Aged; RNA, Viral; Zidovudine | 2003 |
Impact of an educational program on efficacy and adherence with a twice-daily lamivudine/zidovudine/abacavir regimen in underrepresented HIV-infected patients.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Patient Compliance; Patient Education as Topic; RNA, Viral; Zidovudine | 2003 |
Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Follow-Up Studies; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; RNA, Viral; Treatment Outcome; Viral Load; Zidovudine | 2003 |
Field evaluation of an improved assay using a heat-dissociated p24 antigen for adults mainly infected with HIV-1 CRF02_AG strains in Côte d'Ivoire, West Africa.
Topics: Adolescent; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Cote d'Ivoire; Drug Combinations; Enzyme-Linked Immunosorbent Assay; HIV Antibodies; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Middle Aged; Prospective Studies; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Sensitivity and Specificity; Zidovudine | 2003 |
MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult AIDS Clinical Trials Group study.
Topics: Adult; Alleles; ATP Binding Cassette Transporter, Subfamily B, Member 1; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Drug Therapy, Combination; Female; Genes, MDR; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Polymorphism, Single Nucleotide; Retrospective Studies; Ritonavir; RNA, Viral; Zidovudine | 2003 |
Twice-daily Trizivir versus Combivir-abacavir in antiretroviral-experienced adults with human immunodeficiency virus-1 infection: a formulation-switch trial.
Topics: Adolescent; Adult; Analysis of Variance; Anti-HIV Agents; Chemistry, Pharmaceutical; Confidence Intervals; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; RNA, Viral; Zidovudine | 2003 |
Prospective randomized trial of emtricitabine versus lamivudine short-term monotherapy in human immunodeficiency virus-infected patients.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Deoxycytidine; Dose-Response Relationship, Drug; Emtricitabine; HIV Infections; Humans; Lamivudine; Middle Aged; Prospective Studies | 2003 |
Drug resistance mutations during structured treatment interruptions.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Administration Schedule; Drug Resistance, Viral; HIV Infections; HIV Protease; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Microbial Sensitivity Tests; Mutation; Reverse Transcriptase Inhibitors; RNA, Viral | 2003 |
A pilot study to evaluate the safety and feasibility of the administration of AZT/3TC fixed dose combination to HIV infected pregnant women and their infants in Rio de Janeiro, Brazil.
Topics: Administration, Oral; Adult; Anti-HIV Agents; Brazil; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant, Newborn; Lamivudine; Pilot Projects; Pregnancy; Pregnancy Complications, Infectious; Viral Load; Zidovudine | 2003 |
Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Oxazines; RNA, Viral; Stavudine; Time Factors; Treatment Failure; Zidovudine | 2003 |
Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Nelfinavir; Oxazines; Stavudine; Time Factors; Treatment Failure; Zidovudine | 2003 |
Meeting notes from the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Trizivir vs. efavirenz: results from ACTG 5095.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Oxazines; Placebos; Viral Load; Zidovudine | 2003 |
Change to abacavir-lamivudine-tenofovir combination treatment in patients with HIV-1 who had complete virological suppression.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load | 2003 |
Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects: 48-week results.
Topics: Acidosis, Lactic; Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Cholesterol, LDL; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Oligopeptides; Pyridines; RNA, Viral; Stavudine; Treatment Outcome; Triglycerides | 2003 |
TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Male; Nevirapine; Nitriles; Pyridazines; Pyrimidines; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Zidovudine | 2003 |
Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Area Under Curve; Carbamates; CD4 Lymphocyte Count; Cross-Over Studies; Dideoxynucleosides; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphates; RNA, Viral; Sulfonamides | 2004 |
Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.
Topics: Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Global Health; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Mutation; Nelfinavir; Patient Compliance; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Stavudine; Time Factors; Viral Load | 2004 |
The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Organophosphates; Reverse Transcriptase Inhibitors; RNA, Viral; Sulfonamides | 2004 |
Elective cesarean delivery plus short-course lamivudine and zidovudine for the prevention of mother-to-child transmission of human immunodeficiency virus type 1.
Topics: Adult; Anti-HIV Agents; Cesarean Section; Female; HIV Infections; HIV-1; Humans; Incidence; Infant, Newborn; Infant, Newborn, Diseases; Infectious Disease Transmission, Vertical; Lamivudine; Pregnancy; Pregnancy Complications, Infectious; Treatment Outcome; Viral Load; Zidovudine | 2004 |
Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Administration Schedule; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Prospective Studies; Pyrimidinones; Ritonavir; RNA, Viral; Stavudine; Time Factors | 2004 |
Rate of thymidine analogue resistance mutation accumulation with zidovudine- or stavudine-based regimens.
Topics: Drug Resistance, Multiple, Viral; HIV Infections; HIV-1; Humans; Lamivudine; Molecular Sequence Data; Mutation; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 2004 |
Pharmacokinetic characteristics of ritonavir, zidovudine, lamivudine, and stavudine in children with human immunodeficiency virus infection.
Topics: Adolescent; Anti-HIV Agents; Area Under Curve; Child; Child, Preschool; Drug Interactions; Drug Therapy, Combination; Female; Half-Life; HIV Infections; Humans; Lamivudine; Male; Metabolic Clearance Rate; Ritonavir; Stavudine; Zidovudine | 2004 |
Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection.
Topics: Adult; Aged; Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nucleosides; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Zidovudine | 2004 |
A proof-of-concept study of short-cycle intermittent antiretroviral therapy with a once-daily regimen of didanosine, lamivudine, and efavirenz for the treatment of chronic HIV infection.
Topics: Alanine Transaminase; Alkynes; Anti-HIV Agents; Aspartate Aminotransferases; Benzoxazines; Cholesterol; Cyclopropanes; Didanosine; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Polymerase Chain Reaction; RNA, Viral; Triglycerides | 2004 |
Long-term efficacy and safety of atazanavir with stavudine and lamivudine in patients previously treated with nelfinavir or atazanavir.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cholesterol; Cholesterol, LDL; Female; HIV Infections; Humans; Hyperlipidemias; Lamivudine; Lipids; Male; Nelfinavir; Oligopeptides; Pyridines; RNA, Viral; Safety; Stavudine; Time Factors; Triglycerides | 2004 |
Three-year durability of dual-nucleoside versus triple-nucleoside therapy in a Thai population with HIV infection.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Didanosine; Dideoxynucleosides; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Retrospective Studies; RNA, Viral; Stavudine; Thailand; Time Factors; Zidovudine | 2004 |
Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Nelfinavir; Predictive Value of Tests; Pyrimidinones; Risk Factors; Ritonavir; RNA, Viral; Sex Characteristics; Stavudine; Viral Load | 2004 |
A pilot study of once-daily antiretroviral therapy integrated with tuberculosis directly observed therapy in a resource-limited setting.
Topics: Administration, Oral; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Antiretroviral Therapy, Highly Active; Benzoxazines; Costs and Cost Analysis; Cyclopropanes; Didanosine; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Outpatient Clinics, Hospital; Oxazines; Pilot Projects; South Africa; Treatment Outcome; Tuberculosis; Urban Population | 2004 |
Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Double-Blind Method; Drug Administration Schedule; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Oligopeptides; Oxazines; Pyridines; RNA, Viral; Zidovudine | 2004 |
Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Double-Blind Method; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Oxazines; Prospective Studies; Stavudine; Tenofovir; Viral Load | 2004 |
Triple nucleoside treatment with abacavir plus the lamivudine/zidovudine combination tablet (COM) compared to indinavir/COM in antiretroviral therapy-naïve adults: results of a 48-week open-label, equivalence trial (CNA3014).
Topics: Adult; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Male; Patient Compliance; Reverse Transcriptase Inhibitors; RNA; Surveys and Questionnaires; Therapeutic Equivalency; Treatment Outcome; Zidovudine | 2004 |
Predictors of adherence and virologic outcome in HIV-infected patients treated with abacavir- or indinavir-based triple combination HAART also containing lamivudine/zidovudine.
Topics: Adult; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Male; Patient Compliance; Reverse Transcriptase Inhibitors; Risk Factors; Treatment Outcome; Zidovudine | 2004 |
Once-daily versus twice-daily lamivudine, in combination with zidovudine and efavirenz, for the treatment of antiretroviral-naive adults with HIV infection: a randomized equivalence trial.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Disease Progression; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Viral Load; Zidovudine | 2004 |
Impact of indinavir on the quality of life in patients with advanced HIV infection treated with zidovudine and lamivudine.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Male; Middle Aged; Quality of Life; Reverse Transcriptase Inhibitors; Sickness Impact Profile; Survival Analysis; Zidovudine | 2004 |
HIV-1 drug resistance in subjects with advanced HIV-1 infection in whom antiretroviral combination therapy is failing: a substudy of AIDS Clinical Trials Group Protocol 388.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Indinavir; Lamivudine; Male; Nelfinavir; Phenotype; Stavudine; Treatment Failure; Zidovudine | 2004 |
Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Oxazines; RNA, Viral; Zidovudine | 2004 |
Ninety-six-week efficacy of combination therapy with lamivudine and tenofovir in patients coinfected with HIV-1 and wild-type hepatitis B virus.
Topics: Adenine; Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; Hepatitis B; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir | 2004 |
The management of hepatitis B virus/HIV-1 co-infected patients starting their first HAART regimen. Treating two infections for the price of one drug?
Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Aspartate Aminotransferases; Hepatitis B; Hepatitis B virus; HIV Infections; HIV-1; Humans; Lamivudine; Liver; Male; Prospective Studies; Reverse Transcriptase Inhibitors; Treatment Outcome | 2004 |
Pharmacokinetics and safety of stavudine in HIV-infected pregnant women and their infants: Pediatric AIDS Clinical Trials Group protocol 332.
Topics: Adult; Amniotic Fluid; Anti-HIV Agents; Area Under Curve; Drug Therapy, Combination; Female; Half-Life; HIV; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Metabolic Clearance Rate; Pregnancy; Pregnancy Complications, Infectious; Stavudine; Viral Load | 2004 |
Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection.
Topics: Adenine; Adult; Drug Resistance, Viral; Female; Hepatitis B, Chronic; HIV Infections; Humans; Immunosuppressive Agents; Lamivudine; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2004 |
New once-daily HIV combination better tolerated.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Lamivudine; Organophosphonates; Oxazines; Tenofovir; Zidovudine | 2004 |
Persistent antiretroviral activity of nucleoside analogues after prolonged zidovudine and lamivudine therapy as demonstrated by rapid loss of activity after discontinuation.
Topics: Anti-HIV Agents; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Reverse Transcriptase Inhibitors; RNA, Viral; Time Factors; Treatment Outcome; Zidovudine | 2004 |
A randomized study of emtricitabine and lamivudine in stably suppressed patients with HIV.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Deoxycytidine; Emtricitabine; Female; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Male; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Viral Load | 2004 |
A randomized study comparing a three- and four-drug HAART regimen in first-line therapy (QUAD study).
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Viral Load; Zidovudine | 2005 |
Tolerability of postexposure prophylaxis with the combination of zidovudine-lamivudine and lopinavir-ritonavir for HIV infection.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Combinations; Female; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Pyrimidinones; Ritonavir; Viral Load; Zidovudine | 2005 |
Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine.
Topics: Adult; Anti-HIV Agents; Body Composition; Didanosine; Dideoxynucleosides; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Insulin; Insulin Resistance; Lamivudine; Lipids; Male; Middle Aged; Prospective Studies; Stavudine | 2005 |
Tenofovir regimen compared with Combivir.
Topics: Adenine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Europe; Female; Follow-Up Studies; HIV Infections; Humans; Lamivudine; Male; Maximum Tolerated Dose; Organophosphonates; Risk Assessment; Severity of Illness Index; Single-Blind Method; Tenofovir; Treatment Outcome; United States; Viral Load; Zidovudine | 2005 |
Impact of dyslipidemia associated with Highly Active Antiretroviral Therapy (HAART) on cardiovascular risk and life expectancy.
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cardiovascular Diseases; Female; HIV Infections; Humans; Hyperlipidemias; Lamivudine; Life Expectancy; Male; Markov Chains; Middle Aged; Nelfinavir; Oligopeptides; Pyridines; Risk Factors; Stavudine | 2005 |
Contribution of cellular HIV-1 DNA quantification to the efficacy analysis of antiretroviral therapy: a randomized comparison of 2 regimens, including 3 drugs from 2 or 3 classes (TRIANON, ANRS 081).
Topics: Adult; Anti-HIV Agents; DNA, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Leukocytes, Mononuclear; Male; Middle Aged; Nevirapine; Proviruses; RNA, Viral; Stavudine; Treatment Outcome | 2005 |
Plasma HIV-1 RNA decline within the first two weeks of treatment is comparable for nevirapine, efavirenz, or both drugs combined and is not predictive of long-term virologic efficacy: A 2NN substudy.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Kinetics; Lamivudine; Male; Nevirapine; Oxazines; Proportional Hazards Models; RNA, Viral; Stavudine; Treatment Outcome | 2005 |
Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study.
Topics: Adult; Alkynes; Analysis of Variance; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Stavudine | 2005 |
Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: results of the Ziagen Once Daily in Antiretroviral Combination Study.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Oxazines; RNA, Viral; Treatment Outcome; Viral Load | 2005 |
Clinical outcome of long-term lamivudine treated chronic HBV infected and HIV/HBV coinfected patients.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies; Reverse Transcriptase Inhibitors; Time Factors; Treatment Outcome | 2005 |
Plasma pharmacokinetics of once- versus twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1-infected children (PENTA-13).
Topics: Administration, Oral; Adolescent; Age Factors; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; Cross-Over Studies; Dideoxynucleosides; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Infant; Lamivudine; Male; Netherlands; United Kingdom | 2005 |
Pharmacokinetics of reduced-dose indinavir/ritonavir 400/100 mg twice daily in HIV-1-infected Thai patients.
Topics: Administration, Oral; Adult; Cohort Studies; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Hospitals; Humans; Indinavir; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Thailand | 2005 |
Field assessment of generic antiretroviral drugs: a prospective cohort study in Cameroon.
Topics: Adult; Anti-HIV Agents; Cameroon; CD4 Lymphocyte Count; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combination; Drugs, Generic; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Nevirapine; Prospective Studies; Stavudine; Treatment Outcome; Viral Load; Zidovudine | 2005 |
Better maintained adherence on switching from twice-daily to once-daily therapy for HIV: a 24-week randomized trial of treatment simplification using stavudine prolonged-release capsules.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Delayed-Action Preparations; Drug Administration Schedule; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Patient Compliance; Quality of Life; Reverse Transcriptase Inhibitors; Statistics, Nonparametric; Stavudine; Viral Load | 2005 |
Gender differences in health-related quality of life in patients with HIV/AIDS.
Topics: Adult; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Placebos; Quality of Life; Reverse Transcriptase Inhibitors; Sex Factors; Stavudine; United States | 2005 |
Spontaneous recovery of hemoglobin and neutrophil levels in Japanese patients on a long-term Combivir containing regimen.
Topics: Adult; Aged; Anti-HIV Agents; Drug Combinations; Drug Therapy, Combination; Female; Hemoglobins; HIV Infections; Humans; Japan; Lamivudine; Leukocyte Count; Male; Middle Aged; Neutrophils; Reverse Transcriptase Inhibitors; Time Factors; Treatment Outcome; Zidovudine | 2005 |
The efficacy and adverse effects of GPO-VIR (stavudine+lamivudine+nevirapine) in treatment-naïve adult HIV patients.
Topics: Adolescent; Adult; Age Factors; Aged; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Weight; CD4 Lymphocyte Count; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Stavudine | 2005 |
Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Patient Compliance; RNA, Viral; Zidovudine | 2005 |
Antiretroviral treatment simplification with 3 NRTIs or 2 NRTIs plus nevirapine in HIV-1-infected patients treated with successful first-line HAART.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Nevirapine; Patient Compliance; Patient Satisfaction; Prospective Studies; Quality of Life; Reverse Transcriptase Inhibitors; RNA, Viral; Zidovudine | 2005 |
Comparative selection of the K65R and M184V/I mutations in human immunodeficiency virus type 1-infected patients enrolled in a trial of first-line triple-nucleoside analog therapy (Tonus IMEA 021).
Topics: Adenine; Dideoxynucleosides; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Mutation; Organophosphonates; Pilot Projects; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; RNA, Viral; Sequence Analysis, Protein; Tenofovir; Treatment Failure; Viral Load | 2005 |
Results of the ALBI trial: a randomized comparison of stavudine/didanosine, zidovudine/lamivudine and alternating treatment in antiretroviral-naive patients.
Topics: Anti-HIV Agents; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Treatment Outcome; Viral Load; Zidovudine | 1999 |
Stavudine, lamivudine plus novel protease inhibitor therapy in antiretroviral-naive HIV-infected individuals treated for 24 weeks.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Stavudine; Treatment Outcome; Viral Load | 1999 |
An open-label trial of stavudine, lamivudine and efavirenz in the treatment of HIV-positive, treatment-naive patients, and implications for clinical practice.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Treatment Outcome; Viral Load | 1999 |
Effects on immunological and virological outcome of patients using one protease inhibitor or one non-nucleoside reverse transcriptase inhibitor in a triple antiretroviral therapy: normal clinical practice versus clinical trial findings.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Male; Oxazines; Retrospective Studies; Treatment Outcome; Tunisia; Viremia; Zidovudine | 2005 |
Antiretroviral concentrations in breast-feeding infants of women in Botswana receiving antiretroviral treatment.
Topics: Adult; Anti-HIV Agents; Botswana; Breast Feeding; Female; HIV Infections; HIV-1; Humans; Infant; Infectious Disease Transmission, Vertical; Lactation; Lamivudine; Milk, Human; Nevirapine; Reverse Transcriptase Inhibitors; Statistics, Nonparametric; Zidovudine | 2005 |
Management of HIV-1 infection with a combination of nevirapine, stavudine, and lamivudine: a preliminary report on the Nigerian antiretroviral program.
Topics: Academies and Institutes; Administration, Oral; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Drug Therapy, Combination; Exanthema; Government Programs; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Nigeria; Prospective Studies; RNA, Viral; Stavudine; Treatment Outcome; Viral Load | 2005 |
Ritonavir-based highly active antiretroviral therapy in human immunodeficiency virus type 1-infected infants younger than 24 months of age.
Topics: Age Factors; Antiretroviral Therapy, Highly Active; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Lamivudine; Male; Maximum Tolerated Dose; Prospective Studies; Risk Assessment; Ritonavir; Severity of Illness Index; Single-Blind Method; Survival Rate; Treatment Outcome; Zidovudine | 2005 |
Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Nevirapine; Pilot Projects; RNA, Viral; Spain | 2005 |
Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with human immunodeficiency virus-hepatitis C virus coinfection: results of a randomized clinical study.
Topics: Adult; Area Under Curve; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Reverse Transcriptase Inhibitors; Ribavirin; Stavudine; Time Factors; Zidovudine | 2005 |
Brain mitochondrial injury in human immunodeficiency virus-seropositive (HIV+) individuals taking nucleoside reverse transcriptase inhibitors.
Topics: Adult; Aspartic Acid; Brain; Cell Respiration; Didanosine; Female; HIV Infections; Humans; Lamivudine; Magnetic Resonance Spectroscopy; Male; Middle Aged; Mitochondria; Mitochondrial Diseases; Reverse Transcriptase Inhibitors; Stavudine; Treatment Outcome; Zidovudine | 2005 |
Once-daily regimen of saquinavir, ritonavir, didanosine, and lamivudine in HIV-infected patients with standard tuberculosis therapy (TBQD Study).
Topics: Adult; Anti-HIV Agents; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Pilot Projects; Ritonavir; Saquinavir; Spain; Treatment Outcome; Tuberculosis | 2005 |
Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Time Factors; Treatment Failure | 2005 |
Abacavir and lamivudine fixed-dose combination tablet once daily compared with abacavir and lamivudine twice daily in HIV-infected patients over 48 weeks (ESS30008, SEAL).
Topics: Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Combinations; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Treatment Refusal; Viral Load | 2005 |
Patients experiencing early virologic failure on a protease inhibitor- or nonnucleoside reverse transcriptase inhibitor-based initial regimen containing a thymidine analogue and Lamivudine can be successfully treated with a quadruple-nucleoside regimen.
Topics: Antiretroviral Therapy, Highly Active; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Patient Selection; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Treatment Failure; Treatment Outcome; Viral Load | 2006 |
A randomized crossover study to determine bioequivalence of generic and brand name nevirapine, zidovudine, and lamivudine in HIV-negative women in India.
Topics: Administration, Oral; Adult; Anti-HIV Agents; Cohort Studies; Confidence Intervals; Cross-Over Studies; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Drugs, Generic; Female; HIV Infections; HIV Seronegativity; Humans; India; Lamivudine; Nevirapine; Tablets; Therapeutic Equivalency; Zidovudine | 2006 |
A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Black or African American; CD4 Lymphocyte Count; Cholesterol; Dideoxynucleosides; Drug Combinations; Female; Hispanic or Latino; HIV Infections; HIV-1; Humans; Hyperlipidemias; Lactic Acid; Lamivudine; Male; Nelfinavir; Nevirapine; Prospective Studies; Sex Factors; Stavudine; Treatment Outcome; Triglycerides; Zidovudine | 2006 |
Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
Topics: Adenine; Adolescent; Adult; Aged; Alkynes; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Deoxycytidine; Emtricitabine; Female; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Oxazines; Prospective Studies; RNA, Viral; Tenofovir; Zidovudine | 2006 |
Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
Topics: Administration, Oral; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Administration Schedule; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hypercholesterolemia; Hyperglycemia; Hypertriglyceridemia; Indinavir; Lamivudine; Male; Ritonavir; RNA, Viral; Stavudine; Thailand; Treatment Outcome; Viral Load; Withholding Treatment | 2005 |
Increased antiretroviral potency by the addition of enfuvirtide to a four-drug regimen in antiretroviral-naive, HIV-infected patients.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Synergism; Drug Therapy, Combination; Enfuvirtide; HIV Envelope Protein gp41; HIV Fusion Inhibitors; HIV Infections; Humans; Lamivudine; Lopinavir; Organophosphonates; Oxazines; Patient Compliance; Peptide Fragments; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Treatment Outcome | 2006 |
An open-label, randomized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapy.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Oxazines; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Zidovudine | 2006 |
[Clinical trial comparing efficacy and safety of four highly active antiretroviral therapy (HAART) in antiretroviral-naive treatment with advanced HIV infection].
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Didanosine; Disease Progression; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Male; Middle Aged; Ritonavir; Stavudine; Zidovudine | 2006 |
Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study).
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation; Pilot Projects; Reverse Transcriptase Inhibitors; Treatment Failure; Treatment Outcome; Viral Load; Virus Replication | 2006 |
Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005).
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; Humans; Indinavir; Lamivudine; Male; Ritonavir; RNA, Viral; Time Factors; Viral Load; Zidovudine | 2006 |
Efficacy and safety of a once-daily fixed-dose combination of abacavir/lamivudine compared with abacavir twice daily and lamivudine once daily as separate entities in antiretroviral-experienced HIV-1-infected patients (CAL30001 Study).
Topics: Adult; Aged; Anti-HIV Agents; Dideoxynucleosides; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Safety | 2006 |
Incidence of lamivudine resistance associated mutations in pol-gene of HIV-1 in patients from north India: a preliminary report.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Codon; Drug Resistance, Viral; Drug Therapy, Combination; Genes, pol; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Incidence; India; Lamivudine; Mutation; Reverse Transcriptase Inhibitors | 2005 |
Selection of resistance mutations in children receiving prophylaxis with lamivudine or nevirapine for the prevention of postnatal transmission of HIV.
Topics: Drug Resistance, Viral; Female; HIV Infections; HIV Protease; HIV-1; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Mutation; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Rwanda; Selection, Genetic; Species Specificity; Treatment Outcome; Uganda | 2006 |
Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa.
Topics: Adenine; Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Developing Countries; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; RNA, Viral; Tenofovir; Treatment Outcome; Uganda; Viral Load; Zidovudine; Zimbabwe | 2006 |
Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study.
Topics: Adult; ATP Binding Cassette Transporter, Subfamily B, Member 1; Base Sequence; Black People; Cytochrome P-450 CYP3A; DNA Primers; Drug Therapy, Combination; Female; HIV Infections; Humans; Indinavir; Lamivudine; Male; Mitochondrial Proteins; Multidrug Resistance-Associated Proteins; Pharmacogenetics; Pilot Projects; Retrospective Studies; Ribosomal Proteins; Saccharomyces cerevisiae Proteins; Zidovudine | 2006 |
Postexposure prophylaxis for HIV in children and adolescents after sexual assault: a prospective observational study in an urban medical center.
Topics: Adolescent; Adult; Anti-HIV Agents; Child; Drug Combinations; Female; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; New York City; Patient Compliance; Prospective Studies; Regression Analysis; Sex Offenses; Zidovudine | 2007 |
Maternal single-dose nevirapine versus placebo as part of an antiretroviral strategy to prevent mother-to-child HIV transmission in Botswana.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Botswana; Drug Administration Schedule; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Logistic Models; Nevirapine; Postpartum Period; Treatment Outcome; Zidovudine | 2006 |
Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children.
Topics: Anti-HIV Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant; Lamivudine; Lopinavir; Male; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Outcome; Zidovudine | 2006 |
Initiation of antiretroviral treatment with dual nucleoside reverse transcriptase inhibitors in human immunodeficiency virus-infected infants with less advanced disease in a resource-limited setting: a multi-center study in Thailand 1998-2000.
Topics: Developing Countries; Disease Progression; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant; Lamivudine; Male; Prospective Studies; Reverse Transcriptase Inhibitors; Treatment Outcome; Zidovudine | 2005 |
Model for intracellular Lamivudine metabolism in peripheral blood mononuclear cells ex vivo and in human immunodeficiency virus type 1-infected adolescents.
Topics: Adolescent; Adult; Anti-HIV Agents; Bayes Theorem; Cross-Over Studies; HIV Infections; HIV-1; Humans; Lamivudine; Leukocytes, Mononuclear; Models, Biological; Reverse Transcriptase Inhibitors | 2006 |
The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial.
Topics: Carbamates; Dideoxynucleosides; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Organophosphates; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides | 2006 |
The value of serum albumin in pretreatment assessment and monitoring of therapy in HIV/AIDS patients.
Topics: Adult; Anti-HIV Agents; Body Weight; CD4 Lymphocyte Count; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Predictive Value of Tests; Reverse Transcriptase Inhibitors; Sensitivity and Specificity; Serum Albumin; Severity of Illness Index; Stavudine; Treatment Outcome | 2006 |
Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Double-Blind Method; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; RNA, Messenger; Viral Load; Zidovudine | 2006 |
Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903.
Topics: Adenine; Alkynes; Benzoxazines; Cyclopropanes; Double-Blind Method; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Stavudine; Tenofovir; Treatment Outcome | 2006 |
Long-term results of initial therapy with abacavir and Lamivudine combined with Efavirenz, Amprenavir/Ritonavir, or Stavudine.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Oxazines; Ritonavir; Stavudine; Treatment Outcome | 2006 |
Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection.
Topics: Adenine; Anti-HIV Agents; Chi-Square Distribution; DNA, Viral; Drug Resistance, Viral; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Lamivudine; Organophosphonates; Prospective Studies; Reverse Transcriptase Inhibitors; Statistics, Nonparametric; Tenofovir; Treatment Failure | 2006 |
Virologic response of zidovudine, lamivudine, and tenofovir disoproxil fumarate combination in antiretroviral-naive HIV-1-infected patients.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Pilot Projects; Tenofovir; Viral Load; Zidovudine | 2006 |
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Organophosphonates; Oxazines; RNA, Viral; Tenofovir; Time Factors; Viral Load; Zidovudine | 2006 |
Pharmacokinetics of two generic fixed-dose combinations for HIV-infected children (Pedimune Baby & Pedimune Junior) are similar to the branded products in healthy adults.
Topics: Adult; Age Factors; Anti-HIV Agents; Child; Child, Preschool; Drug Therapy, Combination; Drugs, Generic; HIV Infections; Humans; Infant; Lamivudine; Male; Middle Aged; Nevirapine; Pilot Projects; Stavudine; Therapeutic Equivalency | 2007 |
Efficacy and safety of generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-vir) in advanced HIV infection.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Combinations; Drugs, Generic; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Prospective Studies; Retrospective Studies; Reverse Transcriptase Inhibitors; Stavudine; Survival Analysis; Thailand; Viral Load | 2006 |
Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study.
Topics: Absorptiometry, Photon; Adipose Tissue; Adult; Aged; Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Extremities; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Lipid Metabolism; Lipids; Male; Middle Aged; Oxazines; Stavudine; Viral Load | 2007 |
Triple antiretroviral prophylaxis administered during pregnancy and after delivery significantly reduces breast milk viral load: a study within the Drug Resource Enhancement Against AIDS and Malnutrition Program.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV; HIV Infections; Humans; Lamivudine; Milk, Human; Nevirapine; Pilot Projects; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimester, Third; RNA, Viral; Stavudine; Zidovudine | 2007 |
Pharmacokinetic comparison of generic and trade formulations of lamivudine, stavudine and nevirapine in HIV-infected Malawian adults.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Area Under Curve; CD4 Lymphocyte Count; Confidence Intervals; Cross-Over Studies; Drug Administration Schedule; Drugs, Generic; Female; HIV Infections; Humans; Lamivudine; Malawi; Male; Nevirapine; Stavudine; Therapeutic Equivalency; Viral Load | 2007 |
Two-year morbidity-mortality and alternatives to prolonged breast-feeding among children born to HIV-infected mothers in Côte d'Ivoire.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Breast Feeding; Cohort Studies; Cote d'Ivoire; Female; HIV Infections; Humans; Infant; Infant Formula; Infant Mortality; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Milk, Human; Morbidity; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; Time Factors; Treatment Outcome; Zidovudine | 2007 |
Metabolic effects of protease inhibitor-sparing antiretroviral regimens given as initial treatment of HIV-1 Infection (AIDS Clinical Trials Group Study A5095).
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Blood Glucose; Body Composition; Cyclopropanes; Dideoxynucleosides; Double-Blind Method; Female; HIV Infections; HIV-1; Humans; Insulin Resistance; Lactic Acid; Lamivudine; Lipids; Male; Reverse Transcriptase Inhibitors; Zidovudine | 2007 |
Changes in the peripheral blood mtDNA levels in naive patients treated by different nucleoside reverse transcriptase inhibitor combinations and their association with subsequent lipodystrophy.
Topics: Adult; Anti-HIV Agents; Didanosine; DNA, Mitochondrial; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Leukocytes, Mononuclear; Logistic Models; Male; Reverse Transcriptase Inhibitors; Stavudine; Surveys and Questionnaires; Time Factors; Zidovudine | 2007 |
Lamivudine and indinavir/ritonavir maintenance therapy in highly pretreated HIV-infected patients (Vista ANRS 109).
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Resistance, Viral; Endpoint Determination; Female; France; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Indinavir; Lamivudine; Male; Middle Aged; Pilot Projects; Ritonavir; Species Specificity; Viral Load | 2006 |
Treatment of hepatitis B with lamivudine and tenofovir in HIV/HBV-coinfected patients: factors associated with response.
Topics: Adenine; Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Hepatitis B; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir; Viral Load | 2007 |
A randomized trial to evaluate continuation versus discontinuation of lamivudine in individuals failing a lamivudine-containing regimen: the COLATE trial.
Topics: Anti-HIV Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Mutation; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Failure; Treatment Outcome | 2006 |
Antiretroviral efficacy and virological profile of a zidovudine/lamivudine/tenofovir disoproxil fumarate combination therapy in antiretroviral-naive patients.
Topics: Adenine; Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Mutation; Organophosphonates; Pilot Projects; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure; Treatment Outcome; Zidovudine | 2006 |
Effect of efavirenz on the pharmacokinetics of ketoconazole in HIV-infected patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Antifungal Agents; Area Under Curve; Benzoxazines; Candidiasis, Oral; Cyclopropanes; Drug Interactions; Female; Half-Life; HIV Infections; Humans; Ketoconazole; Lamivudine; Male; Middle Aged; Stavudine | 2007 |
Exploratory study comparing the metabolic toxicities of a lopinavir/ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir/ritonavir plus zidovudine/lamivudine nucleoside regimen.
Topics: Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Pyrimidinones; Ritonavir; Saquinavir; Zidovudine | 2007 |
Plasma HIV-1 RNA dynamics in antiretroviral-naive subjects receiving either triple-nucleoside or efavirenz-containing regimens: ACTG A5166s.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Prospective Studies; Regression Analysis; RNA, Viral; Time Factors; Zidovudine | 2007 |
Plasma nevirapine levels and 24-week efficacy of a fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) among Thai HIV-infected patients.
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Drug Combinations; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Nevirapine; Prospective Studies; Stavudine; Thailand; Time Factors; Treatment Outcome | 2007 |
No change in calculated creatinine clearance after tenofovir initiation among Thai patients.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Body Weight; Creatinine; Female; HIV Infections; Humans; Kidney; Kidney Function Tests; Lamivudine; Male; Organophosphonates; Tenofovir; Thailand | 2007 |
ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia.
Topics: Anti-HIV Agents; Cohort Studies; Double-Blind Method; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Longitudinal Studies; Reproducibility of Results; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Sensitivity and Specificity; Stavudine; Viremia; Virus Replication | 2007 |
Molecular basis of antagonism between K70E and K65R tenofovir-associated mutations in HIV-1 reverse transcriptase.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Computer Simulation; Dideoxynucleosides; Drug Resistance, Multiple, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutagenesis, Site-Directed; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2007 |
In utero nucleoside reverse transcriptase inhibitor exposure and signs of possible mitochondrial dysfunction in HIV-uninfected children.
Topics: Anti-HIV Agents; Child, Preschool; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV Reverse Transcriptase; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Male; Maternal-Fetal Exchange; Mitochondrial Diseases; Pregnancy; Pregnancy Complications, Infectious; Prenatal Exposure Delayed Effects; Reverse Transcriptase Inhibitors; Sex Factors; Zidovudine | 2007 |
Lamivudine/abacavir maintains virological superiority over zidovudine/lamivudine and zidovudine/abacavir beyond 5 years in children.
Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Child; Child, Preschool; Dideoxynucleosides; Drug Resistance, Viral; Follow-Up Studies; Growth; HIV Infections; HIV-1; Humans; Infant; Lamivudine; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Viral Load; Zidovudine | 2007 |
The effect of lamivudine therapy and M184V on the antiretroviral activity of didanosine.
Topics: Anti-HIV Agents; Didanosine; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Lamivudine; Point Mutation | 2007 |
Effects of nevirapine, compared with lamivudine, on lipids and lipoproteins in HIV-1-uninfected newborns: the stopping infection from mother-to-child via breast-feeding in Africa lipid substudy.
Topics: Adult; Africa; Anti-HIV Agents; Apolipoproteins; Blood Chemical Analysis; Breast Feeding; Cholesterol, HDL; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Male; Nevirapine | 2007 |
Effects of potent antiretroviral therapy on free testosterone levels and fat-free mass in men in a prospective, randomized trial: A5005s, a substudy of AIDS Clinical Trials Group Study 384.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Didanosine; Double-Blind Method; HIV Infections; Humans; Lamivudine; Longitudinal Studies; Male; Nelfinavir; Prospective Studies; Stavudine; Testosterone; Zidovudine | 2007 |
Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384.
Topics: Absorptiometry, Photon; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Body Composition; Cyclopropanes; Didanosine; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Prospective Studies; Stavudine; Time Factors; Treatment Outcome; United States; Zidovudine | 2007 |
Determinants of high-risk sexual behavior during post-exposure prophylaxis to prevent HIV infection.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; Homosexuality, Male; Humans; Interviews as Topic; Lamivudine; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Risk Factors; Risk-Taking; Sexual Partners; Surveys and Questionnaires; Tenofovir; Treatment Outcome | 2008 |
Fixed dose combination of lamivudine, stavudine and nevirapine in the treatment of pediatric HIV infection: a preliminary report.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Drug Combinations; Follow-Up Studies; HIV Infections; Humans; Infant; Lamivudine; Nevirapine; Prospective Studies; Stavudine; Treatment Outcome | 2007 |
Population pharmacokinetic analysis of lamivudine, stavudine and zidovudine in controlled HIV-infected patients on HAART.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Interactions; Female; HIV Infections; Humans; Indinavir; Lamivudine; Male; Middle Aged; Models, Biological; Nelfinavir; Reverse Transcriptase Inhibitors; Stavudine; Tissue Distribution; Zidovudine | 2007 |
Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study.
Topics: Adenine; Adolescent; Adult; Aged; Australia; Canada; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Latin America; Male; Middle Aged; Organic Chemicals; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Tenofovir; Thailand; Time Factors; Treatment Outcome; United States | 2007 |
A comparison of three initial antiretroviral AIDS regimens.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Double-Blind Method; Drug Therapy, Combination; Follow-Up Studies; HIV; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; RNA, Viral; Zidovudine | 2007 |
144-week data released on Gilead's study 934.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Combinations; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; HIV-1; Humans; Lamivudine; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Time Factors; Viral Load; Zidovudine | 2007 |
Pharmacokinetics of lamivudine, zidovudine, and nevirapine administered as a fixed-dose combination formulation versus coadministration of the individual products.
Topics: Adolescent; Adult; Cross-Sectional Studies; Drug Combinations; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Reverse Transcriptase Inhibitors; Zidovudine | 2007 |
Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients.
Topics: Adult; Aged; Amino Acid Substitution; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lipids; Male; Microbial Sensitivity Tests; Middle Aged; Oligopeptides; Prospective Studies; Pyridines; Ritonavir; RNA, Viral; Stavudine; Viral Load; Withholding Treatment | 2008 |
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis.
Topics: Adenine; Adult; Alkynes; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Zidovudine | 2008 |
Antiretroviral therapy with the integrase inhibitor raltegravir alters decay kinetics of HIV, significantly reducing the second phase.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; HIV; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Linear Models; Organic Chemicals; Organophosphonates; Pyrrolidinones; Raltegravir Potassium; RNA, Viral; Statistics, Nonparametric; Tenofovir; Time Factors; Viral Load; Virus Integration; Virus Latency; Virus Replication | 2007 |
Antiretroviral therapy using zidovudine, lamivudine, and efavirenz in South Africa: tolerability and clinical events.
Topics: Adult; Alkynes; Anemia; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes; Developing Countries; Dizziness; Drug Tolerance; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nausea; Neutropenia; Prospective Studies; South Africa; Treatment Outcome; Viral Load; Vomiting; Zidovudine | 2008 |
Zidovudine/lamivudine contributes to insulin resistance within 3 months of starting combination antiretroviral therapy.
Topics: Adiponectin; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Composition; Glucose; Glycerol; HIV Infections; HIV-1; HIV-Associated Lipodystrophy Syndrome; Humans; Hyperinsulinism; Insulin Resistance; Lamivudine; Lipid Metabolism; Lipids; Lopinavir; Male; Middle Aged; Pyrimidinones; Time Factors; Treatment Outcome; Zidovudine | 2008 |
Induction therapy with trizivir plus efavirenz or lopinavir/ritonavir followed by trizivir alone in naive HIV-1-infected adults.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Treatment Failure; Treatment Outcome; Zidovudine | 2008 |
Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease; HIV-1; Humans; Lamivudine; Lopinavir; Male; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load; Zidovudine | 2008 |
Long-term assessment of didanosine, lamivudine, and efavirenz in antiretroviral-naive patients: 3-year follow-up.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Didanosine; Drug Therapy, Combination; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load | 2008 |
Plasma HIV load and proviral DNA decreases after two standard antiretroviral regimens in HIV-positive patients naïve to antiretrovirals.
Topics: Adenine; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Biomarkers; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cyclopropanes; DNA, Viral; Drug Administration Schedule; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load | 2008 |
Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Treatment Outcome; Viral Load | 2008 |
Twenty-four-week safety and tolerability of nevirapine vs. abacavir in combination with zidovudine/lamivudine as first-line antiretroviral therapy: a randomized double-blind trial (NORA).
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Dideoxynucleosides; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Reverse Transcriptase Inhibitors; Treatment Outcome; Uganda; Zidovudine | 2008 |
Short-term safety and tolerability of a once-daily fixed-dose abacavir-lamivudine combination versus twice-daily dosing of abacavir and lamivudine as separate components: findings from the ALOHA study.
Topics: Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Patient Compliance; Patient Satisfaction; Viral Load | 2008 |
Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets.
Topics: Adolescent; Antiretroviral Therapy, Highly Active; Area Under Curve; Body Weight; Child; Child, Preschool; Drug Administration Schedule; Drug Combinations; Drug Monitoring; Female; HIV Infections; Humans; Infant; Infant, Newborn; Lamivudine; Male; Nevirapine; Reverse Transcriptase Inhibitors; Stavudine; Zambia | 2008 |
Tolerability and effectiveness of first-line regimens combining nevirapine and lamivudine plus zidovudine or stavudine in Cameroon.
Topics: Adult; Anemia; Anti-HIV Agents; Cameroon; CD4 Lymphocyte Count; Cohort Studies; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Kaplan-Meier Estimate; Lamivudine; Male; Multivariate Analysis; Nevirapine; Patient Compliance; Peripheral Nervous System Diseases; Prospective Studies; Stavudine; Treatment Outcome; Viral Load; Zidovudine | 2008 |
Effect of maraviroc on the pharmacokinetics of midazolam, lamivudine/zidovudine, and ethinyloestradiol/levonorgestrel in healthy volunteers.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Anti-HIV Agents; CCR5 Receptor Antagonists; Contraceptives, Oral; Cyclohexanes; Double-Blind Method; Drug Interactions; Drug Therapy, Combination; Ethinyl Estradiol; Female; HIV Infections; Humans; Lamivudine; Levonorgestrel; Male; Maraviroc; Midazolam; Middle Aged; Statistics as Topic; Triazoles; Zidovudine | 2008 |
Changes in metabolic toxicity after switching from stavudine/didanosine to tenofovir/lamivudine--a Staccato trial substudy.
Topics: Absorptiometry, Photon; Adenine; Adult; Anti-HIV Agents; Body Fat Distribution; Didanosine; DNA, Mitochondrial; HIV Infections; Humans; Lamivudine; Lipids; Liver Function Tests; Organophosphonates; Ritonavir; RNA, Viral; Saquinavir; Stavudine; Tenofovir; Thailand | 2008 |
Absence of HIV-1 shedding in male genital tract after 1 year of first-line lopinavir/ritonavir alone or in combination with zidovudine/lamivudine.
Topics: Anti-HIV Agents; Chromatography, High Pressure Liquid; Drug Therapy, Combination; Genitalia, Male; HIV Infections; HIV-1; Humans; Lamivudine; Longitudinal Studies; Lopinavir; Male; Plasma; Pyrimidinones; Ritonavir; RNA, Viral; Semen; Time Factors; Virus Shedding; Zidovudine | 2008 |
Prevention of mother-to-child transmission of HIV-1 through breast-feeding by treating infants prophylactically with lamivudine in Dar es Salaam, Tanzania: the Mitra Study.
Topics: Adult; Breast Feeding; Drug Administration Schedule; Female; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Milk, Human; Pregnancy; Pregnancy Complications, Infectious; Tanzania | 2008 |
Pharmacokinetics of zidovudine and lamivudine during oral uridine supplementation with NucleomaxX.
Topics: Administration, Oral; Area Under Curve; Double-Blind Method; Female; HIV Infections; Humans; Lamivudine; Male; Placebos; Reverse Transcriptase Inhibitors; Uridine; Zidovudine | 2008 |
Long-term subcutaneous tissue changes among antiretroviral-naive persons initiating stavudine, zidovudine, or abacavir with lamivudine.
Topics: Adult; Cohort Studies; Dideoxynucleosides; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Stavudine; Subcutaneous Fat; Zidovudine | 2008 |
Antiviral activity and safety of aplaviroc with lamivudine/zidovudine in HIV-infected, therapy-naive patients: the ASCENT (CCR102881) study.
Topics: Adult; Aged; Anti-HIV Agents; Benzoates; Diketopiperazines; Double-Blind Method; Drug Therapy, Combination; Female; HIV Fusion Inhibitors; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Piperazines; Reverse Transcriptase Inhibitors; Spiro Compounds; Treatment Outcome; Zidovudine | 2008 |
Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Zalcitabine; Zidovudine | 1995 |
Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy.
Topics: Antiviral Agents; Base Sequence; CD4 Lymphocyte Count; Cell Line; Codon; Drug Resistance, Microbial; Drug Therapy, Combination; HeLa Cells; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Molecular Sequence Data; Mutagenesis, Site-Directed; Point Mutation; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; RNA, Viral; Serial Passage; Zalcitabine; Zidovudine | 1995 |
Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study.
Topics: Adult; Antiviral Agents; beta 2-Microglobulin; Biomarkers; Biopterins; CD4 Lymphocyte Count; Disease Progression; Dose-Response Relationship, Drug; HIV Core Protein p24; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Neopterin; Zalcitabine | 1995 |
A phase I/II study of 2'-deoxy-3'-thiacytidine (lamivudine) in patients with advanced human immunodeficiency virus infection.
Topics: Acquired Immunodeficiency Syndrome; Adult; beta 2-Microglobulin; Female; HIV Core Protein p24; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Time Factors; Zalcitabine | 1995 |
Efficacy of lamivudine on replication of hepatitis B virus in HIV-infected patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Virus Replication; Zalcitabine | 1995 |
Genotypic and phenotypic characterization of HIV-1 isolated from patients receiving (--)-2',3'-dideoxy-3'-thiacytidine.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Drug Resistance, Microbial; Genotype; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Lamivudine; Leukocytes, Mononuclear; Male; Middle Aged; Phenotype; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1995 |
Zidovudine and lamivudine: results of phase III studies.
Topics: Antiviral Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Reverse Transcriptase Inhibitors; RNA, Viral; Zalcitabine; Zidovudine | 1995 |
Phase I/II study of 3TC (lamivudine) in HIV-positive, asymptomatic or mild AIDS-related complex patients: sustained reduction in viral markers. The Lamivudine European HIV Working Group.
Topics: Adult; AIDS-Related Complex; Antigen-Antibody Complex; Antiviral Agents; Dose-Response Relationship, Drug; HIV; HIV Core Protein p24; HIV Infections; HIV Seropositivity; Humans; Lamivudine; Leukocytes, Mononuclear; Male; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; Viremia; Zalcitabine | 1995 |
Lamivudine in children with human immunodeficiency virus infection: a phase I/II study. The National Cancer Institute Pediatric Branch-Human Immunodeficiency Virus Working Group.
Topics: Adolescent; Antiviral Agents; Child; Child, Preschool; Disease Progression; Female; HIV Core Protein p24; HIV Infections; Humans; Infant; Lamivudine; Male; Pancreatitis; Risk Factors; RNA, Viral; Treatment Outcome; Zalcitabine | 1996 |
Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Genotype; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Lamivudine; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; RNA, Viral; Zalcitabine; Zidovudine | 1996 |
Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; RNA, Viral; Zalcitabine; Zidovudine | 1996 |
Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. North American HIV Working Party.
Topics: Adult; Antiviral Agents; beta 2-Microglobulin; Biopterins; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; Female; HIV; HIV Core Protein p24; HIV Infections; Humans; Lamivudine; Male; Neopterin; Polymerase Chain Reaction; RNA, Viral; Severity of Illness Index; Time Factors; Treatment Outcome; Zalcitabine; Zidovudine | 1996 |
Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patients.
Topics: Acetamides; Acetophenones; Adult; Antiviral Agents; Case-Control Studies; CD4 Lymphocyte Count; Cross-Over Studies; DNA Mutational Analysis; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Lamivudine; Middle Aged; Pilot Projects; RNA, Viral; Zalcitabine; Zidovudine | 1996 |
HIV-1 RNA levels and the development of clinical disease. North American Lamivudine HIV Working Group.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Disease Progression; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Predictive Value of Tests; Proportional Hazards Models; RNA, Viral; Zidovudine | 1996 |
Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patients.
Topics: Adult; Anti-HIV Agents; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Female; Genes, Viral; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Virus Replication; Zidovudine | 1996 |
CD8+ lymphocyte responses to antiretroviral therapy of HIV infection.
Topics: Acetamides; Acetophenones; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Didanosine; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; Humans; Lamivudine; Lymphocyte Count; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Viral Load; Zalcitabine; Zidovudine | 1996 |
Efficacy of triple combination therapy with zidovudine (ZDV) plus zalcitabine (ddC) plus lamivudine (3TC) versus double (ZDV+3TC) combination therapy in patients previously treated with ZDV+ddC.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Viral Load; Zalcitabine; Zidovudine | 1996 |
Effectiveness of 3TC in HIV clinical trials may be due in part to the M184V substitution in 3TC-resistant HIV-1 reverse transcriptase.
Topics: Adult; Anti-HIV Agents; Child; Child, Preschool; Drug Resistance, Microbial; Female; HIV Antibodies; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Mutation; Neutralization Tests; Viral Load | 1996 |
The treatment of antiretroviral-naive subjects with the 3TC/zidovudine combination: a review of North American (NUCA 3001) and European (NUCB 3001) trials.
Topics: Adolescent; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Europe; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; North America; Viral Load; Zidovudine | 1996 |
Reductions in HIV-1 disease progression for zidovudine/lamivudine relative to control treatments: a meta-analysis of controlled trials.
Topics: Adolescent; Adult; Anti-HIV Agents; Centers for Disease Control and Prevention, U.S.; Disease Progression; Double-Blind Method; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; United States; Zidovudine | 1997 |
Effects of a combination of zidovudine, didanosine, and lamivudine on primary human immunodeficiency virus type 1 infection.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; CD4-CD8 Ratio; Didanosine; DNA, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lymphocytes; Male; Pilot Projects; Proviruses; RNA, Viral; Zidovudine | 1997 |
Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection.
Topics: Adult; Anti-HIV Agents; CD4-Positive T-Lymphocytes; Dendritic Cells; DNA, Viral; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Image Processing, Computer-Assisted; In Situ Hybridization; Kinetics; Lamivudine; Leukocytes, Mononuclear; Macrophages; Palatine Tonsil; Proviruses; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Viral Load; Virus Replication; Zidovudine | 1997 |
A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Male; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Zidovudine | 1997 |
Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; HIV Infections; Humans; Indinavir; Lamivudine; RNA, Viral; Viral Load; Zidovudine | 1997 |
Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure.
Topics: Anti-HIV Agents; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Lymph Nodes; RNA, Viral; Viral Load; Zidovudine | 1997 |
Decrease of HIV-1 RNA levels in lymphoid tissue and peripheral blood during treatment with ritonavir, lamivudine and zidovudine. Ritonavir/3TC/ZDV Study Group.
Topics: Adult; Anti-HIV Agents; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lymphoid Tissue; Male; Palatine Tonsil; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load; Zidovudine | 1998 |
Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy.
Topics: Amino Acid Sequence; Base Sequence; DNA, Viral; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; Genotype; HIV Infections; HIV Protease; HIV Reverse Transcriptase; HIV-1; Humans; Indinavir; Lamivudine; Lymph Nodes; Molecular Sequence Data; Mutation; RNA, Viral; Viral Load; Virus Replication; Zidovudine | 1998 |
Antiviral effect of double and triple drug combinations amongst HIV-infected adults: lessons from the implementation of viral load-driven antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Didanosine; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Multivariate Analysis; Stavudine; Viral Load; Zalcitabine; Zidovudine | 1998 |
The effects of lamivudine treatment on HIV-1 disease progression are highly correlated with plasma HIV-1 RNA and CD4 cell count.
Topics: Acetamides; Acetophenones; Acquired Immunodeficiency Syndrome; Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; RNA, Viral; Treatment Outcome; Viral Load; Zalcitabine; Zidovudine | 1998 |
Pilot study of zidovudine-lamivudine combination therapy in vertically HIV-infected antiretroviral-naive children.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Drug Therapy, Combination; Female; HIV; HIV Infections; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Male; Pilot Projects; RNA, Viral; Viral Load; Zidovudine | 1998 |
Impact of zidovudine plus lamivudine or zalcitabine on health-related quality of life.
Topics: Adult; Anti-Bacterial Agents; Anti-HIV Agents; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Quality of Life; Treatment Outcome; Zalcitabine; Zidovudine | 1998 |
A pilot study of nevirapine, indinavir, and lamivudine among patients with advanced human immunodeficiency virus disease who have had failure of combination nucleoside therapy.
Topics: Anti-HIV Agents; Consumer Product Safety; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Male; Nevirapine; Nucleosides; Pilot Projects; Prospective Studies; Reverse Transcriptase Inhibitors; Treatment Failure; Viral Load | 1998 |
A phase I/II study of the protease inhibitor indinavir in children with HIV infection.
Topics: Adolescent; Adult; Biological Availability; Capsules; CD4 Lymphocyte Count; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Infant; Lamivudine; Male; Suspensions; Viral Load; Virus Replication; Zidovudine | 1998 |
Evolution of cytotoxic T lymphocyte responses to human immunodeficiency virus type 1 in patients with symptomatic primary infection receiving antiretroviral triple therapy.
Topics: Anti-HIV Agents; Cell Line, Transformed; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; T-Lymphocytes, Cytotoxic; Viral Load; Zidovudine | 1998 |
Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315.
Topics: Adult; Anti-HIV Agents; Antigens; B-Lymphocytes; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; HIV Antigens; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hypersensitivity, Delayed; Lamivudine; Lymphocyte Activation; Lymphocyte Count; Male; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; T-Lymphocyte Subsets; Time Factors; Zidovudine | 1998 |
Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Follow-Up Studies; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Viral Load; Zidovudine | 1998 |
Rate of HIV-1 decline following antiretroviral therapy is related to viral load at baseline and drug regimen.
Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Models, Theoretical; Ritonavir; RNA, Viral; Treatment Outcome; Viral Load; Zidovudine | 1998 |
An open randomized controlled trial of zidovudine plus lamivudine versus stavudine plus lamivudine.
Topics: Adult; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Homosexuality, Male; Humans; Indinavir; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; RNA, Viral; Stavudine; Treatment Outcome; Viral Load; Zidovudine | 1998 |
Treatment response and durability of a double protease inhibitor therapy with saquinavir and ritonavir in an observational cohort of HIV-1-infected individuals.
Topics: Adult; Anti-HIV Agents; CD4-CD8 Ratio; Cohort Studies; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Observation; Risk Factors; Ritonavir; Saquinavir; Treatment Failure; Viral Load; Zidovudine | 1998 |
Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring.
Topics: Administration, Oral; Adolescent; Adult; Amniotic Fluid; Anti-HIV Agents; Black People; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Milk, Human; Pregnancy; Random Allocation; RNA, Viral; South Africa; Viral Load; Zidovudine | 1998 |
A randomized study of combined zidovudine-lamivudine versus didanosine monotherapy in children with symptomatic therapy-naive HIV-1 infection. The Pediatric AIDS Clinical Trials Group Protocol 300 Study Team.
Topics: Adolescent; Anti-HIV Agents; CD4 Antigens; Child; Child, Preschool; Didanosine; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lamivudine; Male; Neurodegenerative Diseases; Polymerase Chain Reaction; RNA, Viral; Survival Rate; Zidovudine | 1998 |
Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team.
Topics: Adult; Anti-HIV Agents; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Male; Multivariate Analysis; Remission Induction; RNA, Viral; Treatment Failure; Viral Load; Zidovudine | 1998 |
A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Male; Remission Induction; RNA, Viral; Treatment Failure; Viral Load; Zidovudine | 1998 |
A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. Paediatric European Network for Treatment of AIDS.
Topics: Adolescent; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Didanosine; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant; Lamivudine; Male; Reverse Transcriptase Inhibitors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Zalcitabine; Zidovudine | 1998 |
Highly active antiretroviral therapy results in a decrease in CD8+ T cell activation and preferential reconstitution of the peripheral CD4+ T cell population with memory rather than naive cells.
Topics: Anti-HIV Agents; Antigens, CD; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Drug Therapy, Combination; Flow Cytometry; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Immunologic Memory; Immunophenotyping; Indinavir; Lamivudine; Lymphocyte Activation; Statistics, Nonparametric; T-Lymphocyte Subsets; Viral Load; Zidovudine | 1998 |
Serum and cerebrospinal fluid pharmacokinetics of intravenous and oral lamivudine in human immunodeficiency virus-infected children.
Topics: Administration, Oral; Adolescent; Anti-HIV Agents; Area Under Curve; Child; Child, Preschool; Female; HIV Infections; Humans; Infant; Injections, Intravenous; Lamivudine; Male | 1998 |
Human immunodeficiency virus type 1 expressing the lamivudine-associated M184V mutation in reverse transcriptase shows increased susceptibility to adefovir and decreased replication capability in vitro.
Topics: Adenine; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; In Vitro Techniques; Lamivudine; Organophosphonates; Point Mutation; Reverse Transcriptase Inhibitors; Virus Replication; Zidovudine | 1999 |
Randomized, controlled phase II trial of subcutaneous interleukin-2 in combination with highly active antiretroviral therapy (HAART) in HIV patients.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Injections, Subcutaneous; Interleukin-2; Lamivudine; Male; Prospective Studies; Quality of Life; Reverse Transcriptase Inhibitors; Saquinavir; Viral Load; Zidovudine | 1998 |
Initial multicenter experience with double nucleoside therapy for human immunodeficiency virus infection during pregnancy.
Topics: Adult; Anti-HIV Agents; Canada; Confidence Intervals; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Prospective Studies; Statistics, Nonparametric; Treatment Outcome; United States; Zidovudine | 1998 |
[Amsterdam duration of antiretroviral medication (ADAM)--study: induction-suppression treatment in HIV-I infection, preliminary results].
Topics: Antiviral Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Nelfinavir; Pilot Projects; Saquinavir; Stavudine; Treatment Outcome; Viral Load | 1998 |
[Increased serum level of naive CD8+-T-cells during intensive antiretroviral therapy].
Topics: Antiviral Agents; CD8-Positive T-Lymphocytes; Drug Therapy, Combination; Female; HIV Infections; Humans; Indinavir; Lamivudine; Lymphocyte Count; Male; Saquinavir; Zidovudine | 1998 |
Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team.
Topics: Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Furans; HIV Infections; Humans; Lamivudine; Male; Middle Aged; RNA, Viral; Sulfonamides; Zidovudine | 1999 |
Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations.
Topics: CD4 Lymphocyte Count; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Mutation; Prospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Saquinavir; Viral Load; Zidovudine | 1999 |
[Experiences with antiretroviral combination therapy].
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Male; N-Glycosyl Hydrolases; Retrospective Studies; Ritonavir; RNA, Viral; Zidovudine | 1999 |
Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine.
Topics: Adult; AIDS Dementia Complex; Analysis of Variance; Anti-HIV Agents; CD4 Lymphocyte Count; Chromatography, High Pressure Liquid; Drug Combinations; Follow-Up Studies; HIV Core Protein p24; HIV Infections; HIV-1; Humans; Lamivudine; Middle Aged; RNA, Viral; Spinal Puncture; Stavudine; Zidovudine | 1998 |
Randomized trial comparing saquinavir soft gelatin capsules versus indinavir as part of triple therapy (CHEESE study).
Topics: Adult; Anti-HIV Agents; Capsules; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; Gelatin; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; RNA, Viral; Saquinavir; Treatment Outcome; Zidovudine | 1999 |
Lamivudine for chronic hepatitis B and HIV co-infection.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; DNA, Viral; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; RNA, Viral | 1999 |
Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection.
Topics: Adolescent; Adult; Anti-HIV Agents; Cross-Over Studies; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Zidovudine | 1999 |
Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia.
Topics: Adult; Anti-HIV Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cohort Studies; DNA, Viral; Drug Therapy, Combination; HIV Antibodies; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Leukocytes, Mononuclear; Lymphocyte Activation; Male; Prospective Studies; RNA, Viral; T-Lymphocyte Subsets; Viremia; Zidovudine | 1999 |
The ALBI trial: a randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with human immunodeficiency virus.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Treatment Outcome; Viremia; Zidovudine | 1999 |
HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Male; Prospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Zidovudine | 1999 |
Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group Protocol 306 Invest
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Viral Load; Zidovudine | 1999 |
HIV infection perturbs DNA content of lymphoid cells: partial correction after 'suppression' of virus replication.
Topics: Anti-HIV Agents; Apoptosis; Cell Cycle; Cross-Sectional Studies; DNA; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Leukocytes, Mononuclear; Lymphocyte Activation; Lymphocytes; Ritonavir; RNA, Viral; Viral Load; Virus Replication; Zidovudine | 1999 |
Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR). The CAESAR Coordinating Committee.
Topics: Acetamides; Acetophenones; Adult; Aged; Anti-HIV Agents; Antiviral Agents; Disease Progression; Disease-Free Survival; DNA, Viral; Female; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Placebos; Retrospective Studies; Time Factors | 1999 |
A randomized, controlled trial of indinavir, zidovudine, and lamivudine in adults with advanced human immunodeficiency virus type 1 infection and prior antiretroviral therapy.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Male; Survival Rate; Zidovudine | 1999 |
Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy.
Topics: Acquired Immunodeficiency Syndrome; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Oxazines; Viral Load; Zidovudine | 1999 |
Highly active antiretroviral treatment initiated early in the course of symptomatic primary HIV-1 infection: results of the ANRS 053 trial.
Topics: Anti-HIV Agents; Confidence Intervals; Drug Therapy, Combination; Female; France; HIV Infections; HIV-1; Humans; Lamivudine; Lymphocyte Count; Male; Ritonavir; RNA, Viral; Viral Load; Zidovudine | 1999 |
Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Cytokines; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Hypersensitivity, Delayed; Interleukin-2; Lamivudine; Lymphocyte Activation; Male; T-Lymphocytes; Thalidomide; Viral Load; Zidovudine | 1999 |
Long-term effects of antiretroviral combination therapy on HIV type 1 DNA levels.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Data Interpretation, Statistical; Didanosine; DNA, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Polymerase Chain Reaction; RNA, Viral; Stavudine; Time Factors; Zidovudine | 1999 |
Cell-associated HIV-1 messenger RNA and DNA in T-helper cell and monocytes in asymptomatic HIV-1-infected subjects on HAART plus an inactivated HIV-1 immunogen.
Topics: AIDS Vaccines; Anti-HIV Agents; CD4 Lymphocyte Count; Combined Modality Therapy; DNA, Viral; Drug Therapy, Combination; Freund's Adjuvant; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Monocytes; Pilot Projects; RNA, Viral; T-Lymphocytes, Helper-Inducer; Viral Load; Zidovudine | 1999 |
Preliminary experiences with triple therapy including nelfinavir and two reverse transcriptase inhibitors in previously untreated HIV-infected children.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Didanosine; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant; Lamivudine; Male; Nelfinavir; Prospective Studies; Reverse Transcriptase Inhibitors; Stavudine; Viral Load; Zidovudine | 1999 |
Evidence of stavudine-related phenotypic resistance among zidovudine-pretreated HIV-1-infected subjects receiving a therapeutic regimen of stavudine plus lamivudine.
Topics: Anti-HIV Agents; Drug Resistance, Microbial; Drug Therapy, Combination; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Molecular Sequence Data; Phenotype; Prospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Zidovudine | 1999 |
Lamivudine reduces healthcare resource use when added to zidovudine-containing regimens in patients with HIV infection.
Topics: Adult; Ambulatory Care; Anti-HIV Agents; Double-Blind Method; Drug Therapy, Combination; Female; Health Resources; HIV Infections; Hospitalization; Humans; Lamivudine; Length of Stay; Male; Zidovudine | 1999 |
A prospective cost-consequence analysis of adding lamivudine to zidovudine-containing antiretroviral treatment regimens for HIV infection in the US.
Topics: Adult; Ambulatory Care; Anti-HIV Agents; Cost-Benefit Analysis; Double-Blind Method; Drug Costs; Drug Therapy, Combination; Female; Health Resources; HIV Infections; Hospitalization; Humans; Lamivudine; Length of Stay; Male; Middle Aged; Prospective Studies; United States; Zidovudine | 1999 |
A prospective evaluation of the cost effectiveness of adding lamivudine to zidovudine-containing antiretroviral treatment regimens in HIV infection. European perspective.
Topics: Adult; Ambulatory Care; Anti-HIV Agents; Cost-Benefit Analysis; Double-Blind Method; Drug Costs; Drug Therapy, Combination; Europe; Female; Health Care Costs; Health Resources; HIV Infections; Hospitalization; Humans; Lamivudine; Male; Prospective Studies; Zidovudine | 1999 |
An evaluation of the cost effectiveness of adding lamivudine to zidovudine-containing regimens in HIV infection. Canadian perspective.
Topics: Adult; Ambulatory Care; Anti-HIV Agents; Canada; Cost-Benefit Analysis; Double-Blind Method; Drug Costs; Drug Therapy, Combination; Female; Health Care Costs; Health Resources; HIV Infections; Hospitalization; Humans; Lamivudine; Male; Prospective Studies; Zidovudine | 1999 |
Quality of life and treatment satisfaction after the addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens in treatment-experienced patients with HIV infection.
Topics: Acetamides; Acetophenones; Adult; Anti-HIV Agents; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Patient Satisfaction; Quality of Life; Zidovudine | 1999 |
The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1.
Topics: Anti-HIV Agents; Area Under Curve; Cross-Over Studies; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Monocytes; Phosphorylation; Reverse Transcriptase Inhibitors | 1999 |
Population pharmacokinetics of lamivudine in adult human immunodeficiency virus-infected patients enrolled in two phase III clinical trials.
Topics: Adult; Anti-HIV Agents; Biotransformation; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Nonlinear Dynamics; Population; Regression Analysis | 1999 |
Saquinavir therapy in patients with the advanced HIV infection and liver cirrhosis.
Topics: Adult; Drug Therapy, Combination; Hemophilia A; Hepatitis C; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Liver Cirrhosis; Ritonavir; Saquinavir; Stavudine | 1999 |
A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-CD8 Ratio; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Palatine Tonsil; Ritonavir; RNA, Viral; Spain; Stavudine; Viremia; Zalcitabine; Zidovudine | 1999 |
A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience. Amprenavir PROAB2002 Study Team.
Topics: Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nausea; RNA, Viral; Safety; Sulfonamides; Time Factors; Viremia; Zidovudine | 1999 |
Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team.
Topics: Adult; Alkynes; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Male; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Zidovudine | 1999 |
Alteration of complement protein levels after antiretroviral therapy in HIV-infected persons.
Topics: Anti-HIV Agents; Complement Pathway, Classical; Complement System Proteins; Drug Administration Schedule; Drug Therapy, Combination; HIV Antibodies; HIV Antigens; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Ritonavir; Viral Load; Zidovudine | 1999 |
T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART).
Topics: Anti-HIV Agents; Antigens, CD; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Drug Therapy, Combination; HIV Infections; HIV Seronegativity; HIV-1; Humans; Indinavir; Ki-67 Antigen; Lamivudine; Longitudinal Studies; Lymphocyte Activation; RNA, Viral; Saquinavir; T-Lymphocyte Subsets; T-Lymphocytes; Viral Load; Zidovudine | 2000 |
Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response.
Topics: Anti-HIV Agents; Candida; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Drug Therapy, Combination; HIV Infections; Humans; Hypersensitivity, Delayed; Immune System; Lamivudine; Mumps virus; Ritonavir; RNA, Viral; Zidovudine | 2000 |
Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype.
Topics: Amino Acid Substitution; Drug Resistance, Microbial; Drug Therapy, Combination; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Mutation; Prospective Studies; Reverse Transcriptase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; RNA-Directed DNA Polymerase; Zidovudine | 1999 |
Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team).
Topics: Anti-HIV Agents; Case-Control Studies; Drug Resistance, Microbial; Drug Therapy, Combination; Genotype; HIV; HIV Infections; Humans; Indinavir; Lamivudine; Patient Compliance; Treatment Failure; Viral Load; Zidovudine | 2000 |
Cerebrospinal fluid beta2-microglobulin, monocyte chemotactic protein-1, and soluble tumour necrosis factor alpha receptors before and after treatment with lamivudine plus zidovudine or stavudine.
Topics: Adult; Anti-HIV Agents; beta 2-Microglobulin; Chemokine CCL2; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Middle Aged; Receptors, Tumor Necrosis Factor; Solubility; Stavudine; Zidovudine | 2000 |
Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial. Pediatric AIDS Clinical Trials Group 338 Study Team.
Topics: Adolescent; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Stavudine; Viral Load; Zidovudine | 2000 |
Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team.
Topics: Adult; Anti-HIV Agents; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Middle Aged; Molecular Sequence Data; Mutation; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Viral Load; Zidovudine | 2000 |
RANTES production by T cells and CD8-mediated inhibition of human immunodeficiency virus gene expression before initiation of potent antiretroviral therapy predict sustained suppression of viral replication.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Chemokine CCL5; Gene Expression; HIV Infections; HIV Long Terminal Repeat; HIV-1; Humans; Lamivudine; Predictive Value of Tests; Prospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Saquinavir; Single-Blind Method; T-Lymphocytes; Viral Load; Virus Replication; Zidovudine | 2000 |
Human immunodeficiency virus-infected persons with mutations conferring resistance to zidovudine show reduced virologic responses to hydroxyurea and stavudine-lamivudine.
Topics: Anti-HIV Agents; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Hydroxyurea; Lamivudine; Logistic Models; Mutation; Nucleic Acid Synthesis Inhibitors; Reverse Transcriptase Inhibitors; Stavudine; Viral Load; Zidovudine | 2000 |
Indinavir pharmacokinetics and parmacodynamics in children with human immunodeficiency virus infection.
Topics: Adolescent; Anti-HIV Agents; Area Under Curve; Body Surface Area; CD4 Lymphocyte Count; Child; DNA, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Male; Stavudine; Viral Load | 2000 |
AVANTI 1: randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus loviride in HIV-infected antiretroviral-naive patients. AVANTI Study Group.
Topics: Acetamides; Acetophenones; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Zidovudine | 1999 |
Effects of early antiretroviral treatment on HIV-1 RNA in blood and lymphoid tissue: a randomized trial of double versus triple therapy. Swiss HIV Cohort Study.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lymphoid Tissue; Male; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Time Factors; Viral Load; Zidovudine | 2000 |
A randomized, comparative study of lamivudine plus stavudine, with indinavir or nelfinavir, in treatment-experienced HIV-infected patients.
Topics: Adult; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Kidney Diseases; Lamivudine; Male; Nelfinavir; Patient Compliance; Prospective Studies; Reverse Transcriptase Inhibitors; Stavudine; Treatment Outcome | 2000 |
HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy.
Topics: Cohort Studies; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Phenotype; Reverse Transcriptase Inhibitors; RNA, Viral; Viral Load; Zidovudine | 2000 |
Nevirapine/didanosine/lamivudine once daily in HIV-1-infected intravenous drug users.
Topics: Adult; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Methadone; Nevirapine; Pilot Projects; Prospective Studies; Substance Abuse, Intravenous; Viral Load | 1998 |
Ongoing open-label trials of triple therapy with stavudine and lamivudine or stavudine and didanosine plus nelfinavir.
Topics: Adult; Anti-HIV Agents; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Reverse Transcriptase Inhibitors; Stavudine | 1998 |
AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
Topics: Adult; Anti-HIV Agents; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Male; Patient Compliance; Placebos; Reverse Transcriptase Inhibitors; RNA, Viral; Viral Load; Zidovudine | 2000 |
The effects of protease inhibitor therapy on human immunodeficiency virus type 1 levels in semen (AIDS clinical trials group protocol 850).
Topics: Adult; Carbamates; Double-Blind Method; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Regression Analysis; RNA, Viral; Semen; Sulfonamides; Virus Shedding; Zidovudine | 2000 |
Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection.
Topics: Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Combinations; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Patient Compliance; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Viral Load; Zidovudine | 2000 |
A randomized, controlled, phase II trial comparing escalating doses of subcutaneous interleukin-2 plus antiretrovirals versus antiretrovirals alone in human immunodeficiency virus-infected patients with CD4+ cell counts >/=350/mm3.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Didanosine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Indinavir; Injections, Subcutaneous; Interleukin-2; Lamivudine; Lymphocyte Count; Male; Nelfinavir; Nevirapine; Ritonavir; RNA, Viral; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 2000 |
Maximum suppression of HIV replication leads to the restoration of HIV-specific responses in early HIV disease.
Topics: Adolescent; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Cytokines; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Lymphocyte Activation; Reverse Transcriptase Inhibitors; RNA, Viral; Time Factors; Viral Load; Virus Replication; Zidovudine | 2000 |
Effect of chemokine receptor gene polymorphisms on the response to potent antiretroviral therapy.
Topics: Adult; Alleles; Anti-HIV Agents; Chemokine CXCL12; Chemokines, CXC; Drug Therapy, Combination; Female; Gene Frequency; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Linkage Disequilibrium; Male; Polymorphism, Genetic; Receptors, CCR2; Receptors, CCR5; Receptors, Chemokine; Receptors, Cytokine; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Zidovudine | 2000 |
Dual nucleoside regimens in nonadvanced HIV infection: prospective follow-up of 130 patients, Aquitaine Cohort, 1996 to 1998. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA).
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Didanosine; Drug Therapy, Combination; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lamivudine; Multivariate Analysis; Prospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Treatment Outcome; Zalcitabine; Zidovudine | 2000 |
Clinical and virologic response to combination treatment with indinavir, zidovudine, and lamivudine in children with human immunodeficiency virus-1 infection: a multicenter study in the Netherlands. On behalf of the Dutch Study Group for Children with HIV
Topics: Adolescent; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Infant; Lamivudine; Male; Netherlands; Prospective Studies; Zidovudine | 2000 |
Effect of two different combinations of antiretrovirals (AZT+ddI and AZT+3TC) on cytokine production and apoptosis in asymptomatic HIV infection.
Topics: Anti-HIV Agents; Apoptosis; CD4 Lymphocyte Count; CD4-CD8 Ratio; Cytokines; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Leukocytes, Mononuclear; Prospective Studies; Reverse Transcriptase Inhibitors; Th1 Cells; Viremia; Zidovudine | 2000 |
3-year suppression of HIV viremia with indinavir, zidovudine, and lamivudine.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Genotype; HIV; HIV Infections; Humans; Indinavir; Kidney Calculi; Lamivudine; Male; Middle Aged; RNA, Viral; Viral Load; Viremia; Zidovudine | 2000 |
A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: the OzCombo1 study.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Australia; CD4 Lymphocyte Count; Didanosine; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Male; Stavudine; Viral Load; Zidovudine | 2000 |
Efficacy and safety of twice daily first-line ritonavir/indinavir plus double nucleoside combination therapy in HIV-infected individuals. German Ritonavir/Indinavir Study Group.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Black People; CD4 Lymphocyte Count; Didanosine; Drug Administration Schedule; Female; Germany; HIV Infections; Humans; Indinavir; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Stavudine; Time Factors; White People | 2000 |
Pharmacokinetic consideration on administration regimen of lamivudine in japanese patients infected with HIV-1.
Topics: Adult; Algorithms; Anti-HIV Agents; Area Under Curve; Female; Half-Life; HIV Infections; HIV-1; Humans; Lamivudine; Male; Models, Biological | 2000 |
Recovery of replication-competent virus from CD4 T cell reservoirs and change in coreceptor use in human immunodeficiency virus type 1-infected children responding to highly active antiretroviral therapy.
Topics: Adolescent; CD4-Positive T-Lymphocytes; Cell Differentiation; Child; Coculture Techniques; Female; HIV Infections; HIV-1; Humans; Immunophenotyping; Infant; Lamivudine; Leukocytes, Mononuclear; Male; Nelfinavir; Prospective Studies; Receptors, CCR5; Receptors, CXCR4; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Viral Load; Virus Replication; Zidovudine | 2000 |
Virological and immunological effects of combination antiretroviral therapy with zidovudine, lamivudine, and indinavir during primary human immunodeficiency virus type 1 infection.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Core Protein p24; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Male; Middle Aged; Patient Compliance; Zidovudine | 2000 |
Comparison of a point mutation assay with a line probe assay for the detection of the major mutations in the HIV-1 reverse transcriptase gene associated with reduced susceptibility to nucleoside analogues.
Topics: Acetamides; Acetophenones; Anti-HIV Agents; Codon; DNA; DNA Mutational Analysis; Drug Resistance, Microbial; Drug Therapy, Combination; Evaluation Studies as Topic; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Microbial Sensitivity Tests; Nucleosides; Point Mutation; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 2000 |
A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I).
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Male; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Thymidine; Zidovudine | 2000 |
A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Didanosine; Dideoxynucleosides; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Male; Reverse Transcriptase Inhibitors; Stavudine; Thymidine; Viral Load; Zidovudine | 2000 |
Comparative studies of two-times-daily versus three-times-daily indinavir in combination with zidovudine and lamivudine.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Administration Schedule; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Pilot Projects; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Viral Load; Zidovudine | 2000 |
Effect of lamivudine in HIV-infected persons with prior exposure to zidovudine/didanosine or zidovudine/zalcitabine.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Zalcitabine; Zidovudine | 2000 |
Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIV-infected persons.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Cytidine Triphosphate; Dideoxynucleotides; Dose-Response Relationship, Drug; Drug Therapy, Combination; HIV; HIV Infections; Humans; Lamivudine; Leukocytes, Mononuclear; Middle Aged; Prospective Studies; Regression Analysis; Reverse Transcriptase Inhibitors; RNA, Viral; Thymine Nucleotides; Zidovudine | 2000 |
Patterns of lymphotropic herpesvirus viraemia in HIV-infected patients with Kaposi's sarcoma treated with highly active antiretroviral therapy and liposomal daunorubicin.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Daunorubicin; Didanosine; Drug Therapy, Combination; Herpesvirus 8, Human; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Reverse Transcriptase Inhibitors; Sarcoma, Kaposi; Stavudine; Viremia | 2000 |
Comparison of immunologic restoration and virologic response in plasma, tonsillar tissue, and cerebrospinal fluid in HIV-1-infected patients treated with double versus triple antiretroviral therapy in very early stages: The Spanish EARTH-2 Study. Early An
Topics: Adult; Blood; CD4 Lymphocyte Count; Cell Count; Cerebrospinal Fluid; Cerebrospinal Fluid Proteins; Cohort Studies; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Palatine Tonsil; Point Mutation; Reverse Transcriptase Inhibitors; RNA, Viral; Spain; Stavudine; Time Factors; Viral Load; Zidovudine | 2000 |
HAART tolerability: post-exposure prophylaxis in healthcare workers versus treatment in HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Chemoprevention; Female; Health Personnel; HIV Infections; Humans; Indinavir; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Zidovudine | 2000 |
Amprenavir in combination with lamivudine and zidovudine versus lamivudine and zidovudine alone in HIV-1-infected antiretroviral-naive adults. Amprenavir PROAB3001 International Study Team.
Topics: Adolescent; Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; Furans; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; RNA, Viral; Sulfonamides; Zidovudine | 2000 |
Dose-finding study of once-daily indinavir/ritonavir plus zidovudine and lamivudine in HIV-infected patients.
Topics: Adult; CD4 Lymphocyte Count; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Male; Middle Aged; Pilot Projects; Reverse Transcriptase Inhibitors; Ritonavir; Viral Load; Zidovudine | 2000 |
Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir.
Topics: Adult; Algorithms; Anti-HIV Agents; Area Under Curve; Drug Therapy, Combination; Female; Half-Life; HIV Infections; Humans; Indinavir; Lamivudine; Male; Middle Aged; Patient Compliance; Zidovudine | 2001 |
Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients.
Topics: Adult; Anti-HIV Agents; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Zidovudine | 2000 |
Twice-daily triple nucleoside intensification treatment with lamivudine-zidovudine plus abacavir sustains suppression of human immunodeficiency virus type 1: results of the TARGET Study.
Topics: Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Viral Load; Zidovudine | 2001 |
Virologic and CD4 cell response to zidovudine or zidovudine and lamivudine following didanosine treatment of human immunodeficiency virus infection.
Topics: Adult; CD4 Lymphocyte Count; Didanosine; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Zidovudine | 2001 |
Alterations in T cell phenotype and human immunodeficiency virus type 1-specific cytotoxicity after potent antiretroviral therapy.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Dose-Response Relationship, Immunologic; Drug Therapy, Combination; Epitopes, T-Lymphocyte; Flow Cytometry; HIV Infections; HIV-1; HLA-DR Antigens; Humans; Immunodominant Epitopes; Immunohistochemistry; Immunophenotyping; Indinavir; Lamivudine; Leukocyte Common Antigens; Prospective Studies; Protein Tyrosine Phosphatase, Non-Receptor Type 1; T-Lymphocytes, Cytotoxic; Viral Load; Zidovudine | 2001 |
Indinavir, nevirapine, stavudine, and lamivudine for human immunodeficiency virus-infected, amprenavir-experienced subjects: AIDS Clinical Trials Group protocol 373.
Topics: Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Cross-Over Studies; Dose-Response Relationship, Drug; Female; Furans; HIV Infections; Humans; Indinavir; Lamivudine; Male; Nevirapine; Odds Ratio; Prospective Studies; RNA, Viral; Safety; Stavudine; Sulfonamides; Time Factors; Treatment Outcome; Viral Load | 2001 |
The ADAM study continued: maintenance therapy after 50 weeks of induction therapy.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Administration Schedule; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Nelfinavir; Reverse Transcriptase Inhibitors; RNA, Viral; Saquinavir; Stavudine; Time Factors; Treatment Outcome; Viral Load | 2001 |
ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Stavudine; Viral Load | 2001 |
Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Double-Blind Method; Drug Resistance, Microbial; Female; Genotype; HIV; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; Humans; Indinavir; Lamivudine; Male; Middle Aged; Mutation; Reverse Transcriptase Inhibitors; Survival Analysis; Therapeutic Equivalency; Viral Load; Zidovudine | 2001 |
Long-term virologic and immunologic responses in human immunodeficiency virus type 1-infected children treated with indinavir, zidovudine, and lamivudine.
Topics: Adolescent; Anti-HIV Agents; CD4 Antigens; CD4 Lymphocyte Count; Child; Child, Preschool; Drug Therapy, Combination; Female; Follow-Up Studies; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Leukocyte Common Antigens; Male; Protein Tyrosine Phosphatase, Non-Receptor Type 1; RNA, Viral; Viral Load; Zidovudine | 2001 |
Therapeutic effects of nucleoside analogues on psychomotor slowing in HIV infection.
Topics: Adult; Anti-HIV Agents; Central Nervous System Diseases; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Male; Middle Aged; Motor Skills; Stavudine; Zalcitabine; Zidovudine | 2001 |
Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Female; Granulocyte Colony-Stimulating Factor; HIV Infections; Humans; Indinavir; Lamivudine; Lymphoma, AIDS-Related; Lymphoma, Non-Hodgkin; Male; Middle Aged; Neutropenia; Prednisone; Stavudine; Treatment Outcome; Vincristine; Viral Load | 2001 |
An open-label randomized trial to evaluate different therapeutic strategies of combination therapy in HIV-1 infection: design, rationale, and methods of the initio trial.
Topics: Adult; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Patient Selection; Randomized Controlled Trials as Topic; Research Design; Ritonavir; Sample Size; Saquinavir; Stavudine; Zidovudine | 2001 |
A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults.
Topics: Adult; Area Under Curve; Cross-Over Studies; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Half-Life; HIV Infections; HIV-1; Humans; Lamivudine; Male; Metabolic Clearance Rate; Reverse Transcriptase Inhibitors; Tablets; Zidovudine | 2001 |
Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1.
Topics: Anti-HIV Agents; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Multivariate Analysis; Pregnancy; Pregnancy Complications, Infectious; Viral Load; Zidovudine | 2001 |
Challenges of antiretroviral treatment in transient and drug-using populations: the SUN study.
Topics: Adult; Antiretroviral Therapy, Highly Active; Capsules; CD4 Lymphocyte Count; Chemistry, Pharmaceutical; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Mental Disorders; Patient Compliance; Pilot Projects; Proportional Hazards Models; Reverse Transcriptase Inhibitors; Saquinavir; Substance Abuse, Intravenous; Transients and Migrants; Treatment Outcome; Viral Load; Zidovudine | 2001 |
Open-label phase II trial of amprenavir, abacavir, and fixed-dose zidovudine/lamivudine in newly and chronically HIV-1--infected patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS Dementia Complex; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Chronic Disease; Dideoxynucleosides; Digestive System; Drug Synergism; Ethnicity; Female; Furans; HIV Infections; HIV-1; Humans; Lamivudine; Lymphocyte Subsets; Male; Pregnancy; Research Design; RNA, Viral; Sulfonamides; Treatment Refusal; Zidovudine | 2001 |
Phase II/III Trials of Viracept start.
Topics: Anti-HIV Agents; Blood; CD4 Lymphocyte Count; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Isoquinolines; Lamivudine; Nelfinavir; Pilot Projects; Reverse Transcriptase Inhibitors; Stavudine; Sulfonic Acids; Time Factors; Zidovudine | 1996 |
Final CESARE trial results show continued clinical and survival benefit.
Topics: Acetamides; Acetophenones; Anti-HIV Agents; Antiviral Agents; CD4 Lymphocyte Count; Controlled Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Survival Rate; Zalcitabine; Zidovudine | 1997 |
Phase III results presented on amprenavir triple combination.
Topics: Anti-HIV Agents; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Sulfonamides; Zidovudine | 1998 |
3TC expanded access program: new requirement for CD4 less than 100.
Topics: CD4 Lymphocyte Count; HIV Infections; Humans; Lamivudine; Zalcitabine | 1995 |
Treatment for primary infection.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Cohort Studies; Controlled Clinical Trials as Topic; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Placebos; Pyridines; Ritonavir; Thiazoles; Valine; Zalcitabine; Zidovudine | 1995 |
New double vs. triple antiviral combination study, CD4 200-500, no prior treatment.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Nevirapine; Pyridines; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1995 |
Antiretroviral combination treatment prolongs life in people with HIV/AIDS.
Topics: Antiviral Agents; Clinical Trials as Topic; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1996 |
Protease inhibitors: major study stopped when 3-drug arm proves superior.
Topics: Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Treatment Outcome; Zidovudine | 1997 |
Major pediatric study stopped early: combination treatment better.
Topics: Anti-HIV Agents; Child; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Zidovudine | 1997 |
Combination therapies improve outlook for children with HIV disease.
Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Infant; Lamivudine; Zidovudine | 1997 |
Long-term safety and efficacy of nevirapine, stavudine and lamivudine in a real-world setting.
Topics: Adult; Aged; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Residence Characteristics; Reverse Transcriptase Inhibitors; Stavudine; Time; Treatment Outcome | 2001 |
Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377).
Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; Cohort Studies; Drug Resistance, Microbial; Female; Genotype; HIV Infections; HIV-1; Humans; Infant; Lamivudine; Male; Mutation; Nelfinavir; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Stavudine; Treatment Failure; Viral Load | 2001 |
Lactic acid levels in children perinatally treated with antiretroviral agents to prevent HIV transmission.
Topics: Anti-HIV Agents; Cross-Sectional Studies; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lactic Acid; Lamivudine; Male; Perinatal Care; Pregnancy; Pregnancy Complications, Infectious; Prenatal Care; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 2001 |
Low incidence of genotypic and phenotypic resistance in paediatric HIV-infected patients on long-term first-line antiretroviral triple therapy.
Topics: Adolescent; Child; Child, Preschool; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Genotype; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Indinavir; Infant; Lamivudine; Male; Nelfinavir; Phenotype; Point Mutation; Reverse Transcriptase Inhibitors; Ritonavir; Time; Viral Load; Zidovudine | 2001 |
A randomized, open-label, comparative trial of zidovudine plus lamivudine versus zidovudine plus lamivudine plus didanosine in antiretroviral-naive HIV-1-infected Thai patients.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; RNA, Viral; Thailand; Treatment Outcome; Zidovudine | 2001 |
Pharmacokinetics of zidovudine and lamivudine in neonates following coadministration of oral doses every 12 hours.
Topics: Adult; Area Under Curve; Breast Feeding; Drug Combinations; Enzyme-Linked Immunosorbent Assay; Female; Half-Life; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Metabolic Clearance Rate; Pregnancy; Reverse Transcriptase Inhibitors; RNA, Viral; Viral Load; Zidovudine | 2001 |
AVANTI 3: a randomized, double-blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in HIV-1-infected antiretroviral-naive patients.
Topics: Administration, Oral; Adult; Anti-HIV Agents; Clinical Protocols; Diarrhea; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Male; Nausea; Nelfinavir; Patient Compliance; RNA, Viral; Zidovudine | 2001 |
Treatment intensification with abacavir in HIV-infected patients with at least 12 weeks previous lamivudine/zidovudine treatment.
Topics: Administration, Oral; Adolescent; Adult; Anti-HIV Agents; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; RNA, Viral; Time Factors; Zidovudine | 2001 |
Effects of treatment intensification with hydroxyurea in HIV-infected patients with virologic suppression.
Topics: Adolescent; Adult; Anti-HIV Agents; Case-Control Studies; CD4 Lymphocyte Count; Drug Therapy, Combination; Enzyme Inhibitors; Female; HIV Infections; Humans; Hydroxyurea; Indinavir; Lamivudine; Male; Nucleic Acid Synthesis Inhibitors; Pancreatitis; Prospective Studies; Survival Analysis; Treatment Failure; Viral Load; Zidovudine | 2001 |
Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine.
Topics: Adult; Didanosine; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Male; Microbial Sensitivity Tests; Phenotype; Point Mutation; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 2001 |
Triple nuke therapy--results after one year.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Reverse Transcriptase Inhibitors; Viral Load; Zidovudine | 2001 |
HIV-1 induction-maintenance at the lymph node level: the "Apollo-97" Study.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biopsy; CD4 Lymphocyte Count; Didanosine; DNA, Viral; Drug Therapy, Combination; Female; France; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lymph Nodes; Lymphocyte Subsets; Lymphocytes; Male; Polymerase Chain Reaction; Ritonavir; RNA, Viral; Saquinavir; Time Factors; Viral Load; Viremia; Virus Replication | 2001 |
Potential adverse effects of structured therapeutic interruptions on the pool of HIV-infected cells.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Didanosine; Disease Progression; HIV Infections; HIV-1; Humans; Lamivudine; Lymphocyte Count; Morbidity; Prognosis; Ritonavir; RNA, Viral; Saquinavir; Viral Load; Zidovudine | 2001 |
Randomized, double-blind comparison of two nelfinavir doses plus nucleosides in HIV-infected patients (Agouron study 511).
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Nelfinavir; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Zidovudine | 2001 |
Comparison of the plasma pharmacokinetics of lamivudine during twice and once daily administration in patients with HIV.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Chromatography, High Pressure Liquid; Drug Administration Schedule; Female; Half-Life; HIV Infections; HIV-1; Humans; Lamivudine; Male | 2001 |
Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Protocols; Disease Progression; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Logistic Models; Male; Middle Aged; RNA, Viral; Viral Load; Zidovudine | 2001 |
Pharmacokinetics of nevirapine and lamivudine in patients with HIV-1 infection.
Topics: Adult; Age Factors; Anti-HIV Agents; Double-Blind Method; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Nevirapine; Nucleosides; Placebos; Reverse Transcriptase Inhibitors; Sex Factors; Trimethoprim, Sulfamethoxazole Drug Combination | 2000 |
Failure of stavudine-lamivudine combination therapy in antiretroviral-naive patients with AZT-like HIV-1 resistance mutations.
Topics: Anti-HIV Agents; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Mutation; Stavudine; Treatment Failure; Zidovudine | 2001 |
Pilot study of the effects of intermittent interleukin-2 on human immunodeficiency virus (HIV)-specific immune responses in patients treated during recently acquired HIV infection.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Coculture Techniques; Cyclopropanes; Drug Synergism; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Interferon-gamma; Interleukin-2; Lamivudine; Lymphocyte Activation; Lymphocyte Subsets; Oxazines; Pilot Projects; Reverse Transcriptase Inhibitors; Stavudine | 2002 |
Response to lamivudine-zidovudine plus abacavir twice daily in antiretroviral-naive, incarcerated patients with HIV infection taking directly observed treatment.
Topics: Adolescent; Adult; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Therapy, Combination; Female; Health Care Costs; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Treatment Outcome; Zidovudine | 2002 |
Evidence of immune reconstitution in antiretroviral drug-experienced patients with advanced HIV disease.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Antigens, CD; Antiretroviral Therapy, Highly Active; Benzoxazines; Biomarkers; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Cyclopropanes; Didanosine; Dideoxynucleosides; Double-Blind Method; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Male; Middle Aged; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Treatment Outcome; Viral Load; Zidovudine | 2002 |
Concentration-controlled compared with conventional antiretroviral therapy for HIV infection.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Dose-Response Relationship, Drug; Feasibility Studies; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Male; Middle Aged; Prospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Zidovudine | 2002 |
Final analysis of the Trilège induction-maintenance trial: results at 18 months.
Topics: Adult; Anti-HIV Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Male; Middle Aged; Multivariate Analysis; Reverse Transcriptase Inhibitors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Zidovudine | 2002 |
Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1.
Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; Child; Child, Preschool; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Nelfinavir; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Stavudine | 2002 |
Results of 2 years of treatment with protease-inhibitor--containing antiretroviral therapy in dutch children infected with human immunodeficiency virus type 1.
Topics: Adolescent; CD4 Lymphocyte Count; Child; Child, Preschool; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Infant; Lamivudine; Male; Nelfinavir; Netherlands; Prospective Studies; Reverse Transcriptase Inhibitors; Treatment Outcome; Zidovudine | 2002 |
Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial.
Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant; Lamivudine; Male; Nelfinavir; Reverse Transcriptase Inhibitors; RNA, Viral; Viral Load; Zidovudine | 2002 |
[A clinical trial using zidovudine and lamivudine plus indinavir triple therapy in Chinese individuals with human immunodeficiency virus infection].
Topics: Adult; Aged; Anti-HIV Agents; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; China; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Lymphocyte Count; Male; Middle Aged; RNA, Viral; Time Factors; Treatment Outcome; Viremia; Zidovudine | 2002 |
Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial.
Topics: Adult; Anti-HIV Agents; Breast Feeding; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant Mortality; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Male; Multicenter Studies as Topic; Pregnancy; Risk Factors; South Africa; Tanzania; Treatment Outcome; Uganda; Zidovudine | 2002 |
Therapeutic vaccination in primary HIV infection, the Quest trial.
Topics: AIDS Vaccines; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Carbamates; CD8-Positive T-Lymphocytes; Combined Modality Therapy; Defective Viruses; Dideoxynucleosides; Furans; HIV Infections; Humans; Immunotherapy, Active; Lamivudine; Lymphocyte Count; Sulfonamides; T-Lymphocyte Subsets; Vaccination; Vaccinia virus; Viral Load; Viral Vaccines; Viremia; Zidovudine | 2002 |
Efficacy of zidovudine compared to stavudine, both in combination with lamivudine and indinavir, in human immunodeficiency virus-infected nucleoside-experienced patients with no prior exposure to lamivudine, stavudine, or protease inhibitors (novavir tria
Topics: Adult; Anti-HIV Agents; Double-Blind Method; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Treatment Outcome; Viral Load; Zidovudine | 2002 |
Addition of cyclophosphamide to antiretroviral therapy does not diminish the cellular reservoir in HIV-infected persons.
Topics: Adolescent; Adult; CD4 Lymphocyte Count; Cyclophosphamide; DNA, Viral; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lymphoid Tissue; Male; Middle Aged; Monocytes; Nelfinavir; Pilot Projects; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Viral Load | 2002 |
Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Double-Blind Method; Drug Resistance, Viral; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Nelfinavir; Proportional Hazards Models; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Survival Analysis; Viral Load | 2002 |
The safety and pharmacokinetics of a reverse transcriptase inhibitor, 3TC, in patients with HIV infection: a phase I study.
Topics: Administration, Oral; Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; Headache; HIV Infections; Humans; Infusions, Intravenous; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Zalcitabine | 1992 |
1564 other study(ies) available for lamivudine and HIV Coinfection
| Article | Year |
|---|---|
Antiviral and cellular metabolism interactions between Dexelvucitabine and lamivudine.
Topics: Anti-HIV Agents; Cell Line, Tumor; Cells, Cultured; Drug Interactions; Drug Synergism; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Leukocytes, Mononuclear; Reverse Transcriptase Inhibitors; Zalcitabine | 2007 |
Evidence and possible consequences of the phosphorylation of nucleoside reverse transcriptase inhibitors in human red blood cells.
Topics: Adenine; Anti-HIV Agents; Drug Interactions; Drug Therapy, Combination; Erythrocytes; HIV Infections; Humans; Lamivudine; Nucleosides; Organophosphonates; Phosphorylation; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Zidovudine | 2007 |
Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge.
Topics: Antiviral Agents; Cell Line; Guanine; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans | 2008 |
Human immunodeficiency virus type 1 isolates with the reverse transcriptase (RT) mutation Q145M retain nucleoside and nonnucleoside RT inhibitor susceptibility.
Topics: Amino Acid Sequence; Anti-HIV Agents; Drug Resistance, Viral; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Mutation; Nucleosides; Phenotype; Reverse Transcriptase Inhibitors | 2009 |
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
Topics: Anti-HIV Agents; Cell Line, Tumor; Cell Survival; Cells, Cultured; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Molecular Structure; Reverse Transcriptase Inhibitors | 2009 |
Telbivudine exhibits no inhibitory activity against HIV-1 clinical isolates in vitro.
Topics: Anti-HIV Agents; Antiviral Agents; Drug Resistance, Viral; Guanine; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Nucleosides; Pyrimidinones; Telbivudine; Thymidine | 2010 |
Development of hexadecyloxypropyl tenofovir (CMX157) for treatment of infection caused by wild-type and nucleoside/nucleotide-resistant HIV.
Topics: Adenine; Anti-HIV Agents; Cell Survival; Cells, Cultured; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Macrophages; Nucleosides; Nucleotides; Organophosphonates; Tenofovir | 2010 |
Synthesis and anti-HIV activities of symmetrical dicarboxylate esters of dinucleoside reverse transcriptase inhibitors.
Topics: Anti-HIV Agents; Cell Line; Dicarboxylic Acids; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Reverse Transcriptase Inhibitors; Structure-Activity Relationship | 2012 |
Design, synthesis and anti-HIV evaluation of novel diarylnicotinamide derivatives (DANAs) targeting the entrance channel of the NNRTI binding pocket through structure-guided molecular hybridization.
Topics: Anti-HIV Agents; Catalytic Domain; Dose-Response Relationship, Drug; Drug Design; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Models, Molecular; Molecular Structure; Niacinamide; Protein Conformation; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Tumor Cells, Cultured | 2014 |
Synthesis and anti-HIV activities of unsymmetrical long chain dicarboxylate esters of dinucleoside reverse transcriptase inhibitors.
Topics: Anti-HIV Agents; Dicarboxylic Acids; Esters; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Nucleosides; Reverse Transcriptase Inhibitors | 2017 |
Mechanistic Insight into Antiretroviral Potency of 2'-Deoxy-2'-β-fluoro-4'-azidocytidine (FNC) with a Long-Lasting Effect on HIV-1 Prevention.
Topics: Animals; Anti-HIV Agents; Azides; Deoxycytidine; HIV Infections; HIV-1; Humans; Lamivudine; Macaca mulatta; Models, Molecular; Reverse Transcriptase Inhibitors; Ubiquitination | 2020 |
Detection of archived lamivudine-associated resistance mutations in virologically suppressed, lamivudine-experienced HIV-infected adults by different genotyping techniques (GEN-PRO study).
Topics: Anti-HIV Agents; Cross-Sectional Studies; Drug Resistance, Viral; Genotype; Genotyping Techniques; HIV Infections; Humans; Lamivudine; Mutation; Viral Load | 2021 |
Real-World Experience with Two-Drug Regimens in HIV-1-Infected Patients Beyond the Indication of Clinical Trials: 48 Weeks' Results.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Pharmaceutical Preparations; Retrospective Studies | 2021 |
Analysis of the ternary antiretroviral therapy dolutegravir, lamivudine and abacavir using UV spectrophotometry and chemometric tools.
Topics: Calibration; Dideoxynucleosides; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Least-Squares Analysis; Oxazines; Piperazines; Pyridones; Spectrophotometry; Spectrophotometry, Ultraviolet | 2022 |
Acute myocardial infarction associated with abacavir and tenofovir based antiretroviral drug combinations in the United States.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; HIV Infections; HIV-1; Humans; Lamivudine; Myocardial Infarction; Tenofovir; United States | 2021 |
Characterization of HIV-1 drug resistance among patients with failure of second-line combined antiretroviral therapy in central Ethiopia.
Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; Ethiopia; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Ritonavir; Viral Load | 2022 |
Renal profile of patients treated with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate and dolutegravir/abacavir/lamivudine: 120-week results from a real-world cohort.
Topics: Anti-HIV Agents; Cobicistat; Creatinine; Emtricitabine; Fumarates; HIV Infections; Humans; Lamivudine | 2023 |
Dolutegravir-based dual maintenance regimens combined with lamivudine/emtricitabine or rilpivirine: risk of virological failure in a real-life setting.
Topics: Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Rilpivirine; Viral Load | 2021 |
Acquired HIV drug resistance and virologic monitoring in a HIV hyper-endemic setting in KwaZulu-Natal Province, South Africa.
Topics: Adult; Anti-HIV Agents; Cross-Sectional Studies; Drug Resistance; Drug Resistance, Viral; HIV Infections; Humans; Lamivudine; South Africa | 2021 |
Comparison of the efficacy, safety and durability of a switch to co-formulated RPV/TDF-TAF/FTC or DTG/ABC/3TC in virologically-suppressed HIV-1-infected patients in a single Italian centre: a cohort data analysis.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Drug Combinations; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Immunocompromised Host; Italy; Lamivudine; Male; Middle Aged; Rilpivirine; Treatment Outcome | 2022 |
A Combination of Amino Acid Mutations Leads to Resistance to Multiple Nucleoside Analogs in Reverse Transcriptases from HIV-1 Subtypes B and C.
Topics: Amino Acids; Anti-HIV Agents; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Reverse Transcriptase Inhibitors; Zidovudine | 2022 |
Safety and effectiveness of switching to Abacavir/Lamivudine plus rilpivirine for maintenance therapy in virologically suppressed HIV-1 individuals in Singapore (SEALS).
Topics: Anti-HIV Agents; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Lamivudine; Retrospective Studies; Rilpivirine; Singapore | 2021 |
Changes in Serum Inflammatory Markers in Antiretroviral Therapy-Naive HIV-Infected Patients Starting Dolutegravir/Lamivudine or Dolutegravir/Lamivudine/Abacavir.
Topics: Anti-HIV Agents; Dideoxynucleosides; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Piperazines; Pyridones | 2022 |
Virological outcomes with dolutegravir plus either lamivudine or two NRTIs as switch strategies: a multi-cohort study.
Topics: Cohort Studies; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Retrospective Studies | 2022 |
Weight gain in treatment-naive HIV-1 infected patients starting abacavir/lamivudine/dolutegravir or tenofovir alafenamide/emtricitabine/bictegravir.
Topics: Alanine; Amides; Anti-HIV Agents; Dideoxynucleosides; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Tenofovir; Weight Gain | 2022 |
Impact of nucleos(t)ide reverse transcriptase inhibitor resistance on dolutegravir and protease-inhibitor-based regimens in children and adolescents in Kenya.
Topics: Adolescent; Anti-HIV Agents; Child; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Kenya; Lamivudine; Oxazines; Peptide Hydrolases; Piperazines; Protease Inhibitors; Pyridones; Reverse Transcriptase Inhibitors; Tenofovir | 2022 |
Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naive adults with HIV-1 infection.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Prospective Studies; Pyridones; Tenofovir | 2022 |
Synthesis of (±)-Emtricitabine and (±)-Lamivudine by Chlorotrimethylsilane-Sodium Iodide-Promoted Vorbrüggen Glycosylation.
Topics: Anti-HIV Agents; Deoxycytidine; Emtricitabine; Glycosylation; HIV Infections; HIV-1; Humans; Lamivudine; Sodium Iodide; Trimethylsilyl Compounds; Water | 2022 |
Brief Report: Patients' Experiences and Opinions After Desimplification of Their Single-Tablet Regimens for the Treatment of HIV Infection: A Survey in a Multicentre Cohort.
Topics: Anti-HIV Agents; Drug Combinations; Emtricitabine; HIV Infections; Humans; Lamivudine; Quality of Life; Surveys and Questionnaires; Tablets; Tenofovir | 2022 |
Impact of resistance mutations on efficacy of dolutegravir plus rilpivirine or plus lamivudine as maintenance regimens: a cohort study.
Topics: Anti-HIV Agents; Cohort Studies; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Mutation; Oxazines; Piperazines; Pyridones; Rilpivirine | 2022 |
Nevirapine hair and plasma concentrations and HIV-1 viral suppression among HIV infected ante-partum and post-partum women attended in a mother and child prevention program in Maputo city, Mozambique.
Topics: Adolescent; Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Drug Combinations; Female; Hair; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Logistic Models; Medication Adherence; Mozambique; Nevirapine; Postpartum Period; Pregnancy; Prospective Studies; Viral Load; Young Adult; Zidovudine | 2022 |
Hepatitis B surface antigen and hepatitis B RNA changes in HIV/hepatitis B virus co-infected participants receiving hepatitis B virus-active antiretroviral therapy.
Topics: Adult; Coinfection; Emtricitabine; Female; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Retrospective Studies; RNA | 2022 |
Response to 'The use of tenofovir in patients with COVID-19'.
Topics: Antiviral Agents; COVID-19 Drug Treatment; HIV Infections; Humans; Lamivudine; Tenofovir | 2022 |
Integrase resistance emergence with dolutegravir/lamivudine with prior HIV-1 suppression.
Topics: Drug Resistance, Viral; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV Seropositivity; HIV-1; Humans; Integrases; Lamivudine; Leukocytes, Mononuclear; Male; Oxazines; Piperazines; Pyridones; RNA-Directed DNA Polymerase; Viremia | 2022 |
Developmental Disorder Probability Scores at 6-18 Years Old in Relation to In-Utero/Peripartum Antiretroviral Drug Exposure among Ugandan Children.
Topics: Adolescent; Anti-HIV Agents; Anti-Retroviral Agents; Autism Spectrum Disorder; Child; Developmental Disabilities; Female; HIV Infections; Humans; Lamivudine; Peripartum Period; Pregnancy; Pregnancy Complications, Infectious; Probability; Uganda; Zidovudine | 2022 |
Major revision version 11.0 of the European AIDS Clinical Society Guidelines 2021.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Anti-HIV Agents; Anti-Retroviral Agents; Child; COVID-19 Drug Treatment; Female; HIV Infections; Humans; Lamivudine; Lipopeptides | 2022 |
Patterns and prognosis of holding regimens for people living with HIV in Asian countries.
Topics: Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Prognosis; Reverse Transcriptase Inhibitors; Viral Load; Zidovudine | 2022 |
Use of Generic Antiretroviral Drugs and Single-Tablet Regimen De-Simplification for the Treatment of HIV Infection in Spain.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Drug Combinations; Drugs, Generic; Emtricitabine; HIV Infections; Humans; Lamivudine; Rilpivirine; Spain; Tablets | 2022 |
Long-Term Changes of Inflammatory Biomarkers in Individuals on Suppressive Three-Drug or Two-Drug Antiretroviral Regimens.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Biomarkers; C-Reactive Protein; HIV Infections; Humans; Inflammation; Lamivudine | 2022 |
Forgiveness of INSTI-Containing Regimens at Drug Concentrations Simulating Variable Adherence
Topics: Anti-HIV Agents; Emtricitabine; Forgiveness; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Integrases; Lamivudine; Pyridones | 2022 |
Weight gain during the dolutegravir transition in the African Cohort Study.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Kenya; Lamivudine; Oxazines; Piperazines; Pyridones; Tenofovir; Weight Gain | 2022 |
Similar CD4/CD8 Ratio Recovery After Initiation of Dolutegravir Plus Lamivudine Versus Dolutegravir or Bictegravir-Based Three-Drug Regimens in Naive Adults With HIV.
Topics: Adult; Amides; Anti-HIV Agents; CD8-Positive T-Lymphocytes; Cohort Studies; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Tenofovir | 2022 |
Hepatitis B Virus Genotypes and Antiviral Resistance Mutations in Romanian HIV-HBV Co-Infected Patients.
Topics: Antiviral Agents; Child, Preschool; Coinfection; DNA, Viral; Genotype; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Mutation; Romania | 2022 |
Comparison of three galenic forms of lamivudine in young West African children living with Human Immunodeficiency Virus.
Topics: Anti-HIV Agents; Child; Child, Preschool; HIV Infections; HIV-1; Humans; Lamivudine; Tablets | 2021 |
Doravirine/tenofovir disoproxyl fumarate/lamivudine-induced alopecia: A case report.
Topics: Alopecia; Anti-HIV Agents; Anti-Retroviral Agents; Emtricitabine; Fumarates; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Pyridones; Tenofovir; Triazoles; Viral Load | 2022 |
Simplification from tenofovir disoproxil fumarate plus lamivudine or emtricitabine plus ritonavir-boosted protease inhibitor to ritonavir-boosted atazanavir plus lamivudine in virologically suppressed HIV-infected adults with osteopenia: a pilot study.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Bone Diseases, Metabolic; Drug Substitution; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Pilot Projects; Ritonavir; Tenofovir | 2022 |
Dolutegravir Plus Lamivudine as Initial Therapy for HIV-1 Infected and ARV-naïve Patients in West China, 24-Weeks Results of a Preliminary Real-world Study.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Antiviral Agents; Drug Therapy, Combination; Hepatitis B Surface Antigens; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; RNA; RNA, Viral; Viral Load | 2022 |
Levels of adherence to contemporary antiretroviral regimens and the likelihood of viral suppression: a cohort study in a Brazilian metropolis.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Brazil; Cohort Studies; HIV Infections; Humans; Lamivudine; Prospective Studies; Tenofovir | 2023 |
Risk factors of severe hepatotoxicity among HIV-1 infected individuals initiated on highly active antiretroviral therapy in the Northwest Region of Cameroon.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cameroon; Chemical and Drug Induced Liver Injury; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Risk Factors; Young Adult; Zidovudine | 2022 |
Impact of tenofovir on SARS-CoV-2 infection and severe outcomes among people living with HIV: a propensity score-matched study.
Topics: Anti-HIV Agents; COVID-19; COVID-19 Testing; Emtricitabine; HIV Infections; Humans; Lamivudine; Propensity Score; Prospective Studies; SARS-CoV-2; Tenofovir | 2022 |
Dolutegravir in real life: Self-reported mental and physical health outcomes after transitioning from efavirenz- to dolutegravir-based antiretroviral therapy in a prospective cohort study in Lesotho.
Topics: Adult; Anti-HIV Agents; Benzoxazines; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Lesotho; Male; Middle Aged; Outcome Assessment, Health Care; Oxazines; Prospective Studies; Self Report; Tenofovir | 2023 |
Tenofovir disoproxil fumarate and coronavirus disease 2019 outcomes in men with HIV.
Topics: Anti-HIV Agents; Cohort Studies; COVID-19; COVID-19 Testing; Emtricitabine; HIV Infections; Humans; Lamivudine; Male; SARS-CoV-2; Tenofovir | 2022 |
Minimal Cross-resistance to Tenofovir in Children and Adolescents Failing ART Makes Them Eligible for Tenofovir-Lamivudine-Dolutegravir Treatment.
Topics: Adolescent; Anti-HIV Agents; Child; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Piperazines; Protease Inhibitors; Pyridones; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Zidovudine | 2022 |
Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Drug Resistance; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Malawi; Oxazines; Piperazines; Prospective Studies; Pyridones; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2022 |
Do anti-HIV drugs pose a threat to photosynthetic microorganisms?
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; HIV-1; Humans; Lamivudine; Photosynthesis; Tenofovir; Water | 2022 |
Efficacy, durability, and tolerability of dolutegravir/lamivudine and dolutegravir/rilpivirine for the treatment of HIV in a real-world setting in Belgium.
Topics: Anti-HIV Agents; Belgium; Drug Combinations; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies; Rilpivirine; Treatment Outcome | 2023 |
Population pharmacokinetics and model-informed precision dosing of lamivudine in Chinese HIV-infected patients with mild and moderate impaired renal function.
Topics: Adult; China; Creatinine; HIV Infections; Humans; Kidney; Lamivudine; Prospective Studies; Renal Insufficiency | 2022 |
Virological efficacy of switch to DTG plus 3TC in a retrospective observational cohort of suppressed HIV-1 patients with or without past M184V: the LAMRES study.
Topics: Anti-HIV Agents; HIV Infections; HIV-1; Humans; Lamivudine; Retrospective Studies | 2022 |
Dynamics of Total and Intact HIV-1 DNA in Virologically Suppressed Patients Switching to DTG-Based or ATV-Based Dual Therapy.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; DNA; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Pyridones; Retrospective Studies | 2022 |
Brief Report: Virologic Impact of the Dolutegravir Transition: Prospective Results From the Multinational African Cohort Study.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Cohort Studies; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Prospective Studies; Pyridones; Tenofovir; Uganda; Viral Load | 2022 |
Changes in Serum Inflammatory Markers in Antiretroviral Therapy-Naive HIV-Infected Patients Starting Dolutegravir/Lamivudine or Tenofovir Alafenamide/Emtricitabine/Bictegravir.
Topics: Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Pyridones | 2022 |
Risk factors and prognostic significance of anemia in children with HIV infection on antiretroviral therapy.
Topics: Anemia; Case-Control Studies; Child; HIV Infections; Humans; Lamivudine; Malnutrition; Prognosis; Retrospective Studies; Risk Factors | 2022 |
Serum Interleukin-6 and Weight Loss in Antiretroviral-naïve and Antiretroviral-treated Patients with HIV/AIDS: Relationships and Predictors.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Case-Control Studies; Emtricitabine; HIV Infections; Humans; Interleukin-6; Lamivudine; Middle Aged; Nevirapine; Tenofovir; Weight Loss; Zidovudine | 2022 |
Dolutegravir Plus Lamivudine Dual-Drug Regimen in Treatment-Naive HIV-1-Infected Patients With High-Level Viral Load: Preliminary Data From the Real World.
Topics: Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Preliminary Data; Prospective Studies; Pyridones; Retrospective Studies; RNA, Viral; Viral Load | 2022 |
Higher Risk of Dyslipidemia With Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide than Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate Among Antiretroviral-Naive People Living With HIV in China.
Topics: Adenine; Alanine; Alkynes; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Cholesterol, LDL; Cobicistat; Cyclopropanes; Emtricitabine; HIV Infections; HIV-1; Humans; Hypercholesterolemia; Hypertriglyceridemia; Lamivudine; Lipoproteins, HDL; Quinolones; Retrospective Studies; Tenofovir | 2022 |
Performance of Creatinine- and Cystatin C-Based Equations for Glomerular Filtration Rate Estimation in HIV-1-Infected Individuals Receiving Dolutegravir + Tenofovir Disoproxil Fumarate + Lamivudine as Initial Antiretroviral Therapy: A Retrospective Observ
Topics: Adult; Creatinine; Cystatin C; Female; Glomerular Filtration Rate; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Male; Oxazines; Piperazines; Pyridones; Renal Insufficiency, Chronic; Retrospective Studies; Tenofovir | 2022 |
Efficacy and Safety of a Simplified Lamivudine Plus Dolutegravir Dual Therapy in HIV-1-Infected Patients: A Multicenter Cohort Study in China.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Seropositivity; HIV-1; Homosexuality, Male; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Retrospective Studies; Sexual and Gender Minorities | 2022 |
A post-mortem analysis of tenofovir, lamivudine, efavirenz and fluconazole penetration in female genital tissues.
Topics: Anti-HIV Agents; Autopsy; Benzoxazines; Chromatography, Liquid; Female; Fluconazole; Genitalia, Female; HIV Infections; Humans; Lamivudine; Tandem Mass Spectrometry; Tenofovir | 2022 |
Comparison between the impact of tenofovir alafenamide and that of abacavir on rapid kidney function decline: A retrospective observational study.
Topics: Adenine; Anti-HIV Agents; Dideoxynucleosides; Emtricitabine; HIV Infections; Humans; Kidney; Lamivudine; Retrospective Studies | 2023 |
Risk factors and prognostic significance of platelet count abnormalities in children with HIV infection on antiretroviral therapy.
Topics: Acquired Immunodeficiency Syndrome; Case-Control Studies; CD4 Lymphocyte Count; Child; HIV Infections; Humans; Lamivudine; Nevirapine; Platelet Count; Prognosis; Retrospective Studies; Risk Factors; Thrombocytopenia; Thrombocytosis | 2023 |
Safety and efficacy of pharmacotherapy containing INSTIs and chemotherapy drugs in people living with HIV and concomitant colorectal cancer.
Topics: Amides; Anti-HIV Agents; Colorectal Neoplasms; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Integrase Inhibitors; Lamivudine; Piperazines; Pyridones; Raltegravir Potassium; Tenofovir | 2022 |
Economic evaluation of doravirine/tenofovir disoproxil fumarate/lamivudine for HIV-1-infected adults in Russia: a cost-minimization and budget impact analysis.
Topics: Adult; Anti-HIV Agents; Cost-Benefit Analysis; Drug Combinations; Drugs, Essential; Emtricitabine; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; RNA, Viral; Tenofovir; Viral Load | 2022 |
Real-world implementation of dolutegravir plus lamivudine in people living with HIV in Southwest China.
Topics: Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Retrospective Studies; Viral Load | 2022 |
Adult pure red cell aplasia at Universitas Academic Hospital, Bloemfontein, South Africa: A 9-year review.
Topics: Adult; Anemia; Female; Hemoglobins; HIV Infections; Hospitals; Humans; Immunoglobulins, Intravenous; Lamivudine; Male; Middle Aged; Parvovirus B19, Human; Red-Cell Aplasia, Pure; Retrospective Studies; South Africa; Young Adult | 2022 |
Pharmacokinetics, Tolerability, and Safety of Doravirine and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate Fixed-Dose Combination Tablets in Adolescents Living With HIV: Week 24 Results From IMPAACT 2014.
Topics: Adolescent; Adult; Anti-HIV Agents; Anti-Retroviral Agents; Child; Emtricitabine; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Pyridones; RNA, Viral; Tablets; Tenofovir | 2023 |
Immunological and virological outcomes in children on lamivudine monotherapy: A South African public sector experience.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; HIV Infections; Humans; Lamivudine; Public Sector; South Africa; Treatment Failure; Viral Load | 2022 |
Long-term outcome of lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients.
Topics: Anti-HIV Agents; Antigens, Surface; Creatinine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Prospective Studies; Pyridones; RNA; Viral Load | 2022 |
A predictive model of immune recovery for DTG + 3TC and DTG + RPV used as switching strategies in HIV+ patients.
Topics: Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Pyridones; Rilpivirine | 2022 |
Analysing the efficacy and tolerability of dolutegravir plus either rilpivirine or lamivudine in a multicentre cohort of virologically suppressed PLWHIV.
Topics: Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Pyridones; Rilpivirine | 2022 |
Real-world efficacy and safety of dolutegravir plus lamivudine versus tenofovir plus lamivudine and efavirenz in ART-naïve HIV-1-infected adults.
Topics: Adult; Anti-HIV Agents; Benzoxazines; Creatinine; Dideoxynucleosides; HIV Infections; HIV-1; Humans; Lamivudine; Prospective Studies; Pyridones; RNA; Tenofovir; Triglycerides | 2022 |
[The analysis of the availability of fixed-dose combinations in antiretroviral therapy for HIV infection in the Russian Federation].
Topics: Adenine; Anti-HIV Agents; Drug Combinations; Drugs, Essential; Emtricitabine; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Rilpivirine; Tenofovir | 2021 |
Rate of virological failure and HIV-1 drug resistance among HIV-infected adolescents in routine follow-up on health facilities in Cameroon.
Topics: Adolescent; Anti-HIV Agents; Cameroon; Drug Resistance, Viral; Follow-Up Studies; Health Facilities; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Nevirapine; Retrospective Studies; Viral Load; Zidovudine | 2022 |
Severe abacavir hypersensitivity reaction in a patient with human immunodeficiency virus infection: a case report.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Child; Dideoxynucleosides; Drug Hypersensitivity; Female; HIV Infections; Humans; Kenya; Lamivudine; Vomiting | 2022 |
Efficacy and Safety of a Simplified Lamivudine Plus Dolutegravir Dual Therapy in HIV-1-Infected Patients: A Multicenter Cohort Study in China: Erratum.
Topics: Anti-HIV Agents; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Pyridones | 2022 |
Determinants of therapy failure among adults on first-line antiretroviral therapy in Asmara, Eritrea: a multicenter retrospective matched case-control study.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Case-Control Studies; Emtricitabine; Eritrea; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies; Stavudine; Viral Load | 2022 |
Tenofovir disoproxil fumarate/emtricitabine and severity of coronavirus disease 2019 in people with HIV infection.
Topics: Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; COVID-19; Drug Combinations; Emtricitabine; HIV Infections; Humans; Lamivudine; Middle Aged; SARS-CoV-2; Tenofovir | 2022 |
Doravirine/lamivudine/tenofovir disoproxil fumarate-induced hypertriglyceridemia in a newly diagnosed AIDS patient.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Emtricitabine; Fumarates; HIV Infections; Humans; Hypertriglyceridemia; Lamivudine; Tenofovir | 2022 |
Change in metabolic parameters after switching from triple regimens with tenofovir alafenamide to dolutegravir-based dual therapy. Bi-lipid study.
Topics: Adenine; Anti-HIV Agents; Cholesterol; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Lipids; Male; Middle Aged; Oxazines; Retrospective Studies | 2023 |
Real world efficacy of dolutegravir plus lamivudine in people living with HIV with undetectable viral load after previous failures.
Topics: Anti-HIV Agents; HIV Infections; Humans; Lamivudine; Retrospective Studies; RNA; Viral Load | 2023 |
48-Week effectiveness and tolerability of dolutegravir (DTG) + lamivudine (3TC) in antiretroviral-naïve adults living with HIV: A multicenter real-life cohort.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; COVID-19; HIV Infections; HIV-1; Humans; Lamivudine; Pandemics | 2022 |
Real-World Effectiveness, Tolerability, and Safety of Dolutegravir/Lamivudine in Korea.
Topics: Adult; Anti-HIV Agents; HIV Infections; HIV-1; Humans; Lamivudine; Republic of Korea; Retrospective Studies | 2022 |
Drug resistance in children and adolescents with HIV in Panama.
Topics: Adolescent; Anti-HIV Agents; Anti-Retroviral Agents; Child; Drug Resistance, Viral; Genotype; HIV Infections; Humans; Lamivudine; Mutation; Phylogeny | 2023 |
Dolutegravir-Based Regimen Ensures High Virological Success despite Prior Exposure to Efavirenz-Based First-LINE ART in Cameroon: An Evidence of a Successful Transition Model.
Topics: Adult; Anti-HIV Agents; Benzoxazines; Cameroon; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Tenofovir; Viral Load | 2022 |
Role of HBcAb Positivity in Increase of HIV-RNA Detectability after Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Months 48 Results of a Multicenter Italian Cohort.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Hepatitis B virus; HIV Infections; Humans; Lamivudine; RNA | 2023 |
Growth differences by school-age and adolescence according to in utero and peripartum antiretroviral therapy exposure among Ugandan children.
Topics: Adolescent; Anti-HIV Agents; Anti-Retroviral Agents; Child; Cohort Studies; Female; HIV Infections; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Peripartum Period; Pregnancy; Pregnancy Complications, Infectious; Retrospective Studies; Uganda; Zidovudine | 2023 |
Recycling Tenofovir in Second-line Antiretroviral Treatment With Dolutegravir: Outcomes and Viral Load Trajectories to 72 weeks.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Prospective Studies; Pyridones; Tenofovir; Viral Load; Viremia | 2023 |
Virologic status and pattern of drug resistance mutation among ART-experienced HIV-infected patients in Butuo County, China.
Topics: Anti-HIV Agents; Cross-Sectional Studies; Emtricitabine; HIV Infections; Humans; Lamivudine; Lopinavir; Mutation; Nevirapine; Reverse Transcriptase Inhibitors | 2023 |
Real world use of dolutegravir two drug regimens.
Topics: Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Homosexuality, Male; Humans; Lamivudine; Male; Middle Aged; Pyridones; Sexual and Gender Minorities; Tablets; Viremia | 2023 |
Epidemiology of Tuberculosis Among People Living With HIV in the African Cohort Study From 2013 to 2021.
Topics: CD4 Lymphocyte Count; Cohort Studies; HIV Infections; Humans; Incidence; Lamivudine; Risk Factors; Tenofovir; Thinness; Tuberculosis | 2023 |
Incidence and risk factors of hypertriglyceridemia in males with human immunodeficiency virus who are treated with combination antiretroviral therapy: a retrospective cohort study.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; HIV Infections; HIV-1; Humans; Hypertriglyceridemia; Incidence; Lamivudine; Male; Retrospective Studies; Risk Factors; Tenofovir; Triglycerides | 2023 |
Safety and Effectiveness Analyses of Dolutegravir/Lamivudine in Patients with HIV: 2-Year Report of Post-Marketing Surveillance in Japan.
Topics: Anti-HIV Agents; HIV Infections; Humans; Japan; Lamivudine; Oxazines; Product Surveillance, Postmarketing; Pyridones; RNA | 2023 |
Resistant mutations within the hepatitis B virus reverse transcriptase sequence in treatment failure patients with chronic HBV infection in Vietnam.
Topics: Antiviral Agents; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Mutation; RNA-Directed DNA Polymerase; Telbivudine; Tenofovir; Treatment Failure; Vietnam | 2023 |
Evaluation of treatment efficacy after switching to dolutegravir-lamivudine dual therapy in people living with HIV.
Topics: Adult; Anti-HIV Agents; HIV Infections; HIV-1; Humans; Infant; Lamivudine; Retrospective Studies; Treatment Outcome | 2022 |
Short-term toxicity assessment of combined use of zidovudine, lamivudine and lopinavir/ritonavir in vitro and in vivo.
Topics: Animals; Anti-HIV Agents; Female; HIV Infections; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Male; Mammals; Mice; Rats; Ritonavir; Zidovudine | 2023 |
Effect of different antiretroviral therapy on muscle mass, bone mineral density, and trabecular bone score in Chinese HIV-infected males.
Topics: Adult; Anti-HIV Agents; Bone Density; Cancellous Bone; East Asian People; HIV Infections; Humans; Lamivudine; Male; Muscles; Osteoporosis; Retrospective Studies; Sarcopenia; Stavudine; Tenofovir; Young Adult | 2023 |
An Efficient Humanized Mouse Model for Oral Anti-Retroviral Administration.
Topics: Animals; Anti-HIV Agents; HIV Infections; HIV-1; Humans; Lamivudine; Leukocytes, Mononuclear; Mice | 2023 |
Effectiveness and tolerability of dolutegravir/lamivudine for the treatment of HIV-1 infection in clinical practice.
Topics: Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Pyridones | 2023 |
Efficacy and Safety of Two-Drug Regimens with Dolutegravir plus Rilpivirine or Lamivudine in HIV-1 Virologically Suppressed People Living with HIV.
Topics: Anti-HIV Agents; Drug-Related Side Effects and Adverse Reactions; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Retrospective Studies; Rilpivirine | 2023 |
A real-world observational retrospective cohort study of Canadian people living with HIV switching from nevirapine plus two nucleoside reverse transcriptase inhibitors to dolutegravir/lamivudine.
Topics: Anti-HIV Agents; Canada; HIV Infections; Humans; Lamivudine; Nevirapine; Oxazines; Patient Acceptance of Health Care; Pyridones; Retrospective Studies; Reverse Transcriptase Inhibitors; Viral Load | 2023 |
HIV-1 RNA and DNA Genotyping Drug Resistance Detection in Patients with Low-Level Viremia in Liangshan, China.
Topics: Adult; Anti-HIV Agents; Drug Resistance; Drug Resistance, Viral; Emtricitabine; Female; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Male; Reverse Transcriptase Inhibitors; RNA; Viremia | 2023 |
Three-year efficacy of switching to dolutegravir plus lamivudine: A real-world study.
Topics: Anti-HIV Agents; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Oxazines; RNA | 2023 |
Dolutegravir-associated resistance mutations after first-line treatment failure in Brazil.
Topics: Anti-Retroviral Agents; Brazil; HIV Infections; Humans; Lamivudine; Mutation; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure | 2023 |
No need to modify treatment within the first month after rapid start of a tailored antiretroviral therapy: the TWODAY Study.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Lamivudine; Prospective Studies | 2023 |
HIV-1 genotypic profiling ensures effective response to third-line antiretroviral therapy in Cameroon.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Cameroon; Darunavir; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; Viral Load | 2023 |
Doravirine responses to HIV-1 viruses bearing mutations to NRTIs and NNRTIs under in vitro selective drug pressure.
Topics: Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV Seropositivity; HIV-1; Humans; Lamivudine; Mutation; Reverse Transcriptase Inhibitors; Rilpivirine | 2023 |
Doravirine plus lamivudine two-drug regimen as maintenance antiretroviral therapy in people living with HIV: a French observational study.
Topics: Adult; Anti-HIV Agents; Anti-Retroviral Agents; CD4 Lymphocyte Count; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; RNA; Viral Load | 2023 |
Treatment persistence of bictegravir/emtricitabine/tenofovir alafenamide and efavirenz + lamivudine + tenofovir disoproxil among HIV-1 patients newly starting treatment in Hunan Province in China.
Topics: China; Drug Combinations; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lamivudine; Retrospective Studies; Tenofovir | 2023 |
Weight gain in Namibians with HIV switching from efavirenz to dolutegravir.
Topics: Anti-HIV Agents; Benzoxazines; Emtricitabine; Female; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Male; Retrospective Studies; Tenofovir; Weight Gain | 2023 |
Clinical use and effectiveness of dolutegravir and lamivudine: a long-term, real-world, retrospective study.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Pyridones; Retrospective Studies | 2023 |
Viral suppression in the era of transition to dolutegravir-based therapy in Cameroon: Children at high risk of virological failure due to the lowly transition in pediatrics.
Topics: Adolescent; Adult; Anti-HIV Agents; Cameroon; Child; Cross-Sectional Studies; Female; HIV Infections; Humans; Lamivudine; Male; Pediatrics; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Viral Load | 2023 |
Assessing the Virologic Impact of Archived Resistance in the Dolutegravir/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144.
Topics: Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Retrospective Studies; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load | 2023 |
Quantification of nine antiretroviral drugs in cerebrospinal fluid: An approach to overcome sample collection tube adsorption.
Topics: Adsorption; Ammonium Hydroxide; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Chromatography, Liquid; Emtricitabine; HIV Infections; Humans; Lamivudine; Methanol; Ritonavir; Tandem Mass Spectrometry; Tenofovir; Water | 2023 |
Securing accelerated access to long-acting injectable cabotegravir for HIV prevention in low- and middle-income countries.
Topics: Child; Developing Countries; Drugs, Generic; HIV Infections; Humans; Lamivudine; Tenofovir; United States | 2023 |
Switching to Dolutegravir/lamivudine or Bictegravir/Emtricitabine/Tenofovir alafenamide. A comparative real-world study.
Topics: Adenine; Drug Combinations; Emtricitabine; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Lamivudine; Retrospective Studies; Treatment Outcome | 2023 |
Blood telomere length gain in people living with HIV switching to dolutegravir plus lamivudine versus continuing triple regimen: a longitudinal, prospective, matched, controlled study.
Topics: Adult; Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Prospective Studies; Pyridones; Telomere; Viral Load | 2023 |
Exposure to doravirine, lamivudine, tenofovir, and raltegravir in a patient with HIV after a Roux-en-Y gastric bypass.
Topics: Gastric Bypass; HIV Infections; Humans; Lamivudine; Raltegravir Potassium; Tenofovir | 2023 |
Real-Life Experience on Dolutegravir and Lamivudine as Initial or Switch Therapy in a Silver Population Living with HIV.
Topics: Aged; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Silver | 2023 |
A novel formulation enabled transformation of 3-HIV drugs tenofovir-lamivudine-dolutegravir from short-acting to long-acting all-in-one injectable.
Topics: Animals; Anti-HIV Agents; Drug Combinations; Heterocyclic Compounds, 3-Ring; HIV Infections; Lamivudine; Leukocytes, Mononuclear; Oxazines; Pharmaceutical Preparations; Pyridones; Tenofovir | 2023 |
Prophylaxis by doravirine-lamivudine-tenofovir disoproxil fumarate or elvitegravir-cobicistat-emtricitabine-tenofovir alafenamide after sexual exposure to HIV.
Topics: Adult; Anti-HIV Agents; Cobicistat; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; Fumarates; HIV Infections; Humans; Lamivudine; Tenofovir | 2023 |
Potential cost-effectiveness of community availability of tenofovir, lamivudine, and dolutegravir for HIV prevention and treatment in east, central, southern, and west Africa: a modelling analysis.
Topics: Africa, Western; Cost-Benefit Analysis; Female; HIV Infections; Humans; Lamivudine; Male; Tenofovir | 2023 |
Constructing Antiretroviral Supramolecular Polymers as Long-Acting Injectables through Rational Design of Drug Amphiphiles with Alternating Antiretroviral-Based and Hydrophobic Residues.
Topics: Animals; HIV Infections; Humans; Lamivudine; Mice; Polymers; Water | 2023 |
First case report of a perinatally HIV-infected infant with HIV resistance to dolutegravir associated with tenofovir/lamivudine/dolutegravir use in mothers.
Topics: Anti-HIV Agents; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Infant; Lamivudine; Mothers; Oxazines; Pregnancy; Tenofovir | 2023 |
Comment on: Doravirine plus lamivudine two-drug regimen as maintenance antiretroviral therapy in people living with HIV: a French observational study.
Topics: Anti-Retroviral Agents; HIV Infections; Humans; Lamivudine; Pyridones | 2023 |
Effectiveness, durability and safety of dolutegravir and lamivudine versus bictegravir, emtricitabine and tenofovir alafenamide in a real-world cohort of HIV-infected adults.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Lamivudine; Pyridones | 2023 |
Efficacy and tolerability of dolutegravir/lamivudine versus dolutegravir/rilpivirine in switching from a three-drug regimen based on nonnucleoside reverse transcriptase inhibitors: A retrospective cohort study.
Topics: Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Retrospective Studies; Reverse Transcriptase Inhibitors; Rilpivirine | 2023 |
Comment on: Doravirine plus lamivudine two-drug regimen as maintenance antiretroviral therapy in people living with HIV: a French observational study.
Topics: Anti-Retroviral Agents; HIV Infections; Humans; Lamivudine; Pyridones | 2023 |
HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis.
Topics: Cohort Studies; Drug Resistance, Viral; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV Seropositivity; HIV-1; Humans; Lamivudine; Reverse Transcriptase Inhibitors | 2023 |
Major revision version 12.0 of the European AIDS Clinical Society guidelines 2023.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Anti-Retroviral Agents; Child; COVID-19; Hepatitis C; HIV Infections; Humans; Lamivudine; Practice Guidelines as Topic; Tenofovir | 2023 |
Impact of Treatment Adherence on Efficacy of Dolutegravir + Lamivudine and Dolutegravir + Tenofovir Disoproxil Fumarate/Emtricitabine: Pooled Week 144 Analysis of the GEMINI-1 and GEMINI-2 Clinical Studies.
Topics: Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Pyridones; Tenofovir; Treatment Adherence and Compliance | 2023 |
Tolerability of bictegravir/tenofovir alafenamide/emtricitabine versus dolutegravir/lamivudine as maintenance therapy in a real-life setting.
Topics: Adenine; Anti-HIV Agents; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Lamivudine; Pyridones; Tenofovir | 2023 |
Vaginal microbiome, antiretroviral concentrations, and HIV genital shedding in the setting of hormonal contraception initiation in Malawi.
Topics: Anti-Retroviral Agents; Female; HIV Infections; Hormonal Contraception; Humans; Lamivudine; Levonorgestrel; Malawi; Medroxyprogesterone Acetate; Microbiota; Tenofovir; Vagina | 2023 |
Incidence and factors associated with hepatitis B surface antigen seroclearance in patients co-infected with HBV/HIV during antiretroviral therapy in Guangdong, China.
Topics: Adult; Coinfection; DNA, Viral; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Incidence; Lamivudine; Male; Retrospective Studies; Tenofovir | 2023 |
Antenatal hepatitis B virus sero-prevalence, risk factors, pregnancy outcomes and vertical transmission rate within 24 months after birth in a high HIV prevalence setting.
Topics: Child; Female; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Mothers; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Prevalence; Risk Factors; Seroepidemiologic Studies; Tenofovir | 2023 |
Efficacy and safety profiles of dolutegravir plus lamivudine vs . bictegravir/emtricitabine/tenofovir alafenamide in therapy-naïve adults with HIV-1.
Topics: Adult; Anti-HIV Agents; China; Emtricitabine; HIV Infections; HIV-1; Humans; Lamivudine; Lipids; Retrospective Studies | 2023 |
Proportion of APOBEC3-induced defective HIV DNA after 1 year of dolutegravir + lamivudine simplification in the ANRS 167 LAMIDOL trial.
Topics: Anti-HIV Agents; APOBEC Deaminases; DNA; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Pyridones; Viral Load | 2023 |
Distribution of lamivudine into lymph node HIV reservoir.
Topics: Animals; Anti-HIV Agents; Chylomicrons; HIV Infections; Lamivudine; Lymph Nodes; Rats; Tissue Distribution | 2023 |
Cost-effectiveness analysis of antiretroviral drugs for treatment-naive HIV infection in China.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Cost-Effectiveness Analysis; Dideoxynucleosides; Emtricitabine; HIV Infections; Humans; Lamivudine | 2023 |
Tolerability and effectiveness of albuvirtide combined with dolutegravir for hospitalized people living with HIV/AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Middle Aged; Peptides; Pyridones; Retrospective Studies; Viral Load | 2023 |
Evaluation of the probable synergistic toxicity of selected potentiated antiretroviral and antibiotics on some aquatic biomarker organisms.
Topics: Anti-Bacterial Agents; Aquatic Organisms; Biomarkers; Chromosome Aberrations; Ecosystem; Environmental Monitoring; HIV Infections; Lamivudine; Onions; Pharmaceutical Preparations; Sulfamethoxazole | 2023 |
DOLAMA study: Effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cost-Benefit Analysis; Drug Therapy, Combination; Economics, Pharmaceutical; Fees, Pharmaceutical; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Retrospective Studies; Viral Load | 2019 |
Dual therapy with ritonavir-boosted protease inhibitor (PI) plus lamivudine versus triple therapy with ritonavir-boosted PI plus two nucleos(t)ide reverse-transcriptase inhibitor in HIV-infected patients with viral suppression.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Sustained Virologic Response; Viral Load | 2019 |
Trend of HIV transmitted drug resistance before and after implementation of HAART regimen restriction in the treatment of HIV-1 infected patients in southern Taiwan.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Combinations; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Nevirapine; Prevalence; Reverse Transcriptase Inhibitors; Taiwan; Zidovudine | 2019 |
Dolutegravir Plus Lamivudine as First-Line Regimen in a Multicenter Cohort of HIV-1-Infected Patients: Preliminary Data from Clinical Practice.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation; Oxazines; Piperazines; Practice Patterns, Physicians'; Preliminary Data; Pyridones; RNA, Viral; Sustained Virologic Response | 2020 |
Pharmacokinetic profiles of boosted darunavir, dolutegravir and lamivudine in aging people living with HIV.
Topics: Aged; Aged, 80 and over; Aging; Anti-HIV Agents; Darunavir; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Prospective Studies; Pyridones; Viral Load | 2020 |
A long acting nanoformulated lamivudine ProTide.
Topics: Animals; Anti-HIV Agents; CD4-Positive T-Lymphocytes; Cells, Cultured; HIV Infections; HIV-1; Humans; Lamivudine; Lymph Nodes; Macrophages; Magnetic Resonance Spectroscopy; Mice; Monocytes; Nanomedicine; Nanoparticles; Prodrugs; Rabbits; Rats; Rats, Sprague-Dawley; Spleen | 2019 |
Real-world evaluation of the safety and tolerability of abacavir/dolutegravir/lamivudine in an incarcerated population.
Topics: Adult; Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Illinois; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Prisoners; Prisons; Pyridones; Retrospective Studies; Treatment Outcome | 2019 |
Long-term observation on hepatitis B surface antigen seroclearance in therapy experienced HIV/HBV co-infected Chinese.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Asian People; China; Coinfection; DNA, Viral; Drug Therapy, Combination; Female; Hepatitis B; Hepatitis B Surface Antigens; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies; Tenofovir; Time Factors; Young Adult | 2020 |
Severe hepatotoxicity induced by efavirenz in a treatment-naïve, low body mass index HIV-infected, female patient with no hepatitis and other virus co-infections.
Topics: Adult; Alkynes; Benzoxazines; Body Mass Index; Chemical and Drug Induced Liver Injury; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors | 2019 |
No impact of previous NRTIs resistance in HIV positive patients switched to DTG+2NRTIs under virological control: Time of viral suppression makes the difference.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Combinations; Drug Resistance, Viral; Female; Genes, Viral; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation; Oxazines; Piperazines; Pyridones; Retrospective Studies; Tenofovir; Viral Load | 2019 |
Zidovudine and Lamivudine as Potential Agents to Combat HIV-Associated Neurocognitive Disorder.
Topics: Animals; Anti-HIV Agents; Chromatography, Liquid; Female; HIV Infections; Injections, Intraperitoneal; Lamivudine; Neurocognitive Disorders; Rats; Rats, Sprague-Dawley; Tandem Mass Spectrometry; Tissue Distribution; Zidovudine | 2019 |
HIV 101: fundamentals of antiretroviral therapy.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Integrase Inhibitors; Lamivudine; Life Cycle Stages; Male; Middle Aged; Mutation; Oxazines; Piperazines; Pyridones; RNA, Viral; Tenofovir; Viral Load | 2019 |
Simplified two-drug antiretroviral HIV treatment: novel data and expected impact.
Topics: Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Piperazines; Pyridones | 2019 |
HIV Drug Resistance after Failure of 6 Month First-line Therapy in a Hospital: A Case Series.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Tenofovir; Treatment Failure; Viral Load; Zidovudine | 2019 |
Hepatitis B virus seroprevalence among HIV-infected patients receiving combination antiretroviral therapy three decades after universal neonatal hepatitis B immunization program in Taiwan.
Topics: Adult; Anti-Retroviral Agents; Biomarkers; CD4 Lymphocyte Count; Coinfection; Female; Hemochromatosis; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Immunization Programs; Lamivudine; Male; Retrospective Studies; Seroepidemiologic Studies; Syphilis; Taiwan; Tenofovir; Young Adult | 2021 |
Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30-49 vs ≥50 mL/min.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Creatinine; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Severity of Illness Index | 2019 |
Association of maternal antiretroviral use with microcephaly in children who are HIV-exposed but uninfected (SMARTT): a prospective cohort study.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Drug Combinations; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Male; Microcephaly; Pregnancy; Pregnancy Complications, Infectious; Prospective Studies; Puerto Rico; Tenofovir; Young Adult; Zidovudine | 2020 |
Eligibility for differentiated models of HIV treatment service delivery: an estimate from Malawi and Zambia.
Topics: Adolescent; Adult; Anti-HIV Agents; Eligibility Determination; Female; HIV Infections; Humans; Lamivudine; Malawi; Randomized Controlled Trials as Topic; Tenofovir; Zambia | 2020 |
Genotypic resistance profiles of HIV-2-infected patients from Cape Verde failing first-line antiretroviral therapy.
Topics: Anti-HIV Agents; Cabo Verde; Drug Resistance, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; HIV-2; Humans; Lamivudine; Lopinavir; Reverse Transcriptase Inhibitors; Ritonavir; Viral Load | 2020 |
Rectal and seminal HIV-1 RNA decay towards virological suppression in infected MSM initiating dolutegravir/abacavir/lamivudine.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Dideoxynucleosides; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Homosexuality, Male; Humans; Lamivudine; Longitudinal Studies; Male; Oxazines; Piperazines; Pyridones; RNA Stability; RNA, Viral; Sexual and Gender Minorities; Viral Load | 2020 |
Cohort profile: The Observational cohort for the study of DOlutegravir in Antiretroviral Combination REgimens (ODOACRE).
Topics: Adult; Anti-Retroviral Agents; CD4 Lymphocyte Count; Cohort Studies; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Italy; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Rilpivirine; Treatment Outcome | 2019 |
'High' antiretroviral deintensification strategy and cellular HIV DNA levels.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; DNA, Viral; HIV Infections; HIV-1; Humans; Lamivudine; Nevirapine; Pilot Projects | 2020 |
Single tablet regimen with abacavir/lamivudine/dolutegravir compared with two-drug regimen with lamivudine and dolutegravir as different strategies of simplification from a multicenter HIV cohort study.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Dideoxynucleosides; Drug Combinations; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Retrospective Studies; Tablets; Treatment Outcome | 2019 |
Descriptive analysis of World Health Organization-recommended second-line antiretroviral treatment: A retrospective cohort data analysis.
Topics: Adult; Age Factors; CD4 Lymphocyte Count; Databases, Factual; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Lost to Follow-Up; Male; Medication Adherence; Middle Aged; Retreatment; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; Sex Factors; Tenofovir; Treatment Failure; Viral Load; World Health Organization; Zidovudine | 2019 |
Prior Case of Resistance on Dolutegravir Plus Lamivudine Dual Therapy.
Topics: Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones | 2020 |
Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Retrospective Studies; Reverse Transcriptase Inhibitors; Rilpivirine; Treatment Outcome | 2020 |
Safety and Efficacy of Starting Antiretroviral Therapy in the First Week of Life.
Topics: Anti-HIV Agents; Botswana; Child; Child, Preschool; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Nevirapine; Zidovudine | 2021 |
Continuation of emtricitabine/lamivudine within combination antiretroviral therapy following detection of the M184V/I HIV-1 resistance mutation.
Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Tenofovir; Treatment Failure; United Kingdom | 2020 |
HIV DNA Decay in a Treatment-Naive Patient Starting Dolutegravir Plus Lamivudine with Resistance Mutations to Integrase Inhibitors: A Case Report.
Topics: DNA; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Mutation; Oxazines; Piperazines; Preliminary Data; Pyridones | 2020 |
Traditional Chinese Medicine Can Improve the Immune Reconstruction of HIV/AIDS Patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Drugs, Chinese Herbal; HIV Infections; Humans; Immune Reconstitution; Lamivudine; Medicine, Chinese Traditional; Middle Aged; Pilot Projects; Prospective Studies; T-Lymphocytes; Tenofovir; Treatment Outcome; Young Adult | 2020 |
Kaposi's sarcoma in a HIV-positive patient: an exuberant and widespread case report in the Amazon.
Topics: Adult; Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Oxazines; Piperazines; Pyridones; Sarcoma, Kaposi; Skin Neoplasms; Tenofovir | 2020 |
Incidence and predictors of loss to follow up among adult HIV patients on antiretroviral therapy in University of Gondar Comprehensive Specialized Hospital: A competing risk regression modeling.
Topics: Adolescent; Adult; Ambulatory Care; Anti-Retroviral Agents; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; Hospitals, Special; Humans; Incidence; Lamivudine; Lost to Follow-Up; Male; Nevirapine; Regression Analysis; Retrospective Studies; Risk Factors; Young Adult; Zidovudine | 2020 |
Case Report of Increased Exposure to Antiretrovirals following Sleeve Gastrectomy.
Topics: Adult; Anti-Retroviral Agents; Bariatric Surgery; Dideoxynucleosides; Drug Monitoring; Gastrectomy; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Obesity, Morbid; Oxazines; Piperazines; Pyridones | 2020 |
The S68G polymorphism is a compensatory mutation associated with the drug resistance mutation K65R in CRF01_AE strains.
Topics: Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Mutation Rate; Polymorphism, Genetic; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure; Virus Replication; Zidovudine | 2020 |
Lamivudine-resistant HIV
Topics: Administration, Oral; Animals; Disease Models, Animal; Drug Combinations; Heterocyclic Compounds, 3-Ring; HIV; HIV Infections; Humans; Lamivudine; Mice; Mutation; Oxazines; Piperazines; Pyridones; Treatment Outcome | 2020 |
M184V/I does not impact the efficacy of abacavir/lamivudine/dolutegravir use as switch therapy in virologically suppressed patients.
Topics: Anti-HIV Agents; Dideoxynucleosides; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Retrospective Studies; Viral Load | 2020 |
Evolution of cellular HIV DNA levels in virologically suppressed patients switching to dolutegravir/lamivudine versus maintaining a triple regimen: a prospective, longitudinal, matched, controlled study.
Topics: Anti-HIV Agents; DNA; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Prospective Studies; Pyridones; Viral Load | 2020 |
Antiretroviral Prophylaxis: A Digestive Complication to Know.
Topics: Anti-HIV Agents; Child; Drug-Related Side Effects and Adverse Reactions; HIV Infections; Humans; Lamivudine; Zidovudine | 2021 |
Plasma nucleotide reverse transcriptase inhibitor concentration and their associations with liver and renal parameters in people living with HIV.
Topics: Anti-HIV Agents; Cohort Studies; Cross-Sectional Studies; Drug Combinations; Emtricitabine; HIV Infections; Humans; Kidney; Lamivudine; Liver; Nucleotides; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load | 2020 |
Perinatal Antiretroviral Intensification to Prevent Intrapartum HIV Transmission When Antenatal Antiretroviral Therapy Is Initiated Less Than 8 Weeks Before Delivery.
Topics: Adult; Anti-HIV Agents; Bayes Theorem; Drug Combinations; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Mothers; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; Thailand; Viral Load; Young Adult; Zidovudine | 2020 |
No significant changes in body fat mass in virologically suppressed, HIV-positive patients switched to lamivudine--dolutegravir.
Topics: Adipose Tissue; Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Weight Gain | 2020 |
Movement disorder in a patient with Human Immunodeficiency Virus on an anti-retroviral therapy: A Case Report.
Topics: AIDS Dementia Complex; Alkynes; Anti-HIV Agents; Benzoxazines; Blood-Brain Barrier; Brain Stem; Cerebellar Ataxia; Cerebellum; Cyclopropanes; Drug Substitution; Female; Gait Ataxia; HIV Infections; Humans; Lamivudine; Magnetic Resonance Imaging; Mesencephalon; Middle Aged; Neurodegenerative Diseases; Nystagmus, Pathologic; Panic Disorder; Pons; Postural Balance; Sensation Disorders; Tenofovir; Zidovudine | 2020 |
Monitoring the transition to new antiretroviral treatment regimens through an enhanced data system in Kenya.
Topics: Anti-HIV Agents; Data Systems; Database Management Systems; Drug Monitoring; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Kenya; Lamivudine; Oxazines; Piperazines; Pyridones; Tenofovir; Treatment Outcome; Viral Load | 2020 |
The effect of veno-arterial extracorporeal oxygenation and nasogastric tube administration on the pharmacokinetic profile of abacavir, lamivudine and dolutegravir: a case report.
Topics: Adult; Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Extracorporeal Membrane Oxygenation; Female; Heart-Lung Transplantation; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Intubation, Gastrointestinal; Lamivudine; Oxazines; Piperazines; Pyridones | 2020 |
The Early Results of Vertebral Pathological Compression Fracture of Extra- nodal Lymphoma with HIV-positive Patients Treated by Percutaneous Kyphoplasty.
Topics: Adult; Alkynes; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Benzoxazines; Burkitt Lymphoma; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cementoplasty; Cyclophosphamide; Cyclopropanes; Doxorubicin; Female; Fractures, Compression; HIV Infections; Humans; Kyphoplasty; Lamivudine; Lumbar Vertebrae; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Prednisone; Retrospective Studies; Rituximab; Spinal Fractures; Tenofovir; Tomography, X-Ray Computed; Vincristine; Viral Load | 2020 |
Differential detection of M184V/I between plasma historical HIV genotypes and HIV proviral DNA from PBMCs.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Mutation; Pharmaceutical Preparations; Prospective Studies; Viral Load | 2020 |
Efficacy and safety of abacavir/lamivudine plus rilpivirine as a first-line regimen in treatment-naïve HIV-1 infected adults.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies; Rilpivirine; Singapore; Viral Load | 2020 |
Factors influencing hair lamivudine concentration among people living with HIV in Guangxi, China.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; China; Cross-Sectional Studies; Female; Gas Chromatography-Mass Spectrometry; Hair; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Young Adult | 2020 |
Emergence of dual antiretroviral therapy as a viable regimen option for the treatment of patients with HIV infection.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Rilpivirine | 2020 |
Impact of Lamivudine-Based Antiretroviral Treatment on Hepatitis B Viremia in HIV-Coinfected South Africans.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Coinfection; Female; Follow-Up Studies; Hepatitis B; Hepatitis B virus; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Prospective Studies; Tenofovir; Viral Load; Viremia; Young Adult | 2020 |
The New NNRTI ACC007 Combined with Lamivudine and Tenofovir Disoproxil Fumarate Show Synergy Anti-HIV Activity In Vitro.
Topics: Anti-HIV Agents; Drug Synergism; HIV Infections; HIV-1; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Tenofovir | 2020 |
Prevalence of renal dysfunction among HIV infected patients receiving Tenofovir at Mulago: a cross-sectional study.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Glycosuria; HIV Infections; Humans; Hypercalcemia; Hyperkalemia; Hyperphosphatemia; Hypocalcemia; Hypokalemia; Hypophosphatemia; Lamivudine; Male; Middle Aged; Prevalence; Proteinuria; Renal Insufficiency; Tenofovir; Uganda | 2020 |
Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy : A Cohort Study.
Topics: Adenine; Adult; Aged; Antiretroviral Therapy, Highly Active; Betacoronavirus; Coronavirus Infections; COVID-19; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; Hospitalization; Humans; Incidence; Intensive Care Units; Lamivudine; Male; Middle Aged; Pandemics; Pneumonia, Viral; Reverse Transcriptase Polymerase Chain Reaction; SARS-CoV-2; Severity of Illness Index; Spain; Tenofovir | 2020 |
Cases of coronavirus disease-2019 in HIV-infected transgender women.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Oxazines; Pandemics; Piperazines; Pneumonia, Viral; Pyridones; Ritonavir; SARS-CoV-2; Tenofovir; Transgender Persons | 2020 |
Therapeutic drug monitoring study on the switch from coformulated 600-mg efavirenz, tenofovir disoproxil fumarate, and emtricitabine to coformulated 400-mg efavirenz, tenofovir disoproxil fumarate, and lamivudine among HIV-positive patients with viral sup
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Combinations; Drug Monitoring; Drug Substitution; Emtricitabine; HIV Infections; Humans; Lamivudine; Male; Prospective Studies; Taiwan; Tenofovir; Treatment Outcome; Viral Load | 2021 |
Zidovudine and lamivudine reach higher concentrations in ventricular than in lumbar human cerebrospinal fluid.
Topics: Adult; AIDS Dementia Complex; Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Male; RNA, Viral; Spinal Puncture; Stavudine; Viral Load; Zidovudine | 2020 |
Case report: one case of coronavirus disease 2019 (COVID-19) in a patient co-infected by HIV with a normal CD4
Topics: Alkynes; Anti-Retroviral Agents; Benzoxazines; Betacoronavirus; C-Reactive Protein; CD4 Lymphocyte Count; Chills; Coronavirus Infections; COVID-19; Cyclopropanes; Fatigue; Female; Fever; HIV; HIV Infections; Humans; Immunocompromised Host; Immunoglobulin M; Lamivudine; Middle Aged; Pandemics; Pharyngitis; Pneumonia, Viral; Real-Time Polymerase Chain Reaction; SARS-CoV-2; Sputum; Time Factors; Tomography, X-Ray Computed; Virus Shedding; Zidovudine | 2020 |
Bone density, microarchitecture and tissue quality after 1 year of treatment with dolutegravir/abacavir/lamivudine.
Topics: Anti-HIV Agents; Bone Density; Dideoxynucleosides; Drug Combinations; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Piperazines; Prospective Studies; Pyridones | 2020 |
Simplification to dual therapy containing lamivudine and raltegravir or dolutegravir in HIV-infected patients on virologically suppressive antiretroviral therapy.
Topics: Anti-HIV Agents; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Raltegravir Potassium; Retrospective Studies; Viral Load | 2020 |
Assessing the association between platelets and immune recovery in HIV/HBV co-infected patients: A long-term cohort in Asia.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Blood Platelets; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Cohort Studies; Cyclopropanes; Female; Hepatitis B; Hepatitis B virus; HIV Infections; HIV-1; Humans; Immune Reconstitution; Lamivudine; Longitudinal Studies; Male; Platelet Count; Retrospective Studies; Tenofovir | 2020 |
Engendering health systems in response to national rollout of dolutegravir-based regimens among women of childbearing potential: a qualitative study with stakeholders in South Africa and Uganda.
Topics: Adult; Female; Government Programs; Health Facilities; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Oxazines; Piperazines; Pregnancy; Pyridones; Qualitative Research; South Africa; Tenofovir; Uganda | 2020 |
Changes in bone microarchitecture with abacavir--lamivudine versus tenofovir disoproxil fumarate--emtricitabine in adults living with HIV.
Topics: Absorptiometry, Photon; Adult; Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Emtricitabine; Fractures, Bone; HIV Infections; Humans; Incidence; Lamivudine; Osteoporotic Fractures; Tenofovir | 2020 |
Prevalence and molecular characterization of hepatitis B virus infection in HIV-infected children in Senegal.
Topics: Adolescent; Coinfection; Diagnostic Tests, Routine; DNA, Viral; Female; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Persistent Infection; Phylogeny; Prevalence; Retrospective Studies; Senegal; Viremia | 2021 |
Recurrent ocular syphilis in a patient living with HIV.
Topics: Adult; AIDS-Related Opportunistic Infections; Dideoxynucleosides; Eye Infections, Bacterial; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Neurosyphilis; Oxazines; Penicillin G; Piperazines; Pyridones; Syphilis; Syphilis Serodiagnosis; Treatment Outcome; Treponema pallidum; Uveitis; Visual Acuity | 2020 |
Population Pharmacokinetic and Pharmacodynamic Analysis To Evaluate a Switch to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in People Living with HIV-1.
Topics: Anti-HIV Agents; Emtricitabine; Fumarates; HIV Infections; HIV-1; Humans; Lamivudine; Pyridones; Tenofovir; Triazoles | 2020 |
2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0.
Topics: Age Factors; Anti-Retroviral Agents; Comorbidity; Drug Interactions; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Treatment Outcome; Triazoles | 2020 |
Effect of combination antiretroviral therapy on human immunodeficiency virus 1 specific antibody responses in subtype-C infected children.
Topics: Anti-HIV Agents; Antibodies, Neutralizing; Antibody-Dependent Cell Cytotoxicity; Antiretroviral Therapy, Highly Active; Child, Preschool; Cohort Studies; Dideoxynucleosides; Drug Combinations; HIV Antibodies; HIV Infections; HIV-1; Humans; Infant; Lamivudine; Lopinavir; Ritonavir; Viral Load; Zidovudine | 2020 |
Comparison of HIV-DNA decay in naive patients starting dolutegravir plus lamivudine or dolutegravir-based triple therapy.
Topics: Adult; Anti-HIV Agents; DNA; Drug Combinations; Female; Heterocyclic Compounds, 3-Ring; HIV; HIV Infections; Humans; Lamivudine; Longitudinal Studies; Male; Middle Aged; Oxazines; Piperazines; Prospective Studies; Pyridones | 2020 |
Novel dual HIV maintenance therapy with nevirapine plus lamivudine retain viral suppression through 144 weeks-A proof-of-concept study.
Topics: Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Proof of Concept Study; RNA, Viral | 2020 |
Efficacy and safety of a single-tablet regimen containing tenofovir disoproxil fumarate 300 mg, lamivudine 300 mg and efavirenz 400 mg as a switch strategy in virologically suppressed HIV-1-infected subjects on nonnucleoside reverse transcriptase inhibito
Topics: Adult; Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Combinations; Female; HIV Infections; HIV-1; Humans; India; Lamivudine; Male; Middle Aged; Private Sector; Retrospective Studies; Reverse Transcriptase Inhibitors; Tablets; Tenofovir; Tertiary Care Centers; Treatment Outcome; Viral Load | 2020 |
No Changes in Human Immunodeficiency Virus (HIV) Suppression and Inflammatory Markers in Cerebrospinal Fluid in Patients Randomly Switched to Dolutegravir Plus Lamivudine (Spanish HIV/AIDS Research Network, PreEC/RIS 62).
Topics: Anti-HIV Agents; Biomarkers; Drug Substitution; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Viral Load | 2021 |
Risk factors for delayed viral suppression on first-line antiretroviral therapy among persons living with HIV in Haiti, 2013-2017.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; Female; Haiti; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Risk Factors; Viral Load; Young Adult; Zidovudine | 2020 |
Human Immunodeficiency Virus-1 Subtype-C Genetically Diversify to Acquire Higher Replication Competence in Human Host with Comorbidities.
Topics: Cross-Sectional Studies; HIV Infections; HIV-1; Humans; Lamivudine; Nevirapine | 2021 |
Evolution of blood lipids and risk factors of dyslipidemia among people living with human immunodeficiency virus who had received first-line antiretroviral regimens for 3 years in Shenzhen.
Topics: Aged; Anti-HIV Agents; China; Dyslipidemias; HIV; HIV Infections; Humans; Lamivudine; Lipids; Risk Factors | 2020 |
Risk of Tumor Onset in HIV+ Patients on Two-Drug Regimens: A Cohort Study in an Italian Hospital.
Topics: Adult; Anti-HIV Agents; Cohort Studies; HIV Infections; Hospitals; Humans; Italy; Lamivudine; Longitudinal Studies; Male; Neoplasms; Pharmaceutical Preparations | 2021 |
The effect of protease inhibitor-based dual antiretroviral regimens on CD4/CD8 ratio during the first year of therapy in ART-naïve patients with HIV-infection.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; Viral Load | 2021 |
Weight-adapted fixed-dose combined adult antiretroviral tablets for HIV-infected children.
Topics: Anti-HIV Agents; Body Height; Body Weight; CD4 Lymphocyte Count; Child; Child, Preschool; Dideoxynucleosides; Dose-Response Relationship, Drug; Drug Combinations; Female; HIV Infections; Humans; Lamivudine; Male; Prospective Studies; Spain; Viral Load | 2021 |
Effect of menopause on weight gain, insulin and waist circumference in women with HIV who switch antiretroviral therapy to abacavir/lamivudine/dolutegravir.
Topics: Dideoxynucleosides; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Insulin; Lamivudine; Menopause; Nitriles; Oxazines; Piperazines; Pyridones; Pyrimidines; Raltegravir Potassium; Waist Circumference; Weight Gain | 2021 |
Short-cycle therapy (5 days on/2 days off) with a lamivudine + dolutegravir regimen in a cohort of virologically suppressed patients with HIV infection.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Reverse Transcriptase Inhibitors | 2021 |
Prevalence and evaluation of risk factors of anti-retroviral therapy failure among human immunodeficiency virus/acquired immune deficiency syndrome patients in North India.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; CD4 Lymphocyte Count; HIV; HIV Infections; Humans; India; Lamivudine; Male; Prevalence; Risk Factors; Viral Load; Zidovudine | 2021 |
Re: "No Significant Changes in Weight and Body Fat Mass in Suppressed HIV Infected Patients Switched to Dual Combination Lamivudine Plus Dolutegravir or Raltegravir" by Calza
Topics: Adipose Tissue; Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Raltegravir Potassium | 2021 |
Deep sequencing analysis of M184V/I mutation at the switch and at the time of virological failure of boosted protease inhibitor plus lamivudine or boosted protease inhibitor maintenance strategy (substudy of the ANRS-MOBIDIP trial).
Topics: Anti-HIV Agents; Drug Resistance, Viral; High-Throughput Nucleotide Sequencing; HIV Infections; HIV-1; Humans; Lamivudine; Mutation; Protease Inhibitors; Viral Load | 2021 |
To dose-adjust or not to dose-adjust: lamivudine dose in kidney impairment.
Topics: Anti-HIV Agents; HIV Infections; Humans; Kidney; Lamivudine; Longitudinal Studies | 2021 |
Prevalence of M184V and K65R in proviral DNA from PBMCs in HIV-infected youths with lamivudine/emtricitabine exposure.
Topics: Adolescent; Anti-HIV Agents; Child; DNA; Drug Resistance, Viral; Emtricitabine; HIV Infections; Humans; Lamivudine; Prevalence; Proviruses; Viral Load | 2021 |
A Prospective Study Evaluating Changes in Histology, Clinical and Virologic Outcomes in HBV-HIV Co-infected Adults in North America.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Antiviral Agents; Coinfection; Drug Therapy, Combination; Female; Guanine; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Liver; Male; Middle Aged; North America; Prospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Young Adult | 2021 |
In utero and peripartum antiretroviral exposure as predictor of cognition in 6- to 10-year-old HIV-exposed Ugandan children - a prospective cohort study.
Topics: Anti-HIV Agents; Child; Cognition; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Peripartum Period; Pregnancy; Pregnancy Complications, Infectious; Prospective Studies; Uganda; Zidovudine | 2021 |
Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen.
Topics: Adult; Anti-HIV Agents; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Prospective Studies; Pyridones; South Africa; Tenofovir; Viral Load | 2021 |
Dosing lamivudine or emtricitabine in renal impairment: new data confirm it's time for updated guidance!
Topics: Anti-HIV Agents; Emtricitabine; HIV Infections; Humans; Kidney; Lamivudine | 2021 |
Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study.
Topics: Adult; Anti-HIV Agents; Body Weight; Cohort Studies; Dideoxynucleosides; Drug Combinations; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Emtricitabine, Rilpivirine, Tenofovir Drug Combination; Female; Heart Disease Risk Factors; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Italy; Lamivudine; Lipid Metabolism; Lipids; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Retrospective Studies; Tablets | 2021 |
Growing data for recycling tenofovir and lamivudine with dolutegravir as empiric second-line antiretroviral therapy in resource-limited settings.
Topics: Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Tenofovir | 2021 |
Effectiveness and tolerability of dolutegravir and abacavir/lamivudine administered as two separate pills compared to their equivalent single-tablet regimen in a multicentre cohort in Spain.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Spain; Tablets | 2021 |
Effectiveness, Durability, and Safety of Dolutegravir and Lamivudine Versus Dolutegravir, Lamivudine, and Abacavir in a Real-Life Cohort of HIV-Infected Adults.
Topics: Adult; Anti-HIV Agents; Dideoxynucleosides; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Viral Load | 2022 |
Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: Data from real-life ODOACRE cohort.
Topics: Adult; Cohort Studies; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Oxazines; Raltegravir Potassium; Viral Load | 2021 |
Less is more: A novel single-tablet regimen with two-drugs, dolutegravir/lamivudine.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Tablets | 2021 |
Kinetics of Archived M184V Mutation in Treatment-Experienced Virally Suppressed HIV-Infected Patients.
Topics: Anti-HIV Agents; DNA; Drug Resistance, Viral; Emtricitabine; HIV Infections; HIV-1; Humans; Kinetics; Lamivudine; Mutation; RNA | 2022 |
Five Years With Dolutegravir Plus Lamivudine as a Switch Strategy: Much More Than a Positive Finding.
Topics: Anti-HIV Agents; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Seropositivity; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Retrospective Studies; RNA | 2021 |
Predominance of Hepatitis B Virus Genotype A Among Treated HIV Infected Patients Experiencing High Hepatitis B Virus Drug Resistance in Nairobi, Kenya.
Topics: Adolescent; Adult; Aged; Antiviral Agents; Child; Child, Preschool; Cross-Sectional Studies; DNA, Viral; Drug Resistance, Viral; Emtricitabine; Female; Genes, pol; Genotype; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Kenya; Lamivudine; Male; Middle Aged; Tenofovir; Viral Load; Young Adult | 2017 |
The effect of veno-venous ECMO on the pharmacokinetics of Ritonavir, Darunavir, Tenofovir and Lamivudine.
Topics: Bayes Theorem; Darunavir; Dose-Response Relationship, Drug; Extracorporeal Membrane Oxygenation; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Middle Aged; Ritonavir; Tenofovir | 2017 |
Modelling CD4 T Cell Recovery in Hepatitis C and HIV Co-infected Children Receiving Antiretroviral Therapy.
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Child; Child, Preschool; Cohort Studies; Coinfection; Drug Combinations; Female; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Interferon-alpha; Lamivudine; Lopinavir; Male; Models, Immunological; Polyethylene Glycols; Recombinant Proteins; Recovery of Function; Ribavirin; Ritonavir; Time-to-Treatment; Zidovudine | 2017 |
Bone Density, Microarchitecture, and Tissue Quality After Long-Term Treatment With Tenofovir/Emtricitabine or Abacavir/Lamivudine.
Topics: Absorptiometry, Photon; Anti-HIV Agents; Bone Density; Bone Remodeling; Cross-Sectional Studies; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Spain; Tenofovir | 2017 |
Raltegravir plus lamivudine as 'maintenance therapy' in suppressed HIV-1-infected patients in real-life settings.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Raltegravir Potassium; RNA, Viral; Viral Load | 2017 |
Factors associated with loss to follow-up after occupational HIV exposure in Cape Town, South Africa: a retrospective cohort study.
Topics: Adult; Anti-HIV Agents; Emtricitabine; Female; Health Personnel; HIV Infections; Humans; Infectious Disease Transmission, Patient-to-Professional; Lamivudine; Lost to Follow-Up; Male; Occupational Exposure; Post-Exposure Prophylaxis; Retrospective Studies; South Africa; Stavudine; Tenofovir; Young Adult; Zidovudine | 2017 |
Mark Arnold Wainberg.
Topics: Allergy and Immunology; Anti-HIV Agents; Biomedical Research; Canada; History, 20th Century; History, 21st Century; HIV Infections; Humans; Lamivudine; Male; Microbiology; Pediatrics; Research Personnel | 2017 |
Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse-Transcriptase and Protease in Antiretroviral Treatment-Naive Patients and Response to Regimens Containing Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; Drug Resistance, Viral; Emtricitabine; Europe; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation, Missense; Reverse Transcriptase Inhibitors; Tenofovir; Thymidine; United States | 2017 |
On assessing bioequivalence and interchangeability between generics based on indirect comparisons.
Topics: Anti-HIV Agents; Antimalarials; Artemether; Artemisinins; Computer Simulation; Confidence Intervals; Drugs, Generic; Ethanolamines; Fluorenes; HIV Infections; Humans; Lamivudine; Lumefantrine; Malaria; Models, Statistical; Therapeutic Equivalency; Zidovudine | 2017 |
Dual therapy with a combination of unboosted atazanavir and lamivudine as maintenance treatment in virologically suppressed HIV-1-infected patients.
Topics: Adult; Atazanavir Sulfate; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Treatment Outcome | 2017 |
Stability behavior of antiretroviral drugs and their combinations. 7: Comparative degradation pathways of lamivudine and emtricitabine and explanation to their differential degradation behavior by density functional theory.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; HIV Infections; Lamivudine; Tenofovir | 2017 |
Brief Report: Late Efavirenz-Induced Ataxia and Encephalopathy: A Case Series.
Topics: Adult; Alkynes; Anti-HIV Agents; Ataxia; Benzoxazines; Brain Diseases; CD4 Lymphocyte Count; Cyclopropanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; South Africa; Tenofovir; Treatment Outcome; Viral Load; Young Adult | 2017 |
Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Clinical Decision-Making; Computational Biology; Cross-Sectional Studies; Cyclopropanes; Drug Resistance, Viral; Emtricitabine; Female; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Monitoring, Physiologic; Nevirapine; pol Gene Products, Human Immunodeficiency Virus; Stavudine; Tanzania; Tenofovir; Treatment Failure; Viral Load | 2017 |
Hepatitis B testing and treatment in HIV patients in The Gambia-Compliance with international guidelines and clinical outcomes.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Coinfection; Cross-Sectional Studies; Female; Gambia; Hepatitis B; HIV Infections; Humans; Lamivudine; Male; Mass Screening; Middle Aged; Practice Guidelines as Topic; Tenofovir; Treatment Outcome; Young Adult | 2017 |
[Obesity, high blood pressure, hypercholesterolaemia, and untreated diabetes in HIV-infected and HIV-uninfected Adults in Mbuji-Mayi (Democratic republic of congo)].
Topics: Adult; Antiretroviral Therapy, Highly Active; Case-Control Studies; Cross-Sectional Studies; Delayed Diagnosis; Democratic Republic of the Congo; Diabetes Mellitus; Female; HIV Infections; HIV-1; Humans; Hypercholesterolemia; Hypertension; Lamivudine; Male; Middle Aged; Nevirapine; Obesity; Prevalence; Stavudine | 2017 |
Clinical Experience with the Integrase Inhibitors Dolutegravir and Elvitegravir in HIV-infected Patients: Efficacy, Safety and Tolerance.
Topics: Adult; Aged; Aged, 80 and over; Cobicistat; Dideoxynucleosides; Drug Combinations; Female; Follow-Up Studies; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Quinolones; Retrospective Studies; Risk Factors; Spain; Treatment Outcome; Young Adult | 2017 |
Multi-state models for the analysis of time-to-treatment modification among HIV patients under highly active antiretroviral therapy in Southwest Ethiopia.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Ethiopia; Female; HIV Infections; Humans; Lamivudine; Male; Models, Theoretical; Nevirapine; Pregnancy; Retrospective Studies; Stavudine; Tenofovir; Time-to-Treatment; Treatment Failure; Zidovudine | 2017 |
A retrospective case-cohort study comparing treatment outcomes in abacavir versus stavudine containing first line antiretroviral treatment regimens in children <3yrs old, at a paediatric programme based in Soweto, South Africa.
Topics: Child, Preschool; Dideoxynucleosides; Drug Combinations; Female; HIV; HIV Infections; Humans; Infant; Lamivudine; Lopinavir; Male; Retrospective Studies; Ritonavir; South Africa; Stavudine; Treatment Outcome; Viral Load | 2017 |
Cost-effectiveness of dolutegravir/abacavir/lamivudine in HIV-1 treatment-Naive (TN) patients in France.
Topics: Adult; Algorithms; Anti-HIV Agents; Cost-Benefit Analysis; Dideoxynucleosides; Drug Combinations; France; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Markov Chains; Oxazines; Piperazines; Practice Guidelines as Topic; Pyridones; Quality-Adjusted Life Years; Treatment Outcome | 2018 |
Severe depression as a neuropsychiatric side effect induced by dolutegravir.
Topics: Depression; Dideoxynucleosides; Drug Combinations; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Withholding Treatment | 2018 |
Efficacy and safety of switching from branded to generic antiretrovirals in virologically suppressed HIV-infected patients.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cohort Studies; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Drugs, Generic; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Patient Safety; Poisson Distribution; RNA, Viral; Treatment Outcome; Zidovudine | 2017 |
Accumulation of HIV-1 drug resistance in patients on a standard thymidine analogue-based first line antiretroviral therapy after virological failure: implications for the activity of next-line regimens from a longitudinal study in Mozambique.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Longitudinal Studies; Male; Mozambique; Mutation; Nevirapine; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure; Viral Load; Zidovudine | 2017 |
An observational, retrospective analysis evaluating switching to raltegravir plus abacavir/lamivudine in HIV-1-infected patients: the ORASWIRAL study.
Topics: Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Combinations; HIV Infections; HIV-1; Humans; Lamivudine; Middle Aged; Raltegravir Potassium; Retrospective Studies; Treatment Outcome; Viral Load | 2018 |
A retrospective clinical audit of general practices in Australia to determine the motivation for switch to dolutegravir/abacavir/lamivudine and clinical outcomes.
Topics: Anti-HIV Agents; Australia; Clinical Audit; Dideoxynucleosides; Drug Combinations; Drug Substitution; Female; General Practice; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Kaplan-Meier Estimate; Lamivudine; Male; Motivation; Oxazines; Piperazines; Pyridones; Retrospective Studies; Sustained Virologic Response; Treatment Outcome | 2018 |
M184I/V substitutions and E138K/M184I/V double substitutions in HIV reverse transcriptase do not significantly affect the antiviral activity of EFdA.
Topics: Amino Acid Substitution; Anti-HIV Agents; Clinical Trials as Topic; Deoxyadenosines; Drug Resistance, Viral; Emtricitabine; HEK293 Cells; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutagenesis, Site-Directed; Mutation; Reverse Transcriptase Inhibitors; Rilpivirine; Virus Replication | 2017 |
Human immunodeficiency virus infection acquired through a traditional healer's ritual: a case report.
Topics: Adult; Alkynes; Antiviral Agents; Benzoxazines; Ceremonial Behavior; Cyclopropanes; Enzyme-Linked Immunosorbent Assay; Female; HIV Infections; Humans; Lamivudine; Medicine, Traditional; Tanzania; Tenofovir | 2017 |
HIV-1 DNA ultra-deep sequencing analysis at initiation of the dual therapy dolutegravir + lamivudine in the maintenance DOLULAM pilot study.
Topics: Adult; Anti-HIV Agents; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genetic Variation; Genome, Viral; Genotype; Heterocyclic Compounds, 3-Ring; High-Throughput Nucleotide Sequencing; HIV Infections; HIV Integrase; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Mutation; Oxazines; Pilot Projects; Piperazines; Pyridones | 2017 |
Dolutegravir plus abacavir/lamivudine works in adolescents, but size matters.
Topics: Adolescent; Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Hospitals, Pediatric; Humans; Lamivudine; Male; Oxazines; Piperazines; Pyridones; Referral and Consultation; Spain; Tablets | 2017 |
Validation of an LC-MS/MS assay to simultaneously monitor the intracellular active metabolites of tenofovir, emtricitabine, and lamivudine in dried blood spots.
Topics: Anti-HIV Agents; Chromatography, High Pressure Liquid; Dried Blood Spot Testing; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Lamivudine; Leukocytes, Mononuclear; Liquid-Liquid Extraction; Medication Adherence; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Tenofovir | 2018 |
Concomitant AIDS cholangiopathy and Fanconi syndrome as complications of HIV in a single patient.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Cholangitis; Fanconi Syndrome; Female; HIV Infections; Humans; Lamivudine; Middle Aged; Tenofovir; Zidovudine | 2017 |
Motives for change of first-line antiretroviral therapy regimens in an unselected cohort of HIV/AIDS patients at a major referral centre in South-west Cameroon.
Topics: Adult; Anti-HIV Agents; Cameroon; Cohort Studies; Cross-Sectional Studies; Drug Combinations; Drug Substitution; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Referral and Consultation; Stavudine; Zidovudine | 2017 |
ACTG A5353: A Pilot Study of Dolutegravir Plus Lamivudine for Initial Treatment of Human Immunodeficiency Virus-1 (HIV-1)-infected Participants With HIV-1 RNA <500000 Copies/mL.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Oxazines; Pilot Projects; Piperazines; Pyridones; RNA, Viral; Viral Load | 2018 |
Lamivudine monotherapy in children and adolescents: The devil is in the detail.
Topics: Adolescent; Anti-HIV Agents; Child; Disease Management; Drug Monitoring; Drug Resistance, Viral; Genes, Viral; HIV; HIV Infections; Humans; Lamivudine; Long-Term Care; Medication Adherence; Mutation; Viral Load | 2017 |
Different Degrees of Immune Recovery Using Antiretroviral Regimens with Vonavir or Zidovudine/Lamivudine/Efavirenz in HIVPositive Patients Receiving First Line Treatment in Iran.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Drug Combinations; Female; HIV Infections; HIV-1; Humans; Immunity, Cellular; Iran; Lamivudine; Male; Retrospective Studies; Reverse Transcriptase Inhibitors; Sex Factors; Time Factors; Zidovudine | 2018 |
Simultaneous quantification of four antiretroviral drugs in breast milk samples from HIV-positive women by an ultra-high performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) method.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Breast Feeding; Calibration; Chromatography, High Pressure Liquid; Colostrum; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Milk, Human; Pregnancy; Pregnancy Complications, Infectious; Reference Standards; Reproducibility of Results; Ritonavir; Tandem Mass Spectrometry; Young Adult; Zidovudine | 2018 |
Patient perspectives on de-simplifying their single-tablet co-formulated antiretroviral therapy for societal cost savings.
Topics: Adult; Anti-Retroviral Agents; Canada; Cohort Studies; Cost Savings; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Drugs, Generic; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Oxazines; Patient Compliance; Piperazines; Practice Patterns, Physicians'; Pyridones; Tablets | 2018 |
Brief Report: Abacavir/Lamivudine and Tenofovir/Emtricitabine in Pregnant Women With HIV: Laboratory and Clinical Outcomes in an Observational National Study.
Topics: Adult; AIDS-Associated Nephropathy; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cesarean Section; Cholesterol; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Hemoglobins; HIV Infections; HIV-1; Humans; Hypertension; Lamivudine; Lipoproteins, LDL; Pregnancy; Pregnancy Complications; Pregnancy Outcome; Pregnancy Trimester, Third; RNA, Viral; Tenofovir | 2018 |
Long-term efficacy and safety of rilpivirine plus abacavir and lamivudine in HIV-1 infected patients with undetectable viral load.
Topics: Adult; Anti-HIV Agents; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Kaplan-Meier Estimate; Lamivudine; Linear Models; Male; Middle Aged; Retrospective Studies; Rilpivirine; Time Factors; Treatment Failure; Viral Load | 2018 |
A prospective study of adverse events to antiretroviral therapy in HIV- infected adults in Ekiti State, Nigeria.
Topics: Abdominal Pain; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Substitution; Drug Therapy, Combination; Female; HIV Infections; Humans; Incidence; Lamivudine; Male; Middle Aged; Nausea; Nevirapine; Nigeria; Prospective Studies; Sleep Initiation and Maintenance Disorders; Tenofovir; Young Adult; Zidovudine | 2016 |
Antiretroviral treatment Long-Term (ALT) cohort: a prospective cohort of 10 years of ART-experienced patients in Uganda.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Combinations; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lamivudine; Male; Nevirapine; Prospective Studies; RNA, Viral; Time; Uganda; Viral Load; Zidovudine | 2018 |
Preterm delivery and small-for-gestation outcomes in HIV-infected pregnant women on antiretroviral therapy in rural South Africa: Results from a cohort study, 2010-2015.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Infant, Newborn; Infant, Premature; Infant, Small for Gestational Age; Lamivudine; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Premature Birth; Retrospective Studies; Rural Population; South Africa; Tenofovir; Young Adult | 2018 |
Comparison of adherence to generic multi-tablet regimens vs. brand multi-tablet and brand single-tablet regimens likely to incorporate generic antiretroviral drugs by breaking or not fixed-dose combinations in HIV-infected patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Combinations; Drugs, Generic; Female; HIV Infections; Humans; Lamivudine; Male; Medication Adherence; Middle Aged; Tablets; Viral Load; Zidovudine | 2018 |
Intentional overdose of dolutegravir/abacavir/lamivudine (Triumeq) in a 26-year-old man.
Topics: Adult; Anti-HIV Agents; Area Under Curve; Biological Availability; Dideoxynucleosides; Drug Combinations; Drug Overdose; Fluid Therapy; Half-Life; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Suicide, Attempted; Tablets | 2018 |
Long-Acting Profile of 4 Drugs in 1 Anti-HIV Nanosuspension in Nonhuman Primates for 5 Weeks After a Single Subcutaneous Injection.
Topics: Animals; Anti-HIV Agents; Drug Carriers; Drug Delivery Systems; Drug Therapy, Combination; HIV Infections; Injections, Subcutaneous; Lamivudine; Leukocytes, Mononuclear; Lopinavir; Lymph Nodes; Macaca nemestrina; Male; Nanoparticles; Ritonavir; Tenofovir | 2018 |
Birth Outcomes for Pregnant Women with HIV Using Tenofovir-Emtricitabine.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Disease Transmission, Infectious; Drug Administration Schedule; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Infant, Low Birth Weight; Infant, Newborn; Lamivudine; Lopinavir; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Premature Birth; Risk; Ritonavir; Tenofovir; Zidovudine | 2018 |
Emerging resistance mutations in PI-naive patients failing an atazanavir-based regimen (ANRS multicentre observational study).
Topics: Adult; Atazanavir Sulfate; Dideoxynucleosides; Drug Combinations; Drug Resistance, Viral; Emtricitabine; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation; Retrospective Studies; Tenofovir; Treatment Failure; Viral Load | 2018 |
Adverse reactions associated with first-line regimens in patient initiating antiretroviral therapy.
Topics: Adolescent; Adult; Aged; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Brazil; Cross-Sectional Studies; Cyclopropanes; Drug-Related Side Effects and Adverse Reactions; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Prospective Studies; Pyridones; Quality of Life; Reverse Transcriptase Inhibitors; Tenofovir; Young Adult | 2018 |
Headache in an HIV-Positive Patient: Dangerous Interaction.
Topics: Adult; Anti-HIV Agents; Anticoagulants; Cilostazol; Cytochrome P-450 CYP3A Inhibitors; Dideoxynucleosides; Drug Combinations; Drug Interactions; Enoxaparin; Ergotamine; Ergotism; Headache; HIV Infections; Humans; Ischemia; Lamivudine; Lower Extremity; Male; Nitroglycerin; Ritonavir; Saquinavir; Tetrazoles; Tibial Arteries; Ultrasonography, Doppler, Color; Vasoconstrictor Agents; Vasodilator Agents | 2018 |
Determinants of anti-retroviral regimen changes among HIV/AIDS patients of east and west Wollega zone health institutions, Oromia region, west Ethiopia: a cross-sectional study.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Chemical and Drug Induced Liver Injury; Cross-Sectional Studies; Drug Substitution; Ethiopia; HIV Infections; Humans; Lamivudine; Nevirapine; Peripheral Nervous System Diseases; Retrospective Studies; Stavudine | 2018 |
Raltegravir plus abacavir/lamivudine in virologically suppressed HIV-1-infected patients: 48-week results of the KIRAL study.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Raltegravir Potassium; Retrospective Studies; Treatment Outcome | 2018 |
Severe cholestatic hepatitis related to abacavir/lamivudine/dolutegravir antiretroviral treatment in a HIV-1 infected subject.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Chemical and Drug Induced Liver Injury; Cholestasis; Dideoxynucleosides; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones | 2018 |
Drug resistance outcomes of long-term ART with tenofovir disoproxil fumarate in the absence of virological monitoring.
Topics: Adult; Africa South of the Sahara; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Reverse Transcriptase Inhibitors; Tenofovir; Time Factors; Treatment Outcome; Viral Load; Viremia | 2018 |
First reported case of integrase (R263K, G163R) and reverse transcriptase (M184V)-transmitted drug resistance from a drug-naive patient failing Triumeq.
Topics: Adult; Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Drug Resistance, Viral; Female; Heterocyclic Compounds, 3-Ring; HIV; HIV Infections; HIV Integrase; HIV Reverse Transcriptase; Humans; Lamivudine; Mutation, Missense; Treatment Failure | 2018 |
HIV viral suppression and longevity among a cohort of children initiating antiretroviral therapy in Eastern Cape, South Africa.
Topics: Adult; Alkynes; Ambulatory Care Facilities; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Preschool; Cohort Studies; Cyclopropanes; Dideoxynucleosides; Female; Health Resources; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Male; Medication Adherence; Ritonavir; South Africa; Viral Load | 2018 |
Short Communication: Reduced Nevirapine Concentrations Among HIV-Positive Women Receiving Mefloquine for Intermittent Preventive Treatment for Malaria Control During Pregnancy.
Topics: Adult; Anti-HIV Agents; Antimalarials; Cross-Sectional Studies; Drug Interactions; Female; Fetal Blood; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Kenya; Lamivudine; Malaria; Mefloquine; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; Retrospective Studies; Zidovudine | 2018 |
Substituting Generic Lamivudine for Emtricitabine in Virologically Suppressed HIV-Infected Patients.
Topics: Adult; Anti-HIV Agents; Drugs, Generic; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Medication Adherence; Middle Aged; Patient Compliance; Retrospective Studies; Viral Load | 2018 |
Crushed dolutegravir/abacavir/lamivudine given via nasogastric tube in gastric outlet obstruction caused by cancer resulted in rapid viral load suppression.
Topics: Adenocarcinoma; Anti-Retroviral Agents; Dideoxynucleosides; Gastric Outlet Obstruction; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Intubation, Gastrointestinal; Lamivudine; Male; Middle Aged; Oxazines; Parenteral Nutrition; Piperazines; Pyridones; Stomach Neoplasms; Sustained Virologic Response; Treatment Outcome | 2019 |
A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cholesterol; Cohort Studies; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Rilpivirine; Viral Load | 2019 |
Cost-Effectiveness of Dolutegravir as a First-Line Treatment Option in the HIV-1-Infected Treatment-Naive Patients in Russia.
Topics: Adult; Anti-HIV Agents; Cost-Benefit Analysis; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Male; Oxazines; Piperazines; Pyridones; Quality-Adjusted Life Years; Raltegravir Potassium; Russia | 2018 |
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)-induced Stevens-Johnson syndrome and gynecomastia in an HIV-infected child: A case report.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Substitution; Gynecomastia; HIV Infections; Humans; Lamivudine; Male; Mucositis; Nevirapine; Reverse Transcriptase Inhibitors; Stevens-Johnson Syndrome | 2018 |
Efficacy and safety of the switch of Triumeq® to generic (abacavir + lamivudine) + Tivicay®: data at 24 weeks.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Combinations; Drug Substitution; Drugs, Generic; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Treatment Outcome; Viral Load | 2018 |
Lamivudine monotherapy as a holding regimen for HIV-positive children.
Topics: Adolescent; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Female; HIV Infections; Humans; Lamivudine; Male; Patient Compliance; Prospective Studies; Survival Analysis; Treatment Outcome; Viral Load | 2018 |
Patterns of adverse drug reaction signals in NAFDAC pharmacovigilance activities from January to June 2015: safety of drug use in Nigeria.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Age Factors; Aged; Aged, 80 and over; Anti-HIV Agents; Child; Child, Preschool; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; Humans; Infant; Lamivudine; Male; Middle Aged; Nevirapine; Nigeria; Pharmacovigilance; Sex Factors; Young Adult; Zidovudine | 2018 |
Compromise of Second-Line Antiretroviral Therapy Due to High Rates of Human Immunodeficiency Virus Drug Resistance in Mozambican Treatment-Experienced Children With Virologic Failure.
Topics: Adolescent; Anti-Retroviral Agents; Child; Child, Preschool; Cross-Sectional Studies; Drug Resistance, Viral; Female; HIV; HIV Infections; Humans; Infant; Lamivudine; Male; Mozambique; Nevirapine; Stavudine; Treatment Failure; Viral Load | 2020 |
High Prevalence of HBV Lamivudine-Resistant Mutations in HBV/HIV Co-Infected Patients on Antiretroviral Therapy in the Area with the Highest Prevalence of HIV/HBV Co-Infection in China.
Topics: Adult; Anti-HIV Agents; China; Coinfection; DNA-Directed DNA Polymerase; Drug Resistance, Multiple, Viral; Female; Hepatitis B; Hepatitis B virus; HIV; HIV Infections; Humans; Lamivudine; Male; Multivariate Analysis; Mutation; Prevalence; Tenofovir; Viral Load | 2018 |
Abacavir/lamivudine/dolutegravir single tablet regimen in patients with human immunodeficiency virus and end-stage renal disease on hemodialysis.
Topics: Adult; Aged; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Dideoxynucleosides; Drug Combinations; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Kidney Failure, Chronic; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Renal Dialysis; Tablets; Treatment Outcome; Viral Load | 2019 |
Genital HIV-1 Shedding With Dolutegravir (DTG) Plus Lamivudine (3TC) Dual Therapy.
Topics: Anti-HIV Agents; Female; Genitalia; Genotyping Techniques; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Oxazines; Piperazines; Pyridones; RNA, Viral; Treatment Outcome; Virus Shedding | 2018 |
A two-drug regimen for antiretroviral therapy.
Topics: Adult; Double-Blind Method; Emtricitabine; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Tenofovir | 2019 |
Response of hepatitis B virus to antiretroviral treatment containing lamivudine in HBsAg-positive and HBsAg-negative HIV-positive South African adults.
Topics: Adolescent; Adult; Anti-Retroviral Agents; Child; Cohort Studies; Coinfection; Female; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Middle Aged; South Africa; Treatment Outcome; Viral Load; Young Adult | 2019 |
ART Denial: Results of a Home-Based Study to Validate Self-reported Antiretroviral Use in Rural South Africa.
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Cohort Studies; Emtricitabine; Female; HIV Antibodies; HIV Infections; Humans; Lamivudine; Longitudinal Studies; Male; Middle Aged; Rural Population; Self Report; Sensitivity and Specificity; Social Stigma; South Africa; Surveys and Questionnaires; Viral Load | 2019 |
Changes in bone mineral density in HIV-positive, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy: preliminary results from clinical practice.
Topics: Anti-HIV Agents; Bone Density; Drug Combinations; Drug Substitution; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Retrospective Studies | 2018 |
Adherence, virological outcome, and drug resistance in Chinese HIV patients receiving first-line antiretroviral therapy from 2011 to 2015.
Topics: Adult; Anti-HIV Agents; China; Drug Resistance, Viral; Female; HIV; HIV Infections; Humans; Lamivudine; Male; Medication Adherence; Middle Aged; Retrospective Studies; Stavudine; Sustained Virologic Response; Tenofovir; Zidovudine | 2018 |
Antiretroviral Drug Concentrations in Breastmilk, Maternal HIV Viral Load, and HIV Transmission to the Infant: Results From the BAN Study.
Topics: Adolescent; Adult; Anti-HIV Agents; Breast Feeding; Female; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Middle Aged; Milk, Human; Pregnancy; Ritonavir; RNA, Viral; Viral Load; Young Adult; Zidovudine | 2019 |
Switching from abacavir/lamivudine plus nevirapine to abacavir/lamivudine/dolutegravir in virologically controlled HIV-infected adults (SWAD study).
Topics: Adult; Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Drug Interactions; Drug Substitution; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Oxazines; Pilot Projects; Piperazines; Prospective Studies; Pyridones; Time Factors; Viral Load | 2019 |
Antiretroviral Monotherapy for HIV: Game Over or Future Perspectives?
Topics: Dideoxynucleosides; Heterocyclic Compounds, 3-Ring; HIV; HIV Infections; Humans; Lamivudine; Oxazines; Piperazines; Pyridones | 2019 |
Barrier to Resistance of Dolutegravir in Two-Drug Combinations.
Topics: Anti-HIV Agents; Cell Line; Drug Resistance, Viral; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Quinolones; Rilpivirine | 2019 |
Drug resistance evolution in patients with human immunodeficiency virus-1 under long-term antiretroviral treatment-failure in Yunnan Province, China.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; China; Drug Resistance, Viral; Evolution, Molecular; Female; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; RNA, Viral; Treatment Failure; Young Adult | 2019 |
Simplification of combination antiretroviral therapy (cART) and the brain-a real-life experience.
Topics: Adult; Aging; Antiretroviral Therapy, Highly Active; Brain; Cognition; Cognitive Dysfunction; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Neuropsychological Tests; Quality of Life; Retrospective Studies; Reverse Transcriptase Inhibitors; Severity of Illness Index; Tenofovir | 2019 |
Tenofovir disoproxil fumarate/emtricitabine is associated with a higher risk of hypocalcemia compared to abacavir/lamivudine - results from a German cohort study.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Calcium; Cohort Studies; Dideoxynucleosides; Drug Combinations; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Hypocalcemia; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Prevalence; Pyridones; Retrospective Studies; Tenofovir; Treatment Outcome | 2019 |
Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Cohort Studies; Darunavir; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Retrospective Studies; Ritonavir; Tenofovir; Treatment Outcome; Viral Load | 2019 |
Letter to the editor: switching treatment to lamivudine plus boosted atazanavir or darunavir in virologically suppressed HIV-infected patients - evidence from a large observational cohort.
Topics: Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Darunavir; HIV; HIV Infections; Humans; Lamivudine; Ritonavir | 2019 |
Symfi, Symfi Lo, and Cimduo for HIV.
Topics: Adenine; Administration, Oral; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Drug Interactions; HIV Infections; HIV-1; Humans; Lamivudine; Phosphorous Acids; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2019 |
Long-term improvement in renal, bone, lipid parameters, and CD4/CD8 ratio in HIV-infected patients switching to a dual therapy with lamivudine plus boosted darunavir.
Topics: Adult; Aged; Anti-HIV Agents; Bone Density; CD4-CD8 Ratio; Darunavir; Drug Substitution; Drug Therapy, Combination; Female; HIV Infections; Humans; Kidney Function Tests; Lamivudine; Lipids; Male; Middle Aged; Prospective Studies; Ritonavir; Treatment Outcome; Viral Load | 2019 |
Zidovudine, tenofovir or abacavir? Different adverse effect profiles.
Topics: Dideoxynucleosides; Drug Combinations; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Tenofovir; Zidovudine | 2016 |
Using PBPK Modeling to Predict Drug Exposure and Support Dosage Adjustments in Patients With Renal Impairment: An Example with Lamivudine.
Topics: Aged; Area Under Curve; Computer Simulation; Dose-Response Relationship, Drug; Female; Glomerular Filtration Rate; Healthy Volunteers; HIV Infections; Humans; Kidney; Lamivudine; Male; Middle Aged; Models, Biological; Renal Elimination; Renal Insufficiency; Reverse Transcriptase Inhibitors | 2020 |
Resistance Analysis of Bictegravir-Emtricitabine-Tenofovir Alafenamide in HIV-1 Treatment-Naive Patients through 48 Weeks.
Topics: Adenine; Alanine; Amides; Anti-HIV Agents; Antiviral Agents; Dideoxynucleosides; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lamivudine; Piperazines; Pyridones; Reverse Transcriptase Inhibitors; Tenofovir | 2019 |
Rate of viral load change and adherence of HIV adult patients treated with Efavirenz or Nevirapine antiretroviral regimens at 24 and 48 weeks in Yaoundé, Cameroon: a longitudinal cohort study.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cameroon; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Longitudinal Studies; Male; Middle Aged; Nevirapine; Patient Compliance; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2019 |
Optimising HIV antiretrovirals for mothers and infants.
Topics: Female; HIV Infections; HIV-1; Humans; Infant; Lamivudine; Lopinavir; Mothers; Ritonavir | 2019 |
Long-term virological suppression on first-line efavirenz + tenofovir + emtricitabine/lamivudine for HIV-1.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes; Emtricitabine; Europe; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Sustained Virologic Response; Tenofovir; Treatment Failure; Viral Load; Young Adult | 2019 |
Incidence and types of HIV-1 drug resistance mutation among patients failing first-line antiretroviral therapy.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Antiviral Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Incidence; Lamivudine; Male; Middle Aged; Mutation; Nevirapine; Stavudine; Tenofovir; Treatment Failure; Viral Load; Zidovudine | 2019 |
Prediction Model of Pre-treatment HIV RNA Levels in Naïve Thai HIV-infected Patients: Application for Resource-limited Settings.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Dideoxynucleosides; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; RNA, Viral; Thailand | 2018 |
Symptomatic HIV CNS viral escape among patients on effective cART.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Central Nervous System Viral Diseases; Encephalitis; Female; HIV Infections; Humans; India; Lamivudine; Lopinavir; Male; Plasma; Retrospective Studies; Viral Load | 2019 |
Efficacy and safety of abacavir/lamivudine with raltegravir in treatment-experienced and treatment-naïve patients with HIV-1 infection: an observational, retrospective, multi-centre study.
Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cholesterol; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Female; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Kidney Function Tests; Lamivudine; Liver Function Tests; Male; Middle Aged; Raltegravir Potassium; Treatment Outcome; Triglycerides | 2019 |
Case report of Triumeq (abacavir/dolutegravir/lamivudine) associated rhabdomyolysis in a human immunodeficiency virus (HIV) infected patient.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Rhabdomyolysis | 2019 |
Comparable viral decay with initial dolutegravir plus lamivudine versus dolutegravir-based triple therapy.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Clinical Studies as Topic; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Treatment Outcome; Viral Load | 2019 |
Emtricitabine and lamivudine concentrations in saliva: a simple suitable test for treatment adherence.
Topics: Anti-HIV Agents; Chemistry Techniques, Analytical; Cohort Studies; Emtricitabine; HIV Infections; Humans; Lamivudine; Plasma; Saliva; Specimen Handling; Treatment Adherence and Compliance | 2019 |
Bictegravir and dolutegravir: head to head at 96 weeks.
Topics: Adenine; Alanine; Amides; Dideoxynucleosides; Double-Blind Method; Emtricitabine; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Piperazines; Pyridones; Tenofovir | 2019 |
HIV-1 Tat and opioids act independently to limit antiretroviral brain concentrations and reduce blood-brain barrier integrity.
Topics: Animals; Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Blood-Brain Barrier; Capillary Permeability; Corpus Striatum; Dextrans; Dideoxynucleosides; Female; Fluorescein-5-isothiocyanate; Heterocyclic Compounds, 3-Ring; Hippocampus; HIV Infections; HIV-1; Lamivudine; Mice; Mice, Transgenic; Models, Biological; Morphine; Neurocognitive Disorders; Oxazines; Piperazines; Pyridones; tat Gene Products, Human Immunodeficiency Virus | 2019 |
Neurodevelopmental effects of ante-partum and post-partum antiretroviral exposure in HIV-exposed and uninfected children versus HIV-unexposed and uninfected children in Uganda and Malawi: a prospective cohort study.
Topics: Anti-Retroviral Agents; Breast Feeding; Child, Preschool; Cohort Studies; Drug Combinations; Female; HIV Infections; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Malawi; Male; Post-Exposure Prophylaxis; Postpartum Period; Pre-Exposure Prophylaxis; Pregnancy; Pregnancy Complications, Infectious; Prospective Studies; Ritonavir; Uganda; Zidovudine | 2019 |
Depot Medroxyprogesterone Acetate and the Vaginal Microbiome as Modifiers of Tenofovir Diphosphate and Lamivudine Triphosphate Concentrations in the Female Genital Tract of Ugandan Women: Implications for Tenofovir Disoproxil Fumarate/Lamivudine in Preexp
Topics: Adenine; Anti-HIV Agents; Cytidine Triphosphate; Dideoxynucleotides; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Medroxyprogesterone Acetate; Microbiota; Organophosphates; Pre-Exposure Prophylaxis; Tenofovir; Uganda | 2020 |
Long-term virological and serologic responses of chronic hepatitis B virus infection to tenofovir disoproxil fumarate-containing regimens in patients with HIV and hepatitis B coinfection.
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Substitution; Drug Therapy, Combination; Female; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load | 2019 |
Lamivudine-based maintenance antiretroviral therapies in patients living with HIV-1 with suppressed HIV RNA: derivation of a predictive score for virological failure.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Viral; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Predictive Value of Tests; Retrospective Studies; RNA, Viral; Viral Load | 2019 |
Efficacy and safety of the switch of Triumeq
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Drug Substitution; Drugs, Generic; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies; Spain | 2019 |
Dual therapy with renally adjusted lamivudine and dolutegravir: a switch strategy to manage comorbidity and toxicity in older, suppressed patients?
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Comorbidity; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Kidney; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Retrospective Studies; Treatment Outcome; Viral Load | 2019 |
Drug resistance and optimizing dolutegravir regimens for adolescents and young adults failing antiretroviral therapy.
Topics: Adolescent; Cross-Sectional Studies; Drug Combinations; Drug Resistance, Viral; Female; Genotype; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Medication Adherence; Oxazines; Piperazines; Pyridones; Tenofovir; Treatment Failure; Viral Load; Young Adult; Zimbabwe | 2019 |
Safety of 6-week Neonatal Triple-combination Antiretroviral Postexposure Prophylaxis in High-risk HIV-exposed Infants.
Topics: Anti-Retroviral Agents; Chemoprevention; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Male; Nevirapine; Post-Exposure Prophylaxis; Prospective Studies; Thailand; Treatment Outcome; Zidovudine | 2019 |
Safety and efficacy of Option B+ ART in Malawi: few severe maternal toxicity events or infant HIV infections among pregnant women initiating tenofovir/lamivudine/efavirenz.
Topics: Adult; Alkynes; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Malawi; Pregnancy; Pregnancy Complications, Infectious; Tenofovir; Young Adult | 2019 |
Effects of Highly Active Antiretroviral Therapy on Albuminuria in HIVinfected Persons.
Topics: Adolescent; Adult; Age Factors; Albuminuria; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Female; Glomerular Filtration Rate; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Prospective Studies; Sex Factors; Tenofovir; Young Adult; Zidovudine | 2020 |
[Tenofovir hypersensitivity to tenofovir (DRESS) syndrome in a female patient infected by HIV].
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Asthenia; Benzoxazines; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Eruptions; Drug Hypersensitivity; Drug Substitution; Emtricitabine; Female; Fever; HIV Infections; Humans; Lamivudine; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Syndrome; Tenofovir | 2013 |
Tenofovir-based combination therapy for HIV/HBV co-infection: factors associated with a partial HBV virological response in patients with undetectable HIV viraemia.
Topics: Adenine; Adult; Anti-HIV Agents; Case-Control Studies; Coinfection; Deoxycytidine; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Phosphorous Acids; Viremia | 2013 |
Underreporting of side effects of standard first-line ART in the routine setting in Blantyre, Malawi.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Ambulatory Care Facilities; Anti-HIV Agents; Cross-Sectional Studies; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; Humans; Interviews as Topic; Lamivudine; Lipodystrophy; Malawi; Male; Middle Aged; Nevirapine; Peripheral Nervous System Diseases; Prevalence; Stavudine; Surveys and Questionnaires; Urban Population | 2011 |
Prophylactic effect of antiretroviral therapy on hepatitis B virus infection.
Topics: Adenine; Adult; Alanine Transaminase; Anti-Retroviral Agents; Antibiotic Prophylaxis; Drug Resistance, Viral; Female; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Core Antigens; Hepatitis B Surface Antigens; HIV Infections; Humans; Kaplan-Meier Estimate; Lamivudine; Male; Organophosphonates; Retrospective Studies; Tenofovir | 2013 |
[Pulmonary hypertension in human immunodeficiency virus-infected patients: the role of antiretroviral therapy].
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cross-Sectional Studies; Drug Therapy, Combination; Female; HIV Infections; Humans; Hypertension, Pulmonary; Lamivudine; Male; Middle Aged; Organophosphonates; Prevalence; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Tricuspid Valve Insufficiency; Ultrasonography | 2014 |
Revisiting lactic acidosis in an HIV-1 infected pregnant woman on antiretroviral therapy.
Topics: Acidosis, Lactic; Adult; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Lamivudine; Pregnancy; Pregnancy Complications, Infectious; Stavudine | 2013 |
Cardiometabolic risk factors among HIV patients on antiretroviral therapy.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Cyclopropanes; Female; HIV; HIV Infections; Humans; Insulin Resistance; Lamivudine; Male; Middle Aged; Nevirapine; Organophosphonates; Risk Factors; Stavudine; Tenofovir; Triglycerides; Zambia; Zidovudine | 2013 |
Access to treatment for HBV infection and its consistency with 2008 European guidelines in a multicentre cross-sectional study of HIV/HBV co-infected patients in Italy.
Topics: Adenine; Adult; Anti-Retroviral Agents; Coinfection; Cross-Sectional Studies; Deoxycytidine; Emtricitabine; Europe; Female; Guideline Adherence; Health Services Accessibility; Hepatitis B; HIV Infections; Humans; Infectious Disease Medicine; Italy; Lamivudine; Male; Multivariate Analysis; Organophosphonates; Practice Guidelines as Topic; Regression Analysis; Tenofovir; Treatment Outcome | 2013 |
Talk of HIV cure goes viral.
Topics: Adult; Anti-HIV Agents; CD4-Positive T-Lymphocytes; Child, Preschool; DNA, Viral; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Male; Nevirapine; Primary Prevention; Ritonavir; Secondary Prevention; Time Factors; Zidovudine | 2013 |
Contribution of follicular dendritic cells to persistent HIV viremia.
Topics: Dendritic Cells, Follicular; Drug Combinations; HIV Infections; HIV-1; Humans; Kinetics; Lamivudine; Lopinavir; Models, Biological; Ritonavir; Stavudine; Viral Load; Viremia; Virus Release | 2013 |
Left ventricular hypertrophy detected by echocardiography in HIV-infected patients.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Carbamates; Comorbidity; Cross-Sectional Studies; Cyclopropanes; Diabetes Mellitus; Drug Combinations; Dyslipidemias; Echocardiography; Female; Furans; HIV Infections; Humans; Hypertension; Hypertrophy, Left Ventricular; Lamivudine; Lopinavir; Male; Middle Aged; Nevirapine; Organophosphates; Organophosphonates; Risk Factors; Ritonavir; Smoking; Spain; Sulfonamides; Tenofovir; Zidovudine | 2013 |
Antiretroviral drugs in Africa: a public health versus a market approach.
Topics: Africa; Anti-HIV Agents; Drug Packaging; Health Resources; Health Services Accessibility; HIV Infections; Humans; Lamivudine; Nevirapine; Public Health; Zidovudine | 2013 |
Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir; Thymidine; Treatment Failure; Viral Load; Zidovudine | 2013 |
Baseline CD4 cell counts and outcomes among adult treatment naive HIV patients after taking fixed dose combination GPO-VIR-S and GPO-VIR-Z in Thailand.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Female; Hematologic Tests; HIV Infections; Humans; Immune Reconstitution Inflammatory Syndrome; Kaplan-Meier Estimate; Lamivudine; Male; Middle Aged; Nevirapine; Retrospective Studies; Stavudine; Thailand; Treatment Outcome; Viral Load; Zidovudine | 2013 |
Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002-2009.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Europe; HIV Infections; HIV Protease Inhibitors; HIV Seropositivity; HIV-1; Humans; Lamivudine; Lopinavir; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Risk Factors; Tenofovir; Time Factors; United States | 2013 |
Once-daily darunavir/ritonavir and abacavir/lamivudine versus tenofovir/emtricitabine for treatment-naïve patients with a baseline viral load of more than 100 000 copies/ml.
Topics: Adenine; Anti-HIV Agents; Darunavir; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Organophosphonates; Ritonavir; Sulfonamides; Tenofovir; Viral Load | 2013 |
Economic evaluation of 3-drug antiretroviral regimens for the prevention of mother-to-child HIV transmission in Thailand.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cost-Benefit Analysis; Cyclopropanes; Drug Therapy, Combination; Female; Health Services; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Models, Econometric; Mothers; Nevirapine; Pregnancy; Thailand; Zidovudine | 2015 |
Emtricitabine compared with lamivudine may preserve future therapeutic options in HIV-1-infected children.
Topics: Anti-HIV Agents; Child; Child, Preschool; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; HIV Infections; HIV-1; Humans; Infant; Lamivudine | 2013 |
Adherence to antiretroviral therapy among HIV infected children measured by caretaker report, medication return, and drug level in Dar Es Salaam, Tanzania.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Caregivers; CD4 Lymphocyte Count; Child; Child, Preschool; Cross-Sectional Studies; Drug Administration Schedule; Drug Combinations; Female; HIV Infections; Humans; Lamivudine; Logistic Models; Male; Medication Adherence; Middle Aged; Nevirapine; Odds Ratio; Stavudine; Surveys and Questionnaires; Tanzania; Young Adult; Zidovudine | 2013 |
Transmitted drug-resistance in human immunodeficiency virus-infected adult population in El Salvador, Central America.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Cohort Studies; Dried Blood Spot Testing; Drug Resistance, Viral; El Salvador; Female; Genetic Variation; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Molecular Sequence Data; Phylogeny; pol Gene Products, Human Immunodeficiency Virus; Poverty; Young Adult | 2013 |
Temporal association between incident tuberculosis and poor virological outcomes in a South African antiretroviral treatment service.
Topics: Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cyclopropanes; Disease Progression; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; Humans; Incidence; Lamivudine; Male; Medication Adherence; Nevirapine; Risk Factors; South Africa; Stavudine; Time Factors; Tuberculosis; Viral Load | 2013 |
Clinical experience of raltegravir with abacavir/lamivudine or zidovudine/lamivudine in HIV-infected Korean adults.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lipids; Male; Middle Aged; Prospective Studies; Pyrrolidinones; Raltegravir Potassium; Republic of Korea; Retrospective Studies; Treatment Outcome; Viral Load; Young Adult; Zidovudine | 2013 |
HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomes.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Coinfection; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B; Hepatitis B virus; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Prospective Studies; Reverse Transcriptase Inhibitors; South Africa; Tenofovir; Treatment Outcome; Zambia | 2013 |
Prophylactic effect of lamivudine-based antiretroviral therapy on incident hepatitis B virus infection among HIV-infected patients.
Topics: Anti-Retroviral Agents; Antibiotic Prophylaxis; Hepatitis B; HIV Infections; Humans; Incidence; Kaplan-Meier Estimate; Lamivudine | 2013 |
The impact of choice of NNRTI on short-term treatment outcomes among HIV-infected patients prescribed tenofovir and lamivudine in Johannesburg, South Africa.
Topics: Adenine; Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Reverse Transcriptase Inhibitors; South Africa; Tenofovir; Treatment Outcome; Viral Load | 2013 |
Safety and efficacy of tenofovir/emtricitabine or abacavir/lamivudine in combination with efavirenz in treatment naïve HIV patients: a 5 year retrospective observational cohort study. (the TOKEN Study).
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cardiovascular Diseases; CD4 Lymphocyte Count; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; Humans; Kidney Diseases; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir; Viral Load | 2013 |
HIV-1 drug-resistance surveillance among treatment-experienced and -naïve patients after the implementation of antiretroviral therapy in Ghana.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Drug Resistance, Viral; Epidemiological Monitoring; Female; Ghana; HIV Infections; HIV Protease; HIV-1; Humans; Infant; Lamivudine; Male; Middle Aged; Molecular Epidemiology; Molecular Typing; Mutation, Missense; Nevirapine; Prevalence; Sequence Analysis, DNA; Stavudine; Zidovudine | 2013 |
Anemia and risk factors in HAART naïve and HAART experienced HIV positive persons in south west Ethiopia: a comparative study.
Topics: Adolescent; Adult; Anemia; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Child; Child, Preschool; Cross-Sectional Studies; Female; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Lamivudine; Longitudinal Studies; Male; Middle Aged; Nevirapine; Risk Factors; Social Class; Surveys and Questionnaires; Zidovudine | 2013 |
High-levels of acquired drug resistance in adult patients failing first-line antiretroviral therapy in a rural HIV treatment programme in KwaZulu-Natal, South Africa.
Topics: Adolescent; Adult; Alkynes; Analysis of Variance; Anti-HIV Agents; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation; Nevirapine; Outcome Assessment, Health Care; Prevalence; South Africa; Stavudine; Young Adult; Zidovudine | 2013 |
Child cured of HIV: can this be repeated?
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; Humans; Infant, Newborn; Lamivudine; Nevirapine; Reverse Transcriptase Inhibitors; Zidovudine | 2013 |
The emergence of drug resistant HIV variants at virological failure of HAART combinations containing efavirenz, tenofovir and lamivudine or emtricitabine within the UK Collaborative HIV Cohort.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cohort Studies; Cyclopropanes; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir; Treatment Failure | 2014 |
A model-based approach for the evaluation of once daily dosing of lamivudine in HIV-infected children.
Topics: Anti-HIV Agents; Body Weight; Child; Child, Preschool; Drug Administration Schedule; HIV Infections; Humans; Infant; Lamivudine; Models, Biological | 2014 |
Covariate effects and population pharmacokinetics of lamivudine in HIV-infected children.
Topics: Anti-HIV Agents; Area Under Curve; Child; Child, Preschool; Female; HIV Infections; Humans; Infant; Lamivudine; Male; Models, Biological | 2014 |
Dual therapy with lamivudine + protease inhibitor during pregnancy for prevention of mother-to-child transmission of HIV-1.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Plasma; Pregnancy; Pregnancy Complications, Infectious; Treatment Outcome; Viral Load | 2013 |
Legal, ethical, and economic implications of breaking down once-daily fixed-dose antiretroviral combinations into their single components for cost reduction.
Topics: Anti-HIV Agents; Cost Savings; Drug Administration Schedule; Drug Combinations; Drug Substitution; Drugs, Generic; Economic Recession; Europe; Healthcare Disparities; HIV Infections; Humans; Lamivudine; Medication Adherence; National Health Programs; Patient Compliance; Patient Rights; Public Health; Spain; Therapeutic Equivalency | 2014 |
[Evaluation of tolerance of zidovudine-lamivudine-nevirapine combination in HIV 1 patients in Fann Teaching Hospital in Dakar].
Topics: Adult; Anti-HIV Agents; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV-1; Hospitals, Teaching; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Retrospective Studies; Senegal; Zidovudine | 2013 |
Delayed emergence of HIV-1 variants resistant to 4'-ethynyl-2-fluoro-2'-deoxyadenosine: comparative sequential passage study with lamivudine, tenofovir, emtricitabine and BMS-986001.
Topics: Adenine; Amino Acid Sequence; Anti-HIV Agents; Deoxyadenosines; Deoxycytidine; Drug Resistance, Multiple, Viral; Emtricitabine; HIV Infections; HIV-1; Human Immunodeficiency Virus Proteins; Humans; Lamivudine; Molecular Sequence Data; Molecular Structure; Organophosphonates; Tenofovir; Thymidine | 2014 |
Trends in clinical characteristics of HIV-infected patients initiating antiretroviral therapy in Shanghai from 2006 to 2011.
Topics: Adolescent; Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; China; Cross-Sectional Studies; Female; HIV Infections; Humans; Immune Tolerance; Lamivudine; Male; Middle Aged; Nevirapine; Retrospective Studies; Stavudine; Viral Load; Zidovudine | 2014 |
Preliminary study of quinine pharmacokinetics in pregnant women with malaria-HIV co-infection.
Topics: Adult; Anti-HIV Agents; Antimalarials; Antiretroviral Therapy, Highly Active; Coinfection; Drug Interactions; Female; HIV Infections; Humans; Lamivudine; Malaria, Falciparum; Nevirapine; Parasite Load; Pregnancy; Pregnancy Complications, Infectious; Prospective Studies; Quinidine; Quinine; Stavudine; Treatment Outcome; Young Adult; Zidovudine | 2014 |
Disposition of amodiaquine and desethylamodiaquine in HIV-infected Nigerian subjects on nevirapine-containing antiretroviral therapy.
Topics: Adolescent; Adult; Amodiaquine; Anti-Retroviral Agents; Antimalarials; Antiretroviral Therapy, Highly Active; Artemisinins; Artesunate; Chromatography, High Pressure Liquid; Drug Interactions; Female; HIV Infections; Humans; Lamivudine; Malaria; Male; Middle Aged; Nevirapine; Nigeria; Plasma; Young Adult; Zidovudine | 2014 |
Pharmacogenetics and clinical biomarkers for subtherapeutic plasma efavirenz concentration in HIV-1 infected Thai adults.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Asian People; Benzoxazines; Biomarkers; Cyclopropanes; Cytochrome P-450 Enzyme System; Female; Gene Frequency; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Polymorphism, Single Nucleotide; Prospective Studies; Tenofovir; Young Adult | 2014 |
Clinical profile and response to first-line ARV in HIV patients from Eastern UP and Bihar: a retrospective study.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female; HIV Infections; Humans; India; Lamivudine; Male; Middle Aged; Nevirapine; Retrospective Studies; Reverse Transcriptase Inhibitors; Stavudine; Treatment Outcome; Young Adult; Zidovudine | 2013 |
Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes.
Topics: Adult; Alkynes; Area Under Curve; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Mutation; Pharmacogenetics; Reverse Transcriptase Inhibitors; Treatment Outcome; Uganda; Zidovudine | 2014 |
Virological outcomes and drug resistance in Chinese patients after 12 months of 3TC-based first-line antiretroviral treatment, 2011-2012.
Topics: Adolescent; Adult; Anti-HIV Agents; Anti-Retroviral Agents; CD4 Lymphocyte Count; China; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Treatment Outcome; Viral Load; Young Adult | 2014 |
Hepatitis B and C co-infection among HIV-infected adults while on antiretroviral treatment: long-term survival, CD4 cell count recovery and antiretroviral toxicity in Cambodia.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cambodia; CD4 Lymphocyte Count; Coinfection; Cyclopropanes; Female; Hepatitis B; Hepatitis C; HIV Infections; Humans; Kaplan-Meier Estimate; Lamivudine; Liver; Logistic Models; Male; Middle Aged; Nevirapine; Proportional Hazards Models; Retrospective Studies; Stavudine; Treatment Outcome; Zidovudine | 2014 |
Safety analysis of Epzicom® (lamivudine/abacavir sulfate) in post-marketing surveillance in Japan.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Drug Hypersensitivity; HIV Infections; Humans; Incidence; Japan; Lamivudine; Myocardial Ischemia; Product Surveillance, Postmarketing | 2014 |
Incidence and risk factors for incomplete HBV DNA suppression in HIV/HBV-co-infected patients initiating tenofovir-based therapy.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Coinfection; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Incidence; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Risk Factors; Tenofovir; Viral Load; Viremia | 2014 |
Determinants of virological failure after 1 year's antiretroviral therapy in Vietnamese people with HIV: findings from a retrospective cohort of 13 outpatient clinics in six provinces.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; Female; HIV Infections; Humans; Lamivudine; Logistic Models; Male; Multivariate Analysis; Nevirapine; Predictive Value of Tests; Retrospective Studies; Stavudine; Substance Abuse, Intravenous; Treatment Failure; Viral Load; Young Adult | 2014 |
Virologic and serologic outcomes of mono versus dual HBV therapy and characterization of HIV/HBV coinfection in a US cohort.
Topics: Adenine; Adult; Antibodies, Viral; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Coinfection; Deoxycytidine; DNA, Viral; Emtricitabine; Female; Follow-Up Studies; Hepatitis B; Hepatitis B e Antigens; HIV Infections; Humans; Lamivudine; Logistic Models; Male; Middle Aged; Organophosphonates; Randomized Controlled Trials as Topic; Retrospective Studies; Tenofovir; United States | 2014 |
The financial and service implications of splitting fixed-dose antiretroviral drugs - a case study.
Topics: Adult; Aged; Anti-HIV Agents; Cost-Benefit Analysis; Costs and Cost Analysis; Drug Combinations; Drug Substitution; Female; Health Care Costs; HIV Infections; Humans; Lamivudine; Male; Treatment Outcome; Viral Load; Zidovudine | 2015 |
Uptake of prevention of mother-to-child-transmission using Option B+ in northern rural Malawi: a retrospective cohort study.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Chemoprevention; Cohort Studies; Cyclopropanes; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Malawi; Nevirapine; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Prenatal Care; Retrospective Studies; Rural Population; Tenofovir; Young Adult | 2014 |
Presence of HIV drug resistance in antiretroviral therapy-naive and -experienced patients from Papua New Guinea.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dried Blood Spot Testing; Drug Resistance, Viral; Female; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Papua New Guinea; Reverse Transcriptase Inhibitors; Stavudine; Treatment Failure; Viral Load; Young Adult; Zidovudine | 2014 |
Clinical manifestations and treatment outcomes in HIV-1-infected children receiving antiretroviral therapy in Karachi, Pakistan.
Topics: Anti-HIV Agents; Body Height; Body Weight; CD4 Lymphocyte Count; Child, Preschool; Drug Resistance, Viral; Female; Genotype; HIV; HIV Infections; Humans; Infant; Lamivudine; Male; Nevirapine; Pakistan; Retrospective Studies; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load; Zidovudine | 2014 |
Pharmacokinetics of nevirapine, stavudine and lamivudine in Indian HIV-infected children receiving generic fixed dose combinations.
Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Cross-Sectional Studies; Drugs, Generic; Female; HIV Infections; Humans; Infant; Lamivudine; Male; Nevirapine; Stavudine | 2014 |
Sustained increase of serum creatine phosphokinase levels and progressive muscle abnormalities associated with raltegravir use during 32-week follow-up in an HIV-1 experienced patient on simplified HAART regimen, intolerant to protease inhibitors and abac
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Creatine Kinase; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Muscle Weakness; Myalgia; Pyrrolidinones; Raltegravir Potassium; Zidovudine | 2013 |
Efavirenz promotes β-secretase expression and increased Aβ1-40,42 via oxidative stress and reduced microglial phagocytosis: implications for HIV associated neurocognitive disorders (HAND).
Topics: Alkynes; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Benzoxazines; Cell Line; Cognition Disorders; Cyclopropanes; Female; HIV Infections; Humans; Lamivudine; Mice; Oxidative Stress; Phagocytosis; Reverse Transcriptase Inhibitors; Zidovudine | 2014 |
Initial therapy for HIV: can less be more?
Topics: Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Reverse Transcriptase Inhibitors; Ritonavir | 2014 |
ABCC2*1C and plasma tenofovir concentration are correlated to decreased glomerular filtration rate in patients receiving a tenofovir-containing antiretroviral regimen.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Creatinine; Cyclopropanes; Drug Therapy, Combination; Female; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Kidney; Lamivudine; Male; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Organophosphonates; Polymorphism, Single Nucleotide; Reverse Transcriptase Inhibitors; Tenofovir | 2014 |
Extensive pulmonary involvement with raltegravir-induced DRESS syndrome in a postpartum woman with HIV.
Topics: Adolescent; Anti-HIV Agents; Drug Combinations; Drug Hypersensitivity Syndrome; Female; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Lopinavir; Pleural Effusion; Postpartum Period; Pyrrolidinones; Radiography; Raltegravir Potassium; Respiratory Distress Syndrome; Ritonavir; Zidovudine | 2014 |
Abacavir/lamivudine plus darunavir/ritonavir in routine clinical practice: a multicentre experience in antiretroviral therapy-naive and -experienced patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Darunavir; Dideoxynucleosides; Drug Combinations; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies; Ritonavir; Spain; Sulfonamides; Treatment Outcome; Viral Load; Young Adult | 2014 |
Virological characteristics of occult hepatitis B virus in a North American cohort of human immunodeficiency virus type 1-positive patients on dual active anti-HBV/HIV therapy.
Topics: Adult; Anti-HIV Agents; Asymptomatic Diseases; Base Sequence; DNA, Viral; Female; Gene Products, pol; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Core Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; HIV Infections; HIV-1; Humans; Lamivudine; Leukocytes, Mononuclear; Male; Middle Aged; North America; Sequence Analysis, DNA; Viral Load | 2014 |
In vivo effect of two first-line ART regimens on inflammatory mediators in male HIV patients.
Topics: Adenine; Adult; Alkynes; Animals; Anti-HIV Agents; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Interleukin-10; Interleukin-6; Interleukin-8; Lamivudine; Male; Middle Aged; Organophosphonates; Platelet Activating Factor; Tenofovir; Tumor Necrosis Factor-alpha | 2014 |
Impact of Y181C and/or H221Y mutation patterns of HIV-1 reverse transcriptase on phenotypic resistance to available non-nucleoside and nucleoside inhibitors in China.
Topics: Alkynes; Benzoxazines; China; Cyclopropanes; Drug Resistance, Multiple, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Nevirapine; Phenotype; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 2014 |
Pharmacokinetics of atazanavir/ritonavir among HIV-infected Thai children concomitantly taking tenofovir disoproxil fumarate.
Topics: Adenine; Adolescent; Anti-HIV Agents; Asian People; Atazanavir Sulfate; Child; Female; HIV Infections; Humans; Lamivudine; Male; Oligopeptides; Organophosphonates; Pyridines; Ritonavir; Tenofovir | 2014 |
A new antiviral: chimeric 3TC-AZT phosphonate efficiently inhibits HIV-1 in human tissues ex vivo.
Topics: Anti-HIV Agents; Dideoxynucleotides; Drug Evaluation, Preclinical; HIV Infections; HIV-1; Humans; In Vitro Techniques; Lamivudine; Palatine Tonsil; Thymine Nucleotides; Virus Replication; Zidovudine | 2014 |
HIV is detected in child thought to have been cured.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child, Preschool; Early Medical Intervention; Female; HIV Infections; Humans; Lamivudine; Nevirapine; Viral Load | 2014 |
Side effects and tolerability of post-exposure prophylaxis with zidovudine, lamivudine, and lopinavir/ritonavir: a comparative study with HIV/AIDS patients.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Post-Exposure Prophylaxis; Retrospective Studies; Ritonavir; Zidovudine | 2014 |
Pure red cell aplasia induced by lamivudine without the influence of zidovudine in a patient infected with human immunodeficiency virus.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Biopsy, Needle; Bone Marrow; Diagnosis, Differential; HIV Infections; Humans; Lamivudine; Male; Platelet Count; Red-Cell Aplasia, Pure; Young Adult; Zidovudine | 2014 |
Hepatitis B virus sub-genotype A1 infection is characterized by high replication levels and rapid emergence of drug resistance in HIV-positive adults receiving first-line antiretroviral therapy in Malawi.
Topics: Adult; Anti-HIV Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Malawi; Male; Nevirapine; Phylogeny; Retrospective Studies; Sequence Analysis, DNA; Stavudine; Viral Load; Virus Replication | 2014 |
Hepatitis B virus mother-to-child transmission among HIV-infected women receiving lamivudine-containing antiretroviral regimens during pregnancy and breastfeeding.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Breast Feeding; Child; Coinfection; Female; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Male; Pregnancy; Risk Factors; Young Adult | 2015 |
Optimizing HIV therapy. A consensus project on differences between cytidine analogues and regime compactness.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Consensus; Cytidine; Delphi Technique; Deoxycytidine; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Practice Patterns, Physicians' | 2014 |
Initiation of antiretroviral therapy in HIV-infected adults with skin complaints in northern Tanzania.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Female; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Prospective Studies; RNA, Viral; Severity of Illness Index; Skin Diseases; Stavudine; Tanzania; Young Adult | 2015 |
Overexpression of mitochondrial antioxidant manganese superoxide dismutase (MnSOD) provides protection against AZT- or 3TC-induced endothelial dysfunction.
Topics: Animals; Anti-HIV Agents; Antioxidants; Aorta, Thoracic; Female; HIV Infections; Humans; Lamivudine; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mitochondria; Superoxide Dismutase; Zidovudine | 2014 |
Lopinavir/ritonavir plus lamivudine and abacavir or zidovudine dose ratios for paediatric fixed-dose combinations.
Topics: Administration, Oral; Adolescent; Age Factors; Antiretroviral Therapy, Highly Active; Biological Availability; Child; Child, Preschool; Clinical Trials as Topic; Computer Simulation; Dideoxynucleosides; Drug Combinations; Drug Dosage Calculations; Drug Monitoring; Female; HIV Infections; HIV-1; Humans; Infant; Lamivudine; Lopinavir; Male; Models, Statistical; Ritonavir; Silybin; Silymarin; Viral Load; Zidovudine | 2015 |
A farewell to didanosine: harm reduction and cost savings by eliminating use of didanosine.
Topics: Cost Savings; Didanosine; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Harm Reduction; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Treatment Outcome | 2015 |
Efficacy of dual therapy with lamivudine plus darunavir boosted with ritonavir once daily in HIV-infected patients with nucleoside analogue toxicity.
Topics: Antiretroviral Therapy, Highly Active; Darunavir; Drug Administration Schedule; Drug Synergism; HIV Infections; Humans; Lamivudine; Ritonavir; Sulfonamides; Treatment Outcome | 2015 |
Persistent production of an integrase-deleted HIV-1 variant with no resistance mutation and wild-type proviral DNA in a treated patient.
Topics: Anti-HIV Agents; Base Sequence; Defective Viruses; DNA, Viral; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Immune Evasion; Integrases; Lamivudine; Leukocytes, Mononuclear; Lopinavir; Molecular Sequence Data; Proviruses; Sequence Analysis, DNA; Sequence Deletion; Viral Load; Zidovudine | 2015 |
Incidence and predictors of regimen-modification from first-line antiretroviral therapy in Thailand: a cohort study.
Topics: Adult; Aged; Anti-Retroviral Agents; Asia; CD4 Lymphocyte Count; Cohort Studies; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Incidence; Lamivudine; Lipodystrophy; Male; Middle Aged; Nevirapine; Stavudine; Thailand; Treatment Failure | 2014 |
Dolutegravir efficacy at 48 weeks in key subgroups of treatment-naive HIV-infected individuals in three randomized trials.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Clinical Trials, Phase III as Topic; Coinfection; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Organophosphonates; Oxazines; Piperazines; Pyridones; Pyrrolidinones; Raltegravir Potassium; Randomized Controlled Trials as Topic; Regression Analysis; Retrospective Studies; Ritonavir; Tenofovir; Treatment Outcome; Viral Load | 2015 |
HIV testing in pregnancy.
Topics: Adenine; Anti-HIV Agents; Benzoxazines; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Nevirapine; Organophosphonates; Pregnancy; Pregnancy Complications, Infectious; Rural Population | 2014 |
[Mathematical dynamical models for personalized medicine].
Topics: Anti-HIV Agents; Azacitidine; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Dideoxynucleosides; HIV Infections; HIV-1; HLA-B Antigens; Humans; Lamivudine; Models, Theoretical; Precision Medicine; Receptors, CCR5; Reverse Transcriptase Inhibitors; Virus Attachment | 2014 |
Barriers to simplified HIV treatment in low-resource settings.
Topics: Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Male; Reverse Transcriptase Inhibitors; Ritonavir | 2014 |
A sudden cardiac death induced by sildenafil and sexual activity in an HIV patient with drug interaction, cardiac early repolarization, and arrhythmogenic right ventricular cardiomyopathy.
Topics: Anti-Bacterial Agents; Clarithromycin; Death, Sudden, Cardiac; Dideoxynucleosides; Drug Combinations; Drug Interactions; Electrocardiography; Fatal Outcome; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Piperazines; Purines; Ritonavir; Sexual Behavior; Sildenafil Citrate; Sulfonamides; Vasodilator Agents | 2015 |
Abacavir and lamivudine exposures during pregnancy and non-defect adverse pregnancy outcomes: data from the antiretroviral pregnancy registry.
Topics: Abortion, Spontaneous; Adolescent; Adult; Anti-HIV Agents; Cohort Studies; Dideoxynucleosides; Female; HIV Infections; Humans; Lamivudine; Middle Aged; Pregnancy; Pregnancy Complications, Infectious; Premature Birth; Prospective Studies; Young Adult | 2015 |
Human immunodeficiency virus post-exposure prophylaxis: primum non nocere.
Topics: Adult; Antiviral Agents; Bipolar Disorder; Cytochrome P-450 CYP3A Inhibitors; Dihydroergotamine; Drug Synergism; Drug Therapy, Combination; Ergotism; Female; HIV Infections; Humans; Hypotension, Orthostatic; Lamivudine; Lopinavir; Post-Exposure Prophylaxis; Ritonavir; Vasoconstrictor Agents; Zidovudine | 2015 |
Therapeutic management and evolution of chronic hepatitis B: does HIV still have an impact? The EPIB 2012 study.
Topics: Adult; Antiviral Agents; Cohort Studies; Comorbidity; Disease Progression; Female; France; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; HIV Infections; HIV Seronegativity; HIV Seropositivity; Humans; Lamivudine; Liver Cirrhosis; Liver Neoplasms; Logistic Models; Male; Middle Aged; Multivariate Analysis; Reference Values; Retrospective Studies; Risk Assessment; Statistics, Nonparametric; Survival Analysis; Tenofovir; Treatment Outcome | 2015 |
High incidence of lamivudine-resistance-associated vaccine-escape HBV mutants among HIV-coinfected patients on prolonged antiretroviral therapy.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Coinfection; Cross-Sectional Studies; DNA, Viral; Drug Resistance, Viral; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; India; Lamivudine; Liver Cirrhosis; Reverse Transcriptase Inhibitors; Viral Load | 2015 |
Acute pancreatitis associated with dolutegravir and lamivudine/abacavir administration.
Topics: Adolescent; Anti-HIV Agents; Black or African American; Dideoxynucleosides; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Oxazines; Pancreatitis, Acute Necrotizing; Piperazines; Pyridones | 2015 |
[The efficacy and safety of a therapy regimen including raltegravir and a fixed dose combination of lamivudine and abacavir in previously rifabutin-treated patients with tuberculosis and HIV infection].
Topics: Adult; Anti-HIV Agents; Antibiotics, Antitubercular; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Pyrrolidinones; Raltegravir Potassium; Rifabutin; RNA, Viral; Time Factors; Treatment Outcome; Tuberculosis; Young Adult | 2014 |
Viral and inflammatory markers in cerebrospinal fluid of patients with HIV-1-associated neurocognitive impairment during antiretroviral treatment switch.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Biomarkers; Cognition Disorders; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Drug Substitution; Emtricitabine; Enzyme-Linked Immunosorbent Assay; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Pilot Projects; Prospective Studies; Tenofovir; Tumor Necrosis Factor-alpha; Viral Load | 2015 |
Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing.
Topics: Adenine; Adolescent; Alkynes; Anti-HIV Agents; Benzoxazines; Bone Density; Calcium; CD4 Lymphocyte Count; Child; Child, Preschool; Cyclopropanes; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Organophosphonates; Prospective Studies; RNA, Viral; Tenofovir; Treatment Outcome; Urinalysis; Viral Load | 2015 |
Is zidovudine first-line therapy virologically comparable to tenofovir in resource-limited settings?
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Female; Health Resources; HIV; HIV Infections; Humans; Lamivudine; Lesotho; Logistic Models; Male; Middle Aged; Organophosphonates; Tenofovir; Viral Load; Zidovudine | 2015 |
Hepatitis B e antigen and hepatitis B surface antigen seroclearance with the emergence of lamivudine-associated and core mutations following CD4 elevation in a patient with hepatitis B and HIV.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; DNA, Viral; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Mutation | 2015 |
Reductions in virological failure and drug resistance in Chinese antiretroviral-treated patients due to lamivudine-based regimens, 2003-12.
Topics: Adult; Anti-Retroviral Agents; China; Drug Resistance, Viral; Female; HIV; HIV Infections; Humans; Incidence; Lamivudine; Male; Medication Adherence; Treatment Failure | 2015 |
[Analysis on HIV suppression effect after initiating antiretroviral treatment and related factors among AIDS patients in Henan province during 2008 and 2013].
Topics: Acquired Immunodeficiency Syndrome; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; Health Facilities; HIV Infections; Humans; Lamivudine; Male; Nevirapine; Stavudine; Time-to-Treatment; Treatment Outcome; Zidovudine | 2015 |
Time trends of baseline demographics and clinical characteristics of HIV infected children enrolled in care and treatment service in Dar es Salaam, Tanzania.
Topics: Adolescent; Age Distribution; Alkynes; Ambulatory Care Facilities; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Preschool; Comorbidity; Cyclopropanes; Female; HIV Infections; Humans; Infant; Lamivudine; Linear Models; Male; Nevirapine; Severity of Illness Index; Tanzania; Tuberculosis; Zidovudine | 2015 |
Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Female; Follow-Up Studies; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Pilot Projects; Ritonavir; Treatment Outcome; Viral Load | 2015 |
Progress Toward Eliminating Mother to Child Transmission of HIV in Kenya: Review of Treatment Guideline Uptake and Pediatric Transmission at Four Government Hospitals Between 2010 and 2012.
Topics: Adult; Anti-HIV Agents; Child; Cohort Studies; Developing Countries; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Early Diagnosis; Female; Gestational Age; Government; Guideline Adherence; HIV Infections; Hospitals, Public; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Kenya; Lamivudine; Medication Adherence; Pregnancy; Pregnancy Complications, Infectious; Retrospective Studies; Zidovudine | 2016 |
Cost-effectiveness of DTG + ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; CD4 Lymphocyte Count; Computer Simulation; Cost-Benefit Analysis; Dideoxynucleosides; Drug Combinations; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; HIV-1; Humans; Kaplan-Meier Estimate; Lamivudine; Quality-Adjusted Life Years; United States | 2015 |
Simultaneous And Extended Delivery Of Stavudine, Lamivudine And Nevirapine In Fixed Dose Combination Using Sandwiched Osmotic Tablets For Hiv Therapy.
Topics: Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Carriers; Drug Delivery Systems; Drug Liberation; Drug Stability; HIV Infections; Humans; Lamivudine; Nevirapine; Osmosis; Polyethylene Glycols; Stavudine; Tablets | 2015 |
Raltegravir and Abacavir/Lamivudine in Japanese Treatment-Naïve and Treatment-Experienced Patients with HIV Infection: a 48-Week Retrospective Pilot Analysis.
Topics: Adult; Anti-HIV Agents; Asian People; Dideoxynucleosides; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; Humans; Hyperlipidemias; Kidney Function Tests; Lamivudine; Lipids; Liver Function Tests; Male; Middle Aged; Nausea; Pilot Projects; Raltegravir Potassium; Retrospective Studies; Treatment Outcome; Viral Load; Young Adult | 2016 |
[Comparative and evolutionary profile of people infected with HIV on antiretroviral therapy in Kinshasa, Democratic Republic of Congo].
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Democratic Republic of the Congo; Disease Progression; Drug Combinations; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Ritonavir; Zidovudine | 2014 |
Liver Fibrosis by Transient Elastography and Virologic Outcomes After Introduction of Tenofovir in Lamivudine-Experienced Adults With HIV and Hepatitis B Virus Coinfection in Ghana.
Topics: Adult; Africa South of the Sahara; Antiviral Agents; Coinfection; Cross-Sectional Studies; Elasticity Imaging Techniques; Female; Ghana; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Tenofovir; Treatment Outcome; Viral Load | 2015 |
Excellent clinical outcomes and retention in care for adults with HIV-associated Kaposi sarcoma treated with systemic chemotherapy and integrated antiretroviral therapy in rural Malawi.
Topics: Adult; Cohort Studies; Female; HIV Infections; Humans; Lamivudine; Malawi; Male; Nevirapine; Retrospective Studies; Rural Population; Sarcoma, Kaposi; Stavudine | 2015 |
Adverse events and adherence to HIV post-exposure prophylaxis: a cohort study at the Korle-Bu Teaching Hospital in Accra, Ghana.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Drug Combinations; Female; Ghana; HIV Infections; Hospitals, Teaching; Humans; Infectious Disease Transmission, Patient-to-Professional; Lamivudine; Male; Middle Aged; Occupational Exposure; Post-Exposure Prophylaxis; Young Adult; Zidovudine | 2015 |
Hepatitis B and HIV co-infection is still treated using lamivudine-only antiretroviral therapy combination in Uganda.
Topics: Adult; Alanine Transaminase; Anti-Retroviral Agents; CD4 Lymphocyte Count; Coinfection; Cross-Sectional Studies; Drug Therapy, Combination; Female; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome; Uganda; Viral Load | 2015 |
Estimated glomerular filtration rates through 144 weeks on therapy in HIV-1-infected subjects receiving atazanavir/ritonavir and abacavir/lamivudine or simplified to unboosted atazanavir/abacavir/lamivudine.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Dideoxynucleosides; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Lamivudine; Oligopeptides; Pyridines; Ritonavir | 2015 |
HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons.
Topics: Adult; Aged; Antiviral Agents; Coinfection; Drug Resistance, Viral; Female; Genotype; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies; Switzerland; Tenofovir; Viral Load; Young Adult | 2015 |
Pharmacokinetic Modeling of Lamivudine and Zidovudine Triphosphates Predicts Differential Pharmacokinetics in Seminal Mononuclear Cells and Peripheral Blood Mononuclear Cells.
Topics: Adult; Anti-HIV Agents; Biological Availability; Biological Transport; Blood Cells; Computer Simulation; Cytidine Triphosphate; Dideoxynucleotides; HIV Infections; HIV-1; Humans; Lamivudine; Leukocytes, Mononuclear; Male; Models, Statistical; Semen; Thymine Nucleotides; Time Factors; Zidovudine | 2015 |
Prevalence of drug resistance mutations in HAART patients infected with HIV-1 CRF06_cpx in Estonia.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Didanosine; Dideoxynucleosides; Drug Resistance, Viral; Estonia; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Prevalence; Reverse Transcriptase Inhibitors; Zidovudine | 2016 |
Longitudinal Analysis of Adherence to First-Line Antiretroviral Therapy: Evidence of Treatment Sustainability from an Indian HIV Cohort.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Administration Schedule; Female; HIV Infections; Humans; India; Lamivudine; Longitudinal Studies; Male; Medication Adherence; Middle Aged; Nevirapine; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 2016 |
Hepatitis B surface antigen quantification as a predictor of seroclearance during treatment in HIV-hepatitis B virus coinfected patients from Sub-Saharan Africa.
Topics: Africa; Antiviral Agents; Biomarkers; Cohort Studies; Coinfection; Drug Therapy, Combination; Emtricitabine; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; HIV Infections; Humans; Lamivudine; Predictive Value of Tests; Prospective Studies; Randomized Controlled Trials as Topic; Sensitivity and Specificity; Tenofovir; Time Factors | 2016 |
Epidemiology of HBV infection in a cohort of Ugandan HIV-infected patients and rate and pattern of lamivudine-resistant HBV infection in patients receiving antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Coinfection; Cross-Sectional Studies; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Molecular Sequence Data; Mutation; Uganda | 2015 |
Implementation of isoniazid preventive therapy in an HIV clinic in Cambodia: high rates of discontinuation when combined with antiretroviral therapy.
Topics: Adult; Ambulatory Care Facilities; Anti-HIV Agents; Antitubercular Agents; Cambodia; Drug Interactions; Female; HIV; HIV Infections; Humans; Isoniazid; Lamivudine; Male; Nevirapine; Opportunistic Infections; Patient Dropouts; Retrospective Studies; Stavudine; Tuberculosis | 2015 |
Efficacy and HIV drug resistance profile of second-line ART among patients having received long-term first-line regimens in rural China.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; China; Drug Resistance, Viral; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Mutation; Prospective Studies; Ritonavir; RNA, Viral; Rural Population; Tenofovir; Treatment Outcome; Viral Load | 2015 |
Backbone switch to abacavir/lamivudine fixed-dose combination: implications for antiretroviral therapy optimization.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cytokines; Dideoxynucleosides; Drug Combinations; Drug Substitution; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Prospective Studies; Treatment Outcome; Viral Load | 2015 |
Which Clinician Questions Elicit Accurate Disclosure of Antiretroviral Non-adherence When Talking to Patients?
Topics: Adult; Anti-HIV Agents; Attitude of Health Personnel; Communication; Disclosure; Drug Combinations; Female; HIV Infections; Humans; Interviews as Topic; Lamivudine; Male; Medication Adherence; Middle Aged; Office Visits; Patient Care; Physician-Patient Relations; Zidovudine | 2016 |
COMPARISON OF THAI GOVERNMENT MANUFACTURED TENOFOVIR (TENOFOVIR GPO300) WITH PRIVATELY MANUFACTURED TENOFOVIR (VIREAD) USED ALONG WITH LAMIVUDINE AND EFAVIRENZ TO TREAT THAI HIV PATIENTS.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Government; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Prospective Studies; Reverse Transcriptase Inhibitors; Tenofovir | 2015 |
Changes in Serum Markers of Inflammation and Endothelial Activation in HIV-Infected Antiretroviral Naive Patients Starting A Treatment with Abacavir-Lamivudine or Tenofovir-Emtricitabine Plus Efavirenz.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Biomarkers; Cyclopropanes; Dideoxynucleosides; Drug Combinations; E-Selectin; Emtricitabine; Female; HIV Infections; Humans; Inflammation; Intercellular Adhesion Molecule-1; Interleukin-6; Lamivudine; Male; Middle Aged; P-Selectin; Tenofovir; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1 | 2016 |
Effect of abacavir on sustained virologic response to HCV treatment in HIV/HCV co-infected patients, Cohere in Eurocoord.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Coinfection; Dideoxynucleosides; Drug Combinations; Emtricitabine; Europe; Female; Hepacivirus; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Lamivudine; Male; Middle Aged; Polyethylene Glycols; Recombinant Proteins; Reverse Transcriptase Inhibitors; Ribavirin; Tenofovir; Zidovudine | 2015 |
Adherence to Post-Exposure Prophylaxis (PEP) and Incidence of HIV Seroconversion in a Major North American Cohort.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV Seropositivity; Humans; Incidence; Lamivudine; Lopinavir; Male; Medication Adherence; Middle Aged; Post-Exposure Prophylaxis; Quebec; Ritonavir; Tenofovir; Young Adult; Zidovudine | 2015 |
Nanogel-Conjugated Reverse Transcriptase Inhibitors and Their Combinations as Novel Antiviral Agents with Increased Efficacy against HIV-1 Infection.
Topics: Animals; Anti-HIV Agents; Dideoxynucleosides; Drug Therapy, Combination; Hep G2 Cells; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mice; Nanogels; Polyethylene Glycols; Polyethyleneimine; Polylysine; Reverse Transcriptase Inhibitors; Zidovudine | 2015 |
Outcome of patients on second line antiretroviral therapy under programmatic condition in India.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; India; Lamivudine; Male; Mutation; National Health Programs; Reverse Transcriptase Inhibitors; Survival Rate; Treatment Outcome; Viral Load | 2015 |
Plasma Mitochondrial DNA Levels as a Biomarker of Lipodystrophy Among HIV-infected Patients Treated with Highly Active Antiretroviral Therapy (HAART).
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Biomarkers; Case-Control Studies; Cyclopropanes; DNA, Mitochondrial; Drug Combinations; Female; HIV; HIV Infections; Humans; Lamivudine; Lipodystrophy; Lopinavir; Male; Middle Aged; Mitochondria; Nelfinavir; Predictive Value of Tests; Ritonavir; ROC Curve; Stavudine; Zidovudine | 2015 |
The Cost-effectiveness and Budget Impact of 2-Drug Dolutegravir-Lamivudine Regimens for the Treatment of HIV Infection in the United States.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cost-Benefit Analysis; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Models, Statistical; Oxazines; Piperazines; Pyridones; United States | 2016 |
Concentrations of tenofovir, lamivudine and efavirenz in mothers and children enrolled under the Option B-Plus approach in Malawi.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Chromatography, Liquid; Cyclopropanes; Female; HIV Infections; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Malawi; Pregnancy; Pregnancy Complications, Infectious; Tandem Mass Spectrometry; Tenofovir; Viral Load; Young Adult | 2016 |
Low Prolactin and High 20-α-Hydroxysteroid Dehydrogenase Levels Contribute to Lower Progesterone Levels in HIV-Infected Pregnant Women Exposed to Protease Inhibitor-Based Combination Antiretroviral Therapy.
Topics: 20-alpha-Hydroxysteroid Dehydrogenase; Animals; Anti-HIV Agents; Cells, Cultured; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Mice; Mice, Inbred C57BL; Placenta; Pregnancy; Pregnancy Complications, Infectious; Progesterone; Prolactin; Ritonavir; Trophoblasts; Zidovudine | 2016 |
Lamivudine Monotherapy-Based cART Is Efficacious for HBV Treatment in HIV/HBV Coinfection When Baseline HBV DNA <20,000 IU/mL.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; China; Cohort Studies; Coinfection; DNA, Viral; Drug Therapy, Combination; Emtricitabine; Female; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Prospective Studies; Tenofovir | 2016 |
Hepatitis B immune reconstitution syndrome in a patient with HIV infection.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Coinfection; Hepatitis B; Hepatitis B virus; HIV Infections; HIV-1; Humans; Immune Reconstitution Inflammatory Syndrome; Lamivudine; Treatment Outcome | 2016 |
Top-down and bottom-up modeling in system pharmacology to understand clinical efficacy: An example with NRTIs of HIV-1.
Topics: Anti-HIV Agents; Dose-Response Relationship, Drug; Emtricitabine; HIV Infections; HIV-1; Humans; Lamivudine; Leukocytes, Mononuclear; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2016 |
A Single-Nucleotide Polymorphism in ABCC4 Is Associated with Tenofovir-Related Beta2-Microglobulinuria in Thai Patients with HIV-1 Infection.
Topics: Adult; Antiretroviral Therapy, Highly Active; Female; Gene Frequency; Gene-Environment Interaction; Genotype; HIV Infections; Humans; Kidney Diseases; Lamivudine; Male; Middle Aged; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Nevirapine; Polymorphism, Single Nucleotide; Stavudine; Tenofovir; Thailand | 2016 |
Efficacy and Safety of Tenofovir and Lamivudine in Combination with Efavirenz in Patients Co-infected with Human Immunodeficiency Virus and Hepatitis B Virus in China.
Topics: Adult; Alanine Transaminase; Alkynes; Anti-HIV Agents; Aspartate Aminotransferases; Benzoxazines; CD4-Positive T-Lymphocytes; Coinfection; Cyclopropanes; Female; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Tenofovir | 2016 |
Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study.
Topics: Africa South of the Sahara; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Emtricitabine; Global Health; HIV Infections; HIV-1; Humans; Lamivudine; Pre-Exposure Prophylaxis; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2016 |
Virological responses to lamivudine or emtricitabine when combined with tenofovir and a protease inhibitor in treatment-naïve HIV-1-infected patients in the Dutch AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Netherlands; Treatment Failure; Viral Load; Young Adult | 2016 |
Treatment response to unboosted atazanavir in combination with tenofovir disoproxil fumarate and lamivudine in human immunodeficiency virus-1-infected patients who have achieved virological suppression: A therapeutic drug monitoring and pharmacogenetic st
Topics: Adult; Aged; Atazanavir Sulfate; ATP Binding Cassette Transporter, Subfamily B; Drug Combinations; Drug Monitoring; Female; Glucuronosyltransferase; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hyperbilirubinemia; Lamivudine; Male; Middle Aged; Peroxisome-Targeting Signal 1 Receptor; Pharmacogenomic Testing; Polymorphism, Single Nucleotide; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure; Viral Load; Young Adult | 2017 |
Improved pregnancy outcomes with increasing antiretroviral coverage in South Africa.
Topics: Adolescent; Adult; Anti-Retroviral Agents; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Prenatal Care; South Africa; Stavudine; Young Adult; Zidovudine | 2016 |
Efficacy and safety of switching to abacavir/lamivudine (ABC/3TC) plus rilpivirine (RPV) in virologically suppressed HIV-infected patients on HAART.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Combinations; Drug Substitution; Female; HIV Infections; Humans; Lamivudine; Lipids; Male; Middle Aged; Rilpivirine; Treatment Outcome; Viral Load | 2016 |
Severe reaction to emtricitabine and lamiduvine: evidence of cross-reactivity.
Topics: Anti-HIV Agents; Cross Reactions; Drug Eruptions; Drug Hypersensitivity; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Middle Aged; Patch Tests; Stevens-Johnson Syndrome | 2016 |
Lamivudine Monotherapy: Experience of Medium-term Outcomes in HIV-infected Children Unable to Adhere to Triple Therapy.
Topics: Adolescent; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Disease Progression; Drug Administration Schedule; Female; HIV Infections; Humans; Infant; Infant, Newborn; Lamivudine; Male; Medication Adherence; Retrospective Studies; South Africa; Treatment Outcome; Young Adult | 2016 |
CYP2B6 genotype-based efavirenz dose recommendations during rifampicin-based antituberculosis cotreatment for a sub-Saharan Africa population.
Topics: Adult; Africa South of the Sahara; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Coinfection; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Male; Reverse Transcriptase Inhibitors; Rifampin; Tuberculosis; Viral Load; Zidovudine | 2016 |
Virological Response and Drug Resistance 1 and 2 Years Post-Partum in HIV-Infected Women Initiated on Life-Long Antiretroviral Therapy in Malawi.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Resistance, Viral; Female; Gestational Age; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Malawi; Mutation; Nevirapine; Postpartum Period; Pregnancy; RNA, Viral; Stavudine; Viral Load | 2016 |
Comparative risk of failure of ABC/3TC or TDF/FTC based first-line regimens in patients with a high viral load.
Topics: Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; France; HIV Infections; Humans; Lamivudine; Male; Propensity Score; Prospective Studies; Risk Assessment; Tenofovir; Treatment Failure; Viral Load | 2016 |
Lamivudine Concentration in Hair and Prediction of Virologic Failure and Drug Resistance among HIV Patients Receiving Free ART in China.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biomarkers; CD4 Lymphocyte Count; China; Chromatography, Liquid; Cross-Sectional Studies; Drug Monitoring; Drug Resistance, Viral; Female; Hair; HIV Infections; HIV-1; Humans; Lamivudine; Male; Medication Adherence; Middle Aged; Sensitivity and Specificity; Tandem Mass Spectrometry; Treatment Failure; Viral Load | 2016 |
Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Retrospective Studies; Viral Load | 2016 |
HBV genotypes and drug resistance mutations in antiretroviral treatment-naive and treatment-experienced HBV-HIV-coinfected patients.
Topics: Anti-HIV Agents; Antiviral Agents; Coinfection; Cross-Sectional Studies; DNA, Viral; Drug Resistance, Viral; Genotype; Ghana; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Mutation; Viral Load | 2017 |
Dually Active HIV/HBV Antiretrovirals as Protection Against Incident Hepatitis B Infections: Potential for Prophylaxis.
Topics: Adult; Antiviral Agents; Chemoprevention; Emtricitabine; Female; Follow-Up Studies; Hepatitis B; HIV Infections; Humans; Lamivudine; Male; Prospective Studies; Tenofovir | 2016 |
Assessment of non-standard HIV antiretroviral therapy regimens at Lighthouse Trust in Lilongwe, Malawi.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cross-Sectional Studies; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; Humans; Lamivudine; Malawi; Male; Nevirapine; Stavudine; Treatment Outcome; Trust; Young Adult | 2016 |
Single-tablet antiretroviral treatment (once daily).
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Combinations; Drug Hypersensitivity; Drug Interactions; Drug Resistance, Viral; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Emtricitabine, Rilpivirine, Tenofovir Drug Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Mental Disorders; Oxazines; Piperazines; Pyridones; Viral Load | 2016 |
Evidence of susceptibility to lamivudine-based HAART and genetic stability of hepatitis B virus (HBV) in HIV co-infected patients: A South African longitudinal HBV whole genome study.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Coinfection; DNA, Viral; Evolution, Molecular; Female; Genome, Viral; Genotype; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Lamivudine; Male; Microbial Sensitivity Tests; Middle Aged; Retrospective Studies; South Africa; Viral Load | 2016 |
Estimated Glomerular Filtration Rate Trajectories in HIV-Infected Subjects Treated With Different Ritonavir-Boosted Protease Inhibitors and Tenofovir Disoproxil Fumarate or Abacavir.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Comorbidity; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Viral Load | 2016 |
HIV therapy with unknown HBV status is responsible for higher rate of HBV genome variability in Ethiopia.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Coinfection; Cyclopropanes; DNA, Viral; Drug Resistance, Viral; Ethiopia; Female; Genetic Variation; Genome, Viral; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Immune Evasion; Lamivudine; Male; Mutation; Stavudine; Viral Load; Zidovudine | 2017 |
Treatment Outcomes and Resistance Patterns of Children and Adolescents on Second-Line Antiretroviral Therapy in Asia.
Topics: Adolescent; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Dideoxynucleosides; Drug Resistance, Multiple, Viral; Female; HIV Infections; HIV-1; Humans; Indonesia; Lamivudine; Male; Prospective Studies; Ritonavir; Thailand; Treatment Outcome; Vietnam; Viral Load; Zidovudine | 2016 |
Effect of co-administration of Hypoxis hemerocallidea extract and antiretroviral therapy (HAART) on the histomorphology and seminal parameters in Sprague Dawley rats.
Topics: Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Ascorbic Acid; Chemotherapy, Adjuvant; Herb-Drug Interactions; HIV Infections; Hypoxis; Lamivudine; Male; Nevirapine; Plant Extracts; Rats; Rats, Sprague-Dawley; Seminiferous Tubules; Sperm Count; Sperm Motility; Spermatozoa; Stavudine | 2017 |
Morphine Increases Lamivudine- and Nevirapine-Induced Human Immunodeficiency Virus-1 Drug-Resistant Mutations In Vitro.
Topics: Anti-HIV Agents; Cell Line; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Lamivudine; Morphine; Mutation; Nevirapine; Virus Replication | 2017 |
[Drug resistance and influencing factors in adult AIDS patients receiving antiretroviral treatment in Dehong, Yunnan province].
Topics: Adult; Anti-HIV Agents; China; Cohort Studies; Drug Resistance; HIV Infections; Humans; Incidence; Lamivudine; Male; Mutation; Patient Compliance; Reverse Transcriptase Inhibitors; Risk Factors; Viral Load | 2016 |
Levels of bone markers in a population of infants exposed in utero and during breastfeeding to tenofovir within an Option B+ programme in Malawi.
Topics: Adult; Alkaline Phosphatase; Alkynes; Anti-HIV Agents; Benzoxazines; Biomarkers; Bone Resorption; Breast Feeding; Collagen Type I; Cyclopropanes; Female; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Malawi; Male; Peptides; Pregnancy; Tenofovir; Young Adult | 2016 |
Impact of 48 weeks of atazanavir/ritonavir plus lamivudine dual therapy on cellular HIV-DNA levels in the AtLaS pilot study.
Topics: Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; DNA, Viral; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Leukocytes, Mononuclear; Pilot Projects; Polymerase Chain Reaction; Ritonavir | 2016 |
Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter observational study.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Darunavir; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Male; Medication Adherence; Middle Aged; Proportional Hazards Models; Raltegravir Potassium; Retrospective Studies; Risk; Tenofovir | 2016 |
A severe hypersensitivity reaction to abacavir following re-challenge.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Drug Hypersensitivity; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-1; HLA-B Antigens; Humans; Lamivudine; Oxazines; Piperazines; Pyridones | 2017 |
HIV-1-RNA Decay and Dolutegravir Concentrations in Semen of Patients Starting a First Antiretroviral Regimen.
Topics: Adult; Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Oxazines; Pilot Projects; Piperazines; Plasma; Prospective Studies; Pyridones; RNA Stability; RNA, Viral; Semen; Time Factors; Young Adult | 2016 |
Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Darunavir; Dideoxynucleosides; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Middle Aged; Prospective Studies; Ritonavir; Viral Load | 2017 |
Effects of a switch from tenofovir- to abacavir-based antiretroviral therapy, with or without atazanavir, on renal function.
Topics: Adenine; Adult; Anti-HIV Agents; Atazanavir Sulfate; Deoxycytidine; Dideoxynucleosides; Emtricitabine; Female; HIV Infections; Humans; Kidney; Lamivudine; Male; Middle Aged; Retrospective Studies; Ritonavir; Tenofovir; Viral Load | 2016 |
Long-term efficacy and toxicity of abacavir/lamivudine/nevirapine compared to the most prescribed ARV regimens before 2013 in a French Nationwide Cohort Study.
Topics: Adult; Dideoxynucleosides; Drug Therapy, Combination; Female; France; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Prospective Studies; Reverse Transcriptase Inhibitors; Treatment Outcome | 2016 |
Interchangeability between first-line generic antiretroviral products prequalified by WHO using adjusted indirect comparisons.
Topics: Alkynes; Anti-HIV Agents; Area Under Curve; Benzoxazines; Biological Availability; Cyclopropanes; Drug Combinations; Drugs, Generic; Emtricitabine; HIV Infections; Humans; Lamivudine; Models, Statistical; Tenofovir; Therapeutic Equivalency; World Health Organization | 2017 |
HIV positive patient with HSV-2 encephalitis: case report.
Topics: Acyclovir; Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Darunavir; Dideoxynucleosides; Drug Substitution; Encephalitis, Herpes Simplex; Herpesvirus 2, Human; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Rilpivirine; Ritonavir; Virus Replication | 2016 |
Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Depression; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Glomerular Filtration Rate; HIV Infections; HIV-1; Humans; Kidney; Lamivudine; Lipids; Liver; Male; Middle Aged; Retrospective Studies; Rilpivirine; RNA, Viral; Treatment Outcome | 2016 |
Integrase strand transfer inhibitor-associated diabetes mellitus: A case report.
Topics: Adult; Diabetes Mellitus; Dideoxynucleosides; Drug Combinations; Glycated Hemoglobin; HIV Infections; HIV Integrase Inhibitors; Humans; Lamivudine; Male; Raltegravir Potassium | 2017 |
Abacavir/lamivudine + unboosted atazanavir in routine clinical practice: Twelve years experience.
Topics: Adult; Atazanavir Sulfate; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies; Time Factors | 2018 |
Improved Adherence to Antiretroviral Therapy Observed Among HIV-Infected Children Whose Caregivers had Positive Beliefs in Medicine in Sub-Saharan Africa.
Topics: Africa South of the Sahara; Alkynes; Anti-HIV Agents; Attitude to Health; Benzoxazines; Caregivers; Child; Child, Preschool; Cyclopropanes; Dideoxynucleosides; Female; HIV Infections; Humans; Infant; Lamivudine; Linear Models; Logistic Models; Male; Medication Adherence; Multivariate Analysis; Nevirapine; Randomized Controlled Trials as Topic; Stavudine; Surveys and Questionnaires; Uganda; Zambia; Zidovudine | 2017 |
Virological failure reduced with HIV-serostatus disclosure, extra baseline weight and rising CD4 cells among HIV-positive adults in Northwestern Uganda.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Body Weight; CD4-Positive T-Lymphocytes; Cohort Studies; Cyclopropanes; Disclosure; Female; HIV Infections; HIV Seropositivity; Humans; Kaplan-Meier Estimate; Lamivudine; Male; Nevirapine; Retrospective Studies; Tenofovir; Treatment Outcome; Uganda | 2016 |
Optimization of the strength of the efavirenz/lamivudine/abacavir fixed-dose combination for paediatric patients.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Female; HIV Infections; Humans; Infant; Lamivudine; Male; Models, Theoretical; Young Adult | 2017 |
Antiretroviral treatment for HIV infection: Swedish recommendations 2016.
Topics: Adenine; Adult; Alanine; Anti-HIV Agents; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Combinations; Early Detection of Cancer; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lamivudine; Male; Oxazines; Piperazines; Pre-Exposure Prophylaxis; Pyridones; Sweden; Tenofovir | 2017 |
Survival Outcomes in a Pediatric Antiretroviral Treatment Cohort in Southern Malawi.
Topics: Adolescent; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Preschool; Cohort Studies; Cyclopropanes; Dideoxynucleotides; Female; HIV Infections; HIV Wasting Syndrome; Humans; Infant; Lamivudine; Malawi; Male; Proportional Hazards Models; Retrospective Studies; Rural Population; Stavudine; Survival Analysis; Tuberculosis, Pulmonary; Zidovudine | 2016 |
Are Prophylactic and Therapeutic Target Concentrations Different?: the Case of Lopinavir-Ritonavir or Lamivudine Administered to Infants for Prevention of Mother-to-Child HIV-1 Transmission during Breastfeeding.
Topics: Anti-HIV Agents; Bayes Theorem; Breast Feeding; HIV Infections; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Mothers; Ritonavir | 2017 |
A humanized mouse model for HIV-2 infection and efficacy testing of a single-pill triple-drug combination anti-retroviral therapy.
Topics: Animals; Anti-HIV Agents; CD4-Positive T-Lymphocytes; Dideoxynucleosides; Disease Models, Animal; Drug Therapy, Combination; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV-2; Humans; Lamivudine; Mice; Mice, Inbred BALB C; Oxazines; Piperazines; Pyridones | 2017 |
Occult HIV-1 drug resistance to thymidine analogues following failure of first-line tenofovir combined with a cytosine analogue and nevirapine or efavirenz in sub Saharan Africa: a retrospective multi-centre cohort study.
Topics: Adult; Africa South of the Sahara; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Nevirapine; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure; Viral Load | 2017 |
Triple Drug Combination of Zidovudine, Efavirenz and Lamivudine Loaded Lactoferrin Nanoparticles: an Effective Nano First-Line Regimen for HIV Therapy.
Topics: Alkynes; Animals; Anti-Retroviral Agents; Benzoxazines; Cell Line, Tumor; Cyclopropanes; Drug Combinations; Female; Half-Life; HIV Infections; HIV-1; Humans; Lactoferrin; Lamivudine; Male; Nanoparticles; Rats; Rats, Wistar; Tissue Distribution; Zidovudine | 2017 |
Early antiretroviral treatment (eART) limits viral diversity over time in a long-term HIV viral suppressed perinatally infected child.
Topics: Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Lamivudine; Lopinavir; Male; Nevirapine; Phylogeny; Ritonavir; Zidovudine | 2016 |
Antiretrovirals causing severe pre-eclampsia.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Delivery, Obstetric; Female; HIV Infections; Humans; Infant, Extremely Low Birth Weight; Infant, Newborn; Lamivudine; Nevirapine; Pre-Eclampsia; Pregnancy; Pregnancy Complications, Infectious; Tenofovir; Zidovudine | 2016 |
Response to Tenofovir Among Lamivudine-experienced Hepatitis B and HIV-coinfected Adolescents.
Topics: Adolescent; Adult; Antiviral Agents; Child; Coinfection; DNA, Viral; Hepatitis B; HIV Infections; Humans; Lamivudine; Longitudinal Studies; Prospective Studies; Tenofovir; Young Adult | 2017 |
Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect?
Topics: Anti-HIV Agents; Atazanavir Sulfate; Biological Availability; CD4 Lymphocyte Count; Darunavir; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Drug Dosage Calculations; Drug Interactions; Female; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Piperazines; Pyridones; Retrospective Studies; Rilpivirine; Viral Load | 2017 |
Safety of zidovudine/lamivudine scored tablets in children with HIV infection in Europe and Thailand.
Topics: Anti-HIV Agents; Child; Europe; HIV Infections; Humans; Lamivudine; Tablets; Thailand; Zidovudine | 2017 |
Virological Response to Tenofovir Disoproxil Fumarate in HIV-Positive Patients with Lamivudine-Resistant Hepatitis B Virus Coinfection in an Area Hyperendemic for Hepatitis B Virus Infection.
Topics: Adult; Coinfection; Drug Combinations; Drug Resistance, Viral; Endemic Diseases; Female; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Tenofovir; Treatment Outcome | 2016 |
Real-world persistence with antiretroviral therapy for HIV in the United Kingdom: A multicentre retrospective cohort study.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Medication Adherence; Middle Aged; Retrospective Studies; Rilpivirine; Tenofovir; United Kingdom; Viral Load | 2017 |
Confirmation of factors that influence antiretroviral regimen change and the subsequent patient outcomes at a Regional Hospital in rural KwaZulu-Natal.
Topics: Adolescent; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; HIV Infections; Hospitals; Humans; Lamivudine; Lipodystrophy; Male; Middle Aged; Retrospective Studies; Rural Population; South Africa; Stavudine; Tenofovir; Treatment Outcome; Tuberculosis; Viral Load; Young Adult | 2016 |
Rapid accumulation of HIV-1 thymidine analogue mutations and phenotypic impact following prolonged viral failure on zidovudine-based first-line ART in sub-Saharan Africa.
Topics: Adult; Africa South of the Sahara; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Nevirapine; Polymerase Chain Reaction; Retrospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Thymidine; Treatment Failure; Viral Load; Zidovudine | 2017 |
Triple-drug antiretroviral therapy results in lower HIV maternal-fetal transmission rates but increased adverse effects compared with zidovudine alone.
Topics: Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Pregnancy Complications, Infectious; Zidovudine | 2017 |
Characterization of occult hepatitis B virus infection among HIV positive patients in Cameroon.
Topics: Adolescent; Adult; Base Sequence; Cameroon; Child, Preschool; Coinfection; Cross-Sectional Studies; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Core Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; HIV; HIV Infections; HIV Seropositivity; Humans; Lamivudine; Male; Middle Aged; Mutation; Phylogeny; Prevalence; Prospective Studies; Risk Factors; Sequence Analysis; Young Adult | 2017 |
Pre-exposure prophylaxis for infants exposed to HIV through breast feeding.
Topics: Anti-HIV Agents; Breast Feeding; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Pre-Exposure Prophylaxis | 2017 |
[Biliary and kidney lithiasis during treatment with daclatasvir/sofosbuvir/ribavirin and atazanavir/ritonavir + abacavir/lamivudine in an HIV/HCV genotype 4-infected patient: a case report.]
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Atazanavir Sulfate; Biliary Tract Diseases; Carbamates; Coinfection; Dideoxynucleosides; Drug Combinations; Drug Interactions; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Imidazoles; Kidney Calculi; Lamivudine; Lithiasis; Male; Pyrrolidines; Ribavirin; Ritonavir; Sofosbuvir; Valine | 2017 |
Stability of antiretroviral regimens in patients with viral suppression.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; London; Male; Prospective Studies; Protease Inhibitors; Reverse Transcriptase Inhibitors; RNA, Viral | 2008 |
[Evaluation of antiretroviral therapy in HIV-infected adults in the Department of Haematology, University Hospital of Brazzavllle, Congo].
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Congo; Cyclopropanes; Didanosine; Drug Evaluation; Drug Therapy, Combination; Female; Hematology; HIV Infections; Hospital Departments; Hospitals, University; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Retrospective Studies; Stavudine; Treatment Outcome; Viral Load; Zidovudine | 2008 |
FDA notifications. FDA approval for generic lamivudine/zidovudine.
Topics: Drug Approval; Drugs, Generic; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; United States; United States Food and Drug Administration; Zidovudine | 2008 |
Modelled in vivo HIV fitness under drug selective pressure and estimated genetic barrier towards resistance are predictive for virological response.
Topics: Adult; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Models, Biological; Mutation; Nelfinavir; Predictive Value of Tests; Retrospective Studies; Reverse Transcriptase Inhibitors; Time Factors; Treatment Failure; Viral Load; Zidovudine | 2008 |
Fanconi syndrome and lactic acidosis associated with stavudine and lamivudine therapy.
Topics: Acidosis, Lactic; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Fanconi Syndrome; Female; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Stavudine | 2008 |
Interaction of hepatitis B and C viruses in patients infected with HIV.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; DNA, Viral; Female; Hepacivirus; Hepatitis B; Hepatitis B virus; Hepatitis C; HIV Infections; Humans; Lamivudine; Male; RNA, Viral | 2008 |
Lamivudine-induced red cell aplasia.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; Hematocrit; HIV Infections; Humans; Lamivudine; Leukocyte Count; Platelet Count; Red-Cell Aplasia, Pure; Treatment Outcome | 2008 |
Noncirrhotic portal hypertension in patients with human immunodeficiency virus-1 infection.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Female; HIV Infections; HIV-1; Humans; Hypertension, Portal; Lamivudine; Male; Middle Aged; Risk Factors; Thrombophilia; Viral Load; Zidovudine | 2008 |
Effect of haematological alterations on thalassaemia investigation in HIV-1-infected Thai patients receiving antiretroviral therapy.
Topics: Adult; Anti-Retroviral Agents; Biomarkers; Case-Control Studies; Erythrocyte Indices; Female; Hemoglobin A2; HIV Infections; HIV-1; Humans; Lamivudine; Male; Nevirapine; Osmotic Fragility; Stavudine; Thalassemia; Young Adult | 2008 |
Secure antiretroviral therapy delivery in a resource-limited setting: streamlined to minimize drug resistance and expense.
Topics: Adolescent; Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Developing Countries; Drug Costs; Drug Resistance, Viral; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Prospective Studies; Risk Factors; Stavudine; Thailand; Treatment Failure; Viral Load; Young Adult | 2008 |
Mechanistic basis of zidovudine hypersusceptibility and lamivudine resistance conferred by the deletion of codon 69 in the HIV-1 reverse transcriptase coding region.
Topics: Amino Acid Sequence; Anti-HIV Agents; Codon; Crystallography, X-Ray; Deoxycytosine Nucleotides; DNA, Viral; Drug Resistance, Multiple, Viral; Foscarnet; HIV Infections; HIV Reverse Transcriptase; Humans; Lamivudine; Models, Molecular; Molecular Sequence Data; Mutation; Nucleic Acid Conformation; Protein Conformation; Reverse Transcriptase Inhibitors; Sequence Alignment; Sequence Deletion; Zidovudine | 2008 |
FDA notifications. Tentative approval granted for lamivudine/stavudine.
Topics: Drug Approval; Drug Combinations; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Stavudine; United States; United States Food and Drug Administration | 2008 |
Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Côte d'Ivoire.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cote d'Ivoire; Drug Administration Schedule; Female; HIV Infections; HIV-1; Humans; Infant, Low Birth Weight; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Logistic Models; Nevirapine; Perinatal Mortality; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Zidovudine | 2008 |
A case of human bite by an 11-year old HIV positive girl in a paediatrics ward.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Bites, Human; Child; Cyclopropanes; Female; HIV Infections; Humans; Inpatients; Lamivudine; Male; Zidovudine | 2008 |
Incidence of abacavir hypersensitivity reactions in euroSIDA.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Dideoxynucleosides; Drug Administration Schedule; Drug Hypersensitivity; Drug Therapy, Combination; Europe; Female; HIV Infections; HIV-1; Humans; Incidence; Lamivudine; Male; Middle Aged; Poisson Distribution; Reverse Transcriptase Inhibitors; Treatment Outcome; Zidovudine | 2008 |
Effect of tenofovir subtraction on HIV plasma viraemia, CD4+ T-cell count and resistance in a patient with baseline K65R and M184V mutations.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Treatment Outcome; Viremia | 2008 |
Combination antiretroviral therapy with tenofovir, emtricitabine or lamivudine, and nevirapine.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Lamivudine; Nevirapine; Organophosphonates; Tenofovir | 2008 |
Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; Cohort Studies; Didanosine; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Lamivudine; Lopinavir; Male; Multivariate Analysis; Pyrimidinones; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; South Africa; Stavudine; Treatment Outcome; Zidovudine | 2008 |
Bullous skin eruption in an HIV patient during antiretroviral drugs therapy.
Topics: Adult; Anti-HIV Agents; Didanosine; Drug Eruptions; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Nelfinavir; Skin Diseases, Vesiculobullous | 2008 |
Effectiveness and safety of simplification from tenofovir-lamivudine (TDF-3TC) to tenofovir-emtricitabine (TDF-FTC) co-formulation (Truvada) in virologically suppressed HIV-infected patients on HAART.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Central Nervous System; Cohort Studies; Creatinine; Deoxycytidine; Drug Combinations; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; HIV Infections; HIV-1; Humans; Kidney; Lamivudine; Male; Metabolic Clearance Rate; Middle Aged; Organophosphonates; Organophosphorus Compounds; Retrospective Studies; Risk Factors; RNA, Viral; Tenofovir; Viral Load | 2009 |
Durability of stavudine, lamivudine and nevirapine among advanced HIV-1 infected patients with/without prior co-administration of rifampicin: a 144-week prospective study.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Prospective Studies; Rifampin; RNA, Viral; Stavudine; Thailand; Treatment Outcome; Tuberculosis; Viral Load | 2008 |
Alanine aminotransferase levels are not significantly elevated in patients with HIV/HBV co-infection and lamivudine resistance.
Topics: Adult; AIDS-Related Opportunistic Infections; Alanine Transaminase; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Clinical Audit; DNA, Viral; Drug Resistance, Viral; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Middle Aged | 2008 |
FDA notifications. Generic abacavir and lamivudine combo approved.
Topics: Dideoxynucleosides; Drug Approval; Drug Combinations; Drugs, Generic; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; United States; United States Food and Drug Administration | 2008 |
HIV postexposure prophylaxis after sexual assault: why is it so hard to accomplish?
Topics: Adolescent; Animals; Anti-HIV Agents; Drug Combinations; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Lopinavir; Macaca mulatta; Pyrimidinones; Sex Offenses; Zidovudine | 2008 |
Tolerability of fosamprenavir/ritonavir associated with zidovudine-lamivudine used as postexposure prophylaxis for HIV infection.
Topics: Adult; Anti-HIV Agents; Carbamates; Drug Therapy, Combination; Female; Furans; HIV Infections; Humans; Lamivudine; Male; Organophosphates; Prospective Studies; Ritonavir; Sulfonamides; Zidovudine | 2008 |
[A case of acquired encephalopathy in a child. A cause that we thought had disappeared].
Topics: AIDS Dementia Complex; Anti-HIV Agents; Anti-Infective Agents; Drug Therapy, Combination; Female; Fluconazole; HIV Infections; HIV Protease Inhibitors; HIV Seropositivity; HIV-1; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Polymerase Chain Reaction; Pyrimidinones; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Trimethoprim, Sulfamethoxazole Drug Combination; Zidovudine | 2008 |
In vivo fitness cost of the M184V mutation in multidrug-resistant human immunodeficiency virus type 1 in the absence of lamivudine.
Topics: Anti-HIV Agents; Drug Resistance, Multiple, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation, Missense; Phylogeny; Sequence Analysis, DNA | 2009 |
Occult hepatitis B virus infection in immunocompromised patients.
Topics: Adult; Aged; Case-Control Studies; CD4 Lymphocyte Count; DNA, Viral; Female; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Surface Antigens; Hepatitis B virus; HIV Infections; Humans; Immunocompromised Host; Lamivudine; Male; Middle Aged; Prevalence; Renal Dialysis; Viral Load | 2008 |
Mutational analysis of the mitochondrial tRNA genes and flanking regions in umbilical cord tissue from uninfected infants receiving AZT-based therapies for prophylaxis of HIV-1.
Topics: Base Sequence; Case-Control Studies; DNA Primers; DNA, Mitochondrial; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Infant; Lamivudine; Mutation; Polymorphism, Genetic; Reverse Transcriptase Inhibitors; RNA, Transfer; Umbilical Cord; Zidovudine | 2009 |
Selection of drug-resistant HIV-1 during the early phase of viral decay is uncommon in treatment-naïve patients initiated on a three- or four-drug antiretroviral regimen including lamivudine.
Topics: Adult; Amino Acid Substitution; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Longitudinal Studies; Male; Middle Aged; Mutation, Missense; Plasma; Polymerase Chain Reaction; Selection, Genetic; Sequence Analysis, DNA; Viral Load | 2009 |
Sensitivity of phenotypic susceptibility analyses for nonthymidine nucleoside analogues conferred by K65R or M184V in mixtures with wild-type HIV-1.
Topics: Adenine; Anti-HIV Agents; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Genetic Predisposition to Disease; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Organophosphonates; Phenotype; Plasmids; Tenofovir; Viral Load | 2009 |
The profile of mutational clusters associated with lamivudine resistance can be constrained by HBV genotypes.
Topics: Adult; Alanine Transaminase; Amino Acid Substitution; Antiviral Agents; Aspartate Aminotransferases; Cluster Analysis; DNA Primers; DNA, Viral; Drug Resistance, Viral; Genotype; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Middle Aged; Polymerase Chain Reaction; RNA-Directed DNA Polymerase | 2009 |
Generic lamivudine and abacavir approved.
Topics: Anti-HIV Agents; Child; Dideoxynucleosides; Drug Approval; Drugs, Generic; HIV Infections; HIV-1; Humans; Lamivudine; Reverse Transcriptase Inhibitors; United States; United States Food and Drug Administration | 2008 |
Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients.
Topics: Adenine; Alkynes; Alleles; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Medication Adherence; Mutation, Missense; Nevirapine; Organophosphonates; Plasma; Polymerase Chain Reaction; Selection, Genetic; Tenofovir; Treatment Failure | 2009 |
Molecular analysis of an HBsAg-negative hepatitis B virus mutant selected in a tenofovir-treated HIV-hepatitis B virus co-infected patient.
Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Gene Products, pol; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Mutation; Organophosphonates; Tenofovir; Virus Replication | 2009 |
FDA notifications. FDA approves generic lamivudine.
Topics: Drug Approval; Drugs, Generic; HIV Infections; Lamivudine; Reverse Transcriptase Inhibitors; United States; United States Food and Drug Administration | 2008 |
Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Blood; Breast Feeding; Clinical Trials, Phase II as Topic; Desiccation; Female; HIV Infections; Humans; Infant; Infectious Disease Transmission, Vertical; Lactation; Lamivudine; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors; Young Adult; Zidovudine | 2009 |
A prospective study evaluating clinical outcomes and costs of three NNRTI-based HAART regimens in Kerala, India.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; HIV Infections; HIV-1; Hospitals, Teaching; Humans; India; Lamivudine; Male; Medication Adherence; Nevirapine; Prospective Studies; Stavudine; Treatment Outcome; Zidovudine | 2009 |
Comment on: High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Lamivudine; Nevirapine; Organophosphonates; Tenofovir; Treatment Failure; Viral Load | 2009 |
[Analysis of pre-treatment screening on 160 HIV/AIDS patients receiving highly active antiretroviral therapy ( AZT +3TC + EFV) treatment].
Topics: Adult; Antiretroviral Therapy, Highly Active; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Treatment Outcome; Zidovudine | 2008 |
Prolonged use of tenofovir in HIV/hepatitis B virus (HBV)-coinfected individuals does not lead to HBV polymerase mutations and is associated with persistence of lamivudine HBV polymerase mutations.
Topics: Adenine; Adult; Aged; Antiretroviral Therapy, Highly Active; Antiviral Agents; Cross-Sectional Studies; Drug Resistance, Viral; Female; Gene Products, pol; Genotype; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Polymerase Chain Reaction; Retrospective Studies; Tenofovir; Viral Load; Viremia | 2009 |
[Clinical safety of a generic fixed-dose combination of stavudine/lamivudine/névirapine (Triomune). Study of 297 cases in Togo].
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Child; Child, Preschool; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Stavudine; Togo | 2008 |
Difference in drug resistance patterns between minor HIV-1 populations in cerebrospinal fluid and plasma.
Topics: Adult; Cerebrospinal Fluid; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Longitudinal Studies; Male; Middle Aged; Polymerase Chain Reaction; RNA, Viral; Treatment Failure; Viral Load | 2009 |
Long-term outcome of tenofovir disoproxil fumarate use against hepatitis B in an HIV-coinfected cohort.
Topics: Adenine; Adult; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; Hepatitis B; Hepatitis B Antigens; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Time Factors; Treatment Outcome; Virus Replication | 2009 |
FDA notifications. Tentative approval for fixed-dose combo abacavir/lamivudine.
Topics: Dideoxynucleosides; Drug Approval; Drug Combinations; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; United States; United States Food and Drug Administration | 2009 |
Top stories of 2008. Beyond abacavir/3TC: good news on first-line regimens.
Topics: Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors | 2009 |
Switching Combivir to Truvada keeps HIV undetectable, improves blood fats, fails to improve limb fat.
Topics: Deoxycytidine; Drug Combinations; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; Humans; Lamivudine; Lipids; Lipodystrophy; Organophosphorus Compounds; Viral Load; Zidovudine | 2008 |
Cryptococcal meningoradiculitis: an atypical presentation after initiation of antiretroviral therapy.
Topics: Adult; Amphotericin B; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Retroviral Agents; Ceftriaxone; Ciprofloxacin; Female; HIV Infections; Humans; Lamivudine; Meningitis, Cryptococcal; Nevirapine; Radiculopathy; Stavudine | 2007 |
[Atazanavir-induced nephrolithiasis].
Topics: Adenine; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatitis D, Chronic; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Lopinavir; Male; Nephrolithiasis; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Tenofovir | 2009 |
Report from the 2008 joint ICAAC/IDSA meeting. More data on abacavir/3TC.
Topics: Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors | 2008 |
Highly active antiretroviral therapy-associated ptosis in patients with human immunodeficiency virus.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Blepharoptosis; Carbamates; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Middle Aged; Oculomotor Muscles; Organophosphates; Organophosphonates; Sulfonamides; Tenofovir | 2009 |
Emergence of primary NNRTI resistance mutations without antiretroviral selective pressure in a HAART-treated child.
Topics: Adult; Antiretroviral Therapy, Highly Active; Didanosine; Drug Resistance, Multiple, Viral; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Mutation, Missense; Nelfinavir; Phylogeny; Point Mutation; Pregnancy; Pregnancy Complications, Infectious; Selection, Genetic; Zidovudine | 2009 |
Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients.
Topics: Adenine; Antiviral Agents; Base Sequence; DNA Primers; DNA, Viral; Drug Resistance, Viral; Genetic Variation; Genotype; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Mutation; Organophosphonates; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase | 2009 |
Generic combination approved.
Topics: Anti-HIV Agents; Drug Approval; Drug Combinations; Drugs, Generic; HIV Infections; Humans; Lamivudine; Nevirapine; Reverse Transcriptase Inhibitors; Stavudine; United States; United States Food and Drug Administration | 2009 |
Mitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimen.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Adenine; Adipose Tissue; Adult; Anti-HIV Agents; Body Fat Distribution; CD4 Lymphocyte Count; Deoxyguanosine; F2-Isoprostanes; Glutathione; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Lopinavir; Male; Mitochondria; Organophosphonates; Pyrimidinones; Ritonavir; Stavudine; Tenofovir; Treatment Outcome; Viral Load | 2009 |
Demographic, socio-economic, behavioral and clinical factors predicting virologic failure with generic fixed-dose combination antiretroviral therapy before universal health insurance coverage in northern Thailand.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Demography; Drug Therapy, Combination; Drugs, Generic; Female; Forecasting; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Multivariate Analysis; Nevirapine; Odds Ratio; Patient Compliance; Prospective Studies; Stavudine; Thailand; Treatment Failure; Viral Load | 2009 |
Resistance to antiretrovirals in HIV-infected pregnant women.
Topics: Adult; Anti-HIV Agents; Data Interpretation, Statistical; Drug Resistance, Viral; Female; HIV; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Mutation; Pregnancy; Pregnancy Complications, Infectious; Retrospective Studies; Viral Load; Zidovudine | 2009 |
First-line antiretroviral therapy in resource-limited settings: time to reconsider?
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine | 2009 |
FDA approves three generics.
Topics: Adenine; Anti-HIV Agents; Drug Approval; Drugs, Generic; HIV Infections; Humans; Lamivudine; Lopinavir; Organophosphonates; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; United States; United States Food and Drug Administration | 2009 |
Arthritis as the presenting feature of HIV infection in a child.
Topics: Ankle Joint; Anti-HIV Agents; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Infectious; Child, Preschool; HIV Infections; Humans; Ibuprofen; Knee Joint; Lamivudine; Male; Nevirapine; Pain; Stavudine | 2009 |
Does HIV-1 subtype D have a higher risk of vertical transmission than other HIV subtypes?
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Pregnancy; Pregnancy Complications, Infectious; Pyrimidinones; Risk Factors; Survival Rate; Viral Load; Young Adult | 2009 |
The obstetric face and challenge of HIV/AIDS.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Anti-Infective Agents; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Breast Feeding; Developing Countries; Disease Progression; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Maternal Mortality; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; Trimethoprim, Sulfamethoxazole Drug Combination; World Health Organization; Zidovudine | 2009 |
Lamivudine/zidovudine: paediatric indication. For certain HIV-infected children.
Topics: Child; Drug Approval; Drug Therapy, Combination; Europe; HIV Infections; Humans; Lamivudine; Zidovudine | 2008 |
Virological response to highly active antiretroviral therapy in patients infected with human immunodeficiency virus type 2 (HIV-2) and in patients dually infected with HIV-1 and HIV-2 in the Gambia and emergence of drug-resistant variants.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Female; Gambia; HIV Infections; HIV Protease; HIV Reverse Transcriptase; HIV-1; HIV-2; Humans; Lamivudine; Longitudinal Studies; Lopinavir; Male; Middle Aged; Molecular Sequence Data; Mutation, Missense; Pyrimidinones; Ritonavir; Sequence Analysis, DNA; Treatment Outcome; Viral Load; Zidovudine | 2009 |
Mutations in the thumb-connection and RNase H domain of HIV type-1 reverse transcriptase of antiretroviral treatment-experienced patients.
Topics: Adenine; Alkynes; Amino Acid Substitution; Benzoxazines; Cyclopropanes; Drug Resistance, Multiple, Viral; Genetic Variation; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Organophosphonates; Protein Structure, Tertiary; Reverse Transcriptase Inhibitors; Ribonuclease H, Human Immunodeficiency Virus; Stavudine; Tenofovir | 2009 |
Evolution of drug resistance after virological failure of a first-line highly active antiretroviral therapy regimen in Uganda.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Lamivudine; Mutation; Thymidine; Treatment Failure; Uganda | 2009 |
Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only?
Topics: Adenine; Amino Acid Substitution; Anti-HIV Agents; CD4 Lymphocyte Count; Dideoxynucleosides; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation, Missense; Organophosphonates; Retrospective Studies; Salvage Therapy; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2009 |
HIV patients presenting common adverse drug events caused by highly active antiretroviral therapy in Tanzania.
Topics: Antiretroviral Therapy, Highly Active; Cross-Sectional Studies; Drug Eruptions; HIV Infections; Humans; Incidence; Lamivudine; Nevirapine; Retrospective Studies; Stavudine; Tanzania | 2009 |
Effect of HIV co-infection on mutation patterns of HBV in patients with lamivudine-resistant chronic hepatitis B.
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Gene Products, env; Gene Products, pol; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Mutation, Missense; Retrospective Studies; Sequence Analysis, DNA | 2009 |
Truvada and Epivir are similar at suppressing HIV.
Topics: CD4 Lymphocyte Count; Deoxycytidine; Drug Combinations; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV; HIV Infections; Humans; Lamivudine; Organophosphorus Compounds; Viral Load | 2009 |
Virological and immunological stability in HIV infected patients undergoing partial-treatment interruption.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Drug Combinations; Drug Resistance, Viral; Enfuvirtide; Female; HIV Envelope Protein gp41; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Middle Aged; Peptide Fragments; Treatment Outcome; Viral Load; Withholding Treatment; Zidovudine | 2009 |
Adherence to antiretroviral drug therapy in children with HIV/AIDS in Jamaica.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Anti-HIV Agents; Anti-Retroviral Agents; Biomarkers; CD4 Lymphocyte Count; Child; Child, Preschool; Cross-Sectional Studies; Female; HIV Infections; Humans; Infant; Jamaica; Lamivudine; Male; Medication Adherence; Nevirapine; Surveys and Questionnaires; Young Adult; Zidovudine | 2008 |
The absence of HIV mutations in cerebrospinal fluid and in peripheral blood mononuclear cells during a regimen containing Trizivir plus tenofovir.
Topics: Adenine; Anti-HIV Agents; Cohort Studies; Drug Combinations; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Leukocytes, Mononuclear; Mutation; Organophosphonates; Prospective Studies; Tenofovir; Viremia; Zidovudine | 2009 |
Dissection of regenerating T-Cell responses against tuberculosis in HIV-infected adults sensitized by Mycobacterium tuberculosis.
Topics: Adult; Alkynes; Analysis of Variance; Anti-HIV Agents; Anti-Retroviral Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Cytokines; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Follow-Up Studies; HIV Infections; Humans; Immunization; Lamivudine; Longitudinal Studies; Male; Middle Aged; Mycobacterium tuberculosis; Nevirapine; Stavudine; T-Lymphocytes; Tuberculosis | 2009 |
Therapeutic strategies for chronic hepatitis B virus infection in 2008-optimum dosing lamivudine challenged for HIV-1 infected patients.
Topics: Anti-HIV Agents; Antiviral Agents; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Lamivudine | 2009 |
FDA notifications. Tentative approval for lamivudine.
Topics: Adult; Drug Approval; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; United States; United States Food and Drug Administration | 2009 |
Reversible reduction of nevirapine plasma concentrations during rifampicin treatment in patients coinfected with HIV-1 and tuberculosis.
Topics: Adult; Anti-HIV Agents; Antibiotics, Antitubercular; CD4 Lymphocyte Count; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lamivudine; Longitudinal Studies; Male; Middle Aged; Nevirapine; Prospective Studies; Rifampin; Stavudine; Tuberculosis | 2009 |
Hepatitis B in HIV patients: what is the current treatment and what are the challenges?
Topics: Adenine; Antiviral Agents; Deoxycytidine; DNA, Viral; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B Surface Antigens; Hepatitis B, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Liver Cirrhosis; Nucleosides; Organophosphonates; Polyethylene Glycols; Pyrimidinones; Recombinant Proteins; Telbivudine; Tenofovir; Thymidine; Transaminases | 2009 |
Conserved T cell and natural killer cell function in treatment-experienced adults receiving tenofovir plus didanosine as nucleoside reverse transcription inhibitor backbone.
Topics: Adenine; Adult; CD4 Lymphocyte Count; Cell Proliferation; Didanosine; Drug Therapy, Combination; Flow Cytometry; Fluorescent Antibody Technique; Follow-Up Studies; HIV Infections; HIV-1; Humans; Immunologic Memory; Immunophenotyping; Interferon-gamma; Killer Cells, Natural; Lamivudine; Logistic Models; Male; Middle Aged; Organophosphonates; Reverse Transcriptase Inhibitors; Statistics, Nonparametric; T-Lymphocytes; Tenofovir | 2009 |
Once-daily treatment with saquinavir mesylate (2000 mg) and ritonavir (100 mg) together with a fixed-dose combination of abacavir/lamivudine (600/300 mg) or tenofovir/emtricitabine (245/200 mg) in HIV-1-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Area Under Curve; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Plasma; Ritonavir; RNA, Viral; Saquinavir; Tenofovir; Treatment Outcome; Viral Load | 2009 |
Mother-to-child HIV and HHV-8 transmission in neonates at Saint Camille Medical Centre in Burkina Faso.
Topics: Adult; Anti-HIV Agents; Burkina Faso; CD4 Lymphocyte Count; DNA, Viral; Female; Herpesviridae Infections; Herpesvirus 8, Human; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Nevirapine; Polymerase Chain Reaction; Pregnancy; Pregnancy Complications, Infectious; Young Adult; Zidovudine | 2009 |
Pharmacokinetics of nevirapine in HIV-infected children with and without malnutrition receiving divided adult fixed-dose combination tablets.
Topics: Administration, Oral; Adolescent; Anti-HIV Agents; Child; Child, Preschool; Drug Combinations; Female; HIV Infections; Humans; Infant; Lamivudine; Malawi; Male; Malnutrition; Nevirapine; Plasma; Stavudine; Tablets | 2009 |
Reflections: neurology and the humanities: reflections for October.
Topics: Anti-HIV Agents; Anticonvulsants; Drug Combinations; Drug Interactions; Female; HIV Infections; Humanities; Humans; Lamivudine; Neurology; Nevirapine; Phenobarbital; Seizures; Stavudine | 2009 |
Voriconazole use and pharmacokinetics in combination with interferon-gamma for refractory cryptococcal meningitis in a patient receiving low-dose ritonavir.
Topics: Anti-HIV Agents; Antifungal Agents; Cerebrospinal Fluid; Dideoxynucleosides; Drug Monitoring; HIV Infections; Humans; Interferon-gamma; Lamivudine; Male; Meningitis, Cryptococcal; Pyrimidines; Ritonavir; Serum; Triazoles; Voriconazole; Young Adult | 2010 |
Prior therapy influences the efficacy of lamivudine monotherapy in patients with lamivudine-resistant HIV-1 infection.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation, Missense; Prospective Studies; Treatment Outcome | 2010 |
Serial knife stabbings with HIV exposure--implications for post-exposure prophylaxis.
Topics: Anti-HIV Agents; Crime Victims; Disease Transmission, Infectious; Drug Combinations; Hepatitis B; Hepatitis C; HIV Infections; Humans; Lamivudine; Lopinavir; Post-Exposure Prophylaxis; Pyrimidinones; Viral Load; Wounds, Stab; Zidovudine | 2010 |
The art of managing human immunodeficiency virus infection: a balancing act.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Emtricitabine; HIV Infections; Humans; Lamivudine; Organophosphonates; Tenofovir; Treatment Outcome | 2009 |
Antiretroviral strategies to prevent mother-to-child transmission of HIV: striking a balance between efficacy, feasibility, and resistance.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; Zidovudine | 2009 |
Description of liver disease in a cohort of HIV/HBV coinfected patients.
Topics: Adult; Alanine Transaminase; Analysis of Variance; Anti-HIV Agents; Aspartate Aminotransferases; Cohort Studies; DNA, Viral; Female; Hepatitis B; HIV; HIV Infections; Humans; Lamivudine; Male; Predictive Value of Tests; Proportional Hazards Models; Risk Factors; Statistics, Nonparametric | 2010 |
Postpartum antiretroviral drug resistance in HIV-1-infected women receiving pregnancy-limited antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Mutation; Nelfinavir; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; Zidovudine | 2010 |
FDA notifications. Tentative approval given for combination of abacavir, lamivudine & zidovudine tablets.
Topics: Dideoxynucleosides; Drug Approval; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Tablets; United States; United States Food and Drug Administration; Zidovudine | 2009 |
Satisfactory cross-cultural validity of the ACTG symptom distress module in HIV-1-infected antiretroviral-naive patients.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cultural Competency; Cyclohexanes; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Language; Male; Maraviroc; Middle Aged; Multicenter Studies as Topic; Psychometrics; Randomized Controlled Trials as Topic; Reproducibility of Results; Stress, Psychological; Surveys and Questionnaires; Triazoles; Zidovudine | 2009 |
Antiretroviral exposure and lymphocyte mtDNA content among uninfected infants of HIV-1-infected women.
Topics: Anti-HIV Agents; DNA, Mitochondrial; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Longitudinal Studies; Monocytes; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimester, Third; Prenatal Exposure Delayed Effects; Reference Values; Reverse Transcriptase Inhibitors; Zidovudine | 2009 |
FDA notifications. Lamivudine/zidovudine combination approved for pediatric use.
Topics: Child; Drug Approval; Drug Combinations; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; United States; United States Food and Drug Administration; Zidovudine | 2009 |
Pharmacokinetics of lamivudine & stavudine in generic fixed-dose combinations in HIV-1 infected adults in India.
Topics: Adult; Anti-HIV Agents; Drug Combinations; Female; HIV Infections; HIV-1; Humans; India; Lamivudine; Male; Middle Aged; Pregnancy; Stavudine | 2009 |
Co-infection of Toxoplasma gondii with HBV in HIV-infected and uninfected pregnant women in Burkina Faso.
Topics: Adult; Anti-HIV Agents; Burkina Faso; Female; Hepatitis B; Hepatitis B Antigens; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Complications, Parasitic; Surveys and Questionnaires; Toxoplasma; Toxoplasmosis; Young Adult | 2009 |
Development of an allele-specific PCR for detection of the K65R resistance mutation in patients infected with subtype C human immunodeficiency virus type 1.
Topics: Alkynes; Alleles; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Nevirapine; Polymerase Chain Reaction; Zidovudine | 2010 |
Short communication: transmission of hepatitis B viruses with lamivudine resistance mutations in newly diagnosed HIV individuals.
Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; Female; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Mutation | 2009 |
Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Combinations; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Lamivudine; Microbial Sensitivity Tests; Middle Aged; Mutation, Missense; Organophosphonates; RNA, Viral; Tenofovir; Treatment Failure; Viremia; Young Adult; Zidovudine | 2010 |
[Protocol for the antiviral therapy of hepatitis B and D].
Topics: Adenine; Antiviral Agents; Biopsy; Guanine; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis D; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Interferons; Lamivudine; Liver Cirrhosis; Nucleotides; Organophosphonates; Polyethylene Glycols; Recombinant Proteins; Tenofovir | 2010 |
Evaluation of minority populations of HIV type-1 with K103N and M184V drug resistance mutations among children in Argentina.
Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Argentina; Child; Child, Preschool; Drug Administration Schedule; Drug Resistance, Viral; Female; Genes, pol; HIV Infections; HIV-1; Humans; Infant; Kaplan-Meier Estimate; Lamivudine; Male; Mutation; Nevirapine; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; Selection, Genetic; Sequence Analysis, DNA | 2009 |
FDA notifications. FDA grants approval of generic lamivudine tablets.
Topics: Drug Approval; Drugs, Generic; HIV Infections; Lamivudine; Reverse Transcriptase Inhibitors; United States; United States Food and Drug Administration | 2009 |
Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008.
Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Nevirapine; Oligopeptides; Organophosphonates; Proportional Hazards Models; Prospective Studies; Pyridines; Pyrimidinones; Risk Factors; Switzerland; Tenofovir; Zidovudine | 2010 |
Emerging mutations at virological failure of HAART combinations containing tenofovir and lamivudine or emtricitabine.
Topics: Adenine; Adult; Analysis of Variance; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Organophosphonates; Retrospective Studies; RNA, Viral; Tenofovir; Treatment Failure; Viral Load | 2010 |
FDA notifications. Combination lamivudine and tenofovir tablet approved.
Topics: Drug Approval; Drug Combinations; HIV Infections; Lamivudine; Reverse Transcriptase Inhibitors; Tablets; United States; United States Food and Drug Administration | 2010 |
Epidemiological and biological evidence for a compensatory effect of connection domain mutation N348I on M184V in HIV-1 reverse transcriptase.
Topics: Cell Line; DNA, Viral; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Reverse Transcriptase Inhibitors; Ribonuclease H, Human Immunodeficiency Virus; Selection, Genetic; Statistics, Nonparametric; Zidovudine | 2010 |
A controlled trial of initial antiviral regimens for HIV-1 infection.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Genotype; HIV Infections; HIV-1; Homosexuality, Male; Humans; Lamivudine; Male; Organophosphonates; Tenofovir; Treatment Failure | 2010 |
Efficacy of tenofovir-emtricitabine versus abacavir-lamivudine.
Topics: Adenine; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; HIV Infections; Humans; Lamivudine; Organophosphonates; Tenofovir; Treatment Outcome | 2010 |
Elvucitabine data released at CROI.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials, Phase II as Topic; Cyclopropanes; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Organophosphonates; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load; Zalcitabine | 2010 |
Analysis of RT sequences of subtype C HIV-type 1 isolates from indian patients at failure of a first-line treatment according to clinical and/or immunological WHO guidelines.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; India; Lamivudine; Molecular Sequence Data; Nevirapine; Polymorphism, Single Nucleotide; Stavudine; Treatment Failure; Zidovudine | 2010 |
Virologic and clinical outcomes of hepatitis B virus infection in HIV-HBV coinfected transplant recipients.
Topics: Adult; Aged; Antiviral Agents; Graft Survival; Hepatitis; Hepatitis B; Hepatitis B virus; HIV; HIV Infections; Humans; Immunoglobulins; Immunologic Deficiency Syndromes; Infections; Lamivudine; Liver Cirrhosis; Liver Failure; Liver Transplantation; Longitudinal Studies; Male; Middle Aged; Secondary Prevention; Treatment Outcome; Virus Diseases; Viruses | 2010 |
Hepatitis B virus drug resistance in HIV-1-infected patients taking lamivudine-containing antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Cross-Sectional Studies; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Prevalence; Risk Factors; Treatment Outcome | 2010 |
Drug-resistant mutation patterns in CRF01_AE cases that failed d4T+3TC+nevirapine fixed-dosed, combination treatment: Follow-up study from the Lampang cohort.
Topics: Adult; Amino Acid Substitution; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation, Missense; Nevirapine; Polymorphism, Genetic; Sequence Analysis, DNA; Stavudine; Thailand; Treatment Failure | 2010 |
Limited sampling models to predict the pharmacokinetics of nevirapine, stavudine, and lamivudine in HIV-infected children treated with pediatric fixed-dose combination tablets.
Topics: Anti-HIV Agents; Area Under Curve; Child; Confidence Intervals; Dosage Forms; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Linear Models; Nevirapine; Pediatrics; Predictive Value of Tests; Stavudine; Tablets | 2010 |
Resistance pathways of human immunodeficiency virus type 1 against the combination of zidovudine and lamivudine.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Evolution, Molecular; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation, Missense; Point Mutation; RNA, Viral; Selection, Genetic; Zidovudine | 2010 |
[Durability and tolerability of long-term nevirapine-based HAART].
Topics: Adult; Aged; Antiretroviral Therapy, Highly Active; Comorbidity; Dideoxynucleosides; Female; Hepatitis, Viral, Human; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lipids; Liver Function Tests; Male; Middle Aged; Nevirapine; Retrospective Studies; Stavudine; Viral Load; Young Adult; Zidovudine | 2010 |
The benefit of supplementary feeding for wasted Malawian adults initiating ART.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Anti-Retroviral Agents; Body Mass Index; CD4 Lymphocyte Count; Cohort Studies; Dietary Supplements; Drug Therapy, Combination; Female; HIV Infections; HIV Wasting Syndrome; Humans; Lamivudine; Linear Models; Malawi; Male; Middle Aged; Nevirapine; Retrospective Studies; Risk Factors; Soy Foods; Stavudine; Trimethoprim, Sulfamethoxazole Drug Combination; Young Adult; Zea mays | 2010 |
Breast enlargement in an HIV-infected man on combined antiretroviral therapy: what if it was carcinoma?
Topics: Alkynes; Benzoxazines; Breast Neoplasms, Male; Carcinoma, Intraductal, Noninfiltrating; Cyclopropanes; Didanosine; Drug Therapy, Combination; Gynecomastia; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors | 2010 |
Drug resistance in human immunodeficiency virus type-1 infected Zambian children using adult fixed dose combination stavudine, lamivudine, and nevirapine.
Topics: Amino Acid Substitution; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Cohort Studies; Drug Monitoring; Drug Resistance, Viral; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation, Missense; Nevirapine; Prospective Studies; Stavudine; Treatment Failure; Viral Load; Viral Proteins; Zambia | 2010 |
[Protease inhibitor or non-nucleoside reverse transcriptase inhibitor. ACTG study 5202 in focus].
Topics: Adenine; Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; Humans; Lamivudine; Multicenter Studies as Topic; Oligopeptides; Organophosphonates; Pyridines; Randomized Controlled Trials as Topic; Tenofovir | 2010 |
Steady-state nevirapine, lamivudine and stavudine levels in Malawian HIV-infected children on antiretroviral therapy using split Triomune 30 tablets.
Topics: Adolescent; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Cross-Sectional Studies; Dosage Forms; Drug Administration Schedule; Drug Combinations; Female; HIV Infections; HIV-1; Humans; Infant; Lamivudine; Malawi; Male; Nevirapine; Stavudine; Tablets; Treatment Outcome; Viral Load | 2010 |
Clonal resistance analyses of HIV type-1 after failure of therapy with didanosine, lamivudine and tenofovir.
Topics: Adenine; Anti-HIV Agents; Didanosine; Drug Resistance, Viral; Drug Therapy, Combination; Genome, Viral; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Organophosphonates; Phenotype; Recombination, Genetic; Reverse Transcriptase Inhibitors; Sequence Analysis, DNA; Tenofovir; Treatment Failure | 2010 |
Long-term outcomes of HIV-infected patients with <95% rates of adherence to nonnucleoside reverse-transcriptase inhibitors.
Topics: Adolescent; Adult; Female; HIV Infections; Humans; Lamivudine; Male; Medication Adherence; Middle Aged; Nevirapine; Prospective Studies; Reverse Transcriptase Inhibitors; Stavudine; Treatment Outcome; Viral Load; Young Adult | 2010 |
Virologic and immunologic outcomes in HIV-infected Cambodian children after 18 months of highly active antiretroviral therapy (HAART).
Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cambodia; CD4 Lymphocyte Count; Child; Child, Preschool; Cohort Studies; Directly Observed Therapy; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Human Growth Hormone; Humans; Infant; Lamivudine; Male; Nevirapine; Pilot Projects; Stavudine; Treatment Outcome | 2010 |
Extensive hypertrophic lichen planus in an HIV positive patient.
Topics: Adult; Anti-HIV Agents; Clobetasol; Drug Combinations; Hand Dermatoses; HIV Infections; Humans; Lamivudine; Lichen Planus; Male; Nevirapine; Pruritus; Stavudine; Treatment Outcome; Tuberculosis, Pulmonary | 2010 |
Comparison of two HIV postexposure prophylaxis regimens among men who have sex with men in Amsterdam: adverse effects do not influence compliance.
Topics: Adult; Aged; Anti-HIV Agents; Atazanavir Sulfate; Chemoprevention; Drug Therapy, Combination; HIV Infections; Homosexuality, Male; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Netherlands; Oligopeptides; Patient Compliance; Pyridines; Reverse Transcriptase Inhibitors; Sexual Behavior; Young Adult | 2010 |
High frequency of lamivudine resistance mutations in Brazilian patients co-infected with HIV and hepatitis B.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Brazil; Comorbidity; Cross-Sectional Studies; DNA-Directed DNA Polymerase; Drug Resistance, Viral; Female; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Mutation; Organophosphonates; Tenofovir; Viral Core Proteins; Viral Load; Viral Proteins | 2010 |
Addition of 7 days of zidovudine plus lamivudine to peripartum single-dose nevirapine effectively reduces nevirapine resistance postpartum in HIV-infected mothers in Malawi.
Topics: Adolescent; Adult; Anti-HIV Agents; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Longitudinal Studies; Malawi; Nevirapine; Plasma; Polymerase Chain Reaction; Postpartum Period; Pregnancy; RNA, Viral; Sequence Analysis, DNA; Young Adult; Zidovudine | 2010 |
Immunological response to highly active antiretroviral therapy following treatment for prevention of mother to child transmission of HIV-1: a study in Côte d'Ivoire.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cote d'Ivoire; Female; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Nevirapine; Treatment Outcome; Zidovudine | 2010 |
Discontinuation of standard first-line antiretroviral therapy in a cohort of 1434 Malawian children.
Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Cohort Studies; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; Humans; Infant; Lamivudine; Malawi; Male; Nevirapine; Stavudine; Young Adult | 2010 |
Mechanistic interplay among the M184I HIV-1 reverse transcriptase mutant, the central polypurine tract, cellular dNTP concentrations and drug sensitivity.
Topics: Amino Acid Substitution; Anti-HIV Agents; Cell Line; Deoxyribonucleotides; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Microbial Sensitivity Tests; Mutation, Missense; Protein Binding; Regulatory Sequences, Nucleic Acid; Virus Replication | 2010 |
Recent FDA approvals and changes.
Topics: Anti-HIV Agents; Child; Child, Preschool; Drug Approval; Drug Combinations; Drugs, Generic; HIV Antibodies; HIV Core Protein p24; HIV Infections; HIV-1; HIV-2; Humans; Lamivudine; Nevirapine; Reagent Kits, Diagnostic; Reverse Transcriptase Inhibitors; Tablets; United States; United States Food and Drug Administration; Zidovudine | 2010 |
Genotypic and phenotypic cross-drug resistance of harboring drug-resistant HIV type 1 subtype B' strains from former blood donors in central Chinese provinces.
Topics: Adult; Anti-HIV Agents; Blood Donors; China; Didanosine; Drug Resistance, Multiple, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation; Phenotype; pol Gene Products, Human Immunodeficiency Virus; RNA, Viral; Sequence Analysis, RNA; Stavudine; Zidovudine | 2010 |
Partially active HIV-1 Vif alleles facilitate viral escape from specific antiretrovirals.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antiretroviral Therapy, Highly Active; APOBEC-3G Deaminase; Blotting, Western; Cytidine Deaminase; Cytosine Deaminase; Drug Resistance, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation; vif Gene Products, Human Immunodeficiency Virus; Young Adult | 2010 |
Different evolution of genotypic resistance profiles to emtricitabine versus lamivudine in tenofovir-containing regimens.
Topics: Adaptation, Biological; Adenine; Adult; Amino Acid Substitution; Anti-HIV Agents; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation, Missense; Organophosphonates; pol Gene Products, Human Immunodeficiency Virus; RNA, Viral; Tenofovir | 2010 |
[Two cases of Fanconi's syndrome induced by tenofovir in the Ivory Coast].
Topics: Adenine; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cote d'Ivoire; Cyclopropanes; Drug Therapy, Combination; Enterobacter aerogenes; Enterobacteriaceae Infections; Fanconi Syndrome; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Malaria; Male; Middle Aged; Organophosphonates; Pyelonephritis; Pyrimidinones; Ritonavir; Tenofovir | 2011 |
The impact of gender and anchor drugs on TDF renal toxicity.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Dideoxynucleosides; Emtricitabine; Female; Glomerular Filtration Rate; HIV Infections; Humans; Kidney; Lamivudine; Male; Organophosphonates; Sex Factors; Tenofovir | 2010 |
Stavudine toxicity in women is the main reason for treatment change in a 3-year prospective cohort of adult patients started on first-line antiretroviral treatment in Uganda.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Female; HIV Infections; Humans; Kaplan-Meier Estimate; Lamivudine; Male; Multivariate Analysis; Nevirapine; Prospective Studies; Risk Factors; Sex Factors; Stavudine; Uganda; Zidovudine | 2011 |
Evaluating patients for second-line antiretroviral therapy in India: the role of targeted viral load testing.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Female; HIV; HIV Infections; Humans; India; Lamivudine; Male; Middle Aged; Nevirapine; RNA, Viral; Stavudine; Treatment Failure; Viral Load; Zidovudine | 2010 |
Short Communication: Hepatitis B Virus Harboring Nucleotide Deletions in the Basal Core Promoter in HBe-Positive HIV-Coinfected Patients Under Lamivudine Therapy.
Topics: Anti-HIV Agents; DNA, Viral; Hepatitis B; Hepatitis B Core Antigens; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Longitudinal Studies; Promoter Regions, Genetic; Sequence Analysis, DNA; Sequence Deletion | 2011 |
Antiretroviral adherence and development of drug resistance are the strongest predictors of genital HIV-1 shedding among women initiating treatment.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cervix Uteri; Disease Transmission, Infectious; Drug Resistance, Multiple, Viral; Female; HIV Infections; HIV-1; Humans; Kenya; Lamivudine; Nevirapine; Patient Compliance; Risk Factors; RNA, Viral; Stavudine; Vagina; Virus Shedding | 2010 |
Recent FDA approvals and changes.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Capsules; Clinical Trials as Topic; Drug Approval; Drug Combinations; Drugs, Generic; HIV Infections; Humans; Lamivudine; Nevirapine; Oligopeptides; Pyridines; Reverse Transcriptase Inhibitors; Stavudine; Tablets; United States; United States Food and Drug Administration | 2010 |
Hepatitis B genotype G and high frequency of lamivudine-resistance mutations among human immunodeficiency virus/hepatitis B virus co-infected patients in Brazil.
Topics: Adult; Antiviral Agents; Brazil; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Mutation; Polymerase Chain Reaction; Viral Load | 2010 |
[Human immunodeficiency virus and Chagas disease coinfection treated successfully with benznidazole and a raltegravir-based antiretroviral regimen: a case report].
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Chagas Disease; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Nitroimidazoles; Oligopeptides; Organophosphonates; Paraguay; Pyridines; Pyrrolidinones; Raltegravir Potassium; Ritonavir; Spain; Tenofovir; Trypanocidal Agents; Zidovudine | 2011 |
Occult HBV infection in untreated HIV-infected adults in Côte d'Ivoire.
Topics: Adenine; Adult; Aged; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cote d'Ivoire; Cross-Sectional Studies; Deoxycytidine; DNA, Viral; Emtricitabine; Female; Hepatitis B Antibodies; Hepatitis B Core Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Prevalence; Tenofovir; World Health Organization; Young Adult | 2010 |
Raltegravir and unboosted atazanavir dual therapy in virologically suppressed antiretroviral treatment-experienced HIV patients.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Drug Interactions; Female; Follow-Up Studies; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Middle Aged; Oligopeptides; Pyridines; Pyrrolidinones; Raltegravir Potassium; Retrospective Studies; Reverse Transcriptase Inhibitors; Ritonavir; Viral Load | 2010 |
Reduced dose of stavudine and lipoatrophy in HIV-infected patients in Cameroon.
Topics: Adult; Anti-HIV Agents; Cameroon; CD4 Lymphocyte Count; Cross-Sectional Studies; Female; HIV; HIV Infections; Humans; Lamivudine; Lipodystrophy; Male; Middle Aged; Nevirapine; Stavudine; Zidovudine | 2010 |
[Long-term therapy for chronic hepatitis B in HIV co-infected patients].
Topics: Adenine; Antiretroviral Therapy, Highly Active; Antiviral Agents; Deoxycytidine; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Guanine; Hepatitis B, Chronic; HIV Infections; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Nucleosides; Organophosphonates; Pyrimidinones; Recombinant Proteins; Telbivudine; Tenofovir; Thymidine | 2010 |
A signal processing-based bioinformatics approach to assessing drug resistance: human immunodeficiency virus as a case study.
Topics: Amino Acid Sequence; Anti-HIV Agents; Computational Biology; Drug Resistance; Enfuvirtide; HIV; HIV Envelope Protein gp41; HIV Infections; Humans; Lamivudine; Molecular Sequence Data; Mutation; Peptide Fragments; Phenylpropionates; Pyrimidines; Signal Processing, Computer-Assisted | 2010 |
Prior therapy influences the efficacy of lamivudine monotherapy in patients with lamivudine-resistant HIV-1 infection.
Topics: Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Lamivudine; Salvage Therapy | 2011 |
Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care.
Topics: Adult; Antiretroviral Therapy, Highly Active; Cohort Studies; Didanosine; Dyslipidemias; Female; HIV Infections; HIV-1; Humans; Lamivudine; Longitudinal Studies; Male; Middle Aged; Reverse Transcriptase Inhibitors; Risk Assessment; Risk Factors; Stavudine | 2011 |
Aminotransferase serum levels decrease after initiating antiretroviral treatment in HIV infected patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Combinations; Female; HIV Infections; Humans; Lamivudine; Longitudinal Studies; Lopinavir; Male; Pyrimidinones; Ritonavir; Serum; Transaminases; Zidovudine | 2011 |
Multi-nucleoside reverse transcriptase inhibitor resistant HIV type-1 in a patient from Sierra Leone failing stavudine, lamivudine and nevirapine.
Topics: Adult; Drug Resistance, Multiple, Viral; Genetic Variation; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Monitoring, Physiologic; Mutation; Nevirapine; Nucleosides; Reverse Transcriptase Inhibitors; Sierra Leone; Stavudine; Treatment Failure | 2011 |
FDA notifications. FDA tentatively approves fixed-dose lamivudine/zidovudine.
Topics: Drug Approval; Drug Combinations; Drugs, Generic; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; United States; United States Food and Drug Administration; Zidovudine | 2010 |
HIV-2 infection, end-stage renal disease and protease inhibitor intolerance: which salvage regimen?
Topics: Adenine; Adult; Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; HIV-2; Humans; Kidney Failure, Chronic; Lamivudine; Male; Organophosphonates; Protease Inhibitors; Pyrrolidinones; Raltegravir Potassium; Renal Dialysis; Salvage Therapy; Tenofovir; Treatment Outcome | 2011 |
Self-reported adherence to HAART in South-Eastern Nigeria is related to patients' use of pill box.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Aged; Algorithms; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Feasibility Studies; Female; HIV; HIV Infections; Humans; Lamivudine; Linear Models; Male; Medication Adherence; Middle Aged; Nevirapine; Nigeria; Patient Satisfaction; Prospective Studies; Reminder Systems; Risk Factors; Self Report; Stavudine; Surveys and Questionnaires; Treatment Outcome | 2010 |
Lopinavir/ritonavir-based antiretroviral therapy in human immunodeficiency virus type 1-infected naive children: rare protease inhibitor resistance mutations but high lamivudine/emtricitabine resistance at the time of virologic failure.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Female; HIV Infections; HIV Protease; HIV-1; Humans; Infant; Lamivudine; Lopinavir; Male; Mutation; Paris; Pyrimidinones; Ritonavir; Treatment Failure | 2011 |
Medication-based urolithiasis and atazanavir.
Topics: Anti-Retroviral Agents; Atazanavir Sulfate; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Oligopeptides; Pyridines; Ritonavir; Uric Acid; Urinary Calculi; Urolithiasis | 2011 |
[Immune reconstitution inflammatory syndrome and HIV leprosy co-infection].
Topics: Adrenal Cortex Hormones; Adult; Anti-HIV Agents; Dapsone; Diagnostic Errors; Female; HIV Infections; HIV-1; Humans; Immune Reconstitution Inflammatory Syndrome; Lamivudine; Leprostatic Agents; Leprosy, Borderline; Leprosy, Lepromatous; Neuritis; Nevirapine; Rifampin; Senegal; Stavudine; Tinea Capitis | 2011 |
Clinical experience with nevirapine combined with tenofovir plus emtricitabine or lamivudine-containing regimens in HIV-infected subjects.
Topics: Adenine; Adult; Anti-HIV Agents; Australia; Deoxycytidine; Drug Administration Schedule; Emtricitabine; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lost to Follow-Up; Male; Medical Audit; Middle Aged; Nevirapine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2011 |
Improving retention in the early infant diagnosis of HIV program in rural Mozambique by better service integration.
Topics: Adult; Anti-HIV Agents; Delivery of Health Care; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Mozambique; Nevirapine; Pregnancy; Retrospective Studies; Rural Population; Young Adult; Zidovudine | 2011 |
Interference of replication between hepatitis B and C viruses in patients infected with HIV.
Topics: Adult; Antibodies, Viral; CD4 Lymphocyte Count; Cell Line, Tumor; China; DNA, Viral; Female; Hepacivirus; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis C; HIV; HIV Infections; Humans; Lamivudine; Longitudinal Studies; Male; Mutation; Plasmids; Risk Factors; RNA, Viral; Transfection; Virus Replication | 2011 |
Developmental pharmacokinetics of lamivudine in 580 pediatric patients ranging from neonates to adolescents.
Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Chromatography, High Pressure Liquid; Female; HIV Infections; Humans; Infant; Infant, Newborn; Lamivudine; Male; Retrospective Studies | 2011 |
Nelfinavir and Lamivudine pharmacokinetics during the first two weeks of life.
Topics: Anti-HIV Agents; Area Under Curve; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Male; Nelfinavir; Viral Load | 2011 |
Detection of hepatitis B virus variants in HBV monoinfected and HBV/HIV coinfected Iranian patients under lamivudine treatment.
Topics: Adult; Anti-HIV Agents; Cohort Studies; DNA Mutational Analysis; DNA-Directed DNA Polymerase; Drug Resistance, Viral; Female; Gene Frequency; Genotype; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Iran; Lamivudine; Male; Mutation; Phylogeny | 2011 |
Evaluation of saliva as an alternative matrix for monitoring plasma Zidovudine, Lamivudine and nevirapine concentrations in Rwanda.
Topics: Adult; Anti-HIV Agents; Cross-Sectional Studies; Drug Monitoring; Feasibility Studies; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Medication Adherence; Middle Aged; Nevirapine; Rwanda; Saliva; Zidovudine | 2011 |
HBV primary drug resistance in newly diagnosed HIV-HBV-coinfected individuals in Spain.
Topics: Adult; Cohort Studies; Drug Resistance, Viral; Female; Gene Products, pol; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Reverse Transcriptase Inhibitors; Spain | 2011 |
Comparison of abacavir/lamivudine and tenofovir/emtricitabine among treatment-naive HIV-infected patients initiating therapy.
Topics: Adenine; Adult; Anti-HIV Agents; Canada; Cohort Studies; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug Substitution; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir; Treatment Failure; Virus Replication | 2011 |
Risk of liver-associated morbidity and mortality in a cohort of HIV and HBV coinfected Han Chinese.
Topics: Adult; Alanine Transaminase; Anti-HIV Agents; CD4 Lymphocyte Count; China; Cohort Studies; Coinfection; DNA, Viral; Female; Hepatitis B; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Lamivudine; Liver; Male; Middle Aged; Retrospective Studies; Risk Factors; RNA, Viral; Young Adult | 2011 |
Prevention of mother-to-child transmission of HIV and the health-related Millennium Development Goals: time for a public health approach.
Topics: Adult; Anti-HIV Agents; Breast Feeding; CD4 Lymphocyte Count; Drug Administration Schedule; Drug Therapy, Combination; Female; Goals; Healthy People Programs; HIV Infections; HIV Seropositivity; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Malawi; Male; Nevirapine; Peripartum Period; Pregnancy; Pregnancy Complications, Infectious; Public Health; United Nations; Zidovudine | 2011 |
Genome-wide association study identifies variations in 6p21.3 associated with nevirapine-induced rash.
Topics: Anti-HIV Agents; Chromosomes, Human, Pair 6; Drug Eruptions; Genetic Predisposition to Disease; Genome-Wide Association Study; HIV Infections; Humans; Intracellular Signaling Peptides and Proteins; Lamivudine; Logistic Models; Nevirapine; Polymorphism, Single Nucleotide; Retrospective Studies; Risk Factors; ROC Curve; Stavudine; Thailand | 2011 |
Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; CD4 Lymphocyte Count; Cohort Studies; Deoxycytidine; Dideoxynucleosides; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oligopeptides; Organophosphonates; Pyridines; Retrospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Viral Load | 2011 |
[Coinfection with HIV and HCV: abacavir and ribavirine, why not?].
Topics: Anti-HIV Agents; Antiviral Agents; Coinfection; Dideoxynucleosides; Drug Combinations; Drug Interactions; Hepatitis C, Chronic; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Ribavirin; Zidovudine | 2012 |
Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1.
Topics: Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Inhibitory Concentration 50; Lamivudine; Nitriles; Pyridazines; Pyrimidines; Virus Replication | 2011 |
Optimizing antiretroviral product selection: a sample approach to improving patient outcomes, saving money, and scaling-up health services in developing countries.
Topics: Anti-Retroviral Agents; Atazanavir Sulfate; Developing Countries; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Health Planning; Health Services; HIV Infections; Humans; Lamivudine; Lopinavir; Oligopeptides; Pyridines; Pyrimidinones; Treatment Outcome | 2011 |
Gender difference in 2-year mortality and immunological response to ART in an HIV-infected Chinese population, 2006-2008.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Asian People; CD4 Lymphocyte Count; China; Female; Follow-Up Studies; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies; Sex Factors; Survival Rate; Treatment Outcome; Young Adult | 2011 |
Lamivudine resistance mutations in European patients with hepatitis B and patients co-infected with HIV and hepatitis B.
Topics: Adult; Antiviral Agents; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Mutation, Missense; Retrospective Studies; Treatment Failure; Viral Load; Viremia | 2011 |
Optimizing initial therapy for HIV infection.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Emtricitabine; Female; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Tenofovir | 2011 |
Multiple sclerosis typical clinical and MRI findings in a patient with HIV infection.
Topics: Adult; Age of Onset; Alkynes; Benzoxazines; Brain; CD4 Lymphocyte Count; Cyclopropanes; HIV Infections; Humans; Lamivudine; Magnetic Resonance Imaging; Male; Multiple Sclerosis; Neuroimaging; Stavudine; Treatment Outcome; Viral Load | 2011 |
Efficacy and safety of nevirapine + Kivexa (abacavir/lamivudine) as a simplification strategy for HIV patients with undetectable viral load.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Combinations; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Treatment Outcome; Viral Load | 2011 |
In vitro restoration of Th17 response during HIV infection with an antiretroviral drug and Th17 differentiation cytokines.
Topics: Anti-Retroviral Agents; CD4-Positive T-Lymphocytes; Cell Differentiation; Cells, Cultured; Cytokines; Flow Cytometry; HIV; HIV Infections; Humans; In Vitro Techniques; Lamivudine; Th17 Cells; Virus Replication | 2012 |
HAART induced adverse drug reactions: a retrospective analysis at a tertiary referral health care center in India.
Topics: Alkynes; Anemia; Antiretroviral Therapy, Highly Active; Benzoxazines; Chemical and Drug Induced Liver Injury; Cyclopropanes; Exanthema; Female; Gastritis; HIV Infections; Humans; India; Lamivudine; Male; Nevirapine; Peripheral Nervous System Diseases; Pharmacovigilance; Retrospective Studies; Severity of Illness Index; Sjogren's Syndrome; Stavudine | 2011 |
Molecular analysis of hepatitis B virus (HBV) in an HIV co-infected patient with reactivation of occult HBV infection following discontinuation of lamivudine-including antiretroviral therapy.
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; DNA, Viral; Evolution, Molecular; Female; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Middle Aged; Molecular Sequence Data; Mutation, Missense; Sequence Analysis, DNA | 2011 |
Long-term outcome of primary non-responders to tenofovir therapy in HIV/HBV-co-infected patients: impact of HBV genotype G.
Topics: Adenine; Adult; Anti-HIV Agents; Coinfection; Deoxycytidine; DNA Mutational Analysis; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Female; Genotype; Hepatitis B; Hepatitis B virus; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Retrospective Studies; Tenofovir; Time Factors; Treatment Outcome | 2012 |
Pregnancy-related effects on lamivudine pharmacokinetics in a population study with 228 women.
Topics: Adolescent; Adult; Amniotic Fluid; Anti-HIV Agents; Area Under Curve; Drug Monitoring; Female; Fetal Blood; HIV Infections; Humans; Lamivudine; Maternal-Fetal Exchange; Metabolic Clearance Rate; Models, Biological; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors; Young Adult | 2012 |
Early markers of tubular dysfunction in antiretroviral-experienced HIV-infected patients treated with tenofovir versus abacavir.
Topics: Adenine; Anti-HIV Agents; Biomarkers; Cohort Studies; Cytochromes c; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Female; Glomerular Filtration Rate; Glutathione Transferase; HIV Infections; Humans; Kidney Diseases; Kidney Tubules, Proximal; Lamivudine; Male; Middle Aged; Mitochondria; Organophosphonates; Tenofovir; Time Factors | 2012 |
Management of needlestick injuries: a house officer who has a needlestick.
Topics: Anti-HIV Agents; Blood-Borne Pathogens; Drug Combinations; Emergency Service, Hospital; Health Personnel; HIV Infections; HIV Seropositivity; Humans; Internship and Residency; Lamivudine; Male; Needlestick Injuries; Occupational Exposure; Physicians; Post-Exposure Prophylaxis; Risk; United States; Zidovudine | 2012 |
Differential clinical and virologic impact of hepatitis B virus genotypes B and C on HIV-coinfected patients receiving lamivudine-containing highly active antiretroviral therapy.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Cohort Studies; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Liver; Male; Middle Aged; Prospective Studies; Treatment Outcome | 2012 |
Successful treatment of aciclovir and foscarnet resistant Herpes simplex virus lesions with topical imiquimod in patients infected with human immunodeficiency virus type 1.
Topics: Acyclovir; Administration, Topical; Adult; Aminoquinolines; Antiviral Agents; Drug Resistance, Viral; Foscarnet; Herpes Simplex; HIV Infections; HIV-1; Humans; Imiquimod; Lamivudine; Male; Middle Aged; Nelfinavir; Simplexvirus; Zidovudine | 2012 |
Pharmacokinetics of antiretroviral drug varies with formulation in the target population of children with HIV-1.
Topics: Administration, Oral; Antirheumatic Agents; Chemistry, Pharmaceutical; Child, Preschool; Dideoxynucleosides; Drug Combinations; Female; HIV Infections; HIV-1; Humans; Infant; Lamivudine; Male; Solutions; Tablets; Therapeutic Equivalency; Zidovudine | 2012 |
Costs and benefits of multidrug, multidose antiretroviral therapy for prevention of mother-to-child transmission of HIV in the Dominican Republic.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cost-Benefit Analysis; Cyclopropanes; Dominican Republic; Drug Administration Schedule; Drug Costs; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Nevirapine; Pregnancy; Pregnancy Trimester, Second; Pregnancy Trimester, Third; Zidovudine | 2012 |
Efficacy and safety of once-daily ritonavir-boosted darunavir and abacavir/lamivudine for treatment-naïve patients: a pilot study.
Topics: Adult; Darunavir; Dideoxynucleosides; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Pilot Projects; Retrospective Studies; Ritonavir; Sulfonamides; Treatment Outcome; Viral Load | 2012 |
Lopinavir/ritonavir trough concentrations with the tablet formulation in HIV-1-infected women during the third trimester of pregnancy.
Topics: Adult; Anti-HIV Agents; Drug Combinations; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Trimester, Third; Reverse Transcriptase Inhibitors; Ritonavir; Tablets; Treatment Outcome; Young Adult; Zidovudine | 2012 |
Quasispecies analysis and in vitro susceptibility of HBV strains isolated from HIV-HBV-coinfected patients with delayed response to tenofovir.
Topics: Adenine; Adult; Antiviral Agents; Cloning, Molecular; Coinfection; DNA, Viral; Drug Resistance, Viral; Female; Genotype; Hep G2 Cells; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Mutation; Organophosphonates; Sequence Analysis, DNA; Tenofovir; Transfection | 2012 |
Cytosine deoxyribonucleoside anti-HIV analogues: a small chemical substitution allows relevant activities.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Deoxycytidine; Emtricitabine; HIV Infections; HIV-1; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Structure-Activity Relationship; Treatment Outcome; Zalcitabine | 2012 |
Lamivudine-resistant HBV infection in HIV-positive patients receiving antiretroviral therapy in a public routine clinic in Cameroon.
Topics: Adult; Anti-HIV Agents; Base Sequence; Cameroon; Coinfection; Cross-Sectional Studies; DNA, Viral; Drug Resistance, Viral; Female; Gene Products, pol; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Sequence Analysis, DNA | 2012 |
Low rates of nucleoside reverse transcriptase inhibitor resistance in a well-monitored cohort in South Africa on antiretroviral therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Male; Reverse Transcriptase Inhibitors; RNA, Viral; South Africa; Stavudine; Viral Load | 2012 |
Prevalence of MDR1 C3435T and CYP2B6 G516T polymorphisms among HIV-1 infected South African patients.
Topics: Adolescent; Adult; Alkynes; Analysis of Variance; Anti-HIV Agents; Aryl Hydrocarbon Hydroxylases; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzoxazines; CD4-Positive T-Lymphocytes; Cyclopropanes; Cytochrome P-450 CYP2B6; Female; Gene Frequency; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Multivariate Analysis; Oxidoreductases, N-Demethylating; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; South Africa; Stavudine; Viral Load; Young Adult | 2012 |
Effectiveness of fixed-dose combination stavudine, lamivudine and nevirapine (GPO-VIR) for treatment of naïve HIV patients in Thailand: a 3-year follow-up.
Topics: Adult; Analysis of Variance; Antiretroviral Therapy, Highly Active; Female; Follow-Up Studies; HIV Infections; Humans; Lamivudine; Male; Nevirapine; Prospective Studies; Retrospective Studies; Statistics, Nonparametric; Stavudine; Survival Analysis; Thailand; Treatment Outcome | 2011 |
Exploiting the anti-HIV-1 activity of acyclovir: suppression of primary and drug-resistant HIV isolates and potentiation of the activity by ribavirin.
Topics: Acyclovir; Anti-HIV Agents; Cell Line; Drug Resistance, Viral; Drug Synergism; HIV Fusion Inhibitors; HIV Infections; HIV-1; Humans; Lamivudine; Nevirapine; Palatine Tonsil; Protease Inhibitors; Ribavirin; T-Lymphocytes; Tissue Culture Techniques; Zidovudine | 2012 |
Recombination between variants from genital tract and plasma: evolution of multidrug-resistant HIV type 1.
Topics: Adult; Anti-HIV Agents; Female; Genitalia, Female; HIV Infections; HIV-1; Humans; Lamivudine; Molecular Sequence Data; Nevirapine; Plasma; Recombination, Genetic; RNA, Viral; Sequence Analysis, DNA; Zidovudine | 2012 |
Adverse drug reactions to antiretroviral therapy (ARVs): incidence, type and risk factors in Nigeria.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Cohort Studies; Cyclopropanes; Drug-Related Side Effects and Adverse Reactions; Exanthema; Female; HIV Infections; Humans; Incidence; Lamivudine; Male; Middle Aged; Nevirapine; Nigeria; Organophosphonates; Pain; Retrospective Studies; Risk Factors; Stavudine; Tenofovir; Zidovudine | 2012 |
Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens.
Topics: Adenine; Adult; Anti-HIV Agents; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Female; France; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Mutation, Missense; Organophosphonates; Retrospective Studies; RNA, Viral; Selection, Genetic; Tenofovir; Treatment Failure; Viral Load | 2012 |
Emergence of minor drug-resistant HIV-1 variants after triple antiretroviral prophylaxis for prevention of vertical HIV-1 transmission.
Topics: Adult; Alleles; Anti-Retroviral Agents; Drug Resistance, Viral; Female; Genetic Variation; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Mutation; Nevirapine; Oligonucleotides; Polymerase Chain Reaction; Pregnancy; Pregnancy Complications, Infectious; Tanzania; Zidovudine | 2012 |
Effect of HIV-1 infection and sex on the cellular pharmacology of the antiretroviral drugs zidovudine and lamivudine.
Topics: Adult; Anti-HIV Agents; Black or African American; Cytidine Triphosphate; Dideoxynucleotides; Female; HIV Infections; Humans; Lamivudine; Longitudinal Studies; Male; Prospective Studies; Sex Factors; Thymine Nucleotides; Zidovudine | 2012 |
Drug safety evaluation profile of stavudine plus lamivudine for HIV-1/AIDS infection.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Drug Therapy, Combination; Evidence-Based Medicine; HIV Infections; HIV-1; Humans; Lamivudine; Patient Safety; Reverse Transcriptase Inhibitors; Risk Assessment; Risk Factors; Stavudine; Treatment Outcome | 2012 |
Simultaneous determination of lamivudine, lopinavir, ritonavir, and zidovudine concentration in plasma of HIV-infected patients by HPLC-MS/MS.
Topics: Anti-HIV Agents; Calibration; Chromatography, High Pressure Liquid; HIV Infections; Humans; Lamivudine; Limit of Detection; Lopinavir; Reference Standards; Reproducibility of Results; Ritonavir; Tandem Mass Spectrometry; Zidovudine | 2012 |
Hepatitis B virus variants in HBV mono-infected versus HBV/HIV co-infected patients.
Topics: Anti-HIV Agents; Female; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male | 2012 |
Immunological and virological responses to cART in HIV/HBV co-infected patients from a multicenter cohort.
Topics: Adolescent; Adult; Aged; Anti-Retroviral Agents; CD4 Lymphocyte Count; Coinfection; Disease Progression; DNA, Viral; Female; Hepatitis B; Hepatitis B e Antigens; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Prospective Studies; Treatment Outcome; Young Adult | 2012 |
Immunological characterisation of an unmasking TB-IRIS case.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cyclopropanes; Cytokines; Female; HIV Infections; Humans; Immune Reconstitution Inflammatory Syndrome; Lamivudine; Male; Opportunistic Infections; Stavudine; Thymic Factor, Circulating; Tuberculosis, Pulmonary | 2012 |
Response to valacyclovir in an HIV-infected girl with Epstein Barr infection.
Topics: Acyclovir; Alkynes; Antiretroviral Therapy, Highly Active; Antiviral Agents; Benzoxazines; Child; Cyclopropanes; Epstein-Barr Virus Infections; Female; HIV Infections; Humans; Lamivudine; Valacyclovir; Valine; Zidovudine | 2012 |
Population pharmacokinetic model for adherence evaluation using lamivudine concentration monitoring.
Topics: Absorption; Anti-HIV Agents; Anti-Retroviral Agents; Area Under Curve; Child, Preschool; HIV Infections; Humans; Infant; Lamivudine; Models, Biological | 2012 |
Attrition among human immunodeficiency virus (HIV)- infected patients initiating antiretroviral therapy in China, 2003-2010.
Topics: Age Factors; Anti-HIV Agents; Anti-Retroviral Agents; CD4 Lymphocyte Count; China; Female; HIV Infections; Humans; Lamivudine; Male; Patient Dropouts; Sex Factors | 2012 |
Hepatitis B virus and human immunodeficiency virus drugs in pregnancy: findings from the Antiretroviral Pregnancy Registry.
Topics: Adenine; Adult; Antiviral Agents; Congenital Abnormalities; Female; Hepatitis B; Hepatitis B virus; HIV; HIV Infections; Humans; Lamivudine; Phosphorous Acids; Pregnancy; Pregnancy Complications, Infectious; Prevalence; Prospective Studies; Registries; Retrospective Studies; Risk Factors; Treatment Outcome | 2012 |
Lamivudine or emtricitabine (XTC)/protease inhibitor dual therapy as a harm-reduction strategy in patients with tenofovir-related renal toxicity: a case-control study.
Topics: Adenine; Adult; Aged; Case-Control Studies; CD4 Lymphocyte Count; Chi-Square Distribution; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Kidney Diseases; Kidney Function Tests; Lamivudine; Male; Middle Aged; Organophosphonates; Protease Inhibitors; Retrospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2012 |
Case report: management and HBV sequencing in a patient co-infected with HBV and HIV failing tenofovir.
Topics: Adenine; Anti-HIV Agents; Coinfection; Drug Resistance, Viral; Gene Products, pol; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Sequence Analysis, DNA; Tenofovir; Viral Load; Young Adult | 2012 |
Trends in HIV-1 reverse transcriptase resistance-associated mutations and antiretroviral prescription data from 2003-2010.
Topics: Adenine; Anti-HIV Agents; Deoxycytidine; Drug Prescriptions; Drug Resistance, Viral; Drug Therapy, Combination; Emtricitabine; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Organophosphonates; Prevalence; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure; Zidovudine | 2012 |
Long-term hepatitis B virus (HBV) response to lamivudine-containing highly active antiretroviral therapy in HIV-HBV co-infected patients in Thailand.
Topics: Adult; Alanine Transaminase; Antiretroviral Therapy, Highly Active; CD4-Positive T-Lymphocytes; Drug Resistance, Viral; Female; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Mutation; Thailand; Viral Load; Virus Replication | 2012 |
Response to antiretroviral therapy in occult hepatitis B and HIV co-infection in West Africa.
Topics: Anti-HIV Agents; Body Mass Index; CD4 Lymphocyte Count; Coinfection; Disease Progression; Female; Ghana; Hepatitis B; Hepatitis B Surface Antigens; HIV Infections; Humans; Lamivudine; Male; Prevalence; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load | 2013 |
Organic cation transporters OCT1 and OCT2 determine the accumulation of lamivudine in CD4 cells of HIV-infected patients.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4-Positive T-Lymphocytes; Cytidine Triphosphate; Dideoxynucleotides; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Organic Cation Transport Proteins; Organic Cation Transporter 1; Organic Cation Transporter 2; Phosphorylation; Real-Time Polymerase Chain Reaction; Ritonavir; RNA, Messenger; Tandem Mass Spectrometry; Transfection; Young Adult | 2013 |
Evaluating the cost-effectiveness of combination antiretroviral therapy for the prevention of mother-to-child transmission of HIV in Uganda.
Topics: Anti-HIV Agents; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Pregnancy; Pregnancy Complications, Infectious; Uganda; Zidovudine | 2012 |
Emergence of lamivudine resistance hepatitis B virus mutations in pregnant women infected with HBV and HIV receiving antiretroviral prophylaxis for the prevention of mother-to-infant transmission in Malawi.
Topics: Adolescent; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Malawi; Mutation; Pregnancy; Pregnancy Complications, Infectious; RNA, Viral; Viral Load; Young Adult | 2012 |
Differential effects of tenofovir/emtricitabine and abacavir/lamivudine on human leukocyte recruitment.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Cell Adhesion; Cell Adhesion Molecules; Cell Communication; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine; Endothelial Cells; HIV Infections; Humans; Lamivudine; Leukocytes; Organophosphonates; Tenofovir | 2012 |
Number of daily pills, dosing schedule, self-reported adherence and health status in 2010: a large cross-sectional study of HIV-infected patients on antiretroviral therapy.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Carbamates; CD4 Lymphocyte Count; Cross-Sectional Studies; Deoxycytidine; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Efavirenz, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; Furans; HIV Infections; Humans; Italy; Lamivudine; Male; Medication Adherence; Middle Aged; Nevirapine; Oligopeptides; Organophosphates; Organophosphonates; Oxazines; Pyridines; Self Report; Sulfonamides; Surveys and Questionnaires; Viral Load | 2013 |
Persistence versus reversion of 3TC resistance in HIV-1 determine the rate of emergence of NVP resistance.
Topics: Anti-HIV Agents; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Lamivudine; Mutation; Nevirapine; Serial Passage | 2012 |
Preserving future therapeutic options: should we limit the lamivudine use in young HIV-1 infected children initiating first-line HAART?
Topics: Age Factors; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Infant; Lamivudine; Treatment Outcome | 2013 |
The influence of HLA supertype on thymidine analogue associated with low peripheral fat in HIV.
Topics: Adenine; Anti-HIV Agents; Australia; Biomarkers; Blood Glucose; Body Fat Distribution; CD4 Lymphocyte Count; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Drug Resistance, Viral; Emtricitabine; Female; Genotype; HIV Infections; HIV-Associated Lipodystrophy Syndrome; HLA Antigens; HLA-A1 Antigen; HLA-B8 Antigen; HLA-DQ Antigens; Humans; Lamivudine; Linkage Disequilibrium; Male; Middle Aged; Multicenter Studies as Topic; Organophosphonates; Predictive Value of Tests; Randomized Controlled Trials as Topic; Tenofovir; Thymidine | 2012 |
Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Coinfection; Deoxycytidine; Emtricitabine; Female; Hepatitis B; Hepatitis B e Antigens; Hepatitis B virus; HIV Infections; HIV-1; Humans; Lamivudine; Male; Organophosphonates; Retrospective Studies; Tenofovir; Treatment Outcome; Viral Load; Virus Replication | 2012 |
A case of adverse drug reaction induced by dispensing error.
Topics: Acute Kidney Injury; Aged; Antiretroviral Therapy, Highly Active; Asthenia; Dideoxynucleosides; HIV Infections; Humans; Lamivudine; Male; Medication Errors | 2012 |
[Acute hemolytic anemia in an HIV patient after inhalation of amyl nitrite].
Topics: Administration, Inhalation; Adult; Amyl Nitrite; Anemia, Hemolytic; Anti-HIV Agents; Diagnosis, Differential; Dideoxynucleosides; HIV Infections; Humans; Illicit Drugs; Inhalant Abuse; Iraq; Lamivudine; Male; Travel; Zidovudine | 2012 |
Short communication: lamivudine plus a boosted-protease inhibitor as simplification strategy in HIV-infected patients: proof of concept.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Drug Resistance, Viral; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation, Missense; Retrospective Studies; Treatment Outcome; Viral Load | 2013 |
Frequency of stavudine substitution due to toxicity in children receiving antiretroviral treatment in sub-Saharan Africa.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Child, Preschool; Cohort Studies; Cyclopropanes; Dideoxynucleosides; Drug Substitution; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; HIV Infections; Humans; Infant; Lamivudine; Male; Retrospective Studies; Risk Factors; South Africa; Stavudine; Time Factors | 2013 |
Impact of hepatitis C virus on HIV response to antiretroviral therapy in Nigeria.
Topics: Adult; Alanine Transaminase; Alkynes; Anti-Retroviral Agents; Benzoxazines; Chemical and Drug Induced Liver Injury; Coinfection; Cyclopropanes; Deoxycytidine; Drug Combinations; Drug Therapy, Combination; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Lamivudine; Logistic Models; Male; Nevirapine; Nigeria; Organophosphorus Compounds; RNA, Viral; Stavudine; Zidovudine | 2013 |
Influence of HIV-associated degree of immune suppression on molecular heterogeneity of hepatitis B virus among HIV co-infected patients.
Topics: Adult; Amino Acid Sequence; Anti-HIV Agents; CD4 Lymphocyte Count; Coinfection; DNA, Viral; Female; Genetic Variation; Genotype; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B virus; HIV; HIV Infections; Humans; Immunosuppression Therapy; Lamivudine; Male; Sequence Analysis, DNA; Viral Load | 2013 |
[Efficacy and tolerance of tenofovir-lamivudine-efavirenz combination in HIV-1 patients in Fann Teaching Hospital in Dakar].
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Hospitals, Teaching; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Senegal; Tenofovir; Treatment Outcome | 2013 |
Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Aryl Hydrocarbon Hydroxylases; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP2B6; Drug Interactions; Ethambutol; Female; Genotype; HIV Infections; Humans; Isoniazid; Lamivudine; Male; Middle Aged; Organophosphonates; Oxidoreductases, N-Demethylating; Pharmacogenetics; Polymorphism, Single Nucleotide; Pyrazinamide; Reverse Transcriptase Inhibitors; Rifampin; Tenofovir; Tuberculosis; Young Adult | 2013 |
Impact of antiretroviral pressure on selection of primary human immunodeficiency virus type 1 envelope sequences in vitro.
Topics: Amino Acid Sequence; Anti-HIV Agents; Base Sequence; Cyclohexanes; DNA, Viral; Genetic Variation; Genotype; Glycosylation; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Lamivudine; Maraviroc; Molecular Sequence Data; Phylogeny; Pyrrolidinones; Raltegravir Potassium; Receptors, CCR5; Receptors, CXCR4; Saquinavir; Sequence Analysis, DNA; Triazoles; Viral Tropism | 2013 |
Inhibition of telomerase activity by human immunodeficiency virus (HIV) nucleos(t)ide reverse transcriptase inhibitors: a potential factor contributing to HIV-associated accelerated aging.
Topics: Adenine; Adult; Aging; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Case-Control Studies; Cells, Cultured; Deoxycytidine; Dideoxynucleosides; Emtricitabine; Enzyme Activation; Female; HIV; HIV Infections; Humans; Lamivudine; Leukocytes, Mononuclear; Male; Middle Aged; Organophosphonates; Polymerase Chain Reaction; Regression Analysis; Reverse Transcriptase Inhibitors; Risk Factors; Telomerase; Telomere; Telomere Shortening; Tenofovir; Time Factors; Young Adult; Zidovudine | 2013 |
Initiation of antiretroviral therapy before 6 months of age is associated with faster growth recovery in South African children perinatally infected with human immunodeficiency virus.
Topics: Age Factors; Anthropometry; Anti-Retroviral Agents; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant; Infant, Newborn; Lamivudine; Lopinavir; Male; Ritonavir; South Africa; Stavudine; Time Factors; Treatment Outcome | 2013 |
Risk adapted transmission prophylaxis to prevent vertical HIV-1 transmission: effectiveness and safety of an abbreviated regimen of postnatal oral zidovudine.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Male; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; Retrospective Studies; Risk Factors; Treatment Outcome; Zidovudine | 2013 |
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir an
Topics: Adiposity; Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Body Composition; Bone and Bones; Cognition; Drug Resistance, Viral; Endpoint Determination; Female; Glomerular Filtration Rate; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Neuropsychological Tests; Oligopeptides; Patient Compliance; Pilot Projects; Pregnancy; Pyridines; Quality of Life; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Treatment Failure | 2013 |
The long-term effectiveness of generic adult fixed-dose combination antiretroviral therapy for HIV-infected Ugandan children.
Topics: Adult; Anti-HIV Agents; Antineoplastic Combined Chemotherapy Protocols; Body Weight; CD4 Lymphocyte Count; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedule; Drugs, Generic; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Infant; Kaplan-Meier Estimate; Lamivudine; Male; Medication Adherence; Nevirapine; Stavudine; Time Factors; Treatment Outcome; Viral Load | 2012 |
Anti-HIV agents. Trizivir--three drugs in one pill.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; HIV Infections; Humans; Lamivudine; Zidovudine | 2000 |
Immunophenotypic analyses of CD34(+) cell subsets in bone marrow from HIV-infected patients during highly- active antiretroviral therapy.
Topics: Adult; Antigens, CD34; Antiretroviral Therapy, Highly Active; beta 2-Microglobulin; Bone Marrow Cells; Case-Control Studies; Female; Flow Cytometry; HIV Infections; HIV Protease Inhibitors; Humans; Immunoglobulin G; Immunophenotyping; Indinavir; Lamivudine; Leukocyte Count; Male; Middle Aged; Stavudine; T-Lymphocyte Subsets; Zidovudine | 2002 |
Antiretroviral rounds. Personal and public consequences.
Topics: Adult; Alcohol Drinking; Candidiasis, Oral; CD4 Lymphocyte Count; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Male; Pneumonia, Bacterial; Sexual Partners; Trimethoprim, Sulfamethoxazole Drug Combination; Viral Load; Zidovudine | 2000 |
Geotrichum proctitis after HIV postexposure prophylaxis.
Topics: Drug Therapy, Combination; Female; Geotrichosis; HIV Infections; Humans; Lamivudine; Middle Aged; Proctitis; Reverse Transcriptase Inhibitors; Zidovudine | 2002 |
HIV-1 infection in women.
Topics: CD4 Lymphocyte Count; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Male; Sexual Behavior; Sexually Transmitted Diseases; Thailand; Viral Load; Zidovudine | 2000 |
Immune reconstitution during intensive chemotherapy in patients with human immunodeficiency virus related non-Hodgkin lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; CD4 Lymphocyte Count; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Female; HIV Infections; HIV Protease Inhibitors; Humans; Immunocompromised Host; Immunosuppression Therapy; Indinavir; Lamivudine; Lymphoma, AIDS-Related; Male; Methotrexate; Middle Aged; Prednisone; Reverse Transcriptase Inhibitors; Stavudine; T-Lymphocyte Subsets; Vincristine | 2002 |
Prevalence of G333D/E in naive and pretreated HIV-infected patients.
Topics: Amino Acid Sequence; Drug Resistance, Microbial; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Molecular Sequence Data; Mutation; Reverse Transcriptase Inhibitors; Zidovudine | 2002 |
HIV and refractory anemia with excess blasts (RAEB).
Topics: Adult; Alkynes; Anemia, Refractory, with Excess of Blasts; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; HIV Infections; Humans; Lamivudine; Male; Oxazines; Pancytopenia; Pneumonia; Stavudine; Treatment Outcome | 2002 |
[Cytomegalovirus retinitis after highly active antiretroviral therapy: a case report].
Topics: Adult; AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Cytomegalovirus Retinitis; Didanosine; Ganciclovir; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Retinal Hemorrhage; Reverse Transcriptase Inhibitors; Risk; Saquinavir; Stavudine; Substance Abuse, Intravenous; Zidovudine | 2002 |
Highlights of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).
Topics: Adenine; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; Drug Resistance, Microbial; Drug Therapy; Epoetin Alfa; Erythropoietin; Hepatitis C; HIV Infections; Humans; Lamivudine; Organophosphonates; Organophosphorus Compounds; Recombinant Proteins; Saquinavir; Tenofovir; Zidovudine | 2002 |
Development of a pharmacodynamic model for HIV treatment with nucleoside reverse transcriptase and protease inhibitors.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Cytidine Triphosphate; Dideoxynucleotides; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Models, Statistical; Reverse Transcriptase Inhibitors; Thymine Nucleotides; Viral Load; Zidovudine | 2002 |
Rheumatoid arthritis after 9 years of human immunodeficiency virus infection: possible contribution of tritherapy.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Arthritis, Reactive; HIV; HIV Infections; Humans; Immunocompromised Host; Lamivudine; Male; Saquinavir; Stavudine; Treatment Outcome | 2002 |
Development of drug resistance in HIV-1 patients receiving a combination of stavudine, lamivudine and efavirenz.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Viral; Genes, Viral; HIV Infections; HIV-1; Humans; Lamivudine; Mutation; Oxazines; RNA, Viral; Stavudine; Viral Load; Viremia | 2002 |
Phenotypic and genotypic HIV-1 drug resistance assays provide complementary information.
Topics: Adenine; Anti-HIV Agents; Carbamates; Didanosine; Dideoxynucleosides; Drug Resistance, Viral; Furans; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Microbial Sensitivity Tests; Organophosphonates; Organophosphorus Compounds; Phenotype; Reverse Transcriptase Inhibitors; Sulfonamides; Tenofovir; Zalcitabine | 2002 |
FDA notifications. The use of lamivudine has been expanded.
Topics: HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; United States; United States Food and Drug Administration | 2002 |
Type B lactic acidosis: a rare complication of antiretroviral therapy after cardiac surgery.
Topics: Acidosis, Lactic; Anti-HIV Agents; Aortic Valve; Female; Heart Valve Prosthesis; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Kidney Failure, Chronic; Lamivudine; Middle Aged; Postoperative Complications; Renal Dialysis; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine | 2002 |
Editorial comment: a tale of two viruses.
Topics: Adenine; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B; Hepatitis B Vaccines; HIV Infections; Humans; Lamivudine; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir | 2002 |
[Factors predicting lack of adherence to highly active antiretroviral treatment].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Data Collection; Drug Combinations; Drug Utilization Review; HIV Infections; Humans; Lamivudine; Outpatient Clinics, Hospital; Patient Compliance; Patient Dropouts; Registries; Sensitivity and Specificity; Spain; Treatment Refusal; Zidovudine | 2002 |
Phenotypic and genotypic analysis of biologically cloned human immunodeficiency virus type 1 isolates from patients treated with zidovudine and lamivudine.
Topics: Clone Cells; Drug Resistance, Viral; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Molecular Sequence Data; Mutation; Phenotype; Reverse Transcriptase Inhibitors; Zidovudine | 2002 |
Mean cell volume (MCV) changes in HIV-positive patients taking nucleoside reverse transcriptase inhibitors (NRTIs): a surrogate marker for adherence.
Topics: Biomarkers; Erythrocyte Indices; HIV Infections; Humans; Lamivudine; Patient Compliance; Retrospective Studies; Reverse Transcriptase Inhibitors; Stavudine; Treatment Outcome; Zidovudine | 2002 |
Impact of stavudine phenotype and thymidine analogues mutations on viral response to stavudine plus lamivudine in ALTIS 2 ANRS trial.
Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV-1; Humans; Inhibitory Concentration 50; Lamivudine; Male; Middle Aged; Molecular Sequence Data; Mutation; Phenotype; RNA, Viral; Stavudine; Zidovudine | 2002 |
Therapeutic responses to AZT + 3TC + EFV in advanced antiretroviral naive HIV type 1-infected Ugandan patients.
Topics: Adult; Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Oxazines; Patient Compliance; Reverse Transcriptase Inhibitors; Uganda; Viral Load; Zidovudine | 2002 |
Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus.
Topics: Adenine; Adult; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2003 |
[Exacerbation of chronic hepatitis B after discontinuing of antiretroviral therapy in HIV infection].
Topics: Adult; Anti-HIV Agents; Diagnosis, Differential; Female; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Lamivudine; Time Factors; Virus Replication | 2002 |
Indirect hyperbilirubinemia with indinavir.
Topics: Adult; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; India; Indinavir; Lamivudine; Liver Function Tests; Needlestick Injuries; Prognosis; Risk Assessment; Severity of Illness Index; Zidovudine | 2002 |
Chronic cough induced by abacavir apart from a context of hypersensitivity.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Chronic Disease; Cough; Cyclopropanes; Dideoxynucleosides; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Middle Aged; Nelfinavir; Oxazines; Reverse Transcriptase Inhibitors; Rhinitis; Sputum; Stavudine; Trimethoprim, Sulfamethoxazole Drug Combination | 2002 |
Estimating the length of the first antiretroviral therapy regiment durability in São Paulo, Brazil.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Brazil; Cohort Studies; Drug Administration Schedule; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Patient Compliance; Retrospective Studies; Time Factors; Zidovudine | 2002 |
HIV--a personal perspective.
Topics: Anti-HIV Agents; HIV Infections; Humans; Lamivudine; Needlestick Injuries; Zidovudine | 2000 |
Preventing HIV transmission.
Topics: Anti-HIV Agents; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Nevirapine; Zidovudine | 2003 |
Antiretroviral resistance associated with supervised treatment interruptions in treated acute HIV infection.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Genes, pol; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Mutation; RNA, Viral | 2003 |
Negligence. Liver transplant patient too late to sue Viramune maker.
Topics: Drug Combinations; Drug Industry; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Liver Failure; Liver Transplantation; Malpractice; Nevirapine; Reverse Transcriptase Inhibitors; Zidovudine | 2003 |
Using a database of HIV patients undergoing genotypic resistance test after HAART failure to understand the dynamics of M184V mutation.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Databases, Factual; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Microbial Sensitivity Tests; Mutation; Reverse Transcriptase Inhibitors; Treatment Failure | 2003 |
Abacavir arm stopped in clinical trial.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Randomized Controlled Trials as Topic; Viral Load; Zidovudine | 2003 |
[Measuring the HIV viral load with LCx (Abbott): importance for the therapeutic follow-up of 3 patients infected by type O HIV].
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Resistance, Multiple, Viral; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Male; Oxazines; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Viral Load; Viremia; Zidovudine | 2003 |
Management of severely immunocompromised human immunodeficiency virus type 1-infected African orphans with structured treatment interruption: another kind of salvage therapy.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; Dideoxynucleosides; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; HIV Infections; HIV-1; Humans; Lamivudine; Lymphocyte Count; Salvage Therapy; Zidovudine | 2003 |
Latrogenic nephrogenic diabetes insipidus.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Diabetes Insipidus, Nephrogenic; HIV Infections; Humans; Indinavir; Lamivudine; Male; Ritonavir; Stavudine | 2003 |
Selection of resistance mutations in pregnant women receiving zidovudine and lamivudine to prevent HIV perinatal transmission.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Mutation; Pregnancy; Retrospective Studies; Zidovudine | 2003 |
The effect of lamivudine on the replication of hepatitis B virus in HIV-infected patients depends on the host immune status (CD4 cell count).
Topics: Adult; CD4 Lymphocyte Count; Female; Hepatitis B; Hepatitis B virus; HIV Infections; HIV-1; Humans; Lamivudine; Male; Retrospective Studies; Reverse Transcriptase Inhibitors; Virus Replication | 2003 |
Trizivir trial halted.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Dideoxynucleosides; Drug Combinations; HIV Infections; Humans; Lamivudine; Zidovudine | 2003 |
[Observational study on the efficacy of the application of two classical regimens of triple antiretroviral therapy].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Didanosine; Drug Evaluation; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Male; Retrospective Studies; Reverse Transcriptase Inhibitors; Stavudine; Time Factors; Treatment Outcome; Viral Load; Zidovudine | 2003 |
Prevalence and characterization of lamivudine-resistant hepatitis B virus mutations in HIV-HBV co-infected individuals.
Topics: Adult; Aged; CD4 Lymphocyte Count; Chronic Disease; Cross-Sectional Studies; DNA, Viral; Drug Resistance, Viral; Female; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Mutation; Prevalence; Regression Analysis; Retrospective Studies; Reverse Transcriptase Inhibitors; Statistics, Nonparametric; Viremia | 2003 |
Sequential cutaneous drug reactions to protease inhibitors in the context of occupational post-exposure prophylaxis.
Topics: Adult; Drug Hypersensitivity; Female; Guideline Adherence; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Needlestick Injuries; Occupational Diseases; Occupational Exposure; Zidovudine | 2003 |
[The first nucleotide analog permitted. New hepatitis B therapy helps the problem patients, too].
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Drug Resistance; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Liver Transplantation; Organophosphonates; Placebos; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors | 2003 |
Management of HIV and hepatitis B or C co-infection in 15 HIV treatment centres. Disparity between protocols and practice.
Topics: Ambulatory Care Facilities; Anti-HIV Agents; Antiviral Agents; Clinical Protocols; Female; Guideline Adherence; Health Services Accessibility; Hepatitis B Vaccines; Hepatitis B, Chronic; Hepatitis C, Chronic; HIV Infections; Humans; Interferons; Lamivudine; Male; Mass Screening; Medical Audit; Polymerase Chain Reaction; Practice Guidelines as Topic; Retrospective Studies; Surveys and Questionnaires; United Kingdom | 2003 |
Vertical transmission of HIV in Rio de Janeiro, Brazil.
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Brazil; Cohort Studies; Developing Countries; Female; HIV Infections; Humans; Infant, Low Birth Weight; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Logistic Models; Pregnancy; Pregnancy Complications, Infectious; Risk Factors; Zidovudine | 2003 |
pol gene sequence variation in Swedish HIV-2 patients failing antiretroviral therapy.
Topics: Adolescent; Adult; Africa, Western; Amino Acid Sequence; Amino Acid Substitution; Anti-HIV Agents; Codon; Drug Resistance, Multiple, Viral; Evolution, Molecular; Female; Genes, pol; Genetic Variation; HIV Infections; HIV Protease Inhibitors; HIV-1; HIV-2; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Molecular Sequence Data; Mutation, Missense; Nelfinavir; Prospective Studies; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Sequence Alignment; Sequence Homology, Amino Acid; Sweden; Treatment Failure; Viremia; Zidovudine | 2003 |
[Antiviral agents for reduction of mother-to-child transmission of HIV infection].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Evidence-Based Medicine; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; Randomized Controlled Trials as Topic; Zidovudine | 2003 |
Thailand's do-it-yourself therapy.
Topics: Anti-HIV Agents; Drug Combinations; Drug Compounding; Drug Costs; Drug Industry; Drugs, Generic; HIV Infections; Humans; Lamivudine; Nevirapine; Stavudine; Thailand | 2003 |
Management of chronic hepatitis B in an HIV-positive patient with 3TC-resistant hepatitis B virus.
Topics: Adenine; Adult; Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Interferon-alpha; Lamivudine; Liver Cirrhosis; Male; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2003 |
Warning issued on non-response rates.
Topics: Adenine; Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; HIV Infections; Humans; Lamivudine; Multicenter Studies as Topic; Organophosphonates; Organophosphorus Compounds; Randomized Controlled Trials as Topic; Tenofovir | 2003 |
Safety and efficacy of switching to alternative nucleoside analogues following symptomatic hyperlactatemia and lactic acidosis.
Topics: Acidosis, Lactic; Adult; Alanine Transaminase; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; Humans; Lactates; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Stavudine; Time Factors; Zidovudine | 2003 |
Triple combinations regimens for HIV.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Multicenter Studies as Topic; Organophosphonates; Organophosphorus Compounds; Oxazines; Randomized Controlled Trials as Topic; Tenofovir; Treatment Failure | 2003 |
Dynamics of plasma hepatitis B virus levels after highly active antiretroviral therapy in patients with HIV infection.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; DNA, Viral; Female; Hepatitis B e Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Polymerase Chain Reaction; Retrospective Studies | 2003 |
Meeting notes from the 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Exploring once-daily tenofovir + 3TC + abacavir: an argument for clinical-trials-based data.
Topics: Adenine; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Organophosphonates; Organophosphorus Compounds; Pilot Projects; Reverse Transcriptase Inhibitors; Tenofovir | 2003 |
Failure of combination abacavir + tenofovir + lamivudine (3TC).
Topics: Adenine; Dideoxynucleosides; HIV Infections; Humans; Lamivudine; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir | 2003 |
Meeting notes from the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Suboptimal response to once-daily abacavir + 3TC + tenofovir.
Topics: Adenine; Anti-HIV Agents; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Multicenter Studies as Topic; Organophosphonates; Organophosphorus Compounds; Randomized Controlled Trials as Topic; Tenofovir | 2003 |
Treatment of chronic hepatitis B in the human immunodeficiency virus-infected patient: present and future.
Topics: Adenine; Anti-HIV Agents; Antiviral Agents; Forecasting; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Interferon-alpha; Lamivudine; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir | 2003 |
AACTG A5095, Trizivir, and the role of all-nucleoside regimens: an editorial.
Topics: CD4 Lymphocyte Count; Clinical Trials as Topic; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Viral Load; Zidovudine | 2003 |
Abandon Trizivir when it's working well? A rebuttal.
Topics: Dideoxynucleosides; HIV Infections; Humans; Lamivudine; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Viral Load; Zidovudine | 2003 |
Q151M-mediated multinucleoside resistance: prevalence, risk factors, and response to salvage therapy.
Topics: Adult; Drug Resistance, Multiple; Female; Glutamine; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Methionine; Microbial Sensitivity Tests; Multivariate Analysis; Prevalence; Reverse Transcriptase Inhibitors; Risk Factors; Salvage Therapy | 2004 |
Treatment of primary HIV-1 infection with nonnucleoside reverse transcriptase inhibitor-based therapy is effective and well tolerated.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4-CD8 Ratio; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Flow Cytometry; HIV Infections; HIV-1; Humans; Lamivudine; Lymphocyte Activation; Lymphocyte Subsets; Male; Middle Aged; Oxazines; Reverse Transcriptase Inhibitors; Viral Load; Zidovudine | 2004 |
The renal tolerance of low-dose adefovir dipivoxil by lamivudine-resistant individuals co-infected with hepatitis B and HIV.
Topics: Adenine; Administration, Oral; Adult; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Viral; Female; Follow-Up Studies; Hepatitis B, Chronic; HIV Infections; Humans; Kidney; Kidney Function Tests; Lamivudine; Male; Maximum Tolerated Dose; Middle Aged; Organophosphonates; Prospective Studies; Risk Assessment; Treatment Outcome | 2004 |
HIVNET 012 and Petra.
Topics: Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; Randomized Controlled Trials as Topic; Treatment Outcome; Zidovudine | 2004 |
Comment: Reasons for early abacavir discontinuation in HIV-infected patients.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; HIV Infections; Humans; Lamivudine; Treatment Refusal; Zidovudine | 2004 |
Conference report - antiretroviral therapy update from the 9th European AIDS Conference.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Age Factors; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Botswana; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; HIV Infections; Humans; Lamivudine; Middle Aged; Pulse Therapy, Drug; Reverse Transcriptase Inhibitors; Salvage Therapy; Viral Load; Zidovudine | 2003 |
Early nonresponse for tenofovir regimen.
Topics: Adenine; Anti-HIV Agents; Dideoxynucleosides; HIV Infections; Humans; Lamivudine; Organophosphonates; Organophosphorus Compounds; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure | 2003 |
Efficacy and safety of ritonavir/indinavir 100/400 mg twice daily in combination with two nucleoside analogues in antiretroviral treatment-naive HIV-infected individuals.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Indinavir; Lamivudine; Male; Middle Aged; Prospective Studies; Ritonavir; Stavudine; Zidovudine | 2003 |
Antiretroviral therapy influences cellular susceptibility to apoptosis in vivo.
Topics: Adult; Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Apoptosis; Drug Combinations; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Zidovudine | 2004 |
In vitro activity of stampidine against primary clinical human immunodeficiency virus isolates.
Topics: Cells, Cultured; Dideoxynucleotides; Drug Resistance, Viral; Genotype; HIV; HIV Infections; HIV-1; Humans; Lamivudine; Mutation; Neutrophils; Phenotype; Reverse Transcriptase Inhibitors; Stavudine; Thymidine Monophosphate; Viral Plaque Assay; Zidovudine | 2004 |
Severe anemia secondary to a probable drug interaction between zidovudine and valproic acid.
Topics: Anemia; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Interactions; Epilepsy, Complex Partial; HIV Infections; Humans; Lamivudine; Male; Valproic Acid; Zidovudine | 2004 |
Antiretroviral therapy and HIV/hepatitis B virus coinfection.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Antiviral Agents; Hepatitis B; Hepatitis B virus; HIV; HIV Infections; Humans; Lamivudine; Organophosphonates; Organophosphorus Compounds; Tenofovir | 2004 |
High rate of virologic failure with once-daily ddI/3TC/TDF.
Topics: Adenine; Didanosine; HIV Infections; Humans; Lamivudine; Organophosphonates; Organophosphorus Compounds; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load | 2003 |
Hair loss in an HIV-1 infected woman receiving lopinavir plus ritonavir therapy as first line HAART.
Topics: Adult; Alopecia; Antiretroviral Therapy, Highly Active; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Nelfinavir; Pyrimidinones; Ritonavir; Stavudine | 2003 |
Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV.
Topics: Adult; Anti-HIV Agents; Brazil; Chemoprevention; Cohort Studies; HIV Infections; HIV Seropositivity; Homosexuality, Male; Humans; Lamivudine; Male; Patient Acceptance of Health Care; Sexual Behavior; Surveys and Questionnaires; Zidovudine | 2004 |
Comparison of generic zidovudine + lamivudine (Cipla, Duovir) and the GlaxoSmithKline brand (Combivir) tablets.
Topics: Chromatography, High Pressure Liquid; Costs and Cost Analysis; Drug Combinations; Drugs, Generic; HIV Infections; Humans; Lamivudine; Tablets; Zidovudine | 2004 |
Mitochondrial effects of antiretroviral therapies in asymptomatic patients.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Base Sequence; Cross-Sectional Studies; Didanosine; DNA Primers; DNA, Mitochondrial; Female; HIV Infections; Humans; Lamivudine; Male; Mitochondria; Nelfinavir; Nevirapine; Polymerase Chain Reaction; Stavudine | 2004 |
EU issues warning about HAART regimen.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Didanosine; Dideoxynucleosides; Drug Resistance, Viral; European Union; HIV Infections; Humans; Lamivudine; Organophosphonates; Organophosphorus Compounds; Patient Selection; Pilot Projects; Safety; Tenofovir; Treatment Failure; Viral Load | 2004 |
Mitochondrial damage and DNA depletion in cord blood and umbilical cord from infants exposed in utero to Combivir.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; DNA, Mitochondrial; Drug Combinations; Female; Fetal Blood; HIV Infections; HIV-1; Humans; Infant, Newborn; Lamivudine; Maternal-Fetal Exchange; Microscopy, Electron; Mitochondria; Pilot Projects; Pregnancy; Pregnancy Complications, Infectious; Prenatal Exposure Delayed Effects; Umbilical Cord; Zidovudine | 2004 |
WHO hopes 3-by-5 plan will reverse Africa's HIV/AIDS epidemic.
Topics: Acquired Immunodeficiency Syndrome; Adult; Africa; Anti-HIV Agents; Child; Developing Countries; Disease Outbreaks; Drug Combinations; Female; Foster Home Care; HIV Infections; Humans; Lamivudine; Male; Nevirapine; Reverse Transcriptase Inhibitors; Stavudine; United Nations; World Health Organization | 2004 |
HIV-1 and hepatitis B virus: time for a re-think?
Topics: Acute Disease; Adult; Aged; Anti-HIV Agents; Drug Resistance, Viral; Female; Hepatitis B; HIV Infections; HIV-1; Humans; Lamivudine; Male | 2004 |
Buffalo hump: what the experts suggest.
Topics: Adult; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Lipodystrophy; Male; Reverse Transcriptase Inhibitors; Zidovudine | 2004 |
Long-term follow-up of HIV/HBV coinfected patients from a Greek center.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Follow-Up Studies; Greece; Hepatitis B; Hepatitis B virus; HIV Infections; HIV-1; Humans; Interferon alpha-2; Interferon-alpha; Lamivudine; Polyethylene Glycols; Recombinant Proteins; Retrospective Studies; Reverse Transcriptase Inhibitors | 2004 |
Lamivudine 300 mg in HIV infection: dose change. Once-a-day dosing.
Topics: Adult; Child; Drug Therapy, Combination; France; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Protease Inhibitors; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 2004 |
[Antiretroviral therapy of acute HIV-infection].
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Combinations; Female; HIV Infections; HIV Seropositivity; Humans; Lamivudine; Lymphocyte Count; Male; Nevirapine; Viral Load; Zidovudine | 2004 |
HIV/AIDS in China. A new treatment campaign, but with limited weapons.
Topics: Academies and Institutes; Acquired Immunodeficiency Syndrome; Anti-HIV Agents; China; Drug Costs; Drug Resistance, Viral; Drug Therapy, Combination; Foundations; HIV; HIV Infections; Humans; Lamivudine; Patents as Topic | 2004 |
Benefits of a rapid HIV test for evaluation of the source patient after occupational exposure of healthcare workers.
Topics: AIDS Serodiagnosis; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Blood-Borne Pathogens; Chemoprevention; Diagnostic Tests, Routine; Health Personnel; HIV Infections; Humans; Immunoenzyme Techniques; Infectious Disease Transmission, Patient-to-Professional; Italy; Lamivudine; Occupational Exposure; Pilot Projects; Zidovudine | 2004 |
Immune reconstitution hepatitis in HIV and hepatitis B coinfection, despite lamivudine therapy as part of HAART.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Immunity; Lamivudine; Middle Aged | 2004 |
Haemolytic anaemia after nucleotide antiretroviral treatment discontinuation in a chronic hepatitis B-virus co-infected AIDS patient.
Topics: Adenine; Adult; Anemia, Hemolytic; Antiretroviral Therapy, Highly Active; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Tenofovir | 2004 |
Management of the coinfected patient: human immunodeficiency virus/hepatitis B and human immunodeficiency virus/hepatitis C.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; Chronic Disease; Contraindications; Hepatitis B; Hepatitis C; HIV Infections; Humans; Lamivudine; Liver Diseases; Nucleosides; Practice Guidelines as Topic | 2004 |
In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
Topics: Adenine; Adult; Antiviral Agents; Cell Line; DNA-Directed DNA Polymerase; DNA, Viral; Dose-Response Relationship, Drug; Drug Resistance, Viral; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Middle Aged; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Transfection; Virus Replication | 2004 |
Nucleoside analogue use before and during highly active antiretroviral therapy and virus load rebound.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Australia; Cohort Studies; Didanosine; Drug Administration Schedule; Europe; Female; HIV Infections; Humans; Lamivudine; Male; Proportional Hazards Models; Reverse Transcriptase Inhibitors; Stavudine; Time Factors; Viral Load; Zidovudine | 2004 |
Zidovudine, lamivudine, and abacavir have different effects on resting cells infected with human immunodeficiency virus in vitro.
Topics: Anti-HIV Agents; Cells, Cultured; Dideoxynucleosides; Drug Evaluation, Preclinical; HIV Core Protein p24; HIV Infections; Humans; Immunotoxins; Lamivudine; Phytohemagglutinins; Receptors, Interleukin-2; Reverse Transcriptase Inhibitors; Zidovudine | 2004 |
Triple-nucleoside regimens versus efavirenz.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Oxazines; Research Design; Reverse Transcriptase Inhibitors; Viral Load; Zidovudine | 2004 |
Fatal interruption of a 3TC-containing regimen in a HIV-infected patient due to re-activation of chronic hepatitis B virus infection.
Topics: Anti-HIV Agents; Drug Administration Schedule; Drug Therapy, Combination; Fatal Outcome; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Virus Activation | 2004 |
Triple-nucleoside regimens versus efavirenz.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Oxazines; Patient Compliance; Reverse Transcriptase Inhibitors; Zidovudine | 2004 |
Sweet's syndrome following abacavir therapy.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Female; Hepatitis C, Chronic; HIV Infections; Humans; Lamivudine; Middle Aged; Nelfinavir; Reverse Transcriptase Inhibitors; Sweet Syndrome; Trimethoprim, Sulfamethoxazole Drug Combination | 2004 |
Hepatitis B virus variants in an HIV-HBV co-infected patient at different periods of antiretroviral treatment with and without lamivudine.
Topics: Adult; Anti-HIV Agents; Cloning, Molecular; DNA-Directed DNA Polymerase; DNA, Viral; Drug Resistance, Viral; Fatal Outcome; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Phylogeny; Polymerase Chain Reaction | 2004 |
[3 years' data of tenofovir. Confirmed as a valuable building block].
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; HIV Reverse Transcriptase; Humans; Lamivudine; Organophosphonates; Oxazines; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir | 2004 |
[Valuable combination partner. Great benefit for therapy naive patients].
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Multicenter Studies as Topic; Oxazines; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Viral Load | 2004 |
[Active prevention and treatment of superinfection with HBV, HCV and HIV].
Topics: Adenine; Antiretroviral Therapy, Highly Active; Hepatitis B, Chronic; Hepatitis C, Chronic; HIV Infections; Humans; Lamivudine; Organophosphonates | 2004 |
Tenofovir: new indication. For first-line antiretroviral therapy: wait and see.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Controlled Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Stavudine; Treatment Outcome; Zidovudine | 2004 |
Safety and efficacy of a simplified fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) for the treatment of advanced HIV-infected patients: a 24-week study.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Prospective Studies; Stavudine | 2004 |
Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Nelfinavir; Oligopeptides; Organophosphonates; Oxazines; Pregnancy; Pyrimidinones; Ritonavir; Stavudine; Sulfonamides; Treatment Outcome; Viral Load; Zidovudine | 2004 |
[Simplified treatments for HIV infection].
Topics: Anti-HIV Agents; Cohort Studies; Dideoxynucleosides; Drug Combinations; HIV Infections; Humans; Lamivudine; Randomized Controlled Trials as Topic; Switzerland; Time Factors; Treatment Outcome; Zidovudine | 2004 |
Effect of concurrent zidovudine use on the resistance pathway selected by abacavir-containing regimens.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Resistance, Viral; Drug Therapy, Combination; Genes, Viral; HIV Infections; HIV-1; Humans; Lamivudine; Mutation; Phenotype; Point Mutation; Retrospective Studies; Reverse Transcriptase Inhibitors; Zidovudine | 2004 |
Tenofovir use in a patient with a severe renal impairment.
Topics: Adenine; Adult; Diabetic Nephropathies; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome | 2004 |
Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment.
Topics: Adenine; Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Chronic Disease; DNA-Directed DNA Polymerase; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Outcome; Viral Load | 2004 |
Long-term efficacy after switch from protease inhibitor-containing highly active antiretroviral therapy to abacavir, lamivudine, and zidovudine.
Topics: Adult; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Middle Aged; Prospective Studies; Reverse Transcriptase Inhibitors; Time Factors; Treatment Failure; Zidovudine | 2004 |
[Patients co-infected with HIV and hepatitis-B virus (HBV): the favourable effect of lamivudine, as part of combined antiretroviral therapy, on HBV may be dependent upon the number of CD4-cells].
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; DNA, Viral; Female; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies; Treatment Outcome | 2004 |
Response to the comparison of generic zidovudine plus lamivudine (Cipla, Duovir) and the GlaxoSmithKline brand (Combivir) tablets.
Topics: Chromatography, High Pressure Liquid; Drug Combinations; Drugs, Generic; HIV Infections; Humans; Lamivudine; Tablets; Zidovudine | 2004 |
Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy.
Topics: Adolescent; Adult; Anti-HIV Agents; Base Sequence; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Mutation; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; Prenatal Care; Reverse Transcriptase Inhibitors; RNA, Viral; Zidovudine | 2005 |
Low rate of treatment failure on antiretroviral therapy with tenofovir, lamivudine and zidovudine.
Topics: Adenine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Organophosphonates; Retrospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Treatment Failure; Zidovudine | 2005 |
Effects of prenatal exposure to Zidovudine and Lamivudine on brainstem auditory evoked potentials in infants from HIV-infected women.
Topics: Adult; Anti-HIV Agents; Apgar Score; Evoked Potentials, Auditory, Brain Stem; Female; HIV Infections; Humans; Infant, Newborn; Lamivudine; Pregnancy; Reverse Transcriptase Polymerase Chain Reaction; Zidovudine | 2004 |
Low cost anti-retroviral options: chloroquine based ARV regimen combined with hydroxyurea and lamivudine: a new economical triple therapy.
Topics: Anti-HIV Agents; Chloroquine; Drug Therapy, Combination; HIV Infections; Humans; Hydroxyurea; Lamivudine | 2004 |
[Simplification to lamivudine, zidovudine, and abacavir therapy: impact on adherence, clinical outcome, and economic issues].
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Costs and Cost Analysis; Dideoxynucleosides; HIV Infections; Humans; Lamivudine; Patient Compliance; Retrospective Studies; Zidovudine | 2004 |
Simultaneous determination of the HIV nucleoside analogue reverse transcriptase inhibitors lamivudine, didanosine, stavudine, zidovudine and abacavir in human plasma by reversed phase high performance liquid chromatography.
Topics: Anti-HIV Agents; Chromatography, High Pressure Liquid; Didanosine; Dideoxynucleosides; Drug Stability; HIV; HIV Infections; Humans; Lamivudine; Quality Control; Reproducibility of Results; Reverse Transcriptase Inhibitors; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Stavudine; Zidovudine | 2005 |
Inhibitory drug levels found in breast milk.
Topics: Anti-Retroviral Agents; Female; HIV Infections; Humans; Infant; Lamivudine; Milk, Human; Nevirapine; Zidovudine | 2004 |
HIV/AIDS following sexual assault in Jamaican children and adolescents: a case for HIV post-exposure prophylaxis.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Anti-HIV Agents; Chemoprevention; Child; Child Abuse, Sexual; Drug Therapy, Combination; Female; HIV Infections; Humans; Jamaica; Lamivudine; Male; Rape; Risk Factors; Zidovudine | 2004 |
Combination pill approved in Europe.
Topics: Adolescent; Adult; Anti-HIV Agents; Dideoxynucleosides; Drug Approval; Drug Combinations; Europe; HIV Infections; Humans; Lamivudine | 2005 |
Top stories of 2004. To 3TC or not to 3TC?
Topics: Drug Administration Schedule; Drug Resistance, Viral; HIV Infections; Humans; Lamivudine; Mutation; Reverse Transcriptase Inhibitors | 2005 |
Meeting notes from ICAAC. Tenofovir + emtricitabine vs. AZT + 3TC.
Topics: Adenine; CD4 Lymphocyte Count; Deoxycytidine; Emtricitabine; HIV Infections; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load; Zidovudine | 2005 |
Field efficacy of zidovudine, lamivudine and single-dose nevirapine to prevent peripartum HIV transmission.
Topics: Adult; Anti-HIV Agents; Cote d'Ivoire; Developing Countries; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Nevirapine; Perinatal Care; Pregnancy; Pregnancy Complications, Infectious; Prenatal Care; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Viral Load; Zidovudine | 2005 |
Selection of a rare resistance profile in an HIV-1-infected patient exhibiting a failure to an antiretroviral regimen including tenofovir DF.
Topics: Adenine; Adult; Anti-HIV Agents; Didanosine; Dideoxynucleosides; Drug Resistance, Viral; Female; Gabon; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Lopinavir; Microbial Sensitivity Tests; Mutation; Organophosphonates; Pyrimidinones; Tenofovir; Viral Load | 2005 |
Predictors of residual viremia in HIV-infected patients successfully treated with efavirenz and lamivudine plus either tenofovir or stavudine.
Topics: Adenine; Adolescent; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; DNA, Viral; Female; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Multivariate Analysis; Organophosphonates; Oxazines; RNA, Viral; Stavudine; Tenofovir; Viremia | 2005 |
Two-once-daily fixed-dose NRTI combinations for HIV.
Topics: Anti-HIV Agents; Deoxycytidine; Dideoxynucleosides; Dose-Response Relationship, Drug; Drug Combinations; Drug Hypersensitivity; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; Humans; Lamivudine; Organophosphorus Compounds | 2005 |
Postexposure prophylaxis after sexual assaults: a prospective cohort study.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Brazil; Child; Child, Preschool; Cohort Studies; Drug Administration Schedule; Female; HIV Infections; Humans; Indinavir; Lamivudine; Male; Middle Aged; Nelfinavir; Patient Compliance; Prospective Studies; Rape; Sexually Transmitted Diseases; Zidovudine | 2005 |
Early virologic failure in a pilot study evaluating the efficacy of therapy containing once-daily abacavir, lamivudine, and tenofovir DF in treatment-naive HIV-infected patients.
Topics: Adenine; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Organophosphonates; Pilot Projects; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure; Viral Load | 2005 |
Rapid viral load suppression following generic highly active antiretroviral therapy in Southern Indian HIV-infected patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drugs, Generic; Female; HIV Infections; HIV-1; Humans; India; Lamivudine; Male; Middle Aged; Oxazines; Prospective Studies; Tablets; Treatment Outcome; Viral Load; Zidovudine | 2005 |
[Meningeal cryptococcosis as a sign of immune reconstitution syndrome].
Topics: Adult; AIDS-Related Opportunistic Infections; Amphotericin B; Anti-HIV Agents; Antifungal Agents; Antiretroviral Therapy, Highly Active; CD4-Positive T-Lymphocytes; Fluconazole; Flucytosine; HIV Infections; Humans; Immunologic Memory; Lamivudine; Lopinavir; Male; Meningitis, Cryptococcal; Pyrimidinones; Recurrence; Ritonavir; Syndrome; T-Lymphocyte Subsets; Zidovudine | 2005 |
Copackaged drug regimen approved for PEPFAR.
Topics: Adult; Drug Combinations; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Zidovudine | 2005 |
Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, Malawi.
Topics: Adolescent; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cross-Sectional Studies; Drug Therapy, Combination; Fees and Charges; Female; HIV Infections; Humans; Lamivudine; Malawi; Male; Middle Aged; Nevirapine; Patient Compliance; Stavudine; Treatment Failure; Treatment Outcome; Viral Load | 2005 |
Switching from protease inhibitors to a single-class regimen of abacavir/lamivudine/zidovudine plus tenofovir in patients with HIV load suppression.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load; Zidovudine | 2005 |
Emtricitabine: new preparation. An antiretroviral very similar to lamivudine.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Clinical Trials as Topic; Deoxycytidine; Drugs, Investigational; France; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Viral Load | 2005 |
The use of a triple nucleoside-nucleotide regimen for nonoccupational HIV post-exposure prophylaxis.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Chi-Square Distribution; HIV Infections; Humans; Lamivudine; Male; Nelfinavir; Organophosphonates; Reverse Transcriptase Inhibitors; Risk Assessment; Risk-Taking; Stavudine; Tenofovir; Zidovudine | 2005 |
Recurrence of post-traumatic stress disorder and antiretrovirals.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4-Positive T-Lymphocytes; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Recurrence; RNA, Viral; Stress Disorders, Post-Traumatic; Viral Load; Zidovudine | 2005 |
Discrimination of lamivudine resistant minor HIV-1 variants by selective real-time PCR.
Topics: DNA Primers; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Lamivudine; Point Mutation; Polymerase Chain Reaction; Prevalence; Reproducibility of Results; Reverse Transcriptase Inhibitors; Sensitivity and Specificity; Sweden | 2005 |
No pharmacokinetic drug-drug interaction between nevirapine and paclitaxel.
Topics: Adult; Anti-HIV Agents; Antineoplastic Agents, Phytogenic; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Monitoring; HIV Infections; HIV-1; Humans; Lamivudine; Leg; Male; Nevirapine; Paclitaxel; Palatal Neoplasms; Sarcoma, Kaposi; Skin Neoplasms; Stavudine | 2005 |
Screen for underlying HIV before antiviral treatment for HBV.
Topics: Adult; Antiretroviral Therapy, Highly Active; Contraindications; Drug Resistance, Viral; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Lamivudine; Male; Treatment Failure | 2005 |
Prospective study on the prevention of vertical transmission of HIV in Campo Grande, Mato Grosso do Sul, Brazil, from 1996 to 2001.
Topics: Adolescent; Adult; Anti-HIV Agents; Brazil; Cohort Studies; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Pregnancy; Pregnancy Complications, Infectious; Prospective Studies; Risk Factors; Viral Load; Zidovudine | 2005 |
Effect of antiretroviral drugs on maternal CD4 lymphocyte counts, HIV-1 RNA levels, and anthropometric parameters of their neonates.
Topics: Adolescent; Adult; Anti-HIV Agents; Birth Weight; Case-Control Studies; CD4 Lymphocyte Count; Female; Fetal Development; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Nelfinavir; Pregnancy; Pregnancy Complications, Infectious; Prospective Studies; RNA, Viral; Zidovudine | 2005 |
Antiviral activity of lamivudine in salvage therapy for multidrug-resistant HIV-1 infection.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Multiple, Viral; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation; RNA, Viral; Salvage Therapy; Viral Load | 2005 |
Lack of resistant mutation development after receiving short-course zidovudine plus lamivudine to prevent mother-to-child transmission.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Mutation; Pregnancy; Pregnancy Complications, Infectious; Zidovudine | 2005 |
Reactivation of hepatitis B in an HIV-infected patient with antibodies against hepatitis B core antigen as the only serological marker.
Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Aspartate Aminotransferases; Biomarkers; DNA, Viral; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Core Antigens; HIV Infections; Humans; Lamivudine; Male; Recurrence | 2005 |
Severe efavirenz-induced hypersensitivity syndrome (not-DRESS) with acute renal failure.
Topics: Acute Kidney Injury; Adenine; Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Hypersensitivity; Ghana; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Mycobacterium tuberculosis; Organophosphonates; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; Tuberculosis | 2006 |
Intracellular pharmacokinetics of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in patients receiving triple-nucleoside regimens.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Cytidine Triphosphate; Dideoxynucleosides; Dideoxynucleotides; Drug Interactions; Female; HIV Infections; Humans; Lamivudine; Leukocytes, Mononuclear; Male; Middle Aged; Organophosphonates; Prospective Studies; Tenofovir | 2005 |
Lactic acidosis caused by nucleoside analogues.
Topics: Acidosis, Lactic; Female; HIV Infections; Humans; Lamivudine; Middle Aged; Reverse Transcriptase Inhibitors; Stavudine; Treatment Outcome | 2005 |
Genital HIV-1 viral load is correlated with blood plasma HIV-1 viral load in Brazilian women and is reduced by antiretroviral therapy.
Topics: Adult; Alkynes; Anti-Retroviral Agents; Benzoxazines; Brazil; Cervix Uteri; Cross-Sectional Studies; Cyclopropanes; Female; Genitalia, Female; HIV Infections; HIV-1; Humans; Lamivudine; Longitudinal Studies; Nelfinavir; Prevalence; Time Factors; Vagina; Viral Load; Zidovudine | 2006 |
Determination of nevirapine and efavirenz in plasma using GC/MS in selected ion monitoring mode.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Calibration; Cyclopropanes; Dose-Response Relationship, Drug; Drug Monitoring; Gas Chromatography-Mass Spectrometry; HIV Infections; Humans; Ions; Lamivudine; Molecular Structure; Nevirapine; Oxazines; Reproducibility of Results | 2005 |
Antiretroviral therapy--alternative uses.
Topics: Anti-Retroviral Agents; Breast; Cosmetic Techniques; Drug Combinations; Drug Resistance, Viral; Female; HIV Infections; Humans; Lamivudine; Zidovudine | 2005 |
FDA notifications. Tentative approval of generic lamivudine.
Topics: Drug Approval; Drug Therapy, Combination; Drugs, Generic; HIV Infections; Lamivudine; Reverse Transcriptase Inhibitors; United States; United States Food and Drug Administration | 2005 |
Atazanavir signature I50L resistance substitution accounts for unique phenotype of increased susceptibility to other protease inhibitors in a variety of human immunodeficiency virus type 1 genetic backbones.
Topics: Amino Acid Substitution; Atazanavir Sulfate; Blotting, Western; Cell Line; Dose-Response Relationship, Drug; Drug Resistance, Viral; Genes, Viral; Genetic Vectors; HIV Core Protein p24; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Mutation; Oligopeptides; Phenotype; Pyridines; Reverse Transcriptase Inhibitors | 2005 |
Pharmacokinetics of nevirapine in HIV-infected children receiving an adult fixed-dose combination of stavudine, lamivudine and nevirapine.
Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; Cross-Sectional Studies; Drug Combinations; Drug Evaluation; Female; HIV Infections; Humans; Infant; Lamivudine; Male; Nevirapine; Stavudine; Tablets | 2005 |
Generic nucleoside approved.
Topics: Anti-HIV Agents; Drug Approval; Drugs, Generic; HIV Infections; Humans; India; Lamivudine; United States; United States Food and Drug Administration | 2005 |
The effect of long-term storage on measured plasma lactate concentrations and prospective lactate results from a multicenter trial of antiretroviral therapy.
Topics: Acidosis, Lactic; Anti-HIV Agents; Blood Preservation; Blood Specimen Collection; Didanosine; HIV Infections; Humans; Lactates; Lamivudine; Multicenter Studies as Topic; Oxalates; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Sodium Fluoride; Specimen Handling; Stavudine; Time Factors; Zidovudine | 2005 |
Adherence to combined Lamivudine + Zidovudine versus individual components: a community-based retrospective medicaid claims analysis.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Epidemiologic Methods; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Medicaid; Middle Aged; Patient Compliance; Zidovudine | 2005 |
Replicative fitness of historical and recent HIV-1 isolates suggests HIV-1 attenuation over time.
Topics: Amides; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cells, Cultured; Coculture Techniques; Dendritic Cells; HIV Infections; HIV-1; Humans; Lamivudine; Leukocytes, Mononuclear; Microbial Sensitivity Tests; Phylogeny; Quaternary Ammonium Compounds; Viral Load; Virulence; Virus Replication | 2005 |
Life-threatening maternal and fetal macrocytic anemia from antiretroviral therapy.
Topics: Adult; Anemia, Macrocytic; Anti-HIV Agents; Cesarean Section; Drug Therapy, Combination; Female; Fetal Diseases; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Pregnancy; Pregnancy Complications, Hematologic; Pregnancy Complications, Infectious; Pregnancy Outcome; Viral Load; Zidovudine | 2005 |
Less than the sum of its parts: failure of a tenofovir-abacavir-Lamivudine triple-nucleoside regimen.
Topics: Adenine; Anti-HIV Agents; Dideoxynucleosides; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Organophosphonates; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure | 2005 |
Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Dideoxynucleosides; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Oxazines; Prospective Studies; Reverse Transcriptase Inhibitors; Treatment Failure; Treatment Outcome; Viral Load; Zidovudine | 2005 |
Detection and quantification of proviral HIV-1 184 M/V in circulating CD4(+) T cells of patients on HAART with a viremia less than 1,000 copies/ml.
Topics: Adult; Aged; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4-Positive T-Lymphocytes; Cross-Sectional Studies; DNA, Viral; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation; Proviruses; Viremia | 2005 |
Inhibition of drug-resistant HIV-1 by RNA interference.
Topics: Dose-Response Relationship, Drug; Drug Resistance, Viral; HeLa Cells; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; RNA Interference; RNA, Small Interfering; Virus Replication | 2006 |
Mass needle stick injury in children from the Western cape.
Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Communicable Disease Control; Environmental Exposure; Hepatitis B; Hepatitis B Vaccines; HIV Infections; Humans; Lamivudine; Longitudinal Studies; Medical Waste; Needlestick Injuries; South Africa; Treatment Outcome; Zidovudine | 2006 |
Tumour necrosis factor alpha in fat redistribution syndromes associated with combination antiretroviral therapy in HIV-1-infected patients: potential role in subcutaneous adipocyte apoptosis.
Topics: 3T3 Cells; Adipocytes; Adult; Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Apoptosis; Case-Control Studies; Female; HIV Infections; HIV-1; Humans; In Situ Nick-End Labeling; Lamivudine; Lipodystrophy; Male; Mice; Middle Aged; Prospective Studies; Receptors, Tumor Necrosis Factor, Type I; Receptors, Tumor Necrosis Factor, Type II; Staining and Labeling; Stavudine; Tumor Necrosis Factor-alpha | 2005 |
Hypertriglyceridemia and hypercholesterolemia in human immunodeficiency virus-1-infected children treated with protease inhibitors.
Topics: Adolescent; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; Humans; Hypercholesterolemia; Hypertriglyceridemia; Infant; Lamivudine; Male; Ritonavir; Saquinavir; Zidovudine | 2006 |
[Detection of HIV infection in pregnant women by rapid testing: a successful strategy to reduce its vertical transmission].
Topics: Adolescent; Adult; Anti-HIV Agents; Blotting, Western; Enzyme-Linked Immunosorbent Assay; Female; HIV Antibodies; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Middle Aged; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; Pregnancy Outcome; Prevalence; Uruguay; Zidovudine | 2005 |
Antiretroviral treatment in the Northern Cape.
Topics: Adolescent; Alkynes; Anti-Retroviral Agents; Benzoxazines; CD4 Lymphocyte Count; Child; Child, Preschool; Cyclopropanes; HIV Infections; Humans; Infant; Lamivudine; Lopinavir; Nevirapine; Oxazines; Pyrimidinones; Ritonavir; South Africa; Stavudine; Viral Load | 2005 |
Frequency of drug-resistant variants of HIV-1 coexistent with wild-type in treatment-naive patients of India.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Child; Child, Preschool; Drug Resistance, Viral; Female; Genes, pol; HIV Infections; HIV-1; Humans; India; Infant; Lamivudine; Male; Middle Aged; Mutation; Zidovudine | 2005 |
Cytokine profiles in human immunodeficiency virus-infected children treated with highly active antiretroviral therapy.
Topics: Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Child; Clinical Trials as Topic; Cytokines; Dideoxynucleosides; Drug Combinations; HIV Infections; Humans; Lamivudine; Practice Guidelines as Topic; Practice Patterns, Physicians'; Prognosis; Treatment Outcome; Zidovudine | 2005 |
[New fixed once daily combination as nucleoside backbone. Basis for long-term therapy success].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; Deoxyribonucleosides; Dideoxynucleosides; Drug Combinations; HIV Infections; Humans; Lamivudine; Long-Term Care; Reverse Transcriptase Inhibitors | 2005 |
Occult hepatitis B virus infection before and 1 year after start of HAART in HIV type 1-positive patients.
Topics: Adult; Amino Acid Substitution; Antiretroviral Therapy, Highly Active; DNA, Viral; Female; Genotype; Hepatitis B; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Mutation; Sequence Analysis, DNA | 2005 |
Effectiveness and safety of abacavir, lamivudine, and zidovudine in antiretroviral therapy-naive HIV-infected patients: results from a large multicenter observational cohort.
Topics: Adult; Anti-HIV Agents; Cohort Studies; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Hypersensitivity; Lamivudine; Male; Patient Compliance; Retrospective Studies; Spain; Treatment Failure; Zidovudine | 2006 |
HIV-1 reverse transcriptase gene 103K/N and 184M/V combinations in tandem: detection and quantification of HIV-1 populations in the CD45RO+ T-cell compartment by a double-ARMS real-time PCR assay.
Topics: Adult; Aged; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Cross-Sectional Studies; Cyclopropanes; Genes, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Immunologic Memory; Lamivudine; Leukocyte Common Antigens; Male; Middle Aged; Mutation; Nevirapine; Oxazines; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; T-Lymphocytes; Viral Load | 2006 |
Wild type and YMDD variant of hepatitis B virus: no difference in viral kinetics on lamivudine/tenofovir therapy in HIV-HBV co-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; DNA, Viral; Drug Resistance, Viral; Genetic Variation; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Kinetics; Lamivudine; Male; Middle Aged; Organophosphonates; RNA, Viral; Tenofovir | 2006 |
Low risk of nevirapine resistance mutations in the prevention of mother-to-child transmission of HIV-1: Agence Nationale de Recherches sur le SIDA Ditrame Plus, Abidjan, Cote d'Ivoire.
Topics: Cote d'Ivoire; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Mothers; Mutation; Nevirapine; Perinatal Care; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors; Viral Load; Zidovudine | 2006 |
[HIV infection presenting with bilateral optic neuropathy].
Topics: AIDS Serodiagnosis; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Disease Progression; Drug Therapy, Combination; Evoked Potentials, Visual; Facial Nerve Diseases; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Ischemia; Lamivudine; Lopinavir; Male; Meningitis, Viral; Methylprednisolone; Middle Aged; Optic Disk; Optic Nerve Diseases; Polyradiculopathy; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Visual Fields; Zidovudine | 2006 |
Dynamics of proviral HIV-1 184M/V in circulating CD4+ T-cells: a 90 days follow-up study after initiation/switch of HAART.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Antigens; CD4-Positive T-Lymphocytes; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lamivudine; Mutation; Prospective Studies; Viral Load | 2006 |
Long-term experience with combination antiretroviral therapy that contains nelfinavir for up to 7 years in a pediatric cohort.
Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Child; Child, Preschool; Disease Progression; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant; Lamivudine; Nelfinavir; Reverse Transcriptase Inhibitors; Stavudine; Treatment Failure | 2006 |
Anti-hepatitis B virus efficacy of tenofovir disoproxil fumarate in HIV-infected patients.
Topics: Adenine; Adult; Antiviral Agents; Cohort Studies; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepatitis B; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Retrospective Studies; Tenofovir; Treatment Outcome | 2006 |
Antiretroviral nucleosides, deoxynucleotide carrier and mitochondrial DNA: evidence supporting the DNA pol gamma hypothesis.
Topics: Animals; DNA; DNA, Mitochondrial; Echocardiography; Genes, pol; HIV Infections; HIV-1; Humans; Immunoblotting; Lamivudine; Membrane Transport Proteins; Mice; Mice, Transgenic; Microscopy, Electron, Transmission; Mitochondria, Heart; Mitochondrial Membrane Transport Proteins; Models, Molecular; Myocardium; Reverse Transcriptase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; Stavudine; Zidovudine | 2006 |
Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy.
Topics: Adult; Alkynes; Anti-HIV Agents; Area Under Curve; Benzoxazines; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Nevirapine; Oxazines; Patient Compliance; Proportional Hazards Models; Prospective Studies; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; RNA, Viral; ROC Curve; Stavudine | 2006 |
Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Resistance, Viral; Genes, pol; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Immune Tolerance; Lamivudine; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; Viral Envelope Proteins; Viral Load; Viremia | 2006 |
Virological response to HIV-1 nucleoside/nucleotide reverse transcriptase inhibitors-based, tenofovir DF-including regimens in the ANRS Aquitaine Cohort.
Topics: Adenine; Cohort Studies; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; France; HIV Infections; HIV Reverse Transcriptase; HIV-1; Hospitals, University; Humans; Lamivudine; Mutation; Organophosphonates; Retrospective Studies; Reverse Transcriptase Inhibitors; Species Specificity; Tenofovir; Treatment Outcome; Viral Load; Zidovudine | 2006 |
Unrecognized near-fatal hyperlactatemia in an HIV-infected infant exposed to nucleoside reverse transcriptase inhibitors.
Topics: Anti-HIV Agents; Female; HIV Infections; Humans; Infant, Newborn; Lactates; Lamivudine; Male; Mitochondria; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 2007 |
Real-time nucleic acid sequence-based amplification assay to quantify changes in mitochondrial DNA concentrations in cell cultures and blood cells from HIV-infected patients receiving antiviral therapy.
Topics: Anti-HIV Agents; Base Sequence; Blood Platelets; Cell Nucleus; Cells, Cultured; Didanosine; DNA, Mitochondrial; Drug Therapy, Combination; Feasibility Studies; Fibroblasts; HIV Infections; Humans; Indinavir; Lactic Acid; Lamivudine; Leukocytes, Mononuclear; Nucleic Acid Amplification Techniques; Pyruvic Acid; Stavudine; Zalcitabine | 2006 |
Cerebral vasculopathy with aneurysm formation in HIV-infected young adults.
Topics: Adult; Anti-HIV Agents; Female; Fibrinolytic Agents; HIV Infections; Humans; Intracranial Aneurysm; Lamivudine; Stroke | 2006 |
Emtricitabine intolerance in treatment-experienced patients switched from lamivudine: a method of assessing toxicity.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Emtricitabine; HIV Infections; Humans; Lamivudine; Randomized Controlled Trials as Topic; Viral Load | 2006 |
Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Prospective Studies; Reverse Transcriptase Inhibitors; Tenofovir; Viral Load; Viremia; Zidovudine | 2006 |
Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Developing Countries; Drug Administration Schedule; Drugs, Generic; Epidemiologic Methods; Female; HIV Infections; Humans; Lamivudine; Male; Medically Underserved Area; Nevirapine; Reverse Transcriptase Inhibitors; Stavudine; Treatment Outcome | 2006 |
Investigating new antiretroviral combinations.
Topics: Adenine; Anti-HIV Agents; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Organophosphonates; Pilot Projects; Randomized Controlled Trials as Topic; Tenofovir | 2006 |
Adherence and acceptability of once daily Lamivudine and abacavir in human immunodeficiency virus type-1 infected children.
Topics: Adolescent; Age Factors; Child; Child, Preschool; Dideoxynucleosides; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lamivudine; Male; Patient Acceptance of Health Care; Patient Compliance; Prospective Studies; Risk Assessment; Sex Factors; Single-Blind Method; Treatment Outcome; United Kingdom; Viral Load | 2006 |
Tenofovir DF and emtricitabine vs. zidovudine and lamivudine.
Topics: Adenine; Anti-Retroviral Agents; Bias; Data Interpretation, Statistical; Deoxycytidine; Emtricitabine; HIV Infections; Humans; Lamivudine; Organophosphonates; Research Design; Tenofovir; Zidovudine | 2006 |
Electronic chip fights counterfeiting.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; Drug Industry; Drug Labeling; Electronics; Fraud; HIV Infections; Humans; Lamivudine; United States; Zidovudine | 2006 |
Virologic and immunologic efficacy of the tenofovir/didanosine/lamivudine regimen.
Topics: Adenine; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2006 |
Tenofovir DF and emtricitabine vs. zidovudine and lamivudine.
Topics: Adenine; Bone Density; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; HIV; HIV Infections; Humans; Lamivudine; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Zidovudine | 2006 |
Virological and immunological response to Combivir and emergence of drug resistance mutations in a cohort of HIV-2 patients in The Gambia.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Combinations; Drug Resistance, Viral; HIV Infections; HIV-2; Humans; Lamivudine; Mutation; Viral Load; Zidovudine | 2006 |
Rapid improvement of liver function in a patient with HIV and hepatitis B coinfection treated with lamivudine and tenofovir.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; Hepatitis; HIV Infections; Humans; Lamivudine; Liver Function Tests; Organophosphonates; Tenofovir; Zidovudine | 2006 |
Plasma lipid concentrations after 1.5 years of exposure to nevirapine or efavirenz together with stavudine and lamivudine.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cholesterol; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Lipids; Lipoproteins; Nevirapine; Oxazines; Reverse Transcriptase Inhibitors; Stavudine; Triglycerides | 2006 |
Lamivudine monotherapy in an HIV-infected patient with the M184V mutation.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Hepatitis; HIV Infections; HIV-1; Humans; Hypertriglyceridemia; Lamivudine; Male; Middle Aged | 2006 |
Mitochondrial dysfunction following perinatal exposure to nucleoside analogues.
Topics: Anti-HIV Agents; Child; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Lamivudine; Mitochondrial Diseases; Nervous System Diseases; Pregnancy; Pregnancy Complications, Infectious; Prenatal Exposure Delayed Effects; Zidovudine | 2006 |
Long-term safety and tolerability of the lamivudine/abacavir combination as components of highly active antiretroviral therapy.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Controlled Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; Drug Hypersensitivity; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Incidence; Lamivudine; Male; Oxazines; Prospective Studies; Time Factors; Treatment Outcome; Zidovudine | 2006 |
Impact of lamivudine on the risk of liver-related death in 2,041 HBsAg- and HIV-positive individuals: results from an inter-cohort analysis.
Topics: Adult; Carcinoma, Hepatocellular; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis C Antibodies; HIV Infections; Humans; Lamivudine; Liver Neoplasms; Male; Retrospective Studies; Reverse Transcriptase Inhibitors; Risk Factors; Survival Analysis | 2006 |
Long-term follow-up of patients with initial early virologic failure after being treated with once-daily tenofovir/abacavir/lamivudine.
Topics: Adenine; Anti-HIV Agents; Dideoxynucleosides; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Follow-Up Studies; HIV; HIV Infections; Humans; Lamivudine; Organophosphonates; RNA, Viral; Tenofovir; Treatment Failure | 2006 |
Virological outcome of chronic hepatitis B virus infection in HIV-coinfected patients receiving anti-HBV active antiretroviral therapy.
Topics: Adenine; Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Chi-Square Distribution; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Regression Analysis; RNA, Viral; Statistics, Nonparametric; Tenofovir; Treatment Outcome | 2006 |
Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV.
Topics: Adult; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Benzoxazines; CD4 Lymphocyte Count; Chromatography, High Pressure Liquid; Cyclopropanes; Didanosine; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Longitudinal Studies; Male; Oxazines; Rifampin; Treatment Outcome; Tuberculosis, Pulmonary; Viral Load | 2006 |
Diminished selection for thymidine-analog mutations associated with the presence of M184V in Ethiopian children infected with HIV subtype C receiving lamivudine-containing therapy.
Topics: Anti-HIV Agents; Child; Child, Preschool; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant; Inhibitory Concentration 50; Lamivudine; Male; Microbial Sensitivity Tests; Mutation; Phenotype; Reverse Transcriptase Inhibitors; Selection, Genetic; Thymidine; Virus Replication; Zidovudine | 2006 |
Patterns of hepatitis B virus infection in Brazilian human immunodeficiency virus infected patients: high prevalence of occult infection and low frequency of lamivudine resistant mutations.
Topics: Adult; Anti-HIV Agents; Brazil; DNA, Viral; Drug Resistance, Viral; Enzyme-Linked Immunosorbent Assay; Female; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Core Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Risk Factors; Viral Load | 2006 |
Persistence of a sexually transmitted highly resistant HIV-1: pol quasispecies evolution over 33 months in the absence of treatment.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; Genes, pol; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Reverse Transcriptase Inhibitors; Viral Load | 2006 |
The M184V mutation: what it does, how to prevent it, and what to do with it when it's there.
Topics: Anti-HIV Agents; Deoxycytidine; Drug Resistance, Viral; Emtricitabine; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Virus Physiological Phenomena | 2006 |
[Effects of traditional Chinese medicine on CD4 + T cell counts and HIV viral loads during structured treatment interruption in highly active antiretroviral therapy].
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Follow-Up Studies; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Phytotherapy; Time Factors; Treatment Outcome; Viral Load; Zidovudine | 2006 |
Weight and body shape changes in a treatment-naive population after 6 months of nevirapine-based generic highly active antiretroviral therapy in South India.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Composition; Body Weight; CD4 Lymphocyte Count; Cohort Studies; Female; HIV Infections; Humans; India; Lamivudine; Male; Nevirapine; Stavudine; Zidovudine | 2007 |
Report from the XVI International AIDS Conference. Efavirenz for high viral load and low CD4--a secondary analysis of ACTG 5095.
Topics: Alkynes; Benzoxazines; CD4 Lymphocyte Count; Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; HIV Infections; Humans; Lamivudine; Oxazines; Reverse Transcriptase Inhibitors; Viral Load; Zidovudine | 2006 |
Aminotransferase elevation in HIV/hepatitis B virus co-infected patients treated with two active hepatitis B virus drugs.
Topics: Adenine; Adult; Antiretroviral Therapy, Highly Active; DNA, Viral; Female; Hepatitis B; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir; Transaminases | 2006 |
Simultaneous measurement of intracellular triphosphate metabolites of zidovudine, lamivudine and abacavir (carbovir) in human peripheral blood mononuclear cells by combined anion exchange solid phase extraction and LC-MS/MS.
Topics: Chromatography, High Pressure Liquid; Dideoxynucleosides; HIV Infections; Humans; Lamivudine; Phosphates; Reference Standards; Reverse Transcriptase Inhibitors; Tandem Mass Spectrometry; Zidovudine | 2007 |
Painless periungual pyogenic granulomata associated with reverse transcriptase inhibitor therapy in a patient with human immunodeficiency virus infection.
Topics: Anti-HIV Agents; Drug Combinations; Granuloma, Pyogenic; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Nail Diseases; Reverse Transcriptase Inhibitors; Zidovudine | 2007 |
Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails.
Topics: Adult; Cohort Studies; Developing Countries; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Male; Nevirapine; Reverse Transcriptase Inhibitors; Stavudine; Thailand; Treatment Failure; Viral Load | 2007 |
Drug resistance after failure of initial antiretroviral therapy in resource-limited countries.
Topics: Developing Countries; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Nevirapine; Protease Inhibitors; Reverse Transcriptase Inhibitors; Stavudine; Treatment Failure; Viral Load | 2007 |
Persistence of lamivudine-sensitive HIV-1 quasispecies in the presence of lamivudine in vitro and in vivo.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Kinetics; Lamivudine; Mutation; Retrospective Studies; RNA, Viral; T-Lymphocytes; Time Factors; Viral Load; Virus Replication; Zidovudine | 2007 |
Anti-HIV agents. Abacavir--as good as AZT?
Topics: Adult; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Viral Load; Zidovudine | 2003 |
Anti-HIV agents. Low rate of early virologic failure seen with a combination of Trizivir and tenofovir.
Topics: Adenine; Dideoxynucleosides; Drug Combinations; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Organophosphonates; Tenofovir; Viral Load; Zidovudine | 2004 |
Hepatitis B virus genotypes and lamivudine resistance mutations in HIV/hepatitis B virus-coinfected patients.
Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; Female; Genes, Viral; Genotype; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Mutation | 2007 |
Lamivudine and famciclovir treatment in HIV patients with acute hepatitis B virus infection and hepatitis B reactivation.
Topics: 2-Aminopurine; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Famciclovir; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Reverse Transcriptase Inhibitors; Virus Activation | 2007 |
Abacavir hypersensitivity reaction after switching from the twice-daily to the once-daily formulation.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Drug Administration Schedule; Drug Hypersensitivity; HIV Infections; Humans; Lamivudine; Male; Oxazines; RNA, Viral | 2007 |
Both long-term HIV infection and highly active antiretroviral therapy are independent risk factors for early carotid atherosclerosis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atherosclerosis; Carotid Arteries; Carotid Artery Diseases; Case-Control Studies; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Risk Factors; Tunica Intima | 2008 |
Evidence of ongoing immune reconstitution in subjects with sustained viral suppression following 6 years of lopinavir-ritonavir treatment.
Topics: Adult; Anti-HIV Agents; Biomarkers; CD4-CD8 Ratio; Clinical Trials, Phase II as Topic; Cohort Studies; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Pyrimidinones; Ritonavir; RNA, Viral; Stavudine | 2007 |
Clinical toxicity of highly active antiretroviral therapy in a home-based AIDS care program in rural Uganda.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Chemical and Drug Induced Liver Injury; Cyclopropanes; Exanthema; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Multivariate Analysis; Nevirapine; Pancreatitis; Peripheral Nervous System Diseases; Proportional Hazards Models; Rural Health; Stavudine; Survival Analysis; Uganda | 2007 |
Identification of lamivudine conformers by Raman scattering measurements and quantum chemical calculations.
Topics: HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Models, Molecular; Powders; Quantum Theory; Reverse Transcriptase Inhibitors; Spectrum Analysis, Raman | 2007 |
Cervical lipomatosis in HIV-infected patients: a case-control study.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Case-Control Studies; Cohort Studies; Female; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Humans; Lamivudine; Lipomatosis; Logistic Models; Male; Middle Aged; Prevalence; Risk Factors; Spain; Spinal Diseases; Stavudine | 2007 |
Experience with the use of a first-line regimen of stavudine, lamivudine and nevirapine in patients in the TREAT Asia HIV Observational Database.
Topics: Adult; Anti-HIV Agents; Asia; Australia; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Nevirapine; Stavudine; Treatment Outcome | 2007 |
Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Child; Child Development; Child, Preschool; Cholesterol; Cohort Studies; Cyclopropanes; Didanosine; Dideoxynucleosides; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Viral; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Infant; Lamivudine; Male; Oxazines; Patient Compliance; Prospective Studies; Treatment Outcome | 2007 |
Rare selection of the K65R mutation in antiretroviral-naive patients failing a first-line abacavir/ lamivudine-containing HAART regimen.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Failure; Viral Load | 2006 |
Plasma lopinavir trough levels in a group of pregnant women on lopinavir, ritonavir, zidovudine, and lamivudine.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Lopinavir; Pregnancy; Pregnancy Complications, Infectious; Prospective Studies; Pyrimidinones; Ritonavir; Viral Load; Zidovudine | 2007 |
The effects of highly active antiretroviral therapy (HAART) of stavudine, lamivudine and nevirapine on the CD4 lymphocyte count of HIV-infected Africans: the Nigerian experience.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Case-Control Studies; CD4 Lymphocyte Count; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Nigeria; Prognosis; Stavudine; Treatment Outcome | 2006 |
Lamivudine-associated macrocytosis in HIV-infected patients.
Topics: Adult; Anemia, Macrocytic; Erythrocyte Indices; Female; HIV; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies | 2007 |
Less sensitive HIV-1 enzyme immunoassay as an adjuvant method for monitoring patients receiving antiretroviral therapy.
Topics: Anti-HIV Agents; Drug Monitoring; HIV Infections; HIV-1; Immunoenzyme Techniques; Indinavir; Lamivudine; Sensitivity and Specificity; Time Factors; Virus Replication; Zidovudine | 2007 |
Age-dependent pharmacokinetics of lamivudine in HIV-infected children.
Topics: Aging; Algorithms; Anti-HIV Agents; Area Under Curve; Body Weight; Child; Child, Preschool; Female; HIV Infections; Humans; Lamivudine; Male; Sex Characteristics | 2007 |
Reactivation of lamivudine-resistant occult hepatitis B in an HIV-infected patient undergoing cytotoxic chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Viral; Hepatitis B; Hepatitis B virus; HIV; HIV Infections; Humans; Lamivudine; Lymphoma, Non-Hodgkin; Male; Virus Activation | 2007 |
No response to first-line tenofovir+lamivudine+efavirenz despite optimization according to baseline resistance testing: impact of resistant minority variants on efficacy of low genetic barrier drugs.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Resistance, Multiple, Viral; HIV Infections; HIV-1; Humans; Lamivudine; Male; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2007 |
Efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine (GPO-VIR) in Thai HIV-infected patients.
Topics: Adult; Anti-Retroviral Agents; Drug Combinations; Drugs, Generic; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Retrospective Studies; Stavudine; Thailand; Treatment Outcome | 2007 |
[Vitiligo in a black patient associated with HIV infection and repigmentation under antiretroviral therapy].
Topics: Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Lamivudine; Nevirapine; Treatment Outcome; Vitiligo; Zidovudine | 2007 |
Rapid selection of drug-resistant HIV-1 during the first months of suppressive ART in treatment-naive patients.
Topics: Adult; Aged; Alleles; Anti-Retroviral Agents; Drug Resistance, Viral; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; Risk Assessment; Selection, Genetic; Viral Load | 2007 |
Nevirapine clearance from plasma in African adults stopping therapy: a pharmacokinetic substudy.
Topics: Adult; Cohort Studies; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Nevirapine; Reverse Transcriptase Inhibitors; Stavudine; Uganda; Zidovudine; Zimbabwe | 2007 |
Response to Schmutz et al., 'Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection'.
Topics: Adenine; Drug Therapy, Combination; Hepatitis B; HIV Infections; Humans; Lamivudine; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Treatment Failure | 2007 |
Can urine lamivudine be used to monitor antiretroviral treatment adherence?
Topics: Adolescent; Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Lamivudine; Male; Monitoring, Physiologic; Patient Compliance | 2006 |
Lamivudine and second-line antiretroviral regimens.
Topics: Anti-HIV Agents; HIV Infections; HIV-1; Humans; Lamivudine | 2007 |
Association of serum lipid levels with HIV serostatus, specific antiretroviral agents, and treatment regimens.
Topics: Adenine; Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Black People; Cholesterol; Cross-Sectional Studies; Cyclopropanes; Didanosine; Dideoxynucleosides; Drug Therapy, Combination; Fasting; Female; Hispanic or Latino; HIV Infections; HIV Protease Inhibitors; HIV Seronegativity; HIV Seropositivity; HIV-1; Humans; Indinavir; Lamivudine; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Multivariate Analysis; Nelfinavir; Nevirapine; Organophosphonates; Ritonavir; Stavudine; Tenofovir; Triglycerides; United States; White People | 2007 |
Virologic characterization of HIV type 1 with a codon 70 deletion in reverse transcriptase.
Topics: Adenine; Antiviral Agents; Cell Line, Transformed; Codon; Deoxycytidine; Didanosine; Dideoxynucleosides; Drug Resistance, Viral; Emtricitabine; HeLa Cells; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Organophosphonates; Point Mutation; Reassortant Viruses; Reverse Transcriptase Inhibitors; Tenofovir | 2007 |
Nevirapine concentrations in HIV-infected children treated with divided fixed-dose combination antiretroviral tablets in Malawi and Zambia.
Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Cross-Sectional Studies; Drug Combinations; Drug Monitoring; Female; HIV Infections; Humans; Infant; Lamivudine; Malawi; Male; Nevirapine; Reverse Transcriptase Inhibitors; Stavudine; Tablets; Treatment Outcome; Zambia | 2007 |
Hypogonadism in HIV-1-infected men is common and does not resolve during antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Drug Therapy, Combination; Follicle Stimulating Hormone; HIV Infections; HIV-1; Humans; Hypogonadism; Lamivudine; Luteinizing Hormone; Male; Prevalence; Reverse Transcriptase Inhibitors; RNA, Viral; Switzerland; Testosterone; Time Factors; Treatment Outcome; Viral Load; Zidovudine | 2007 |
Evolution of resistance mutations during low-level viral replication in HIV-1-infected patients treated with zidovudine/lamivudine/abacavir as a first-line regimen.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; Dideoxynucleosides; DNA, Viral; Drug Combinations; Drug Monitoring; Drug Resistance, Viral; Follow-Up Studies; Genotype; Germany; HIV Infections; HIV-1; Humans; Lamivudine; Methionine; Mutation; Reverse Transcriptase Inhibitors; Thymidine; Time Factors; Treatment Failure; Valine; Viral Load; Virus Replication; Zidovudine | 2007 |
Hepatitis B virus genotype distribution and its lamivudine-resistant mutants in HIV-coinfected patients with chronic and occult hepatitis B.
Topics: Adult; Aged; Anti-HIV Agents; Drug Resistance, Viral; Female; Genotype; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Molecular Sequence Data; Mutation; Phylogeny | 2007 |
Assessment of adverse events associated with antiretroviral regimens for postexposure prophylaxis for occupational and nonoccupational exposures to prevent transmission of human immunodeficiency virus.
Topics: Adenine; Adult; Anti-HIV Agents; Chemoprevention; Drug Combinations; Female; HIV Infections; Humans; Lamivudine; Logistic Models; Male; Middle Aged; New York; Occupational Exposure; Occupational Health Services; Organophosphonates; Patient Compliance; Public Health Administration; Retrospective Studies; Risk Factors; Sex Factors; Student Health Services; Tenofovir; Universities; Zidovudine | 2007 |
Antiretroviral therapy in children: Indian experience.
Topics: Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; Drug Therapy, Combination; Feasibility Studies; Female; Guideline Adherence; HIV Infections; Humans; India; Infant; Lamivudine; Male; Nevirapine; Patient Compliance; Pilot Projects; Stavudine | 2007 |
Dynamics of 103K/N and 184M/V HIV-1 drug resistant populations: relative comparison in plasma virus RNA versus CD45RO+T cell proviral DNA.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; DNA, Viral; Drug Resistance, Viral; Drug Therapy, Combination; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Leukocyte Common Antigens; Mutation; Nevirapine; Nucleic Acid Amplification Techniques; Proviruses; Reverse Transcriptase Inhibitors; RNA, Viral; T-Lymphocytes; Viremia | 2007 |
Transmission of multidrug-resistant HIV-1: 5 years of immunological and virological survey.
Topics: Adenine; Anti-Retroviral Agents; CD4 Lymphocyte Count; Drug Resistance, Multiple, Viral; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lopinavir; Mutation; Organophosphonates; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Tenofovir; Viral Load | 2007 |
Performance of a World Health Organization first-line regimen (stavudine/lamivudine/nevirapine) in antiretroviral-naïve individuals in a Western setting.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; British Columbia; CD4 Lymphocyte Count; Cohort Studies; Drug Resistance, Multiple, Viral; HIV Infections; HIV-1; Humans; Lamivudine; Nevirapine; Proportional Hazards Models; Retrospective Studies; Reverse Transcriptase Inhibitors; Stavudine; Viral Load; World Health Organization | 2007 |
FDA notifications. FDA tentatively approves generic lamivudine.
Topics: Drug Approval; Drugs, Generic; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; United States; United States Food and Drug Administration | 2007 |
FDA notifications. FDA grants tentative approval to two ART drugs under expedited review.
Topics: Drug Approval; Drug Combinations; Drugs, Generic; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Stavudine; United States; United States Food and Drug Administration | 2007 |
The HBV drug entecavir - effects on HIV-1 replication and resistance.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Drug Resistance, Viral; Guanine; Hepatitis B; Hepatitis B virus; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation; Phylogeny; Reverse Transcriptase Inhibitors; Reverse Transcription; RNA, Viral; Virus Replication; Zidovudine | 2007 |
Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase.
Topics: Adenine; DNA Repair; Drug Resistance, Multiple, Viral; Genetic Engineering; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Models, Molecular; Mutation; Organophosphonates; Protein Binding; Reverse Transcriptase Inhibitors; Tenofovir; Thymidine | 2007 |
Porphyria cutanea tarda in an HIV-1-infected patient after the initiation of tipranavir/ritonavir: case report.
Topics: Adenine; Antiretroviral Therapy, Highly Active; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Middle Aged; Organophosphonates; Porphyria Cutanea Tarda; Pyridines; Pyrones; Reverse Transcriptase Inhibitors; Ritonavir; Sulfonamides; Tenofovir | 2007 |
Long-term foscarnet therapy remodels thymidine analogue mutations and alters resistance to zidovudine and lamivudine in HIV-1.
Topics: Amino Acid Substitution; Anti-HIV Agents; Drug Resistance, Multiple, Viral; Evolution, Molecular; Foscarnet; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Microbial Sensitivity Tests; Point Mutation; Reverse Transcriptase Inhibitors; Species Specificity; Thymidine; Time Factors; Zidovudine | 2007 |
HPV oral infection. Case report of an HIV-positive Nigerian sex worker.
Topics: Adenine; Adult; Alphapapillomavirus; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Deoxycytidine; Dideoxynucleosides; Emtricitabine; Female; HIV Infections; Humans; Italy; Lamivudine; Lopinavir; Mouth Mucosa; Nigeria; Organophosphonates; Papillomavirus Infections; Pyrimidinones; Ritonavir; Sex Work; Stomatitis; Tenofovir; Treatment Refusal; Zidovudine | 2007 |
Polymorphisms and drug resistance analysis of HIV-1 CRF01_AE strains circulating in Fujian Province, China.
Topics: Adult; Amino Acid Sequence; China; Cohort Studies; Consensus Sequence; Databases, Factual; Drug Resistance, Multiple, Viral; Female; Genetic Variation; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Middle Aged; Molecular Sequence Data; Mutation; Nevirapine; Polymorphism, Genetic; Prevalence; Reverse Transcriptase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; Sequence Homology, Amino Acid; Stavudine | 2007 |
Symptomatic hyperlactatemia associated with nucleoside analogue reverse-transcriptase inhibitor use in HIV-infected patients: a report of 24 cases in a resource-limited setting (Uganda).
Topics: Acidosis, Lactic; Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Lactic Acid; Lamivudine; Male; Middle Aged; Nevirapine; Reverse Transcriptase Inhibitors; Stavudine; Uganda | 2007 |
Antiretroviral agents and acid-base balance at delivery of the neonate.
Topics: Acid-Base Equilibrium; Adult; Anti-HIV Agents; Case-Control Studies; Drug Therapy, Combination; Female; Fetal Blood; HIV Infections; Humans; Hydrogen-Ion Concentration; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Nelfinavir; Pregnancy; Pregnancy Outcome; Prospective Studies; Zidovudine | 2007 |
Comparison of the effectiveness of initial combined antiretroviral therapy with nelfinavir or efavirenz at a university-based outpatient service in Brazil.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Clinical Protocols; Cohort Studies; Cyclopropanes; Female; Follow-Up Studies; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Retrospective Studies; RNA, Viral; Treatment Outcome; Viral Load; Zidovudine | 2007 |
Hair loss induced by lopinavir-ritonavir.
Topics: Adult; Alkynes; Alopecia; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Probability; Pyrimidinones; Ritonavir | 2007 |
Development of a highly efficient extraction technique and specific multiplex assay for measuring antiretroviral drug concentrations in breast milk.
Topics: Chromatography, High Pressure Liquid; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Milk, Human; Nevirapine; Postpartum Period; Reproducibility of Results; Reverse Transcriptase Inhibitors; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Stavudine; Zidovudine | 2007 |
Nevirapine-based antiretroviral therapy started early in the course of tuberculosis treatment in adult Malawians.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antitubercular Agents; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Malawi; Middle Aged; Nevirapine; Reverse Transcriptase Inhibitors; Rifampin; Stavudine; Treatment Outcome; Tuberculosis | 2007 |
Hepatitis B virus and HIV coinfection: results of a survey on treatment practices and recommendations for therapy.
Topics: Adenine; Adult; Anti-Retroviral Agents; Antiviral Agents; Drug Therapy, Combination; Female; Guideline Adherence; Health Care Surveys; Hepatitis B Vaccines; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Organophosphonates; Practice Guidelines as Topic; Practice Patterns, Physicians'; Tenofovir; United States | 2007 |
Impact of highly active antiretroviral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion.
Topics: Adult; Antiretroviral Therapy, Highly Active; Antiviral Agents; Female; Follow-Up Studies; France; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Middle Aged | 2007 |
Screening for and treating hepatitis B virus in patients with HIV infection.
Topics: Antiviral Agents; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Mass Screening; Practice Guidelines as Topic | 2007 |
Effects of antiretroviral agents during pregnancy on liver enzymes and amylase in HIV-exposed, uninfected newborn infants.
Topics: Adolescent; Adult; Amylases; Anti-HIV Agents; Cohort Studies; Control Groups; Drug Therapy, Combination; Female; Fetal Blood; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Liver; Male; Nelfinavir; Pregnancy; Prospective Studies; Transaminases; Zidovudine | 2007 |
Identification of a novel hepatitis B virus precore/core deletion mutant in HIV/hepatitis B virus co-infected individuals.
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; DNA, Viral; Gene Deletion; Genome, Viral; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Polymerase Chain Reaction; Prospective Studies; Sequence Analysis, DNA; Viral Core Proteins | 2007 |
[Update on HIV infection in Mayotte].
Topics: Adult; Anti-HIV Agents; Comoros; Dideoxynucleosides; Drug Combinations; Female; Heterosexuality; HIV Infections; HIV Seropositivity; Homosexuality; Humans; Lamivudine; Male; Middle Aged; Transfusion Reaction; Viremia; Zidovudine | 2007 |
Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy.
Topics: Adolescent; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Developing Countries; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Lamivudine; Logistic Models; Male; Multivariate Analysis; Nevirapine; Reverse Transcriptase Inhibitors; Sex Factors; Stavudine; Uganda; Viral Load | 2007 |
Predictors and kinetics of occult hepatitis B virus infection in HIV-infected persons.
Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Biomarkers; Carrier State; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cohort Studies; DNA, Viral; Female; Hepatitis B; Hepatitis B Antibodies; Hepatitis B Core Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; HIV Infections; HIV-1; Humans; Lamivudine; London; Male; Organophosphonates; Prevalence; Tenofovir | 2007 |
Prednisolone mediated suppression of HIV-1 viral load strongly correlates with C-C chemokine CCL2: In vivo and in vitro findings.
Topics: Alkynes; Anti-HIV Agents; Anti-Inflammatory Agents; Benzoxazines; Chemokine CCL2; Cyclopropanes; Drug Resistance, Viral; Flow Cytometry; Gene Expression; HIV Infections; HIV-1; Humans; In Vitro Techniques; Interleukin-8; Lamivudine; Male; Prednisolone; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Necrosis Factor-alpha; Uveitis; Viral Load; Viremia; Zidovudine | 2007 |
Lopinavir-ritonavir dramatically affects the pharmacokinetics of irinotecan in HIV patients with Kaposi's sarcoma.
Topics: Adenine; Adult; Aged; Anti-HIV Agents; Antineoplastic Agents, Phytogenic; Antiretroviral Therapy, Highly Active; Area Under Curve; Camptothecin; Drug Therapy, Combination; HIV Infections; Humans; Irinotecan; Lamivudine; Lopinavir; Male; Middle Aged; Organophosphonates; Pyrimidinones; Ritonavir; Sarcoma, Kaposi; Tenofovir; White People | 2008 |
Antiretroviral treatment and prevention of peripartum and postnatal HIV transmission in West Africa: evaluation of a two-tiered approach.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Breast Feeding; CD4 Lymphocyte Count; Cohort Studies; Cote d'Ivoire; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Infant; Infant, Low Birth Weight; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Male; Nevirapine; Pregnancy; Pregnancy Complications, Infectious; Program Evaluation; Puerperal Disorders; Viral Load; Zidovudine | 2007 |
Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis.
Topics: Adenine; Administration, Oral; Adult; Alkynes; Anti-Retroviral Agents; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Deoxycytidine; Drug Therapy, Combination; Emtricitabine; Female; Genitalia, Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Lopinavir; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Tenofovir; Zidovudine | 2007 |
Early virological response of zidovudine/lamivudine/abacavir for patients co-infected with HIV and tuberculosis in Uganda.
Topics: Adult; Antitubercular Agents; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Hypersensitivity; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Neutropenia; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Tuberculosis, Pulmonary; Zidovudine | 2007 |
First use of tamoxifen in an HIV patient with encapsulating peritoneal sclerosis.
Topics: Anti-HIV Agents; Drug Therapy, Combination; Estrogen Antagonists; Glucocorticoids; HIV Infections; Humans; Kidney Failure, Chronic; Lamivudine; Male; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Peritoneal Diseases; Saquinavir; Sclerosis; Tamoxifen; Zidovudine | 2007 |
Human immunodeficiency virus infection in a child presenting as herpes zoster ophthalmicus.
Topics: Acyclovir; Child; Eye Diseases; Herpes Zoster Ophthalmicus; HIV Infections; Humans; Lamivudine; Male; Nevirapine; Zidovudine | 2007 |
Efficacy of highly active antiretroviral therapy in HIV-1 infected children in Kenya.
Topics: Adolescent; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Weight; CD4 Lymphocyte Count; Child; Child, Preschool; Drugs, Generic; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Kenya; Lamivudine; Male; Nevirapine; Prospective Studies; RNA, Viral; Viral Load; Zidovudine | 2007 |
Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
Topics: Amino Acid Motifs; Anti-HIV Agents; Antiviral Agents; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Lamivudine; Molecular Sequence Data; Mutation; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Sequence Analysis, DNA; South Africa | 2007 |
High prevalence of primary lamivudine and nelfinavir resistance in HIV-1-infected pregnant women in the United States, 1998-2004.
Topics: Adolescent; Adult; Drug Resistance, Viral; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Mutation; Nelfinavir; Pregnancy; Pregnancy Complications, Infectious; Prevalence; Reverse Transcriptase Inhibitors; United States | 2007 |
Population pharmacokinetics of lamivudine in human immunodeficiency virus-exposed and -infected infants.
Topics: Anti-HIV Agents; Area Under Curve; Clinical Trials as Topic; Creatinine; Drug Administration Schedule; Female; HIV; HIV Infections; Humans; Infant; Infant, Newborn; Lamivudine; Male; Meta-Analysis as Topic; Metabolic Clearance Rate | 2007 |
Genotypic resistance in HIV-infected naive patients receiving abacavir plus lamivudine and efavirenz.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Resistance, Viral; HIV Infections; HIV-1; Humans; Lamivudine; Mutation; Spain; Species Specificity; Treatment Failure; Viral Load | 2007 |
Intracellular nucleoside triphosphate concentrations in HIV-infected patients on dual nucleoside reverse transcriptase inhibitor therapy.
Topics: Anti-HIV Agents; Cytidine Triphosphate; Dideoxynucleotides; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Leukocytes, Mononuclear; Male; Reverse Transcriptase Inhibitors; Stavudine; Thymine Nucleotides; Zidovudine | 2007 |
[Rapid development of anemia in a HIV-positive patient with alpha-thalassemia after zidovudine therapy].
Topics: Adult; alpha-Thalassemia; Anemia; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Diagnosis, Differential; Folic Acid; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Male; Zidovudine | 2007 |
Specificity enhancement with LC-positive ESI-MS/MS for the measurement of nucleotides: application to the quantitative determination of carbovir triphosphate, lamivudine triphosphate and tenofovir diphosphate in human peripheral blood mononuclear cells.
Topics: Adenine; Anti-HIV Agents; Cytidine Triphosphate; Deoxyguanine Nucleotides; Dideoxynucleosides; Dideoxynucleotides; HIV Infections; Humans; Lamivudine; Leukocytes, Mononuclear; Organophosphonates; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Tenofovir | 2008 |
Presence of M184I/V in minor HIV-1 populations of patients with lamivudine and/or didanosine treatment failure.
Topics: Adult; Aged; Didanosine; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; RNA-Directed DNA Polymerase; Treatment Failure; Viral Load | 2007 |
Tenofovir resistance among HIV-infected patients failing a fixed-dose combination of stavudine, lamivudine, and nevirapine in a resource-limited setting.
Topics: Adenine; Adult; Anti-HIV Agents; Cohort Studies; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Nevirapine; Organophosphonates; Stavudine; Tenofovir; Thailand; Treatment Outcome | 2007 |
Regression of a cervical spinal mass following highly active antiretroviral therapy (HAART) in child with advanced human immunodeficiency virus (HIV) disease.
Topics: Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Cervical Vertebrae; Child; Disease Progression; Female; HIV Infections; Humans; Lamivudine; Nevirapine; Remission, Spontaneous; Spinal Neoplasms; Stavudine; Time Factors | 2007 |
Efficacy and safety of a once daily regimen with efavirenz, lamivudine, and didanosine, with and without food, as initial therapy for HIV Infection: the ELADI study.
Topics: Adult; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Drug Administration Schedule; Female; Food; HIV; HIV Infections; Humans; Lamivudine; Male; Spain; Viral Load | 2007 |
Non-occupational post exposure prophylaxis as a biobehavioral HIV-prevention intervention.
Topics: Adult; Anti-HIV Agents; Attitude to Health; Drug Combinations; Feasibility Studies; Female; Follow-Up Studies; HIV Infections; Humans; Lamivudine; Male; Risk-Taking; Treatment Outcome; Zidovudine | 2008 |
Dandy-Walker variant in an infant prenatally exposed to antiretroviral medication.
Topics: Adult; Anti-Retroviral Agents; Dandy-Walker Syndrome; Female; Heart Ventricles; HIV Infections; Humans; Infant, Newborn; Lamivudine; Male; Nevirapine; Pregnancy; Prenatal Exposure Delayed Effects; Stavudine; Trimethoprim, Sulfamethoxazole Drug Combination | 2007 |
Liver enzymes elevation and immune reconstitution among treatment-naïve HIV-infected patients instituting antiretroviral therapy.
Topics: Adult; Alanine Transaminase; Alkynes; Anti-HIV Agents; Anti-Retroviral Agents; Aspartate Aminotransferases; Benzoxazines; CD4-Positive T-Lymphocytes; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis B; Hepatitis C; HIV Infections; Humans; Immune Reconstitution Inflammatory Syndrome; Lamivudine; Linear Models; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Risk Factors; Stavudine; Zidovudine | 2007 |
Selection of L74V mutation in reverse transcriptase of HIV-1 subtype D by a tenofovir DF-lamivudine based regimen.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Female; Follow-Up Studies; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir | 2007 |
[Diagnosis and therapy for attention-getting infections (discussion)].
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Cause of Death; Cross Infection; Disease Outbreaks; Drug Resistance, Multiple, Bacterial; Drug Resistance, Viral; Global Health; Hepatitis B; HIV Infections; Humans; Japan; Lamivudine; Measles; Practice Guidelines as Topic; Pseudomonas Infections; Reverse Transcriptase Inhibitors; Viral Vaccines | 2007 |
Triple antiretroviral therapy improves psoriasis associated with human immunodeficiency virus infection: a clinico-therapeutic experience.
Topics: Adult; Anti-HIV Agents; HIV Infections; Humans; Lamivudine; Male; Nevirapine; Psoriasis; Stavudine | 2008 |
Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study.
Topics: Adult; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; Dideoxynucleosides; Drug Therapy, Combination; Female; Genes, MDR; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation; Prognosis; Proportional Hazards Models; Reverse Transcriptase Inhibitors; RNA, Viral; Switzerland; Treatment Failure; Viral Load; Zidovudine | 2007 |
Positive outcomes of HAART at 24 months in HIV-infected patients in Cambodia.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cambodia; CD4 Lymphocyte Count; Cross-Sectional Studies; Cyclopropanes; Developing Countries; Feasibility Studies; Female; HIV Infections; HIV-1; Humans; Lamivudine; Logistic Models; Male; Prospective Studies; RNA, Viral; Stavudine; Treatment Outcome; Viral Load | 2007 |
HIV drug resistance after the use of generic fixed-dose combination stavudine/lamivudine/nevirapine as standard first-line regimen.
Topics: Adult; Developing Countries; Drug Combinations; Drug Resistance, Multiple, Viral; Drugs, Generic; Female; Genes, MDR; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mali; Mutation; Nevirapine; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Treatment Failure; Viral Load | 2007 |
Evolution of bone mineral density in AIDS patients on treatment with zidovudine/lamivudine plus abacavir or lopinavir/ritonavir.
Topics: Absorptiometry, Photon; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bone Density; Case-Control Studies; Dideoxynucleosides; Femur Neck; HIV Infections; Humans; Lamivudine; Lopinavir; Lumbar Vertebrae; Male; Middle Aged; Prospective Studies; Pyrimidinones; Ritonavir; Zidovudine | 2008 |
HIV-1 replication capacity and genotype changes in patients undergoing treatment interruption or lamivudine monotherapy.
Topics: Adult; Amino Acid Substitution; CD4-CD8 Ratio; HIV Infections; HIV-1; Humans; Lamivudine; Mutation, Missense; Virus Replication | 2008 |
An efficient tool for surveying CRF01_AE HIV type 1 resistance in Thailand to combined stavudine-lamivudine-nevirapine treatment: mutagenically separated PCR targeting M184I/V.
Topics: Anti-HIV Agents; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Mutation; Nevirapine; Polymerase Chain Reaction; Sensitivity and Specificity; Stavudine; Thailand | 2007 |
Persistence of genotypic resistance to nelfinavir among women exposed to prophylactic antiretroviral therapy during pregnancy.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Resistance, Viral; Female; Genotype; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Mutation; Nelfinavir; Pregnancy; Pregnancy Complications, Infectious; Viral Load; Zidovudine | 2007 |
Frequent occurrence of chronic hepatitis B virus infection among West African HIV type-1-infected children.
Topics: Adolescent; Africa, Western; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; Cote d'Ivoire; Female; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Infant; Lamivudine; Longitudinal Studies; Male; Prevalence; Retrospective Studies | 2008 |
Extensive hypopigmentation after starting antiretroviral treatment in an human immunodeficiency virus (HIV)-seropositive African woman.
Topics: Adult; Anti-HIV Agents; Anti-Infective Agents; Female; HIV Infections; Humans; Hypopigmentation; Lamivudine; Nevirapine; Photosensitivity Disorders; Skin; Stavudine; Trimethoprim, Sulfamethoxazole Drug Combination | 2008 |
Tenofovir DF plus lamivudine or emtricitabine for nonoccupational postexposure prophylaxis (NPEP) in a Boston Community Health Center.
Topics: Adenine; Adolescent; Adult; Aged; Anti-HIV Agents; Boston; Clinical Trials, Phase IV as Topic; Community Health Centers; Deoxycytidine; Disease Transmission, Infectious; Drug Therapy, Combination; Emtricitabine; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Tenofovir; Treatment Outcome | 2008 |
Tenofovir-based rescue therapy for advanced liver disease in 6 patients coinfected with HIV and hepatitis B virus and receiving lamivudine.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Viral; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Homosexuality, Male; Humans; Lamivudine; Liver Diseases; Male; Organophosphonates; Tenofovir; Transaminases; Viral Load | 2008 |
Effect of isolated V118I mutation in reverse transcriptase on response to first-line antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Case-Control Studies; CD4 Lymphocyte Count; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Middle Aged; Mutation; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Zidovudine | 2008 |
Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cote d'Ivoire; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Microbial Sensitivity Tests; Nevirapine; Pregnancy; RNA, Viral; Treatment Outcome; Treatment Refusal; Viral Load; Zidovudine | 2008 |
Reduced dNTP binding affinity of 3TC-resistant M184I HIV-1 reverse transcriptase variants responsible for viral infection failure in macrophage.
Topics: Amino Acid Substitution; Cell Line; Deoxyribonucleotides; DNA, Viral; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Macrophages; Mutation, Missense; Protein Structure, Quaternary; Protein Structure, Secondary; Reverse Transcriptase Inhibitors | 2008 |
Virological response to salvage therapy in HIV-infected persons carrying the reverse transcriptase K65R mutation.
Topics: Adult; Aged; Anti-HIV Agents; Female; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Italy; Lamivudine; Lopinavir; Male; Middle Aged; Mutation; Pyrimidinones; Retrospective Studies; Ritonavir; RNA, Viral; Salvage Therapy; Thymidine; Treatment Outcome | 2007 |
Lipodystrophy and metabolic changes in HIV-infected children on non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
Topics: Adolescent; Alkynes; Antiretroviral Therapy, Highly Active; Benzoxazines; Child; Child, Preschool; Cyclopropanes; Female; HIV Infections; HIV-1; Humans; Hypercholesterolemia; Hyperglycemia; Hypertriglyceridemia; Lamivudine; Lipodystrophy; Male; Nevirapine; Prevalence; Reverse Transcriptase Inhibitors; Stavudine; Thailand | 2007 |
18-month effectiveness of short-course antiretroviral regimens combined with alternatives to breastfeeding to prevent HIV mother-to-child transmission.
Topics: Africa; Anti-HIV Agents; Breast Feeding; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Nevirapine; Proportional Hazards Models; Survival Rate; Treatment Outcome; Zidovudine | 2008 |
Prevalence and risk factors for developing K65R mutations among HIV-1 infected patients who fail an initial regimen of fixed-dose combination of stavudine, lamivudine, and nevirapine.
Topics: Adult; Amino Acid Substitution; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Viral; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation, Missense; Nevirapine; Prevalence; Risk Factors; RNA, Viral; Stavudine; Viral Load | 2008 |
Development of a population simulation model for HIV monotherapy virological outcomes using lamivudine.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Cytidine Triphosphate; Dideoxynucleotides; HIV; HIV Infections; Humans; Inhibitory Concentration 50; Kinetics; Lamivudine; Models, Biological; Monte Carlo Method; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load | 2007 |
Cost-effectiveness analysis of emtricitabine/tenofovir versus lamivudine/zidovudine, in combination with efavirenz, in antiretroviral-naive, HIV-1-infected patients.
Topics: Adenine; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cost-Benefit Analysis; Cyclopropanes; Decision Trees; Deoxycytidine; Drug Costs; Emtricitabine; Health Care Costs; Health Resources; HIV Infections; HIV-1; Humans; Lamivudine; Models, Economic; Organophosphonates; Reverse Transcriptase Inhibitors; Tenofovir; Time Factors; Treatment Outcome; Zidovudine | 2008 |
Finally--PMTCT dual therapy.
Topics: Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Practice Guidelines as Topic; Pregnancy; South Africa | 2008 |
HIV study yields unexpected preliminary efficacy results.
Topics: Anti-Retroviral Agents; Clinical Trials as Topic; Deoxycytidine; Dideoxynucleosides; Drug Combinations; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; HIV Infections; HIV-1; Humans; Lamivudine; Organophosphorus Compounds; Viral Load | 2008 |
Prospective cohort study of HIV post-exposure prophylaxis for sexual assault survivors.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Child; Child, Preschool; Cohort Studies; Drug Combinations; Female; HIV Infections; Humans; Lamivudine; Lopinavir; Male; Middle Aged; Ontario; Pyrimidinones; Rape; Risk Factors; Zidovudine | 2008 |
Low rate of emergence of nevirapine and lamivudine resistance after post-partum interruption of a triple-drug regimen.
Topics: Adult; Anti-HIV Agents; DNA, Viral; Drug Administration Schedule; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Mutation; Nevirapine; Postpartum Period; Pregnancy | 2008 |
High levels of zidovudine (AZT) and its intracellular phosphate metabolites in AZT- and AZT-lamivudine-treated newborns of human immunodeficiency virus-infected mothers.
Topics: Anti-HIV Agents; Dideoxynucleotides; Female; Follow-Up Studies; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Leukocytes, Mononuclear; Male; Pregnancy; Pregnancy Complications, Infectious; Prospective Studies; Thymine Nucleotides; Zidovudine | 2008 |
Rapid scaling-up of antiretroviral therapy in 10,000 adults in Côte d'Ivoire: 2-year outcomes and determinants.
Topics: Adult; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cote d'Ivoire; Drug Administration Schedule; Female; Follow-Up Studies; HIV; HIV Infections; HIV-1; HIV-2; Humans; Lamivudine; Male; Nevirapine; Survival Analysis; Treatment Outcome; Zidovudine | 2008 |
[Polyneuropathies in patients treated with HAART in Bobo-Dioulasso hospital, Burkina Faso].
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Burkina Faso; CD4 Lymphocyte Count; Cyclopropanes; Female; Follow-Up Studies; Foot Diseases; HIV Infections; Humans; Hypesthesia; Lamivudine; Male; Middle Aged; Nevirapine; Pain; Paresthesia; Polyneuropathies; Reflex, Abnormal; Sensory Thresholds; Stavudine; Vibration | 2008 |
New formulations approved for children.
Topics: Anti-HIV Agents; Chemistry, Pharmaceutical; Child; Child, Preschool; Dideoxynucleosides; Drug Approval; Drug Combinations; European Union; HIV Infections; Humans; Infant; Infant, Newborn; Lamivudine; Reverse Transcriptase Inhibitors; Zidovudine | 2008 |
The anti-HIV activity of entecavir: a multicentre evaluation of lamivudine-experienced and lamivudine-naive patients.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; CD4 Lymphocyte Count; DNA, Viral; Drug Evaluation; Drug Resistance, Viral; Female; Guanine; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Mutation; Retrospective Studies; Reverse Transcriptase Inhibitors; Risk Factors; RNA, Viral | 2008 |
Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1-infected patients with multidrug-resistant virus: a multicentre pilot study.
Topics: Adenine; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Resistance, Multiple, Viral; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Middle Aged; Organophosphonates; Pilot Projects; Reverse Transcriptase Inhibitors; RNA, Viral; Tenofovir; Thymidine; Viral Load; Zidovudine | 2008 |
Relevance of the organic cation transporters 1 and 2 for antiretroviral drug therapy in human immunodeficiency virus infection.
Topics: Cell Line; Chromatography, High Pressure Liquid; HIV Infections; Humans; Lamivudine; Lymph Nodes; Organic Cation Transport Proteins; Organic Cation Transporter 1; Organic Cation Transporter 2; Reverse Transcriptase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Zalcitabine | 2008 |
FDA advised to license three anti-HIV agents.
Topics: Adult; Antiviral Agents; Child; Drug Approval; HIV Infections; HIV Protease Inhibitors; Humans; Isoquinolines; Lamivudine; Quinolines; Saquinavir; Stavudine; United States; United States Food and Drug Administration; Zalcitabine | 1995 |
A quarter-century of antiviral therapy.
Topics: Antiviral Agents; Drug Therapy, Combination; Hepatitis B; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Zalcitabine; Zidovudine | 1995 |
Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC).
Topics: CD4 Lymphocyte Count; Drug Resistance, Microbial; HIV Core Protein p24; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Longitudinal Studies; Male; Reverse Transcriptase Inhibitors; RNA, Viral; Zalcitabine | 1995 |
Determination of 2'-deoxy-3'-thiacytidine (3TC) in human urine by liquid chromatography: direct injection with column switching.
Topics: Chromatography, High Pressure Liquid; HIV Infections; Humans; Lamivudine; Reproducibility of Results; Zalcitabine | 1994 |
Generation of drug-resistant variants of human immunodeficiency virus type 1 by in vitro passage in increasing concentrations of 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Drug Resistance; HIV Infections; HIV-1; Humans; Lamivudine; Zalcitabine | 1993 |
In vitro immunotoxicity of +/- 2'-deoxy-3'-thiacytidine, a new anti-HIV agent.
Topics: Antiviral Agents; B-Lymphocytes; CD3 Complex; Cytokines; Female; HIV Infections; HIV-1; Humans; Immunoglobulins; Lamivudine; Lymphocyte Activation; Male; Phytohemagglutinins; T-Lymphocytes; Zalcitabine; Zidovudine | 1993 |
Recognition of the highly conserved YMDD region in the human immunodeficiency virus type 1 reverse transcriptase by HLA-A2-restricted cytotoxic T lymphocytes from an asymptomatic long-term nonprogressor.
Topics: Amino Acid Sequence; Antiviral Agents; Base Sequence; Conserved Sequence; Deoxycytidine; Didanosine; DNA Primers; Drug Resistance, Microbial; Epitopes; HIV Infections; HIV Reverse Transcriptase; HIV-1; HLA-A2 Antigen; Humans; Lamivudine; Molecular Sequence Data; Oligopeptides; Polymerase Chain Reaction; RNA-Directed DNA Polymerase; T-Lymphocytes, Cytotoxic; Zalcitabine | 1996 |
A new HIV/AIDS drug.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Antiviral Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant; Lamivudine; Male; Zalcitabine; Zidovudine | 1996 |
New drugs for HIV infection.
Topics: Antiviral Agents; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Isoquinolines; Lamivudine; Pyridines; Quinolines; Ritonavir; Saquinavir; Stavudine; Thiazoles; Valine; Zalcitabine | 1996 |
Lamivudine as adjunct therapy in HIV.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Zalcitabine; Zidovudine | 1996 |
Viral dynamics in hepatitis B virus infection.
Topics: Alanine Transaminase; Antiviral Agents; Dose-Response Relationship, Drug; Hepatitis B; Hepatitis B e Antigens; Hepatitis B virus; HIV Infections; Humans; Kinetics; Lamivudine; Models, Biological; Regression Analysis; Reverse Transcriptase Inhibitors; Time Factors; Viremia; Virus Replication; Zalcitabine | 1996 |
Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase.
Topics: Antiviral Agents; Base Composition; Base Sequence; Deoxyribonucleotides; Drug Resistance, Microbial; HIV Antibodies; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Isoquinolines; Lamivudine; Molecular Sequence Data; Mutation; Neutralization Tests; Quinolines; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Saquinavir; Virus Replication; Zalcitabine | 1996 |
New nucleoside analogue, lamivudine, released for HIV therapy.
Topics: Antiviral Agents; Drug Therapy, Combination; HIV Infections; Lamivudine; Zalcitabine; Zidovudine | 1996 |
New guidelines set for occupational HIV exposure.
Topics: Accidents, Occupational; Antiviral Agents; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Infectious Disease Transmission, Patient-to-Professional; Lamivudine; Practice Guidelines as Topic; Pyridines; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 1996 |
Human immunodeficiency virus type 1 kinetics in lymph nodes compared with plasma.
Topics: Antiviral Agents; Biopsy; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Kinetics; Lamivudine; Lymph Nodes; RNA, Viral; Viremia; Zalcitabine; Zidovudine | 1996 |
Kinetics of viral clearance in plasma, peripheral blood mononuclear cells and lymph nodes.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Leukocytes, Mononuclear; Lymph Nodes; Male; Plasma; RNA, Viral; Time Factors; Zidovudine | 1996 |
New combinations of drug therapies for the treatment of the human immunodeficiency virus (HIV)
Topics: Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Protease Inhibitors; Time Factors; Zidovudine | 1996 |
An update on HIV/AIDS.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; United States; Viremia; Zidovudine | 1996 |
Potential role of lamivudine (3TC) in the clearance of chronic hepatitis B virus infection in a patient coinfected with human immunodeficiency virus type.
Topics: Adult; Anti-HIV Agents; Chronic Disease; Hepatitis B; Hepatitis B virus; HIV Infections; HIV-1; Humans; Lamivudine; Male | 1996 |
Concomitant combination therapy for HIV infection preferable over sequential therapy with 3TC and non-nucleoside reverse transcriptase inhibitors.
Topics: Base Sequence; Cell Line; DNA Primers; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Microbial Sensitivity Tests; Point Mutation; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; Uracil; Virus Replication | 1996 |
Lamivudine-zidovudine treatment and clinical end points.
Topics: Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Zidovudine | 1996 |
[Lamivudine-zidovudine combination treatment].
Topics: Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Zidovudine | 1996 |
[HIV: less resistance due to combined treatment].
Topics: Adult; Anti-HIV Agents; Computer Graphics; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Time Factors; Zidovudine | 1996 |
Reverse transcriptase fidelity and HIV-1 variation.
Topics: Anti-HIV Agents; Antigenic Variation; Drug Resistance, Microbial; Epitopes; Genetic Variation; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Reverse Transcriptase Inhibitors | 1997 |
Reverse transcriptase fidelity and HIV-1 variation.
Topics: Anti-HIV Agents; Cells, Cultured; Drug Resistance, Microbial; Drug Therapy, Combination; Genetic Variation; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Reverse Transcriptase Inhibitors; Zidovudine | 1997 |
Reverse transcriptase fidelity and HIV-1 variation.
Topics: Anti-HIV Agents; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Reverse Transcriptase Inhibitors | 1997 |
HIV postexposure prophylaxis: new recommendations.
Topics: Anti-HIV Agents; Blood-Borne Pathogens; Chemoprevention; Drug Combinations; Guidelines as Topic; Health Personnel; HIV Infections; Humans; Indinavir; Infectious Disease Transmission, Patient-to-Professional; Lamivudine; Occupational Diseases; Zidovudine | 1997 |
Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals. North American Lamivudine HIV Working Group.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Double-Blind Method; Drug Therapy, Combination; HIV; HIV Infections; Humans; Lamivudine; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Viral Load; Zidovudine | 1997 |
Focusing on the second phase of plasma HIV-1 RNA clearance.
Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Reverse Transcriptase Inhibitors; RNA, Viral; Virus Replication; Zidovudine | 1997 |
Saquinavir interaction with midazolam: pharmacokinetic considerations when prescribing protease inhibitors for patients with HIV disease.
Topics: Adult; Anti-HIV Agents; Cytochrome P-450 Enzyme System; Drug Interactions; HIV Infections; HIV Protease Inhibitors; Humans; Hypnotics and Sedatives; Lamivudine; Liver; Male; Midazolam; Saquinavir; Trimethoprim, Sulfamethoxazole Drug Combination; Zidovudine | 1997 |
The art of 'HAART': researchers probe the potential and limits of aggressive HIV treatments.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Zidovudine | 1997 |
Effect of antiretroviral combination therapy (zidovudine/didanosine or zidovudine/lamivudine) on quantitative plasma human immunodeficiency virus-ribonucleic acid in children and adolescents infected with human immunodeficiency virus.
Topics: Adolescent; AIDS-Related Opportunistic Infections; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant; Lamivudine; Male; RNA, Viral; Time Factors; Viral Load; Viremia; Zidovudine | 1997 |
Human immunodeficiency virus drug therapy and virus load.
Topics: Anti-HIV Agents; HIV Infections; HIV-1; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Viral Load; Zidovudine | 1997 |
Initial appearance of the 184Ile variant in lamivudine-treated patients is caused by the mutational bias of human immunodeficiency virus type 1 reverse transcriptase.
Topics: Anti-HIV Agents; Genetic Variation; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Reverse Transcriptase Inhibitors; Threonine | 1997 |
[Antiretroviral drugs in the primary and secondary prevention of HIV infection].
Topics: Antiviral Agents; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Zidovudine | 1997 |
HIV trial stopped early after good results.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Zidovudine | 1997 |
Treatment options for human immunodeficiency virus.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Child; Didanosine; Drug Approval; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infant, Newborn; Lamivudine; Male; Saquinavir; Stavudine; United States; United States Food and Drug Administration; Zalcitabine; Zidovudine | 1996 |
Decay characteristics of HIV-1-infected compartments during combination therapy.
Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; Drug Therapy, Combination; Half-Life; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Isoquinolines; Lamivudine; Leukocytes, Mononuclear; Macrophages; Mathematics; Models, Biological; Nelfinavir; Proviruses; Reverse Transcriptase Inhibitors; RNA, Viral; Sulfonic Acids; Viral Load; Viremia; Virus Latency; Zidovudine | 1997 |
Response of HIV-associated thrombocytopenia to triple agent antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Male; Saquinavir; Thrombocytopenia; Zalcitabine; Zidovudine | 1997 |
New drugs--reports of new drugs recently approved by the FDA. Lamivudine.
Topics: Administration, Oral; Anti-HIV Agents; Area Under Curve; Biological Availability; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Reverse Transcriptase Inhibitors; United States; United States Food and Drug Administration; Zidovudine | 1997 |
Quantification of HIV-1 viral load in lymphoid and blood cells: assessment during four-drug combination therapy.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; DNA, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Leukocytes, Mononuclear; Lymph Nodes; Male; Polymerase Chain Reaction; RNA, Viral; Saquinavir; Viral Load; Viremia; Zidovudine | 1997 |
Increased fidelity of drug-selected M184V mutated HIV-1 reverse transcriptase as the basis for the effectiveness of 3TC in HIV clinical trials.
Topics: Anti-HIV Agents; Child; Child, Preschool; Drug Resistance, Microbial; Female; Genes, env; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Microbial Sensitivity Tests; Point Mutation; Reverse Transcriptase Inhibitors; RNA, Viral; Zidovudine | 1997 |
A branched DNA signal amplification assay for quantification of nucleic acid targets below 100 molecules/ml.
Topics: Adenosine; Anti-HIV Agents; Cytidine; DNA; DNA, Viral; Drug Therapy, Combination; Guanosine; HIV; HIV Infections; Humans; Isoquinolines; Lamivudine; Nelfinavir; Nucleic Acid Hybridization; RNA, Viral; Sulfonic Acids; Zidovudine | 1997 |
Downregulation of increased CD95 (APO-1/Fas) ligand in T cells from human immunodeficiency virus-type 1-infected children after antiretroviral therapy.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Child; Didanosine; Drug Therapy, Combination; Fas Ligand Protein; fas Receptor; Gene Expression Regulation; HIV Infections; HIV-1; Humans; Lamivudine; Membrane Glycoproteins; Reverse Transcriptase Inhibitors; RNA, Messenger; T-Lymphocytes; Time Factors; Transcription, Genetic; Zalcitabine; Zidovudine | 1997 |
Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo.
Topics: Amino Acid Sequence; Anti-HIV Agents; CD4 Lymphocyte Count; DNA Mutational Analysis; DNA, Viral; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Molecular Sequence Data; Mutation; RNA, Viral; Zidovudine | 1997 |
Cure or control of HIV/AIDS?
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Infections; Humans; Indinavir; Lamivudine; Models, Biological; Nevirapine; Pyridines; Ritonavir; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 1997 |
Addition of lamivudine to the drug regimen in patients with advanced HIV disease on nucleoside therapy.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged | 1997 |
Postexposure chemoprophylaxis for occupational exposure to HIV in the dental office.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Anti-HIV Agents; Chemoprevention; Child; Dental Auxiliaries; Dentists; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Infectious Disease Transmission, Patient-to-Professional; Lamivudine; Occupational Diseases; Occupational Exposure; Practice Guidelines as Topic; Risk Factors; United States; United States Public Health Service; Universal Precautions; Zidovudine | 1997 |
Human immunodeficiency virus type 1 dynamics in different lymphoid tissue compartments.
Topics: Adult; Anti-HIV Agents; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Leukocytes, Mononuclear; Lymphoid Tissue; Male; RNA, Viral; Zidovudine | 1997 |
[The management of the occupational exposures of health workers to HIV].
Topics: Anti-HIV Agents; Drug Interactions; Drug Therapy, Combination; Health Personnel; HIV Infections; HIV-1; Humans; Indinavir; Infectious Disease Transmission, Patient-to-Professional; Lamivudine; Occupational Exposure; Saquinavir; Zidovudine | 1997 |
Lamivudine-stavudine-induced liver failure in hepatitis B cirrhosis.
Topics: Aged; Anti-HIV Agents; Ascites; Drug Combinations; Hepatitis B; Hepatitis, Chronic; HIV Infections; Humans; Jaundice; Lamivudine; Liver Cirrhosis; Liver Failure; Male; Reverse Transcriptase Inhibitors; Stavudine | 1997 |
Protease inhibitor therapy in children with perinatally acquired HIV infection.
Topics: Anti-HIV Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Indinavir; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Male; Protease Inhibitors; Retrospective Studies; Ritonavir; Saquinavir; Stavudine; Zidovudine | 1997 |
Stavudine plus lamivudine in advanced human immunodeficiency virus disease: a short-term pilot study.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Pilot Projects; Stavudine | 1997 |
Recovery of replication-competent HIV despite prolonged suppression of plasma viremia.
Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; Coculture Techniques; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Immunologic Memory; Indinavir; Lamivudine; Lymphocyte Activation; Mutation; RNA, Viral; T-Lymphocyte Subsets; Viral Load; Viremia; Virus Activation; Virus Latency; Virus Replication; Zidovudine | 1997 |
[HIV-therapy: as early and as intensive as possible].
Topics: Anti-HIV Agents; Clinical Trials as Topic; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Reverse Transcriptase Inhibitors; Stavudine; Time Factors; Treatment Outcome; Zidovudine | 1997 |
First combination drug for patients with HIV.
Topics: Anti-HIV Agents; Drug Combinations; HIV Infections; Humans; Lamivudine; Zidovudine | 1997 |
Drugs for HIV infection.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Delavirdine; Diarrhea; Didanosine; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Nevirapine; Protease Inhibitors; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Virus Replication; Zalcitabine; Zidovudine | 1997 |
[Lamivudine treatment: realities and expectations].
Topics: Anti-HIV Agents; Antiviral Agents; DNA, Viral; Hepatitis B virus; Hepatitis B, Chronic; HIV; HIV Infections; Humans; Interferons; Lamivudine; Polymerase Chain Reaction | 1997 |
Safety and efficacy of two different triple drug combinations in which either lamivudine or didanosine were administered with stavudine plus indinavir.
Topics: Anti-HIV Agents; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Indinavir; Lamivudine; Reverse Transcriptase Inhibitors; Stavudine; Treatment Outcome | 1997 |
Indinavir urinary stones as origin of upper urinary tract obstruction.
Topics: Aged; Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Male; Ureteral Calculi; Ureteral Obstruction; Zidovudine | 1997 |
HIV-1 RNA detectable with ultrasensitive quantitative polymerase chain reaction in plasma but not in cerebrospinal fluid during combination treatment with zidovudine, lamivudine and indinavir.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Monitoring; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Polymerase Chain Reaction; RNA, Viral; Zidovudine | 1998 |
Drug susceptibility of subtypes A,B,C,D, and E human immunodeficiency virus type 1 primary isolates.
Topics: Anti-HIV Agents; Cell Line, Transformed; Cells, Cultured; Didanosine; Foscarnet; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Leukocytes, Mononuclear; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir; Zidovudine | 1998 |
[Stavudine and lamivudine. Two new nucleoside analogues efficient against HIV].
Topics: Anti-HIV Agents; HIV Infections; Humans; Lamivudine; Stavudine | 1998 |
thy/liv-SCID-hu mice: a system for investigating the in vivo effects of multidrug therapy on plasma viremia and human immunodeficiency virus replication in lymphoid tissues.
Topics: Animals; Anti-HIV Agents; Chronic Disease; Drug Resistance, Microbial; Drug Therapy, Combination; Fetal Tissue Transplantation; Flow Cytometry; HIV Infections; HIV-1; Lamivudine; Leukocytes, Mononuclear; Liver Transplantation; Mice; Mice, SCID; Recurrence; Ritonavir; RNA, Viral; Saquinavir; Thymus Gland; Viremia; Zidovudine | 1998 |
Oligonucleotide ligation assay for detecting mutations in the human immunodeficiency virus type 1 pol gene that are associated with resistance to zidovudine, didanosine, and lamivudine.
Topics: Anti-HIV Agents; Codon; Didanosine; Drug Resistance, Microbial; Genes, pol; HIV Infections; HIV-1; Humans; Lamivudine; Mutation; Oligonucleotide Probes; Polymerase Chain Reaction; RNA, Viral; Sensitivity and Specificity; Sequence Analysis, DNA; Zidovudine | 1998 |
Paediatric AIDS--is now not the right time to act?
Topics: Adult; Anti-HIV Agents; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Pregnancy; Pregnancy Complications, Infectious; Zidovudine | 1997 |
Survival in 2367 zidovudine-treated patients according to use of other nucleoside analogue drugs. The EuroSIDA Study Group.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Didanosine; Dideoxynucleosides; Disease Progression; Drug Therapy, Combination; Europe; Female; Follow-Up Studies; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Proportional Hazards Models; Prospective Studies; Stavudine; Survival Analysis; Zalcitabine; Zidovudine | 1998 |
Glaxo cuts HIV drug cost for developing world.
Topics: Anti-HIV Agents; Costs and Cost Analysis; Developing Countries; Drug Industry; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors; Zidovudine | 1998 |
Profound and unanticipated anemia with lamivudine-zidovudine combination therapy in zidovudine-experienced patients with HIV infection.
Topics: Adult; Anemia; Anti-HIV Agents; Drug Interactions; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Zidovudine | 1998 |
Drug shows potency against HIV.
Topics: Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Zidovudine | 1996 |
Changes in CD4+ and CD8+ T cell subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Immunologic Memory; Indinavir; Lamivudine; Lymphocyte Activation; Lymphocyte Count; Middle Aged; Prospective Studies; Receptors, Antigen, T-Cell, alpha-beta; RNA, Viral; T-Lymphocyte Subsets; Viral Load; Zidovudine | 1998 |
Acute HIV syndrome after discontinuation of antiretroviral therapy in a patient treated before seroconversion.
Topics: Adult; Anti-HIV Agents; CD4-CD8 Ratio; Drug Therapy, Combination; HIV Infections; HIV Seropositivity; Humans; Lamivudine; Male; Ritonavir; RNA, Viral; T-Lymphocytes, Cytotoxic; Zidovudine | 1998 |
Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy: association with therapy failure.
Topics: Anti-HIV Agents; Cross-Sectional Studies; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; Follow-Up Studies; HIV Infections; HIV-1; Humans; Lamivudine; Retrospective Studies; Reverse Transcriptase Inhibitors; Treatment Failure; Zidovudine | 1998 |
Profound anemia in a newborn infant of a mother receiving antiretroviral therapy.
Topics: Adult; Anemia; Anti-HIV Agents; CD4 Lymphocyte Count; Female; HIV Infections; Humans; Infant, Newborn; Lamivudine; Leukocyte Count; Male; Polymerase Chain Reaction; Pregnancy; Pregnancy Complications, Infectious; Viral Load; Zalcitabine; Zidovudine | 1998 |
The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors.
Topics: Anti-HIV Agents; Cohort Studies; Didanosine; Dideoxynucleosides; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Methionine; Point Mutation; Reverse Transcriptase Inhibitors; Stavudine; Valine; Zalcitabine; Zidovudine | 1998 |
Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease.
Topics: Adult; Aged; Anti-HIV Agents; Cohort Studies; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Male; Middle Aged; Prospective Studies; Reverse Transcriptase Inhibitors; Stavudine; Treatment Outcome; Zidovudine | 1998 |
Persistence of HIV-1 variants harbouring the zidovudine resistance mutation at pol codon 215 in patients who respond to triple combination therapy.
Topics: Adult; Anti-HIV Agents; Codon; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Genes, pol; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Male; Mutation; Prospective Studies; Reverse Transcriptase Inhibitors; Stavudine; Treatment Outcome; Virus Latency; Zidovudine | 1998 |
Cost-effectiveness of antiviral drug therapy to reduce mother-to-child HIV transmission in sub-Saharan Africa.
Topics: Africa South of the Sahara; Anti-HIV Agents; Breast Feeding; Cost-Benefit Analysis; Drug Costs; Drug Therapy, Combination; Female; Health Care Costs; HIV Infections; HIV Seroprevalence; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Pregnancy; Pregnancy Complications, Infectious; Treatment Outcome; Zidovudine | 1998 |
[HIV infection: DuPont Pharma presents the results of its antiretroviral agent].
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Evaluation; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Indinavir; Lamivudine; Oxazines; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Outcome; Viremia; Zidovudine | 1998 |
Lamivudine-induced paronychia.
Topics: Adult; Anti-HIV Agents; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Paronychia | 1998 |
Comparison of two antiretroviral triple combinations including the protease inhibitor indinavir in children infected with human immunodeficiency virus.
Topics: Adolescent; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Cohort Studies; Disease Progression; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Infant; Lamivudine; Male; Reverse Transcriptase Inhibitors; Statistics, Nonparametric; Viral Load; Zidovudine | 1998 |
Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain.
Topics: Adult; Anti-HIV Agents; Cross-Sectional Studies; Didanosine; Dideoxynucleosides; Drug Resistance, Microbial; Female; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Prevalence; Reverse Transcriptase Inhibitors; Spain; Zalcitabine; Zidovudine | 1998 |
Cost-effectiveness of chemoprophylaxis after occupational exposure to HIV.
Topics: Anti-HIV Agents; Cost-Benefit Analysis; HIV Infections; Humans; Indinavir; Lamivudine; Occupational Exposure; United States; Zidovudine | 1998 |
Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection.
Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; DNA, Viral; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Reverse Transcriptase Inhibitors; Virus Integration; Virus Latency; Virus Replication; Zidovudine | 1998 |
Efficient inhibition of both syncytium-inducing and non-syncytium-inducing wild-type HIV-1 by lamivudine in vivo.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Codon; DNA, Viral; Drug Resistance, Microbial; Giant Cells; HIV Infections; HIV-1; Humans; Lamivudine; Mutation; Proviruses; Reverse Transcriptase Inhibitors; RNA, Viral; Viral Load; Virus Replication | 1998 |
Prevalence of mutation associated to resistance with nucleoside analogues in a cohort of naïve HIV-1 positive subjects during the period 1984-1997.
Topics: Adult; Drug Resistance, Microbial; Female; HIV Infections; HIV Reverse Transcriptase; Humans; Lamivudine; Male; Middle Aged; Mutation; Reverse Transcriptase Inhibitors; Zidovudine | 1998 |
"Buffalo hump" in HIV-1 infection.
Topics: Adipose Tissue; Adult; Anti-HIV Agents; Body Composition; HIV Infections; HIV-1; Humans; Lamivudine; Male; Stavudine | 1998 |
Therapeutic and other interventions to reduce the risk of mother-to-child transmission of HIV-1 in Europe. The European Collaborative Study.
Topics: Adult; Anti-HIV Agents; Breast Feeding; Cesarean Section; Cohort Studies; Didanosine; Europe; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Pregnancy; Pregnancy Complications, Infectious; Prenatal Care; Prospective Studies; Risk Factors; Zidovudine | 1998 |
Comparison of the LiPA HIV-1 RT test, selective PCR and direct solid phase sequencing for the detection of HIV-1 drug resistance mutations.
Topics: Anti-HIV Agents; Codon; Didanosine; DNA Probes; Drug Resistance, Microbial; Drug Therapy, Combination; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Polymerase Chain Reaction; Sequence Analysis, DNA; Zalcitabine; Zidovudine | 1998 |
Alternative multidrug regimen provides improved suppression of HIV-1 replication over triple therapy.
Topics: Adult; Anti-HIV Agents; Data Interpretation, Statistical; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Male; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Virus Replication; Zidovudine | 1998 |
Clinical experience with adding delavirdine to combination therapy in patients in whom multiple antiretroviral treatment including protease inhibitors has failed.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Delavirdine; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Treatment Failure; Viral Load; Zidovudine | 1998 |
Occupational exposure to blood and body fluids: new postexposure prophylaxis recommendations. United States Occupational Safety and Health Administration.
Topics: Anti-HIV Agents; Blood-Borne Pathogens; Dental Staff; Dentistry; HIV Infections; Humans; Indinavir; Infectious Disease Transmission, Patient-to-Professional; Lamivudine; Mandatory Reporting; Occupational Exposure; Risk Factors; Risk Management; Surveys and Questionnaires; Zidovudine | 1998 |
Chemoprophylaxis after occupational exposure to human immunodeficiency virus in forensic autopsy.
Topics: Anti-HIV Agents; Drug Therapy, Combination; Forensic Medicine; HIV; HIV Infections; Humans; Indinavir; Lamivudine; Occupational Exposure; Zidovudine | 1998 |
Resolution of severe Kaposi's sarcoma after initiation of antiretroviral triple therapy.
Topics: Adult; Anti-HIV Agents; Antibiotics, Antineoplastic; Doxorubicin; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Interferon-alpha; Lamivudine; Liposomes; Male; Remission Induction; Reverse Transcriptase Inhibitors; Sarcoma, Kaposi; Stavudine | 1998 |
Cerebrospinal fluid levels of antiretroviral medications: abstract and commentary.
Topics: Anti-HIV Agents; Blood-Brain Barrier; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; RNA, Viral; Stavudine; Zidovudine | 1998 |
Quantitative determination of (-)-2'-deoxy-3'-thiacytidine (lamivudine) in human plasma, saliva and cerebrospinal fluid by high-performance liquid chromatography with ultraviolet detection.
Topics: Anti-HIV Agents; Chromatography, High Pressure Liquid; HIV Infections; HIV-1; Humans; Lamivudine; Reproducibility of Results; Reverse Transcriptase Inhibitors; Saliva; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Toxoplasmosis, Cerebral | 1998 |
Clozapine treatment of HIV-associated psychosis--too much bone marrow toxicity?
Topics: Adult; Anti-HIV Agents; Antipsychotic Agents; Clozapine; Drug Interactions; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Male; Neutropenia; Psychotic Disorders; Zidovudine | 1998 |
Development of a new cartridge radioimmunoassay for determination of intracellular levels of lamivudine triphosphate in the peripheral blood mononuclear cells of human immunodeficiency virus-infected patients.
Topics: Animals; Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Leukocytes, Mononuclear; Rabbits; Radioimmunoassay; Zidovudine | 1998 |
Taste and smell complaints in HIV-infected patients.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Clarithromycin; Didanosine; Female; HIV Infections; Humans; Indinavir; Lamivudine; Male; Middle Aged; Quality of Life; Ritonavir; Smell; Surveys and Questionnaires; Taste; Trimethoprim, Sulfamethoxazole Drug Combination; Zidovudine | 1998 |
Effect of antiretroviral therapy and viral load on the perceived risk of HIV transmission and the need for safer sexual practices.
Topics: Anti-HIV Agents; Attitude to Health; CD4 Lymphocyte Count; Female; HIV Infections; Humans; Lamivudine; Male; Protease Inhibitors; Reverse Transcriptase Inhibitors; Risk Factors; Sexual Behavior; Sexual Partners; Sexually Transmitted Diseases, Viral; Surveys and Questionnaires; Viral Load; Zidovudine | 1998 |
Cost of preventing HIV infection after sexual exposure.
Topics: Anti-HIV Agents; Cost-Benefit Analysis; Female; HIV Infections; Humans; Indinavir; Lamivudine; Male; Models, Theoretical; Reproducibility of Results; Sexual Behavior; Zidovudine | 1998 |
Intracellular nucleotides of (-)-2',3'-deoxy-3'-thiacytidine in peripheral blood mononuclear cells of a patient infected with human immunodeficiency virus.
Topics: Anti-HIV Agents; Cells, Cultured; Chromatography, High Pressure Liquid; HIV Infections; Humans; Lamivudine; Leukocytes, Mononuclear; Nucleotides | 1998 |
Precipitous declines in hemoglobin levels associated with combination zidovudine and lamivudine therapy.
Topics: Adult; Anemia; Anti-HIV Agents; Drug Therapy, Combination; Female; Hemoglobins; HIV Infections; Humans; Lamivudine; Male; Reverse Transcriptase Inhibitors; Zidovudine | 1998 |
Acute generalized exanthematous pustulosis: a cutaneous adverse effect due to prophylactic antiviral therapy with protease inhibitor.
Topics: Acute Disease; Adult; Anti-HIV Agents; Diagnosis, Differential; Drug Eruptions; Exanthema; HIV Infections; Humans; Lamivudine; Male; Protease Inhibitors; Skin Diseases, Vesiculobullous; Zidovudine | 1998 |
Rapidly evolving hepatitis C virus-related cirrhosis in a human immunodeficiency virus-infected patient receiving triple antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Drug Therapy, Combination; Female; Hepatitis C; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Liver Cirrhosis; Reverse Transcriptase Inhibitors; Stavudine | 1998 |
Highly active antiretroviral therapy during early HIV infection reverses T-cell activation and maturation abnormalities. Swiss HIV Cohort Study.
Topics: Acute Disease; ADP-ribosyl Cyclase; ADP-ribosyl Cyclase 1; Anti-HIV Agents; Antigens, CD; Antigens, Differentiation; Biomarkers; Female; HIV Infections; HLA-DR Antigens; Humans; Lamivudine; Leukocyte Common Antigens; Lymphocyte Activation; Lymphocyte Count; Male; Membrane Glycoproteins; NAD+ Nucleosidase; Prospective Studies; Ritonavir; RNA, Viral; T-Lymphocytes; Viral Load; Zidovudine | 1998 |
Phase III results of second-generation HIV protease inhibitor reported.
Topics: Anti-HIV Agents; Carbamates; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Sulfonamides; Viral Load; Zidovudine | 1998 |
Decay of HIV-1 DNA in patients receiving suppressive antiretroviral therapy.
Topics: Adult; Amino Acid Sequence; Anti-HIV Agents; Base Sequence; CD4 Lymphocyte Count; DNA, Viral; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Genes, pol; Genotype; Half-Life; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Indinavir; Lamivudine; Leukocytes, Mononuclear; Longitudinal Studies; Male; Molecular Sequence Data; Mutation; Retrospective Studies; RNA, Viral; Zidovudine | 1998 |
Expression of CD38 on CD8 T cells predicts maintenance of high viraemia in HAART-treated HIV-1-infected children. Highly active antiretroviral therapy.
Topics: ADP-ribosyl Cyclase; ADP-ribosyl Cyclase 1; Antigens, CD; Antigens, Differentiation; CD8-Positive T-Lymphocytes; Child; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Membrane Glycoproteins; NAD+ Nucleosidase; Stavudine; Viremia | 1998 |
HIV-1 peripheral neuropathy and combination antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Male; Middle Aged; Nelfinavir; Nevirapine; Peripheral Nervous System Diseases; Saquinavir; Zidovudine | 1998 |
Report updates recommendations for health workers exposed to HIV.
Topics: Anti-HIV Agents; Drug Administration Schedule; Drug Therapy, Combination; Health Personnel; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Occupational Exposure; Practice Guidelines as Topic; United States; United States Public Health Service; Zidovudine | 1998 |
Immunologic and virologic response of HIV-2 infection to antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; DNA, Viral; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-2; Humans; Indinavir; Lamivudine; Male; Proviruses; Reverse Transcriptase Inhibitors; Viral Load; Zidovudine | 1998 |
Adhesive capsulitis of the shoulder induced by protease inhibitor therapy. Three new cases.
Topics: Adult; Bursitis; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Male; Middle Aged; Shoulder Joint; Stavudine | 1998 |
[Clinical case of the month. Apropos of pancytopenia in a seropositive patient].
Topics: Adult; Anemia, Aplastic; Anti-HIV Agents; Bone Marrow; HIV Infections; HIV Seropositivity; HIV-1; Humans; Indinavir; Lamivudine; Male; Pancytopenia; Stavudine; Zidovudine | 1998 |
Persistent parvovirus B19 related anemia of seven years' duration in an HIV-infected patient: complete remission associated with highly active antiretroviral therapy.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Erythrocyte Transfusion; HIV Infections; Humans; Immunoglobulins, Intravenous; Lamivudine; Male; Parvoviridae Infections; Parvovirus B19, Human; Red-Cell Aplasia, Pure; Remission Induction; Ritonavir; Saquinavir; Zidovudine | 1999 |
Genotypic and phenotypic resistance under zidovudine and lamivudine therapy in human immunodeficiency virus-infected children.
Topics: Anti-HIV Agents; Child; Child, Preschool; Drug Resistance; Female; Genotype; HIV Infections; HIV-1; Humans; Infant; Lamivudine; Male; Phenotype; Zidovudine | 1999 |
Cheap treatment cuts HIV transmission.
Topics: Africa; Anti-HIV Agents; Controlled Clinical Trials as Topic; Drug Therapy, Combination; Ethics, Medical; Female; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Labor, Obstetric; Lamivudine; Placebos; Pregnancy; Pregnancy Complications, Infectious; Zidovudine | 1999 |
Antiretroviral drugs: new agents, new combinations line up against HIV.
Topics: Antiviral Agents; Australia; Didanosine; Drug Therapy, Combination; Europe; HIV; HIV Infections; Humans; Lamivudine; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Ritonavir; Thiazoles; United States; Valine; Zalcitabine; Zidovudine | 1996 |
PHS recommends preventive drugs for HIV exposures.
Topics: Antiviral Agents; Health Personnel; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Occupational Exposure; Pyridines; United States; United States Public Health Service; Virus Replication; Zalcitabine; Zidovudine | 1996 |
Modelling the cost effectiveness of lamivudine/zidovudine combination therapy in HIV infection.
Topics: Adult; Cost-Benefit Analysis; Drug Combinations; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Models, Economic; Zidovudine | 1997 |
The cost-effectiveness of treatment with lamivudine and zidovudine compared with zidovudine alone: a comparison of Markov model and trial data estimates.
Topics: Cost-Benefit Analysis; Drug Therapy, Combination; Health Care Costs; HIV Infections; Humans; Lamivudine; Markov Chains; Models, Econometric; Reverse Transcriptase Inhibitors; United States; Zidovudine | 1998 |
Early lipodystrophy occurring during post-exposure prophylaxis.
Topics: Adult; Anti-HIV Agents; HIV Infections; Homosexuality, Male; Humans; Lamivudine; Lipodystrophy; Male; Rape; Zidovudine | 1998 |
Persistent alterations in T-cell repertoire, cytokine and chemokine receptor gene expression after 1 year of highly active antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; CD4-Positive T-Lymphocytes; Cytokines; Female; Gene Expression; HIV Infections; HIV Protease Inhibitors; Humans; Interferon-gamma; Interleukin-10; Interleukin-13; Interleukin-2; Interleukin-4; Lamivudine; Longitudinal Studies; Male; Receptors, CCR3; Receptors, CCR5; Receptors, Chemokine; Receptors, CXCR4; Receptors, Interleukin; Receptors, Interleukin-12; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Messenger; Saquinavir; Zidovudine | 1999 |
Combined stavudine and lamivudine during pregnancy.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant; Lamivudine; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors; Stavudine | 1999 |
Combination antiretroviral therapy including ritonavir in children infected with human immunodeficiency.
Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Zidovudine | 1999 |
Highly active antiretroviral therapy used to treat concurrent hepatitis B and human immunodeficiency virus infections.
Topics: Adult; Anti-HIV Agents; Biopsy, Needle; Drug Therapy, Combination; Gene Products, pol; Hepatitis B Antibodies; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Liver; Male; Zidovudine | 1999 |
[AZT and 3TC treatment in a pregnant woman with HIV infection].
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Pregnancy; Pregnancy Complications, Infectious; Zidovudine | 1999 |
Modeling the long-term outcomes and costs of HIV antiretroviral therapy using HIV RNA levels: application to a clinical trial.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Cost-Benefit Analysis; Costs and Cost Analysis; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Models, Biological; Models, Economic; Outcome and Process Assessment, Health Care; Reverse Transcriptase Inhibitors; RNA, Viral; Time Factors; Treatment Outcome; Viral Load; Zidovudine | 1999 |
[Infectious diseases in 1998].
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-HIV Agents; Antiviral Agents; Bacterial Vaccines; Blood Donors; Clinical Trials as Topic; Drug Therapy, Combination; Hepatitis C; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Interferons; Lamivudine; Middle Aged; Multicenter Studies as Topic; Pneumonia, Pneumococcal; Randomized Controlled Trials as Topic; Ribavirin; Streptococcus pneumoniae; Transfusion Reaction; Zidovudine | 1999 |
Antiviral treatment for human immunodeficiency virus patients co-infected with hepatitis B virus: combined effect for both infections, an obtainable goal?
Topics: Anti-HIV Agents; DNA, Viral; Drug Resistance, Microbial; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Recurrence | 1999 |
Paronychia associated with antiretroviral therapy.
Topics: Administration, Topical; Adult; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Inflammatory Agents; Clobetasol; Drug Therapy, Combination; Female; Glucocorticoids; HIV Infections; Humans; Indinavir; Lamivudine; Male; Middle Aged; Mupirocin; Paronychia | 1999 |
New nucleoside analog.
Topics: Drug Administration Schedule; HIV Infections; Humans; Lamivudine; Nucleosides; Reverse Transcriptase Inhibitors; Viral Load | 1999 |
Salvage therapy with ritonavir-saquinavir plus two nucleoside reverse transcriptase inhibitors in patients failing with amprenavir-zidovudine-lamivudine.
Topics: Adult; Anti-HIV Agents; Carbamates; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; Salvage Therapy; Saquinavir; Sulfonamides; Zidovudine | 1999 |
HBV resistance in HIV patients.
Topics: Anti-HIV Agents; Drug Resistance, Microbial; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine | 1999 |
Needle-stick injuries and HIV infection: a surgeon's personal experience and review of postexposure prophylaxis. St. Paul's Ocular AIDS Group.
Topics: Anti-HIV Agents; Dacryocystorhinostomy; Drug Therapy, Combination; HIV Infections; HIV Seropositivity; Humans; Indinavir; Infectious Disease Transmission, Patient-to-Professional; Lamivudine; Male; Middle Aged; Needlestick Injuries; Occupational Exposure; Ophthalmology; Primary Prevention; Risk Factors; Zidovudine | 1999 |
Levels of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte effector and memory responses decline after suppression of viremia with highly active antiretroviral therapy.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Cytotoxicity, Immunologic; Drug Therapy, Combination; Epitopes, T-Lymphocyte; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Immunologic Memory; Indinavir; Lamivudine; Longitudinal Studies; Reverse Transcriptase Inhibitors; Stavudine; T-Lymphocytes, Cytotoxic; Viral Load; Viremia; Zidovudine | 1999 |
Multiple drug resistance genotype causing failure of antiretroviral treatment in an HIV-infected patient heavily exposed to nucleoside analogues.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Multiple; Drug Therapy, Combination; Genes, MDR; HIV Infections; HIV-1; Humans; Lamivudine; Male; Nucleosides; Point Mutation; Zidovudine | 1999 |
Presence of mutation conferring resistance to lamivudine in plasma and cerebrospinal fluid of HIV-1-infected patients.
Topics: Anti-HIV Agents; Drug Resistance, Microbial; Genes, pol; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Point Mutation; Polymerase Chain Reaction; RNA, Viral | 1999 |
Antiviral effect of AZT versus stavudine in combination with lamivudine and indinavir in the context of a populational study.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Male; Stavudine; Viremia; Zidovudine | 1999 |
Human immunodeficiency virus and hepatitis B virus co-infection in two siblings: viral loads markedly reduced by triple-therapy including lamivudine.
Topics: Anti-HIV Agents; Child, Preschool; Comorbidity; DNA, Viral; Drug Therapy, Combination; Hepatitis B; HIV Infections; HIV-1; Humans; Lamivudine; Male; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load | 1999 |
Is nucleoside analogue monotherapy sufficient for treatment of HBV infection? Lessons from HIV.
Topics: 2-Aminopurine; Anti-HIV Agents; Antiviral Agents; Deoxyguanosine; Famciclovir; Hepatitis B; HIV Infections; Humans; Lamivudine | 1999 |
IAS position paper on prevention of HIV 1 mother-to-child transmission. International Aids Society.
Topics: Anti-HIV Agents; Child, Preschool; Developing Countries; Female; HIV Infections; HIV-1; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Pregnancy; Pregnancy Complications, Infectious; Program Development; Reverse Transcriptase Inhibitors; Societies, Medical; Zidovudine | 1999 |
Dynamics of viral load rebound and immunological changes after stopping effective antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cerebrospinal Fluid; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Immunophenotyping; Lamivudine; Lymphocyte Activation; Lymphoid Tissue; Male; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Stavudine; Viral Load | 1999 |
Long-term antiretroviral combination therapy including lamivudine in HIV-1 infected women during pregnancy.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors | 1999 |
Hepatitis B virus (HBV) mutations associated with resistance to lamivudine in patients coinfected with HBV and human immunodeficiency virus.
Topics: Anti-HIV Agents; Drug Resistance, Microbial; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Mutation | 1999 |
Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Drug Resistance; Hepatitis B e Antigens; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Recurrence; Retrospective Studies; Treatment Failure | 1999 |
Quality of life in asymptomatic patients with early HIV infection initiating antiretroviral therapy. Swiss HIV Cohort Study.
Topics: Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Quality of Life; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Ritonavir; Sickness Impact Profile; Zidovudine | 1999 |
The use of human immunodeficiency virus postexposure prophylaxis after successful artificial insemination.
Topics: Adult; Antiviral Agents; Female; HIV Infections; HIV Seropositivity; Humans; Indinavir; Insemination, Artificial, Heterologous; Lamivudine; Male; Pregnancy; Tissue Donors; Zidovudine | 1999 |
Rapid development of genotypic resistance to lamivudine when combined with zidovudine in pregnancy.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Mutation; Polymerase Chain Reaction; Pregnancy; Pregnancy Complications, Infectious; Prospective Studies; RNA-Directed DNA Polymerase; Viral Load; Zidovudine | 1999 |
Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues.
Topics: Acidosis, Lactic; Anti-HIV Agents; Child, Preschool; DNA, Mitochondrial; Female; France; HIV Infections; HIV-1; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Maternal-Fetal Exchange; Mitochondrial Encephalomyopathies; Pregnancy; Prenatal Exposure Delayed Effects; Reference Values; Retrospective Studies; Zidovudine | 1999 |
Diabetic ketoacidosis in an HIV patient: a new mechanism of HIV protease inhibitor-induced glucose intolerance.
Topics: Diabetic Ketoacidosis; Drug Therapy, Combination; Glucose Intolerance; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Stavudine | 1999 |
Pharmacokinetics of nelfinavir in an HIV patient with renal insufficiency.
Topics: Anti-HIV Agents; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Renal Insufficiency; Reverse Transcriptase Inhibitors; Zidovudine | 1999 |
Avascular necrosis in HIV infection.
Topics: Adult; Anti-HIV Agents; Follow-Up Studies; HIV Infections; Humans; Lamivudine; Male; Osteonecrosis; Reverse Transcriptase Inhibitors; Saquinavir | 1999 |
Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients.
Topics: Adult; Amino Acid Sequence; Anti-HIV Agents; Cohort Studies; DNA-Directed DNA Polymerase; DNA, Viral; Drug Resistance, Microbial; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Polymerase Chain Reaction | 1999 |
Combination therapy with alpha interferon and lamivudine in patients with chronic hepatitis B and HIV infection.
Topics: Adult; Anti-HIV Agents; Antiviral Agents; Drug Therapy, Combination; Hepatitis B, Chronic; HIV Infections; Humans; Interferon-alpha; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Treatment Outcome | 1999 |
Nucleoside analogues achieve high concentrations in seminal plasma: relationship between drug concentration and virus burden.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; RNA, Viral; Semen; Viral Load; Zidovudine | 1999 |
Severe anemia as a newly recognized side-effect caused by lamivudine.
Topics: Anemia; Anti-HIV Agents; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Zidovudine | 1999 |
Saquinavir hard gel suppresses viral load insufficiently in HIV-infected patients naive to anti-retroviral therapy: a retrospective cohort study.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Controlled Clinical Trials as Topic; Denmark; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Male; Multicenter Studies as Topic; Retrospective Studies; Ritonavir; RNA, Viral; Saquinavir; Viral Load; Zidovudine | 1999 |
The name game: lamivudine-lamotrigine dispensing error presenting as human immunodeficiency virus-associated fever of unknown origin.
Topics: Adult; Anti-HIV Agents; Anticonvulsants; Fever of Unknown Origin; HIV Infections; Humans; Lamivudine; Lamotrigine; Male; Medication Errors; Triazines | 1999 |
Highly active antiretroviral therapy: progress and pitfalls.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; HIV Infections; Humans; Indinavir; Lamivudine; Stavudine; Virus Replication | 1999 |
Clinical and immuno-virologic characterization of the efficacy of stavudine, lamivudine, and indinavir in human immunodeficiency virus infection.
Topics: Adolescent; Anti-HIV Agents; CD4 Lymphocyte Count; Cell Division; Child; Drug Therapy, Combination; HIV Infections; Humans; Hypersensitivity, Delayed; Indinavir; Infectious Disease Transmission, Vertical; Lamivudine; Skin Tests; Stavudine; T-Lymphocytes; Treatment Outcome | 1999 |
Highly active anti-retroviral therapy (HAART) is associated with a lower level of CD4+ T cell apoptosis in HIV-infected patients.
Topics: Adult; Aged; Anti-HIV Agents; Apoptosis; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Didanosine; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Middle Aged; Multivariate Analysis; Retrospective Studies; Stavudine; Viral Load; Zalcitabine; Zidovudine | 1999 |
Activation of CD8 T cells normalizes and correlates with the level of infectious provirus in tonsils during highly active antiretroviral therapy in early HIV-1 infection.
Topics: ADP-ribosyl Cyclase; ADP-ribosyl Cyclase 1; Adult; Anti-HIV Agents; Antigens, CD; Antigens, Differentiation; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Female; HIV Infections; HIV-1; HLA-DR Antigens; Humans; Indinavir; Lamivudine; Lymphocyte Activation; Male; Membrane Glycoproteins; NAD+ Nucleosidase; Palatine Tonsil; Proviruses; T-Lymphocyte Subsets; Time Factors; Viremia; Virus Replication; Zidovudine | 1999 |
Selective vertical transmission of HIV: lamivudine-resistant maternal clone undetectable by conventional resistance testing.
Topics: Adult; Anti-HIV Agents; Base Sequence; DNA Primers; Drug Resistance, Microbial; Female; HIV Infections; HIV Reverse Transcriptase; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Pregnancy; Pregnancy Complications, Infectious | 1999 |
Plasma platelet-activating factor acetylhydrolase activity in human immunodeficiency virus infection and the acquired immunodeficiency syndrome.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Acquired Immunodeficiency Syndrome; Acute-Phase Proteins; Adult; Anti-HIV Agents; Cytokines; Female; HIV Infections; Humans; Infections; Lamivudine; Lipids; Lipoproteins; Male; Middle Aged; Phospholipases A; Protease Inhibitors | 1999 |
Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort.
Topics: Adult; Aged; Anti-HIV Agents; CD4 Lymphocyte Count; Cohort Studies; Didanosine; Disease Progression; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Incidence; Indinavir; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Risk Factors; Ritonavir; RNA, Viral; Salvage Therapy; Saquinavir; Stavudine; Switzerland; Treatment Failure; Viral Load; Zalcitabine; Zidovudine | 1999 |
Effect of combination antiretroviral therapy on T-cell immunity in acute human immunodeficiency virus type 1 infection.
Topics: Acute Disease; Adult; Anti-HIV Agents; Candida; CD4 Lymphocyte Count; Chronic Disease; Cytokines; Cytotoxicity, Immunologic; Drug Therapy, Combination; Female; HIV Antigens; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Lymphocyte Activation; Male; Middle Aged; Prospective Studies; T-Lymphocytes; Tetanus Toxoid; Viral Load; Zidovudine | 2000 |
Thymic size and lymphocyte restoration in patients with human immunodeficiency virus infection after 48 weeks of zidovudine, lamivudine, and ritonavir therapy.
Topics: Adult; Aged; Anti-HIV Agents; CD4-Positive T-Lymphocytes; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lymphocytes; Male; Middle Aged; Ritonavir; T-Lymphocyte Subsets; Thymus Gland; Tomography; Zidovudine | 2000 |
Stavudine, lamivudine and indinavir in drug abusing and non-drug abusing HIV-infected patients: adherence, side effects and efficacy.
Topics: Adult; Anti-HIV Agents; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Male; Patient Compliance; Reverse Transcriptase Inhibitors; Stavudine; Substance Abuse, Intravenous | 1999 |
Quantitation of human immunodeficiency virus type 1 group O load in plasma by measuring reverse transcriptase activity.
Topics: Adult; Anti-HIV Agents; Female; Guinea; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Indinavir; Lamivudine; Male; Middle Aged; Molecular Sequence Data; Spain; Stavudine; Viral Load; Viremia | 2000 |
Complete reversibility of severe nucleoside-induced lipodystrophy.
Topics: Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Lipodystrophy; Middle Aged; Reverse Transcriptase Inhibitors; Stavudine | 1999 |
Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens.
Topics: Anti-HIV Agents; Drug Resistance, Microbial; Drug Therapy, Combination; Genotype; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Phenotype; RNA, Viral; Treatment Failure; Viral Load; Zidovudine | 2000 |
Remission of HIV myelopathy after highly active antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Nelfinavir; Remission Induction; Spinal Cord Diseases; Stavudine | 2000 |
Effortless unintentional smoking cessation after lamivudine-zidovudine-indinavir post-exposure anti-HIV chemoprophylaxis.
Topics: Adult; Anti-HIV Agents; HIV Infections; Humans; Indinavir; Lamivudine; Male; Smoking; Smoking Cessation; Zidovudine | 1999 |
[Emergence of resistant hepatitis B virus strains during long-term lamivudine therapy in human immunodeficiency virus co-infected patients].
Topics: Adult; Anti-HIV Agents; Drug Resistance, Microbial; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Middle Aged; Prospective Studies; Time Factors | 2000 |
A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V.
Topics: Anti-HIV Agents; Drug Resistance, Microbial; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutagenesis, Site-Directed; Mutation; Phenotype; Reverse Transcriptase Inhibitors; Sequence Analysis, DNA; Zidovudine | 2000 |
Antiviral activity of 2'-deoxy-3'-oxa-4'-thiocytidine (BCH-10652) against lamivudine-resistant human immunodeficiency virus type 1 in SCID-hu Thy/Liv mice.
Topics: Animals; Anti-HIV Agents; Deoxycytidine; Disease Models, Animal; Drug Resistance, Microbial; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Leukocytes, Mononuclear; Mice; Mice, SCID; Reverse Transcriptase Inhibitors; Thionucleosides; Virus Replication | 2000 |
Drugs for HIV infection.
Topics: Anti-HIV Agents; Didanosine; Dideoxynucleosides; Drug Costs; Drug Therapy, Combination; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors; Stavudine; Zalcitabine; Zidovudine | 2000 |
[Thrombocytopenic thrombotic purpura, HIV, and antiviral therapy].
Topics: Adult; Anti-HIV Agents; HIV Infections; Humans; Indinavir; Lamivudine; Purpura, Thrombotic Thrombocytopenic; Stavudine | 1999 |
Initiation of antiretroviral therapy during primary HIV-1 infection induces rapid stabilization of the T-cell receptor beta chain repertoire and reduces the level of T-cell oligoclonality.
Topics: Acute Disease; Anti-HIV Agents; Clone Cells; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; Gene Rearrangement, beta-Chain T-Cell Antigen Receptor; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Indinavir; Lamivudine; Lymphocyte Activation; Polymerase Chain Reaction; RNA-Directed DNA Polymerase; Saquinavir; T-Lymphocytes, Cytotoxic; Viremia; Zidovudine | 2000 |
A model of HIV-1 pathogenesis that includes an intracellular delay.
Topics: Anti-HIV Agents; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Models, Biological; Numerical Analysis, Computer-Assisted; Reverse Transcriptase Inhibitors; Zidovudine | 2000 |
Tolerability and side-effects of post-exposure prophylaxis for HIV infection.
Topics: Anti-HIV Agents; Drug Combinations; Drug Tolerance; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; London; Needlestick Injuries; Patient Compliance; Personnel, Hospital; Retrospective Studies; Zidovudine | 2000 |
Emergence of dual resistance to zidovudine and lamivudine in HIV-1-infected patients treated with zidovudine plus lamivudine as initial therapy.
Topics: Amino Acid Sequence; Anti-HIV Agents; Codon; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Molecular Sequence Data; Mutation; Randomized Controlled Trials as Topic; Reverse Transcriptase Inhibitors; Sequence Homology, Amino Acid; Zidovudine | 2000 |
Normalization of CD4+ cell numbers and reduced levels of memory CD8+ cells in blood and tonsillar tissue after highly active antiretroviral therapy in early HIV type-1 infection.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Immunologic Memory; Indinavir; Lamivudine; Male; Palatine Tonsil; Reverse Transcriptase Inhibitors; T-Lymphocyte Subsets; Time Factors; Viremia; Zidovudine | 2000 |
Are nelfinavir-containing regimens effective as second-line triple therapy?
Topics: Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Nelfinavir; Nevirapine; Retrospective Studies; Reverse Transcriptase Inhibitors; Stavudine | 2000 |
Early immune reconstitution after potent antiretroviral therapy in HIV-infected children correlates with the increase in thymus volume.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Child; Cohort Studies; Didanosine; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Organ Size; Reverse Transcriptase Inhibitors; Stavudine; Thymus Gland; Viral Load; Zidovudine | 2000 |
[First HIV triple therapy with one tablet].
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Combinations; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Tablets; Zidovudine | 2000 |
Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA.
Topics: Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cohort Studies; Dideoxynucleosides; Furans; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Lymph Nodes; Nelfinavir; Reverse Transcriptase Inhibitors; RNA, Viral; Saquinavir; Stavudine; Sulfonamides; Time Factors; Viral Load; Viremia; Zidovudine | 2000 |
The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis.
Topics: Adenosine Triphosphate; Anti-HIV Agents; Base Sequence; Diphosphates; DNA, Viral; Drug Resistance, Microbial; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Molecular Sequence Data; Mutation; Reverse Transcriptase Inhibitors; Templates, Genetic; Zidovudine | 2000 |
Mitigation of hepato-cellular injury caused by HAART with glycyrrhizin compound in patients co-infected with HIV and HCV.
Topics: Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Cysteine; Drug Combinations; Drug Therapy, Combination; Glycine; Glycyrrhetinic Acid; Hemophilia A; Hepatitis C; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Stavudine; Viral Load; Zalcitabine; Zidovudine | 1999 |
[A two-year follow-up of zidovudine plus lamivudine combined with indinavir in antivival naive HIV-infected patients].
Topics: Anti-HIV Agents; Drug Therapy, Combination; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Reverse Transcriptase Inhibitors; Zidovudine | 2000 |
Amprenavir study results released.
Topics: Anti-HIV Agents; Carbamates; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Sulfonamides; Viral Load; Zidovudine | 1999 |
Anti-human immunodeficiency virus type 1 (HIV-1) CD8(+) T-lymphocyte reactivity during combination antiretroviral therapy in HIV-1-infected patients with advanced immunodeficiency.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; Cell Lineage; Drug Therapy, Combination; Gene Products, gag; Gene Products, pol; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Interferon-gamma; Lamivudine; Longitudinal Studies; Lymphocyte Activation; Peptides; Phenotype; Phosphoproteins; Reverse Transcriptase Inhibitors; T-Lymphocytes, Cytotoxic; Viral Load; Viral Matrix Proteins; Zidovudine | 2000 |
The efficacy and tolerability of combination antiretroviral therapy in pregnancy: infant and maternal outcome.
Topics: Adolescent; Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Infant; Lamivudine; Male; Nelfinavir; Nevirapine; Pregnancy; Pregnancy Outcome; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Treatment Outcome; Zidovudine | 2000 |
Immune repopulation after HAART in previously untreated HIV-1-infected children. Paediatric European Network for Treatment of AIDS (PENTA) Steering Committee.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Dideoxynucleosides; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; HIV-1; Humans; Immunologic Memory; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Male; Nelfinavir; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load; Zidovudine | 2000 |
Baseline HIV type 1 genotypic resistance to a newly added nucleoside analog is predictive of virologic failure of the new therapy.
Topics: CD4 Lymphocyte Count; Didanosine; Drug Resistance, Microbial; Female; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Polymerase Chain Reaction; Predictive Value of Tests; Retrospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Viral Load; Zalcitabine; Zidovudine | 2000 |
HAART and Mycobacterium avium complex in an HIV infected patient with severe factor VII deficiency.
Topics: Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; CD4 Lymphocyte Count; Factor VII Deficiency; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Male; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine | 2000 |
Efavirenz in HIV infection.
Topics: Alkynes; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Oxazines; Research Design; Reverse Transcriptase Inhibitors; RNA, Viral; Viral Load; Zidovudine | 2000 |
Specific recognition of lamivudine-resistant HIV-1 by cytotoxic T lymphocytes.
Topics: Adult; Anti-HIV Agents; Cell Line; Cytotoxicity, Immunologic; Drug Resistance, Microbial; Drug Therapy, Combination; Epitopes, T-Lymphocyte; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; HLA-A2 Antigen; Humans; Lamivudine; Lymphocyte Activation; Male; Mutation; Reverse Transcriptase Inhibitors; T-Lymphocytes, Cytotoxic | 2000 |
Highly active antiretroviral therapy inhibits cytokine production in HIV-uninfected subjects.
Topics: Adult; Anti-HIV Agents; Child; Cytokines; Drug Therapy, Combination; HIV Infections; HIV Seronegativity; Humans; Indinavir; Lamivudine; Reverse Transcriptase Inhibitors; Zidovudine | 2000 |
Primary lamivudine resistance in acute/early human immunodeficiency virus infection.
Topics: Acute Disease; Adult; Anti-HIV Agents; Drug Resistance, Microbial; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Lamivudine; Male; Reverse Transcriptase Inhibitors; Viral Load | 1999 |
Decreased exposure to saquinavir in HIV-1-infected patients after long-term antiretroviral therapy including ritonavir and saquinavir.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; RNA, Viral; Saquinavir; Stavudine; Time Factors | 2000 |
Post-kala-azar dermal leishmaniasis during highly active antiretroviral therapy in an AIDS patient infected with Leishmania infantum.
Topics: Adult; Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; Humans; Indinavir; Lamivudine; Leishmania infantum; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Stavudine | 2000 |
Cutaneous side effects induced by indinavir.
Topics: Adult; Alopecia; Didanosine; Drug Eruptions; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Lipodystrophy; Male; Middle Aged; Pruritus; Pyoderma Gangrenosum; Retrospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Scalp Dermatoses; Skin; Stavudine; Zalcitabine; Zidovudine | 2000 |
Zidovudine + lamivudine: new preparation. Fewer tablets required.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Drug Combinations; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Zidovudine | 1999 |
Prevalence of primary resistance to zidovudine and lamivudine in drug-naive human immunodeficiency virus type-1 infected patients: high proportion of reverse transcriptase codon 215 mutant in circulating lymphocytes and free virus.
Topics: Anti-HIV Agents; Codon; DNA, Viral; Drug Resistance, Microbial; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Lymphocytes; Nucleic Acid Hybridization; Polymerase Chain Reaction; Proviruses; Reverse Transcriptase Inhibitors; RNA, Viral; Viral Load; Zidovudine | 2000 |
Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: the relative roles of drift and selection.
Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; Drug Resistance, Microbial; Gene Frequency; HIV Infections; HIV-1; Humans; Lamivudine; Male; Point Mutation; Reverse Transcriptase Inhibitors; Selection, Genetic; Stochastic Processes; Viral Load | 2000 |
Failure to develop HIV infection after receipt of HIV-contaminated blood and postexposure prophylaxis.
Topics: Adolescent; Anti-HIV Agents; Drug Administration Schedule; Drug Therapy, Combination; HIV; HIV Infections; Humans; Indinavir; Lamivudine; Nelfinavir; Transfusion Reaction; Zidovudine | 2000 |
Simultaneous determination of lamivudine and zidovudine concentrations in human seminal plasma using high-performance liquid chromatography and tandem mass spectrometry.
Topics: Anti-HIV Agents; Calibration; Chromatography, High Pressure Liquid; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Male; Mass Spectrometry; Reference Standards; Reverse Transcriptase Inhibitors; Semen; Zidovudine | 2000 |
Evolution of lamivudine-resistant hepatitis B virus and HIV-1 in co-infected individuals: an analysis of the CAESAR study. CAESAR co-ordinating committee.
Topics: CD4 Lymphocyte Count; Drug Resistance, Microbial; Hepatitis B; Hepatitis B virus; HIV Infections; HIV-1; Humans; Lamivudine; Retrospective Studies; Reverse Transcriptase Inhibitors; Viral Load | 2000 |
Onset of HIV-1 antibody production after highly active antiretroviral therapy in a seronegative HIV-1-infected child.
Topics: Anti-HIV Agents; Antibody Formation; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female; HIV Antibodies; HIV Infections; HIV Seronegativity; HIV-1; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Nelfinavir; Pregnancy; Pregnancy Complications, Infectious; Viremia; Zidovudine | 2000 |
Steatosis-lactic acidosis syndrome associated with stavudine and lamivudine therapy.
Topics: Acidosis, Lactic; Adult; Anti-HIV Agents; Fatal Outcome; Fatty Liver; Female; Hepatomegaly; HIV Infections; Humans; Lamivudine; Stavudine; Syndrome | 2000 |
Efavirenz decreases methadone blood concentrations.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Interactions; Female; HIV Infections; Humans; Lamivudine; Methadone; Oxazines; Reverse Transcriptase Inhibitors; Stavudine; Substance Withdrawal Syndrome | 2000 |
[Human immunodeficiency virus: current pregnancy aspects].
Topics: Anti-HIV Agents; Cesarean Section; Drug Therapy, Combination; Female; HIV Infections; HIV-1; HIV-2; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Pregnancy; Pregnancy Complications, Infectious; Zidovudine | 2000 |
[Antiretroviral drugs and pregnancy: apropos of an alert regarding mitochondrial pathology and nucleoside analogs].
Topics: Abnormalities, Drug-Induced; Animals; Anti-HIV Agents; Female; HIV Infections; Humans; Lamivudine; Mitochondrial Myopathies; Pregnancy; Pregnancy Complications, Infectious; Reverse Transcriptase Inhibitors; Risk; Zidovudine | 2000 |
Correlation between human immunodeficiency virus genotypic resistance and virologic response in patients receiving nelfinavir monotherapy or nelfinavir with lamivudine and zidovudine.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Resistance, Microbial; Drug Therapy, Combination; Genotype; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Mutation; Nelfinavir; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; RNA, Viral; Zidovudine | 2000 |
Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection.
Topics: Absorptiometry, Photon; Adipose Tissue; Adult; Cohort Studies; Didanosine; Female; HIV Infections; HIV Protease Inhibitors; HIV Wasting Syndrome; Humans; Lamivudine; Longitudinal Studies; Male; Middle Aged; Reverse Transcriptase Inhibitors; Risk Factors; Stavudine; Time Factors; Zidovudine | 2000 |
Lactic acidosis associated with nucleoside analog therapy in an HIV-positive patient.
Topics: Acidosis, Lactic; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Diagnosis, Differential; Female; HIV Infections; Humans; Lamivudine; Nevirapine; Reverse Transcriptase Inhibitors; Stavudine | 2000 |
Adherence, side effects and efficacy of stavudine plus lamivudine plus nelfinavir in treatment-experienced HIV-infected patients.
Topics: Adult; CD4 Lymphocyte Count; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Logistic Models; Male; Nelfinavir; Patient Compliance; Polymerase Chain Reaction; Prospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Statistics, Nonparametric; Stavudine; Substance Abuse, Intravenous | 2000 |
Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2'-deoxy-3'-oxa-4'-thiocytidine, dOTC].
Topics: Anti-HIV Agents; Cells, Cultured; Deoxycytidine; Didanosine; Drug Combinations; Drug Resistance, Microbial; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Molecular Structure; Mutation; Nevirapine; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Stavudine; T-Lymphocytes; Thionucleosides; Zidovudine | 2000 |
The effect of highly active antiretroviral therapy on binding and neutralizing antibody responses to human immunodeficiency virus type 1 infection.
Topics: Anti-HIV Agents; Carbamates; Dideoxynucleosides; Furans; HIV Antibodies; HIV Core Protein p24; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Lamivudine; Neutralization Tests; Ritonavir; Sulfonamides; Zidovudine | 2000 |
Surveillance of antiretroviral prescriptions.
Topics: Anti-HIV Agents; Data Collection; Drug Prescriptions; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Nelfinavir; Puerto Rico; Stavudine; United States | 2000 |
Intensification of background antiretroviral therapy with abacavir during low-level failure may restore optimal suppression.
Topics: Adult; Aged; Anti-HIV Agents; Dideoxynucleosides; Drug Resistance; Female; Follow-Up Studies; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Retrospective Studies; Reverse Transcriptase Inhibitors; RNA, Viral; Treatment Failure; Viral Load; Zidovudine | 2000 |
Dynamics of HIV-1 viral load rebound among patients with previous suppression of viral replication.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Male; Models, Biological; Predictive Value of Tests; Reverse Transcriptase Inhibitors; RNA, Viral; Viral Load; Virus Replication; Zidovudine | 2000 |
Mitochondrial and peroxisomal dysfunction following perinatal exposure to antiretroviral drugs.
Topics: Anti-HIV Agents; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Lamivudine; Male; Mitochondria; Perinatal Care; Peroxisomes; Pregnancy; Pregnancy Complications, Infectious; Prenatal Exposure Delayed Effects; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Zidovudine | 2000 |
Drugs for non-HIV viral infections.
Topics: 2-Aminopurine; Acetamides; Acyclovir; Aged; Amantadine; Animals; Anti-HIV Agents; Antiviral Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Enzyme Inhibitors; Famciclovir; Ganciclovir; Guanidines; Guanine; Herpes Simplex; Herpes Zoster; History, 18th Century; HIV Infections; Humans; Injections, Intravenous; Interferon-alpha; Lamivudine; Neuraminidase; Oseltamivir; Pyrans; Rats; Ribavirin; Sialic Acids; Teratogens; Valacyclovir; Valine; Zanamivir | 1999 |
[Lactic acidosis type B. A life-threatening adverse effect of antiretroviral therapy].
Topics: Acidosis, Lactic; Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Stavudine | 2000 |
Concentrations of nevirapine, lamivudine and stavudine in semen of HIV-1-infected men.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; HIV Infections; HIV-1; Humans; Lamivudine; Male; Nevirapine; Prospective Studies; Reverse Transcriptase Inhibitors; Semen; Stavudine | 2000 |
Postexposure prophylaxis for HIV after sexual assault.
Topics: Adult; Anti-HIV Agents; Chemoprevention; Female; HIV Infections; Humans; Lamivudine; Male; Retrospective Studies; San Francisco; Sex Offenses; Zidovudine | 2000 |
Abacavir: new preparation. Risks limit the value.
Topics: Adult; Antiviral Agents; Child; Clinical Trials as Topic; Cost-Benefit Analysis; Dideoxynucleosides; Drug Hypersensitivity; Drug Interactions; Drug Therapy, Combination; France; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Risk Assessment; Treatment Outcome; Zidovudine | 2000 |
Prevention of mother-child HIV transmission: progress and problems.
Topics: Africa; Antiviral Agents; Breast Feeding; Cesarean Section; Clinical Trials as Topic; Cohort Studies; Developing Countries; Drug Therapy, Combination; Europe; Female; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Mitochondrial Myopathies; Nervous System Diseases; Nevirapine; Pregnancy; Pregnancy Trimester, Third; Reverse Transcriptase Inhibitors; Thailand; United States; Zidovudine | 2000 |
[Antiretroviral therapy in HIV infection. Effects of the introduction of new drugs on health care expenditures, 1994-1999].
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Cohort Studies; Drug Costs; Drug Prescriptions; Health Expenditures; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Italy; Lamivudine; Retrospective Studies; Reverse Transcriptase Inhibitors | 2000 |
Hepatitis B exacerbation with a precore mutant virus following withdrawal of lamivudine in a human immunodeficiency virus-infected patient.
Topics: Adult; Anti-HIV Agents; Female; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV-1; Humans; Lamivudine; Mutation | 2000 |
Brief report: effect of antiretroviral agents on T-lymphocyte subset counts in healthy HIV-negative individuals. The Italian Registry on Antiretroviral Postexposure Prophylaxis.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Female; Health Personnel; HIV Infections; HIV Seronegativity; Humans; Lamivudine; Longitudinal Studies; Lymphocyte Count; Male; Occupational Diseases; Retrospective Studies; T-Lymphocyte Subsets; Zidovudine | 2000 |
Simultaneous quantitation of intracellular zidovudine and lamivudine triphosphates in human immunodeficiency virus-infected individuals.
Topics: Anti-HIV Agents; Chromatography, Ion Exchange; Cytidine Triphosphate; Dideoxynucleotides; HIV Infections; Humans; Lamivudine; Reference Standards; Thymine Nucleotides; Zidovudine | 2000 |
Evidence of a source of HIV type 1 within the central nervous system by ultraintensive sampling of cerebrospinal fluid and plasma.
Topics: Adult; Anti-HIV Agents; Central Nervous System; Drug Resistance, Microbial; Genetic Variation; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Nelfinavir; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Time Factors | 2000 |
Exacerbation of hepatitis B infection following cessation of lamivudine therapy.
Topics: Adult; Anti-HIV Agents; Female; Hepatitis C, Chronic; HIV Infections; Humans; Lamivudine; Recurrence | 2000 |
Antiviral resistance of biologic HIV-2 clones obtained from individuals on nucleoside reverse transcriptase inhibitor therapy.
Topics: Adult; Amino Acid Sequence; Consensus Sequence; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Genes, Viral; Genotype; HIV Infections; HIV-2; Humans; Lamivudine; Male; Molecular Sequence Data; Phenotype; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Zidovudine | 2000 |
Prevalence of novel lamivudine-resistant genotypes (E44D/A, V118I) in naive and pretreated HIV-infected individuals.
Topics: Anti-HIV Agents; Drug Resistance, Microbial; Genome, Viral; HIV Infections; Humans; Lamivudine; Spain | 2000 |
Lactic acidosis secondary to nucleoside analogue antiretroviral therapy.
Topics: Acidosis, Lactic; Anti-HIV Agents; Female; HIV Infections; Humans; Lamivudine; Middle Aged; Reverse Transcriptase Inhibitors; Stavudine | 2000 |
A genotypic analysis of patients receiving Zidovudine with either Lamivudine, Didanosine or Zalcitabine dual therapy using the LiPA point mutation assay to detect genotypic variation at codons 41, 69, 70, 74, 184 and 215.
Topics: Anti-HIV Agents; Codon; Didanosine; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; Genotype; HIV Infections; HIV Seropositivity; HIV-1; Humans; Lamivudine; Nucleic Acid Hybridization; Point Mutation; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Zalcitabine; Zidovudine | 2000 |
[Prevalence of primary mutations in human immunodeficiency virus with resistance to nucleoside analogues in previously untreated patients from Andalusia. Andalusian Group for the Study of Infectious diseases (GAEI)].
Topics: Adult; Anti-HIV Agents; CD4 Antigens; Codon; Data Interpretation, Statistical; DNA, Viral; Drug Resistance, Microbial; Female; Genotype; HIV; HIV Infections; Humans; Lamivudine; Male; Mutation; Polymerase Chain Reaction; Reverse Transcriptase Inhibitors; RNA, Viral; Spain; Viral Load; Zidovudine | 2000 |
Sudden unexpected death as a consequence of indinavir-induced nephropathy. A case report.
Topics: Acute Kidney Injury; AIDS Dementia Complex; Antiretroviral Therapy, Highly Active; Crystallization; Death, Sudden, Cardiac; Diagnosis, Differential; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Male; Middle Aged; Solubility; Stavudine; Syncope; Ventricular Fibrillation; Water-Electrolyte Imbalance | 2000 |
Comparison of T-cell subsets' reconstitution after 12 months of highly active antiretroviral therapy initiated during early versus advanced states of HIV disease.
Topics: Adult; Aged; Antibodies, Monoclonal; Antiretroviral Therapy, Highly Active; Female; Flow Cytometry; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Lymphocyte Activation; Lymphocyte Count; Male; Middle Aged; Pilot Projects; Prospective Studies; Reverse Transcriptase Inhibitors; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; RNA, Viral; Scintillation Counting; Statistics, Nonparametric; Stavudine; T-Lymphocyte Subsets; Tritium; Viral Load | 2000 |
Multicenter review of protease inhibitors in 89 pregnancies.
Topics: Adolescent; Adult; Antiretroviral Therapy, Highly Active; Apgar Score; CD4-Positive T-Lymphocytes; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Linear Models; Multicenter Studies as Topic; Pregnancy; Pregnancy Complications, Infectious; Puerto Rico; Regression Analysis; Retrospective Studies; Reverse Transcriptase Inhibitors; Surveys and Questionnaires; United States; Viral Load; Zidovudine | 2000 |
Sustained responses to dual nucleoside therapy in women.
Topics: Adult; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Middle Aged; Reverse Transcriptase Inhibitors; Stavudine; Viral Load; Zidovudine | 2000 |
Simultaneous quantitation of the 5'-triphosphate metabolites of zidovudine, lamivudine, and stavudine in peripheral mononuclear blood cells of HIV infected patients by high-performance liquid chromatography tandem mass spectrometry.
Topics: Anti-HIV Agents; Calibration; Chromatography, High Pressure Liquid; Cytidine Triphosphate; Dideoxynucleotides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Mass Spectrometry; Monocytes; Reference Standards; Sensitivity and Specificity; Stavudine; Thymine Nucleotides; Zidovudine | 2000 |
Oral lesions in HIV/AIDS patients undergoing highly active antiretroviral treatment including protease inhibitors: a new face of oral AIDS?
Topics: Adult; Aged; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Candidiasis, Oral; Case-Control Studies; CD4 Lymphocyte Count; Female; Gingivitis; Herpes Labialis; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Leukoplakia, Hairy; Male; Middle Aged; Mouth Diseases; Periodontitis; Prevalence; Viral Load; Xerostomia; Zidovudine | 2000 |
Highly active antiretroviral therapy normalizes the potential for MIP-1alpha production in HIV infection.
Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cells, Cultured; Chemokine CCL3; Chemokine CCL4; Chemokine CCL5; Disease Progression; Enzyme-Linked Immunosorbent Assay; Female; HIV Infections; HIV-1; Humans; Lamivudine; Lymphocyte Count; Lymphocytes; Macrophage Inflammatory Proteins; Male; Nelfinavir; Stavudine; Viral Load; Viremia | 2000 |
A multiple-site-specific heteroduplex tracking assay as a tool for the study of viral population dynamics.
Topics: Antiviral Agents; Base Sequence; Cross-Sectional Studies; DNA Probes; Drug Resistance, Microbial; Evolution, Molecular; Genetic Variation; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Longitudinal Studies; Nevirapine; Nucleic Acid Heteroduplexes; Point Mutation; Reproducibility of Results; Reverse Transcriptase Inhibitors; RNA, Viral; Saquinavir; Selection, Genetic; Sensitivity and Specificity | 2001 |
Dosage of lamivudine in a haemodialysis patient.
Topics: Adult; AIDS-Related Complex; Anti-HIV Agents; HIV Infections; Humans; Kidney Failure, Chronic; Lamivudine; Male; Renal Dialysis | 2000 |
Selective expansion of a minor proportion of drug-resistant HIV-1 by antiretroviral pressure in vitro.
Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; Cells, Cultured; Drug Resistance, Microbial; Genetic Variation; Genotype; HIV Infections; HIV-1; Humans; Lamivudine; Oligonucleotide Array Sequence Analysis; Phenotype; Reverse Transcriptase Inhibitors; Selection, Genetic; Zidovudine | 2000 |
Reduction in CD8+ cell noncytotoxic anti-HIV activity in individuals receiving highly active antiretroviral therapy during primary infection.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4-CD8 Ratio; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Depression, Chemical; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hydroxyurea; Immunity, Cellular; Indinavir; Lamivudine; Lymphocyte Count; Male; Middle Aged; Nelfinavir; Reverse Transcriptase Inhibitors; RNA, Viral; Stavudine; Treatment Refusal; Viral Load; Viremia; Zidovudine | 2001 |
Induction-maintenance (5 --> 3 drugs) in HIV-infected patients with high viral load.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; HIV Infections; Humans; Lamivudine; Nelfinavir; Nitriles; Prospective Studies; Pyrrolidines; Remission Induction; Saquinavir; Stavudine; Treatment Outcome; Viral Load | 2000 |
Protease inhibitor therapy in HIV-infected children.
Topics: Adolescent; Age Factors; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Child; Child, Preschool; Didanosine; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Lamivudine; Male; Nelfinavir; Patient Compliance; Retrospective Studies; Stavudine; Treatment Outcome; Viral Load; Zidovudine | 2000 |
Indinavir, zidovudine, lamivudine: 3-year follow-up.
Topics: Anti-HIV Agents; Drug Therapy, Combination; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Kidney Calculi; Lamivudine; Risk Factors; Zidovudine | 2001 |
Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco PEP Study.
Topics: Adolescent; Adult; Aged; Anti-HIV Agents; Contact Tracing; Counseling; Didanosine; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Nelfinavir; Patient Compliance; Reverse Transcriptase Inhibitors; Risk Factors; Risk-Taking; Sexually Transmitted Diseases, Viral; Substance Abuse, Intravenous; Time Factors; Zidovudine | 2001 |
Increased turnover of CCR5+ and redistribution of CCR5- CD4 T lymphocytes during primary human immunodeficiency virus type 1 infection.
Topics: Adult; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Dideoxynucleosides; Epstein-Barr Virus Infections; Flow Cytometry; Furans; Genotype; HIV Infections; HIV-1; Humans; Immunoglobulin M; Lamivudine; Longitudinal Studies; Male; Proto-Oncogene Proteins c-bcl-2; Receptors, CCR5; Sulfonamides; Time Factors; Zidovudine | 2001 |
Association between high serum prolactin levels and concomitant infections in HIV-infected patients.
Topics: Adolescent; Adult; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Anti-Infective Agents; CD4-CD8 Ratio; Female; HIV Infections; Humans; Immunoglobulins; Indinavir; Lamivudine; Male; Prolactin; Sex Factors; T-Lymphocyte Subsets; Trimethoprim, Sulfamethoxazole Drug Combination; Viral Load; Zidovudine | 2001 |
FDA approves Trizivir for HIV infection.
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Approval; Drug Combinations; HIV Infections; Humans; Lamivudine; United States; United States Food and Drug Administration; Zidovudine | 2000 |
Changes in host cell molecules acquired by circulating HIV-1 in patients treated with highly active antiretroviral therapy and interleukin-2.
Topics: Anti-HIV Agents; Antigens, CD; Antiretroviral Therapy, Highly Active; B7-2 Antigen; CD4 Lymphocyte Count; CD58 Antigens; Fas Ligand Protein; HIV Infections; HIV Protease Inhibitors; HIV-1; HLA-DR Antigens; Humans; Indinavir; Interleukin-2; L-Selectin; Lamivudine; Leukocyte Common Antigens; Membrane Glycoproteins; Membrane Proteins; Reverse Transcriptase Inhibitors; Stavudine; Viremia; Virion | 2001 |
Renal tubular acidosis and hypophosphataemia after treatment with nucleoside reverse transcriptase inhibitors.
Topics: Acidosis, Renal Tubular; Adult; Anti-HIV Agents; Female; HIV Infections; Humans; Hypophosphatemia; Lamivudine; Reverse Transcriptase Inhibitors; Stavudine | 2001 |
Triple-drug tablet approved for HIV infection.
Topics: Anti-HIV Agents; Chemistry, Pharmaceutical; Dideoxynucleosides; Drug Combinations; Drug Labeling; HIV Infections; Humans; Lamivudine; Tablets; Zidovudine | 2001 |
Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures--worldwide, 1997-2000.
Topics: Adult; Anti-HIV Agents; Chemical and Drug Induced Liver Injury; Drug Eruptions; Female; HIV Infections; Humans; Lamivudine; Liver Failure; Male; Nevirapine; Occupational Exposure; Reverse Transcriptase Inhibitors; Rhabdomyolysis; Zidovudine | 2001 |
Treatment interruption after one year of triple nucleoside analogue therapy for primary HIV infection.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Time Factors; Viral Load; Zidovudine | 2001 |
In vitro evolution of the human immunodeficiency virus type 1 gag-protease region and maintenance of reverse transcriptase resistance following prolonged drug exposure.
Topics: Drug Resistance, Microbial; Drug Resistance, Multiple; Evolution, Molecular; Gene Products, gag; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Microbial Sensitivity Tests; Molecular Sequence Data; Reverse Transcriptase Inhibitors; Zidovudine | 2001 |
Quantification of HIV-1 proviral DNA in patients with undetectable plasma viremia over long-term highly active antiretroviral therapy.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; DNA, Viral; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Polymerase Chain Reaction; Proviruses; Reverse Transcriptase Inhibitors; RNA, Viral; Time Factors; Viremia; Zidovudine | 2000 |
Primary genotypic and phenotypic HIV-1 drug resistance in recent seroconverters in Madrid.
Topics: Drug Resistance, Microbial; Drug Resistance, Multiple; Genotype; HIV Infections; HIV Protease; HIV Reverse Transcriptase; HIV Seropositivity; HIV-1; Humans; Lamivudine; Mutation; Phenotype; Protease Inhibitors; Reverse Transcriptase Inhibitors; Spain; Viral Load; Zidovudine | 2001 |
Evaluation of chronic hepatitis B virus (HBV) infection in coinfected patients receiving lamivudine as a component of anti-human immunodeficiency virus regimens.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Drug Resistance; Female; Hepatitis B Antibodies; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; Humans; Lamivudine; Male; Prospective Studies; Viral Load | 2001 |
[Bilateral hip necrosis, corticoids, and human immunodeficiency virus protease inhibitors].
Topics: Aged; Antiretroviral Therapy, Highly Active; Dexamethasone; Didanosine; Femur Head Necrosis; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Male; Prednisone; Zidovudine | 2001 |
Dynamics of seminal plasma HIV-1 decline after antiretroviral treatment.
Topics: Alkynes; Antiretroviral Therapy, Highly Active; Antiviral Agents; Benzoxazines; Cyclopropanes; Didanosine; Environmental Monitoring; HIV Infections; HIV-1; Humans; Hydroxyurea; Lamivudine; Male; Oxazines; Semen; Time Factors; Viral Load | 2001 |
Failure of postexposure prophylaxis after sexual exposure to HIV.
Topics: Adult; Antiretroviral Therapy, Highly Active; Copulation; Female; HIV Antibodies; HIV Infections; HIV-1; Humans; Lamivudine; Male; Nelfinavir; Treatment Failure; Viral Load; Zidovudine | 2001 |
Residual human immunodeficiency virus (HIV) Type 1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years.
Topics: Cohort Studies; DNA, Viral; Female; Genitalia; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Longitudinal Studies; Lymph Nodes; Male; Molecular Sequence Data; Randomized Controlled Trials as Topic; RNA, Viral; Time Factors; Viral Load; Viremia; Virus Replication; Zidovudine | 2001 |
Reduced HIV-stimulated T-helper cell reactivity in cord blood with short-course antiretroviral treatment for prevention of maternal-infant transmission.
Topics: Amino Acid Sequence; Anti-HIV Agents; Clinical Trials as Topic; Female; Fetal Blood; Gene Products, env; HIV Infections; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Male; Molecular Sequence Data; Peptide Fragments; South Africa; T-Lymphocytes, Helper-Inducer; Zidovudine | 2001 |
[Management of pregnant women infected with HIV at Bichat Hospital between 1990 and 1998: analysis of 202 pregnancies].
Topics: Africa South of the Sahara; Antiviral Agents; Cesarean Section; Female; France; Hepatitis B; Hepatitis C; HIV Infections; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Papillomaviridae; Papillomavirus Infections; Pregnancy; Pregnancy Complications, Infectious; Risk Factors; Sexually Transmitted Diseases; Zidovudine | 2001 |
Viral excretion in cervicovaginal secretions of HIV-1-infected women receiving antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; DNA, Viral; Female; Genitalia, Female; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Longitudinal Studies; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Statistics, Nonparametric; Viral Load; Viremia; Virus Shedding; Zidovudine | 2001 |
Combination prophylaxis for prevention of maternal-infant HIV transmission: beyond 076.
Topics: Adult; Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Pregnancy; Pregnancy Complications, Infectious; Zidovudine | 2001 |
Mutations in the non-nucleoside binding-pocket interfere with the multi-nucleoside resistance phenotype.
Topics: Anti-HIV Agents; Antiviral Agents; Binding Sites; Drug Resistance, Microbial; Drug Resistance, Multiple; Genotype; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Nucleosides; Phenotype; Quinoxalines; Reverse Transcriptase Inhibitors | 2001 |
Tolerability of postexposure prophylaxis with zidovudine, lamivudine, and nelfinavir for human immunodeficiency virus infection.
Topics: Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Nelfinavir; Prospective Studies; Reverse Transcriptase Inhibitors; Zidovudine | 2001 |
Smaller amounts of antiretroviral drugs are needed when combined with an active ribozyme against HIV-1.
Topics: Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cell Line; Cyclopropanes; Didanosine; Dose-Response Relationship, Drug; Enzyme Inhibitors; HIV Core Protein p24; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Oxazines; Protease Inhibitors; Reverse Transcriptase Inhibitors; RNA, Catalytic; T-Lymphocytes; Time Factors | 2001 |
Resistance to (-)-2',3'-dideoxy-3'-thiacytidine (3TC) in HIV-1 isolated from paediatric patients.
Topics: Anti-HIV Agents; Child; Codon; Drug Resistance, Microbial; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Longitudinal Studies; Male; Mutation; Phenotype; Reverse Transcriptase Inhibitors; Viral Load | 1996 |
Impact of antiretroviral therapy on hepatitis C viraemia in HIV-infected patients.
Topics: Anti-HIV Agents; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Lamivudine; RNA, Viral; Viremia; Zidovudine | 1996 |
Results of long-term follow-up of HIV-infected patients treated with lamivudine monotherapy, followed by a combination of lamivudine and zidovudine.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Follow-Up Studies; HIV Infections; Humans; Lamivudine; Male; Zidovudine | 1997 |
Hypercholesterolemia in a health care worker receiving thyroxine after postexposure prophylaxis for human immunodeficiency virus infection.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Interactions; Female; Health Personnel; HIV Infections; HIV Protease Inhibitors; Humans; Hypercholesterolemia; Indinavir; Lamivudine; Nelfinavir; Occupational Exposure; Reverse Transcriptase Inhibitors; Thyroxine; Zidovudine | 2001 |
Combination trials with 3TC/AZT stopped as clinical benefit shown.
Topics: Anti-HIV Agents; Disease Progression; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Multicenter Studies as Topic | 1996 |
AIDS treatments seek to eradicate virus, restore immunity.
Topics: Adjuvants, Immunologic; Anti-HIV Agents; Combined Modality Therapy; HIV Infections; Humans; Lamivudine; Ritonavir; Thymus Gland; Viral Load; Zidovudine | 1996 |
Glaxo Wellcome expands Patient Assistance Program for 3TC.
Topics: Anti-HIV Agents; Drug Costs; Drug Industry; HIV Infections; Humans; Lamivudine; Medical Assistance; State Government; United States | 1996 |
ACTG 315 drug cocktail restores immune function.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Ritonavir; RNA, Viral; Viral Load; Zidovudine | 1997 |
Anti-HIV effects of nelfinavir reported after ten months of combination therapy.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lymphoid Tissue; Nelfinavir; Zidovudine | 1997 |
Head-to-head study of protease inhibitors.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Saquinavir; Zidovudine | 1998 |
Data in from first head-to-head protease inhibitor.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Saquinavir; Viral Load; Zidovudine | 1998 |
Double protease inhibitor regimens with amprenavir show promise.
Topics: Anti-HIV Agents; Carbamates; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Saquinavir; Sulfonamides; Viral Load; Zidovudine | 1998 |
AZT studies reinforce benefits of combination.
Topics: Antiviral Agents; CD4-Positive T-Lymphocytes; Didanosine; Drug Synergism; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Lymphocyte Count; Zalcitabine; Zidovudine | 1995 |
Combination 3TC/AZT therapy shows promise.
Topics: CD4 Lymphocyte Count; Codon; Drug Resistance; Drug Therapy, Combination; Drug Tolerance; HIV Infections; Humans; Lamivudine; Mutation; Zalcitabine; Zidovudine | 1995 |
Clinical progress and transmission perils stressed at second human retroviruses conference.
Topics: Acyclovir; AIDS Vaccines; AIDS-Related Opportunistic Infections; Antineoplastic Agents; Antiviral Agents; CD4 Lymphocyte Count; Cytomegalovirus Retinitis; Herpesviridae; HIV Infections; Humans; Interleukin-2; Lamivudine; Lymphoma, Non-Hodgkin; Retroviridae; Sarcoma, Kaposi; Zalcitabine; Zidovudine | 1995 |
Treatment briefs.
Topics: CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Industry; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Nerve Growth Factors; Nervous System Diseases; Pyridines; Recombinant Proteins; Stavudine; Zalcitabine; Zidovudine | 1995 |
3TC rules change again.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Health Care Rationing; Health Priorities; HIV Infections; Humans; Lamivudine; Pharmaceutical Services; United States; Zalcitabine | 1995 |
3TC: the good news and the bad news.
Topics: CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Therapy, Combination; Europe; HIV Infections; Humans; Lamivudine; United States; Zalcitabine; Zidovudine | 1995 |
What we know about anti-HIV drugs.
Topics: Antiviral Agents; Didanosine; DNA, Viral; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; RNA, Viral; Stavudine; Zalcitabine; Zidovudine | 1995 |
3TC expanded access update.
Topics: Antiviral Agents; HIV Infections; Humans; Lamivudine; Zalcitabine | 1995 |
Lamivudine useful against hepatitis B-HIV co-infection.
Topics: Antiviral Agents; CD4 Lymphocyte Count; DNA, Viral; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Virus Replication; Zalcitabine; Zidovudine | 1995 |
Combination antiretroviral treatment: new views, evolving practices.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Cells, Cultured; Clinical Trials as Topic; Drug Administration Schedule; Drug Approval; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; United States; United States Food and Drug Administration; Zalcitabine; Zidovudine | 1995 |
Combination treatment and single drugs: interview with Margaret Poscher, M.D. Interview by John S. James.
Topics: Acyclovir; Administration, Oral; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Ganciclovir; HIV Infections; Humans; Lamivudine; Stavudine; Zalcitabine; Zidovudine | 1995 |
New antiretroviral strategies: interview with Marcus Conant, M.D. Interview by John S. James.
Topics: Antiviral Agents; CD4 Lymphocyte Count; DNA, Viral; Drug Therapy, Combination; HIV; HIV Infections; Humans; Isoquinolines; Lamivudine; Peripheral Nervous System Diseases; Protease Inhibitors; Quinolines; Saquinavir; Stavudine; Zalcitabine; Zidovudine | 1995 |
A closer look at 3TC. Interview by Mark Mascolini.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; Hepatitis B; HIV Infections; Humans; Lamivudine; Zalcitabine; Zidovudine | 1995 |
Antiretroviral drug resistance.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; RNA, Viral; Stavudine; Viremia; Zalcitabine; Zidovudine | 1995 |
A Lisbon traviata. Are clinicians ready to sing addio to monotherapy and libiamo to combinations?
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; HIV; HIV Infections; Humans; Hydroxyurea; Indinavir; Interleukin-2; Lamivudine; Mutation; Pyridines; RNA, Viral; Zalcitabine; Zidovudine | 1995 |
Update on clinical trials of combination therapies for HIV infection.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Child; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Hydroxyurea; Lamivudine; RNA-Directed DNA Polymerase; Stavudine; Zalcitabine; Zidovudine | 1995 |
Protease inhibitors and prevention of cross resistance.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Carbamates; Didanosine; Drug Resistance, Microbial; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Isoquinolines; Lamivudine; Nelfinavir; Pyridines; Quinolines; Saquinavir; Sulfonamides; Zalcitabine; Zidovudine | 1995 |
3TC and saquinavir: we need them now.
Topics: Antiviral Agents; Drug Approval; HIV Infections; HIV Protease Inhibitors; Humans; Isoquinolines; Lamivudine; Quinolines; Saquinavir; United States; United States Food and Drug Administration; Zalcitabine; Zidovudine | 1995 |
Roaches of inner space.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Infections; Lamivudine; Mutation; T-Lymphocytes, Cytotoxic; Virulence; Virus Replication; Zalcitabine; Zidovudine | 1995 |
Conference looks at HIV drug resistance.
Topics: Antiviral Agents; Carbamates; CD4 Lymphocyte Count; Drug Resistance, Microbial; Furans; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Isoquinolines; Lamivudine; Pyridines; Quinolines; Ritonavir; Saquinavir; Sulfonamides; Thiazoles; Valine; Viremia; Zalcitabine; Zidovudine | 1995 |
An interview with Charles A.B. Boucher, MD, PhD. Interview by Mark Mascolini.
Topics: Antiviral Agents; Drug Resistance, Microbial; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Mutation; RNA, Viral; Zalcitabine; Zidovudine | 1995 |
3TC/AZT: just another combination.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Zalcitabine; Zidovudine | 1995 |
FDA approves 3TC and saquinavir. Food and Drug Administration.
Topics: Antiviral Agents; Drug Approval; Drug Resistance, Microbial; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Isoquinolines; Lamivudine; Quinolines; Saquinavir; United States; United States Food and Drug Administration; Zalcitabine | 1995 |
Combination therapy increases survival.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Stavudine; Zalcitabine; Zidovudine | 1995 |
Lamivudine (3TC) approved for combination use with AZT.
Topics: Adult; Antiviral Agents; Drug Approval; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Zalcitabine; Zidovudine | 1995 |
3TC approved: now for the tough questions.
Topics: Adult; Antiviral Agents; CD4 Lymphocyte Count; Child; Drug Approval; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Mutation; Zalcitabine; Zidovudine | 1995 |
Merck protease inhibitor: more news from Retroviruses Conference.
Topics: CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Pyridines; Zalcitabine; Zidovudine | 1996 |
Potent new AIDS drugs underscore promise of combination therapy.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; CD4 Lymphocyte Count; Drug Approval; Drug Resistance; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV Seropositivity; Humans; Isoquinolines; Lamivudine; Quinolines; Saquinavir; United States; United States Food and Drug Administration; Zalcitabine; Zidovudine | 1996 |
Clinicians experiment with post-exposure drug pairs.
Topics: Antiviral Agents; Drug Synergism; Drug Therapy, Combination; Health Personnel; HIV Infections; Humans; Infectious Disease Transmission, Patient-to-Professional; Lamivudine; Needlestick Injuries; Occupational Exposure; Zalcitabine; Zidovudine | 1996 |
A surprisingly potent nucleoside analogue.
Topics: Adult; Antiviral Agents; HIV Infections; HIV-1; Humans; Lamivudine; Nucleosides; RNA, Viral; Zalcitabine; Zidovudine | 1996 |
AZT and 3TC.
Topics: CD4 Lymphocyte Count; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Zalcitabine; Zidovudine | 1996 |
CDC takes aggressive stance on postexposure prophylaxis. Centers for Disease Control and Prevention.
Topics: Antiviral Agents; Blood-Borne Pathogens; Centers for Disease Control and Prevention, U.S.; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Infectious Disease Transmission, Patient-to-Professional; Lamivudine; Occupational Exposure; Pyridines; Risk Factors; United States; Zalcitabine; Zidovudine | 1996 |
3TC: Glaxo Wellcome broadens patient assistance.
Topics: Antiviral Agents; Drug Industry; Financing, Organized; HIV Infections; Humans; Lamivudine; Zalcitabine | 1996 |
Nipping HIV in the bud.
Topics: Antiviral Agents; CD4 Lymphocyte Count; Didanosine; DNA, Viral; Drug Resistance, Microbial; Drug Therapy, Combination; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Isoquinolines; Lamivudine; Pyridines; Quinolines; Ritonavir; Saquinavir; Stavudine; Thiazoles; Valine; Virus Replication; Zalcitabine; Zidovudine | 1996 |
Top AIDS researchers' strategy for antiretroviral treatment.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; CD4 Lymphocyte Count; Didanosine; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Patient Compliance; Practice Guidelines as Topic; RNA, Viral; Stavudine; Zalcitabine; Zidovudine | 1996 |
3TC: combination trial stopped early as clinical benefit shown.
Topics: Antiviral Agents; Clinical Trials as Topic; Didanosine; Disease Progression; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Placebos; Treatment Failure; Zalcitabine; Zidovudine | 1996 |
3TC treatment may slow HIV mutations, development of drug resistance.
Topics: Drug Resistance, Microbial; HIV; HIV Infections; Humans; Lamivudine; Mutation; Zalcitabine | 1996 |
Eradication of HIV: the cutting edge of clinical trial design.
Topics: Antiviral Agents; Clinical Trials as Topic; Drug Therapy, Combination; HIV Infections; Humans; Indinavir; Lamivudine; Pyridines; Zalcitabine; Zidovudine | 1996 |
Outdated yet out-of-reach: AIDS society treatment guidelines at the International Conference.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Antiviral Agents; CD4 Lymphocyte Count; Decision Making; Didanosine; Drug Therapy, Combination; HIV; HIV Infections; Humans; Lamivudine; Practice Guidelines as Topic; Zalcitabine; Zidovudine | 1996 |
New findings bring hope to Vancouver AIDS conference.
Topics: Adult; AIDS Vaccines; Antiviral Agents; Clinical Trials as Topic; Developing Countries; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Lamivudine; Reverse Transcriptase Inhibitors; Ritonavir; Viral Load; Zidovudine | 1996 |
ddI and d4T plus protease inhibitors.
Topics: Anti-HIV Agents; Didanosine; HIV Infections; Humans; Lamivudine; Stavudine; Zalcitabine; Zidovudine | 1996 |
Dethroning AZT.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Didanosine; Drug Therapy, Combination; HIV Infections; Humans; Hydroxyurea; Lamivudine; Oxazines; Stavudine; Viral Load; Zidovudine | 1997 |
Study shows three drugs better than two.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Stavudine; United States; Zidovudine | 1997 |
Study confirms that protease inhibitor cocktail can delay HIV disease progression and death.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Reverse Transcriptase Inhibitors; United States; Zidovudine | 1997 |
NIAID researchers present new findings at retrovirus meeting. National Institute of Allergy and Infectious Diseases.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Chemokines; Clinical Trials as Topic; Clone Cells; Dendritic Cells; Didanosine; Disease Progression; Drug Therapy, Combination; Female; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Interleukin-10; Killer Cells, Natural; Lamivudine; Male; Nevirapine; Pyridines; Receptors, Cytokine; Reverse Transcriptase Inhibitors; Ritonavir; Virus Replication; Zalcitabine; Zidovudine | 1997 |
Nelfinavir at six months.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Child; Clinical Trials as Topic; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Isoquinolines; Lamivudine; Nelfinavir; Sulfonic Acids; Viral Load; Zidovudine | 1997 |
ACTG 320: last of the body count trials?
Topics: Anti-HIV Agents; Clinical Trials as Topic; Drug Therapy, Combination; Ethics, Medical; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Male; Reverse Transcriptase Inhibitors; Zidovudine | 1997 |
Nelfinavir - major trial results at retroviruses conference.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Isoquinolines; Lamivudine; Nelfinavir; Stavudine; Sulfonic Acids; Viral Load; Zidovudine | 1997 |
ICAAC update.
Topics: Acetamides; Acetophenones; Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Clinical Trials as Topic; Disease Progression; Drug Therapy, Combination; Drugs, Investigational; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Sulfonamides; Viral Load | 1996 |
New recommendations on health care worker exposure to HIV.
Topics: Anti-HIV Agents; Disease Transmission, Infectious; Drug Therapy, Combination; Guidelines as Topic; Health Personnel; HIV; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Occupational Exposure; Risk Factors; Viral Load; Zidovudine | 1996 |
Some relief from the epidemic.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Anti-HIV Agents; Centers for Disease Control and Prevention, U.S.; Drug Costs; Drug Therapy, Combination; Female; Health Services Accessibility; HIV Infections; HIV Protease Inhibitors; Hospitalization; Humans; Lamivudine; Male; New York City; Population Surveillance; Prevalence; United States | 1997 |
Spring cleaning in trial land.
Topics: Anti-HIV Agents; Brazil; CD4 Lymphocyte Count; Clinical Trials as Topic; Disease Progression; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Saquinavir; Stavudine; United States; Viral Load; Zidovudine | 1997 |
Newly approved PI provides treatment options.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Isoquinolines; Lamivudine; Nelfinavir; Sulfonic Acids; Viral Load; Zidovudine | 1997 |
3-drug therapy reduces deaths and new AIDS-related illnesses by 50%.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 1997 |
Nelfinavir (Viracept).
Topics: Adolescent; Anti-HIV Agents; CD4 Lymphocyte Count; Child; Child, Preschool; Drug Approval; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Isoquinolines; Lamivudine; Nelfinavir; Reverse Transcriptase Inhibitors; Sulfonic Acids; United States; United States Food and Drug Administration; Viral Load; Virus Replication; Zidovudine | 1997 |
141 (Vertex-478).
Topics: Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Clinical Trials, Phase II as Topic; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Sulfonamides; Viral Load; Zidovudine | 1997 |
Experience with PEP finds most patients stop early.
Topics: Anti-HIV Agents; British Columbia; Drug Therapy, Combination; Female; Health Services Accessibility; HIV Infections; Homosexuality, Male; Humans; Lamivudine; Male; Occupational Diseases; Patient Compliance; Sexually Transmitted Diseases; Time Factors; United States; Zidovudine | 1997 |
Combo therapy for children and adolescents.
Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Clinical Trials as Topic; Didanosine; Disease Progression; Drug Therapy, Combination; HIV Infections; Humans; Infant; Lamivudine; Zidovudine | 1997 |
Two drugs better than one for children.
Topics: Anti-HIV Agents; Child; Disease Progression; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Zidovudine | 1997 |
What you need to know about Combivir.
Topics: Anti-HIV Agents; Drug Combinations; Guidelines as Topic; HIV Infections; Humans; Lamivudine; Patient Compliance; Zidovudine | 1998 |
ACTG 343: three drugs better than two for maintaining HIV suppression.
Topics: AIDS Vaccines; Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Reverse Transcriptase Inhibitors; Saquinavir; Stavudine; Viral Load; Zidovudine | 1998 |
New ways to take old drugs.
Topics: Anti-HIV Agents; Biological Availability; Drug Combinations; Drug Storage; HIV Infections; Humans; Lamivudine; Saquinavir; Zidovudine | 1998 |
Reevaluating initial therapy.
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Didanosine; DNA, Viral; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Polymerase Chain Reaction; Stavudine; Viral Load; Zidovudine | 1998 |
New drugs: amprenavir and abacavir.
Topics: Anti-HIV Agents; Carbamates; CD4 Lymphocyte Count; Dideoxynucleosides; Drug Administration Schedule; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Sulfonamides; Viral Load; Zidovudine | 1998 |
New guidelines issued for occupational exposures.
Topics: Anti-HIV Agents; Drug Therapy, Combination; Health Personnel; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Occupational Exposure; Practice Guidelines as Topic; United States; United States Public Health Service; Zidovudine | 1998 |
Giving improper dose of HIV drug is not proof of indifference.
Topics: Anti-HIV Agents; Disabled Persons; Dose-Response Relationship, Drug; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Prisoners; Reverse Transcriptase Inhibitors; Texas; Zidovudine | 1998 |
Updated postexposure guidelines stress need for expert advice.
Topics: Anti-HIV Agents; Centers for Disease Control and Prevention, U.S.; Drug Therapy, Combination; Female; Guidelines as Topic; Health Personnel; HIV Infections; HIV Protease Inhibitors; Humans; Infectious Disease Transmission, Patient-to-Professional; Lamivudine; Male; Occupational Diseases; Occupational Exposure; Pregnancy; Registries; United States; Zidovudine | 1998 |
Registry finds 3 drugs most favored PEP regimen.
Topics: Anti-HIV Agents; Centers for Disease Control and Prevention, U.S.; Drug Combinations; Drug Therapy, Combination; Guidelines as Topic; Health Personnel; HIV Infections; HIV Protease Inhibitors; Humans; Infectious Disease Transmission, Patient-to-Professional; Lamivudine; Occupational Diseases; Occupational Exposure; Registries; United States; Zidovudine | 1998 |
New drugs on the horizon.
Topics: Adenine; Alkynes; Anti-HIV Agents; Benzoxazines; Carbamates; Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Oxazines; Reverse Transcriptase Inhibitors; Sulfonamides; United States; Zidovudine | 1998 |
Lower dose maintenance therapy?
Topics: Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Trials as Topic; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; RNA, Viral; Viral Load; Zidovudine | 1998 |
Too little of a good thing.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Nelfinavir; Patient Compliance; Peripheral Nervous System Diseases; Reverse Transcriptase Inhibitors; Stavudine; Viral Load | 1998 |
First once-daily drug simplifies dosing, offers new options in HIV-1 treatment.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Child; Cyclopropanes; Drug Resistance, Microbial; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Oxazines; Patient Compliance; Reverse Transcriptase Inhibitors; Zidovudine | 1998 |
A new approach to initial antiretroviral therapy: protease-sparing combination regimens.
Topics: Alkynes; Anti-HIV Agents; Antineoplastic Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; Drug Resistance, Microbial; Drug Therapy, Combination; Drugs, Investigational; HIV Infections; HIV Protease Inhibitors; Humans; Hydroxyurea; Lamivudine; Lipodystrophy; Oxazines; Reverse Transcriptase Inhibitors; Time Factors; Zidovudine | 1998 |
Triple-drug therapy may mean lifelong commitment.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Drug Therapy, Combination; France; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Patient Compliance; United States; Zidovudine | 1999 |
A new HAART on the horizon says the proof is in the potency.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Oxazines; Patient Compliance; Pregnancy; Reverse Transcriptase Inhibitors; Zidovudine | 1999 |
Some existing drugs work on resistant HIV.
Topics: Anti-HIV Agents; Carbamates; Dioxolanes; Drug Resistance, Microbial; Drug Therapy, Combination; Furans; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Purine Nucleosides; Pyridines; Pyrones; Sulfonamides | 2000 |
New study shows efavirenz effective with d4T and 3TC.
Topics: Alkynes; Anti-HIV Agents; Benzoxazines; Cerebrospinal Fluid; Clinical Trials as Topic; Cyclopropanes; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Male; Oxazines; Reverse Transcriptase Inhibitors; Stavudine; Vagina; Viral Load; Zidovudine | 1999 |
Opportunistic infections update.
Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Antiviral Agents; Drug Interactions; Drug Resistance, Microbial; Drug Therapy, Combination; Hepatitis B; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Lamivudine; Liver; Ribavirin | 1998 |
Promising findings from the PETRA study of perinatal transmission.
Topics: Anti-HIV Agents; Drug Therapy, Combination; Female; HIV Infections; Humans; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Lamivudine; Pregnancy; Randomized Controlled Trials as Topic; South Africa; Tanzania; Uganda; Zidovudine | 1999 |
3TC approved for children.
Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Drug Approval; HIV Infections; Humans; Infant; Lamivudine; Reverse Transcriptase Inhibitors; United States; United States Food and Drug Administration | 1999 |
Nukes alone.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Dideoxynucleosides; Drug Administration Schedule; Drug Therapy, Combination; France; HIV Infections; Humans; Lamivudine; Zidovudine | 1999 |
Indian pharmaceutical introduces low-priced 3TC.
Topics: Anti-HIV Agents; Drug Industry; HIV Infections; Humans; India; Lamivudine | 1998 |
Lamivudine-resistant hepatitis B detected in HIV-infected patients.
Topics: Anti-HIV Agents; Drug Resistance, Microbial; Hepatitis B; HIV Infections; Humans; Lamivudine; Mutation; Polymerase Chain Reaction | 1999 |
Any toxic relief in sight? The induction/maintenance approach to therapy.
Topics: Anti-HIV Agents; Clinical Trials as Topic; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Nelfinavir; Saquinavir; Stavudine; T-Lymphocytes; Viral Load; Virus Replication | 1998 |
Differing reverse transcriptase mutation patterns in individuals experiencing viral rebound on first-line regimens with stavudine/didanosine and stavudine/lamivudine.
Topics: Anti-HIV Agents; Didanosine; DNA Mutational Analysis; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Mutation; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Stavudine | 2001 |
[Compact therapy with 2 tablets daily. Initial triple combination tablet simplifies HIV therapy].
Topics: Anti-HIV Agents; Dideoxynucleosides; Drug Administration Schedule; Drug Combinations; HIV Infections; Humans; Lamivudine; Patient Compliance; Zidovudine | 2001 |
[Results of the TRIZAL Study. Therapy change with positive concomitant effect].
Topics: Anti-HIV Agents; Cholesterol; Clinical Trials as Topic; Dideoxynucleosides; Drug Combinations; HIV Infections; Humans; Lamivudine; Treatment Outcome; Triglycerides; Zidovudine | 2001 |
Residual human immunodeficiency virus type 1 infection in lymphoid tissue during highly active antiretroviral therapy: quantitation and virus characterization.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Disease Progression; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Lamivudine; Longitudinal Studies; Lymphoid Tissue; Phenotype; Proviruses; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Viral Load; Viremia; Virus Replication; Zidovudine | 2001 |
CT appearances of HIV-related lipodystrophy syndrome.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Mass Index; HIV Infections; Humans; Indinavir; Lamivudine; Lipodystrophy; Male; Tomography, X-Ray Computed; Treatment Outcome; Zidovudine | 2001 |
Choosing which nuke to use first.
Topics: Didanosine; Dideoxynucleosides; Drug Administration Schedule; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 2001 |
Selection by AZT and rapid replacement in the absence of drugs of HIV type 1 resistant to multiple nucleoside analogs.
Topics: Amino Acid Sequence; Anti-HIV Agents; Base Sequence; DNA, Viral; Drug Resistance, Microbial; Drug Resistance, Multiple; Evolution, Molecular; Genetic Heterogeneity; HIV Infections; HIV Protease Inhibitors; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Molecular Sequence Data; Mutagenesis, Insertional; Phylogeny; Reverse Transcriptase Inhibitors; Saquinavir; Stavudine; Time Factors; Zidovudine | 2001 |
[Symptomatic hyperlactemia in patients infected with the human immunodeficiency virus treated with nucleoside analogs].
Topics: Adult; Anti-HIV Agents; Didanosine; Female; HIV Infections; HIV Reverse Transcriptase; Humans; Lactic Acid; Lamivudine; Male; Reverse Transcriptase Inhibitors; Zidovudine | 2001 |
Prevalence and predictive value of intermittent viremia with combination hiv therapy.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Drug Resistance, Microbial; HIV; HIV Infections; Humans; Indinavir; Lamivudine; Predictive Value of Tests; Prevalence; Proportional Hazards Models; Retrospective Studies; RNA, Viral; Viral Load; Viremia; Virus Replication; Zidovudine | 2001 |
A pilot trial of indinavir, ritonavir, didanosine, and lamivudine in a once-daily four-drug regimen for HIV infection.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cholesterol; Didanosine; Drug Evaluation; Drug Therapy, Combination; Genotype; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Male; Middle Aged; Pilot Projects; Ritonavir; Safety; Treatment Outcome; Triglycerides; Viral Load | 2001 |
Long-term evaluation of T-cell subset changes after effective combination antiretroviral therapy during asymptomatic HIV-infection.
Topics: Anti-HIV Agents; Case-Control Studies; Female; HIV Infections; HLA-DR Antigens; Humans; Lamivudine; Leukocyte Common Antigens; Longitudinal Studies; Lymphocyte Count; Male; Prospective Studies; Randomized Controlled Trials as Topic; Retrospective Studies; Ritonavir; T-Lymphocyte Subsets; Viral Load; Zidovudine | 2001 |
Hepatitis B, lamivudine, and HIV.
Topics: Anti-HIV Agents; Drug Resistance, Microbial; Hepatitis B; HIV Infections; Humans; Lamivudine; Reverse Transcriptase Inhibitors | 2001 |
Susceptibility of human T cell leukemia virus type 1 to reverse-transcriptase inhibitors: evidence for resistance to lamivudine.
Topics: Amino Acid Sequence; Deltaretrovirus Infections; Drug Resistance, Microbial; HIV Infections; HIV Reverse Transcriptase; HIV-1; Human T-lymphotropic virus 1; Humans; Lamivudine; Microbial Sensitivity Tests; Molecular Sequence Data; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase | 2001 |
Potent antiretroviral therapy initiates normalization of hypergammaglobulinemia and a decline in HIV type 1-specific antibody responses.
Topics: Adult; Anti-HIV Agents; CD4-Positive T-Lymphocytes; Drug Therapy, Combination; Female; HIV Antibodies; HIV Core Protein p24; HIV Envelope Protein gp120; HIV Infections; HIV-1; Humans; Hypergammaglobulinemia; Immunoglobulin G; Lamivudine; Male; Middle Aged; Retrospective Studies; Ritonavir; RNA, Viral; Treatment Failure; Viral Load; Zidovudine | 2001 |
Lipid abnormalities in a healthcare worker receiving HIV prophylaxis.
Topics: Adult; Allied Health Personnel; Anti-HIV Agents; Cholesterol; Cholesterol, LDL; Drug Combinations; Drug Monitoring; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Hypercholesterolemia; Lamivudine; Needlestick Injuries; Nelfinavir; Practice Guidelines as Topic; Renal Dialysis; Reverse Transcriptase Inhibitors; Zidovudine | 2001 |
Neurological disorders after zidovudine exposure in utero.
Topics: Female; France; HIV Infections; Humans; Infant, Newborn; Lamivudine; Mitochondria; Neurotoxicity Syndromes; Pregnancy; Prenatal Exposure Delayed Effects; Retrospective Studies; United States; Zidovudine | 1999 |
[HIV-HBV coinfection and the liver].
Topics: Biopsy; Didanosine; Drug Therapy, Combination; Hepatitis B; HIV Infections; Humans; Lamivudine; Liver Cirrhosis; Male; Middle Aged; Ritonavir; Saquinavir; Stavudine | 2001 |
Antiretroviral rounds. When success is a pain.
Topics: Abdominal Pain; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Male; Nelfinavir; Oxazines; Reverse Transcriptase Inhibitors; Viral Load; Zidovudine | 2001 |
Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study.
Topics: Adenine; Adult; Alanine Transaminase; Anti-HIV Agents; Antiviral Agents; DNA, Viral; Drug Administration Schedule; Drug Resistance, Microbial; Female; Hepatitis B; Hepatitis B virus; HIV Infections; HIV-1; Humans; Lamivudine; Male; Organophosphonates; Pilot Projects; Viral Load | 2001 |
Recent advances in the management and treatment of GI and hepatic diseases associated with HIV: Part 2.
Topics: Amantadine; Antiviral Agents; Hepatitis B; Hepatitis C; HIV; HIV Infections; Humans; Interferon-alpha; Lamivudine; Risk Factors | 2001 |
An ALS-like syndrome with new HIV infection and complete response to antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Brain; Drug Therapy, Combination; Female; Follow-Up Studies; HIV Infections; Humans; Lamivudine; Magnetic Resonance Imaging; Motor Neuron Disease; Nelfinavir; Neurologic Examination; Treatment Outcome; Zidovudine | 2001 |
[Acceptance of antiretroviral therapy. HIV-infected patients assess convenient triple combination].
Topics: Anti-HIV Agents; Clinical Trials as Topic; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Patient Acceptance of Health Care; Patient Compliance; Zidovudine | 2001 |
Transient relapses ("blips") of plasma HIV RNA levels during HAART are associated with drug resistance.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; HIV; HIV Infections; Humans; Lamivudine; Mutation; Recurrence; Reverse Transcriptase Polymerase Chain Reaction; RNA, Viral; Viral Load | 2001 |
HIV/Hepatitis B and C co-infection: pathogenic interactions, natural history and therapy.
Topics: Antiretroviral Therapy, Highly Active; Antiviral Agents; Hepatitis B; Hepatitis C; HIV Infections; Humans; Interferon-alpha; Lamivudine | 2001 |
Acute hepatitis B by sexual transmission after interruption of lamivudine-containing antiretroviral regimen.
Topics: Acute Disease; Adult; Anti-HIV Agents; Coitus; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis B; HIV Infections; Humans; Lamivudine; Male; Pregnancy; Reverse Transcriptase Inhibitors; Sexually Transmitted Diseases, Viral | 2001 |
YMDD-mutant HBV strain as a cause of liver failure in an HIV-infected patient.
Topics: Adult; Drug Resistance, Microbial; Genotype; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Liver Failure; Male; Mutation; Reverse Transcriptase Inhibitors; Substance Abuse, Intravenous | 2001 |
Inhibition of purified recombinant reverse transcriptase from wild-type and zidovudine-resistant clinical isolates of human immunodeficiency virus type 1 by zidovudine, stavudine, and lamivudine triphosphates.
Topics: Anti-HIV Agents; Cytidine Triphosphate; Dideoxynucleotides; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Escherichia coli; HIV Infections; HIV-1; Lamivudine; Recombinant Proteins; Reverse Transcriptase Inhibitors; RNA-Directed DNA Polymerase; Stavudine; Thymine Nucleotides; Transfection; Zidovudine | 2001 |
Failure of combination therapy with lamivudine and famciclovir following lamivudine monotherapy for hepatitis B virus infection in patients coinfected with human immunodeficiency virus-1.
Topics: 2-Aminopurine; Antiviral Agents; Drug Resistance, Microbial; Drug Therapy, Combination; Famciclovir; Hepatitis B; Hepatitis B virus; HIV Infections; HIV-1; Humans; Lamivudine; Male; Mutation; Treatment Failure | 2001 |
Lamivudine (Epivir).
Topics: Drug Resistance, Microbial; HIV; HIV Infections; Humans; Lamivudine; Practice Guidelines as Topic; Reverse Transcriptase Inhibitors | 2000 |
Absolute lymphocyte count as surrogate for CD4+ cell count in monitoring response to antiretroviral therapy.
Topics: Adolescent; Adult; Analysis of Variance; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Female; HIV Infections; Humans; Lamivudine; Lymphocyte Count; Male; Middle Aged; Sensitivity and Specificity; Time Factors; Zidovudine | 2001 |
A simple, once-daily dosing regimen for treating HIV-1 infection in intravenous drug users.
Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Nevirapine; Pilot Projects; Polymerase Chain Reaction; RNA, Viral; Substance Abuse, Intravenous; Treatment Refusal; Viral Load | 2000 |
A case of lipodystrophy after the initiation of zidovudine, lamivudine and efavirenz in an asymptomatic HIV-1-infected patient.
Topics: Abdomen; Adipose Tissue; Adult; Alkynes; Benzoxazines; Cyclopropanes; Drug Therapy, Combination; HIV Infections; HIV-1; Humans; Lamivudine; Lipodystrophy; Male; Oxazines; Reverse Transcriptase Inhibitors; Tomography, X-Ray Computed; Zidovudine | 2000 |
Primary infection with a lamivudine-resistant hepatitis B virus.
Topics: Adult; Anti-HIV Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B; Hepatitis B virus; HIV Infections; HIV-1; Humans; Lamivudine; Male; Reverse Transcriptase Inhibitors | 2002 |
Development of enzymatic assays for quantification of intracellular lamivudine and carbovir triphosphate levels in peripheral blood mononuclear cells from human immunodeficiency virus-infected patients.
Topics: Chemistry Techniques, Analytical; Deoxyguanine Nucleotides; HIV Infections; Humans; Lamivudine; Quality Control; Reference Standards | 2002 |
Summaries for patients. Predictors of outcomes in patients with HIV infection treated with indinavir, zidovudine, and lamivudine.
Topics: Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Clinical Protocols; Disease Progression; Drug Therapy, Combination; Female; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Male; Middle Aged; RNA, Viral; Viral Load; Zidovudine | 2001 |
Severe ototoxicity in a health care worker who received postexposure prophylaxis with stavudine, lamivudine, and nevirapine after occupational exposure to HIV.
Topics: Adult; Anti-HIV Agents; Chemoprevention; Female; Health Personnel; Hearing Disorders; HIV Infections; Humans; Lamivudine; Nevirapine; Occupational Exposure; Stavudine | 2002 |
Successful control of subfulminant hepatitis related to lamivudine-resistant hepatitis B virus in an HIV-infected patient.
Topics: Adult; Antiviral Agents; Ganciclovir; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Male; Treatment Outcome | 2001 |
Antiretroviral rounds. A very discordant response.
Topics: Alkynes; Benzoxazines; CD4 Lymphocyte Count; Cyclopropanes; Dideoxynucleosides; Drug Therapy, Combination; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Oxazines; Practice Patterns, Physicians'; Reverse Transcriptase Inhibitors; Stavudine; Viral Load | 2002 |
Prevalence and genetic heterogeneity of the reverse transcriptase T69S-S-X insertion in pretreated HIV-infected patients.
Topics: Anti-HIV Agents; Didanosine; Drug Resistance, Viral; Genetic Heterogeneity; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Mutagenesis; Prevalence; Reverse Transcriptase Inhibitors; Spain; Zidovudine | 2001 |
Fulminant hepatitis B due to a lamivudine-resistant mutant of HBV in a patient coinfected with HIV.
Topics: Anti-HIV Agents; Drug Resistance, Viral; Fatal Outcome; Hepatitis B; Hepatitis B virus; HIV Infections; Humans; Lamivudine; Liver Failure; Male; Middle Aged; Mutation | 2002 |
Persistent HIV-1-specific cellular responses despite prolonged therapeutic viral suppression.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD28 Antigens; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cohort Studies; HIV Antigens; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Immunophenotyping; Indinavir; Interferon-gamma; Lamivudine; Membrane Glycoproteins; Palatine Tonsil; Perforin; Pore Forming Cytotoxic Proteins; Reverse Transcriptase Inhibitors; RNA, Viral; Time Factors; Treatment Outcome | 2002 |
Myelomeningocele in a child with intrauterine exposure to efavirenz.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Female; HIV Infections; Humans; Infant, Newborn; Lamivudine; Male; Maternal Exposure; Meningomyelocele; Oxazines; Pregnancy; Pregnancy Complications, Infectious; Prenatal Exposure Delayed Effects; Reverse Transcriptase Inhibitors; Stavudine | 2002 |
Efavirenz-induced leukocytoclastic vasculitis.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; Biopsy, Needle; Cyclopropanes; Drug Therapy, Combination; Follow-Up Studies; HIV Infections; Humans; Lamivudine; Male; Oxazines; Prednisone; Risk Assessment; Severity of Illness Index; Skin; Stavudine; Treatment Outcome; Vasculitis, Leukocytoclastic, Cutaneous | 2002 |
Resistance to antiretroviral treatment in Gabon: need for implementation of guidelines on antiretroviral therapy use and HIV-1 drug resistance monitoring in developing countries.
Topics: Anti-HIV Agents; Developing Countries; Didanosine; Drug Resistance, Viral; Gabon; HIV Infections; HIV Protease; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Population Surveillance; Practice Guidelines as Topic; Reverse Transcriptase Inhibitors; Stavudine; Zidovudine | 2002 |
Lack of control of T cell apoptosis under HAART. Influence of therapy regimen in vivo and in vitro.
Topics: Adjuvants, Immunologic; Adult; Antibodies, Monoclonal; Antiretroviral Therapy, Highly Active; Apoptosis; Case-Control Studies; Caspase 3; Caspase 8; Caspase 9; Caspases; CD3 Complex; CD4 Lymphocyte Count; fas Receptor; Female; HIV Infections; Humans; In Vitro Techniques; Lamivudine; Male; Middle Aged; Reverse Transcriptase Inhibitors; Ritonavir; T-Lymphocytes | 2002 |
Regression of HIV-associated pulmonary arterial hypertension and long-term survival during antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Anticoagulants; Drug Therapy, Combination; Echocardiography; Follow-Up Studies; HIV Infections; Humans; Hypertension, Pulmonary; Lamivudine; Male; Nelfinavir; Severity of Illness Index; Stavudine; Treatment Outcome; Zidovudine | 2001 |
Recurrent hypersensitivity to Combivir.
Topics: Adult; Anti-HIV Agents; Drug Combinations; Drug Hypersensitivity; Female; HIV Infections; HIV-1; Humans; Lamivudine; Recurrence; Zidovudine | 2002 |
Skin eruption 8 days after a single dose of efavirenz-containing combination therapy.
Topics: Adult; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; Cyclopropanes; Drug Eruptions; Female; HIV Infections; HIV-1; Humans; Lamivudine; Oxazines; Spouses; Stavudine; Time Factors | 2001 |
Parallel decline of CD8+/CD38++ T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection.
Topics: Adult; Anti-HIV Agents; Antigens, CD; Antiretroviral Therapy, Highly Active; Biomarkers; Carbamates; CD48 Antigen; CD8-Positive T-Lymphocytes; Dideoxynucleosides; Female; Furans; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lamivudine; Lymphocyte Count; Male; Middle Aged; Reverse Transcriptase Inhibitors; Sulfonamides; T-Lymphocyte Subsets; Treatment Outcome; Viral Load; Viremia; Zidovudine | 2002 |
Virological and immunological responses to a once-a-day antiretroviral regimen with didanosine, lamivudine and efavirenz.
Topics: Adult; Alkynes; Anti-HIV Agents; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Didanosine; Drug Administration Schedule; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Middle Aged; Oxazines; Prospective Studies; RNA, Viral | 2001 |
Transplacental genotoxicity of combined antiretroviral nucleoside analogue therapy in Erythrocebus patas monkeys.
Topics: Animals; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; DNA; DNA Damage; Erythrocebus patas; Female; Fetus; HIV Infections; HIV-1; Humans; Infectious Disease Transmission, Vertical; Lamivudine; Maternal-Fetal Exchange; Placenta; Pregnancy; Reverse Transcriptase Inhibitors; Telomere; Zidovudine | 2002 |
Prescribing practices in a population-based HIV postexposure prophylaxis program.
Topics: Accidents; Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Bites, Human; British Columbia; Community-Acquired Infections; Disease Transmission, Infectious; Drug Prescriptions; Drug Utilization; Female; Follow-Up Studies; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; Male; Mucous Membrane; Needlestick Injuries; Nelfinavir; Occupational Exposure; Practice Patterns, Physicians'; Rape; Reverse Transcriptase Inhibitors; Risk; Skin; Stavudine | 2002 |
Switching to zidovudine plus lamivudine plus abacavir maintains viral suppression in patients with high viral load before antiretroviral therapy: a retrospective clinical cohort analysis.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Cohort Studies; Dideoxynucleosides; Drug Evaluation; HIV Infections; HIV Protease Inhibitors; Humans; Lamivudine; London; Retrospective Studies; Reverse Transcriptase Inhibitors; Treatment Outcome; Viral Load; Viremia; Zidovudine | 2002 |
[Post-exposure prophylaxis in Zambia; the experiences of a tropical disease specialist following a cut accidentally incurred while operating on an HIV positive patient].
Topics: Adult; Anti-HIV Agents; Health Personnel; HIV Infections; Humans; Indinavir; Infectious Disease Transmission, Patient-to-Professional; Lamivudine; Male; Reverse Transcriptase Inhibitors; Zambia; Zidovudine | 2002 |
DPC 817: a cytidine nucleoside analog with activity against zidovudine- and lamivudine-resistant viral variants.
Topics: Animals; Anti-HIV Agents; Cytidine; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Macaca mulatta; Nucleosides; Reverse Transcriptase Inhibitors; Zalcitabine; Zidovudine | 2002 |
Human immunodeficiency virus (HIV) Type 1 reverse transcriptase resistance mutations in hepatitis B virus (HBV)-HIV-coinfected patients treated for HBV chronic infection once daily with 10 milligrams of adefovir dipivoxil combined with lamivudine.
Topics: Adenine; Antiviral Agents; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis B virus; Hepatitis B, Chronic; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Mutation; Organophosphonates; Reverse Transcriptase Inhibitors | 2002 |
Improved long-term suppression of HIV-1 replication with a triple-class multidrug regimen compared with standard of care antiretroviral therapy.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Dideoxynucleosides; Follow-Up Studies; HIV Infections; HIV-1; Humans; Indinavir; Lamivudine; Middle Aged; Nevirapine; Reverse Transcriptase Inhibitors; RNA, Viral; Time Factors; Viral Load; Virus Replication; Zidovudine | 2002 |
Genotypic drug resistance during HIV-1 primary infection in France (1996-1999): frequency and response to treatment.
Topics: Adult; Antiretroviral Therapy, Highly Active; Cohort Studies; Drug Resistance, Viral; Female; France; Genotype; HIV Infections; HIV Protease; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Male; Ritonavir; RNA, Viral; Viral Load; Zidovudine | 2002 |
Severe HIV-associated thrombocytopenia despite effective highly active antiretroviral therapy in a vertically infected child.
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Infectious Disease Transmission, Vertical; Lamivudine; Male; Nelfinavir; Reverse Transcriptase Inhibitors; Stavudine; Thrombocytopenia | 2002 |
Safety and tolerability of combination antiretroviral post-exposure prophylaxis in a population-based setting.
Topics: Anti-HIV Agents; Chemoprevention; Drug Therapy, Combination; Female; HIV Infections; Humans; Lamivudine; Male; Nelfinavir; Occupational Exposure; Reverse Transcriptase Inhibitors; Stavudine; Surveys and Questionnaires | 2002 |
[Drug combination therapy for children infected with HIV/AIDS--own experience].
Topics: Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Child; Child, Preschool; Didanosine; Drug Resistance, Viral; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Humans; Infant; Lamivudine; Male; Nelfinavir; Poland; Reverse Transcriptase Inhibitors; Stavudine; Treatment Outcome; Viral Load; Zidovudine | 2001 |
Needlestick transmission of hepatitis C.
Topics: Accidents, Occupational; Acute Disease; Adult; Anti-HIV Agents; Antiviral Agents; Asthenia; Exanthema; Hepacivirus; Hepatitis C; Hepatitis C Antibodies; HIV Infections; Humans; Infectious Disease Transmission, Patient-to-Professional; Interferon alpha-2; Interferon-alpha; Internship and Residency; Lamivudine; Needlestick Injuries; Nelfinavir; Occupational Exposure; Physicians; Polyethylene Glycols; Recombinant Proteins; Ribavirin; RNA, Viral; Viremia; Zidovudine | 2002 |
Delayed recovery of effector memory CD4+ T cells by highly active antiretroviral therapy in a patient with HIV-1 infection.
Topics: Adult; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4-Positive T-Lymphocytes; HIV Infections; HIV-1; Humans; Immunologic Memory; Lamivudine; Lymphocyte Count; Male; Nelfinavir; Time Factors; Zidovudine | 2002 |
Thailand markets low-cost, 3-in-1 antiretroviral medication.
Topics: Drug Combinations; Drug Costs; HIV Infections; Humans; Lamivudine; Nevirapine; Reverse Transcriptase Inhibitors; Stavudine; Thailand | 2002 |
Gynaecomastia associated with combination antiretroviral therapy including protease inhibitors for human immunodeficiency virus infection.
Topics: Anti-HIV Agents; Diagnosis, Differential; Drug Therapy, Combination; Gynecomastia; HIV Infections; HIV Protease Inhibitors; HIV-1; Homosexuality, Male; Humans; Lamivudine; Male; Middle Aged; Ritonavir; Saquinavir; Stavudine | 1999 |
Transmission of drug-resistant HIV after an occupational exposure despite postexposure prophylaxis with a combination drug regimen.
Topics: Adult; Anti-HIV Agents; Health Personnel; HIV; HIV Infections; Humans; Infectious Disease Transmission, Patient-to-Professional; Lamivudine; Needlestick Injuries; Occupational Exposure; Treatment Failure; Zidovudine | 2002 |
Human immunodeficiency virus 1 strains resistant to nucleoside inhibitors of reverse transcriptase in isolates from the Czech Republic as monitored by line probe assay and nucleotide sequencing.
Topics: Base Sequence; Codon; Czech Republic; Didanosine; Drug Resistance, Viral; HIV Infections; HIV Reverse Transcriptase; HIV-1; Humans; Lamivudine; Molecular Probe Techniques; Molecular Sequence Data; Mutation; Phylogeny; Prevalence; Reverse Transcriptase Inhibitors; Sequence Analysis, DNA; Zalcitabine; Zidovudine | 2001 |
[Antiretroviral prophylaxis in a pregnant hospital worker].
Topics: Adult; Anti-HIV Agents; Female; Health Personnel; HIV Infections; Humans; Lamivudine; Pregnancy | 2002 |
A case of flare syndrome.
Topics: Acute Disease; Adult; AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Antiviral Agents; CD4 Lymphocyte Count; Cidofovir; Cytomegalovirus Retinitis; Cytosine; Drug Therapy, Combination; Ganciclovir; HIV Infections; Humans; Indinavir; Lamivudine; Male; Organophosphonates; Organophosphorus Compounds; Zidovudine | 2001 |
Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy.
Topics: Adult; Alanine Transaminase; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Chemical and Drug Induced Liver Injury; Cohort Studies; Female; Hepatitis B; Hepatitis C; HIV Infections; HIV-1; Humans; Incidence; Lamivudine; Liver Function Tests; Male; Nevirapine; Proportional Hazards Models; Retrospective Studies; Reverse Transcriptase Inhibitors; Risk Factors; Ritonavir; Sex Factors; Transaminases | 2002 |